FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Wang, R
Schoenfeld, DA
Hoeppner, B
Evins, AE
AF Wang, Rui
Schoenfeld, David A.
Hoeppner, Bettina
Evins, A. Eden
TI Detecting treatment-covariate interactions using permutation methods
SO STATISTICS IN MEDICINE
LA English
DT Article
DE interactions; multiple covariates; permutation methods; subgroup
analysis; variable selection
ID CLINICAL-TRIALS; LINEAR-MODELS; COX MODEL; REGRESSION; SELECTION; TESTS;
SUBSETS
AB The primary objective of a Randomized Clinical Trial usually is to investigate whether one treatment is better than its alternatives on average. However, treatment effects may vary across different patient subpopulations. In contrast to demonstrating one treatment is superior to another on the average sense, one is often more concerned with the question that, for a particular patient, or a group of patients with similar characteristics, which treatment strategy is most appropriate to achieve a desired outcome. Various interaction tests have been proposed to detect treatment effect heterogeneity; however, they typically examine covariates one at a time, do not offer an integrated approach that incorporates all available information, and can greatly increase the chance of a false positive finding when the number of covariates is large. We propose a new permutation test for the null hypothesis of no interaction effects for any covariate. The proposed test allows us to consider the interaction effects of many covariates simultaneously without having to group subjects into subsets based on pre-specified criteria and applies generally to randomized clinical trials of multiple treatments. The test provides an attractive alternative to the standard likelihood ratio test, especially when the number of covariates is large. We illustrate the proposed methods using a dataset from the Treatment of Adolescents with Depression Study. Copyright (c) 2015John Wiley & Sons, Ltd.
C1 [Wang, Rui] Brigham & Womens Hosp, Dept Med & Neurol, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
[Wang, Rui] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Wang, Rui; Schoenfeld, David A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Schoenfeld, David A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Hoeppner, Bettina; Evins, A. Eden] Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02114 USA.
RP Wang, R (reprint author), Brigham & Womens Hosp, Dept Med & Neurol, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA.
EM rwang8@partners.org
FU National Institutes of Health [R01 AI24643, K24 DA030443]
FX This research was supported by grants R01 AI24643 and K24 DA030443 from
the National Institutes of Health. We are grateful to Dr Janet Wozniak
for her help in identifying variables of interest in the TADS dataset.
We thank the Editor, Associate Editor, two reviewers for their comments,
which improved the paper.
NR 32
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD MAY 30
PY 2015
VL 34
IS 12
BP 2035
EP 2047
DI 10.1002/sim.6457
PG 13
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA CH6GJ
UT WOS:000354134200005
PM 25736915
ER
PT J
AU Pace-Schott, EF
Germain, A
Milad, MR
AF Pace-Schott, Edward F.
Germain, Anne
Milad, Mohammed R.
TI Sleep and REM sleep disturbance in the pathophysiology of PTSD: the role
of extinction memory
SO BIOLOGY OF MOOD & ANXIETY DISORDERS
LA English
DT Review
DE Extinction; Sleep; REM sleep; PTSD; Anxiety; Insomnia; Stress
ID POSTTRAUMATIC-STRESS-DISORDER; CORTICOTROPIN-RELEASING-FACTOR;
EYE-MOVEMENT SLEEP; OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL
THERAPY; MEDIAL PREFRONTAL CORTEX; PLACEBO-CONTROLLED TRIAL; HEALTHY
CONTROL SUBJECTS; SOCIAL ANXIETY DISORDER; HEART-RATE-VARIABILITY
AB Post-traumatic stress disorder (PTSD) is accompanied by disturbed sleep and an impaired ability to learn and remember extinction of conditioned fear. Following a traumatic event, the full spectrum of PTSD symptoms typically requires several months to develop. During this time, sleep disturbances such as insomnia, nightmares, and fragmented rapid eye movement sleep predict later development of PTSD symptoms. Only a minority of individuals exposed to trauma go on to develop PTSD. We hypothesize that sleep disturbance resulting from an acute trauma, or predating the traumatic experience, may contribute to the etiology of PTSD. Because symptoms can worsen over time, we suggest that continued sleep disturbances can also maintain and exacerbate PTSD. Sleep disturbance may result in failure of extinction memory to persist and generalize, and we suggest that this constitutes one, non-exclusive mechanism by which poor sleep contributes to the development and perpetuation of PTSD. Also reviewed are neuroendocrine systems that show abnormalities in PTSD, and in which stress responses and sleep disturbance potentially produce synergistic effects that interfere with extinction learning and memory. Preliminary evidence that insomnia alone can disrupt sleep-dependent emotional processes including consolidation of extinction memory is also discussed. We suggest that optimizing sleep quality following trauma, and even strategically timing sleep to strengthen extinction memories therapeutically instantiated during exposure therapy, may allow sleep itself to be recruited in the treatment of PTSD and other trauma and stress-related disorders.
C1 [Pace-Schott, Edward F.; Milad, Mohammed R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Dept Psychiat, Charlestown, MA 02129 USA.
[Germain, Anne] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
RP Pace-Schott, EF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Dept Psychiat, CNY 149 13th St Room 2624, Charlestown, MA 02129 USA.
EM epace-schott@mgh.harvard.edu
FU NIMH NIH HHS [R01 MH097965, R21 MH101567, R21 MH090357]
NR 268
TC 8
Z9 8
U1 9
U2 24
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2045-5380
J9 BIOL MOOD ANXIETY DI
JI Biol. Mood Anxiety Disord.
PD MAY 29
PY 2015
VL 5
AR 3
DI 10.1186/s13587-015-0018-9
PG 19
WC Behavioral Sciences
SC Behavioral Sciences
GA CL4IV
UT WOS:000356916700001
PM 26034578
ER
PT J
AU Brito, H
Martins, AC
Lavrado, J
Mendes, E
Francisco, AP
Santos, SA
Ohnmacht, SA
Kim, NS
Rodrigues, CMP
Moreira, R
Neidle, S
Borralho, PM
Paulo, A
AF Brito, Hugo
Martins, Ana Claudia
Lavrado, Joao
Mendes, Eduarda
Francisco, Ana Paula
Santos, Sofia A.
Ohnmacht, Stephan A.
Kim, Nam-Soon
Rodrigues, Cecilia M. P.
Moreira, Rui
Neidle, Stephen
Borralho, Pedro M.
Paulo, Alexandra
TI Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate
Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives
SO PLOS ONE
LA English
DT Article
ID TELOMERIC G-QUADRUPLEX; RNA G-QUADRUPLEXES; COLORECTAL-CANCER; DRUG
DISCOVERY; BINDING; DNA; ACTIVATION; APOPTOSIS; PROMOTER; STABILIZATION
AB Background
A guanine-rich strand within the promoter of the KRAS gene can fold into an intra-molecular G-quadruplex structure (G4), which has an important role in the regulation of KRAS transcription. We have previously identified indolo[3,2-b]quinolines with a 7-carboxylate group and three alkylamine side chains (IQ3A) as effective G4 stabilizers and promising selective anticancer leads. Herein we investigated the anticancer mechanism of action of these compounds, which we hypothesized due to stabilization of the G4 sequence in the KRAS promoter and subsequent down-regulation of gene expression.
Methodology/Principal Findings
IQ3A compounds showed greater stabilization of G4 compared to duplex DNA structures and reduced KRAS promoter activity in a dual luciferase reporter assay. Moreover, IQ3A compounds showed high anti-proliferative activity in HCT116 and SW620 colon cancer cells (IC50 < 2.69 mu M), without eliciting cell death in non-malignant HEK293T human embryonic kidney, and human colon fibroblasts CCD18co. IQ3A compounds significantly reduced KRAS mRNA and protein steady-state levels at IC50 concentrations, and increased p53 protein steady-state levels and cell death by apoptosis in HCT116 cells (mut KRAS, wt p53). Furthermore, KRAS silencing in HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic cell lines induced a higher level of cell death, and a higher IQ3A-induced cell death in HCT116 p53(+/+) compared to HCT116 p53(-/-).
Conclusions
Herein we provide evidence that G4 ligands such as IQ3A compounds can target G4 motifs present in KRAS promoter, down-regulate the expression of the mutant KRAS gene through inhibition of transcription and translation, and induce cell death by apoptosis in colon cancer cell lines. Thus, targeting KRAS at the genomic level with G4 ligands may be a new anticancer therapy strategy for colon cancer.
C1 [Brito, Hugo; Rodrigues, Cecilia M. P.; Borralho, Pedro M.] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Cell Funct & Therapeut Targeting Grp, P-1649003 Lisbon, Portugal.
[Martins, Ana Claudia; Lavrado, Joao; Santos, Sofia A.; Moreira, Rui; Paulo, Alexandra] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Med Chem Grp, P-1649003 Lisbon, Portugal.
[Mendes, Eduarda; Francisco, Ana Paula] Univ Lisbon, Fac Pharm, P-1649003 Lisbon, Portugal.
[Santos, Sofia A.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Ohnmacht, Stephan A.; Neidle, Stephen] UCL, UCL Sch Pharm, London WC1N 1AX, England.
[Kim, Nam-Soon] Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305333, South Korea.
RP Borralho, PM (reprint author), Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Cell Funct & Therapeut Targeting Grp, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal.
EM mapaulo@ff.ulisboa.pt; borralho@ff.ulisboa.pt
RI Moreira, Rui/G-7485-2011; Paulo, Alexandra/M-6683-2013; Francisco,
Ana/M-4178-2013; Mendes, Eduarda/E-1398-2015; iMed.ULisboa,
iMed.ULisboa/C-6292-2014; Rodrigues, Cecilia/M-3572-2013; iMed.ULisboa,
MedChem /B-4834-2014; iMed.ULisboa, CellFun /A-4244-2014; Lavrado, Joao
Paulo/D-6757-2011; PTMS, RNEM/C-1589-2014; Borralho, Pedro/C-2727-2011;
OI Moreira, Rui/0000-0003-0727-9852; Paulo, Alexandra/0000-0003-1433-5402;
Francisco, Ana/0000-0001-6602-2075; Mendes, Eduarda/0000-0002-7926-8821;
Rodrigues, Cecilia/0000-0002-4829-754X; Lavrado, Joao
Paulo/0000-0001-7746-5808; Borralho, Pedro/0000-0003-4488-7240; Brito,
Hugo/0000-0002-4520-7203
FU Fundacao para a Ciencia e Tecnologia (FCT) Portugal
[EXPL/QEQ-MED/0502/2012, HMSP-ICT/0018/2011, PEst-OE/SAU/UI4013/2014];
FCT [SFRH/BPD/72903/2010]; SAS [SFRH/BD/80162/2011]; Pancreatic Cancer
Research Fund; Medical Research Council
FX Authors from iMed-ULisboa acknowledge Fundacao para a Ciencia e
Tecnologia (FCT), Portugal, for financial support through project grants
EXPL/QEQ-MED/0502/2012, HMSP-ICT/0018/2011, and PEst-OE/SAU/UI4013/2014.
HB, CMPR and PMB also thank Sociedade Portuguesa de Gastroenterologia
and the Korea Human Gene Bank (KHGB), Medical Genomics Research Center,
KRIBB, Republic of Korea. JL acknowledges FCT for the Post-Doctoral
grant SFRH/BPD/72903/2010 and SAS for PhD grant SFRH/BD/80162/2011. The
Neidle laboratory acknowledges support from the Pancreatic Cancer
Research Fund and the Medical Research Council. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 36
TC 4
Z9 5
U1 2
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2015
VL 10
IS 5
AR e0126891
DI 10.1371/journal.pone.0126891
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2MQ
UT WOS:000355319400025
PM 26024321
ER
PT J
AU Hu, CH
Cheng, L
Sepulcre, J
Johnson, KA
Fakhri, GE
Lu, M
Li, QZ
AF Hu, Chenhui
Cheng, Lin
Sepulcre, Jorge
Johnson, Keith A.
Fakhri, Georges E.
Lu, M.
Li, Quanzheng
TI A Spectral Graph Regression Model for Learning Brain Connectivity of
Alzheimer's Disease
SO PLOS ONE
LA English
DT Article
ID INVERSE COVARIANCE ESTIMATION; FUNCTIONAL MRI; CORTICAL HUBS; NETWORKS;
DEMENTIA; ORGANIZATION; CONNECTOME; FMRI; PET
AB Understanding network features of brain pathology is essential to reveal underpinnings of neurodegenerative diseases. In this paper, we introduce a novel graph regression model (GRM) for learning structural brain connectivity of Alzheimer's disease (AD) measured by amyloid-beta deposits. The proposed GRM regards C-11-labeled Pittsburgh Compound-B (PiB) positron emission tomography (PET) imaging data as smooth signals defined on an unknown graph. This graph is then estimated through an optimization framework, which fits the graph to the data with an adjustable level of uniformity of the connection weights. Under the assumed data model, results based on simulated data illustrate that our approach can accurately reconstruct the underlying network, often with better reconstruction than those obtained by both sample correlation and l1-regularized partial correlation estimation. Evaluations performed upon PiB-PET imaging data of 30 AD and 40 elderly normal control (NC) subjects demonstrate that the connectivity patterns revealed by the GRM are easy to interpret and consistent with known pathology. Moreover, the hubs of the reconstructed networks match the cortical hubs given by functional MRI. The discriminative network features including both global connectivity measurements and degree statistics of specific nodes discovered from the AD and NC amyloid-beta networks provide new potential biomarkers for preclinical and clinical AD.
C1 [Hu, Chenhui; Lu, M.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Cheng, Lin] Trinity Coll, Dept Engn, Hartford, CT 06106 USA.
[Sepulcre, Jorge; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Fakhri, Georges E.; Li, Quanzheng] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA.
RP Li, QZ (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA.
EM Li.Quanzheng@mgh.harvard.edu
FU National Institutes of Health [R01EB013293, 1K23EB19023-01]; National
Institute on Aging [P01AG036694, R01AG034556, R01AG037497]; Alzheimer's
Association Zenith Award
FX This work was funded by grants from the National Institutes of Health
(R01EB013293 and 1K23EB19023-01), the National Institute on Aging Grants
(P01AG036694, R01AG034556, and R01AG037497), and the Alzheimer's
Association Zenith Award. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 58
TC 2
Z9 2
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2015
VL 10
IS 5
AR e0128136
DI 10.1371/journal.pone.0128136
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2MQ
UT WOS:000355319400072
PM 26024224
ER
PT J
AU Pignon, JC
Grisanzio, C
Carvo, I
Werner, L
Regan, M
Wilson, EL
Signoretti, S
AF Pignon, Jean-Christophe
Grisanzio, Chiara
Carvo, Ingrid
Werner, Lillian
Regan, Meredith
Wilson, E. Lynette
Signoretti, Sabina
TI Cell Kinetic Studies Fail to Identify Sequentially Proliferating
Progenitors as the Major Source of Epithelial Renewal in the Adult
Murine Prostate
SO PLOS ONE
LA English
DT Article
ID INVOLVE SPECIALIZED PROGENITORS; ANDROGEN-INDUCED REGENERATION;
STEM-CELLS; MOUSE PROSTATE; LUMINAL CELLS; REGIONAL-VARIATION; DUCTAL
SYSTEM; RAT PROSTATE; BASAL-CELLS; BETA-CELLS
AB There is evidence that stem cells and their progeny play a role in the development of the prostate. Although stem cells are also considered to give rise to differentiated progeny in the adult prostate epithelium ex vivo, the cohort of adult prostate stem cells in vivo as well as the mechanisms by which the adult prostate epithelium is maintained and regenerated remain highly controversial. We have attempted to resolve this conundrum by performing in vivo tracing of serially replicating cells after the sequential administration of two thymidine analogues to mice. Our results show that, during normal prostate homeostasis, sequentially proliferating cells are detected at a rate that is consistent with a stochastic process. These findings indicate that in vivo, under steady-state conditions, most adult prostate epithelial cells do not represent the progeny of a small number of specialized progenitors that generate sequentially replicating transit-amplifying (TA) cells but are formed by stochastic cell division. Similarly, no rapidly cycling TA cells were detected during regeneration following one cycle of androgen-mediated involution/regeneration of the prostate epithelium. These findings greatly enhance our understanding of the mechanisms regulating prostate epithelial cell renewal and may have significant implications in defining the cell of origin of proliferative prostatic diseases.
C1 [Pignon, Jean-Christophe; Grisanzio, Chiara; Carvo, Ingrid; Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Pignon, Jean-Christophe; Grisanzio, Chiara; Werner, Lillian; Regan, Meredith; Signoretti, Sabina] Harvard Univ, Sch Med, Boston, MA USA.
[Grisanzio, Chiara; Signoretti, Sabina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Werner, Lillian; Regan, Meredith] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA.
[Wilson, E. Lynette] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
[Wilson, E. Lynette] NYU, Sch Med, Dept Urol, New York, NY 10003 USA.
RP Signoretti, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM ssignoretti@partners.org
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases Grants [1R21DK72152, 1R01DK089975];
Harvard Stem Cell Institute [5R01CA132641]
FX This work was supported by National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases Grants
1R21DK72152 and 1R01DK089975 and the Harvard Stem Cell Institute (SS)
and 5R01CA132641 (ELW). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 43
TC 0
Z9 0
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2015
VL 10
IS 5
AR e0128489
DI 10.1371/journal.pone.0128489
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2MQ
UT WOS:000355319400093
PM 26024527
ER
PT J
AU Hepworth, MR
Fung, TC
Masur, SH
Kelsen, JR
McConnell, FM
Dubrot, J
Withers, DR
Hugues, S
Farrar, MA
Reith, W
Eberl, G
Baldassano, RN
Laufer, TM
Elson, CO
Sonnenberg, GF
AF Hepworth, Matthew R.
Fung, Thomas C.
Masur, Samuel H.
Kelsen, Judith R.
McConnell, Fiona M.
Dubrot, Juan
Withers, David R.
Hugues, Stephanie
Farrar, Michael A.
Reith, Walter
Eberl, Gerard
Baldassano, Robert N.
Laufer, Terri M.
Elson, Charles O.
Sonnenberg, Gregory F.
TI Group 3 innate lymphoid cells mediate intestinal selection of commensal
bacteria-specific CD4(+) T cells
SO SCIENCE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; CLASS-II TRANSACTIVATOR; NEGATIVE SELECTION;
DENDRITIC CELLS; IMMUNE-SYSTEM; PROMOTER-IV; HOMEOSTASIS; MICROBIOTA;
RESPONSES; EXPRESSION
AB Inflammatory CD4(+) T cell responses to self or commensal bacteria underlie the pathogenesis of autoimmunity and inflammatory bowel disease (IBD), respectively. Although selection of self-specific T cells in the thymus limits responses to mammalian tissue antigens, the mechanisms that control selection of commensal bacteria-specific T cells remain poorly understood. Here, we demonstrate that group 3 innate lymphoid cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is regulated similarly to thymic epithelial cells and that MHCII+ ILC3s directly induce cell death of activated commensal bacteria-specific T cells. Further, MHCII on colonic ILC3s was reduced in pediatric IBD patients. Collectively, these results define a selection pathway for commensal bacteria-specific CD4(+) T cells in the intestine and suggest that this process is dysregulated in human IBD.
C1 [Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA.
[Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Dept Microbiol & Immunol, Weill Cornell Med Coll, New York, NY 10021 USA.
[Fung, Thomas C.; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Masur, Samuel H.; Kelsen, Judith R.; Baldassano, Robert N.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
[McConnell, Fiona M.; Withers, David R.] Univ Birmingham, MRC, Coll Med & Dent Sci, Ctr Immune Regulat, Birmingham, W Midlands, England.
[Hugues, Stephanie; Reith, Walter] Univ Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland.
[Farrar, Michael A.] Univ Minnesota, Ctr Immunol, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Eberl, Gerard] Inst Pasteur, Microenvironm & Immun Unit, Paris, France.
[Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Elson, Charles O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Elson, Charles O.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
RP Sonnenberg, GF (reprint author), Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA.
EM gfsonnenberg@med.cornell.edu
RI Withers, David/C-7055-2015
OI Withers, David/0000-0003-3757-7594
FU National Institutes of Health [DP5OD012116, DK071176]; National
Institute of Allergy and Infectious Diseases Mucosal Immunology Studies
Team (MIST) Scholar Award in Mucosal Immunity; Institute for
Translational Medicine and Therapeutics Transdisciplinary Program in
Translational Medicine and Therapeutics (from the U.S. National Center
for Research Resources) [UL1-RR024134]; Crohn's and Colitis Foundation
of America (CCFA) [297365]; Cancer Research Institute Student Training
and Research in Tumor immunology (STaRT) grant; Wellcome Trust Research
Career Development Fellowship
FX The authors thank members of the Sonnenberg laboratory for discussions
and critical reading of the manuscript. We thank C. Hunter and S. Wagage
(University of Pennsylvania) for the Ahr-deficient mice; I. Brodsky
(University of Pennsylvania) for the Caspase 1/11-deficient mice; and M.
Jenkins, J. Walter, and T. Dileepan (University of Minnesota) for
tetramer reagents and protocols. Data presented in this manuscript are
tabulated in the main paper and in the supplementary materials.
Microarray data are accessible at Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo) via accession number GSE67076. CBir1 Tg mice
are available from University of Alabama, Rorc(gamma t)-GfpTG
and RorcCre mice are available from Institut Pasteur,
STAT5-CA mice are available from University of Minnesota,
IAbbSTOPfl/fl mice and CD11c Tg mice are available from
University of Pennsylvania, and Il23a deficient mice are available from
Janssen Research and Development LLC, all under Material Transfer
Agreement. Research in the Sonnenberg laboratory is supported by the
National Institutes of Health (DP5OD012116), the National Institute of
Allergy and Infectious Diseases Mucosal Immunology Studies Team (MIST)
Scholar Award in Mucosal Immunity, and the Institute for Translational
Medicine and Therapeutics Transdisciplinary Program in Translational
Medicine and Therapeutics (UL1-RR024134 from the U.S. National Center
for Research Resources). M.R.H. is supported by a research fellowship
from the Crohn's and Colitis Foundation of America (CCFA, no. 297365).
T.C.F. is supported by a Cancer Research Institute Student Training and
Research in Tumor immunology (STaRT) grant. D.R.W. is supported by a
Wellcome Trust Research Career Development Fellowship. C.O.E. is
supported by the National Institutes of Health (DK071176).
NR 41
TC 59
Z9 62
U1 10
U2 33
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 29
PY 2015
VL 348
IS 6238
BP 1031
EP 1035
DI 10.1126/science.aaa4812
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ1WU
UT WOS:000355276600048
PM 25908663
ER
PT J
AU Armand, P
AF Armand, Philippe
TI Immune checkpoint blockade in hematologic malignancies
SO BLOOD
LA English
DT Review
ID B-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; DEATH-LIGAND 1; REED-STERNBERG
CELLS; T-CELLS; CANCER-IMMUNOTHERAPY; FOLLICULAR LYMPHOMA; ADVANCED
MELANOMA; MYELODYSPLASTIC SYNDROMES; ANTI-PD-L1 ANTIBODY
AB Therapeutic blockade of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programmed-death 1 (PD-1), has become a paradigm-shifting treatment in solid tumor oncology. Hematologic malignancies (HMs), many of which are known to have clinically exploitable immune sensitivity, are a natural target for this type of treatment. Several clinical trials of checkpoint blockade have been conducted in HM, with preliminary results suggesting the therapeutic usefulness of this approach across several tumor types. In particular, the results of PD-1 blockade in Hodgkin lymphoma (HL) are remarkable, and raise hope that it may alter the treatment landscape in this disease. However, numerous questions remain about the optimal role of checkpoint blockade both in HL and beyond. Those questions are the focus of this review, in the hope that, if we are at the dawn of a new day in HM immunotherapy, we may begin to envision its morning.
C1 [Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Armand, P (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM parmand@partners.org
FU Merck; Bristol-Myers Squibb
FX Conflict-of-interest disclosure: P.A. has received research funding from
Merck, Bristol-Myers Squibb, and consultancy fees from Merck.
NR 71
TC 52
Z9 53
U1 2
U2 14
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 28
PY 2015
VL 125
IS 22
BP 3393
EP 3400
DI 10.1182/blood-2015-02-567453
PG 8
WC Hematology
SC Hematology
GA CK1PR
UT WOS:000355979800010
PM 25833961
ER
PT J
AU Owens, EA
Hyun, H
Tawney, JG
Choi, HS
Henary, M
AF Owens, Eric A.
Hyun, Hoon
Tawney, Joseph G.
Choi, Hak Soo
Henary, Maged
TI Correlating Molecular Character of NIR Imaging Agents with
Tissue-Specific Uptake
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NEAR-INFRARED FLUOROPHORES; HUMAN SERUM-ALBUMIN; GUIDED SURGERY; CLICK
REACTION; SIDE-CHAINS; BINDING; SYSTEM; HEAD; DYES; SPECT
AB Near-infrared (NIR) fluorescent contrast agents are emerging in optical imaging as sensitive, cost-effective, and nonharmful alternatives to current agents that emit harmful ionizing radiation. Developing spectrally distinct NIR fluorophores to visualize sensitive vital tissues to selectively avoid them during surgical resection of diseased tissue is of great significance. Herein, we report the synthetic variation of pentamethine cyanine fluorophores with modifications of physicochemical, properties toward prompting tissue-specific uptake into sensitive tissues (i.e., endocrine glands). Tissue-specific targeting and biodistribution studies revealed localization of contrast agents in the adrenal and pituitary glands, pancreas, and lymph nodes with dependence on molecular characteristics. Incorporation of hydrophobic heterocyclic rings, alkyl groups, and halogens allowed a fine tuning capability to the hydrophobic character and dipole moment for observing perturbation in biological activity in response to minor structural alterations. These NIR contrast agents have potential for clinical translation for intraoperative imaging in the,delineation of delicate glands.
C1 [Owens, Eric A.; Tawney, Joseph G.; Henary, Maged] Georgia State Univ, Ctr Biotechnol & Drug Design, Ctr Diagnost & Therapeut, Dept Chem, Atlanta, GA 30303 USA.
[Hyun, Hoon; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Hyun, Hoon; Choi, Hak Soo] Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Choi, HS (reprint author), BIDMC, Room SL-436A,330 Brookline Ave, Boston, MA 02215 USA.
EM hchoi@bidmc.harvard.eduaddress; mhenaryl@gsu.edu
RI Choi, Hak Soo/C-9954-2011
FU Georgia State University dissertation grant; Brains and Behavior grant;
NIH/NIBIB grant [R01-EB-011523]; Center for Diagnostics and Therapeutics
(CDT) at Georgia State University; Georgia State University Center for
Diagnostics and Therapeutics
FX This study was supported by the Georgia State University dissertation
grant to E.A.O, the Brains and Behavior grant (M.H.) and the NIH/NIBIB
grant no. R01-EB-011523 (HSC). E.A.O. was supported by a predoctoral
fellowship through the Center for Diagnostics and Therapeutics (CDT) at
Georgia State University. M.H. also appreciates the support from the
Georgia State University Center for Diagnostics and Therapeutics.
NR 33
TC 7
Z9 7
U1 5
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 28
PY 2015
VL 58
IS 10
BP 4348
EP 4356
DI 10.1021/acs.jmedchem.5b00475
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CJ4YS
UT WOS:000355495200017
PM 25923454
ER
PT J
AU Patch, AM
Christie, EL
Etemadmoghadam, D
Garsed, DW
George, J
Fereday, S
Nones, K
Cowin, P
Alsop, K
Bailey, PJ
Kassahn, KS
Newell, F
Quinn, MCJ
Kazakoff, S
Quek, K
Wilhelm-Benartzi, C
Curry, E
Leong, HS
Hamilton, A
Mileshkin, L
Au-Yeung, G
Kennedy, C
Hung, JL
Chiew, YE
Harnett, P
Friedlander, M
Quinn, M
Pyman, J
Cordner, S
O'Brien, P
Leditschke, J
Young, G
Strachan, K
Waring, P
Azar, W
Mitchell, C
Traficante, N
Hendley, J
Thorne, H
Shackleton, M
Miller, DK
Arnau, GM
Tothill, RW
Holloway, TP
Semple, T
Harliwong, I
Nourse, C
Nourbakhsh, E
Manning, S
Idrisoglu, S
Bruxner, TJC
Christ, AN
Poudel, B
Holmes, O
Anderson, M
Leonard, C
Lonie, A
Hall, N
Wood, S
Taylor, DF
Xu, QY
Fink, JL
Waddell, N
Drapkin, R
Stronach, E
Gabra, H
Brown, R
Jewell, A
Nagaraj, SH
Markham, E
Wilson, PJ
Ellul, J
McNally, O
Doyle, MA
Vedururu, R
Stewart, C
Lengyel, E
Pearson, JV
Waddell, N
deFazio, A
Grimmond, SM
Bowtell, DDL
AF Patch, Ann-Marie
Christie, Elizabeth L.
Etemadmoghadam, Dariush
Garsed, Dale W.
George, Joshy
Fereday, Sian
Nones, Katia
Cowin, Prue
Alsop, Kathryn
Bailey, Peter J.
Kassahn, Karin S.
Newell, Felicity
Quinn, Michael C. J.
Kazakoff, Stephen
Quek, Kelly
Wilhelm-Benartzi, Charlotte
Curry, Ed
Leong, Huei San
Hamilton, Anne
Mileshkin, Linda
Au-Yeung, George
Kennedy, Catherine
Hung, Jillian
Chiew, Yoke-Eng
Harnett, Paul
Friedlander, Michael
Quinn, Michael
Pyman, Jan
Cordner, Stephen
O'Brien, Patricia
Leditschke, Jodie
Young, Greg
Strachan, Kate
Waring, Paul
Azar, Walid
Mitchell, Chris
Traficante, Nadia
Hendley, Joy
Thorne, Heather
Shackleton, Mark
Miller, David K.
Arnau, Gisela Mir
Tothill, Richard W.
Holloway, Timothy P.
Semple, Timothy
Harliwong, Ivon
Nourse, Craig
Nourbakhsh, Ehsan
Manning, Suzanne
Idrisoglu, Senel
Bruxner, Timothy J. C.
Christ, Angelika N.
Poudel, Barsha
Holmes, Oliver
Anderson, Matthew
Leonard, Conrad
Lonie, Andrew
Hall, Nathan
Wood, Scott
Taylor, Darrin F.
Xu, Qinying
Fink, J. Lynn
Waddell, Nick
Drapkin, Ronny
Stronach, Euan
Gabra, Hani
Brown, Robert
Jewell, Andrea
Nagaraj, Shivashankar H.
Markham, Emma
Wilson, Peter J.
Ellul, Jason
McNally, Orla
Doyle, Maria A.
Vedururu, Ravikiran
Stewart, Collin
Lengyel, Ernst
Pearson, John V.
Waddell, Nicola
deFazio, Anna
Grimmond, Sean M.
Bowtell, David D. L.
CA Australian Ovarian Canc Study Grp
TI Whole-genome characterization of chemoresistant ovarian cancer
SO NATURE
LA English
DT Article
ID GAMMA-RAY BURSTS; HUBBLE-SPACE-TELESCOPE; COPY-NUMBER ALTERATION; M87
JET; 3C 264; CHEMOTHERAPY RESISTANCE; MUTATIONAL PROCESSES; INTERNAL
SHOCKS; CLINICAL-TRIALS; CARCINOMA
AB Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.
C1 [Patch, Ann-Marie; Nones, Katia; Bailey, Peter J.; Kassahn, Karin S.; Newell, Felicity; Quinn, Michael C. J.; Kazakoff, Stephen; Quek, Kelly; Miller, David K.; Harliwong, Ivon; Nourse, Craig; Nourbakhsh, Ehsan; Manning, Suzanne; Idrisoglu, Senel; Bruxner, Timothy J. C.; Christ, Angelika N.; Poudel, Barsha; Holmes, Oliver; Anderson, Matthew; Leonard, Conrad; Wood, Scott; Taylor, Darrin F.; Xu, Qinying; Fink, J. Lynn; Waddell, Nick; Nagaraj, Shivashankar H.; Markham, Emma; Wilson, Peter J.; Pearson, John V.; Waddell, Nicola; Grimmond, Sean M.] Univ Queensland, Inst Mol Biosci, Queensland Ctr Med Genom, Brisbane, Qld 4067, Australia.
[Patch, Ann-Marie; Nones, Katia; Quinn, Michael C. J.; Kazakoff, Stephen; Holmes, Oliver; Leonard, Conrad; Wood, Scott; Xu, Qinying; Pearson, John V.; Waddell, Nicola] QIMR Berghofer Med Res Inst, Brisbane, Qld 4006, Australia.
[Christie, Elizabeth L.; Etemadmoghadam, Dariush; Garsed, Dale W.; Fereday, Sian; Cowin, Prue; Alsop, Kathryn; Leong, Huei San; Hamilton, Anne; Mileshkin, Linda; Au-Yeung, George; Azar, Walid; Mitchell, Chris; Traficante, Nadia; Hendley, Joy; Thorne, Heather; Shackleton, Mark; Arnau, Gisela Mir; Tothill, Richard W.; Holloway, Timothy P.; Semple, Timothy; Ellul, Jason; Doyle, Maria A.; Vedururu, Ravikiran; Bowtell, David D. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia.
[Etemadmoghadam, Dariush; Waring, Paul; Bowtell, David D. L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
[Etemadmoghadam, Dariush; Mileshkin, Linda; Shackleton, Mark; Tothill, Richard W.; Bowtell, David D. L.] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Parkville, Vic 3052, Australia.
[George, Joshy] Jackson Lab Genom Med, Farmington, CT 06030 USA.
[Bailey, Peter J.; Grimmond, Sean M.] Univ Glasgow, Inst Canc Sci, WolfsonWohl Canc Res Ctr, Glasgow G61 1QH, Lanark, Scotland.
[Kassahn, Karin S.] SA Pathol, Technol Adv Unit, Genet & Mol Pathol, Adelaide, SA 5000, Australia.
[Wilhelm-Benartzi, Charlotte; Curry, Ed; Stronach, Euan; Gabra, Hani; Brown, Robert; Bowtell, David D. L.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, London W12 0HS, England.
[Hamilton, Anne] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia.
[Hamilton, Anne; Quinn, Michael; Pyman, Jan] Royal Womens Hosp, Parkville, Vic 3052, Australia.
[Kennedy, Catherine; Hung, Jillian; Chiew, Yoke-Eng; McNally, Orla; deFazio, Anna] Univ Sydney, Westmead Millennium Inst, Ctr Canc Res, Sydney, NSW 2145, Australia.
[Kennedy, Catherine; Hung, Jillian; Chiew, Yoke-Eng; McNally, Orla; deFazio, Anna] Westmead Hosp, Dept Gynaecol Oncol, Sydney, NSW 2145, Australia.
[Harnett, Paul] Crown Princess Mary Canc Ctr, Sydney, NSW 2145, Australia.
[Harnett, Paul] Univ Sydney, Westmead Hosp, Sydney, NSW 2145, Australia.
[Friedlander, Michael] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW 2031, Australia.
[Cordner, Stephen; O'Brien, Patricia; Leditschke, Jodie; Young, Greg; Strachan, Kate] Victorian Inst Forens Med, Southbank, Vic 3006, Australia.
[Lonie, Andrew] Victorian Life Sci Computat Initiat, Carlton, Vic 3053, Australia.
[Hall, Nathan] La Trobe Inst Mol Sci, Bundoora, Vic 3083, Australia.
[Drapkin, Ronny] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jewell, Andrea; Lengyel, Ernst] Univ Chicago, Chicago, IL 60637 USA.
[Stewart, Collin] Univ Western Australia, Crawley, WA 6009, Australia.
[Bowtell, David D. L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.
RP Bowtell, DDL (reprint author), Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia.
EM david.bowtell@petermac.org
RI Fink, Lynn/C-2031-2008; Nicklin, James/F-8035-2013; Drapkin,
Ronny/E-9944-2016; Bowtell, David/H-1007-2016; Waddell, Nic/H-4929-2015;
Grimmond, Sean/J-5304-2016; Pearson, John/F-2249-2011; Harnett,
Paul/D-4090-2014; Wyld, David/B-8893-2015;
OI Tothill, Richard/0000-0003-4522-1184; Wilhelm-Benartzi,
Charlotte/0000-0003-4927-6158; Lonie, Andrew/0000-0002-2006-3856; Fink,
Lynn/0000-0003-2912-6048; Nicklin, James/0000-0001-5378-496X; Drapkin,
Ronny/0000-0002-6912-6977; Bowtell, David/0000-0001-9089-7525; Grimmond,
Sean/0000-0002-8102-7998; Pearson, John/0000-0003-0904-4598; Harnett,
Paul/0000-0001-7021-0642; Garsed, Dale/0000-0003-1223-0121; Wyld,
David/0000-0001-9523-4333; Christie, Elizabeth/0000-0002-9959-7024
FU National Health and Medical Research Council of Australia (NHMRC)
[ID631701, ID400413, ID400281]; Worldwide Cancer Research [09-0676];
Cancer Australia [1004673]; US Army Medical Research and Materiel
Command [DAMD17-01-1-0729]; Cancer Council Victoria; Queensland Cancer
Fund; Cancer Council New South Wales; Cancer Council South Australia;
Cancer Foundation of Western Australia; Cancer Council Tasmania; Agar
family; Ovarian Cancer Australia; Ovarian Cancer Action (UK); NHMRC [ID
310670, ID628903]; Cancer Institute of New South Wales; Peter MacCallum
Cancer Centre Foundation
FX The AOCS gratefully acknowledge the cooperation of the participating
institutions in Australia, and also acknowledge the contribution of the
study nurses, research assistants and all clinical and scientific
collaborators including L. Galletta, C. Emmanuel, L. Bowes and J. Hallo.
The authors acknowledge assistance from C. Anderson and D. Gwynne. The
CASCADE investigators would like to thank the CASCADE Management
Committee, all staff at the Victorian Institute of Forensic Medicine, D.
Stevens and Tobin Brothers Funerals. The investigators would like to
thank the Australia New Zealand Gynaecological Oncology Group (ANZGOG)
and the women, and their families, who participated in these research
programs. This work was supported by the National Health and Medical
Research Council of Australia (NHMRC ID631701), Worldwide Cancer
Research (09-0676) and Cancer Australia (1004673). The Australian
Ovarian Cancer Study was supported by the US Army Medical Research and
Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria,
Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer
Council South Australia, The Cancer Foundation of Western Australia, The
Cancer Council Tasmania and the National Health and Medical Research
Council of Australia (NHMRC; ID400413, ID400281). The AOCS gratefully
acknowledges additional support from S. Boldeman, the Agar family,
Ovarian Cancer Australia and Ovarian Cancer Action (UK). The
Gynaecological Oncology Biobank at Westmead, a member of the
Australasian Biospecimen Network-Oncology group, was supported by grants
from the NHMRC (ID 310670, ID628903) and the Cancer Institute of New
South Wales. The CASCADE study was supported by the Peter MacCallum
Cancer Centre Foundation, and in kind by the Victorian Institute of
Forensic Medicine and Tobin Brothers Funerals.
NR 90
TC 156
Z9 159
U1 16
U2 92
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 28
PY 2015
VL 521
IS 7553
BP 489
EP 494
DI 10.1038/nature14410
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2AN
UT WOS:000355286600037
PM 26017449
ER
PT J
AU Park, SY
Yang, JS
Schmider, AB
Soberman, RJ
Hsu, VW
AF Park, Seung-Yeol
Yang, Jia-Shu
Schmider, Angela B.
Soberman, Roy J.
Hsu, Victor W.
TI Coordinated regulation of bidirectional COPI transport at the Golgi by
CDC42
SO NATURE
LA English
DT Article
ID CISTERNAL MATURATION; MEMBRANE CURVATURE; VESICLE FORMATION; ARFGAP1
PROMOTES; APPARATUS; COMPLEX; YEAST
AB The Golgi complex has a central role in the intracellular sorting of secretory proteins(1,2). Anterograde transport through the Golgi has been explained by the movement of Golgi cisternae, known as cisternal maturation(3-5). Because this explanation is now appreciated to be incomplete(6), interest has developed in understanding tubules that connect the Golgi cisternae(7-9). Here we show that the coat protein (COPI) complex sorts anterograde cargoes into these tubules in human cells. Moreover, the small GTPase CDC42 regulates bidirectional Golgi transport by targeting the dual functions of COPI in cargo sorting and carrier formation. CDC42 also directly imparts membrane curvature to promote COPI tubule formation. Our findings further reveal that COPI tubular transport complements cisternal maturation in explaining how anterograde Golgi transport is achieved, and that bidirectional COPI transport is modulated by environmental cues through CDC42.
C1 [Park, Seung-Yeol; Yang, Jia-Shu; Hsu, Victor W.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Park, Seung-Yeol; Yang, Jia-Shu; Schmider, Angela B.; Soberman, Roy J.; Hsu, Victor W.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Schmider, Angela B.; Soberman, Roy J.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA.
[Schmider, Angela B.; Soberman, Roy J.] Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA.
[Soberman, Roy J.] Massachusetts Gen Hosp, Mol Imaging Core, Charlestown, MA 02129 USA.
RP Hsu, VW (reprint author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.
EM vhsu@research.bwh.harvard.edu
FU National Institutes of Health [R01GM058615, R01AI068871, R01AR065538,
1S10RR027931-01, K01DK089145]; National Research Foundation of Korea
[2014R1A6A3A03056673]
FX We thank J. Li, M. Bai, X. Michelet and C. Alves for discussions, and M.
Ericsson for electron microscopy technical advice. This work was funded
by grants from the National Institutes of Health to V.W.H.
(R01GM058615), R.J.S. (R01AI068871, R01AR065538 and 1S10RR027931-01),
A.B.S. (K01DK089145), and also by the Basic Science Research Program of
the National Research Foundation of Korea to S.-Y.P.
(2014R1A6A3A03056673).
NR 24
TC 11
Z9 11
U1 4
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 28
PY 2015
VL 521
IS 7553
BP 529
EP U257
DI 10.1038/nature14457
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2AN
UT WOS:000355286600045
PM 25945738
ER
PT J
AU Halpern, SD
French, B
Small, DS
Saulsgiver, K
Harhay, MO
Audrain-McGovern, J
Loewenstein, G
Brennan, TA
Asch, DA
Volpp, KG
AF Halpern, Scott D.
French, Benjamin
Small, Dylan S.
Saulsgiver, Kathryn
Harhay, Michael O.
Audrain-McGovern, Janet
Loewenstein, George
Brennan, Troyen A.
Asch, David A.
Volpp, Kevin G.
TI Randomized Trial of Four Financial-Incentive Programs for Smoking
Cessation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID INSTRUMENTAL VARIABLES; ADAPTIVE DESIGNS; COLLECTIVE DYNAMICS;
CLINICAL-TRIALS; WEIGHT-LOSS; BEHAVIOR; THERAPY; HEALTH; PAY; DEPENDENCE
AB BACKGROUND
Financial incentives promote many health behaviors, but effective ways to deliver health incentives remain uncertain.
METHODS
We randomly assigned CVS Caremark employees and their relatives and friends to one of four incentive programs or to usual care for smoking cessation. Two of the incentive programs targeted individuals, and two targeted groups of six participants. One of the individual-oriented programs and one of the group-oriented programs entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care included informational resources and free smoking-cessation aids.
RESULTS
Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted the assignment, as compared with 13.7% of those assigned to deposit-based programs (P<0.001). In intention-to-treat analyses, rates of sustained abstinence from smoking through 6 months were higher with each of the four incentive programs (range, 9.4 to 16.0%) than with usual care (6.0%) (P<0.05 for all comparisons); the superiority of reward-based programs was sustained through 12 months. Group-oriented and individual-oriented programs were associated with similar 6-month abstinence rates (13.7% and 12.1%, respectively; P = 0.29). Reward-based programs were associated with higher abstinence rates than deposit-based programs (15.7% vs. 10.2%, P<0.001). However, in instrumental-variable analyses that accounted for differential acceptance, the rate of abstinence at 6 months was 13.2 percentage points (95% confidence interval, 3.1 to 22.8) higher in the deposit-based programs than in the reward-based programs among the estimated 13.7% of the participants who would accept participation in either type of program.
CONCLUSIONS
Reward-based programs were much more commonly accepted than deposit-based programs, leading to higher rates of sustained abstinence from smoking. Group-oriented incentive programs were no more effective than individual-oriented programs. (Funded by the National Institutes of Health and CVS Caremark; ClinicalTrials.gov number, NCT01526265.)
C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Audrain-McGovern, Janet] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Small, Dylan S.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Ctr Hlth Care Innovat, Philadelphia, PA USA.
[Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA.
[Brennan, Troyen A.] CVS Caremark, Woonsocket, RI USA.
RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM shalpern@exchange.upenn.edu
FU NCI NIH HHS [R01 CA159932]; NIA NIH HHS [RC2 AG036592]
NR 45
TC 55
Z9 56
U1 4
U2 25
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 28
PY 2015
VL 372
IS 22
BP 2108
EP 2117
DI 10.1056/NEJMoa1414293
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ0EI
UT WOS:000355146800006
PM 25970009
ER
PT J
AU Kamdar, MM
Doyle, KP
Sequist, LV
Rinehart, TJ
Maytal, G
Flores, EJ
Mino-Kenudson, M
AF Kamdar, Mihir M.
Doyle, Kathleen P.
Sequist, Lecia V.
Rinehart, Todd J.
Maytal, Guy
Flores, Efren J.
Mino-Kenudson, Mari
TI Case 17-2015: A 44-Year-Old Woman with Intractable Pain Due to
Metastatic Lung Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID OPIOID-INDUCED HYPERALGESIA; PALLIATIVE SEDATION; CLINICAL-TRIAL;
GUIDELINES; DELIVERY; ADENOCARCINOMA; MECHANISMS; TOLERANCE; GEFITINIB;
ERLOTINIB
C1 [Kamdar, Mihir M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA.
[Sequist, Lecia V.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA.
[Maytal, Guy] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Flores, Efren J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Harvard Univ, Sch Med, Dept Palliat Care, Boston, MA USA.
[Sequist, Lecia V.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA.
[Maytal, Guy] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Flores, Efren J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Kamdar, MM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
NR 28
TC 3
Z9 3
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 28
PY 2015
VL 372
IS 22
BP 2137
EP 2147
DI 10.1056/NEJMcpc1404141
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ0EI
UT WOS:000355146800012
PM 26017825
ER
PT J
AU Khalil, HA
Lei, NY
Nie, WX
Lewis, MS
Stelzner, MG
Martin, MG
Dunn, JCY
Yoo, J
AF Khalil, Hassan A.
Lei, Nan Ye
Nie, Wenxian
Lewis, Michael S.
Stelzner, Matthias G.
Martin, Martin G.
Dunn, James C. Y.
Yoo, James
TI Primary Myofibroblasts Maintain Short-Term Viability following
Submucosal Injection in Syngeneic, Immune-Competent Mice Utilizing
Murine Colonoscopy
SO PLOS ONE
LA English
DT Article
ID HUMAN COLONIC MYOFIBROBLASTS; TNF-ALPHA; EXPRESSION; MODELS; COX-2; EGFR
AB The myofibroblast is an important stromal cell of the gastrointestinal tract. Current in vitro and in vivo models either do not accurately recreate stromal-epithelial interactions or are not specific to myofibroblasts. We sought to create an animal model that would allow the study of myofibroblast-epithelial interactions. We isolated and cultured colonic myofibroblasts from FVB mice. Cells were alpha-SMA and vimentin positive but desmin negative on immunoblot analysis. We injected the myofibroblasts into the colonic submucosa of syngeneic adult mice (n = 8) via a miniendoscopic system. We then isolated green fluorescent protein (GFP) positive colonic myofibroblasts from C57BL/6-Tg(CAG-EGFP) 1Osb/Jmice and injected them into the colonic lamina propria of C57BL/6J mice at 1x10(5) (n = 14), 1x10(6) (n = 9), or 5x10(6) cells/mL (n = 4). A subset of mice were injected with serum-free media and ink without cells (n = 3). Mice underwent repeat endoscopy and euthanasia one or 7 days after injection. Colons were isolated and either fixed in 10% formalin or the inked sites were individually excised and lysed for DNA. We assessed the injection sites via histology and immunohistochemical stains for alpha-SMA and GFP. We used qPCR to quantify GFP DNA transcripts at the lamina propria injection sites. Submucosal injection ofmyofibroblasts resulted in the formation of a subepithelial wheal on endoscopy, which persisted to day 7. Myofibroblasts injected either into the submucosa or lamina propria maintained viability on post-injection day 7 as evidenced by positive alpha-SMA staining. qPCR of lamina propria injections showed a dose-dependent increase in GFP DNA transcripts on post-injection day 1, whereas the number of transcripts on day 7 was equivalent for the concentrations injected. We demonstrate short-term survival of primary cultured colonic myofibroblasts in syngeneic mice. This may prove to be a valuable model for studying the role ofmyofibroblasts in states of health and disease.
C1 [Khalil, Hassan A.; Lei, Nan Ye; Nie, Wenxian; Stelzner, Matthias G.; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Lewis, Michael S.] VA Greater Los Angeles Hlth Syst, Dept Pathol & Lab Med, Los Angeles, CA USA.
[Stelzner, Matthias G.] VA Greater Los Angeles Hlth Syst, Dept Surg, Los Angeles, CA USA.
[Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90024 USA.
[Yoo, James] Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA.
RP Yoo, J (reprint author), Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA.
EM JYoo@tuftsmedicalcenter.org
OI Khalil, Hassan/0000-0002-3835-1290
FU National Institutes of Health K08 award [DK085136-03]; National
Institute of Diabetes and Digestive and Kidney Diseases; National
Institute of Allergy and Infectious Diseases [DK085535]
FX This project was funded by a National Institutes of Health K08 award
#DK085136-03 (JY), and was performed as a project of the Intestinal Stem
Cell Consortium (https://iscc.coh.org), a collaborative research project
funded by the National Institute of Diabetes and Digestive and Kidney
Diseases and the National Institute of Allergy and Infectious Diseases
#DK085535 (MGM, JCYD, MS). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 15
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 27
PY 2015
VL 10
IS 5
AR e0127258
DI 10.1371/journal.pone.0127258
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0RO
UT WOS:000355185600077
PM 26016485
ER
PT J
AU Traverso, G
Langer, R
AF Traverso, Giovanni
Langer, Robert
TI Engineering precision
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID ADHERENCE; DELIVERY
C1 [Traverso, Giovanni] Massachusetts Gen Hosp, Med, Div Gastroenterol, Boston, MA 02114 USA.
[Traverso, Giovanni] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Langer, Robert] MIT, Cambridge, MA 02139 USA.
RP Traverso, G (reprint author), Massachusetts Gen Hosp, Med, Div Gastroenterol, Boston, MA 02114 USA.
EM ctraverso@partners.org
NR 8
TC 3
Z9 3
U1 2
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 27
PY 2015
VL 7
IS 289
AR 289ed6
DI 10.1126/scitranslmed.aab1943
PG 2
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA CJ0PS
UT WOS:000355179800001
PM 26019214
ER
PT J
AU O'Neill, BT
Lauritzen, HPMM
Hirshman, MF
Smyth, G
Goodyear, LJ
Kahn, CR
AF O'Neill, Brian T.
Lauritzen, Hans P. M. M.
Hirshman, Michael F.
Smyth, Graham
Goodyear, Laurie J.
Kahn, C. Ronald
TI Differential Role of Insulin/IGF-1 Receptor Signaling in Muscle Growth
and Glucose Homeostasis
SO CELL REPORTS
LA English
DT Article
ID MOUSE SKELETAL-MUSCLE; LIVING MICE; GLUT4 TRANSLOCATION; T-TUBULES;
IN-VIVO; IGF-I; TBC1D1; METABOLISM; RESISTANCE; TRANSPORT
AB Insulin and insulin-like growth factor 1 (IGF-1) are major regulators of muscle protein and glucose homeostasis. To determine how these pathways interact, we generated mice with muscle-specific knockout of IGF-1 receptor (IGF1R) and insulin receptor (IR). These MIGIRKO mice showed >60% decrease in muscle mass. Despite a complete lack of insulin/IGF-1 signaling in muscle, MIGIRKO mice displayed normal glucose and insulin tolerance. Indeed, MIGIRKO mice showed fasting hypoglycemia and increased basal glucose uptake. This was secondary to decreased TBC1D1 resulting in increased Glut4 and Glut1 membrane localization. Interestingly, overexpression of a dominant-negative IGF1R in muscle induced glucose intolerance in MIGIRKO animals. Thus, loss of insulin/IGF-1 signaling impairs muscle growth, but not whole-body glucose tolerance due to increased membrane localization of glucose transporters. Nonetheless, presence of a dominant-negative receptor, even in the absence of functional IR/IGF1R, induces glucose intolerance, indicating that interactions between these receptors and other proteins in muscle can impair glucose homeostasis.
C1 [O'Neill, Brian T.; Lauritzen, Hans P. M. M.; Hirshman, Michael F.; Smyth, Graham; Goodyear, Laurie J.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA.
RP Kahn, CR (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA.
EM c.ronald.kahn@joslin.harvard.edu
FU NIH [R01 DK-031036, R01AR42238]; NIDDK of the NIH [K08DK100543]; Mayo
Clinic Metabolomics Resource Core grant from the NIDDK [U24DK100469];
Mayo Clinic CTSA grant from NCATS of the NIH [UL1 TR000135]
FX This work was supported by NIH grants R01 DK-031036 (to C.R.K.) and
R01AR42238 (to L.J.G.). B.T.O. was funded by a K08 training award from
the NIDDK of the NIH (K08DK100543), Mayo Clinic Metabolomics Resource
Core grant U24DK100469 from the NIDDK, which originates from the NIH
Director's Common Fund, and Mayo Clinic CTSA grant UL1 TR000135 from
NCATS of the NIH. The Joslin Diabetes Center DRC core facility was used
for part of this work (P30 DK36836).
NR 41
TC 7
Z9 8
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY 26
PY 2015
VL 11
IS 8
BP 1220
EP 1235
DI 10.1016/j.celrep.2015.04.037
PG 16
WC Cell Biology
SC Cell Biology
GA CJ0CO
UT WOS:000355140300008
PM 25981038
ER
PT J
AU Bhatt, AB
Foster, E
Kuehl, K
Alpert, J
Brabeck, S
Crumb, S
Davidson, WR
Earing, MG
Ghoshhajra, BB
Karamlou, T
Mital, S
Ting, J
Tseng, ZH
AF Bhatt, Ami B.
Foster, Elyse
Kuehl, Karen
Alpert, Joseph
Brabeck, Stephen
Crumb, Stephen
Davidson, William R., Jr.
Earing, Michael G.
Ghoshhajra, Brian B.
Karamlou, Tara
Mital, Seema
Ting, Jennifer
Tseng, Zian H.
CA Amer Heart Assoc Council
TI Congenital Heart Disease in the Older Adult A Scientific Statement From
the American Heart Association
SO CIRCULATION
LA English
DT Editorial Material
DE AHA Scientific Statements; congenital heart defect; cardiac surgical
procedures; cardiac imaging techniques; cardiac arrhythmia; heart
failure; cardiac valves
ID PULMONARY VALVE-REPLACEMENT; ATRIAL SEPTAL-DEFECT; RADIOFREQUENCY
CATHETER ABLATION; SYSTEMIC RIGHT VENTRICLE; SUDDEN CARDIAC DEATH;
INTRAATRIAL REENTRANT TACHYCARDIA; ACUTE KIDNEY INJURY; ARTERIAL SWITCH
OPERATION; ANOMALOUS AORTIC ORIGIN; CAUSE NOONAN-SYNDROME
C1 [Alpert, Joseph] Univ Arizona, Tucson, AZ 85721 USA.
[Bhatt, Ami B.; Ghoshhajra, Brian B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Brabeck, Stephen] Cardiopulm Associates, Macon, GA USA.
[Davidson, William R., Jr.] Penn State Univ, Coll Med, University Pk, PA 16802 USA.
[Earing, Michael G.] Med Coll Wisconsin, Milwaukee, WI USA.
[Foster, Elyse; Karamlou, Tara; Tseng, Zian H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kuehl, Karen] Childrens Natl Med Ctr, Washington, DC USA.
[Mital, Seema] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Ting, Jennifer] Penn State Hershey Heart & Vasc Inst, Hershey, PA USA.
RP Bhatt, AB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 424
TC 17
Z9 20
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAY 26
PY 2015
VL 131
IS 21
BP 1884
EP 1931
DI 10.1161/CIR.0000000000000204
PG 48
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CJ0PY
UT WOS:000355180400017
PM 25896865
ER
PT J
AU Case, MA
Volpp, KG
Patel, MS
AF Case, Meredith A.
Volpp, Kevin G.
Patel, Mitesh S.
TI Electronic Devices and Applications to Track Physical Activity Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Case, Meredith A.] Univ Penn, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Case, MA (reprint author), Univ Penn, 423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mpatel@upenn.edu
NR 3
TC 0
Z9 0
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 26
PY 2015
VL 313
IS 20
BP 2080
EP 2080
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA CJ0DC
UT WOS:000355142400029
PM 26010644
ER
PT J
AU Malik, R
Freilinger, T
Anttila, V
Vander Heiden, J
Traylor, M
de Vries, B
Holliday, EG
Terwindt, GM
Sturm, J
Bis, JC
Hopewell, JC
Ferrari, MD
Rannikmae, K
Wessman, M
Kallela, M
Kubisch, C
Fornage, M
Meschia, JF
Lehtimaki, T
Sudlow, C
Clarke, R
Chasman, DI
Mitchell, BD
Maguire, J
Kaprio, J
Farrall, M
Raitakari, OT
Kurth, T
Ikram, MA
Reiner, AP
Longstreth, WT
Rothwell, PM
Strachan, DP
Sharma, P
Seshadri, S
Quaye, L
Cherkas, L
Schurks, M
Rosand, J
Ligthart, L
Boncoraglio, GB
Smith, GD
van Duijn, CM
Stefansson, K
Worrall, BB
Nyholt, DR
Markus, HS
van den Maagdenberg, AMJM
Cotsapas, C
Zwart, JA
Palotie, A
Dichgans, M
AF Malik, Rainer
Freilinger, Tobias
Anttila, Verneri
Vander Heiden, Jason
Traylor, Matthew
de Vries, Boukje
Holliday, Elizabeth G.
Terwindt, Gisela M.
Sturm, Jonathan
Bis, Joshua C.
Hopewell, Jemma C.
Ferrari, Michel D.
Rannikmae, Kristiina
Wessman, Maija
Kallela, Mikko
Kubisch, Christian
Fornage, Myriam
Meschia, James F.
Lehtimaki, Terho
Sudlow, Cathie
Clarke, Robert
Chasman, Daniel I.
Mitchell, Braxton D.
Maguire, Jane
Kaprio, Jaakko
Farrall, Martin
Raitakari, Olli T.
Kurth, Tobias
Ikram, M. Arfan
Reiner, Alex P.
Longstreth, W. T., Jr.
Rothwell, Peter M.
Strachan, David P.
Sharma, Pankaj
Seshadri, Sudha
Quaye, Lydia
Cherkas, Lynn
Schuerks, Markus
Rosand, Jonathan
Ligthart, Lannie
Boncoraglio, Giorgio B.
Smith, George Davey
van Duijn, Cornelia M.
Stefansson, Kari
Worrall, Bradford B.
Nyholt, Dale R.
Markus, Hugh S.
van den Maagdenberg, Arn M. J. M.
Cotsapas, Chris
Zwart, John A.
Palotie, Aarno
Dichgans, Martin
CA Int Headache Genetics Consortium
METASTROKE Collaboration Int Strok
TI Shared genetic basis for migraine and ischemic stroke: A genome-wide
analysis of common variants
SO NEUROLOGY
LA English
DT Article
ID SUSCEPTIBILITY LOCI; CANDIDATE GENE; RISK-FACTORS; METAANALYSIS;
ASSOCIATION; AURA; DISEASE; COMPLEX; SUBTYPE
AB Objective:To quantify genetic overlap between migraine and ischemic stroke (IS) with respect to common genetic variation.Methods:We applied 4 different approaches to large-scale meta-analyses of genome-wide data on migraine (23,285 cases and 95,425 controls) and IS (12,389 cases and 62,004 controls). First, we queried known genome-wide significant loci for both disorders, looking for potential overlap of signals. We then analyzed the overall shared genetic load using polygenic scores and estimated the genetic correlation between disease subtypes using data derived from these models. We further interrogated genomic regions of shared risk using analysis of covariance patterns between the 2 phenotypes using cross-phenotype spatial mapping.Results:We found substantial genetic overlap between migraine and IS using all 4 approaches. Migraine without aura (MO) showed much stronger overlap with IS and its subtypes than migraine with aura (MA). The strongest overlap existed between MO and large artery stroke (LAS; p = 6.4 x 10(-28) for the LAS polygenic score in MO) and between MO and cardioembolic stroke (CE; p = 2.7 x 10(-20) for the CE score in MO).Conclusions:Our findings indicate shared genetic susceptibility to migraine and IS, with a particularly strong overlap between MO and both LAS and CE pointing towards shared mechanisms. Our observations on MA are consistent with a limited role of common genetic variants in this subtype.
C1 [Malik, Rainer; Freilinger, Tobias; Dichgans, Martin] Univ Munich, Inst Stroke & Dementia Res, Munich, Germany.
[Freilinger, Tobias] Univ Klinikum Tubingen, Abt Neurol Schwerpunkt Epileptol, Tubingen, Germany.
[Freilinger, Tobias] Univ Klinikum Tubingen, Abt Neurol Schwerpunkt Epileptol, Tubingen, Germany.
[Zwart, John A.] Oslo Univ Hosp, Dept Neurol, Oslo, Norway.
[Zwart, John A.] Oslo Univ Hosp, FORMI, Oslo, Norway.
Univ Oslo, N-0316 Oslo, Norway.
[Anttila, Verneri; Palotie, Aarno] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Rosand, Jonathan; Palotie, Aarno] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Anttila, Verneri; Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA.
[Anttila, Verneri; Palotie, Aarno] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Anttila, Verneri; Chasman, Daniel I.; Kurth, Tobias; Rosand, Jonathan] Harvard Univ, Sch Med, Boston, MA USA.
[Vander Heiden, Jason] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA.
[Traylor, Matthew; Markus, Hugh S.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 1TN, England.
[de Vries, Boukje; van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RA Leiden, Netherlands.
[Terwindt, Gisela M.; Ferrari, Michel D.; van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands.
[Holliday, Elizabeth G.; Maguire, Jane] Univ Newcastle, Newcastle, NSW 2300, Australia.
[Holliday, Elizabeth G.; Maguire, Jane] Hunter Med Res Inst, Newcastle, NSW, Australia.
[Sturm, Jonathan] Univ Newcastle, Fac Hlth, Sch Hlth Sci, Newcastle, NSW 2300, Australia.
[Maguire, Jane] Univ Newcastle, Fac Hlth & Med, Sch Nursing & Midwifery, Newcastle, NSW 2300, Australia.
[Maguire, Jane] Univ Newcastle, Ctr Translat Neurosci & Mental Hlth, Newcastle, NSW 2300, Australia.
[Sturm, Jonathan] Cent Coast Hlth Dist, Dept Neurosci, Gosford, Australia.
[Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Hopewell, Jemma C.; Clarke, Robert] Univ Oxford, Clin Trial Serv Unit, Oxford OX1 2JD, England.
[Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
[Farrall, Martin] Univ Oxford, Dept Cardiovasc Med, Oxford OX1 2JD, England.
[Rothwell, Peter M.] Univ Oxford, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX1 2JD, England.
[Rannikmae, Kristiina; Sudlow, Cathie] Univ Edinburgh, Div Clin Neurosci, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
[Wessman, Maija] Folkhalsan Res Ctr, Inst Genet, Helsinki, Finland.
[Wessman, Maija; Kaprio, Jaakko; Palotie, Aarno] Univ Helsinki, FIMM, FIN-00014 Helsinki, Finland.
[Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland.
[Kallela, Mikko] Univ Helsinki, Dept Neurol, Cent Hosp, FIN-00014 Helsinki, Finland.
[Kubisch, Christian] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany.
[Kubisch, Christian] Univ Ulm, Inst Human Genet, D-89069 Ulm, Germany.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
[Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Sch Med, FIN-33101 Tampere, Finland.
Univ Tampere, Fimlab Labs, Sch Med, FIN-33101 Tampere, Finland.
[Chasman, Daniel I.; Kurth, Tobias; Schuerks, Markus] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Mitchell, Braxton D.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth & Alcohol Res, Helsinki, Finland.
[Raitakari, Olli T.] Univ Turku, Dept Clin Physiol & Nucl Med, SF-20500 Turku, Finland.
[Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, SF-20500 Turku, Finland.
Turku Univ Hosp, Turku, Finland.
[Kurth, Tobias] Res Ctr Epidemiol & Biostat, INSERM, U897, Team Neuroepidemiol, Bordeaux, France.
[Kurth, Tobias] Univ Bordeaux, Coll Hlth Sci, Bordeaux, France.
[Ikram, M. Arfan; van Duijn, Cornelia M.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
[Ikram, M. Arfan] Erasmus MC Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands.
[Ikram, M. Arfan] Erasmus MC Univ Med Ctr, Dept Radiol, Rotterdam, Netherlands.
[Ikram, M. Arfan; van Duijn, Cornelia M.] Netherlands Consortium Hlth Ageing, Leiden, Netherlands.
[Reiner, Alex P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London WC1E 7HU, England.
[Sharma, Pankaj] Univ London Imperial Coll Sci Technol & Med, ICCRU, London SW7 2AZ, England.
[Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Quaye, Lydia; Cherkas, Lynn] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
[Schuerks, Markus] Univ Hosp Essen, Dept Neurol, Essen, Germany.
[Ligthart, Lannie] Vrije Univ Amsterdam, Ctr Human Genet Res, Amsterdam, Netherlands.
[Ligthart, Lannie] Vrije Univ Amsterdam, Div Neurocrit Care & Emergency Neurol, Dept Biol Psychol, Amsterdam, Netherlands.
[Boncoraglio, Giorgio B.] Ist Neurol Carlo Besta, Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Dept Cerebrovasc Dis, Milan, Italy.
[Smith, George Davey] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol BS8 1TH, Avon, England.
[Stefansson, Kari] deCODE Genet, Reykjavik, Iceland.
[Worrall, Bradford B.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
[Worrall, Bradford B.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA.
[Nyholt, Dale R.] QIMR Berghofer, Neurogenet Lab, Brisbane, Qld, Australia.
[Cotsapas, Chris] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Palotie, Aarno] Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England.
[Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany.
RP Dichgans, M (reprint author), Univ Munich, Inst Stroke & Dementia Res, Munich, Germany.
EM martin.dichgans@med.uni-muenchen.de
RI Kubisch, Christian/F-1893-2011; Boncoraglio, Giorgio/B-8647-2011; Kurth,
Tobias/A-9243-2012;
OI Traylor, Matthew/0000-0001-6624-8621; Kubisch,
Christian/0000-0003-4220-0978; Gillman, Matthew/0000-0002-2340-6930;
Plomin, Robert/0000-0002-0756-3629; Cotsapas, Chris/0000-0002-7772-5910;
Winsvold, Bendik Slagsvold/0000-0003-4171-8919; Davey Smith,
George/0000-0002-1407-8314; Kurth, Tobias/0000-0001-7169-2620; Anttila,
Verneri/0000-0002-0073-4675; Gormley, Padhraig/0000-0002-8908-6968;
Seshadri, Sudha/0000-0001-6135-2622; Stefansson,
Hreinn/0000-0002-9331-6666
FU University of Newcastle; Australian National and Medical Health Research
Council (NHMRC) [569257]; Australian National Heart Foundation (NHF) [G
04S 1623]; Gladys M Brawn Fellowship scheme; Vincent Fairfax Family
Foundation in Australia; National Heart, Lung, and Blood Institute
[HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367,
R01HL086694, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019,
N01-HC-55020, N01-HC-55021]; National Human Genome Research Institute
[U01HG004402]; NIH [HHSN268200625226C, UL1RR025005, AA07535, AA07728,
AA13320, AA13321, AA14041, AA11998, AA17688, DA012854, DA019951]; NIH
Roadmap for Medical Research; Dept. of Health (UK); Henry Smith Charity;
UK-India Education Research Institutive (UKIERI) from the British
Council; National Institute of Neurological Disorders and Stroke;
National Institute on Aging [AG-023629, AG-15928, AG-0098, AG-027058];
National Center for Research Resources at the National Center for
Advancing Translational Sciences, Clinical and Translational Science
Institute [UL1RR033176, UL1TR000124, DK063491]; European Community's
Seventh Framework Programme (FP7); ENGAGE project
[HEALTH-F4-2007-201413]; National Heart, Lung and Blood Institute's
Framingham Heart Study [N01-HC-25195, N02-HL-6-4278]; National Institute
of Neurological Disorders and Stroke [NS17950, U01 NS069208, NS-061836];
National Heart, Lung, and Blood Association [HL93029]; National
Institute of Aging [AG033193]; NIH Genes, Environment and Health
Initiative (GEI) as part of the GENEVA consortium under the NIH Genes,
Environment and Health Initiative [U01 HG004436]; Mid-Atlantic Nutrition
and Obesity Research Center [P30 DK072488]; Office of Research and
Development, Medical Research Service; Baltimore Geriatrics Research,
Education, and Clinical Center of the Department of Veterans Affairs;
federal contract from the NIH [HHSN268200782096C]; Division of Adult and
Community Health, Centers for Disease Control; NIH Office of Research on
Women's Health [R01 NS45012, U01 NS069208-01]; UK Medical Research
Council; British Heart Foundation; Merck Co.; Roche Vitamins Ltd.;
British Heart Foundation Centre of Research Excellence, Oxford
[RE/08/004]; Intramural Research Program of the National Institute on
Aging, NIH [Z01 AG-000954-06, Z01 AG-000015-50]; NIH-National Institute
of Neurological Disorders and Stroke [R01 NS-42733, R01 NS-39987];
American Heart Association/Bugher Foundation Centers for Stroke
Prevention Research [0775010N]; National Heart, Lung, and Blood
Institute's STAMPEED genomics research program [R01 HL087676]; National
Center for Research Resources [U54 RR020278]; Italian Ministry of Health
[RC 2007/LR6, RC 2008/LR6, RC 2009/LR8, RC 2010/LR8]; Netherlands
Organization of Scientific Research [175.010.2005.011]; Netherlands
Genomics Initiative (NGI)/Netherlands Organization for Scientific
Research (NWO); Netherlands Consortium for Healthy Ageing [050-060-810];
Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands
Organization for Health Research and Development; Research Institute for
Diseases in the Elderly; Ministry of Education, Culture, and Science;
Ministry for Health, Welfare, and Sports; European Commission;
Municipality of Rotterdam; Netherlands Heart Foundation (Nederlandse
Hartstichting) [2009B102]; Wellcome Trust, as part of the Wellcome Trust
Case Control Consortium 2 project [085475/B/08/Z, 085475/Z/08/Z,
WT084724MA]; Medical Research Council [G0000934]; Stroke Association;
Dunhill Medical Trust; National Institute of Health Research (NIHR); IHR
Biomedical Research Centre, Oxford; Wellcome Trust (clinician scientist
award); Binks Trust; Scottish Funding Council; Chief Scientist Office;
BHF Center of Research Excellence in Oxford; Wellcome Trust core award
[090532/Z/09/Z]; NIHR Senior Investigator award; Wellcome Trust
[WT088806, 068545/Z/02, 076113/B/04/Z, WT089062, 098051]; 23andMe;
Sanger Centre; Centre National de Genotypage; Australian National Health
and Medical Research Council [241944, 339462, 389927, 389875, 389891,
389892, 389938, 442915, 442981, 496739, 552485, 552498]; Australian
Research Council [A7960034, A79906588, A79801419, DP0770096, DP0212016,
DP0343921]; EU [FP5-QLG2-CT-2002-01254, LSM-CT-2004-504837]; ENGAGE
[HEALTH-F4-2007-201413, FP7-HEALTH-201413, FT0991022, 613674,
HEALTHF4-2007-201413]; National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK); National Institute of Allergy and Infectious
Diseases (NIAID); National Human Genome Research Institute (NHGRI);
National Institute of Child Health and Human Development (NICHD);
Juvenile Diabetes Research Foundation International (JDRF); JDRF;
National Institute for Health Research Cambridge Biomedical Research
Centre; Wellcome Trust Strategic Award [079895]; European Commission
Framework Programme 6 [018996]; French Ministry of Research; Netherlands
Organization for Scientific Research (NWO); Erasmus MC; Netherlands
Genomics Initiative (NGI); European Special Populations Research Network
(EUROSPAN) through the European Commission FP6 STRP grant [018947,
LSHG-CT-2006-01947]; Netherlands Organisation for Scientific Research
(NWO); Centre for Medical Systems Biology [CMSB1, CMSB2]; Academy of
Finland Center of Excellence in Complex Disease Genetics [213506,
129680]; Academy of Finland [205585, 141054, 134309, 126925, 121584,
124282, 129378, 117787, 41071, 00213, 200923, 251704, 139795];
ENGAGE-European Network for Genetic and Genomic Epidemiology,
FP7-HEALTH-F4-2007 [201413]; U.S.- P.H.S. NIH [AA-12502, AA-00145,
AA-09203, AA15416, K02AA018755]; South-Eastern Norway Regional Health
Authority [2010075, 2011083]; Unger-Vetlesen Medical Fund; Ullevaal
fund; Academy of Finland (Center of Excellence in Complex Disease
Genetics and SALVE) [104781, 120315, 129269, 1114194, 139900/24300796];
University Hospital Oulu, Biocenter; University of Oulu, Finland
[75617]; European Commission (EUROBLCS, Framework 5 award)
[QLG1-CT-2000-01643]; NHLBI through the STAMPEED program
[5R01HL087679-02, 1RL1MH083268-01]; NIH/NIMH [5R01MH63706: 02]; Medical
Research Council, UK [G0500539, G0600705, G0600331, PrevMet-Syn/SALVE,
PS0476]; Wellcome Trust, UK [GR069224, WT089549]; Biocentrum Helsinki;
Netherlands Organization for Scientific Research (NWO: MagW/ZonMW
grants) [904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717,
Addiction-31160008 Middelgroot-911-09-032, Spinozapremie 56-464-14192];
Center for Medical Systems Biology (CSMB, NWO Genomics),
NBIC/BioAssist/RK [2008.024]; Biobanking and Biomolecular Resources
Research Infrastructure (BBMRI-NL) [184.021.007]; VU University's
Institute for Health and Care Research (EMGO+); Neuroscience Campus
Amsterdam (NCA); European Science Foundation (ESF) [EU/QLRT-2001-01254];
European Community's Seventh Framework Program (FP7); European Science
Council (ERC) [230374]; NIH (NIH) [R01D0042157-01A]; Genetic Association
Information Network (GAIN) of the Foundation for the US NIH (NIMH)
[MH081802]; Geestkracht program of the Netherlands Organisation for
Health Research and Development (Zon-Mw) [10-000-1002]; VU University
Medical Center; GGZ inGeest; Arkin; Leiden University Medical Center;
GGZ Rivierduinen; University Medical Center Groningen; Lentis; GGZ
Friesland; GGZ Drenthe; Scientific Institute for Quality of Healthcare
[IQ healthcare]; Netherlands Institute for Health Services Research
[NIVEL]; Netherlands Institute of Mental Health and Addiction [Trimbos
Institute]); Research Institute for Diseases in the Elderly [014-93-015,
RIDE2]; Netherlands Genomics Initiative (NGI)/Netherlands Organisation
for Scientific Research (NWO) [050-060-810]; Erasmus Medical Center;
Erasmus University, Rotterdam; Netherlands Organization for the Health
Research and Development (ZonMw); Research Institute for Diseases in the
Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for
Health, Welfare and Sports; European Commission (DG XII); Netherlands
Organization of Scientific Research (NWO) [918-46-615, 904-61-096,
904-61-133, 948-00-010]; Dept. of Health via the National Institute for
Health Research (NIHR) comprehensive Biomedical Research Centre award;
King's College London; Chronic Disease Research Foundation; National
Cancer Institute [CA-47988]; Social Insurance Institution of Finland,
Kuopio, Tampere; Turku University Hospital Medical Funds [9M048, 9N035];
Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of
Cardiovascular Research; Finnish Cultural Foundation; Tampere
Tuberculosis Foundation; Emil Aaltonen Foundation; German Federal
Ministry of Education and Research (BMBF) [01GS08120, 01GS1103,
01GS08121]; German Federal Ministry of Education and Research; State of
Bavaria; Munich Center of Health Sciences [MC Health] as part of
LMUinnovativ); Helmholtz Center Munich; German Research Center for
Environmental Health; Center for Molecular Medicine Cologne; Heinz
Nixdorf Foundation for the Heinz Nixdorf Recall study; Deutsche
Forschungsgemeinschaft (DFG); Academy of Finland Center of Excellence
for Complex Disease Genetics; EuroHead project [LSM-CT-2004-504837];
Finnish Neurology Foundation; Biomedicum Helsinki Foundation; Orion
Farmos Research Foundation; Academy of Finland, Center of Excellence in
Complex Disease Genetics [213506, 129680]; ENGAGE Consortium
[HEALTH-F4-2007-201413]; EU/SYNSYS-Synaptic Systems [242167]; Sigrid
Juselius Foundation, Finland; Folkhalsan Research Foundation, Finland;
Medicinska Understodsforeningen Liv Halsa; Helsinki University Central
Hospital; Netherlands Organization for Health Research and Development
(ZonMw) [90700217]; VIDI (ZonMw) [91711319]; Netherlands Organisation
for Scientific Research (NWO) VICI [918.56.602]; Spinoza grants;
EUROHEADPAIN [602633]; Center for Medical Systems Biology (CMSB);
Netherlands Genomics Initiative/Netherlands Organisation for Scientific
Research (NGI/NWO) [050-060-409]; Vascular Dementia Research Foundation;
[HL-093029]; [HHSN268201200036C]; [U01 DK062418]; [N01-HC-35129];
[N01 HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133];
[N01-HC-85239]; [HL080295]; [HL087652]; [HL105756]; [R01 HL085251];
[R01 HL073410]; [HL-043851]; [HL-080467]; [HL-099355];
[N01-HC-85082]; [N01-HC-85083]; [N01-HC-85084]; [N01-HC-85085];
[N01-HC-85086]; [R01-HL087641]; [U01 HL096917]; [R01-HL093029];
[N01-HC-85079]; [N01-HC-85080]; [N01-HC-85081]; [N01-HC-55022]
FX The Australian Stroke Genetics Collaboration (ASGC) Australian
population control data were derived from the Hunter Community Study.
The authors thank the University of Newcastle for funding and the men
and women of the Hunter region who participated in this study. This
research was funded by grants from the Australian National and Medical
Health Research Council (NHMRC Project Grant ID: 569257), the Australian
National Heart Foundation (NHF Project Grant ID: G 04S 1623), the
University of Newcastle, the Gladys M Brawn Fellowship scheme, and the
Vincent Fairfax Family Foundation in Australia. The Atherosclerosis Risk
in Communities Study (ARIC) is carried out as a collaborative study
supported by National Heart, Lung, and Blood Institute contracts
(HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367, and
R01HL086694; National Human Genome Research Institute contract
U01HG004402; NIH contract HHSN268200625226C and National Heart, Lung,
and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018,
N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022; and grants
R01-HL087641, U01 HL096917 (Mosley), and R01-HL093029 (Fornage).
Infrastructure was partly supported by Grant UL1RR025005, a component of
the NIH and NIH Roadmap for Medical Research. ARIC analyses performed as
part of the METASTROKE project were supported by grant HL-093029 to M.
Fornage. Bio-Repository of DNA in Stroke (BRAINS) is partly funded by a
Senior Fellowship from the Dept. of Health (UK) to Dr. Pankaj Sharma,
the Henry Smith Charity and the UK-India Education Research Institutive
(UKIERI) from the British Council. Cardiovascular Health Study (CHS)
research was supported by National Heart, Lung, and Blood Institute
contracts N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082,
N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086; N01-HC-35129,
N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and
N01-HC-85239, and by HHSN268201200036C and National Heart, Lung, and
Blood Institute grants HL080295, HL087652, and HL105756, with additional
contribution from the National Institute of Neurological Disorders and
Stroke. Additional support was provided through AG-023629, AG-15928,
AG-0098, and AG-027058 from the National Institute on Aging. See also
http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping at
Cedars-Sinai Medical Center was supported in part by the National Center
for Research Resources, grant UL1RR033176, and is now at the National
Center for Advancing Translational Sciences, Clinical and Translational
Science Institute grant UL1TR000124, in addition to the National
Institute of Diabetes and Digestive and Kidney Disease grant DK063491 to
the Southern California Diabetes Endocrinology Research Center. deCODE
Genetics Work performed at deCODE was funded in part through a grant
from the European Community's Seventh Framework Programme
(FP7/2007-2013), the ENGAGE project grant agreement
HEALTH-F4-2007-201413. Framingham Heart Study (FHS): this work was
supported by the dedication of the Framingham Heart Study participants,
the National Heart, Lung and Blood Institute's Framingham Heart Study
(Contract Nos. N01-HC-25195 and N02-HL-6-4278), and by grants from the
National Institute of Neurological Disorders and Stroke (NS17950), the
National Heart, Lung, and Blood Association (HL93029), and the National
Institute of Aging (AG033193).; The Genetics of Early Onset Stroke
(GEOS) Study, Baltimore, was supported by the NIH Genes, Environment and
Health Initiative (GEI) Grant U01 HG004436, as part of the GENEVA
consortium under the NIH Genes, Environment and Health Initiative, with
additional support provided by the Mid-Atlantic Nutrition and Obesity
Research Center (P30 DK072488); and the Office of Research and
Development, Medical Research Service, and the Baltimore Geriatrics
Research, Education, and Clinical Center of the Department of Veterans
Affairs. Genotyping services were provided by The Johns Hopkins
University Center for Inherited Disease Research (CIDR), which is fully
funded through a federal contract from the NIH to The Johns Hopkins
University (contract HHSN268200782096C). Assistance with data cleaning
was provided by the GENEVA Coordinating Center (U01 HG 004446; PI Bruce
S. Weir). Study recruitment and assembly of datasets were supported by a
Cooperative Agreement with the Division of Adult and Community Health,
Centers for Disease Control, and by grants from the National Institute
of Neurological Disorders and Stroke and the NIH Office of Research on
Women's Health (R01 NS45012, U01 NS069208-01). Heart Protection Study
(HPS) (ISRCTN48489393) was supported by the UK Medical Research Council,
British Heart Foundation, Merck & Co. (manufacturers of simvastatin),
and Roche Vitamins Ltd. (manufacturers of vitamins). Genotyping was
supported by a grant to Oxford University and CNG from Merck & Co. Jemma
C. Hopewell acknowledges support from the British Heart Foundation
Centre of Research Excellence, Oxford (RE/08/004). The Heart and
Vascular Health Study (HVH) research reported in this article was funded
by National Heart, Lung, and Blood Institute grants R01 HL085251 and R01
HL073410. The Ischemic Stroke Genetics Study (ISGS)/Siblings With
Ischemic Stroke Study (SWISS): The ISGS/SWISS study was supported in
part by the Intramural Research Program of the National Institute on
Aging, NIH project Z01 AG-000954-06. ISGS/SWISS used samples and
clinical data from the NIH-National Institute of Neurological Disorders
and Stroke Human Genetics Resource Center DNA and Cell Line Repository
(http://ccr.coriell.org/ninds), human subjects protocol numbers 2003-081
and 2004-147. ISGS/SWISS used stroke-free participants from the
Baltimore Longitudinal Study of Aging (BLSA) as controls. The inclusion
of BLSA samples was supported in part by the Intramural Research Program
of the National Institute on Aging, NIH project Z01 AG-000015-50, human
subjects protocol number 2003-078. The ISGS study was funded by
NIH-National Institute of Neurological Disorders and Stroke Grant R01
NS-42733 (J.F. Meschia, PI). The SWISS study was funded by NIH-National
Institute of Neurological Disorders and Stroke Grant R01 NS-39987 (J.F.
Meschia, PI). This study utilized the high-performance computational
capabilities of the Biowulf Linux cluster at the NIH
(http://biowulf.nih.gov). The MGH Genes Affecting Stroke Risk and
Outcome Study (MGH-GASROS): GASROS was supported by The National
Institute of Neurological Disorders and Stroke (U01 NS069208), the
American Heart Association/Bugher Foundation Centers for Stroke
Prevention Research 0775010N, the NIH and National Heart, Lung, and
Blood Institute's STAMPEED genomics research program (R01 HL087676), and
a grant from the National Center for Research Resources. The Broad
Institute Center for Genotyping and Analysis is supported by grant U54
RR020278 from the National Center for Research resources.; Milano-Besta
Stroke Register Collection and genotyping of the Milan cases within
CEDIR were supported by Annual Research Funding of the Italian Ministry
of Health (grant numbers RC 2007/LR6, RC 2008/LR6; RC 2009/LR8; RC
2010/LR8). PROCARDIS control samples were supported by FP6
LSHM-CT-2007-037273. The Rotterdam Study was supported by the
Netherlands Organization of Scientific Research (175.010.2005.011), the
Netherlands Genomics Initiative (NGI)/Netherlands Organization for
Scientific Research (NWO), Netherlands Consortium for Healthy Ageing
(050-060-810), the Erasmus Medical Center and Erasmus University,
Rotterdam, the Netherlands Organization for Health Research and
Development, the Research Institute for Diseases in the Elderly, the
Ministry of Education, Culture, and Science, the Ministry for Health,
Welfare, and Sports, the European Commission, and the Municipality of
Rotterdam to the Rotterdam Study. Further funding was obtained from the
Netherlands Heart Foundation (Nederlandse Hartstichting) 2009B102. The
Wellcome Trust Case-Control Consortium 2 (WTCCC2): The principal funding
for the WTCCC2 stroke study was provided by the Wellcome Trust, as part
of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z
and 085475/Z/08/Z and WT084724MA). The Stroke Association provided
additional support for collection of some of the St George's, London
cases. The Oxford cases were collected as part of the Oxford Vascular
Study, which is funded by the Medical Research Council, Stroke
Association, Dunhill Medical Trust, National Institute of Health
Research (NIHR), and the NIHR Biomedical Research Centre, Oxford. The
Edinburgh Stroke Study was supported by the Wellcome Trust (clinician
scientist award to Dr. Sudlow) and the Binks Trust. Sample processing
occurred in the Genetics Core Laboratory of the Wellcome Trust Clinical
Research Facility, Western General Hospital, Edinburgh. Much of the
neuroimaging occurred in the Scottish Funding Council Brain Imaging
Research Centre (www.sbirc.ed.ac.uk), Division of Clinical
Neurosciences, University of Edinburgh, a core area of the Wellcome
Trust Clinical Research Facility and part of the SINAPSE (Scottish
Imaging Network-A Platform for Scientific Excellence) collaboration
(www.sinapse.ac.uk), funded by the Scottish Funding Council and the
Chief Scientist Office. Collection of the Munich cases and data analysis
was supported by the Vascular Dementia Research Foundation. Martin
Farrall acknowledges support from the BHF Center of Research Excellence
in Oxford and the Wellcome Trust core award (090532/Z/09/Z). Hugh Markus
is supported by an NIHR Senior Investigator award. ALSPAC: The authors
thank the families who took part in this study, the midwives for their
help in recruiting them, and the whole ALSPAC team, which includes
interviewers, computer and laboratory technicians, clerical workers,
research scientists, volunteers, managers, receptionists, and nurses.
The UK Medical Research Council and Wellcome Trust (092731), together
with the University of Bristol, provide core support for the ALSPAC
study. A grant from the Wellcome Trust funded collection of GWAS data in
ALSPAC mothers (WT088806) and a grant from 23andMe, together with
support from the Sanger Centre and Centre National de Genotypage funded
GWAS data in the offspring.; Australian Twin Migraine: The Australian
cohort was supported by NIH grants AA07535, AA07728, AA13320, AA13321,
AA14041, AA11998, AA17688, DA012854, and DA019951; by grants from the
Australian National Health and Medical Research Council (241944, 339462,
389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485,
and 552498); by grants from the Australian Research Council (A7960034,
A79906588, A79801419, DP0770096, DP0212016, and DP0343921); and by the
EU-funded GenomEUtwin (FP5-QLG2-CT-2002-01254) and ENGAGE
(FP7-HEALTH-201413) projects. D.R.N. (FT0991022, 613674). The authors
thank P. Visscher, D. Duffy, A. Henders, B. Usher, E. Souzeau, A. Kuot,
A. McMellon, P.A.F. Madden, M.J. Wright, M.J. Campbell, A. Caracella, L.
Bowdler, S. Smith, S. Gordon, B. Haddon, D. Smyth, H. Beeby, O. Zheng,
and B. Chapman for their input into project management, databases,
phenotype collection, and sample collection, processing, and genotyping.
British 58 Birth Cohort: The authors acknowledge use of phenotype and
genotype data from the British 1958 Birth Cohort DNA collection, funded
by the Medical Research Council grant G0000934 and the Wellcome Trust
grant 068545/Z/02 (http://www.b58cgene.sgul.ac.uk/). Genotyping for the
B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z.
The B58C-T1DGC genotyping utilized resources provided by the Type 1
Diabetes Genetics Consortium, a collaborative clinical study sponsored
by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institute of Allergy and Infectious Diseases (NIAID),
National Human Genome Research Institute (NHGRI), National Institute of
Child Health and Human Development (NICHD), and Juvenile Diabetes
Research Foundation International (JDRF) and supported by U01 DK062418.
B58C-T1DGC. GWAS data were deposited by the Diabetes and Inflammation
Laboratory, Cambridge Institute for Medical Research (CIMR), University
of Cambridge, which is funded by JDRF, the Wellcome Trust and the
National Institute for Health Research Cambridge Biomedical Research
Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award
(079895). The B58C-GABRIEL genotyping was supported by a contract from
the European Commission Framework Programme 6 (018996) and grants from
the French Ministry of Research. Erasmus Rucphen Family: The Erasmus
Rucphen Family was supported by grants from The Netherlands Organization
for Scientific Research (NWO), Erasmus MC, and the Netherlands Genomics
Initiative (NGI)-sponsored Center of Medical Systems Biology (CMSB). The
genotyping for the ERF study was supported by European Special
Populations Research Network (EUROSPAN) through the European Commission
FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further
supported by grants from the Netherlands Organisation for Scientific
Research (NWO), Erasmus MC, the Centre for Medical Systems Biology
(CMSB1 and CMSB2), and the Netherlands Genomics Initiative (NGI). The
authors thank all the patients and their relatives, general
practitioners, and neurologists for their contributions and P. Veraart
for her help in genealogy, Jeannette Vergeer for the supervision of the
laboratory work, and P. Snijders for his help in data collection.
FinnTwin: Academy of Finland Center of Excellence in Complex Disease
Genetics (grant numbers 213506, 129680), the Academy of Finland (grants
205585 and 141054 to J.K.), ENGAGE-European Network for Genetic and
Genomic Epidemiology, FP7-HEALTH-F4-2007, grant agreement number 201413,
and U.S.- P.H.S.; NIH grants AA-12502, AA-00145, AA-09203, AA15416, and
K02AA018755. HUNT: The Nord-Trondelag Health Study (The HUNT Study) is a
collaboration between HUNT Research Centre (Faculty of Medicine,
Norwegian University of Science and Technology, NTNU), Nord-Trondelag
County Council, Central Norway Health Authority, and the Norwegian
Institute of Public Institute of Public Health. The current study was
supported by the South-Eastern Norway Regional Health Authority (2010075
and 2011083 to B.S.W. and J.A.Z.), Unger-Vetlesen Medical Fund (to
B.S.W.), and the Ullevaal fund (to B.S.W.). Genotyping was performed by
Avazeh Tashakkori-Ghanbarian, Simon Potter, and Sarah Hunt (calling and
quality control) and Douglas Simpkin (production) at Wellcome Trust
Sanger Institute. Northern Finland Birth Cohort 1966 (NFBC1966):
NFBC1966 received financial support from the Academy of Finland (project
grants 104781, 120315, 129269, 1114194, 139900/24300796, Center of
Excellence in Complex Disease Genetics and SALVE), University Hospital
Oulu, Biocenter, University of Oulu, Finland (75617), the European
Commission (EUROBLCS, Framework 5 award QLG1-CT-2000-01643), NHLBI grant
5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH
(5R01MH63706: 02), ENGAGE project and grant agreement
HEALTH-F4-2007-201413, the Medical Research Council, UK (G0500539,
G0600705, G0600331, PrevMet-Syn/SALVE, PS0476), and the Wellcome Trust
(project grant GR069224, WT089549), UK. The DNA extractions, sample
quality controls, biobank upkeeping, and aliquotting was performed in
the National Public Health Institute, Biomedicum Helsinki, Finland, and
supported financially by the Academy of Finland and Biocentrum Helsinki.
The authors acknowledge the contribution of the late Academian of
Science Leena Peltonen. NTR/NESDA: Funding was obtained from the
Netherlands Organization for Scientific Research (NWO: MagW/ZonMW grants
904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717,
Addiction-31160008 Middelgroot-911-09-032, Spinozapremie 56-464-14192),
Center for Medical Systems Biology (CSMB, NWO Genomics),
NBIC/BioAssist/RK (2008.024), Biobanking and Biomolecular Resources
Research Infrastructure (BBMRI-NL, 184.021.007), the VU University's
Institute for Health and Care Research (EMGO+) and Neuroscience Campus
Amsterdam (NCA), the European Science Foundation (ESF,
EU/QLRT-2001-01254), the European Community's Seventh Framework Program
(FP7/2007-2013), ENGAGE (HEALTHF4-2007-201413), the European Science
Council (ERC Advanced, 230374), and the NIH (NIH, R01D0042157-01A). Part
of the genotyping and analyses were funded by the Genetic Association
Information Network (GAIN) of the Foundation for the US NIH (NIMH,
MH081802). The infrastructure for the NESDA study (www.nesda.nl) is
funded through the Geestkracht program of the Netherlands Organisation
for Health Research and Development (Zon-Mw, grant number 10-000-1002)
and is supported by participating universities and mental health care
organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden
University Medical Center, GGZ Rivierduinen, University Medical Center
Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for
Quality of Healthcare [IQ healthcare], Netherlands Institute for Health
Services Research [NIVEL], and Netherlands Institute of Mental Health
and Addiction [Trimbos Institute]). Rotterdam studies: The generation
and management of GWAS genotype data for the Rotterdam Study is
supported by the Netherlands Organisation of Scientific Research NWO
Investments (175.010.2005.; 011, 911-03-012). This study is funded by
the Research Institute for Diseases in the Elderly (014-93-015; RIDE2),
the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for
Scientific Research (NWO) project 050-060-810. The Rotterdam Study is
funded by Erasmus Medical Center and Erasmus University, Rotterdam,
Netherlands Organization for the Health Research and Development
(ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the
Ministry of Education, Culture and Science, the Ministry for Health,
Welfare and Sports, the European Commission (DG XII), and the
Municipality of Rotterdam. The Rotterdam Scan Study is supported by the
Netherlands Organization of Scientific Research (NWO) project
918-46-615, 904-61-096, 904-61-133, and 948-00-010. TwinsUK: The study
was funded by the Wellcome Trust, European Community's Seventh Framework
Programme (FP7/2007-2013), ENGAGE project grant agreement
(HEALTH-F4-2007-201413). The study also receives support from the Dept.
of Health via the National Institute for Health Research (NIHR)
comprehensive Biomedical Research Centre award to Guy's & St. Thomas'
NHS Foundation Trust in partnership with King's College London.
Genotyping was performed by The Wellcome Trust Sanger Institute, support
of the National Eye Institute via an NIH/CIDR genotyping project. This
project was partly funded by the Chronic Disease Research Foundation
with money raised by the walking twins, Hazel Green and Christine
Dafter. WGHS: Genetic analysis of migraine in the WGHS is supported by a
grant from the National Institute of Neurological Disorders and Stroke
(NS-061836). The Women's Health Study and the Women's Genome Health
Study are supported by grants from the National Heart, Lung, and Blood
Institute (HL-043851, HL-080467, and HL-099355) and the National Cancer
Institute (CA-47988). Genome-wide genotyping and collaborative
scientific support was provided by Amgen. Young Finns: The Young Finns
Study has been financially supported by the Academy of Finland: grants
134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi),
and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio,
Tampere, and Turku University Hospital Medical Funds (grant 9M048 and
9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation,
Finnish Foundation of Cardiovascular Research and Finnish Cultural
Foundation, Tampere Tuberculosis Foundation, and Emil Aaltonen
Foundation (T.L). Technical assistance in the statistical analyses by
Ville Aalto and Irina Lisinen is acknowledged. Cologne/Kiel/Ulm
clinic-based studies (part of German MA and MO studies): This research
was funded by the German Federal Ministry of Education and Research
(BMBF) within the framework of the National Genome Research Network
(NGFN-Plus; grants 01GS08120 and 01GS1103 to C.K.; the German Federal
Ministry of Education and Research and by the State of Bavaria and
supported within the Munich Center of Health Sciences [MC Health] as
part of LMUinnovativ) for the KORA research platform, which was
initiated by the Helmholtz Center Munich, German Research Center for
Environmental Health, the Center for Molecular Medicine Cologne (to
C.K.), and the Heinz Nixdorf Foundation for the Heinz Nixdorf Recall
study, and the Deutsche Forschungsgemeinschaft (DFG; to C.K.). Finnish
clinic-based study: This work was supported by the Wellcome Trust (grant
WT089062) and, among others, by the Academy of Finland (200923 to A.P.,
00213 to M.W.; ); the Academy of Finland Center of Excellence for
Complex Disease Genetics; the EuroHead project (LSM-CT-2004-504837); the
Finnish Cultural Foundation (to V.A.); the Finnish Neurology Foundation,
Biomedicum Helsinki Foundation (to V.A.); the Orion Farmos Research
Foundation (to V.A.); the Wellcome Trust (grant number 098051 to A.P.);
the Academy of Finland (grant number 251704 to A.P., and 139795 to
M.W.); the Academy of Finland, Center of Excellence in Complex Disease
Genetics, (grant numbers 213506 and 129680 to A.P. and J.K.); the
European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE
Consortium (grant agreement HEALTH-F4-2007-201413); EU/SYNSYS-Synaptic
Systems (grant number 242167 to A.P.); the Sigrid Juselius Foundation,
Finland (to A.P.); the Folkhalsan Research Foundation, Finland (to
M.W.); Medicinska Understodsforeningen Liv & Halsa (to M.W.), and the
Helsinki University Central Hospital (to M.K., V.A.). LUMINA
clinic-based studies: Supported by the Netherlands Organization for
Health Research and Development (ZonMw) no. 90700217 and VIDI (ZonMw)
no. 91711319 (to G. M.T.); the Netherlands Organisation for Scientific
Research (NWO) VICI (918.56.602) and Spinoza (2009) grants (to M.D.F.);
the EU-funded EuroHead project (LSM-CT-2004-504837) and EUROHEADPAIN
(no. 602633); and the Center for Medical Systems Biology (CMSB)
established in the Netherlands Genomics Initiative/Netherlands
Organisation for Scientific Research (NGI/NWO), project 050-060-409 (to
M.D.F. and A. M. J.M.v.d.M.). Munich clinic-based studies (part of
German MA and MO studies): Supported by the German Federal Ministry of
Education and Research (BMBF) (grant 01GS08121 to M.D. along with
support in the context of the German National Genome Research Network,
NGFN-2 and NGFN-plus, for the Heinz Nixdorf Recall Study) and an
unrestricted grant of the Vascular Dementia Research Foundation (to
M.D.).
NR 38
TC 21
Z9 21
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 26
PY 2015
VL 84
IS 21
BP 2132
EP 2145
DI 10.1212/WNL.0000000000001606
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA CJ2LT
UT WOS:000355317000012
PM 25934857
ER
PT J
AU Filley, CM
Brown, MS
Onderko, K
Ray, M
Bennett, RE
Berry-Kravis, E
Grigsby, J
AF Filley, Christopher M.
Brown, Mark S.
Onderko, Karen
Ray, Megan
Bennett, Rachael E.
Berry-Kravis, Elizabeth
Grigsby, Jim
TI White matter disease and cognitive impairment in FMR1 premutation
carriers
SO NEUROLOGY
LA English
DT Article
ID TREMOR/ATAXIA SYNDROME FXTAS; VOXEL-BASED ANALYSIS; PHENOTYPE; DEMENTIA;
DYSFUNCTION; INSIGHTS; MALES
AB Objective:This cross-sectional, observational study examined the role of white matter involvement in the cognitive impairment of individuals with the fragile X mental retardation 1 (FMR1) premutation.Methods:Eight asymptomatic premutation carriers, 5 participants with fragile X tremor/ataxia syndrome (FXTAS), and 7 noncarrier controls were studied. The mean age of the asymptomatic premutation carriers, participants with FXTAS, and noncarrier controls was 60, 71, and 67 years, respectively. Magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) were used to examine the middle cerebellar peduncles (MCP) and the genu and splenium of the corpus callosum in relation to executive function and processing speed. MRS measures were N-acetyl aspartate/creatine (NAA/Cr) and choline/creatine, and fractional anisotropy (FA) was used for DTI. Executive function was assessed with the Behavioral Dyscontrol Scale and the Controlled Oral Word Association Test (COWAT), and processing speed with the Symbol Digit Modalities Test.Results:Among all 13 FMR1 premutation carriers, significant correlations were found between N-acetyl aspartate/creatine and choline/creatine in the MCP and COWAT scores, and between FA in the genu and performance on the Behavioral Dyscontrol Scale, COWAT, and Symbol Digit Modalities Test; a correlation was also found between FA in the splenium and COWAT performance. In all regions studied, participants with FXTAS had the lowest mean FA.Conclusion:Microstructural white matter disease as determined by MRS and DTI correlated with executive dysfunction and slowed processing speed in these FMR1 premutation carriers. Neuroimaging abnormalities in the genu and MCP suggest that disruption of white matter within frontocerebellar networks has an important role in the cognitive impairment associated with the FMR1 premutation.
C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA.
[Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA.
[Brown, Mark S.] Univ Colorado, Sch Med, Dept Radiol, Boulder, CO 80309 USA.
[Bennett, Rachael E.; Grigsby, Jim] Univ Colorado, Sch Med, Dept Med, Boulder, CO 80309 USA.
[Onderko, Karen; Ray, Megan; Grigsby, Jim] Univ Colorado Denver, Dept Psychol, Denver, CO USA.
[Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Pediat, Chicago, IL 60612 USA.
[Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
RP Filley, CM (reprint author), Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA.
EM christopher.filley@ucdenver.edu
FU Strategic Initiative Review Committee of the University of Colorado
School of Medicine
FX Funded by the Strategic Initiative Review Committee of the University of
Colorado School of Medicine.
NR 34
TC 9
Z9 9
U1 4
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 26
PY 2015
VL 84
IS 21
BP 2146
EP 2152
DI 10.1212/WNL.0000000000001612
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA CJ2LT
UT WOS:000355317000014
PM 25925982
ER
PT J
AU Growdon, ME
Schultz, AP
Dagley, AS
Amariglio, RE
Hedden, T
Rentz, DM
Johnson, KA
Sperling, RA
Albers, MW
Marshall, GA
AF Growdon, Matthew E.
Schultz, Aaron P.
Dagley, Alexander S.
Amariglio, Rebecca E.
Hedden, Trey
Rentz, Dorene M.
Johnson, Keith A.
Sperling, Reisa A.
Albers, Mark W.
Marshall, Gad A.
TI Odor identification and Alzheimer disease biomarkers in clinically
normal elderly
SO NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; MINI-MENTAL-STATE;
OLFACTORY DEFICITS; OLDER-ADULTS; DEMENTIA; DECLINE; AGE;
NEURODEGENERATION; DEPOSITION
AB Objectives:Our objective was to investigate cross-sectional associations between odor identification ability and imaging biomarkers of neurodegeneration and amyloid deposition in clinically normal (CN) elderly individuals, specifically testing the hypothesis that there may be an interaction between amyloid deposition and neurodegeneration in predicting odor identification dysfunction.Methods:Data were collected on 215 CN participants from the Harvard Aging Brain Study. Measurements included the 40-item University of Pennsylvania Smell Identification Test and neuropsychological testing, hippocampal volume (HV) and entorhinal cortex (EC) thickness from MRI, and amyloid burden using Pittsburgh compound B (PiB) PET. A linear regression model with backward elimination (p < 0.05 retention) evaluated the cross-sectional association between the University of Pennsylvania Smell Identification Test and amyloid burden, HV, and EC thickness, assessing for effect modification by PiB status. Covariates included age, sex, premorbid intelligence, APOE epsilon 4 carrier status, and Boston Naming Test.Results:In unadjusted univariate analyses, worse olfaction was associated with decreased HV (p < 0.001), thinner EC (p = 0.003), worse episodic memory (p = 0.03), and marginally associated with greater amyloid burden (binary PiB status, p = 0.06). In the multivariate model, thinner EC in PiB-positive individuals (interaction term) was associated with worse olfaction (p = 0.02).Conclusions:In CN elderly, worse odor identification was associated with markers of neurodegeneration. Furthermore, individuals with elevated cortical amyloid and thinner EC exhibited worse odor identification, elucidating the potential contribution of olfactory testing to detect preclinical AD in CN individuals.
C1 [Growdon, Matthew E.; Amariglio, Rebecca E.; Hedden, Trey; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Albers, Mark W.; Marshall, Gad A.] Harvard Univ, Sch Med, Boston, MA 02138 USA.
[Growdon, Matthew E.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Schultz, Aaron P.; Dagley, Alexander S.; Hedden, Trey; Sperling, Reisa A.; Albers, Mark W.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Schultz, Aaron P.; Dagley, Alexander S.; Amariglio, Rebecca E.; Rentz, Dorene M.; Sperling, Reisa A.; Albers, Mark W.; Marshall, Gad A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Schultz, Aaron P.; Dagley, Alexander S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Hedden, Trey; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Albers, Mark W.] Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Boston, MA 02114 USA.
[Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
RP Marshall, GA (reprint author), Harvard Univ, Sch Med, Boston, MA 02138 USA.
EM gamarshall@partners.org
FU Harvard Aging Brain Study [P01 AGO36694, R01 AG037497]; Massachusetts
Alzheimer's Disease Research Center [P50 AG005134]; [R01 AG027435];
[K23 AG033634]; [K24 AG035007]; [DP2 OD006662]
FX This study was supported by the Harvard Aging Brain Study (P01 AGO36694,
R01 AG037497), R01 AG027435, K23 AG033634, K24 AG035007, the
Massachusetts Alzheimer's Disease Research Center (P50 AG005134), and
DP2 OD006662.
NR 40
TC 11
Z9 11
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 26
PY 2015
VL 84
IS 21
BP 2153
EP 2160
DI 10.1212/WNL.0000000000001614
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA CJ2LT
UT WOS:000355317000015
PM 25934852
ER
PT J
AU Gerlee, P
Altrock, PM
AF Gerlee, Philip
Altrock, Philipp M.
TI Complexity and stability in growing cancer cell populations
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Letter
ID HETEROGENEITY; DYNAMICS
C1 [Gerlee, Philip] Chalmers, Math Sci, SE-41296 Gothenburg, Sweden.
[Gerlee, Philip] Univ Gothenburg, Math Sci, SE-40530 Gothenburg, Sweden.
[Altrock, Philipp M.] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA.
[Altrock, Philipp M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Altrock, Philipp M.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02215 USA.
RP Gerlee, P (reprint author), Chalmers, Math Sci, SE-41296 Gothenburg, Sweden.
EM gerlee@chalmers.se
NR 5
TC 3
Z9 3
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 26
PY 2015
VL 112
IS 21
BP E2742
EP E2743
DI 10.1073/pnas.1505115112
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ1AJ
UT WOS:000355213200003
PM 25941414
ER
PT J
AU Harrison, MRM
Bussmann, J
Huang, Y
Zhao, L
Osorio, A
Burns, CG
Burns, CE
Sucov, HM
Siekmann, AF
Lien, CL
AF Harrison, Michael R. M.
Bussmann, Jeroen
Huang, Ying
Zhao, Long
Osorio, Arthela
Burns, C. Geoffrey
Burns, Caroline E.
Sucov, Henry M.
Siekmann, Arndt F.
Lien, Ching-Ling
TI Chemokine-Guided Angiogenesis Directs Coronary Vasculature Formation in
Zebrafish
SO DEVELOPMENTAL CELL
LA English
DT Article
ID DOGFISH SCYLIORHINUS-CANICULA; HEART REGENERATION; ENDOTHELIAL-CELLS;
ASSOCIATION ANALYSIS; PROEPICARDIAL ORGAN; NETWORK FORMATION;
ARTERY-DISEASE; RECEPTOR CXCR4; MIGRATION; CARDIOMYOCYTES
AB Interruption of the coronary blood supply severely impairs heart function with often fatal consequences for patients. However, the formation and maturation of these coronary vessels is not fully understood. Here we provide a detailed analysis of coronary vessel development in zebrafish. We observe that coronary vessels form in zebrafish by angiogenic sprouting of arterial cells derived from the endocardium at the atrioventricular canal. Endothelial cells express the CXC-motif chemokine receptor Cxcr4a and migrate to vascularize the ventricle under the guidance of the myocardium-expressed ligand Cxcl12b. cxcr4a mutant zebrafish fail to form a vascular network, whereas ectopic expression of Cxcl12b ligand induces coronary vessel formation. Importantly, cxcr4a mutant zebrafish fail to undergo heart regeneration following injury. Our results suggest that chemokine signaling has an essential role in coronary vessel formation by directing migration of endocardium-derived endothelial cells. Poorly developed vasculature in cxcr4a mutants likely underlies decreased regenerative potential in adults.
C1 [Harrison, Michael R. M.; Huang, Ying; Osorio, Arthela; Lien, Ching-Ling] Childrens Hosp Los Angeles, Saban Res Inst, Heart Inst, Los Angeles, CA 90027 USA.
[Harrison, Michael R. M.; Huang, Ying; Osorio, Arthela; Lien, Ching-Ling] Childrens Hosp Los Angeles, Program Dev Biol & Regenerat Med, Los Angeles, CA 90027 USA.
[Bussmann, Jeroen; Siekmann, Arndt F.] Max Planck Inst Mol Biomed, D-48149 Munster, Germany.
[Zhao, Long; Burns, C. Geoffrey; Burns, Caroline E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Zhao, Long; Burns, C. Geoffrey; Burns, Caroline E.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Sucov, Henry M.] Univ So Calif, Broad CIRM Ctr, Los Angeles, CA 90033 USA.
[Sucov, Henry M.] Univ So Calif, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90033 USA.
[Lien, Ching-Ling] Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA.
[Lien, Ching-Ling] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
RP Lien, CL (reprint author), Childrens Hosp Los Angeles, Saban Res Inst, Heart Inst, Los Angeles, CA 90027 USA.
EM clien@chla.usc.edu
RI Zhao, Long/A-6439-2014
FU National Heart, Lung and Blood Institute Grant [R01HL096121]; California
Institute for Regenerative Medicine [TG2-01168]; Saban Research
Institute; Max Planck Society; Deutsche Forschungsgemeinschaft [DFG
SI-1374/3-1]; ERC [260794-ZebrafishAngio]; DFG Cells-in-Motion Cluster
of Excellence, University of Munster, Germany [EXC 1003-CIM]; European
Molecular Biology Organization long-term fellowship;
[Sonderforschungsbereich (SFB) 629]
FX We are grateful to G. Crump for providing the fli1a endothelial enhancer
and S. Megason for providing the H2B-Cerulean fusion construct and for
zebrafish lines from various groups. We also thank M. Chao, J. Chen, G.
Crump, V. Kaartinen, and C. Pearson for critical reading of the
manuscript. We acknowledge the assistance of E. Fernandez and the
facilities of the CHLA microscopy core, S. Sumida and R. Kim for
insightful comments, and D. Warburton and V. Starnes for helpful
discussion and support. This work was supported by National Heart, Lung
and Blood Institute Grant (R01HL096121 to C.-L. L.), a postdoctoral
fellowship from the California Institute for Regenerative Medicine
(TG2-01168; CIRM Scholar, M.R.M.H.), and a Research Career Development
Fellowship from the Saban Research Institute (to M.R.M.H.). This work
was furthermore funded by the Max Planck Society (to A.F.S.), the
Deutsche Forschungsgemeinschaft (DFG SI-1374/3-1; to A.F.S.), the
Sonderforschungsbereich (SFB) 629, and an ERC starting grant
(260794-ZebrafishAngio; to A.F.S.). This work was supported by the DFG
Cells-in-Motion Cluster of Excellence (EXC 1003-CIM), University of
Munster, Germany. J.B. was supported by a European Molecular Biology
Organization long-term fellowship.
NR 56
TC 15
Z9 16
U1 2
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD MAY 26
PY 2015
VL 33
IS 4
BP 442
EP 454
DI 10.1016/j.devcel.2015.04.001
PG 13
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA CJ0FT
UT WOS:000355151900009
PM 26017769
ER
PT J
AU Yeh, RW
Kereiakes, DJ
Steg, PG
Windecker, S
Rinaldi, MJ
Gershlick, AH
Cutlip, DE
Cohen, DJ
Tanguay, JF
Jacobs, A
Wiviott, SD
Massaro, JM
Iancu, AC
Mauri, L
AF Yeh, Robert W.
Kereiakes, Dean J.
Steg, Philippe Gabriel
Windecker, Stephan
Rinaldi, Michael J.
Gershlick, Anthony H.
Cutlip, Donald E.
Cohen, David J.
Tanguay, Jean-Francois
Jacobs, Alice
Wiviott, Stephen D.
Massaro, Joseph M.
Iancu, Adrian C.
Mauri, Laura
CA DAPT Study Investigators
TI Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After
PCI in Patients With and Without Acute Myocardial Infarction
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE acute coronary syndromes; antiplatelet therapy; myocardial infarction;
percutaneous coronary intervention; randomized clinical trial
ID DRUG-ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED
CLINICAL-TRIAL; BARE-METAL; GUIDELINES; THROMBOSIS; METAANALYSIS;
DEFINITIONS; MULTICENTER; PLACEMENT
AB BACKGROUND The benefits and risks of prolonged dual antiplatelet therapy may be different for patients with acute myocardial infarction (MI) compared with more stable presentations.
OBJECTIVES This study sought to assess the benefits and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coronary stent implantation with and without MI.
METHODS The Dual Antiplatelet Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30 versus 12 months of dual antiplatelet therapy after coronary stenting. The effect of continued thienopyridine on ischemic and bleeding events among patients initially presenting with versus without MI was assessed. The coprimary endpoints were definite or probable stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE). The primary safety endpoint was GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries) moderate or severe bleeding.
RESULTS Of 11,648 randomized patients (9,961 treated with drug-eluting stents, 1,687 with bare-metal stents), 30.7% presented with MI. Between 12 and 30 months, continued thienopyridine reduced stent thrombosis compared with placebo in patients with and without MI at presentation (MI group, 0.5% vs. 1.9%, p < 0.001; no MI group, 0.4% vs. 1.1%, p < 0.001; interaction p = 0.69). The reduction in MACCE for continued thienopyridine was greater for patients with MI (3.9% vs. 6.8%; p < 0.001) compared with those with no MI (4.4% vs. 5.3%; p = 0.08; interaction p = 0.03). In both groups, continued thienopyridine reduced MI (2.2% vs. 5.2%, p < 0.001 for MI; 2.1% vs. 3.5%, p < 0.001 for no MI; interaction p = 0.15) but increased bleeding (1.9% vs. 0.8%, p = 0.005 for MI; 2.6% vs. 1.7%, p = 0.007 for no MI; interaction p = 0.21).
CONCLUSIONS Compared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thrombosis and MI in patients with and without MI, and increased bleeding. (C) 2015 by the American College of Cardiology Foundation.
C1 [Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cutlip, Donald E.; Mauri, Laura] Harvard Clin Res Inst, Boston, MA USA.
[Cutlip, Donald E.; Mauri, Laura] Harvard Univ, Sch Med, Boston, MA USA.
[Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
[Steg, Philippe Gabriel] Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA.
[Gershlick, Anthony H.] Univ Paris Diderot, INSERM, U 1148, Paris, France.
[Rinaldi, Michael J.] Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ FIRE, Paris, France.
[Gershlick, Anthony H.] Royal Brompton Hosp, Imperial Coll, NHLI, London SW3 6LY, England.
[Windecker, Stephan; Cutlip, Donald E.] Univ Hosp Bern, Bern, Switzerland.
[Cohen, David J.] Carolinas HealthCare Syst, Sanger Heart & Vasc Inst, Charlotte, NC USA.
[Cohen, David J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
[Tanguay, Jean-Francois] Univ Hosp Leicester, Natl Inst Hlth Res, Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England.
[Jacobs, Alice] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Wiviott, Stephen D.] Univ Missouri, Kansas City Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[Massaro, Joseph M.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA.
[Mauri, Laura] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Jacobs, Alice; Iancu, Adrian C.] Univ Med Iuliu Hatieganu, Inst Heart, Cluj Napoca, Romania.
RP Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
EM lmauri1@partners.org
RI 刘, 李陆/H-8469-2015; bashzar, salman/R-5748-2016
FU Harvard Clinical Research Institute; Abbott; Boston Scientific
Corporation; Cordis Corporation; Medtronic, Inc.; Bristol-Myers Squibb
Company/Sanofi Pharmaceuticals Partnership; Eli Lilly and Company;
Daiichi-Sankyo Company Limited; U.S. Department of Health and Human
Services [1RO1FD003870-01]; Gilead Sciences; Merck; Amarin; AstraZeneca;
Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo;
GlaxoSmithKline; Eli Lilly; Merck-Sharpe-Dohme; Novartis; Otsuka;
Pfizer; Roche; Medtronic; Sanofi; Servier; Vivus; Janssen; Medicines
Company; Orexigen; Sanofi and Servier; Biotronik; Boston Scientific;
Edwards Lifesciences; St. Jude; Biosensors; Cordis Inc.; Abbott
Vascular; National Heart, Lung, and Blood Institute; Ikaria; Arena; Eli
Lilly/Daiichi-Sankyo; Eisai; Aegerion; Angelmed; Xoma; ICON Clinical;
Boston Clinical Research Institute; Sanofi/Bristol-Myers Squibb; Recor;
St. Jude Medical
FX This research is sponsored by the Harvard Clinical Research Institute
and funded by Abbott, Boston Scientific Corporation, Cordis Corporation,
Medtronic, Inc., Bristol-Myers Squibb Company/Sanofi Pharmaceuticals
Partnership, Eli Lilly and Company, and Daiichi-Sankyo Company Limited,
and the U.S. Department of Health and Human Services (1RO1FD003870-01).
Dr. Yeh is on the advisory board of Abbott Vascular; and has received
consulting fees from Gilead Sciences and Merck. Dr. Kereiakes has served
as a consultant for Boston Scientific and Abbott Vascular. Dr. Steg has
received personal fees from Amarin, AstraZeneca, Bayer,
Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo,
GlaxoSmithKline, Eli Lilly, Merck-Sharpe-Dohme, Novartis, Otsuka,
Pfizer, Roche, Medtronic, Sanofi, Servier, Vivus, Janssen, The Medicines
Company, and Orexigen; and has received grants from Sanofi and Servier.
Dr. Windecker has received research grants to the institution from
Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic,
The Medicines Company, and St. Jude; and speaker fees from AstraZeneca,
Eli Lilly, Abbott, Biotronik, Boston Scientific, Bayer, and Biosensors.
Dr. Gershlick has received personal fees from Medtronic and Abbott; and
grants from The Medicines Company. Dr. Cutlip has received other fees
from Medtronic, Boston Scientific, Cordis Inc., and Abbott Vascular; and
grants from the National Heart, Lung, and Blood Institute during the
conduct of the study. Dr. Cohen has received research grant support to
the institution from Eli Lilly, AstraZeneca, Daiichi-Sankyo, Abbott
Vascular, Boston Scientific, and Medtronic; and consulting fees from Eli
Lilly, AstraZeneca, Abbott Vascular, and Medtronic. Dr. Tanguay has
received personal fees and other from Abbott Vascular, AstraZeneca,
Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sanofi; personal
fees from Bayer, Roche, and Servier; and other fees from Ikaria and
Merck. Dr. Wiviott has received grants and personal fees from
AstraZeneca, Bristol-Myers Squibb, Arena, and Eli Lilly/Daiichi-Sankyo;
grants from Eisai, Merck, and Sanofi; and personal fees from Aegerion,
Angelmed, Janssen, Xoma, ICON Clinical, and the Boston Clinical Research
Institute. Dr. Massaro has received personal fees from the Harvard
Clinical Research Institute during the conduct of the study. Dr. Mauri
has received institutional research grants from Abbott, Boston
Scientific, Cordis, Medtronic, Eli Lilly/Daiichi-Sankyo, and
Sanofi/Bristol-Myers Squibb; and personal fees from Medtronic, Recor,
St. Jude Medical, and Biotronik. All other authors have reported that
they have no relationships relevant to the contents of this paper to
disclose. P. K. Shah, MD, served as Guest Editor for this paper.
NR 25
TC 64
Z9 66
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 26
PY 2015
VL 65
IS 20
BP 2211
EP 2221
DI 10.1016/j.jacc.2015.03.003
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CI5DM
UT WOS:000354773100009
PM 25787199
ER
PT J
AU Goldstein, JN
Refaai, MA
Milling, TJ
Lewis, B
Goldberg-Alberts, R
Hug, BA
Sarode, R
AF Goldstein, Joshua N.
Refaai, Majed A.
Milling, Truman J., Jr.
Lewis, Brandon
Goldberg-Alberts, Robert
Hug, Bruce A.
Sarode, Ravi
TI Four-factor prothrombin complex concentrate versus plasma for rapid
vitamin K antagonist reversal in patients needing urgent surgical or
invasive interventions: a phase 3b, open-label, non-inferiority,
randomised trial
SO LANCET
LA English
DT Article
ID FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; WARFARIN REVERSAL;
ANTICOAGULATION; SAFETY; METAANALYSIS; 3-FACTOR; SURGERY
AB Background Rapid reversal of vitamin K antagonist (VKA)-induced anticoagulation is often necessary for patients needing urgent surgical or invasive procedures. The optimum means of VKA reversal has not been established in comparative clinical trials. We compared the efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) with that of plasma in VKA-treated patients needing urgent surgical or invasive procedures.
Methods In a multicentre, open-label, phase 3b randomised trial we enrolled patients aged 18 years or older needing rapid VKA reversal before an urgent surgical or invasive procedure. We randomly assigned patients in a 1: 1 ratio to receive vitamin K concomitant with a single dose of either 4F-PCC (Beriplex/Kcentra/Confidex; CSL Behring, Marburg, Germany) or plasma, with dosing based on international normalised ratio (INR) and weight. The primary endpoint was effective haemostasis, and the co-primary endpoint was rapid INR reduction (<= 1.3 at 0.5 h after infusion end). The analyses were intended to evaluate, in a hierarchical fashion, first non-inferiority (lower limit 95% CI greater than -10% for group difference) for both endpoints, then superiority (lower limit 95% CI > 0%) if non-inferiority was achieved. Adverse events and serious adverse events were reported to days 10 and 45, respectively. This trial is registered at ClinicalTrials.gov, number NCT00803101.
Findings 181 patients were randomised (4F-PCC n=90; plasma n=91). The intention-to-treat efficacy population comprised 168 patients (4F-PCC, n=87; plasma, n=81). Effective haemostasis was achieved in 78 (90%) patients in the 4F-PCC group compared with 61 (75%) patients in the plasma group, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 14.3%, 95% CI 2.8-25.8). Rapid INR reduction was achieved in 48 (55%) patients in the 4F-PCC group compared with eight (10%) patients in the plasma group, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 45.3%, 95% CI 31.9-56.4). The safety profile of 4F-PCC was generally similar to that of plasma; 49 (56%) patients receiving 4F-PCC had adverse events compared with 53 (60%) patients receiving plasma. Adverse events of interest were thromboembolic adverse events (six [7%] patients receiving 4F-PCC vs seven [8%] patients receiving plasma), fluid overload or similar cardiac events (three [3%] patients vs 11 [13%] patients), and late bleeding events (three [3%] patients vs four [5%] patients).
Interpretation 4F-PCC is non-inferior and superior to plasma for rapid INR reversal and effective haemostasis in patients needing VKA reversal for urgent surgical or invasive procedures.
C1 [Goldstein, Joshua N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Refaai, Majed A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Milling, Truman J., Jr.] Univ Med Ctr Brackenridge, Seton UT Southwestern Clin Res Inst Austin, Dell Childrens Med Ctr, Austin, TX USA.
[Lewis, Brandon] Texas A&M Hlth Sci Ctr, St Joseph Reg Hlth Ctr, Bryan, College Stn, TX USA.
[Goldberg-Alberts, Robert; Hug, Bruce A.] CSL Behring LLC, King Of Prussia, PA USA.
[Sarode, Ravi] UT Southwestern Med Ctr, Dallas, TX USA.
RP Goldstein, JN (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.
EM jgoldstein@mgh.harvard.edu
RI Goldstein, Joshua/H-8953-2016
FU CSL Behring
FX Funding CSL Behring.
NR 29
TC 64
Z9 64
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 23
PY 2015
VL 385
IS 9982
BP 2077
EP 2087
DI 10.1016/S0140-6736(14)61685-8
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI7XK
UT WOS:000354979100027
PM 25728933
ER
PT J
AU Khor, B
Gagnon, JD
Goel, G
Roche, MI
Conway, KL
Tran, K
Aldrich, LN
Sundberg, TB
Paterson, AM
Mordecai, S
Dombkowski, D
Schirmer, M
Tan, PH
Bhan, AK
Roychoudhuri, R
Restifo, NP
O'Shea, JJ
Medoff, BD
Shamji, AF
Schreiber, SL
Sharpe, AH
Shaw, SY
Xavier, RJ
AF Khor, Bernard
Gagnon, John D.
Goel, Gautam
Roche, Marly I.
Conway, Kara L.
Tran, Khoa
Aldrich, Leslie N.
Sundberg, Thomas B.
Paterson, Alison M.
Mordecai, Scott
Dombkowski, David
Schirmer, Melanie
Tan, Pauline H.
Bhan, Atul K.
Roychoudhuri, Rahul
Restifo, Nicholas P.
O'Shea, John J.
Medoff, Benjamin D.
Shamji, Alykhan F.
Schreiber, Stuart L.
Sharpe, Arlene H.
Shaw, Stanley Y.
Xavier, Ramnik J.
TI The kinase DYRK1A reciprocally regulates the differentiation of Th17 and
regulatory T cells
SO ELIFE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; PATHOGENIC T(H)17 CELLS; RETINOIC-ACID;
TRANSCRIPTIONAL SIGNATURE; FOXP3 EXPRESSION; GENE-EXPRESSION; SMALL
MOLECULES; NUCLEAR FACTOR; DOWN-SYNDROME; REG-CELLS
AB The balance between Th17 and T regulatory (T-reg) cells critically modulates immune homeostasis, with an inadequate Treg response contributing to inflammatory disease. Using an unbiased chemical biology approach, we identified a novel role for the dual specificity tyrosinephosphorylation-regulated kinase DYRK1A in regulating this balance. Inhibition of DYRK1A enhances Treg differentiation and impairs Th17 differentiation without affecting known pathways of T-reg/Th17 differentiation. Thus, DYRK1A represents a novel mechanistic node at the branch point between commitment to either Treg or Th17 lineages. Importantly, both Treg cells generated using the DYRK1A inhibitor harmine and direct administration of harmine itself potently attenuate inflammation in multiple experimental models of systemic autoimmunity and mucosal inflammation. Our results identify DYRK1A as a physiologically relevant regulator of T-reg cell differentiation and suggest a broader role for other DYRK family members in immune homeostasis. These results are discussed in the context of human diseases associated with dysregulated DYRK activity.
C1 [Khor, Bernard; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Khor, Bernard; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA.
[Khor, Bernard; Goel, Gautam; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA.
[Khor, Bernard; Gagnon, John D.; Conway, Kara L.; Aldrich, Leslie N.; Sundberg, Thomas B.; Schirmer, Melanie; Shamji, Alykhan F.; Schreiber, Stuart L.; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Khor, Bernard; Mordecai, Scott; Dombkowski, David; Bhan, Atul K.] Massachusetts Gen Hosp, Pathol Serv, Boston, MA 02114 USA.
[Roche, Marly I.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Tran, Khoa; Tan, Pauline H.; Shaw, Stanley Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Aldrich, Leslie N.; Schreiber, Stuart L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Paterson, Alison M.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Paterson, Alison M.; Sharpe, Arlene H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Roychoudhuri, Rahul; Restifo, Nicholas P.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[O'Shea, John J.] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA.
RP Xavier, RJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
EM xavier@molbio.mgh.harvard.edu
RI Roychoudhuri, Rahul/A-7442-2010;
OI Roychoudhuri, Rahul/0000-0002-5392-1853; Gagnon,
John/0000-0001-6208-5781; Schirmer, Melanie/0000-0001-6456-3679; Khor,
Bernard/0000-0003-4689-5092; Restifo, Nicholas P./0000-0003-4229-4580
NR 84
TC 5
Z9 5
U1 0
U2 0
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAY 22
PY 2015
VL 4
AR e05920
DI 10.7554/eLife.05920
PG 27
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DJ5QI
UT WOS:000374264300001
ER
PT J
AU de Figueiredo, ASP
Salmon, AB
Bruno, F
Jimenez, F
Martinez, HG
Halade, GV
Ahuja, SS
Clark, RA
DeFronzo, RA
Abboud, HE
El Jamali, A
AF de Figueiredo, Alvaro Souto Padron
Salmon, Adam B.
Bruno, Francesca
Jimenez, Fabio
Martinez, Herman G.
Halade, Ganesh V.
Ahuja, Seema S.
Clark, Robert A.
DeFronzo, Ralph A.
Abboud, Hanna E.
El Jamali, Amina
TI Nox2 Mediates Skeletal Muscle Insulin Resistance Induced by a High Fat
Diet
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NADPH OXIDASE ACTIVITY; ELECTRON-TRANSPORT; DIABETES-MELLITUS; OXIDATIVE
STRESS; PLASMA-MEMBRANE; NAD(P)H OXIDASE; L6 MYOTUBES; GLUCOSE; GLUT4;
DYSFUNCTION
AB Inflammation and oxidative stress through the production of reactive oxygen species (ROS) are consistently associated with metabolic syndrome/type 2 diabetes. Although the role of Nox2, a major ROS-generating enzyme, is well described in host defense and inflammation, little is known about its potential role in insulin resistance in skeletal muscle. Insulin resistance induced by a high fat diet was mitigated in Nox2-null mice compared with wild-type mice after 3 or 9 months on the diet. High fat feeding increased Nox2 expression, superoxide production, and impaired insulin signaling in skeletal muscle tissue of wild-type mice but not in Nox2-null mice. Exposure of C2C12 cultured myotubes to either high glucose concentration, palmitate, or H2O2 decreases insulin-induced Akt phosphorylation and glucose uptake. Pretreatment with catalase abrogated these effects, indicating a key role for H2O2 in mediating insulin resistance. Down-regulation of Nox2 in C2C12 cells by shRNA prevented insulin resistance induced by high glucose or palmitate but not H2O2. These data indicate that increased production of ROS in insulin resistance induced by high glucose in skeletal muscle cells is a consequence of Nox2 activation. This is the first report to show that Nox2 is a key mediator of insulin resistance in skeletal muscle.
C1 [de Figueiredo, Alvaro Souto Padron; Bruno, Francesca; Jimenez, Fabio; Martinez, Herman G.; Halade, Ganesh V.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.; El Jamali, Amina] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Salmon, Adam B.] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Salmon, Adam B.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX 78229 USA.
RP El Jamali, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM AkoulouzeBik@uthscsa.edu
RI Regan, Clinton/E-6250-2012
FU National Institutes of Health [P30 CA054174, P30 AG013319, P01 AG019316]
FX The confocal microscopy studies were performed in the Institutional
Optical Imaging Facility of the University of Texas Health Science
Center at San Antonio, which is supported by National Institutes of
Health Grants P30 CA054174 (Cancer Therapy and Research Center), P30
AG013319 (Nathan Shock Center), and P01 AG019316 (Aging, Oxidative
Stress, and Cell Death). We thank Drs. Alain Virion for helpful
discussions, Dr. John Cornell for insightful advice on statistical
analysis, Dr. James Lechleiter for expert guidance on the confocal
microscope image acquisition and analysis, and Yimin Wu, Maria Gamez,
and Jacob Crandall for expert technical assistance.
NR 48
TC 10
Z9 10
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 22
PY 2015
VL 290
IS 21
BP 13427
EP 13439
DI 10.1074/jbc.M114.626077
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CI7WL
UT WOS:000354975700038
ER
PT J
AU Rotem, A
Ram, O
Shoresh, N
Sperling, RA
Schnall-Levin, M
Zhang, HD
Basu, A
Bernstein, BE
Weitz, DA
AF Rotem, Assaf
Ram, Oren
Shoresh, Noam
Sperling, Ralph A.
Schnall-Levin, Michael
Zhang, Huidan
Basu, Anindita
Bernstein, Bradley E.
Weitz, David A.
TI High-Throughput Single-Cell Labeling (Hi-SCL) for RNA-Seq Using
Drop-Based Microfluidics
SO PLOS ONE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HETEROGENEITY; SURFACTANTS; EMULSIONS; EVOLUTION;
CYTOMETRY; IMMUNE; CANCER; GENES; MASS
AB The importance of single-cell level data is increasingly appreciated, and significant advances in this direction have been made in recent years. Common to these technologies is the need to physically segregate individual cells into containers, such as wells or chambers of a micro-fluidics chip. High-throughput Single-Cell Labeling (Hi-SCL) in drops is a novel method that uses drop-based libraries of oligonucleotide barcodes to index individual cells in a population. The use of drops as containers, and a microfluidics platform to manipulate them en-masse, yields a highly scalable methodological framework. Once tagged, labeled molecules from different cells may be mixed without losing the cell-of-origin information. Here we demonstrate an application of the method for generating RNA-sequencing data for multiple individual cells within a population. Barcoded oligonucleotides are used to prime cDNA synthesis within drops. Barcoded cDNAs are then combined and subjected to second generation sequencing. The data are deconvoluted based on the barcodes, yielding single-cell mRNA expression data. In a proof-of-concept set of experiments we show that this method yields data comparable to other existing methods, but with unique potential for assaying very large numbers of cells.
C1 [Rotem, Assaf; Sperling, Ralph A.; Zhang, Huidan; Basu, Anindita; Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Rotem, Assaf; Sperling, Ralph A.; Zhang, Huidan; Basu, Anindita; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Rotem, Assaf; Ram, Oren; Shoresh, Noam; Schnall-Levin, Michael; Basu, Anindita; Bernstein, Bradley E.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Bernstein, Bradley E.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Ram, Oren; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ram, Oren; Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA USA.
[Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
RP Rotem, A (reprint author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
EM acerotem@gmail.com
RI Zhang, Huidan/K-8399-2015
FU Harvard Materials Science Research and Engineering Center [DMR-0820484];
National Science Foundation [DMR-1310266]; Defense Advanced Research
Projects Agency [HR0011-11-C-0093]; German Research Foundation [SP
1282/1-1]; National Heart, Lung and Blood Institute [U01 HL100395];
National Human Genome Research Institute [P50HG006193]
FX Harvard Materials Science Research and Engineering Center (DMR-0820484),
National Science Foundation (DMR-1310266), Defense Advanced Research
Projects Agency (HR0011-11-C-0093), German Research Foundation (SP
1282/1-1), the National Heart, Lung and Blood Institute (U01 HL100395),
and the National Human Genome Research Institute (P50HG006193). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 28
TC 18
Z9 18
U1 4
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2015
VL 10
IS 5
AR e0116328
DI 10.1371/journal.pone.0116328
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7GR
UT WOS:000354931700001
PM 26000628
ER
PT J
AU Guo, W
Hight, AE
Chen, JX
Klapoetke, NC
Hancock, KE
Shinn-Cunningham, BG
Boyden, ES
Lee, DJ
Polley, DB
AF Guo, Wei
Hight, Ariel E.
Chen, Jenny X.
Klapoetke, Nathan C.
Hancock, Kenneth E.
Shinn-Cunningham, Barbara G.
Boyden, Edward S.
Lee, Daniel J.
Polley, Daniel B.
TI Hearing the light: neural and perceptual encoding of optogenetic
stimulation in the central auditory pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BRAIN-STEM IMPLANT; INFERIOR COLLICULUS; FUNCTIONAL-ORGANIZATION; SPEECH
RECOGNITION; SENSORY RESPONSES; COCHLEAR IMPLANTS; VISUAL-CORTEX; MOUSE;
NEURONS; ACTIVATION
AB Optogenetics provides a means to dissect the organization and function of neural circuits. Optogenetics also offers the translational promise of restoring sensation, enabling movement or supplanting abnormal activity patterns in pathological brain circuits. However, the inherent sluggishness of evoked photocurrents in conventional channelrhodopsins has hampered the development of optoprostheses that adequately mimic the rate and timing of natural spike patterning. Here, we explore the feasibility and limitations of a central auditory optoprosthesis by photoactivating mouse auditory midbrain neurons that either express channelrhodopsin-2 (ChR2) or Chronos, a channelrhodopsin with ultra-fast channel kinetics. Chronos-mediated spike fidelity surpassed ChR2 and natural acoustic stimulation to support a superior code for the detection and discrimination of rapid pulse trains. Interestingly, this midbrain coding advantage did not translate to a perceptual advantage, as behavioral detection of midbrain activation was equivalent with both opsins. Auditory cortex recordings revealed that the precisely synchronized midbrain responses had been converted to a simplified rate code that was indistinguishable between opsins and less robust overall than acoustic stimulation. These findings demonstrate the temporal coding benefits that can be realized with next-generation channelrhodopsins, but also highlight the challenge of inducing variegated patterns of forebrain spiking activity that support adaptive perception and behavior.
C1 [Guo, Wei; Hight, Ariel E.; Chen, Jenny X.; Hancock, Kenneth E.; Lee, Daniel J.; Polley, Daniel B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Guo, Wei; Shinn-Cunningham, Barbara G.; Polley, Daniel B.] Boston Univ, Ctr Computat Neurosci & Neural Technol, Boston, MA 02215 USA.
[Hight, Ariel E.] Harvard Univ, Med Sch HMS, Program Speech Hearing Biosci & Technol, Boston, MA 02115 USA.
[Chen, Jenny X.] HMS, New Pathway MD Program, Boston, MA 02115 USA.
[Klapoetke, Nathan C.; Boyden, Edward S.] MIT, Synthet Neurobiol Grp, MIT Media Lab, Cambridge, MA 02139 USA.
[Klapoetke, Nathan C.; Boyden, Edward S.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Hancock, Kenneth E.; Lee, Daniel J.; Polley, Daniel B.] HMS, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Shinn-Cunningham, Barbara G.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
RP Guo, W (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
EM weiguo@bu.edu; daniel_polley@meei.harvard.edu
FU NIH [R21012894, P30 DC5029, T32 DC000038]; HHMI international student
research fellowship
FX This work is supported by NIH grants R21012894 (D.P.), P30 DC5029, T32
DC000038 (A.E.H.), and an HHMI international student research fellowship
(W.G.)
NR 60
TC 7
Z9 8
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 22
PY 2015
VL 5
AR 10319
DI 10.1038/srep10319
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ5GX
UT WOS:000355516800001
PM 26000557
ER
PT J
AU Burton, MJ
Curtis, JR
Yang, S
Chen, L
Singh, JA
Mikuls, TR
Winthrop, KL
Baddley, JW
AF Burton, Mary Jane
Curtis, Jeffrey R.
Yang, Shuo
Chen, Lang
Singh, Jasvinder A.
Mikuls, Ted R.
Winthrop, Kevin L.
Baddley, John W.
TI Safety of biologic and nonbiologic disease-modifying antirheumatic drug
therapy in veterans with rheumatoid arthritis and hepatitis B virus
infection: a retrospective cohort study
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID LONG-TERM SAFETY; IMMUNOSUPPRESSIVE THERAPY; POSITIVE PATIENTS; OCCULT
CARRIERS; REACTIVATION; RECOMMENDATIONS; HEPATOTOXICITY; MANAGEMENT;
ANTIGEN; RISK
AB Introduction: We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort.
Methods: We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data from the US Veterans Health Administration. Eligible episodes had evidence of HBV infection (HBV surface antigen, HBV core antibody, HBV e-antibody and/or HBV DNA) and had a baseline alanine aminotransferase (ALT) < 1.5 times the upper limit of laboratory normal within 90 days prior to initiation of a new biologic or nonbiologic DMARD. The main outcome of interest was hepatotoxicity, defined as ALT elevation > 100 IU/mL. Results were reported as the cumulative incidence of treatment episodes achieving hepatotoxicity at 3, 6 and 12 months post biologic exposure.
Results: Five hundred sixty-six unique RA patients with HBV contributed 959 treatment episodes. Mean age was 62.1 +/- 10.3 years; 91.8% were male. Hepatotoxicity was uncommon, with 26 events identified among 959 episodes (2.7%) within 12 months. Hepatotoxicity was comparable between biologic and nonbiologic DMARDs (2.6% vs. 2.8%, P = 0.87). The median time between HBV screening and starting a new RA drug was 504 days (IQR 144, 1,163). Follow-up HBV testing occurred among 14 hepatotoxicity episodes (53.8%) at a median of 202 days (IQR 82, 716) from the date of ALT elevation. A total of 146 (15.2%) treatment episodes received at least one test for HBV DNA at any point in the observation period.
Conclusions: Among US veterans with RA and HBV the risk of hepatotoxicity is low (2.7%), and comparable between biologic and nonbiologic DMARDS (2.8% vs. 2.6%, P = 0.87). HBV testing associated with DMARD initiation or hepatotoxicity was infrequent.
C1 [Burton, Mary Jane] GV Sonny Montgomery VA Med Ctr, Jackson, MS 39216 USA.
[Burton, Mary Jane] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
[Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Birmingham VAMC, Birmingham, AL 35233 USA.
[Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL 35233 USA.
[Mikuls, Ted R.] UNMC, Omaha VAMC, Omaha, NE 68105 USA.
[Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Burton, MJ (reprint author), GV Sonny Montgomery VA Med Ctr, 1500 E Woodrow Wilson Ave, Jackson, MS 39216 USA.
EM Mary.burton2@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development; Bristol Myers Squibb; Veterans Affairs
Clinical Science Research and Development (VA CSRD) [1IK2CX00536];
Agency for Healthcare Research and Quality (AHRQ) [R01 HS018517]; Agency
for Health Quality and Research Center for Education and Research on
Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of
Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34
AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National
Cancer Institute (NCI) [U10 CA149950]; Patient-Centered Outcomes
Research Institute (PCORI) [CE-1304-6631]; VA CSR&D Merit Review Awards
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development as well as an
investigator-initiated grant from Bristol Myers Squibb. Dr. Burton's
work was supported by Veterans Affairs Clinical Science Research and
Development (VA CSR&D) (Grant 1IK2CX00536, PI-Burton). Dr. Curtis was
supported by the Agency for Healthcare Research and Quality (AHRQ) (R01
HS018517). Dr. Singh is supported by grants from the Agency for Health
Quality and Research Center for Education and Research on Therapeutics
(AHRQ CERTs) U19 HS021110, National Institute of Arthritis,
Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891,
National Institute of Aging (NIA) U01 AG018947, National Cancer
Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from
the Patient-Centered Outcomes Research Institute (PCORI). Dr. Mikuls is
supported by VA CSR&D Merit Review Awards. Funding organizations did not
contribute to study design, data collection, data analysis and
interpretation, or manuscript preparation and submission.
NR 35
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD MAY 22
PY 2015
VL 17
AR 136
DI 10.1186/s13075-015-0628-z
PG 9
WC Rheumatology
SC Rheumatology
GA CI7UU
UT WOS:000354971100001
PM 26001631
ER
PT J
AU Wyllie, E
Rincon, SP
Pierce, VM
AF Wyllie, Elaine
Rincon, Sandra P.
Pierce, Virginia M.
TI Case 16-2015: A 9-Year-Old Girl with Loss of Consciousness and Seizures
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CAT-SCRATCH DISEASE; BARTONELLA-HENSELAE DNA; EHLERS-DANLOS-SYNDROME;
STATUS EPILEPTICUS; ACUTE ENCEPHALOPATHY; CHILDREN; ENCEPHALITIS;
DIAGNOSIS; MANAGEMENT; EPIDEMIOLOGY
C1 [Wyllie, Elaine] Cleveland Clin, Epilepsy Ctr, Neurol Inst, Cleveland, OH 44106 USA.
[Wyllie, Elaine] Cleveland Clin, Inst Pediat, Cleveland, OH USA.
[Wyllie, Elaine] Case Western Reserve Univ, Cleveland Clin Lerner, Coll Med, Cleveland, OH 44106 USA.
[Rincon, Sandra P.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Pierce, Virginia M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Pierce, Virginia M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Rincon, Sandra P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Pierce, Virginia M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Pierce, Virginia M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Wyllie, E (reprint author), Cleveland Clin, Epilepsy Ctr, Neurol Inst, Cleveland, OH 44106 USA.
NR 47
TC 0
Z9 0
U1 2
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2015
VL 372
IS 21
BP 2050
EP 2058
DI 10.1056/NEJMcpc1501149
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5PD
UT WOS:000354809300013
PM 25992750
ER
PT J
AU Grytdal, SP
Rimland, D
Shirley, SH
Rodriguez-Barradas, MC
Goetz, MB
Brown, ST
Lucero-Obusan, C
Holodniy, M
Graber, C
Parashar, U
Vinje, J
Lopman, B
AF Grytdal, Scott P.
Rimland, David
Shirley, S. Hannah
Rodriguez-Barradas, Maria C.
Goetz, Matthew Bidwell
Brown, Sheldon T.
Lucero-Obusan, Cynthia
Holodniy, Mark
Graber, Christopher
Parashar, Umesh
Vinje, Jan
Lopman, Ben
TI Incidence of Medically-Attended Norovirus-Associated Acute
Gastroenteritis in Four Veteran's Affairs Medical Center Populations in
the United States, 2011-2012
SO PLOS ONE
LA English
DT Article
ID INFECTIOUS INTESTINAL DISEASE; SURVEILLANCE; COMMUNITY; ENGLAND; DEATHS
AB An estimated 179 million acute gastroenteritis (AGE) illnesses occur annually in the United States. The role of noroviruses in hospital-related AGE has not been well-documented in the U. S. We estimated the population incidence of community-acquired outpatient and inpatient norovirus AGE encounters, as well as hospital-acquired inpatient norovirus AGE among inpatients at four Veterans Affairs (VA) Medical Centers (VAMCs). Fifty (4%) of 1,160 stool specimens collected <= 7 days from symptom onset tested positive for norovirus. During a one year period, the estimated incidence of outpatient, community-and hospital-acquired inpatient norovirus AGE was 188 cases, 11 cases, and 54 cases/100,000 patients, respectively. This study demonstrates the incidence of outpatient and community- and hospital-acquired inpatient norovirus AGE among the VA population seeking care at these four VAMCs.
C1 [Grytdal, Scott P.; Shirley, S. Hannah; Parashar, Umesh; Vinje, Jan; Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
[Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Washington, DC USA.
[Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Palo Alto, CA USA.
[Holodniy, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Grytdal, SP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
EM spgrytdal@cdc.gov
OI Goetz, Matthew/0000-0003-4542-992X
FU Centers for Disease Control and Prevention
FX Funding provided by Centers for Disease Control and Prevention. The
funders participated in the study design, data analysis, decision to
publish, and preparation of the manuscript.
NR 17
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2015
VL 10
IS 5
AR e0126733
DI 10.1371/journal.pone.0126733
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK7VW
UT WOS:000356444000030
PM 25996826
ER
PT J
AU Viollet, L
Glusman, G
Murphy, KJ
Newcomb, TM
Reyna, SP
Sweney, M
Nelson, B
Andermann, F
Andermann, E
Acsadi, G
Barbano, RL
Brown, C
Brunkow, ME
Chugani, HT
Cheyette, SR
Collins, A
DeBrosse, SD
Galas, D
Friedman, J
Hood, L
Huff, C
Jorde, LB
King, MD
LaSalle, B
Leventer, RJ
Lewelt, AJ
Massart, MB
Merida, MR
Ptacek, LJ
Roach, JC
Rust, RS
Renault, F
Sanger, TD
de Menezes, MAS
Tennyson, R
Uldall, P
Zhang, Y
Zupanc, M
Xin, WN
Silver, K
Swoboda, KJ
AF Viollet, Louis
Glusman, Gustavo
Murphy, Kelley J.
Newcomb, Tara M.
Reyna, Sandra P.
Sweney, Matthew
Nelson, Benjamin
Andermann, Frederick
Andermann, Eva
Acsadi, Gyula
Barbano, Richard L.
Brown, Candida
Brunkow, Mary E.
Chugani, Harry T.
Cheyette, Sarah R.
Collins, Abigail
DeBrosse, Suzanne D.
Galas, David
Friedman, Jennifer
Hood, Lee
Huff, Chad
Jorde, Lynn B.
King, Mary D.
LaSalle, Bernie
Leventer, Richard J.
Lewelt, Aga J.
Massart, Mylynda B.
Merida, Mario R., II
Ptacek, Louis J.
Roach, Jared C.
Rust, Robert S.
Renault, Francis
Sanger, Terry D.
de Menezes, Marcio A. Sotero
Tennyson, Rachel
Uldall, Peter
Zhang, Yue
Zupanc, Mary
Xin, Winnie
Silver, Kenneth
Swoboda, Kathryn J.
TI Alternating Hemiplegia of Childhood: Retrospective Genetic Study and
Genotype-Phenotype Correlations in 187 Subjects from the US AHCF
Registry
SO PLOS ONE
LA English
DT Article
ID ONSET DYSTONIA-PARKINSONISM; GLUTAMATE TRANSPORTER EAAT1; DE-NOVO
MUTATIONS; ATP1A3 MUTATION; CLINICAL-MANIFESTATIONS; ALPHA-3 ISOFORM;
NA+ INTERACTION; K+-ATPASE; SPECTRUM; AFFINITY
AB Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase. Published studies to date indicate 2 recurrent mutations, D801N and E815K, and a more severe phenotype in the E815K cohort. We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012. Clinical data were abstracted from standardized caregivers' questionnaires and medical records and confirmed by expert clinicians. We identified ATP1A3 mutations by Sanger and whole genome sequencing, and compared phenotypes within and between 4 groups of subjects, those with D801N, E815K, other ATP1A3 or no ATP1A3 mutations. We identified heterozygous ATP1A3 mutations in 154 of 187 (82%) AHC patients. Of 34 unique mutations, 31 (91%) are missense, and 16 (47%) had not been previously reported. Concordant with prior studies, more than 2/3 of all mutations are clustered in exons 17 and 18. Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K (26%) and 11 had G937R (8%) mutations. Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus. This study further expands the number and spectrum of ATP1A3 mutations associated with AHC and confirms a more deleterious effect of the E815K mutation on selected neurologic outcomes. However, the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies.
C1 [Viollet, Louis; Murphy, Kelley J.; Newcomb, Tara M.; Reyna, Sandra P.; Sweney, Matthew; Nelson, Benjamin; Tennyson, Rachel; Swoboda, Kathryn J.] Univ Utah, Dept Neurol, Pediat Motor Disorders Res Program, Salt Lake City, UT 84112 USA.
[Viollet, Louis; Murphy, Kelley J.; Newcomb, Tara M.; Reyna, Sandra P.; Sweney, Matthew; Nelson, Benjamin; Tennyson, Rachel; Swoboda, Kathryn J.] Univ Utah, Dept Pediat, Pediat Motor Disorders Res Program, Salt Lake City, UT USA.
[Glusman, Gustavo; Brunkow, Mary E.; Hood, Lee; Roach, Jared C.] Inst Syst Biol, Seattle, WA USA.
[Andermann, Frederick; Andermann, Eva] McGill Univ, Montreal Neurol Inst & Hosp, Neurogenet Unit, Montreal, PQ, Canada.
[Acsadi, Gyula] Connecticut Childrens Med Ctr, Dept Pediat, Hartford, CT USA.
[Acsadi, Gyula] Connecticut Childrens Med Ctr, Dept Neurol, Hartford, CT USA.
[Barbano, Richard L.] Univ Connecticut, Sch Med, Hartford, CT 06112 USA.
[Brown, Candida] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY USA.
[Chugani, Harry T.] Affiliate Stanford Hlth Alliance, Diablo Valley Child Neurol, Pleasant Hill, CA USA.
[Cheyette, Sarah R.] Wayne State Univ, Childrens Hosp Michigan, Div Pediat Neurol, Detroit, MI USA.
[Collins, Abigail] Palo Alto Med Fdn Redwood City Clin, Dept Child Neurol, Redwood City, CA USA.
[DeBrosse, Suzanne D.] Univ Colorado Hosp, Childrens Hosp Colorado, Dept Pediat Neurol, Aurora, CO USA.
[DeBrosse, Suzanne D.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
[Galas, David] Case Western Reserve Univ, Dept Genome Sci Pediat & Neurol, Cleveland, OH 44106 USA.
[Friedman, Jennifer] Pacific Northwest Diabet Res Inst, Seattle, WA USA.
[Friedman, Jennifer] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Huff, Chad] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.
[Jorde, Lynn B.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[King, Mary D.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA.
[King, Mary D.] Univ Coll Dublin, Sch Med & Med Sci, Dept Pediat, Dublin 2, Ireland.
[LaSalle, Bernie] Univ Coll Dublin, Sch Med & Med Sci, Dept Neurol, Dublin 2, Ireland.
[Leventer, Richard J.] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT USA.
[Lewelt, Aga J.] Univ Melbourne, Royal Childrens Hosp, Childrens Neurosci Ctr, Murdoch Childrens Res Inst,Dept Paediat, Parkville, Vic 3052, Australia.
[Massart, Mylynda B.] Univ Florida, Coll Med, Dept Pediat, Jacksonville, FL USA.
[Merida, Mario R., II] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA USA.
[Ptacek, Louis J.] Stevens Henager Coll, Salt Lake City, UT USA.
[Rust, Robert S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Renault, Francis] Univ Virginia UVA Hlth Syst, Ctr Med Eth & Humanities Med, Charlottesville, VA USA.
[Sanger, Terry D.] Hop Armand Trousseau, AP HP, Dept Neurophysiol, Paris, France.
[de Menezes, Marcio A. Sotero] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
[Uldall, Peter] Swedish Neurosci Inst, Swedish Med Ctr, Seattle, WA USA.
[Zhang, Yue] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, Dept Paediat & Adolescent Med, DK-2100 Copenhagen, Denmark.
[Zupanc, Mary] Univ Utah, Study Design & Biostat Ctr, Salt Lake City, UT USA.
[Zupanc, Mary] Univ Calif, Childrens Hosp, Dept Neurol, Orange, CA USA.
[Xin, Winnie] Univ Calif, Dept Pediat, Orange, CA USA.
[Xin, Winnie] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Neurol, Boston, MA 02114 USA.
[Silver, Kenneth] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
[Silver, Kenneth] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.
[Silver, Kenneth] Comer Childrens Hosp, Chicago, IL USA.
RP Swoboda, KJ (reprint author), Univ Utah, Dept Neurol, Pediat Motor Disorders Res Program, Salt Lake City, UT 84112 USA.
EM swoboda@genetics.utah.edu
OI Glusman, Gustavo/0000-0001-8060-5955
FU Alternating Hemiplegia of Childhood Foundation; University of
Luxembourg-Institute for Systems Biology Strategic Partnership;
Luxembourg Centre for Systems Biomedicine; National Institute of General
Medical Sciences Center for Systems Biology [P50 GM076547]
FX The Alternating Hemiplegia of Childhood Foundation
(http://ahckids.org/). Funds were received by KJS. The association
Genetique Actions (http://www.genetique-actions.fr/). Funds were
received by LV. The University of Luxembourg-Institute for Systems
Biology Strategic Partnership
(http://www.partnerships.systemsbiology.net/517/). Funds were received
by LH. The Luxembourg Centre for Systems Biomedicine
(http://wwwfr.uni.lu/lcsb). Funds were received by LH. The National
Institute of General Medical Sciences Center for Systems Biology
(http://www.nigms.nih.gov/research/specificareas/sysbio/Pages/default.as
px) P50 GM076547. Funds were received by LH. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 52
TC 10
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2015
VL 10
IS 5
AR e0127045
DI 10.1371/journal.pone.0127045
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK7VW
UT WOS:000356444000041
PM 25996915
ER
PT J
AU Yeh, RW
Cohen, DJ
Mauri, L
AF Yeh, Robert W.
Cohen, David J.
Mauri, Laura
TI Close encounters with errors of the second kind: evaluating risks and
benefits of long-term dual antiplatelet therapy
SO EUROPEAN HEART JOURNAL
LA English
DT Editorial Material
ID PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION;
DRUG-ELUTING STENTS; TRIAL; CLOPIDOGREL
C1 [Yeh, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Cohen, David J.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Mauri, Laura] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
RP Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
EM lmauri1@partners.org
NR 15
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD MAY 21
PY 2015
VL 36
IS 20
BP 1216
EP 1218
DI 10.1093/eurheartj/ehv082
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CK4HW
UT WOS:000356185900009
PM 25796054
ER
PT J
AU Veenstra, RG
Flynn, R
Kreymborg, K
McDonald-Hyman, C
Saha, A
Taylor, PA
Osborn, MJ
Panoskaltsis-Mortari, A
Schmitt-Graeff, A
Lieberknect, E
Murphy, WJ
Serody, JS
Munn, DH
Freeman, GJ
Allison, JP
Mak, TW
van den Brink, M
Zeiser, R
Blazar, BR
AF Veenstra, Rachelle G.
Flynn, Ryan
Kreymborg, Katharina
McDonald-Hyman, Cameron
Saha, Asim
Taylor, Patricia A.
Osborn, Mark J.
Panoskaltsis-Mortari, Angela
Schmitt-Graeff, Annette
Lieberknect, Elisabeth
Murphy, William J.
Serody, Jonathan S.
Munn, David H.
Freeman, Gordon J.
Allison, James P.
Mak, Tak W.
van den Brink, Marcel
Zeiser, Robert
Blazar, Bruce R.
TI B7-H3 expression in donor T cells and host cells negatively regulates
acute graft-versus-host disease lethality
SO BLOOD
LA English
DT Article
ID IFN-GAMMA; B7 FAMILY; IN-VIVO; ACTIVATION; RESPONSES; DIFFERENTIATION;
BLOCKADE; MOLECULE; MEMBER
AB Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H3(-/-) vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H3(-/-) vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H3(-/-) Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augmenthost B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications.
C1 [Veenstra, Rachelle G.; Flynn, Ryan; McDonald-Hyman, Cameron; Saha, Asim; Taylor, Patricia A.; Osborn, Mark J.; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Ctr Canc, Minneapolis, MN 55455 USA.
[Kreymborg, Katharina; Allison, James P.; van den Brink, Marcel] Mem Sloan Kettering Canc Ctr, Dept Immunol & Med, New York, NY 10021 USA.
[Schmitt-Graeff, Annette] Univ Freiburg, Med Ctr, Dept Pathol, Freiburg, Germany.
[Lieberknect, Elisabeth; Zeiser, Robert] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Freiburg, Germany.
[Murphy, William J.] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA.
[Serody, Jonathan S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA.
[Munn, David H.] Med Coll Georgia, Dept Pediat, Immunotherapy Ctr, Augusta, GA 30912 USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.
[Mak, Tak W.] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5S 1A1, Canada.
RP Blazar, BR (reprint author), Univ Minnesota, Dept Pediat, MMC 109, Minneapolis, MN 55455 USA.
EM blaza001@umn.edu
FU National Institutes of Health from the National Heart, Lung, and Blood
Institute [R01 HL56067]; National Institute of Allergy and Infectious
Diseases [R01 AI 34495, P01 AI 056299, T32 AI 007313]
FX This work was supported in part by National Institutes of Health grants
R01 HL56067 from the National Heart, Lung, and Blood Institute, and R01
AI 34495, P01 AI 056299, and T32 AI 007313 from the National Institute
of Allergy and Infectious Diseases.
NR 25
TC 10
Z9 11
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 21
PY 2015
VL 125
IS 21
BP 3335
EP 3346
DI 10.1182/blood-2014-09-603357
PG 12
WC Hematology
SC Hematology
GA CJ7QF
UT WOS:000355691700018
PM 25814530
ER
PT J
AU Underhill, M
Berry, D
Dalton, E
Schienda, J
Syngal, S
AF Underhill, Meghan
Berry, Donna
Dalton, Emily
Schienda, Jaclyn
Syngal, Sapna
TI Patient experiences living with pancreatic cancer risk
SO HEREDITARY CANCER IN CLINICAL PRACTICE
LA English
DT Article
DE Pancreatic cancer risk; Qualitative research; Patient reported
experience
ID HEREDITARY BREAST; COLORECTAL-CANCER; FAMILY-MEMBERS; RECEPTIVITY;
SURVEILLANCE; PROGRAMS
AB Background: Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk.
Purpose: To understand the meaning and experience of living with familial PancCa risk and to explore experiences related to screening and prevention of PancCa.
Methods: Participants underwent semi-structured, in-depth interviews. Adults without PancCa and who met familial or hereditary risk criteria were eligible. Thematic analysis was completed on the transcripts in order to identify patterns, consistencies, and differences. Narrative review of existing literature related to women living with hereditary breast and ovarian cancer (HBOC) risk was completed to explore similarities and differences between published findings and our current findings.
Results: Nineteen individuals (9 male, 10 female) participated. Major themes addressed participants' family experiences with PancCa and PancCa death and the associated grief from the experiences. Family experiences impacted how participants interpreted and approached their own cancer risk and participated in the cancer screening program. Participants wanted to control their cancer risk and sought information and resources to prevent PancCa or PancCa related death. Distress related to risk was not described as constant but occurred around salient time points.
Conclusion & future implications: Study results begin to describe the lived experience of individuals with PancCa risk. Through this research we have uncovered important variables to further understand, measure, and intervene upon in future research. Distress related to risk was not described as ongoing, but occurred around specific and salient time points that brought risk to the forefront. Individuals with familial PancCa risk may have a unique experience compared to other hereditary cancer syndromes due to the high mortality of the disease and uncertainty related to prevention and early detection outcomes.
C1 [Underhill, Meghan; Berry, Donna; Schienda, Jaclyn; Syngal, Sapna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dalton, Emily] Dana Farber Canc Inst, Ambry Genet, Boston, MA 02115 USA.
RP Underhill, M (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
EM Meghanl_underhill@dfci.harvard.edu
FU Daisy Foundation's J. Patrick Bames Grants for Nursing Research and
Evidence-Based Practice Projects [JPB-2011-65-A]; National Cancer
Institute Cancer & Health Disparities Fellowship Funding
[NCIU54CA156732]; NCI [K24113433, R01CA097075]
FX The Daisy Foundation's J. Patrick Bames Grants for Nursing Research and
Evidence-Based Practice Projects (JPB-2011-65-A); National Cancer
Institute Cancer & Health Disparities Fellowship Funding
(NCIU54CA156732), and NCI Grants K24113433 and R01CA097075.
NR 28
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1731-2302
EI 1897-4287
J9 HERED CANCER CLIN PR
JI Hered. Cancer Clin. Pract.
PD MAY 21
PY 2015
VL 13
AR 13
DI 10.1186/s13053-015-0034-1
PG 9
WC Oncology
SC Oncology
GA CJ9AF
UT WOS:000355794000001
PM 26029287
ER
PT J
AU Weinberger, AD
Gilmore, MS
AF Weinberger, Ariel D.
Gilmore, Michael S.
TI A CRISPR View of Cleavage
SO CELL
LA English
DT Editorial Material
ID CAS SYSTEM; THERMOPHILUS; PROKARYOTES; COMPLEX
AB Seminal studies showed that CRISPR-Cas systems provide adaptive immunity in prokaryotes and promising gene-editing tools from bacteria to humans. Yet, reports diverged on whether some CRISPR systems naturally target DNA or RNA. Here, Samai and colleagues unify the studies, showing that a single type III CRISPR-Cas system cleaves both DNA and RNA targets, independently.
C1 [Weinberger, Ariel D.] Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
[Gilmore, Michael S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
[Gilmore, Michael S.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
RP Weinberger, AD (reprint author), Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
EM ariel.weinberger@wyss.harvard.edu
FU NIAID NIH HHS [F32AI102520]; NIGMS NIH HHS [GM106337]
NR 9
TC 1
Z9 1
U1 2
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 21
PY 2015
VL 161
IS 5
BP 964
EP 966
DI 10.1016/j.cell.2015.05.003
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GA
UT WOS:000355152600005
PM 26000476
ER
PT J
AU Liu, JL
Lee, J
Hernandez, MAS
Mazitschek, R
Ozcan, U
AF Liu, Junli
Lee, Jaemin
Hernandez, Mario Andres Salazar
Mazitschek, Ralph
Ozcan, Umut
TI Treatment of Obesity with Celastrol
SO CELL
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE;
GLUCOSE-HOMEOSTASIS; LEPTIN RESISTANCE; ENERGY-BALANCE; ER STRESS; MICE;
WEIGHT; GENE
AB Despite all modern advances in medicine, an effective drug treatment of obesity has not been found yet. Discovery of leptin two decades ago created hopes for treatment of obesity. However, development of leptin resistance has been a big obstacle, mitigating a leptin-centric treatment of obesity. Here, by using in silico drug-screening methods, we discovered that Celastrol, a pentacyclic triterpene extracted from the roots of Tripterygium Wilfordi (thunder god vine) plant, is a powerful anti-obesity agent. Celastrol suppresses food intake, blocks reduction of energy expenditure, and leads to up to 45% weight loss in hyperleptinemic diet-induced obese (DIO) mice by increasing leptin sensitivity, but it is ineffective in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mouse models. These results indicate that Celastrol is a leptin sensitizer and a promising agent for the pharmacological treatment of obesity.
C1 [Liu, Junli; Lee, Jaemin; Hernandez, Mario Andres Salazar; Ozcan, Umut] Harvard Univ, Boston Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02130 USA.
[Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Mazitschek, Ralph] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
RP Ozcan, U (reprint author), Harvard Univ, Boston Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02130 USA.
EM umut.ozcan@childrens.harvard.edu
OI Lee, Jaemin/0000-0002-0224-7141
FU Department of Medicine, Boston Children's Hospital; National Institutes
of Health [R01DK098496]; American Diabetes Association Career
Development grant [7-09-CD-10]; Fidelity Biosciences Research Initiative
FX We greatly appreciate the time of Morris F. White and Joseph A. Majzoub
for critical reading of our manuscript and for their contributions and
suggestions. We thank Serkan Cabi, Isin Cakir, and Safak Mert for their
experimental contributions to this work. This work was mainly supported
by the funds provided to U.O. from Department of Medicine, Boston
Children's Hospital and also by grant R01DK098496 provided to U.O. by
the National Institutes of Health, American Diabetes Association Career
Development grant #7-09-CD-10, and support from Fidelity Biosciences
Research Initiative. U.O. is a scientific founder, shareholder, and
scientific advisory board and board of directors member of ERX
Pharmaceuticals Inc.
NR 30
TC 46
Z9 53
U1 9
U2 59
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 21
PY 2015
VL 161
IS 5
BP 999
EP 1011
DI 10.1016/j.cell.2015.05.011
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GA
UT WOS:000355152600009
PM 26000480
ER
PT J
AU Zomer, A
Maynard, C
Verweij, FJ
Kamermans, A
Schafer, R
Beerling, E
Schiffelers, RM
de Wit, E
Berenguer, J
Ellenbroek, SIJ
Wurdinger, T
Pegtel, DM
van Rheenen, J
AF Zomer, Anoek
Maynard, Carrie
Verweij, Frederik Johannes
Kamermans, Alwin
Schafer, Ronny
Beerling, Evelyne
Schiffelers, Raymond Michel
de Wit, Elzo
Berenguer, Jordi
Ellenbroek, Saskia Inge Johanna
Wurdinger, Thomas
Pegtel, Dirk Michiel
van Rheenen, Jacco
TI In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of
Metastatic Behavior
SO CELL
LA English
DT Article
ID EXOSOMES; CANCER; CELLS; MICROVESICLES; MICROENVIRONMENT; HALLMARKS;
PROGRESSION; BIOMARKERS; INVASION; TUMORS
AB Most cancer cells release heterogeneous populations of extracellular vesicles (EVs) containing proteins, lipids, and nucleic acids. In vitro experiments showed that EV uptake can lead to transfer of functional mRNA and altered cellular behavior. However, similar in vivo experiments remain challenging because cells that take up EVs cannot be discriminated from non-EV-receiving cells. Here, we used the Cre-LoxP system to directly identify tumor cells that take up EVs in vivo. We show that EVs released by malignant tumor cells are taken up by less malignant tumor cells located within the same and within distant tumors and that these EVs carry mRNAs involved in migration and metastasis. By intravital imaging, we show that the less malignant tumor cells that take up EVs display enhanced migratory behavior and metastatic capacity. We postulate that tumor cells locally and systemically share molecules carried by EVs in vivo and that this affects cellular behavior.
C1 [Zomer, Anoek; Maynard, Carrie; Kamermans, Alwin; Schafer, Ronny; Beerling, Evelyne; de Wit, Elzo; Ellenbroek, Saskia Inge Johanna; van Rheenen, Jacco] Hubrecht Inst KNAW, Canc Genom Netherlands, NL-3584 CT Utrecht, Netherlands.
[Zomer, Anoek; Maynard, Carrie; Kamermans, Alwin; Schafer, Ronny; Beerling, Evelyne; de Wit, Elzo; Ellenbroek, Saskia Inge Johanna; van Rheenen, Jacco] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands.
[Verweij, Frederik Johannes; Pegtel, Dirk Michiel] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Pathol, NL-1081 HV Amsterdam, Netherlands.
[Schiffelers, Raymond Michel] Univ Med Ctr Utrecht, Lab Clin Chem & Haematol, NL-3584 CX Utrecht, Netherlands.
[Berenguer, Jordi; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands.
[Wurdinger, Thomas] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
[Wurdinger, Thomas] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP van Rheenen, J (reprint author), Hubrecht Inst KNAW, Canc Genom Netherlands, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.
EM j.vanrheenen@hubrecht.eu
RI Pegtel, Dirk/M-8393-2015;
OI Pegtel, Dirk/0000-0002-7357-4406; de Wit, Elzo/0000-0003-2883-1415;
Zomer, Anoek/0000-0001-7209-6476
FU VENI fellowships [91696087, 700.10.402]; VIDI fellowships [91710330,
91711366]; Dutch Organization of Scientific Research (NWO) [823.02.017,
175.010.2007.00, 834.11.002]; Dutch Cancer Society (KWF) [HUBR
2009-4621, VU 2009-3775]; European Research Council [260627, 336540];
Association for International Cancer Research (AICR) [13-0297]
FX We thank all members of the van Rheenen group for critically reading
this manuscript, and we thank Anko de Graaff and the Hubrecht Imaging
Center for imaging support. We thank Wouter Karthaus for his help with
cloning the floxed-DsRed-floxed-eGFP construct, Chloe Prunier for
imaging assistance, and Marcel Fens for assistance at the nanosight.
This work was supported by the VENI fellowships 91696087 (M.P.) and
700.10.402 (E.d.W.); VIDI fellowships 91710330 (J.v.R.), 91711366
(T.W.), and a research grant 823.02.017 (J.v.R. from the Dutch
Organization of Scientific Research (NWO); grants from the Dutch Cancer
Society (KWF): HUBR 2009-4621 (A.Z. and J.v.R.) and VU 2009-3775 (M.P.
and F.V.); European Research Council Starting Researchers grants 260627
(R.S.) and 336540 (T.W.); Association for International Cancer Research
(AICR; 13-0297; J.v.R.); and equipment grants (175.010.2007.00 and
834.11.002) from the Dutch Organization of Scientific Research (NWO).
NR 29
TC 84
Z9 87
U1 16
U2 62
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 21
PY 2015
VL 161
IS 5
BP 1046
EP 1057
DI 10.1016/j.cell.2015.04.042
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GA
UT WOS:000355152600013
PM 26000481
ER
PT J
AU Macosko, EZ
Basu, A
Satija, R
Nemesh, J
Shekhar, K
Goldman, M
Tirosh, I
Bialas, AR
Kamitaki, N
Martersteck, EM
Trombetta, JJ
Weitz, DA
Sanes, JR
Shalek, AK
Regev, A
McCarroll, SA
AF Macosko, Evan Z.
Basu, Anindita
Satija, Rahul
Nemesh, James
Shekhar, Karthik
Goldman, Melissa
Tirosh, Itay
Bialas, Allison R.
Kamitaki, Nolan
Martersteck, Emily M.
Trombetta, John J.
Weitz, David A.
Sanes, Joshua R.
Shalek, Alex K.
Regev, Aviv
McCarroll, Steven A.
TI Highly Parallel Genome-wide Expression Profiling of Individual Cells
Using Nanoliter Droplets
SO CELL
LA English
DT Article
ID SINGLE-CELL; RNA-SEQ; MAMMALIAN RETINA; AMACRINE CELLS; DIGITAL PCR;
GENE; DNA; CRYSTALLIN; LENS
AB Cells, the basic units of biological structure and function, vary broadly in type and state. Single-cell genomics can characterize cell identity and function, but limitations of ease and scale have prevented its broad application. Here we describe Drop-seq, a strategy for quickly profiling thousands of individual cells by separating them into nanoliter-sized aqueous droplets, associating a different barcode with each cell's RNAs, and sequencing them all together. Drop-seq analyzes mRNA transcripts from thousands of individual cells simultaneously while remembering transcripts' cell of origin. We analyzed transcriptomes from 44,808 mouse retinal cells and identified 39 transcriptionally distinct cell populations, creating a molecular atlas of gene expression for known retinal cell classes and novel candidate cell subtypes. Drop-seq will accelerate biological discovery by enabling routine transcriptional profiling at single-cell resolution.
C1 [Macosko, Evan Z.; Nemesh, James; Goldman, Melissa; Kamitaki, Nolan; McCarroll, Steven A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Macosko, Evan Z.; Nemesh, James; Goldman, Melissa; Kamitaki, Nolan; McCarroll, Steven A.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Macosko, Evan Z.; Nemesh, James; Kamitaki, Nolan; McCarroll, Steven A.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Basu, Anindita; Satija, Rahul; Shekhar, Karthik; Tirosh, Itay; Trombetta, John J.; Shalek, Alex K.; Regev, Aviv] Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA.
[Basu, Anindita; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Satija, Rahul] New York Genome Ctr, New York, NY 10013 USA.
[Satija, Rahul] NYU, Dept Biol, New York, NY 10003 USA.
[Bialas, Allison R.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Martersteck, Emily M.; Sanes, Joshua R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Martersteck, Emily M.; Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Shalek, Alex K.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
[Shalek, Alex K.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
[Shalek, Alex K.] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Regev, Aviv] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Regev, Aviv] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Macosko, EZ (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
EM emacosko@genetics.med.harvard.edu; mccarroll@genetics.med.harvard.edu
OI Shalek, Alex K./0000-0001-5670-8778
FU Stanley Center for Psychiatric Research; MGH Psychiatry Residency
Research Program; Stanley-MGH Fellowship in Psychiatric Neuroscience;
Stewart Trust Fellows Award; Simons Foundation; NHGRI CEGS [P50
HG006193]; Klarman Cell Observatory; NIMH [U01MH105960, R25MH094612];
NIH [F32 HD075541]; National Science Foundation [ECS-0335765,
DMR-1310266]; Harvard Materials Research Science and Engineering Center
[DMR-1420570]
FX This work was supported by the Stanley Center for Psychiatric Research
(to S.M.), the MGH Psychiatry Residency Research Program and Stanley-MGH
Fellowship in Psychiatric Neuroscience (to E.Z.M.), a Stewart Trust
Fellows Award (to S.M.), a grant from the Simons Foundation to the
Simons Center for the Social Brain at MIT (to A.R., S.M., and D.W.), an
NHGRI CEGS P50 HG006193 (to A.R.), the Klarman Cell Observatory (to A.R.
and A.B.), NIMH grant U01MH105960 (to S.M., A.R. and J.R.S.), NIMH grant
R25MH094612 (to E.M.), NIH F32 HD075541 (to R.S.). AR is an investigator
of the Howard Hughes Medical Institute. Microfluidic device fabrication
was performed at the Harvard Center for Nanoscale Systems (CNS), a
member of the National Nanotechnology Infrastructure Network (National
Science Foundation award no. ECS-0335765), with support from the
National Science Foundation (DMR-1310266) and the Harvard Materials
Research Science and Engineering Center (DMR-1420570). We thank
Christina Usher and Leslie Gaffney for contributions to the manuscript
figures and Chris Patil for helpful comments on the manuscript. We thank
Connie Cepko for helpful conversations about the retina data, Beth
Stevens for advice on retinal dissociations, and Assaf Rotem and Huidan
Zhang for advice on microfluidics design and fabrication. A.R. is a
member of the Scientific Advisory Board for Thermo Fisher Scientific and
Syros Pharmaceuticals and a consultant for Driver Genomics.
NR 41
TC 291
Z9 297
U1 46
U2 187
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 21
PY 2015
VL 161
IS 5
BP 1202
EP 1214
DI 10.1016/j.cell.2015.05.002
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GA
UT WOS:000355152600025
PM 26000488
ER
PT J
AU Robinson, D
Van Allen, EM
Wu, YM
Schultz, N
Lonigro, RJ
Mosquera, JM
Montgomery, B
Taplin, ME
Pritchard, CC
Attard, G
Beltran, H
Abida, W
Bradley, RK
Vinson, J
Cao, XH
Vats, P
Kunju, LP
Hussain, M
Feng, FY
Tomlins, SA
Cooney, KA
Smith, DC
Brennan, C
Siddiqui, J
Mehra, R
Chen, Y
Rathkopf, DE
Morris, MJ
Solomon, SB
Durack, JC
Reuter, VE
Gopalan, A
Gao, JJ
Loda, M
Lis, RT
Bowden, M
Balk, SP
Gaviola, G
Sougnez, C
Gupta, M
Yu, EY
Mostaghel, EA
Cheng, HH
Mulcahy, H
True, LD
Plymate, SR
Dvinge, H
Ferraldeschi, R
Flohr, P
Miranda, S
Zafeiriou, Z
Tunariu, N
Mateo, J
Perez-Lopez, R
Demichelis, F
Robinson, BD
Schiffman, M
Nanus, DM
Tagawa, ST
Sigaras, A
Eng, KW
Elemento, O
Sboner, A
Heath, EI
Scher, HI
Pienta, KJ
Kantoff, P
de Bono, JS
Rubin, MA
Nelson, PS
Garraway, LA
Sawyers, CL
Chinnaiyan, AM
AF Robinson, Dan
Van Allen, Eliezer M.
Wu, Yi-Mi
Schultz, Nikolaus
Lonigro, Robert J.
Mosquera, Juan-Miguel
Montgomery, Bruce
Taplin, Mary-Ellen
Pritchard, Colin C.
Attard, Gerhardt
Beltran, Himisha
Abida, Wassim
Bradley, Robert K.
Vinson, Jake
Cao, Xuhong
Vats, Pankaj
Kunju, Lakshmi P.
Hussain, Maha
Feng, Felix Y.
Tomlins, Scott A.
Cooney, Kathleen A.
Smith, David C.
Brennan, Christine
Siddiqui, Javed
Mehra, Rohit
Chen, Yu
Rathkopf, Dana E.
Morris, Michael J.
Solomon, Stephen B.
Durack, Jeremy C.
Reuter, Victor E.
Gopalan, Anuradha
Gao, Jianjiong
Loda, Massimo
Lis, Rosina T.
Bowden, Michaela
Balk, Stephen P.
Gaviola, Glenn
Sougnez, Carrie
Gupta, Manaswi
Yu, Evan Y.
Mostaghel, Elahe A.
Cheng, Heather H.
Mulcahy, Hyojeong
True, Lawrence D.
Plymate, Stephen R.
Dvinge, Heidi
Ferraldeschi, Roberta
Flohr, Penny
Miranda, Susana
Zafeiriou, Zafeiris
Tunariu, Nina
Mateo, Joaquin
Perez-Lopez, Raquel
Demichelis, Francesca
Robinson, Brian D.
Schiffman, Marc
Nanus, David M.
Tagawa, Scott T.
Sigaras, Alexandros
Eng, Kenneth W.
Elemento, Olivier
Sboner, Andrea
Heath, Elisabeth I.
Scher, Howard I.
Pienta, Kenneth J.
Kantoff, Philip
de Bono, Johann S.
Rubin, Mark A.
Nelson, Peter S.
Garraway, Levi A.
Sawyers, Charles L.
Chinnaiyan, Arul M.
TI Integrative Clinical Genomics of Advanced Prostate Cancer
SO CELL
LA English
DT Article
ID ETS GENE FUSIONS; INCREASED SURVIVAL; MUTATIONS; REARRANGEMENTS;
ENZALUTAMIDE; CHEMOTHERAPY; ABIRATERONE; INHIBITION; DISCOVERY;
HETEROGENEITY
AB Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, beta-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
C1 [Robinson, Dan; Wu, Yi-Mi; Lonigro, Robert J.; Cao, Xuhong; Vats, Pankaj; Kunju, Lakshmi P.; Feng, Felix Y.; Tomlins, Scott A.; Brennan, Christine; Siddiqui, Javed; Mehra, Rohit; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
[Robinson, Dan; Wu, Yi-Mi; Kunju, Lakshmi P.; Tomlins, Scott A.; Mehra, Rohit; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
[Van Allen, Eliezer M.; Taplin, Mary-Ellen; Loda, Massimo; Lis, Rosina T.; Bowden, Michaela; Kantoff, Philip; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Van Allen, Eliezer M.; Loda, Massimo; Sougnez, Carrie; Gupta, Manaswi; Garraway, Levi A.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA.
[Schultz, Nikolaus] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
[Mosquera, Juan-Miguel; Robinson, Brian D.; Sboner, Andrea; Rubin, Mark A.] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA.
[Mosquera, Juan-Miguel; Beltran, Himisha; Demichelis, Francesca; Robinson, Brian D.; Schiffman, Marc; Nanus, David M.; Tagawa, Scott T.; Sigaras, Alexandros; Eng, Kenneth W.; Sboner, Andrea; Rubin, Mark A.] Cornell Univ, Weill Med Coll, Inst Precis Med, New York, NY 10021 USA.
[Mosquera, Juan-Miguel; Beltran, Himisha; Robinson, Brian D.; Nanus, David M.; Tagawa, Scott T.; Rubin, Mark A.] New York Presbyterian Hosp, New York, NY 10021 USA.
[Montgomery, Bruce; Bradley, Robert K.; Mostaghel, Elahe A.; Cheng, Heather H.; Dvinge, Heidi] Univ Washington, Computat Biol Program, Div Publ Hlth Sci, Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA.
[Montgomery, Bruce; Bradley, Robert K.; Mostaghel, Elahe A.; Cheng, Heather H.; Dvinge, Heidi] Univ Washington, Div Basic Sci, Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA.
[Montgomery, Bruce; Yu, Evan Y.; Mostaghel, Elahe A.; Cheng, Heather H.; Plymate, Stephen R.; Nelson, Peter S.] Univ Washington, Dept Med, Seattle, WA 98109 USA.
[Montgomery, Bruce; Yu, Evan Y.; Mostaghel, Elahe A.; Cheng, Heather H.; Plymate, Stephen R.; Nelson, Peter S.] Univ Washington, VAPSHCS, Seattle, WA 98109 USA.
[Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Inst Canc Res, Div Clin Studies, Canc Biomarkers Team, London SM2 5NG, England.
[Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Prostate Canc Targeted Therapy Grp, London SM2 5NG, England.
[Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London SM2 5NG, England.
[Beltran, Himisha; Chen, Yu; Rathkopf, Dana E.; Morris, Michael J.; Nanus, David M.; Tagawa, Scott T.; Scher, Howard I.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.
[Abida, Wassim; Chen, Yu; Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Vinson, Jake] Mem Sloan Kettering Canc Ctr, Prostate Canc Clin Trials Consortium, New York, NY 10065 USA.
[Hussain, Maha; Cooney, Kathleen A.; Smith, David C.] Univ Michigan, Sch Med, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Kunju, Lakshmi P.; Hussain, Maha; Feng, Felix Y.; Tomlins, Scott A.; Cooney, Kathleen A.; Smith, David C.; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.
[Hussain, Maha; Tomlins, Scott A.; Cooney, Kathleen A.; Smith, David C.; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA.
[Feng, Felix Y.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
[Abida, Wassim; Chen, Yu; Rathkopf, Dana E.; Morris, Michael J.; Scher, Howard I.] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA.
[Solomon, Stephen B.; Durack, Jeremy C.] Mem Sloan Kettering Canc Ctr, Dept Radiol Serv, Intervent Radiol, New York, NY 10065 USA.
[Reuter, Victor E.; Gopalan, Anuradha] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Loda, Massimo; Lis, Rosina T.; Bowden, Michaela] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA.
[Balk, Stephen P.] Harvard Univ, Sch Med, Div Hematol Oncol, Dept Med,Beth Israel Deaconess Canc Ctr,Beth Isra, Boston, MA 02215 USA.
[Gaviola, Glenn] Brigham & Womens Hosp, Dept Musculoskeletal Radiol, Boston, MA 02115 USA.
[Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Mulcahy, Hyojeong] Univ Washington, Dept Radiol, Seattle, WA 98109 USA.
[True, Lawrence D.] Univ Washington, Dept Pathol, Med Ctr, Seattle, WA 98109 USA.
[Demichelis, Francesca] Univ Trento, Ctr Integrat Biol, CIBIO, Lab Computat Oncol, I-38123 Mattarello Tn, Italy.
[Sigaras, Alexandros; Eng, Kenneth W.; Elemento, Olivier; Sboner, Andrea] Cornell Univ, Dept Physiol & Biophys, Inst Computat Biomed, Weill Med Coll, New York, NY 10021 USA.
[Schiffman, Marc] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, Div Intervent Radiol, New York, NY 10021 USA.
[Sigaras, Alexandros; Eng, Kenneth W.] Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.
[Heath, Elisabeth I.] Wayne State Univ, Dept Oncol, Sch Med, Detroit, MI 48201 USA.
[Heath, Elisabeth I.] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA.
[Pienta, Kenneth J.] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA.
[Pienta, Kenneth J.] Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA.
[Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.
[Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Mosquera, Juan-Miguel; Beltran, Himisha; Robinson, Brian D.; Schiffman, Marc; Nanus, David M.; Tagawa, Scott T.; Sboner, Andrea; Rubin, Mark A.; Nelson, Peter S.] Cornell Univ, Weill Med Coll, Meyer Canc, New York, NY 10021 USA.
[Loda, Massimo; Bowden, Michaela] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Schultz, Nikolaus; Gao, Jianjiong] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, New York, NY 10065 USA.
[Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA.
[Cao, Xuhong; Chinnaiyan, Arul M.] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.
RP Sawyers, CL (reprint author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
EM sawyersc@mskcc.org; arul@umich.edu
RI Sawyers, Charles/G-5327-2016;
OI Rathkopf, Dana/0000-0002-4503-7582; Dvinge, Heidi/0000-0003-1741-0738;
Bradley, Robert/0000-0002-8046-1063; Rubin, Mark/0000-0002-8321-9950;
Attard, Gerhardt/0000-0002-4811-7983; Demichelis,
Francesca/0000-0002-8266-8631; Durack, Jeremy/0000-0002-0672-9586;
Morris, Michael J./0000-0002-9454-0096
FU Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team
Translational Cancer Research Grant; NIH: Clinical Sequencing
Exploratory Research (CSER) [UM1HG006508]; NIH: Early Detection Research
Network grant [UO1 CA111275]; NIH: Prostate SPORE [P50 CA186786, P50
CA092629, P50 CA90381, P50 CA097186, P01 CA163227, R01 CA116337, R01
CA155169, R01 CA092629]; DoD [W81XWH-09-1-0147, DOD PC121341, PC131820];
Starr Cancer Consortium; Damon Runyon Cancer Research Foundation
[CI-67-13]; PCF Young Investigator Award; NIH [1K08CA188615]; Prostate
Cancer Foundation Young Investigator Awards; Movember Foundation; ECMC
network from Cancer Research UK; Department of Health in the UK; BRC
grant; Prostate Cancer UK, PCF
FX We thank the affected individuals who participated in this study to
better understand the feasibility and utility of precision medicine
approaches for advanced prostate cancer. Individuals at our respective
institutions who helped with this study are listed by institution.
University of Michigan: Karen Giles, Lynda Hodges, Erica Rabban, Ning
Yu, Fengyun Su, Rui Wang, Brendan Veeneman, and Moshe Talpaz. MSKCC:
Brett Carver, Kristen Curtis, and Julie Filipenko. DFCI/Broad: Zhenwei
Zhang, Daniele Depalo, and Joseph Kramkowski. University of Washington:
Jina Taub, Hiep Nguyen, Colm Morrissey, and Robert Vessella. ICR/Royal
Marsden: Suzanne Carreira, Ines Figueiredo, and Daniel Nava Rodrigues.
This work was supported by a Stand Up To Cancer-Prostate Cancer
Foundation Prostate Dream Team Translational Cancer Research Grant.
Stand Up To Cancer is a program of the Entertainment Industry Foundation
administered by the American Association for Cancer Research
(SU2C-AACR-DT0712). The project was also supported by the following NIH
awards: Clinical Sequencing Exploratory Research (CSER) UM1HG006508
(A.M.C.), Early Detection Research Network grant UO1 CA111275(A.M.C.),
Prostate SPORE grants P50 CA186786 (A.M.C.), P50 CA092629 (H.I.S.,
C.L.S., and Y.C.), P50 CA90381 (P.K.), and P50 CA097186 (P.S.N., B.M.,
E.A.M., and L.D.T.), P01 CA163227 (P.S.N., S.P., R.K.B., H.D.), R01
CA116337 (M.A.R., H.B., F.D.), R01 CA155169 (C.L.S.), R01 CA092629, P50
CA092629 (H.I.S., C.L.S., and Y.C.), and R01 CA155169 (C.L.S.). This
work was supported by the following DoD awards: W81XWH-09-1-0147 (PCCTC)
and DOD PC121341 (H.B.). This work was also supported by the Starr
Cancer Consortium (N.S., M.R., C.S., Y.C., L.A.G.). A.M.C. is an A.
Alfred Taubman Scholar and an American Cancer Society Professor. H.B. is
supported by Damon Runyon Cancer Research Foundation CI-67-13. C.P. is
supported by a PCF Young Investigator Award and DoD PC131820. E.M.V. is
supported by a NIH 1K08CA188615. E.M.V., N.S., and F.Y.F. are supported
by Prostate Cancer Foundation Young Investigator Awards. The RM and ICR
team is supported by the Movember Foundation and Prostate Cancer UK,
PCF, the ECMC network from Cancer Research UK, the Department of Health
in the UK, and BRC grant funding.
NR 64
TC 320
Z9 324
U1 23
U2 88
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 21
PY 2015
VL 161
IS 5
BP 1215
EP 1228
DI 10.1016/j.cell.2015.05.001
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GA
UT WOS:000355152600026
PM 26000489
ER
PT J
AU Wang, JH
Gray, NS
AF Wang, Jinhua
Gray, Nathanael S.
TI SnapShot: Kinase Inhibitors I
SO MOLECULAR CELL
LA English
DT Editorial Material
ID SELECTIVITY; UPDATE
C1 [Wang, Jinhua; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Wang, Jinhua; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Wang, JH (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
NR 9
TC 2
Z9 2
U1 2
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAY 21
PY 2015
VL 58
IS 4
BP 708
EP U161
DI 10.1016/j.molcel.2015.05.001
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GO
UT WOS:000355154000017
ER
PT J
AU Wang, JH
Gray, NS
AF Wang, Jinhua
Gray, Nathanael S.
TI SnapShot: Kinase Inhibitors II
SO MOLECULAR CELL
LA English
DT Editorial Material
ID SELECTIVITY; UPDATE
C1 [Wang, Jinhua; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Wang, Jinhua; Gray, Nathanael S.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA.
RP Wang, JH (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
NR 9
TC 2
Z9 2
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAY 21
PY 2015
VL 58
IS 4
BP 710
EP U163
DI 10.1016/j.molcel.2015.05.002
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ0GO
UT WOS:000355154000018
ER
PT J
AU Lin, YT
McMahon, SJ
Paganetti, H
Schuemann, J
AF Lin, Yuting
McMahon, Stephen J.
Paganetti, Harald
Schuemann, Jan
TI Biological modeling of gold nanoparticle enhanced radiotherapy for
proton therapy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE gold nanoparticle; radiotherapy; proton therapy; local effect model;
biological model
ID MONTE-CARLO-SIMULATION; RADIATION-THERAPY; DOSE ENHANCEMENT; ION
IRRADIATION; BEAM THERAPY; CELLS; RADIOSENSITIZATION; ENERGY; SIZE;
SENSITIVITY
AB Gold nanoparticles (GNPs) have shown potential as a radiosensitizer for radiation therapy using photon beams. Recently, experimental studies have been carried out using proton beams showing the GNP enhanced responses in proton therapy. In this work, we established a biological model to investigate the change in survival of irradiated cells due to the radiosensitizing effect of gold nanoparticles. Results for proton, megavoltage (MV) photon and kilovoltage (kV) photon beams are compared. For each particle source, we assessed various treatment depths, GNP cellular uptakes and sizes. We showed that kilovoltage photons caused the highest enhancement due to the high interaction probability between GNPs and kV photons. The cell survival fraction can be significantly reduced for both proton and MV photon irradiations if GNPs accumulate in the cell. For instance, the sensitizer enhancement ratio (SER) is 1.33 for protons in the middle of a spread out Bragg peak for 1 mu M of internalized 50 nm GNPs. If the GNPs can all be internalized into the cell nucleus, the SER for proton therapy increases from 1.33 to 1.81. The results also show that for the same mass of GNPs in the cells, one can expect the greatest sensitization by smaller GNPs, i.e. a SER of 1.33 for 1 mu M of internalized 50 nm GNPs and a SER of 3.98 for the same mass of 2 nm GNPs. We concluded that if the GNPs cannot be internalized into the cytoplasm, no GNP enhancement will be observed for proton treatment. Meanwhile, proton radiotherapy can potentially be enhanced with GNPs if they can be internalized into cells, and especially the cell nucleus.
C1 [Lin, Yuting; McMahon, Stephen J.; Paganetti, Harald; Schuemann, Jan] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Lin, Yuting; McMahon, Stephen J.; Paganetti, Harald; Schuemann, Jan] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[McMahon, Stephen J.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7AE, Antrim, North Ireland.
RP Lin, YT (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM ylin20@partners.org
NR 47
TC 9
Z9 11
U1 6
U2 28
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 21
PY 2015
VL 60
IS 10
BP 4149
EP 4168
DI 10.1088/0031-9155/60/10/4149
PG 20
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA CJ0XI
UT WOS:000355203100019
PM 25953956
ER
PT J
AU Sawyer, RG
Claridge, JA
Nathens, AB
Rotstein, OD
Duane, TM
Evans, HL
Cook, CH
O'Neill, PJ
Mazuski, JE
Askari, R
Wilson, MA
Napolitano, LM
Namias, N
Miller, PR
Dellinger, EP
Watson, CM
Coimbra, R
Dent, DL
Lowry, SF
Cocanour, CS
West, MA
Banton, KL
Cheadle, WG
Lipsett, PA
Guidry, CA
Popovsky, K
AF Sawyer, R. G.
Claridge, J. A.
Nathens, A. B.
Rotstein, O. D.
Duane, T. M.
Evans, H. L.
Cook, C. H.
O'Neill, P. J.
Mazuski, J. E.
Askari, R.
Wilson, M. A.
Napolitano, L. M.
Namias, N.
Miller, P. R.
Dellinger, E. P.
Watson, C. M.
Coimbra, R.
Dent, D. L.
Lowry, S. F.
Cocanour, C. S.
West, M. A.
Banton, K. L.
Cheadle, W. G.
Lipsett, P. A.
Guidry, C. A.
Popovsky, K.
TI Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ANTIBIOTIC-THERAPY; CHILDREN GUIDELINES; DISEASES SOCIETY;
RANDOMIZED-TRIAL; MANAGEMENT; MORTALITY; SEPSIS; ADULTS; DIAGNOSIS;
BACTERIAL
AB BACKGROUND
The successful treatment of intraabdominal infection requires a combination of anatomical source control and antibiotics. The appropriate duration of antimicrobial therapy remains unclear.
METHODS
We randomly assigned 518 patients with complicated intraabdominal infection and adequate source control to receive antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, with a maximum of 10 days of therapy (control group), or to receive a fixed course of antibiotics (experimental group) for 4 +/- 1 calendar days. The primary outcome was a composite of surgical-site infection, recurrent intraabdominal infection, or death within 30 days after the index source-control procedure, according to treatment group. Secondary outcomes included the duration of therapy and rates of subsequent infections.
RESULTS
Surgical-site infection, recurrent intraabdominal infection, or death occurred in 56 of 257 patients in the experimental group (21.8%), as compared with 58 of 260 patients in the control group (22.3%) (absolute difference, -0.5 percentage point; 95% confidence interval [CI], -7.0 to 8.0; P = 0.92). The median duration of antibiotic therapy was 4.0 days (interquartile range, 4.0 to 5.0) in the experimental group, as compared with 8.0 days (interquartile range, 5.0 to 10.0) in the control group (absolute difference, -4.0 days; 95% CI, -4.7 to -3.3; P<0.001). No significant between-group differences were found in the individual rates of the components of the primary outcome or in other secondary outcomes.
CONCLUSIONS
In patients with intraabdominal infections who had undergone an adequate source-control procedure, the outcomes after fixed-duration antibiotic therapy (approximately 4 days) were similar to those after a longer course of antibiotics (approximately 8 days) that extended until after the resolution of physiological abnormalities.
C1 [Sawyer, R. G.; Guidry, C. A.; Popovsky, K.] Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA 22908 USA.
[Duane, T. M.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA.
[Claridge, J. A.] Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA.
[Nathens, A. B.; Rotstein, O. D.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
[Evans, H. L.; Dellinger, E. P.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Cook, C. H.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
[Askari, R.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[O'Neill, P. J.] Maricopa Integrated Hlth Syst, Dept Surg, Phoenix, AZ USA.
[Mazuski, J. E.] Washington Univ, Dept Surg, St Louis, MO USA.
[Wilson, M. A.] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA.
[Napolitano, L. M.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
[Namias, N.] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.
[Miller, P. R.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA.
[Watson, C. M.] Univ S Carolina, Dept Surg, Columbia, SC 29208 USA.
[Coimbra, R.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Cocanour, C. S.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA.
[West, M. A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Dent, D. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Lowry, S. F.] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA.
[Banton, K. L.] Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA.
[Cheadle, W. G.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.
[Lipsett, P. A.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
RP Sawyer, RG (reprint author), Univ Virginia Hlth Syst, Dept Surg, Box 800709, Charlottesville, VA 22908 USA.
EM rws2k@virginia.edu
FU National Institutes of Health [R01GM081510, T32 AI078875]; 3M; Pfizer;
Bayer; Merck; AstraZeneca; Baxter; Ortho-McNeil; Targanta Therapeutics;
Schering-Plough; Astellas; CareFusion; Durata Therapeutics; Rib-X
Pharmaceuticals; Affinium Pharmaceuticals; Tetraphase Pharmaceuticals;
R-Pharm; Applied Medical
FX Supported by grants (R01GM081510 and T32 AI078875) from the National
Institutes of Health.; Dr. Sawyer reports receiving consulting fees from
3M and Pfizer; Dr. Duane, lecture fees from Pfizer; Dr. O'Neill, fees
for serving on a surgical review panel for Cubist; Dr. Mazuski, fees for
serving on advisory boards from AstraZeneca, Cubist, Merck, and Pfizer,
consulting fees from Bayer, lecture fees from Merck, and grant support
from AstraZeneca, Bayer, Merck, and Pfizer; and Dr. Dellinger, fees for
serving on advisory boards from Merck, Baxter, Ortho-McNeil, Targanta
Therapeutics, Schering-Plough, Astellas, CareFusion, Durata
Therapeutics, Pfizer, Rib-X Pharmaceuticals, Affinium Pharmaceuticals,
Tetraphase Pharmaceuticals, and R-Pharm, and lecture fees from Applied
Medical. No other potential conflict of interest relevant to this
article was reported.
NR 18
TC 74
Z9 79
U1 0
U2 12
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2015
VL 372
IS 21
BP 1996
EP 2005
DI 10.1056/NEJMoa1411162
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5PD
UT WOS:000354809300006
PM 25992746
ER
PT J
AU Postow, MA
Chesney, J
Pavlick, AC
Robert, C
Grossmann, K
McDermott, D
Linette, GP
Meyer, N
Giguere, JK
Agarwala, SS
Shaheen, M
Ernstoff, MS
Minor, D
Salama, AK
Taylor, M
Ott, PA
Rollin, LM
Horak, C
Gagnier, P
Wolchok, JD
Hodi, FS
AF Postow, Michael A.
Chesney, Jason
Pavlick, Anna C.
Robert, Caroline
Grossmann, Kenneth
McDermott, David
Linette, Gerald P.
Meyer, Nicolas
Giguere, Jeffrey K.
Agarwala, Sanjiv S.
Shaheen, Montaser
Ernstoff, Marc S.
Minor, David
Salama, April K.
Taylor, Matthew
Ott, Patrick A.
Rollin, Linda M.
Horak, Christine
Gagnier, Paul
Wolchok, Jedd D.
Hodi, F. Stephen
TI Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID MEK INHIBITION; COMBINED BRAF; OPEN-LABEL; MUTATION; VEMURAFENIB;
RESPONSES; SAFETY; PD-1; ASSOCIATION; DABRAFENIB
AB BACKGROUND
In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.
METHODS
In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2: 1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors.
RESULTS
Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication.
CONCLUSIONS
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile.
C1 [Postow, Michael A.; Wolchok, Jedd D.] NYU, Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Postow, Michael A.; Wolchok, Jedd D.] NYU, Weill Cornell Med Coll, New York, NY USA.
[Pavlick, Anna C.] NYU, Perlmutter Canc Ctr, New York, NY USA.
[Chesney, Jason] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
[Robert, Caroline] Inst Gustave Roussy, Villejuif, France.
[Robert, Caroline] Univ Paris 11, Orsay, France.
[Meyer, Nicolas] Inst Univ Canc, Toulouse, France.
[Grossmann, Kenneth] Huntsman Canc Inst, Salt Lake City, UT USA.
[McDermott, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Ott, Patrick A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Linette, Gerald P.] Washington Univ, St Louis, MO USA.
[Giguere, Jeffrey K.] Greenville Hlth Syst, Greenville, SC USA.
[Agarwala, Sanjiv S.] St Lukes Canc Ctr, Bethlehem, PA USA.
[Shaheen, Montaser] Univ New Mexico, Albuquerque, NM 87131 USA.
[Ernstoff, Marc S.] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA.
[Minor, David] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA.
[Salama, April K.] Duke Univ, Durham, NC USA.
[Taylor, Matthew] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Horak, Christine] Bristol Myers Squibb Co, Lawrenceville, NJ USA.
[Rollin, Linda M.; Gagnier, Paul] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
RP Hodi, FS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM wolchokj@mskcc.org; stephen_hodi@dfci.harvard.edu
FU Bristol-Myers Squibb
FX Supported by Bristol-Myers Squibb.
NR 25
TC 499
Z9 510
U1 5
U2 34
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2015
VL 372
IS 21
BP 2006
EP 2017
DI 10.1056/NEJMoa1414428
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5PD
UT WOS:000354809300007
PM 25891304
ER
PT J
AU Garon, EB
Rizvi, NA
Hui, RN
Leighl, N
Balmanoukian, AS
Eder, JP
Patnaik, A
Aggarwal, C
Gubens, M
Horn, L
Carcereny, E
Ahn, MJ
Felip, E
Lee, JS
Hellmann, MD
Hamid, O
Goldman, JW
Soria, JC
Dolled-Filhart, M
Rutledge, RZ
Zhang, J
Lunceford, JK
Rangwala, R
Lubiniecki, GM
Roach, C
Emancipator, K
Gandhi, L
AF Garon, Edward B.
Rizvi, Naiyer A.
Hui, Rina
Leighl, Natasha
Balmanoukian, Ani S.
Eder, Joseph Paul
Patnaik, Amita
Aggarwal, Charu
Gubens, Matthew
Horn, Leora
Carcereny, Enric
Ahn, Myung-Ju
Felip, Enriqueta
Lee, Jong-Seok
Hellmann, Matthew D.
Hamid, Omid
Goldman, Jonathan W.
Soria, Jean-Charles
Dolled-Filhart, Marisa
Rutledge, Ruth Z.
Zhang, Jin
Lunceford, Jared K.
Rangwala, Reshma
Lubiniecki, Gregory M.
Roach, Charlotte
Emancipator, Kenneth
Gandhi, Leena
CA KEYNOTE-001 Investigators
TI Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ANTI-PD-L1 ANTIBODY; PD-L1 EXPRESSION; BLOCKADE; CHEMOTHERAPY; B7-H1;
ACTIVATION; MELANOMA; SAFETY; CRIZOTINIB; RESPONSES
AB BACKGROUND
We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.
METHODS
We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review.
RESULTS
Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached.
CONCLUSIONS
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.
C1 [Garon, Edward B.; Goldman, Jonathan W.] UCLA, David Geffen Sch Med, Santa Monica, CA 90404 USA.
[Balmanoukian, Ani S.; Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
[Gubens, Matthew] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Roach, Charlotte] Dako, Carpinteria, CA USA.
[Rizvi, Naiyer A.] Columbia Univ, New York, NY USA.
[Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Hellmann, Matthew D.] Weill Cornell Med Coll, New York, NY USA.
[Hui, Rina] Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia.
[Leighl, Natasha] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Eder, Joseph Paul] Yale Univ, New Haven, CT USA.
[Patnaik, Amita] South Texas Accelerated Res Therapeut, San Antonio, TX USA.
[Aggarwal, Charu] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Carcereny, Enric] Catalan Inst Oncol Badalona, Badalona, Spain.
[Felip, Enriqueta] Vall dHebron Univ Hosp, Barcelona, Spain.
[Felip, Enriqueta] Vall dHebron Inst Oncol, Barcelona, Spain.
[Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Lee, Jong-Seok] Seoul Natl Univ, Seoul, South Korea.
[Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France.
[Soria, Jean-Charles] Univ Paris 11, Villejuif, France.
[Dolled-Filhart, Marisa; Rutledge, Ruth Z.; Zhang, Jin; Lunceford, Jared K.; Rangwala, Reshma; Lubiniecki, Gregory M.; Emancipator, Kenneth] Merck, Kenilworth, NJ USA.
[Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Garon, EB (reprint author), UCLA, David Geffen Sch Med, Translat Oncol Res Lab, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA.
EM egaron@mednet.ucla.edu
RI Garassino, Marina/D-7128-2017; Zhang, Jin/E-8298-2017;
OI Garassino, Marina/0000-0002-3821-5598; Santini,
Daniele/0000-0002-9118-3337; Gandhi, Leena/0000-0002-2398-9179
FU Merck Sharp & Dohme, a subsidiary of Merck
FX Supported by Merck Sharp & Dohme, a subsidiary of Merck.
NR 40
TC 725
Z9 760
U1 45
U2 121
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2015
VL 372
IS 21
BP 2018
EP 2028
DI 10.1056/NEJMoa1501824
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5PD
UT WOS:000354809300008
PM 25891174
ER
PT J
AU Olfson, M
Druss, BG
Marcus, SC
AF Olfson, Mark
Druss, Benjamin G.
Marcus, Steven C.
TI Trends in Mental Health Care among Children and Adolescents
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PSYCHOSOCIAL TREATMENTS; IMPAIRMENT; DEPRESSION; MEDICATION; DISORDER;
AMERICANS
AB BACKGROUND
Increasing mental health treatment of young people and broadening conceptualizations of psychopathology have triggered concerns about a disproportionate increase in the treatment of youths with low levels of mental health impairment.
METHODS
We analyzed the 1996-1998, 2003-2005, and 2010-2012 Medical Expenditure Panel Surveys, which were nationally representative surveys of U.S. households, for trends in outpatient use of mental health services by persons 6 to 17 years of age; 53,622 persons were included in the analysis. Mental health impairment was measured with the use of the Columbia Impairment Scale (range, 0 to 52, with higher scores indicating more severe impairment); we classified youths with scores of 16 or higher as having more severe impairment and those with scores of less than 16 as having less severe impairment.
RESULTS
The percentage of youths receiving any outpatient mental health service increased from 9.2% in 1996-1998 to 13.3% in 2010-2012 (odds ratio, 1.52; 95% confidence interval, 1.35 to 1.72). The proportionate increase in the use of mental health services among youths with more severe impairment (from 26.2% to 43.9%) was larger than that among youths with less severe or no impairment (from 6.7% to 9.6%). However, the absolute increase in annual service use was larger among youths with less severe or no impairment (from 2.74 million to 4.19 million) than among those with more severe impairment (from 1.56 million to 2.28 million). Significant overall increases occurred in the use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including stimulants and related medications (from 4.0% to 6.6%), antidepressants (from 1.5% to 2.6%), and antipsychotic drugs (from 0.2% to 1.2%).
CONCLUSIONS
Outpatient mental health treatment and psychotropic-medication use in children and adolescents increased in the United States between 1996-1998 and 2010-2012. Although youths with less severe or no impairment accounted for most of the absolute increase in service use, youths with more severe impairment had the greatest relative increase in use, yet fewer than half accessed services in 2010-2012.
C1 [Olfson, Mark] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USA.
[Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Druss, Benjamin G.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA.
[Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Marcus, Steven C.] Univ Penn, Sch Social Practice & Policy, Philadelphia, PA 19104 USA.
RP Olfson, M (reprint author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA.
EM mo49@cumc.columbia.edu
FU Agency for Healthcare Research and Quality [U19 HS021112]; New York
State Psychiatric Institute
FX Supported by a grant (U19 HS021112) from the Agency for Healthcare
Research and Quality and by the New York State Psychiatric Institute.
NR 39
TC 27
Z9 28
U1 5
U2 15
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 21
PY 2015
VL 372
IS 21
BP 2029
EP 2038
DI 10.1056/NEJMsa1413512
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5PD
UT WOS:000354809300009
PM 25992747
ER
PT J
AU Jung, M
Lin, L
Viswanath, K
AF Jung, Minsoo
Lin, Leesa
Viswanath, Kasisomayajula
TI Effect of media use on mothers' vaccination of their children in
sub-Saharan Africa
SO VACCINE
LA English
DT Article
DE Immunizations; Child health; Media use; Health communication;
Sub-Saharan African countries
ID HEALTH; IMMUNIZATION; INFLUENZA; PARENTS; COVERAGE; PROGRAMS;
DETERMINANTS; BEHAVIORS; KNOWLEDGE
AB While several studies have examined the crucial role that parents' vaccination behaviors play in reducing disease spread and severity among children, few have evaluated the connection between parents' media use and their decision on whether or not to vaccinate their child, specifically in relation to the BCG (Bacillus Calmetter Guerin), DPT (Diptheria, Pertussis, Tetanus) polio, and measles vaccines. Media channels are a critical source of health information for parents, which is especially true in Sub-Saharan Africa, as there is often a dearth of local healthcare providers. The aim of this paper is to investigate the role that media use plays in a mothers' choice to vaccinate their infant children in sub-Saharan Africa, specifically focusing on whether media use is associated with socioeconomic status (SES) and a mothers' vaccination of their children. Cross-sectional data from the Demographic Health Surveys of 13 sub-Saharan countries (2004-2010) were pooled. A multivariate Poisson regression of 151,209 women was used to calculate adjusted relative ratios and 95% confidence intervals for the associations among SES, media use, and immunization. Education and wealth were found to be strongly and positively associated with vaccine-uptake behaviors. The effects of media use (radio and television) were found to be associated with the relationships between SES and vaccine uptake. However, it did not reduce the impact of SES on vaccination. These findings indicate that mass media may be an important tool for future efforts to reduce the health discrepancies between children from high- and low-socioeconomic backgrounds. Going forward, immunization strategies should include communication plans that will address and mitigate potential immunization disparities among parents of different SES backgrounds. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea.
[Lin, Leesa; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Lin, Leesa; Viswanath, Kasisomayajula] Harvard Univ, Dept Social & Behav Sci, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
RP Jung, M (reprint author), Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea.
EM mins.jung@gmail.com
OI Jung, Minsoo/0000-0003-3317-6507
NR 50
TC 1
Z9 1
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2015
VL 33
IS 22
BP 2551
EP 2557
DI 10.1016/j.vaccine.2015.04.021
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CI8SA
UT WOS:000355040800007
PM 25896379
ER
PT J
AU Shen, Y
Li, J
Nitta, M
Futalan, D
Steed, T
Treiber, JM
Taich, Z
Stevens, D
Wykosky, J
Chen, HZ
Carter, BS
Becher, OJ
Kennedy, R
Esashi, F
Sarkaria, JN
Furnari, FB
Cavenee, WK
Desai, A
Chen, CC
AF Shen, Ying
Li, Jie
Nitta, Masayuki
Futalan, Diahnn
Steed, Tyler
Treiber, Jeffrey M.
Taich, Zack
Stevens, Deanna
Wykosky, Jill
Chen, Hong-Zhuan
Carter, Bob S.
Becher, Oren J.
Kennedy, Richard
Esashi, Fumiko
Sarkaria, Jann N.
Furnari, Frank B.
Cavenee, Webster K.
Desai, Arshad
Chen, Clark C.
TI Orthogonal targeting of EGFRvIII expressing glioblastomas through
simultaneous EGFR and PLK1 inhibition
SO ONCOTARGET
LA English
DT Article
DE EGFR; EGFRvIII; glioblastoma; synthetic lethality
ID GROWTH-FACTOR RECEPTOR; SYNTHETIC LETHAL INTERACTIONS; DNA-DAMAGE
RESPONSE; STRAND BREAK REPAIR; KINASE INHIBITORS; TUMOR-SUPPRESSOR;
UP-REGULATION; CANCER; CELLS; ONCOGENE
AB We identified a synthetic lethality between PLK1 silencing and the expression of an oncogenic Epidermal Growth Factor Receptor, EGFRvIII. PLK1 promoted homologous recombination (HR), mitigating EGFRvIII induced oncogenic stress resulting from DNA damage accumulation. Accordingly, PLK1 inhibition enhanced the cytotoxic effects of the DNA damaging agent, temozolomide (TMZ). This effect was significantly more pronounced in an Ink4a/Arf(-/-) EGFRvIII glioblastoma model relative to an Ink4a/Arf(-/-) PDGF-beta model. The tumoricidal and TMZ-sensitizing effects of BI2536 were uniformly observed across Ink4a/Arf(-/-) EGFRvIII glioblastoma clones that acquired independent resistance mechanisms to EGFR inhibitors, suggesting these resistant clones retain oncogenic stress that required PLK1 compensation. Although BI2536 significantly augmented the anti-neoplastic effect of EGFR inhibitors in the Ink4a/Arf(-/-) EGFRvIII model, durable response was not achieved until TMZ was added. Our results suggest that optimal therapeutic effect against glioblastomas requires a "multi-orthogonal" combination tailored to the molecular physiology associated with the target cancer genome.
C1 [Shen, Ying; Li, Jie; Futalan, Diahnn; Steed, Tyler; Treiber, Jeffrey M.; Taich, Zack; Carter, Bob S.; Chen, Clark C.] Univ Calif San Diego, Ctr Theoret & Appl Neurooncol, Moores Canc Ctr, Div Neurosurg, San Diego, CA 92103 USA.
[Shen, Ying; Chen, Hong-Zhuan] Shanghai Jiao Tong Univ, Dept Pharmacol & Chem Biol, Sch Med, Shanghai 200030, Peoples R China.
[Shen, Ying; Chen, Hong-Zhuan] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Translat Med, Sch Med, Shanghai 200030, Peoples R China.
[Nitta, Masayuki] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Stevens, Deanna; Wykosky, Jill; Furnari, Frank B.; Cavenee, Webster K.; Desai, Arshad] Univ Calif San Diego, San Diego Branch, Ludwig Inst Canc Res, San Diego, CA 92103 USA.
[Becher, Oren J.] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA.
[Becher, Oren J.] Duke Univ, Med Ctr, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA.
[Kennedy, Richard] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
[Esashi, Fumiko] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
[Sarkaria, Jann N.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA.
RP Chen, CC (reprint author), Univ Calif San Diego, Ctr Theoret & Appl Neurooncol, Moores Canc Ctr, Div Neurosurg, San Diego, CA 92103 USA.
EM clarkchen@ucsd.edu
RI Li, Jie/L-1737-2015
OI Li, Jie/0000-0002-0590-9817
FU Doris Duke Charitable Foundation Clinical Scientist Development Award;
Sontag Foundation Distinguished Scientist Award; Burroughs Welcome Fund
Career Awards for Medical Scientists; Kimmel Scholar award; Discovery
Grant from the American Brain Tumor Association; Accelerated Brain
Cancer Cure; William Guy Forbeck Research Foundation; National Natural
Science Foundation of China [81473232]; National Basic Research Program
of China (973 Program) [2010CB529800]; James S. McDonnell Foundation;
[P01-CA95616/NIH]; [R01-NS080939/NIH]
FX We are grateful to the reagent donators (Dr. David Pellman and Dr. David
Weinstock). CCC is supported by the Doris Duke Charitable Foundation
Clinical Scientist Development Award (http://www.ddcf.org), the Sontag
Foundation Distinguished Scientist Award
(http://www.sontagfoundation.com), the Burroughs Welcome Fund Career
Awards for Medical Scientists (http://www.bwfund.org), the Kimmel
Scholar award (http://www.kimmel.org), a Discovery Grant from the
American Brain Tumor Association (http://www.abta.org), a Grant from
Accelerated Brain Cancer Cure (http://abc2.org/) and the William Guy
Forbeck Research Foundation (http://wgfrf.org/). SY is supported by
National Natural Science Foundation of China (81473232) and National
Basic Research Program of China (973 Program) (2010CB529800). WKC and
FBF are supported by P01-CA95616/NIH and R01-NS080939/NIH. FBF is
supported by James S. McDonnell Foundation (https://www.jsmf.org/).
NR 47
TC 4
Z9 5
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 20
PY 2015
VL 6
IS 14
BP 11751
EP 11767
PG 17
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CO2SZ
UT WOS:000359008200004
PM 26059434
ER
PT J
AU Cirenajwis, H
Ekedahl, H
Lauss, M
Harbst, K
Carneiro, A
Enoksson, J
Rosengren, F
Werner-Hartman, L
Torngren, T
Kvist, A
Fredlund, E
Bendahl, PO
Jirstrom, K
Lundgren, L
Howlin, J
Borg, A
Gruvberger-Saal, SK
Saal, LH
Nielsen, K
Ringner, M
Tsao, H
Olsson, H
Ingvar, C
Staaf, J
Jonsson, G
AF Cirenajwis, Helena
Ekedahl, Henrik
Lauss, Martin
Harbst, Katja
Carneiro, Ana
Enoksson, Jens
Rosengren, Frida
Werner-Hartman, Linda
Torngren, Therese
Kvist, Anders
Fredlund, Erik
Bendahl, Par-Ola
Jirstrom, Karin
Lundgren, Lotta
Howlin, Jillian
Borg, Ake
Gruvberger-Saal, Sofia K.
Saal, Lao H.
Nielsen, Kari
Ringner, Markus
Tsao, Hensin
Olsson, Hakan
Ingvar, Christian
Staaf, Johan
Jonsson, Goran
TI Molecular stratification of metastatic melanoma using gene expression
profiling : Prediction of survival outcome and benefit from molecular
targeted therapy
SO ONCOTARGET
LA English
DT Article
DE gene expression; melanoma; BRAF; BRAF inhibitor; mutation
ID STAGE-III MELANOMA; CUTANEOUS MELANOMA; CANCER GENOMICS; BRAF INHIBITOR;
RESISTANCE; MUTATIONS; LANDSCAPE
AB Melanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and normal-like), which are predictive of survival outcome as well as informative of biology. Herein, we employed a population-based metastatic melanoma cohort and external cohorts to determine the prognostic and predictive significance of the gene expression phenotypes. We performed expression profiling on 214 cutaneous melanoma tumors and found an increased risk of developing distant metastases in the pigmentation (HR, 1.9; 95% CI, 1.05-3.28; P=0.03) and proliferative (HR, 2.8; 95% CI, 1.43-5.57; P=0.003) groups as compared to the high-immune response group. Further genetic characterization of melanomas using targeted deep-sequencing revealed similar mutational patterns across these phenotypes. We also used publicly available expression profiling data from melanoma patients treated with targeted or vaccine therapy in order to determine if our signatures predicted therapeutic response. In patients receiving targeted therapy, melanomas resistant to targeted therapy were enriched in the MITF-low proliferative subtype as compared to pretreatment biopsies (P=0.02). In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy.
C1 [Cirenajwis, Helena; Lauss, Martin; Harbst, Katja; Carneiro, Ana; Rosengren, Frida; Werner-Hartman, Linda; Torngren, Therese; Kvist, Anders; Bendahl, Par-Ola; Lundgren, Lotta; Howlin, Jillian; Borg, Ake; Gruvberger-Saal, Sofia K.; Saal, Lao H.; Ringner, Markus; Olsson, Hakan; Staaf, Johan; Jonsson, Goran] Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden.
[Ekedahl, Henrik; Ingvar, Christian] Lund Univ, Dept Clin Sci, Div Surg, Lund, Sweden.
[Carneiro, Ana; Lundgren, Lotta; Olsson, Hakan] Lund Univ, Dept Oncol, Skane Univ Hosp, Lund, Sweden.
[Enoksson, Jens; Jirstrom, Karin] Lund Univ, Dept Clin Pathol, Skane Univ Hosp, Lund, Sweden.
[Fredlund, Erik] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Nielsen, Kari] Helsingborg Gen Hosp, Dept Dermatol, Helsingborg, Sweden.
[Tsao, Hensin] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Jonsson, G (reprint author), Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden.
EM goran_b.jonsson@med.lu.se
RI Ringner, Markus/G-3641-2011;
OI Ringner, Markus/0000-0001-5469-8940; Saal, Lao/0000-0002-0815-1896
FU Swedish Cancer Society; Swedish Research Council; BioCARE; Berta Kamprad
Foundation; King Gustaf V Jubilee foundation; Gunnar Nilsson Cancer
foundation; Mats Paulsson's foundation; Stefan Paulsson's foundation;
ALF; European council [ERC-2011-294576]
FX The study was supported by the Swedish Cancer Society, the Swedish
Research Council, BioCARE, the Berta Kamprad Foundation, the King Gustaf
V Jubilee foundation, the Gunnar Nilsson Cancer foundation, Mats
Paulsson's foundation, Stefan Paulsson's foundation and the governmental
funding for healthcare research (ALF). The United States NIH (K24
CA149202 to HT). HO was supported by the European council
ERC-2011-294576. We wish to thank Kristina Lovgren, Inger Remse and
Bjorn Nodin for their assistance with the immunohistochemical staining.
NR 36
TC 15
Z9 15
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 20
PY 2015
VL 6
IS 14
BP 12297
EP 12309
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CO2SZ
UT WOS:000359008200041
PM 25909218
ER
PT J
AU Abou-Alfa, GK
Mayer, RJ
Cosgrove, D
Capanu, M
Choti, MA
Atreya, CE
Ang, C
Kelley, RK
Do, RKG
Gordan, JD
Zhu, AX
Ly, M
Nolan, P
Lubin, L
Harding, JJ
Saltz, L
Venook, AP
AF Abou-Alfa, Ghassan K.
Mayer, Robert J.
Cosgrove, David
Capanu, Marinela
Choti, Michael A.
Atreya, Chloe Evelyn
Ang, Celina
Kelley, Robin Kate
Do, Richard Kinh Gian
Gordan, John Dozier
Zhu, Andrew X.
Ly, Michele
Nolan, Patrick
Lubin, Lakeisha
Harding, James J.
Saltz, Leonard
Venook, Alan P.
TI Randomized phase II study of everolimus (E), leuprolide plus letrozole
(LL), and E plus LL (ELL) in patients (pts) with unresectable
fibrolamellar carcinoma (FLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sidney Kimmel Comp Canc Ctr, Baltimore, MD USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15149
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902918
ER
PT J
AU Abramson, JS
Arnason, JE
LaCasce, AS
Redd, R
Barnes, JA
Sokol, L
Joyce, R
Avigan, D
Neuberg, DS
Takvorian, T
Hochberg, EP
Bello, CM
AF Abramson, Jeremy S.
Arnason, Jon E.
LaCasce, Ann S.
Redd, Robert
Barnes, Jeffrey A.
Sokol, Lubomir
Joyce, Robin
Avigan, David
Neuberg, Donna S.
Takvorian, Tak
Hochberg, Ephraim P.
Bello, Celeste M.
TI Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin
lymphoma: A phase II trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8505
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901818
ER
PT J
AU Abramson, JS
Davids, MS
Werner, L
Fisher, DC
Armand, P
Amrein, PC
Neuberg, DS
Hochberg, EP
Brown, JR
AF Abramson, Jeremy S.
Davids, Matthew Steven
Werner, Lillian
Fisher, David Christopher
Armand, Philippe
Amrein, Philip C.
Neuberg, Donna S.
Hochberg, Ephraim P.
Brown, Jennifer R.
TI Lenalidomide added to bendamustine-rituximab for untreated chronic
lymphocytic leukemia (CLL): A phase 1 study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7082
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901618
ER
PT J
AU Abu Zaid, MI
Sesso, HD
Fung, C
Feldman, DR
Hamilton, RJ
Vaughn, DJ
Beard, C
Moore, MJ
Sahasrabudhe, DM
Johnson, E
Fossa, S
Einhorn, LH
Travis, LB
AF Abu Zaid, Mohammad Issam
Sesso, Howard D.
Fung, Chunkit
Feldman, Darren Richard
Hamilton, Robert James
Vaughn, David J.
Beard, Clair
Moore, Malcolm J.
Sahasrabudhe, Deepak M.
Johnson, Eileen
Fossa, Sophie
Einhorn, Lawrence H.
Travis, Lois B.
CA Platinum Study Grp
TI Chronic health conditions (CHCs) following cisplatin-based chemotherapy
(CHEM): A multi-institutional study of 680 testicular cancer survivors
(TCS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
Harvard Univ, Sch Med, Div Prevent Med, Boston, MA USA.
Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Toronto, Princess Margaret Hosp, Div Surg Oncol, Toronto, ON, Canada.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA.
Univ Rochester, Sch Med & Dent, Rochester, NY USA.
Oslo Univ Hosp, Oslo, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9519
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902014
ER
PT J
AU Aghajanian, C
Filiaci, VL
Dizon, DS
Carlson, J
Powell, MA
Secord, AA
Tewari, KS
Bender, D
O'Malley, DM
Stuckey, A
Rotmensch, J
Levine, DA
Lankes, HA
Moore, KN
AF Aghajanian, Carol
Filiaci, Virginia L.
Dizon, Don S.
Carlson, Jay
Powell, Matthew A.
Secord, Angeles Alvarez
Tewari, Krishnansu Sujata
Bender, David
O'Malley, David M.
Stuckey, Ashley
Rotmensch, Jacob
Levine, Douglas A.
Lankes, Heather A.
Moore, Kathleen N.
TI A randomized phase II study of paclitaxel/carboplatin/bevacizumab,
paclitaxel/carboplatin/temsirolimus and
ixabepilone/carboplatin/bevacizumab as initial therapy for measurable
stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
NRG Oncol, Buffalo, NY USA.
GOG Fdn Inc SDMC, Buffalo, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Canc Res Ozarks, Springfield, MO USA.
Washington Univ, Sch Med, St Louis, MO USA.
Duke Univ, Med Ctr, Duke Canc Inst, Div Gynecol Oncol, Durham, NC USA.
UC Irvine, Med Ctr, Orange, CA USA.
Univ Iowa, Iowa City, IA USA.
Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
Brown Univ, Women & Infants Hosp, Providence, RI USA.
Univ Gyn Onc Assoc, Chicago, IL USA.
Gyn Onc Grp, Buffalo, NY USA.
Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
RI OMalley, David/E-3789-2011
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5500
PG 2
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901158
ER
PT J
AU Alabi, SF
Vasquez, R
Antillon, F
Polanco, AC
Orellana, E
Perez-Atayde, A
Albanti, I
Friedrich, P
Rodriguez-Galindo, C
Ribeiro, K
Frazier, AL
Garrido, C
AF Alabi, Soad Fuentes
Vasquez, Roberto
Antillon, Federico
Polanco, Ana C.
Orellana, Elisabeth
Perez-Atayde, Antonio
Albanti, Irini
Friedrich, Paola
Rodriguez-Galindo, Carlos
Ribeiro, Karina
Frazier, A. Lindsay
Garrido, Claudia
TI Implementation of pediatric population-based cancer registries (PBCR) in
Central America (CA).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hosp Benjamin Bloom, San Salvador, El Salvador.
Unidad Nacl Oncol Pediat, Guatemala City, Guatemala.
Boston Childrens Hosp, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp, Boston, MA 02115 USA.
Santa Casa Sch Med, Sao Paulo, Brazil.
Fundacao Oncoctr, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e12624
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902422
ER
PT J
AU Albiges, L
Xie, WL
Chen, YH
Boher, JM
Valenca, LB
Bernard, BD
Culine, S
Habibian, M
Carducci, MA
DiPaola, RS
Liu, G
Pomerantz, M
Nakabayashi, M
Kantoff, PW
Fizazi, K
Gravis, G
Sweeney, C
AF Albiges, Laurence
Xie, Wanling
Chen, Yu-Hui
Boher, Jean-Marie
Valenca, Loana Bueno
Bernard, Brandon David
Culine, Stephane
Habibian, Muriel
Carducci, Michael Anthony
DiPaola, Robert S.
Liu, Glenn
Pomerantz, Mark
Nakabayashi, Mari
Kantoff, Philip W.
Fizazi, Karim
Gravis, Gwenaelle
Sweeney, Christopher
TI Disease burden and outcome in metastatic hormone sensitive prostate
cancer (mHSPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Brookline, MA USA.
Aix Marseille Univ, Inst J Paoli I Calmettes, Biostat, Marseille, France.
Clin Cehon, Salvador, BA, Brazil.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Hop St Louis, Dept Med Oncol, Paris, France.
UNICANC, Paris, France.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc, Baltimore, MD USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Paris Sud, Inst Gustave Roussy, Dept Canc Med, Villejuif, France.
Hop Jour, Inst J Paoli I Calmettes, Med Oncol, Marseille, France.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5052
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901096
ER
PT J
AU Albiges, L
Murray, B
Brooks, A
Cherniack, A
Berger, A
Creighton, CJ
Ricketts, C
Bottaro, DP
Srinivasan, R
Schmidt, LS
Meyerson, M
Spellman, P
Linehan, WM
Choueiri, TK
AF Albiges, Laurence
Murray, Bradley
Brooks, Angela
Cherniack, Andrew
Berger, Alice
Creighton, Chad J.
Ricketts, Christopher
Bottaro, Donald P.
Srinivasan, Ramaprasad
Schmidt, Laura S.
Meyerson, Matthew
Spellman, Paul
Linehan, W. Marston
Choueiri, Toni K.
CA Canc Genome Atlas TCGA Kidney
TI Distinct MET alterations to induce a common phenotype and to define a
MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas
(TCGA) Kidney Renal Papillary (KIRP) Working Group
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Broad Inst, Boston, MA USA.
Broad Inst, Cambridge, MA USA.
Baylor Coll Med, Houston, TX 77030 USA.
NCI, Urol Oncol Branch, Bethesda, MD 20892 USA.
NCI, Bethesda, MD 20892 USA.
NIH, Bethesda, MD 20892 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dana Farber Canc Inst,Brigham & Womens Hosp,Broad, Boston, MA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NCI, NIH, Bethesda, MD 20892 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4521
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900989
ER
PT J
AU Amin, A
Lawson, DH
Salama, AK
Koon, HB
Guthrie, TH
Thomas, SS
O'Day, S
Shaheen, MF
Zhang, B
Francis, S
Hodi, FS
AF Amin, Asim
Lawson, David H.
Salama, April K.
Koon, Henry B.
Guthrie, Troy H.
Thomas, Sajeve Samuel
O'Day, Steven
Shaheen, Montaser F.
Zhang, Bin
Francis, Stephen
Hodi, F. Stephen
TI A single-arm, open-label, phase II study to evaluate the safety of
vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated
metastatic melanoma (MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
Baptist Canc Inst, Jacksonville, FL USA.
Univ Texas MD Anderson Canc Ctr, Orlando, FL USA.
Beverly Hills Canc Ctr, Los Angeles Skin Canc Inst, Beverly Hills, CA USA.
Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
Bristol Myers Squibb, Wallingford, NJ USA.
Bristol Myers Squibb, Braine Lalleud, Belgium.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9032
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901942
ER
PT J
AU Antonarakis, ES
Kibel, AS
Adams, GW
Karsh, LI
Elfiky, A
Shore, ND
Vogelzang, NJ
Corman, JM
Maher, JC
DeVries, T
McCoy, C
Sheikh, NA
Drake, CG
AF Antonarakis, Emmanuel S.
Kibel, Adam S.
Adams, George W.
Karsh, Lawrence Ivan
Elfiky, Aymen
Shore, Neal D.
Vogelzang, Nicholas J.
Corman, John M.
Maher, Johnathan Cartwright
DeVries, Todd
McCoy, Candice
Sheikh, Nadeem A.
Drake, Charles G.
TI Immune responses and clinical outcomes in STAND, a randomized phase 2
study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen
deprivation therapy (ADT) in biochemically-recurrent prostate cancer
(BRPC) after local therapy failure.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Harvard Univ, Brigham & Womens Hosp, Urol Surg, Boston, MA 02115 USA.
Urol Ctr Alabama, Homewood, AL USA.
Urol Ctr Colorado, Clin Res, Denver, CO USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
US Oncol Res Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Virginia Mason Hosp, Seattle, WA USA.
Seattle Med Ctr, Seattle, WA USA.
Dendreon Corp, Seattle, WA USA.
Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5030
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901073
ER
PT J
AU Antonia, SJ
Bendell, JC
Taylor, MH
Calvo, E
Jaeger, D
De Braud, FG
Ott, PA
Pietanza, MC
Horn, L
Le, DT
Morse, M
Lopez-Martin, JA
Ascierto, PA
Christensen, O
Grosso, J
Simon, JS
Lin, CS
Eder, JP
AF Antonia, Scott Joseph
Bendell, Johanna C.
Taylor, Matthew Hiram
Calvo, Emiliano
Jaeger, Dirk
De Braud, Filippo G.
Ott, Patrick Alexander
Pietanza, M. Catherine
Horn, Leora
Le, Dung T.
Morse, Michael
Lopez-Martin, Jose A.
Ascierto, Paolo Antonio
Christensen, Olaf
Grosso, Joseph
Simon, Jason S.
Lin, Chen-Sheng
Eder, Joseph Paul
TI Phase I/II study of nivolumab with or without ipilimumab for treatment
of recurrent small cell lung cancer (SCLC): CA209-032.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain.
Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Duke Univ, Med Ctr, Durham, NC USA.
Hosp 12 Octubre, E-28041 Madrid, Spain.
Ist Nazl Tumori IRCCS, Naples, Italy.
Bristol Myers Squibb Co, Princeton, NJ USA.
Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA.
NR 0
TC 2
Z9 2
U1 4
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901633
ER
PT J
AU Argiris, A
Li, SL
Savvides, P
Forastiere, AA
Burtness, B
AF Argiris, Athanassios
Li, Shuli
Savvides, Panayiotis
Forastiere, Arlene A.
Burtness, Barbara
TI Safety analysis of a phase III randomized trial of chemotherapy with or
without bevacizumab (B) in recurrent or metastatic squamous cell
carcinoma of the head and neck (R/M SCCHN).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
James Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6022
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901335
ER
PT J
AU Armstrong, TS
Wen, PY
Reardon, DA
Phuphanich, S
Aiken, R
Landolfi, JC
Curry, WT
Zhu, JJ
Glantz, MJ
Peereboom, DM
Markert, J
LaRocca, RV
O'Rourke, D
Fink, KL
Kim, LJ
Gruber, ML
Lesser, GJ
Pan, E
Kesari, S
Yu, J
AF Armstrong, Terri S.
Wen, Patrick Y.
Reardon, David A.
Phuphanich, Surasak
Aiken, Robert
Landolfi, Joseph C.
Curry, William T.
Zhu, Jay-Jiguang
Glantz, Michael J.
Peereboom, David M.
Markert, James
LaRocca, Renato V.
O'Rourke, Donald
Fink, Karen L.
Kim, Lyndon J.
Gruber, Michael L.
Lesser, Glenn Jay
Pan, Edward
Kesari, Santosh
Yu, John
TI Comparative impact of treatment on clinical benefit in patients with
glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr Houston, Sch Nursing, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Ctr Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
JFK Medcl Ctr, NJ Neurosci Inst, Edison, NJ USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas Houston, Med Sch Houston, Houston, TX USA.
Penn State Milton S Hershey Medel Ctr, Hinsdale, MA USA.
Cleveland Clin, Fndtn Desk, Cleveland, OH 44106 USA.
Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
Norton Canc Inst, Louisville, KY USA.
Univ Penn, Philadelphia, PA 19104 USA.
Baylor Res Inst, Dallas, TX USA.
Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
NYU, Ctr Clin Canc, Englewood, NJ USA.
Wake Forest Univ, Winston Salem, NC 27109 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Calif San Diego, La Jolla, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2036
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900495
ER
PT J
AU Arney, J
Chen, GQJ
Helm, A
Braun, U
Richardson, PA
Chen, P
Hayes, TG
AF Arney, Jennifer
Chen, Guoqing J.
Helm, Ashley
Braun, Ursula
Richardson, Peter A.
Chen, Ping
Hayes, Teresa Gray
TI Oncologists perceptions and behaviors regarding genomic-based targeted
therapy: Findings of a pilot study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Houston Clear Lake City, Dept Sociol, Houston, TX 77058 USA.
Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
Univ Kansas, Sch Med, Kansas City, KS USA.
Kansas City VA Med Ctr, Dept Vet Affairs, Vet Hlth Adm, Off Res & Dev, Kansas City, KS USA.
Effectiveness & Safety Michael E DeBakey VAMC, Dept Vet Affairs, Vet Hlth Adm, Off Res & Development, Houston, TX USA.
Effectiveness & Safety Michael E DeBakey VAMC, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Univ Massachusetts, Boston, MA 02125 USA.
Michael E DeBakey VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17560
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903530
ER
PT J
AU Atkins, MB
Choueiri, TK
Hodi, FS
Thompson, JA
Hwu, WJ
McDermott, DF
Brookes, M
Tosolini, A
Ebbinghaus, S
Yang, ZJ
Gause, CK
Perini, RF
Ribas, A
AF Atkins, Michael B.
Choueiri, Toni K.
Hodi, F. Stephen
Thompson, John A.
Hwu, Wen-Jen
McDermott, David F.
Brookes, Melissa
Tosolini, Alessandra
Ebbinghaus, Scot
Yang, Zijiang
Gause, Christine K.
Perini, Rodolfo F.
Ribas, Antoni
TI Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts)
with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from
the KEYNOTE-029 phase 1 study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Washington, Seattle, WA 98195 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 5
Z9 5
U1 2
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3009
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900643
ER
PT J
AU Atreya, CE
Van Cutsem, E
Bendell, JC
Andre, T
Schellens, JHM
Gordon, MS
Mcree, AJ
O'Dwyer, PJ
Muro, K
Tabernero, J
van Geel, R
Sidhu, R
Greger, JG
Rangwala, FA
Motwani, M
Wu, YH
Orford, KW
Corcoran, RB
AF Atreya, Chloe Evelyn
Van Cutsem, Eric
Bendell, Johanna C.
Andre, Thierry
Schellens, Jan H. M.
Gordon, Michael S.
McRee, Autumn Jackson
O'Dwyer, Peter J.
Muro, Kei
Tabernero, Josep
van Geel, Robin
Sidhu, Roger
Greger, James G.
Rangwala, Fatima A.
Motwani, Monica
Wu, Yuehui
Orford, Keith W.
Corcoran, Ryan Bruce
TI Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor
dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts)
with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Hosp Leuven, Leuven, Belgium.
Sarah Cannon Res Inst, Nashville, TN USA.
Hop St Antoine, F-75571 Paris, France.
Netherlands Canc Inst, Amsterdam, Netherlands.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan.
Vall dHebron Univ Hosp, Barcelona, Spain.
Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
Amgen Inc, Thousand Oaks, CA 91320 USA.
GlaxoSmithKline, Collegeville, PA USA.
GlaxoSmithKline, Res Triangle Pk, NC USA.
GlaxoSmithKline, Audubon, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 103
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900112
ER
PT J
AU Atri, M
Zhang, Z
Dehdashti, F
Lee, S
Ali, S
Koh, WJ
Moore, KN
Landrum, LM
Kim, JW
DiSilvestro, P
Eisenhauer, EL
Schnell, FM
Gold, M
AF Atri, Mostafa
Zhang, Zheng
Dehdashti, Farrokh
Lee, Susanna
Ali, Shamshad
Koh, Wui-Jin
Moore, Kathleen N.
Landrum, Lisa Michelle
Kim, Jae-Weon
DiSilvestro, Paul
Eisenhauer, Eric Lawernce
Schnell, Frederick M.
Gold, Michael
TI Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node
metastasis in advanced cervical cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hlth Network, Toronto, ON, Canada.
Brown Univ, Providence, RI 02912 USA.
Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Rosewell Pk Canc Inst, Buffalo, NY USA.
Univ Washington, Seattle, WA 98195 USA.
Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA.
Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
Seoul Natl Univ, Seoul, South Korea.
Brown Univ, Women & Infants Hosp, Warren Alpert Med Sch, Providence, RI USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Cent Georgia Canc Care PC, Macon, GA USA.
Tulsa Canc Inst, Tulsa, OK USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5585
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901251
ER
PT J
AU Babu, KG
Majumder, B
Thiyagarajan, S
Ulaganathan, B
Surindran, R
Shenoy, A
Kuriakose, MA
Loda, M
Beroukhim, R
Horowitz, P
Agarwal, S
Radhakrishnan, P
Sundaram, M
Sengupta, S
Majumder, PK
AF Babu, Kanaka Govind
Majumder, Biswanath
Thiyagarajan, Saravanan
Ulaganathan, Baraneedharan
Surindran, Rajagopal
Shenoy, Ashok
Kuriakose, Moni A.
Loda, Massimo
Beroukhim, Rameen
Horowitz, Peleg
Agarwal, Shivani
Radhakrishnan, Padhma
Sundaram, Mallik
Sengupta, Shiladitya
Majumder, Pradip K.
TI Application of a robust and novel ex vivo platform mimicking patient
heterogenous tumor microenvironment for personalized cancer treatment.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Kidwai Mem Inst Oncol, Bangalore, Karnataka, India.
Mitra Biotech, Bangalore, Karnataka, India.
Mitra Biotech Private Ltd, Kiran Mazumdar Shaw Canc Ctr, Bangalore, Karnataka, India.
Mitra Biotech, Zion, IL USA.
Stanley Med Coll, Madras, Tamil Nadu, India.
1Kidwai Mem Inst Oncol, Bangalore, Karnataka, India.
Narayana Hrudayalaya Hosp, Majumdar Shaw Canc Inst, Bangalore, Karnataka, India.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Indian Inst Sci, Bangalore 560012, Karnataka, India.
Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
Mitra Biotech, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6029
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901342
ER
PT J
AU Bajorin, DF
Plimack, ER
Siefker-Radtke, AO
Choueiri, TK
De Wit, R
Sonpavde, G
Gipson, A
Brown, H
Mai, YB
Pang, L
Perini, RF
Bellmunt, J
AF Bajorin, Dean F.
Plimack, Elizabeth R.
Siefker-Radtke, Arlene O.
Choueiri, Toni K.
De Wit, Ronald
Sonpavde, Guru
Gipson, Adrianna
Brown, Holly
Mai, Yabing
Pang, Lei
Perini, Rodolfo F.
Bellmunt, Joaquim
TI KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line
therapy for patients (pts) with unresectable or metastatic urothelial
cancer ineligible for cisplatin-based therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Fox Chase Canc Ctr, Genitourinary Clin Res, Philadelphia, PA 19111 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Erasmus MC Canc Inst, Rotterdam, Netherlands.
Univ Alabama Birmingham UAB, Med, Ctr Comprehens Canc, Birmingham, AL USA.
Merck & Co Inc, Kenilworth, NJ USA.
Dana Farber Canc Inst Dana Farber, Bladder Canc Ctr, Brigham & Womens Canc Ctr, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4572
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904764
ER
PT J
AU Bambury, RM
Jordan, E
Zabor, EC
Bouvier, N
Al-Ahmadie, H
Boyd, ME
Mullane, SA
Cha, EK
Ostrovnaya, I
Hyman, DM
Bochner, BH
Arcila, ME
Solit, DB
Bajorin, DF
Bellmunt, J
Berger, MF
Iyer, G
Rosenberg, JE
AF Bambury, Richard Martin
Jordan, Emmet
Zabor, Emily Craig
Bouvier, Nancy
Al-Ahmadie, Hikmat
Boyd, Mariel Elena
Mullane, Stephanie A.
Cha, Eugene K.
Ostrovnaya, Irina
Hyman, David Michael
Bochner, Bernard H.
Arcila, Maria E.
Solit, David B.
Bajorin, Dean F.
Bellmunt, Joaquim
Berger, Michael F.
Iyer, Gopa
Rosenberg, Jonathan E.
TI Association of somatic mutations in DNA damage repair (DDR) genes with
efficacy of platinum-based chemotherapy in advanced urothelial
carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Mem Sloan Kettering Canc Ctr, Enniscorthy, Wexford, Ireland.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4532
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901003
ER
PT J
AU Bardia, A
Vahdat, LT
Diamond, JR
Starodub, A
Moroose, RL
Isakoff, SJ
Ocean, AJ
Berlin, J
Messersmith, WA
Thomas, SS
Wilhelm, F
Wegener, WA
Maliakal, PP
Sharkey, RM
Goldenberg, DM
Mayer, IA
AF Bardia, Aditya
Vahdat, Linda T.
Diamond, Jennifer Robinson
Starodub, Alexander
Moroose, Rebecca L.
Isakoff, Steven J.
Ocean, Allyson J.
Berlin, Jordan
Messersmith, Wells A.
Thomas, Sajeve Samuel
Wilhelm, Francois
Wegener, William A.
Maliakal, Pius P.
Sharkey, Robert M.
Goldenberg, David M.
Mayer, Ingrid A.
TI Therapy of refractory/relapsed metastatic triple-negative breast cancer
(TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC),
sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Colorado Denver, Aurora, CO USA.
Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA.
Univ Texas MD Anderson Canc Ctr, Winter Pk, FL USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ Colorado Canc Ctr, Aurora, CO USA.
Univ Florida Hlth Canc Ctr Orlando Hlth, Orlando, FL USA.
Immunomedics Inc, Morris Plains, NJ USA.
Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1016
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900097
ER
PT J
AU Barr, PM
Brown, JR
Hillmen, P
O'Brien, S
Barrientos, JC
Reddy, NM
Coutre, S
Mulligan, SP
Jager, U
Furman, RR
Cymbalista, F
Montillo, M
Dearden, C
Robak, T
Moreno, C
Pagel, J
Burger, JA
Suzuki, S
James, DF
Byrd, JC
AF Barr, Paul M.
Brown, Jennifer R.
Hillmen, Peter
O'Brien, Susan
Barrientos, Jacqueline Claudia
Reddy, Nishitha M.
Coutre, Steven
Mulligan, Stephen P.
Jaeger, Ulrich
Furman, Richard R.
Cymbalista, Florence
Montillo, Marco
Dearden, Claire
Robak, Tadeusz
Moreno, Carol
Pagel, John
Burger, Jan Andreas
Suzuki, Samuel
James, Danelle Frances
Byrd, John C.
TI Dose adherence and baseline exposure analysis of the ibrutinib 420 mg
dose administered to patients with previously treated chronic
lymphocytic leukemia (CLL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Rochester, Wilmot Canc Inst, Rochester, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
North Shore LIJ Canc Inst, Lake Success, NY USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Royal N Shore Hosp, Sydney, NSW, Australia.
Med Univ Vienna, Vienna, Austria.
New York Presbyterian Hosp, Weill Cornell Med College, New York, NY USA.
Hop Avicenne, Paris, France.
Osped Niguarda Ca Granda, Milan, Italy.
Royal Marsden Hosp, London SW3 6JJ, England.
Med Univ Lodz, Lodz, Poland.
Hosp Santa Creu & Sant Pau, Barcelona, Spain.
Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Med Oncol, Seattle, WA 98195 USA.
Pharmacyclics Inc, Sunnyvale, CA USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
NR 0
TC 2
Z9 2
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7012
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901548
ER
PT J
AU Barrett, ED
Olivier, KM
Saylor, PJ
Michaelson, MD
Lee, RJ
AF Barrett, Erika D.
Olivier, Kara M.
Saylor, Philip James
Michaelson, M. Dror
Lee, Richard J.
TI Activity of gemcitabine and vinorelbine in patients with metastatic
urothelial carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15507
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903057
ER
PT J
AU Baselga, J
Cortes, J
De Laurentiis, M
Dieras, V
Harbeck, N
Im, YH
Jacot, W
Krop, IE
Verma, S
Wilson, TR
Lin, R
Schimmoller, F
Hsu, JY
AF Baselga, Jose
Cortes, Javier
De Laurentiis, Michelino
Dieras, Veronique
Harbeck, Nadia
Im, Young-Hyuck
Jacot, William
Krop, Ian E.
Verma, Sunil
Wilson, Timothy R.
Lin, Ray
Schimmoller, Frauke
Hsu, Jerry Y.
TI SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib
(GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor
(ER)-positive, HER2-negative locally advanced or metastatic breast
cancer (BC) enriched for pts with PIK3CA mutant tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
DHebron Univ Hosp, Barcelona, Spain.
Fdn G Pascale, Ist Nazl Tumori, Naples, Italy.
Inst Curie, Paris, France.
Brustzentrum Univ Munchen, Munich, Germany.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Inst Canc Montpellier, Montpellier, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Div Med Oncol, Toronto, ON, Canada.
Genentech Inc, San Francisco, CA 94080 USA.
Genentech Inc, San Mateo, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS629
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904821
ER
PT J
AU Bauer, TM
Shaw, AT
Solomon, B
Besse, B
James, LP
Clancy, JS
Mugundu, G
Martini, JF
Abbattista, A
Felip, E
AF Bauer, Todd Michael
Shaw, Alice Tsang
Solomon, Ben
Besse, Benjamin
James, Leonard P.
Clancy, Jill S.
Mugundu, Ganesh
Martini, Jean-Francois
Abbattista, Antonello
Felip, Enriqueta
TI Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor,
in patients with advanced non-small-cell lung cancer harboring specific
molecular alterations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol, Nashville, TN USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
Gustave Roussy, Villejuif, France.
Pfizer, New York, NY USA.
Inventiv Clin, Princeton, NJ USA.
Pfizer, San Diego, CA USA.
Pfizer, Milan, Italy.
Vall dHebron Univ Hosp, Barcelona, Spain.
NR 0
TC 1
Z9 1
U1 3
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2620
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904698
ER
PT J
AU Bauman, JR
Piotrowska, Z
Scribner, E
Temel, B
Sequist, LV
Heist, RS
Temel, JS
AF Bauman, Jessica Ruth
Piotrowska, Zofia
Scribner, Emily
Temel, Brandon
Sequist, Lecia V.
Heist, Rebecca Suk
Temel, Jennifer S.
TI End of life (EOL) care in patients with metastatic lung cancer harboring
EGFR-mutations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20508
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904141
ER
PT J
AU Bedard, PL
Davies, MA
Kopetz, S
Flaherty, KT
Shapiro, G
Luke, JJ
Spreafico, A
Wu, B
Gomez, C
Cartot-Cotton, S
Mazuir, F
Micallef, S
Demers, B
Juric, D
AF Bedard, Philippe L.
Davies, Michael A.
Kopetz, Scott
Flaherty, Keith T.
Shapiro, Geoffrey
Luke, Jason John
Spreafico, Anna
Wu, Bin
Gomez, Corinne
Cartot-Cotton, Sylvaine
Mazuir, Florent
Micallef, Sandrine
Demers, Brigitte
Juric, Dejan
TI First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301
in patients with advanced solid tumors (NCT01673737).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Chicago Med, Chicago, IL USA.
Agios Pharmaceut, Cambridge, MA USA.
Sanofi R&D, Alfortville, France.
Sanofi R&D, Vitry Sur Seine, France.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2564
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900597
ER
PT J
AU Bellmunt, J
Sonpavde, G
De Wit, R
Choueiri, TK
Siefker-Radtke, AO
Plimack, ER
Lewis, NM
Brown, H
Mai, YB
Gause, CK
Kaufman, DR
Bajorin, DF
AF Bellmunt, Joaquim
Sonpavde, Guru
De Wit, Ronald
Choueiri, Toni K.
Siefker-Radtke, Arlene O.
Plimack, Elizabeth R.
Lewis, Nicole M.
Brown, Holly
Mai, Yabing
Gause, Christine K.
Kaufman, David Ross
Bajorin, Dean F.
TI KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus
paclitaxel, docetaxel, or vinflunine for previously treated metastatic
urothelial cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
Erasmus MC Canc Inst, Rotterdam, Netherlands.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4571
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904763
ER
PT J
AU Bellmunt, J
Valderrama, BP
Font, A
Virizuela, JA
Climent, MA
Polo, SH
Mellado, B
Lainez, N
del Alba, AG
Arranz, JA
Guzman, JCV
LLorente, MDM
Castellano, DE
Gallardo, E
del Muro, XG
Anido, U
Domenech, M
Puente, J
Gracia, JLP
Garcia-Donas, J
AF Bellmunt, Joaquim
Perez Valderrama, Begona
Font, Albert
Antonio Virizuela, Juan
Angel Climent, Miguel
Hernando Polo, Susana
Mellado, Begona
Lainez, Nuria
Gonzalez del Alba, Aranzazu
Angel Arranz, Jose
Villa Guzman, Jose Carlos
del Mar LLorente, Maria
Castellano, Daniel E.
Gallardo, Enrique
Garcia del Muro, Xavier
Anido, Urbano
Domenech, Montserrat
Puente, Javier
Perez Gracia, Jose Luis
Garcia-Donas, Jesus
TI Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with
advanced urothelial carcinoma (UC): Preliminary analysis of a randomized
placebo controlled phase II trial (MAJA trial)-SOGUG 2011-02
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Hosp Univ Virgen Rocio, Seville, Spain.
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain.
Hosp Univ Virgen Macarena, Seville, Spain.
Fdn Inst Valenciano Oncol, Valencia, Spain.
Hosp Univ Fdn Alcorcon, Alcorcon, Spain.
Hosp Clin Barcelona, Translat Genom & Targeted Therapeut Oncology, IDIBAPS, Dept Med Oncol, Barcelona, Spain.
Complejo Hosp Navarra, Pamplona, Spain.
Hosp Univ Son Espases, Palma De Mallorca, Spain.
Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
Hosp Gen Univ Ciudad Real, Ciudad Real, Spain.
Hosp Gen Elda Virgen Salud, Elda, Spain.
Hosp Univ 12 Octubre, Madrid, Spain.
Corp Sanitaria Parc Tauli, Sabadell, Spain.
Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain.
Complexo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain.
Hosp Althaia, Manresa, Spain.
Hosp Clin Univ San Carlos, Madrid, Spain.
Univ Navarra Clin, Madrid, Spain.
Ctr Integral Oncol Clara Campal, Madrid, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4529
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900997
ER
PT J
AU Bellmunt, J
Eigl, BJ
Senkus-Konefka, E
Loriot, Y
Twardowski, P
Castellano, DE
Blais, N
Sridhar, SS
Sternberg, CN
Retz, M
Blumenstein, BA
Jacobs, C
Stewart, PS
Petrylak, DP
AF Bellmunt, Joaquim
Eigl, Bernhard J.
Senkus-Konefka, Elzbieta
Loriot, Yohann
Twardowski, Przemyslaw
Castellano, Daniel E.
Blais, Normand
Sridhar, Srikala S.
Sternberg, Cora N.
Retz, Margitta
Blumenstein, Brent A.
Jacobs, Cindy
Stewart, Patricia S.
Petrylak, Daniel Peter
TI First-line randomized phase II study of gemcitabine/cisplatin plus
apatorsen or placebo in patients with advanced bladder cancer: The
International Borealis-1 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
BC Canc Agcy, Vancouver, BC, Canada.
Med Univ Gdansk, Gdansk, Poland.
Grand Paris, Gustave Roussy, Dept Canc Med, Villejuif, France.
City Hope Natl Med Ctr, Duarte, CA USA.
Hosp Univ 12 Octubre, Madrid, Spain.
Hop Notre Dame CHUM, Montreal, PQ, Canada.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
San Camillo Forlanini Hosp, Rome, Italy.
Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany.
Trial Architecture Consulting, Washington, DC USA.
OncoGenex Pharmaceut Inc, Bothell, WA USA.
Yale Comprehens Canc Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900971
ER
PT J
AU Beltran, H
Prandi, D
Mosquera, JM
Giannopoulou, E
Puca, L
Marotz, C
Nanus, DM
Tagawa, ST
Elemento, O
Van Allen, EM
Sboner, A
Garraway, LA
Rubin, MA
Demichelis, F
AF Beltran, Himisha
Prandi, Davide
Mosquera, Juan Miguel
Giannopoulou, Eugenia
Puca, Loredana
Marotz, Clarisse
Nanus, David M.
Tagawa, Scott T.
Elemento, Olivier
Van Allen, Eliezer Mendel
Sboner, Andrea
Garraway, Levi A.
Rubin, Mark A.
Demichelis, Francesca
TI Defining a molecular subclass of treatment resistant prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Weill Cornell Med Coll, New York, NY USA.
Univ Trento, Trento, Italy.
Weill Cornell Med Coll, Dept Med, Inst Precis Med, New York, NY USA.
New York Presbyterian Hosp, New York, NY USA.
Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Weill Cornell Med Coll, Dept Pathol & Lab Med, Inst Computat Biomed, Dept Med,Inst Precis Med, New York, NY USA.
Univ Trento, New York, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5004
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901045
ER
PT J
AU Bernard, BD
Markt, SC
Albiges, L
Miller, R
Pettersson, A
Beard, C
Sweeney, C
AF Bernard, Brandon David
Markt, Sarah C.
Albiges, Laurence
Miller, Rowan
Pettersson, Andreas
Beard, Clair
Sweeney, Christopher
TI Sunlight and testicular germ cell tumor rates in the USA
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Mt Vernon Canc Ctr, London, England.
Karolinska Inst, Stockholm, Sweden.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15565
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903111
ER
PT J
AU Bernard, BD
Markt, SC
Albiges, L
Miller, R
Beard, C
Sweeney, C
AF Bernard, Brandon David
Markt, Sarah C.
Albiges, Laurence
Miller, Rowan
Beard, Clair
Sweeney, Christopher
TI Melanoma risk in men with testicular germ cell tumors in the United
States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Mt Vernon Canc Ctr, London, England.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15554
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903101
ER
PT J
AU Berry, DL
Hong, FX
Halpenny, B
AF Berry, Donna Lynn
Hong, Fangxin
Halpenny, Barbara
TI Psychosocial outcomes of the electronic self-report assessment for
cancer-II randomized trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Biostat Core, Boston, MA 02115 USA.
Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6515
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901430
ER
PT J
AU Best, M
Sol, N
Kooi, I
Nilsson, J
Westerman, B
Ylstra, B
Dorsman, J
Smit, EF
Verheul, HMW
Reijneveld, JC
Tannous, BA
Wesseling, P
Wurdinger, T
AF Best, Myron
Sol, Nik
Kooi, Irsan
Nilsson, Jonas
Westerman, Bart
Ylstra, Bauke
Dorsman, Josephine
Smit, Egbert F.
Verheul, Henk M. W.
Reijneveld, Jaap C.
Tannous, Bakhos A.
Wesseling, Pieter
Wurdinger, Thomas
TI Allowance of tumor-educated platelets for multiclass liquid biopsy-based
diagnosis of cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden.
Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
Netherlands Canc Inst, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.
Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Neurosci Program, Cambridge, MA 02138 USA.
RI Wesseling, P./H-8114-2014; Ylstra, Bauke/D-2906-2012
OI Wesseling, P./0000-0001-5453-5201; Ylstra, Bauke/0000-0001-9479-3010
NR 0
TC 0
Z9 0
U1 1
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 11058
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900317
ER
PT J
AU Birrer, MJ
Choi, Y
Brady, MF
Mannel, RS
Burger, RA
Wei, W
Husain, A
Bais, C
AF Birrer, Michael J.
Choi, YounJeong
Brady, Mark F.
Mannel, Robert S.
Burger, Robert Allen
Wei, Wei
Husain, Amreen
Bais, Carlos
CA NRG Oncol Gynecologic Oncology Grp
TI Retrospective analysis of candidate predictive tumor biomarkers (BMs)
for efficacy in the GOG-0218 trial evaluating front-line
carboplatin-paclitaxel (CP) +/- bevacizumab (BEV) for epithelial ovarian
cancer (EOC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA.
Genentech Inc, San Francisco, CA 94080 USA.
NRG Stat & Data Ctr, Roswell Pk Canc Inst, Buffalo, NY USA.
Univ Oklahoma, Oklahoma City, OK USA.
Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc Res,Gillette Ctr Gynecol Oncol, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5505
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901163
ER
PT J
AU Blachly, JS
Brown, JR
Barrientos, JC
Jain, N
Kelly, V
Garnick, S
Rodstrom, J
Sweeney, J
Tang, S
Byrd, JC
AF Blachly, James Stewart
Brown, Jennifer R.
Barrientos, Jacqueline Claudia
Jain, Nitin
Kelly, Virginia
Garnick, Stephanie
Rodstrom, Jill
Sweeney, Jennifer
Tang, Shijie
Byrd, John C.
TI A phase 1b trial of duvelisib, a PI3K-delta,gamma inhibitor, in
combination with obinutuzumab in patients with CLL/SLL previously
treated with a Bruton's tyrosine kinase inhibitor (BTKi).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Infin Pharmaceut, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS7100
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904843
ER
PT J
AU Borghaei, H
O'Malley, DM
Seward, SM
Bauer, TM
Perez, RP
Oza, AM
Jeong, W
Michenzie, MF
Kirby, MW
Chandorkar, G
Ruiz-Soto, R
Birrer, MJ
Moore, KN
AF Borghaei, Hossein
O'Malley, David M.
Seward, Shelly Marie
Bauer, Todd Michael
Perez, Raymond P.
Oza, Amit M.
Jeong, Woondong
Michenzie, Mary F.
Kirby, Maurice William
Chandorkar, Gurudatt
Ruiz-Soto, Rodrigo
Birrer, Michael J.
Moore, Kathleen N.
TI Phase 1 study of IMGN853, a folate receptor alpha (FR alpha)-targeting
antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian
cancer (EOC) and other FRA-positive solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
Wayne State Univ, Karmanos Canc Inst, Huntington Woods, MI USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Kansas, Fairway, KS USA.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Westchester Hem Onc Grp, Westchester, NY USA.
ImmunoGen Inc, Dedham, MA USA.
ImmunoGen Inc, Waltham, MA USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
RI OMalley, David/E-3789-2011; Perez, Raymond/R-6159-2016
OI Perez, Raymond/0000-0002-7432-2411
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5558
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901221
ER
PT J
AU Braunstein, LZ
Galland, S
Goldberg, S
Sadek, BT
Shenouda, M
Abi-Raad, R
MacDonald, SM
Taghian, AG
AF Braunstein, Lior Zvi
Galland, Sigolene
Goldberg, Saveli
Sadek, Betro T.
Shenouda, Mina
Abi-Raad, Rita
MacDonald, Shannon M.
Taghian, Alphonse G.
TI Breast cancer with extensive regional lymph node involvement: Toward
optimizing local management.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Rad Onc Prog, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Perrysburg, OH USA.
Yale Univ, New Haven, CT USA.
Francis H Burr Proton Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1053
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900166
ER
PT J
AU Brose, MS
Schlumberger, M
Tahara, M
Wirth, LJ
Robinson, B
Elisei, R
Newbold, K
Kiyota, N
Hoff, AO
Dutcus, C
Song, J
Sherman, SI
Taylor, MH
AF Brose, Marcia S.
Schlumberger, Martin
Tahara, Makoto
Wirth, Lori J.
Robinson, Bruce
Elisei, Rossella
Newbold, Kate
Kiyota, Naomi
Hoff, Ana O.
Dutcus, Corina
Song, James
Sherman, Steven I.
Taylor, Matthew Hiram
TI Effect of age and lenvatinib treatment on overall survival for patients
with I-131-refractory differentiated thyroid cancer in SELECT
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France.
Univ Paris Sud, Villejuif, France.
Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia.
Univ Pisa, Dept Clin & Expt Med, Endocrine Unit, Pisa, Italy.
Royal Marsden Hosp Natl Hlth Serv Trust, London, England.
Kobe Univ Hosp, Dept Med Oncol & Hematol, Kobe, Hyogo, Japan.
Univ Sao Paulo, Inst Canc Estado Sao Paulo, Dept Endocrinol, Sao Paulo, Brazil.
Eisai Inc, Woodcliff Lake, NJ USA.
Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Div Internal Med, Houston, TX 77030 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
RI Kiyota, Naomi/K-3226-2016
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6048
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901363
ER
PT J
AU Burgess, MA
Crowley, J
Reinke, DK
Riedel, RF
George, S
Movva, S
Van Tine, BA
Davis, LE
Schuetze, S
Hu, J
Attia, S
Priebat, DA
Reed, DR
D'Angelo, SP
Okuno, SH
Maki, RG
Patel, S
Baker, LH
Tawbi, HAH
AF Burgess, Melissa Amber
Crowley, John
Reinke, Denise K.
Riedel, Richard F.
George, Suzanne
Movva, Sujana
Van Tine, Brian Andrew
Davis, Lara Emily
Schuetze, Scott
Hu, James
Attia, Steven
Priebat, Dennis A.
Reed, Damon R.
D'Angelo, Sandra P.
Okuno, Scott H.
Maki, Robert G.
Patel, Shreyaskumar
Baker, Laurence H.
Tawbi, Hussein Abdul-Hassan
TI SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in
patients (Pts) with advanced sarcomas.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Pittsburgh Phys, Pittsburgh, PA USA.
Canc Rsrch & Biostat, Seattle, WA USA.
SARC, Ann Arbor, MI USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Washington Univ, St Louis, MO USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ So Calif, Norris Comp Canc Ctr, Los Angeles, CA USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Washington Hosp Ctr, Washington, DC 20010 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mayo Clin, Rochester, MN USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS10578
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904654
ER
PT J
AU Burris, HA
Brose, MS
Shaw, AT
Bauer, TM
Farago, AF
Doebele, RC
Smith, S
Fernandes, M
Cruickshank, S
Low, JA
AF Burris, Howard A.
Brose, Marcia S.
Shaw, Alice Tsang
Bauer, Todd Michael
Farago, Anna F.
Doebele, Robert Charles
Smith, Steven
Fernandes, Michele
Cruickshank, Scott
Low, Jennifer A.
TI A first-in-human study of LOXO-101, a highly selective inhibitor of the
tropomyosin receptor kinase (TRK) family.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Colorado, Aurora, CO USA.
Loxo Oncol, San Francisco, CA USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2624
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904702
ER
PT J
AU Burris, HA
Hurwitz, H
Perez, EA
Spigel, D
Swanton, C
Hainsworth, JD
Leon, L
Beattie, M
Brammer, M
Sweeney, C
AF Burris, Howard A.
Hurwitz, Herbert
Perez, Edith A.
Spigel, David
Swanton, Charles
Hainsworth, John D.
Leon, Larry
Beattie, Mary
Brammer, Melissa
Sweeney, Christopher
TI MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab,
erlotinib, vemurafenib, and vismodegib in patients who have advanced
solid tumors with mutations or gene expression abnormalities targeted by
these agents.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Duke Univ, Med Ctr, Durham, NC USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Canc Res UK London Res Inst, London WC2A 3PX, England.
Genentech Inc, San Francisco, CA 94080 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS11111
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904669
ER
PT J
AU Buzaglo, JS
Karten, C
Miller, MF
Greer, JA
Weiss, ES
Mauro, MJ
AF Buzaglo, Joanne S.
Karten, Clare
Miller, Melissa F.
Greer, Joseph A.
Weiss, Elisa S.
Mauro, Michael J.
TI Treatment-adherence beliefs and behaviors in patients with chronic
myeloid leukemia (CML).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Res & Training Inst, Canc Support Community, Philadelphia, PA USA.
CTK Consults, Hartsdale, NY USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Leukemia & Lymphoma Soc, White Plains, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9558
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902053
ER
PT J
AU Cai, XZ
Chandra, V
Ou, YM
Emblem, KE
Muzikansky, A
Evans, J
Kalpathy-Cramer, J
Dietrich, J
Chi, AS
Wen, PY
Rosen, BR
Batchelor, T
Gerstner, ER
AF Cai, Xuezhu
Chandra, Vyshak
Ou, Yangming
Emblem, Kyrre E.
Muzikansky, Alona
Evans, John
Kalpathy-Cramer, Jayashree
Dietrich, Jorg
Chi, Andrew S.
Wen, Patrick Y.
Rosen, Bruce R.
Batchelor, Tracy
Gerstner, Elizabeth Robins
TI Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with
recurrent glioblastoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
VCU Sch Medcn, Richmond, VA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
AA Martinos Ctr Biomed Imaging, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Martinos Ctr Biomed Imaging, Charlestown, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2025
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900484
ER
PT J
AU Calip, GS
Law, E
Winer, EP
Ko, N
AF Calip, Gregory Sampang
Law, Ernest
Winer, Eric P.
Ko, Naomi
TI Racial and ethnic differences in risk of second primary cancers among
breast cancer survivors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Illinois, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Boston Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e12592
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902396
ER
PT J
AU Calkins, A
Szalat, R
Dreze, M
Schnorenberg, M
Ceccaldi, R
Iglehart, JD
Lazaro, JB
AF Calkins, Anne
Szalat, Raphael
Dreze, Matija
Schnorenberg, Mathew
Ceccaldi, Raphael
Iglehart, J. Dirk
Lazaro, Jean-Bernard
TI Measurement of nucleotide excision repair activity and correlation with
cisplatin sensitivity.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Tennessee, Coll Med, Memphis, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1077
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900236
ER
PT J
AU Camidge, DR
Bazhenova, L
Salgia, R
Langer, CJ
Gold, KA
Rosell, R
Shaw, AT
Weiss, GJ
Narasimhan, NI
Dorer, DJ
Rivera, VM
Clackson, TP
Conlan, MG
Kerstein, D
Haluska, FG
Gettinger, SN
AF Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Langer, Corey J.
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice Tsang
Weiss, Glen J.
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Clackson, Timothy Piers
Conlan, Maureen G.
Kerstein, David
Haluska, Frank G.
Gettinger, Scott N.
TI Safety and efficacy of brigatinib (AP26113) in advanced malignancies,
including ALK plus non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado, Ctr Canc, Aurora, CO USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Canc Treatment Ctr Amer, Western Reg Med Ctr, Goodyear, AZ USA.
ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 23
Z9 23
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8062
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901774
ER
PT J
AU Cash, T
McIlvaine, E
Krailo, MD
Lessnick, SL
Lawlor, ER
Laack, NN
Sorger, J
Marina, N
Grier, HE
Granowetter, L
Womer, RB
DuBois, SG
AF Cash, Thomas
McIlvaine, Elizabeth
Krailo, Mark D.
Lessnick, Stephen L.
Lawlor, Elizabeth R.
Laack, Nadia N.
Sorger, Joel
Marina, Neyssa
Grier, Holcombe E.
Granowetter, Linda
Womer, Richard B.
DuBois, Steven G.
TI Comparison of clinical features and outcomes in patients with
extraskeletal versus skeletal localized Ewing sarcoma: A report from the
Children's Oncology Group.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
Childrens Oncol Grp, Monrovia, CA USA.
Childrens Onc Grp, Arcadia, CA USA.
Huntsman Canc Inst, Salt Lake City, UT USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Mayo Clin, Rochester, MN USA.
Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NYU, Med Ctr, New York, NY USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10051
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900059
ER
PT J
AU Cassier, PA
Maki, RG
Wagner, AJ
Bompas, E
Gelderblom, H
Kroep, JR
Thomas, DM
Italiano, A
Seddon, BM
Van der Graaf, WTA
Domont, J
Blay, JY
Stacchiotti, S
AF Cassier, Philippe Alexandre
Maki, Robert G.
Wagner, Andrew J.
Bompas, Emmanuelle
Gelderblom, Hans
Kroep, Judith R.
Thomas, David Morgan
Italiano, Antoine
Seddon, Beatrice M.
Van der Graaf, Winette T. A.
Domont, Julien
Blay, Jean-Yves
Stacchiotti, Silvia
TI Imatinib mesylate (IM) activity in patients (pts) with locally advanced
tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ctr Leon Berard, Dept Med, F-69373 Lyon, France.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ctr Rene Gauducheau, Dept Med Oncol, St Herblain, France.
Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands.
Leiden Univ, Med Ctr, Amstelveen, Netherlands.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
CLCC Inst Bergonie, Bordeaux, France.
Univ Coll Hosp, New Malden, England.
Radboudumc, Nijmegen, Netherlands.
Inst Gustave Roussy, Villejuif, France.
Ist Nazl Tumori, I-20133 Milan, Italy.
RI van der Graaf, Winette/A-5006-2014; Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10561
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900201
ER
PT J
AU Castillo, JJ
Glezerman, IG
Boklage, SH
Chiodo, JA
Tidwell, BA
Lamerato, LE
Schulman, KL
AF Castillo, Jorge J.
Glezerman, Ilya G.
Boklage, Susan H.
Chiodo, Joseph A.
Tidwell, Beni A.
Lamerato, Lois E.
Schulman, Kathy L.
TI Prognostic significance of hypervolemic or euvolemic hyponatremia in
patients with lymphoma, breast, lung, or colorectal cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Otsuka Amer Pharmaceut Inc, Princeton, NJ USA.
Outcomes Res Solut Inc, Waltham, MA USA.
Henry Ford Hlth Syst, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17554
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903525
ER
PT J
AU Cejas, P
Mullane, SA
Van Allen, EM
Barletta, JA
Bowden, M
Taplin, ME
Pomerantz, M
Choueiri, TK
Kwiatkowski, DJ
Long, H
Bellmunt, J
AF Cejas, Paloma
Mullane, Stephanie A.
Van Allen, Eliezer Mendel
Barletta, Justine A.
Bowden, Michaela
Taplin, Mary-Ellen
Pomerantz, Mark
Choueiri, Toni K.
Kwiatkowski, David J.
Long, Henry
Bellmunt, Joaquim
TI Evaluating the frequency and functional consequences of epigenetic
mutations on outcome derived from urothelial tumor sequencing in
non-muscle invasive bladder cancer (NMIBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15519
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903067
ER
PT J
AU Chan, A
Delaloge, S
Holmes, FA
Moy, B
Iwata, H
Harvey, VJ
Robert, NJ
Silovski, T
Gokmen, E
Von Minckwitz, G
Ejlertsen, B
Chia, SKL
Mansi, J
Barrios, CH
Gnant, M
Wong, A
Bryce, R
Yao, B
Martin, M
AF Chan, Arlene
Delaloge, Suzette
Holmes, Frankie Ann
Moy, Beverly
Iwata, Hiroji
Harvey, Vernon J.
Robert, Nicholas J.
Silovski, Tajana
Gokmen, Erhan
Von Minckwitz, Gunter
Ejlertsen, Bent
Chia, Stephen K. L.
Mansi, Janine
Barrios, Carlos H.
Gnant, Michael
Wong, Alvin
Bryce, Richard
Yao, Bin
Martin, Miguel
TI Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive
early breast cancer: Primary analysis at 2 years of a phase 3,
randomized, placebo-controlled trial (ExteNET).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Breast Canc Res Ctr WA, Perth, WA, Australia.
Curtin Univ, Perth, WA 6845, Australia.
Inst Gustave Roussy, Villejuif, France.
Texas Oncol PA, Houston, TX USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Aichi Canc Ctr, Chikusa Ku, Nagoya, Aichi 464, Japan.
Auckland Hosp, Auckland, New Zealand.
US Oncol Network, Virginia Canc Specialists, Fairfax, VA USA.
Univ Hosp Tumors, UHC Sestre Milosrdnice, Zagreb, Croatia.
Ege Univ, Fac Med, Div Med Oncol, Izmir, Turkey.
GBG Forschungs GmbH, Luisenkrankenhaus, Dusseldorf, Neu Isenburg, Germany.
Rigshosp, DK-2100 Copenhagen, Denmark.
BC Canc Agcy, Vancouver, BC, Canada.
Guys Hosp, London SE1 9RT, England.
PUCRS Sch Med, Porto Alegre, RS, Brazil.
Med Univ Vienna, Vienna, Austria.
Puma Biotechnol Inc, Los Angeles, CA USA.
Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
NR 0
TC 1
Z9 1
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 508
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901115
ER
PT J
AU Chang, SM
Zhang, PX
Cairncross, JG
Gilbert, MR
Bahary, JP
Dolinskas, C
Aldape, KD
Chakravarti, A
Schiff, D
Jaeckle, KA
Brown, PD
Barger, G
Werner-Wasik, M
Shih, HA
Brachman, D
Penas-Prado, M
Robins, HI
Belanger, K
Schultz, CJ
Mehta, MP
AF Chang, Susan Marina
Zhang, Peixin
Cairncross, J. Gregory
Gilbert, Mark R.
Bahary, Jean-Paul
Dolinskas, Carol
Aldape, Kenneth D.
Chakravarti, Arnab
Schiff, David
Jaeckle, Kurt A.
Brown, Paul D.
Barger, Geoffrey
Werner-Wasik, Maria
Shih, Helen Alice
Brachman, David
Penas-Prado, Marta
Robins, H. Ian
Belanger, Karl
Schultz, Christopher J.
Mehta, Minesh P.
TI Results of NRG oncology/RTOG 9813: A phase III randomized study of
radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea
(NU) therapy for anaplastic astrocytoma (AA)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UC San Francisco, San Francisco, CA USA.
NRG Oncol, Philadelphia, PA USA.
Southern Alberta Canc Rsrch Inst, Calgary, AB, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
Univ Penn, Philadelphia, PA 19104 USA.
Ohio State Univ, Arthur G James Canc Ctr, Dublin, OH USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Mayo Clin Florida, Jacksonville, FL USA.
Wayne State Univ, Sch Med, Detroit, MI USA.
Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Arizona Oncol Serv Fdn, Phoenix, AZ USA.
Univ Wisconsin, Comp Canc Ctr, Madison, WI USA.
Hop Notre Dame de Bon Secours, Montreal, PQ H2L 4K8, Canada.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Univ Maryland Med Syst, Baltimore, MD USA.
RI Gilbert, Mark/J-7494-2016
OI Gilbert, Mark/0000-0003-2556-9722
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2002
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900461
ER
PT J
AU Chau, I
Peck-Radosavljevic, M
Borg, C
Malfertheiner, P
Seitz, JF
Park, JO
Ryoo, BY
Yen, CJ
Kudo, M
Poon, RTP
Pastorelli, D
Blanc, JF
Chung, HC
Baron, AD
Okusaka, T
Cui, ZLL
Girvan, AC
Abada, P
Yang, L
Zhu, AX
AF Chau, Ian
Peck-Radosavljevic, Markus
Borg, Christophe
Malfertheiner, Peter
Seitz, Jean Francois
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Kudo, Masatoshi
Poon, Ronnie Tung-Ping
Pastorelli, Davide
Blanc, Jean-Frederic
Chung, Hyun Cheol
Baron, Ari David
Okusaka, Takuji
Cui, Zhanglin Lin
Girvan, Allicia C.
Abada, Paolo
Yang, Ling
Zhu, Andrew X.
TI Ramucirumab (RAM) as second-line treatment in patients (pts) with
advanced hepatocellular carcinoma following first-line therapy with
sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH
study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Royal Marsden, London, England.
Royal Marsden, Surrey, England.
Vienna Gen Hosp, Dept Gastroenterol & Hepatol, Vienna, Austria.
Med Univ, Vienna, Austria.
Univ Hosp Besancon, Besancon, France.
Univ Magdeburg, D-39106 Magdeburg, Germany.
Hop Enfants La Timone, Marseille, France.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan.
Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan.
Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy.
Hop St Andre, Bordeaux, France.
Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Canc Ctr,Inst Canc Res,Div Med Oncol, Seoul, South Korea.
Calif Pacific Med Ctr, San Francisco, CA USA.
Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
Eli Lilly & Co, Bridgewater, NJ USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4077
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900915
ER
PT J
AU Chawla, SP
Schoffski, P
Blay, JY
Jones, RL
Gelderblom, H
Attia, S
Chmielowski, B
Van Tine, BA
Trent, JC
Patel, S
Wagner, AJ
Viele, JK
Chugh, R
Le Cesne, A
Tinoco, G
Sankhala, KK
Falcone, J
Schweizer, C
Weil, S
Maki, RG
AF Chawla, Sant P.
Schoffski, Patrick
Blay, Jean-Yves
Jones, Robin Lewis
Gelderblom, Hans
Attia, Steven
Chmielowski, Bartosz
Van Tine, Brian Andrew
Trent, Jonathan C.
Patel, Shreyaskumar
Wagner, Andrew J.
Viele, James Kert
Chugh, Rashmi
Le Cesne, Axel
Tinoco, Gabriel
Sankhala, Kamalesh Kumar
Falcone, Julianne
Schweizer, Charles
Weil, Susan
Maki, Robert G.
TI A study of the safety and efficacy of the combination of gemcitabine and
docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue
sarcoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarcoma Oncol Ctr, Santa Monica, CA USA.
Univ Hosp Leuven, Leuven, Belgium.
Univ Lyon 1, F-69365 Lyon, France.
Ctr Leon Berard, F-69373 Lyon, France.
Royal Marsden Hosp, London SW3 6JJ, England.
Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands.
Mayo Clin, Jacksonville, FL 32224 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Washington Univ, St Louis, MO USA.
Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Berry Consultants, College Stn, TX USA.
Univ Michigain Hlth Syst, Ann Arbor, MI USA.
Inst Gustave Roussy, Villejuif, France.
Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA.
Morphotek Inc, Exton, PA USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS10577
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904653
ER
PT J
AU Chen, AB
Li, L
Cronin, A
Brooks, G
Kavanagh, BD
Schrag, D
AF Chen, Aileen B.
Li, Ling
Cronin, Angel
Brooks, Gabriel
Kavanagh, Brian D.
Schrag, Deborah
TI How should we estimate costs of care attributable to cancer?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901418
ER
PT J
AU Chen, YW
Gelpi-Hammerschmidt, F
Wu, CP
Bellmunt, J
Chang, SL
AF Chen, Yu-Wei
Gelpi-Hammerschmidt, Francisco
Wu, Chao-Ping
Bellmunt, Joaquim
Chang, Steven L.
TI Contemporary use of lymph node dissection at nephroureterectomy in
treating upper tract urothelial carcinoma: A US population-based
analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
Urol Oncol, Boston, MA USA.
Albert Einstein Coll Med, Dept Med, Jacobi Med Ctr, Bronx, NY 10467 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dept Surg, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15634
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903172
ER
PT J
AU Choueiri, TK
Hahn, NM
Alva, AS
Lauer, RC
Dreicer, R
Picus, J
Pili, R
Balar, AV
Sonpavde, G
Hoffman-Censits, JH
Guancial, EA
Alter, R
Regan, MM
Jacobs, C
Stewart, PS
Pal, SK
Rosenberg, JE
AF Choueiri, Toni K.
Hahn, Noah M.
Alva, Ajjai Shivaram
Lauer, Richard C.
Dreicer, Robert
Picus, Joel
Pili, Roberto
Balar, Arjun Vasant
Sonpavde, Guru
Hoffman-Censits, Jean H.
Guancial, Elizabeth A.
Alter, Robert
Regan, Meredith M.
Jacobs, Cindy
Stewart, Patricia S.
Pal, Sumanta Kumar
Rosenberg, Jonathan E.
TI The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427
(Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory
metastatic urothelial cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Med Inst, Indianapolis, IN USA.
Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Washington Univ, Div Oncol, St Louis, MO USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA.
Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Univ Rochester, Wilmot Canc Inst, Rochester, NY USA.
John Theurer Canc Ctr, Hackensack, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
OncoGenex Pharmaceut Inc, Bothell, WA USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4577
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904769
ER
PT J
AU Choueiri, TK
Fishman, MN
Escudier, B
McDermott, DF
Kluger, HM
Stadler, WM
Perez-Gracia, JL
McNeel, DG
Curti, BD
Harrison, MR
Plimack, ER
Appleman, LJ
Fong, L
Drake, CG
Young, TC
Chasalow, SD
Ross-Macdonald, P
Simon, JS
Walker, D
Sznol, M
AF Choueiri, Toni K.
Fishman, Mayer N.
Escudier, Bernard
McDermott, David F.
Kluger, Harriet M.
Stadler, Walter Michael
Perez-Gracia, Jose Luis
McNeel, Douglas G.
Curti, Brendan D.
Harrison, Michael Roger
Plimack, Elizabeth R.
Appleman, Leonard Joseph
Fong, Lawrence
Drake, Charles G.
Young, Tina C.
Chasalow, Scott D.
Ross-Macdonald, Petra
Simon, Jason S.
Walker, Dana
Sznol, Mario
TI Immunomodulatory activity of nivolumab in metastatic renal cell
carcinoma (mRCC): Association of biomarkers with clinical outcomes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Inst Gustave Roussy, Villejuif, France.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Yale Canc Ctr, New Haven, CT USA.
Univ Chicago Med, Chicago, IL USA.
Univ Navarra Clin, Pamplona, Spain.
Univ Wisconsin, Dept Med, Madison, WI USA.
Providence Canc Ctr, Earle Chiles Res Inst, Portland, OR USA.
Duke Univ, Med Ctr, Durham, NC USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Pittsburgh, Med Ctr UPMC Canc Pavil, Pittsburgh, PA USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Yale Univ, Sch Med, New Haven, CT USA.
Yale Canc Ctr, New Haven, CT USA.
NR 0
TC 12
Z9 12
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4500
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900968
ER
PT J
AU Cleary, JM
Mayer, RJ
Van Cutsem, E
Yamashita, F
Yoshisue, K
Ieiri, I
Ohtsu, A
Lenz, HJ
AF Cleary, James M.
Mayer, Robert J.
Van Cutsem, Eric
Yamashita, Fumiaki
Yoshisue, Kunihiro
Ieiri, Ichiro
Ohtsu, Atsushi
Lenz, Heinz-Josef
TI Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts)
with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials
and the phase 3 RECOURSE trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Leuven, Leuven, Belgium.
Taiho Pharmaceut Co Ltd, Tokyo, Japan.
Kyushu Univ, Fukuoka 812, Japan.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2579
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900612
ER
PT J
AU Cmelak, A
Li, SL
Marur, S
Zhao, WQ
Westra, WH
Chung, CH
Gillison, ML
Gilbert, J
Bauman, JE
Wagner, LI
Ferris, RL
Trevarthen, DR
Murphy, BA
Galloway, T
Burtness, B
AF Cmelak, Anthony
Li, Shuli
Marur, Shanthi
Zhao, Weiqiang
Westra, William H.
Chung, Christine H.
Gillison, Maura L.
Gilbert, Jill
Bauman, Julie E.
Wagner, Lynne I.
Ferris, Robert L.
Trevarthen, David R.
Murphy, Barbara A.
Galloway, Thomas
Burtness, Barbara
TI Symptom reduction from IMRT dose deintensification: Results from ECOG
1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS
V2).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins, Kimmel Canc Ctr, Baltimore, MD USA.
Ohio State Univ, Columbus, OH 43210 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Colorado Canc Res Program, Denver, CO USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6021
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901334
ER
PT J
AU Cohen, EEW
Licitra, LF
Fayette, J
Gauler, TC
Clement, PM
Grau, JJ
Del Campo, JM
Mailliez, A
Haddad, RI
Vermorken, JB
Tahara, M
Guigay, J
Geoffrois, L
Merlano, MC
Dupuis, NF
Burtness, B
Gibson, N
Solca, F
Ehrnrooth, E
Machiels, JPH
AF Cohen, Ezra E. W.
Licitra, Lisa F.
Fayette, Jerome
Gauler, Thomas Christoph
Clement, Paul M.
Jose Grau, Juan
Maria Del Campo, Jose
Mailliez, Audrey
Haddad, Robert I.
Vermorken, Jan B.
Tahara, Makoto
Guigay, Joel
Geoffrois, Lionnel
Merlano, Marco C.
Dupuis, Nicholas F.
Burtness, Barbara
Gibson, Neil
Solca, Flavio
Ehrnrooth, Eva
Machiels, Jean-Pascal H.
TI Biomarker analysis in recurrent and/or metastatic head and neck squamous
cell carcinoma (R/M HNSCC) patients (pts) treated with second-line
afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Univ Lyon, Leon Berard Ctr, Lyon, France.
Univ Lyon, Hosp Civils Lyon, Lyon, France.
Univ Hosp Essen, West German Canc Ctr, Essen, Germany.
Katholieke Univ Leuven, Dept Oncol, Leuven, Germany.
Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain.
Hosp Univ Vall DHebron, Dept Med Oncol, Barcelona, Spain.
Ctr Oscar Lambret, F-59020 Lille, France.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
Univ Antwerp Hosp, Edegem, Netherlands.
East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan.
Gustave Roussy, Villejuif, France.
Ctr Antoine Lacassagne, F-06054 Nice, France.
Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France.
Azienda Osped Santa Croce & Carle, Cuneo, Italy.
Biodesix Inc, Boulder, CO USA.
Fox Chase Canc Ctr, New Haven, CT USA.
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Boehringer Ingelheim Denmark AS, Copenhagen, Denmark.
Catholic Univ Louvain, Inst Roi Albert II, Serv Oncol Med, Clin Univ St Luc, B-1200 Brussels, Belgium.
Catholic Univ Louvain, Inst Rech Clin & Expt Pole MIRO, B-1200 Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6023
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901336
ER
PT J
AU Colleoni, M
Gray, KP
Gelber, SI
Lang, I
Thurlimann, BJK
Gianni, L
Abdi, EA
Price, KN
Gelber, RD
Viale, G
Coates, AS
Goldhirsch, A
AF Colleoni, Marco
Gray, Kathryn P.
Gelber, Shari I.
Lang, Istvan
Thurlimann, Beat J. K.
Gianni, Lorenzo
Abdi, Ehtesham A.
Price, Karen N.
Gelber, Richard D.
Viale, Giuseppe
Coates, Alan S.
Goldhirsch, Aron
CA Int Breast Canc Study Grp
TI Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for
receptor-negative early breast cancer (BC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 European Inst Oncol, Milan, MI, Italy.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Natl Inst Oncol, Budapest, Hungary.
Kantonsspital, St Gallen, Switzerland.
Onc Dept Infermi Hosp, Cesena, FC, Italy.
Tweed Hosp, Tweed Heads, NSW, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
European Inst Oncol, Div Pathol, Milan, Italy.
Univ Sydney, Sydney, NSW 2006, Australia.
European Inst Oncol, Milan, Italy.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1002
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900024
ER
PT J
AU Connolly, RM
Zhao, FM
Miller, K
Tevaarwerk, A
Wagner, LI
Lee, MJ
Murray, J
Gray, RJ
Piekarz, R
Zujewski, JA
Sparano, JA
AF Connolly, Roisin M.
Zhao, Fengmin
Miller, Kathy
Tevaarwerk, Amye
Wagner, Lynne I.
Lee, Min-Jung
Murray, Judy
Gray, Robert James
Piekarz, Richard
Zujewski, Jo Anne
Sparano, Joseph A.
TI E2112: Randomized phase III trial of endocrine therapy plus
entinostat/placebo in patients with hormone receptor-positive advanced
breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Dana Farber Canc Inst, Malden, MA USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Northwestern Univ, Feinberg Sch, Chicago, IL 60611 USA.
NIH, Bethesda, MD 20892 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA.
NCI, NIH, Bethesda, MD 20892 USA.
Montefiore Med Ctr, Bronx, NY 10467 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS636
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904828
ER
PT J
AU Coutre, S
Barrientos, JC
Brown, JR
De Vos, S
Furman, RR
Keating, MJ
O'Brien, SM
Pagel, JM
Sharman, JP
Zelenetz, AD
Newcomb, T
Cho, Y
Aguilar, C
Dreiling, L
AF Coutre, Steven
Barrientos, Jacqueline Claudia
Brown, Jennifer R.
De Vos, Sven
Furman, Richard R.
Keating, Michael J.
O'Brien, Susan Mary
Pagel, John M.
Sharman, Jeff Porter
Zelenetz, Andrew David
Newcomb, Terry
Cho, Yoonjin
Aguilar, Christopher
Dreiling, Lyndah
TI Safety of idelalisib in B-cell malignancies: Integrated analysis of
eight clinical trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA.
New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
UC Irvine Hlth, Chao Family Comprehens Canc Ctr, Orange, CA USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Gilead Sci Inc, Foster City, CA 94404 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e18030
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903763
ER
PT J
AU Coyne, GHO
Kummar, S
Do, KT
Holbeck, S
Hollingshead, MG
Horneffer, Y
Juwara, L
Srivastava, AK
Rubinstein, L
Piekarz, R
Sharon, E
Streicher, H
Conley, BA
Antony, R
Collins, JM
Chen, A
Doroshow, JH
AF Coyne, Geraldine Helen O'Sullivan
Kummar, Shivaani
Khanh Tu Do
Holbeck, Susan
Hollingshead, Melinda G.
Horneffer, Yvonne
Juwara, Lamin
Srivastava, Apurva K.
Rubinstein, Larry
Piekarz, Richard
Sharon, Elad
Streicher, Howard
Conley, Barbara A.
Antony, Ramya
Collins, Jerry M.
Chen, Alice
Doroshow, James H.
TI Phase I trial of the combination of bortezomib and clofarabine in adults
with refractory solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Early Clin Trials Dev Program, Bethesda, MD USA.
Stanford Univ, Sch Med, Phase Clin Res Program 1, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
NCI, Div Canc Treatment & Diag, NIH, Frederick, MD 21701 USA.
NCI, Bethesda, MD 20892 USA.
Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA.
Div Canc Treatment & Diag, Bethesda, MD USA.
NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA.
NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
NCI, Rockville, MD USA.
Leidos Biomed Res Inc, Frederick, MD USA.
NCI, DCTD, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2614
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904692
ER
PT J
AU Currow, DC
Temel, JS
Fearon, K
Yan, Y
Friend, J
Abernethy, AP
AF Currow, David Christopher
Temel, Jennifer S.
Fearon, Kenneth
Yan, Ying
Friend, John
Abernethy, Amy Pickar
TI A safety extension study of anamorelin in advanced non-small cell lung
cancer patients with cachexia: ROMANA 3.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Flinders Univ S Australia, Adelaide, SA 5001, Australia.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
Helsinn Therapeut US Inc, Bridgewater, NJ USA.
Duke Univ, Durham, NC USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20715
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904316
ER
PT J
AU D'Agostino, NM
Edelstein, K
Zhang, N
Recklitis, CJ
Brinkman, TM
Srivastava, D
Leisenring, WM
Robison, LL
Armstrong, GT
Krull, KR
AF D'Agostino, Norma Mammone
Edelstein, Kim
Zhang, Nan
Recklitis, Christopher J.
Brinkman, Tara M.
Srivastava, Deokumar
Leisenring, Wendy M.
Robison, Leslie L.
Armstrong, Gregory T.
Krull, Kevin R.
TI Patterns and predictors of psychological distress in adult survivors of
childhood cancer: A Childhood Cancer Survivor Study (CCSS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10065
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900074
ER
PT J
AU Daud, A
Weber, JS
Sosman, JA
Kim, K
Gonzalez, R
Hamid, O
Infante, JR
Cebon, JS
Schuchter, LM
Long, GV
Algazi, AP
Kudchadkar, RR
Puzanov, I
Lawrence, DP
Kefford, R
Kline, AS
Del Buono, HL
Sun, P
McDowell, DO
Flaherty, K
AF Daud, Adil
Weber, Jeffrey S.
Sosman, Jeffrey Alan
Kim, Kevin
Gonzalez, Rene
Hamid, Omid
Infante, Jeffrey R.
Cebon, Jonathan S.
Schuchter, Lynn Mara
Long, Georgina V.
Algazi, Alain Patrick
Kudchadkar, Ragini Reiney
Puzanov, Igor
Lawrence, Donald P.
Kefford, Richard
Kline, Amy S.
Del Buono, Heather Lynn
Sun, Peng
McDowell, Diane Opatt
Flaherty, Keith
TI Updated overall survival (OS) results for BRF113220, a phase I-II study
of dabrafenib alone versus combined dabrafenib and trametinib in
patients with BRAF V600 metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UC San Francisco, San Francisco, CA USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Melanoma Inst Australia, Sydney, NSW, Australia.
Univ Sydney, Sydney, NSW, Australia.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Crown Princess Mary Canc Ctr, Sydney, NSW, Australia.
GlaxoSmithKline, Collegeville, PA USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9036
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901946
ER
PT J
AU Daud, A
Ribas, A
Robert, C
Hodi, FS
Wolchok, JD
Joshua, AM
Hwu, WJ
Weber, JS
Gangadhar, TC
Joseph, RW
Dronca, RS
Patnaik, A
Zarour, HM
Kefford, R
Lindia, JA
Li, XN
Ebbinghaus, S
Kang, SP
Hamid, O
AF Daud, Adil
Ribas, Antoni
Robert, Caroline
Hodi, F. Stephen
Wolchok, Jedd D.
Joshua, Anthony M.
Hwu, Wen-Jen
Weber, Jeffrey S.
Gangadhar, Tara C.
Joseph, Richard Wayne
Dronca, Roxana Stefania
Patnaik, Amita
Zarour, Hassane M.
Kefford, Richard
Lindia, Jill Ann
Li, Xiaoyun Nicole
Ebbinghaus, Scot
Kang, Soonmo Peter
Hamid, Omid
TI Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled
analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in
KEYNOTE-001.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UC San Francisco, San Francisco, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Mayo Clin Jacksonville, Jacksonville, FL 32224 USA.
Mayo Clin, Rochester, MN USA.
START, San Antonio, TX USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Crown Princess Mary Canc Ctr, Sydney, NSW, Australia.
Merck & Co Inc, Kenilworth, NJ USA.
Angeles Clin, Los Angeles, CA USA.
Res Inst, Los Angeles, CA USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9005
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901915
ER
PT J
AU Davis, ID
Stockler, MR
Martin, AJ
Marchesin, V
Deignan, O
McDermott, R
Parulekar, WR
North, SA
Graham, B
Long, AP
Roncolato, FT
Yip, S
Hague, W
Dazo, C
Coskinas, X
Sweeney, C
AF Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
Marchesin, Vittorio
Deignan, Olwyn
McDermott, Ray
Parulekar, Wendy R.
North, Scott A.
Graham, Barbara
Long, Anne Poh
Roncolato, Felicia T.
Yip, Sonia
Hague, Wendy
Dazo, Carlo
Coskinas, Xanthi
Sweeney, Christopher
TI Randomised phase 3 trial of enzalutamide in first line androgen
deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET
Trial (ANZUP 1304).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia.
Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia.
ICORG, Dublin, Ireland.
Queens Univ, NCIC Clin Trials Grp, Canc Res Inst, Kingston, ON, Canada.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Queens Univ, Kingston, ON, Canada.
Royal Perth Hosp, Willetton, WA, Australia.
NHMRC Clin Trials Ctr, Camperdown, NSW, Australia.
Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia.
NHMRC Clin Trials Ctr, Sydney, NSW, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Stockler, Martin/N-3859-2016
OI Stockler, Martin/0000-0003-3793-8724
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5077
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904786
ER
PT J
AU de Velasco, G
Fay, AP
Culhane, A
Hakimi, AA
Voss, MH
Tannir, NM
Tamboli, P
Appleman, LJ
Bellmunt, J
Rathmell, K
Albiges, LK
Hsieh, J
Heng, DYC
Signoretti, S
Choueiri, TK
AF de Velasco, Guillermo
Fay, Andre Poisl
Culhane, Aedin
Hakimi, A. Ari
Voss, Martin Henner
Tannir, Nizar M.
Tamboli, Pheroze
Appleman, Leonard Joseph
Bellmunt, Joaquim
Rathmell, Kimryn
Albiges, Laurence K.
Hsieh, James
Heng, Daniel Yick Chin
Signoretti, Sabina
Choueiri, Toni K.
TI Prognostic value of genomic signatures in metastatic Clear Cell Renal
Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
Harvard Univ, Brookline, MA USA.
Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4560
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901031
ER
PT J
AU Demetri, GD
von Mehren, M
Jones, RL
Hensley, ML
Schuetze, S
Staddon, AP
Milhem, MM
Elias, AD
Ganjoo, KN
Tawbi, HAH
Van Tine, BA
Spira, AI
Dean, AP
Khokhar, NZ
Park, YC
Knoblauch, RE
Parekh, TV
Maki, RG
Patel, S
AF Demetri, George D.
von Mehren, Margaret
Jones, Robin Lewis
Hensley, Martee Leigh
Schuetze, Scott
Staddon, Arthur P.
Milhem, Mohammed M.
Elias, Anthony D.
Ganjoo, Kristen N.
Tawbi, Hussein Abdul-Hassan
Van Tine, Brian Andrew
Spira, Alexander I.
Dean, Andrew Peter
Khokhar, Nushmia Z.
Park, Youn Choi
Knoblauch, Roland Elmar
Parekh, Trilok V.
Maki, Robert G.
Patel, Shreyaskumar
TI A randomized phase III study of trabectedin (T) or dacarbazine (D) for
the treatment of patients (pts) with advanced liposarcoma (LPS) or
leiomyosarcoma (LMS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
Univ Colorado Canc Ctr, Aurora, CO USA.
Stanford Univ, Stanford, CA 94305 USA.
Univ Pittsburgh Canc Inst, Pittsburgh, PA USA.
Washington Univ, St Louis, MO USA.
US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA.
St John God Hosp Subiaco, Subiaco, WA, Australia.
Janssen Pharmaceut, Raritan, NJ USA.
Janssen Res & Dev LLC, Raritan, NJ USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 5
Z9 5
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900137
ER
PT J
AU Dickler, MN
Barry, WT
Cirrincione, CT
Ellis, MJ
Moynahan, ME
Innocenti, F
Hurria, A
Rugo, HS
Lake, D
Hahn, OM
Schneider, BP
Tripathy, D
Winer, EP
Hudis, CA
AF Dickler, Maura N.
Barry, William Thomas
Cirrincione, Constance T.
Ellis, Matthew James
Moynahan, Mary Ellen
Innocenti, Federico
Hurria, Arti
Rugo, Hope S.
Lake, Diana
Hahn, Olwen Mary
Schneider, Bryan P.
Tripathy, Debu
Winer, Eric P.
Hudis, Clifford A.
TI Phase III trial evaluating the addition of bevacizumab to letrozole as
first-line endocrine therapy for treatment of hormone-receptor positive
advanced breast cancer: CALGB 40503 (Alliance).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Washington Univ, St Louis, MO USA.
Univ N Carolina, Chapel Hill, NC USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Chicago, Chicago, IL 60637 USA.
Indiana Univ Simon Canc Ctr, Indianapolis, IN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 501
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901051
ER
PT J
AU Diefenbach, CSM
Li, HL
Kahl, BS
Robertson, MJ
Cohen, J
Advani, RH
Ambinder, R
Fenske, TS
Ansell, SM
AF Diefenbach, Catherine S. Magid
Li, Hailun
Kahl, Brad S.
Robertson, Michael J.
Cohen, Jonathan
Advani, Ranjana H.
Ambinder, Richard
Fenske, Timothy S.
Ansell, Stephen Maxted
TI A phase I study with an expansion cohort of the combination of
ipilimumab and brentuximab vedotin in patients with relapsed/refractory
Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group
(E4412).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Emory Univ, Atlanta, GA 30322 USA.
Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA.
Johns Hopkins Sch Med, Baltimore, MD USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS8602
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904864
ER
PT J
AU Dimopoulos, MA
Leleu, X
Matous, J
MacDonald, D
Trotman, J
Oriol, A
Shustik, C
Tedeschi, A
Garcia-Sanz, R
Heffner, LT
Ma, S
Mahe, B
Tam, C
Tournilhac, O
Li, JL
Singh, P
Bilotti, E
Graef, T
Treon, SP
Buske, C
AF Dimopoulos, Meletios A.
Leleu, Xavier
Matous, Jeffrey
MacDonald, David
Trotman, Judith
Oriol, Albert
Shustik, Chaim
Tedeschi, Alessandra
Garcia-Sanz, Ramon
Heffner, Leonard T.
Ma, Shuo
Mahe, Beatrice
Tam, Constantine
Tournilhac, Olivier
Li, Jianling
Singh, Priyanka
Bilotti, Elizabeth
Graef, Thorsten
Treon, Steven P.
Buske, Christian
TI A randomized, double-blind, placebo-controlled, phase 3 study of
rituximab with or without ibrutinib for Waldenstrom's macroglobulinemia
(PCYC-1127-CA).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece.
Hop Claude Huriez, Serv Malad Sang, Lille, France.
Colorado Blood Canc Inst, Denver, CO USA.
Dalhousie Univ, Div Hematol, Halifax, NS, Canada.
Concord Hosp, Dept Haematol, Sydney, NSW, Australia.
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain.
Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada.
Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy.
Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain.
Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA.
Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Univ Hosp, Hematol, Nantes, France.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
St Vincents Hosp, East Melbourne, Australia.
Univ Auvergne, UFR Med, INSERM CIC 501, CREaT,EA3846, Clermont Ferrand, France.
Pharmacyclics Inc, Sunnyvale, CA USA.
Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
Univ Ulm, Inst Expt Canc Res, D-89069 Ulm, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS8599
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904861
ER
PT J
AU Dizon, DS
Brady, WE
Lankes, HA
Jandial, DA
Howell, SB
Schilder, RJ
Beumer, JH
Christner, SM
Strychor, S
Powell, MA
Hagemann, AR
Moore, KN
Walker, JL
DiSilvestro, P
Fracasso, PM
AF Dizon, Don S.
Brady, William E.
Lankes, Heather A.
Jandial, Danielle A.
Howell, Stephen B.
Schilder, Russell J.
Beumer, Jan Hendrik
Christner, Susan M.
Strychor, Sandra
Powell, Matthew A.
Hagemann, Andrea R.
Moore, Kathleen N.
Walker, Joan L.
DiSilvestro, Paul
Fracasso, Paula M.
CA NRG Oncology
TI Results of a phase I pharmacokinetic study of intraperitoneal bortezomib
(B) and carboplatin (C) in patients with persistent or recurrent ovarian
cancer (OC): An NRG/Gynecologic Oncology Group study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Gyn Onc Grp, Buffalo, NY USA.
UC Irvine, Orange, CA USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Washington Univ, Sch Med, St Louis, MO USA.
Siteman Canc Ctr, St Louis, MO USA.
Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
OUHSC, Stephenson Canc Ctr, Oklahoma City, OK USA.
Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Providence, RI 02912 USA.
Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5515
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901174
ER
PT J
AU El-Jawahri, A
Shin, J
Traeger, L
Knight, H
Fishbein, JN
VanDusen, H
Keenan, T
Jackson, VA
Volandes, AE
Temel, JS
AF El-Jawahri, Areej
Shin, Jennifer
Traeger, Lara
Knight, Helen
Fishbein, Joel Nathan
VanDusen, Harry
Keenan, Tanya
Jackson, Vicki A.
Volandes, Angelo E.
Temel, Jennifer S.
TI Qualitative study of patients' and family caregivers' (FC) perceptions
and information preferences about hospice.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20501
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904134
ER
PT J
AU El-Jawahri, A
Temel, JS
Ramchandran, K
Jackson, VA
Chang, Y
Walker-Corkery, E
Mann, E
Volandes, AE
AF El-Jawahri, Areej
Temel, Jennifer S.
Ramchandran, Kavitha
Jackson, Vicki A.
Chang, Yuchiao
Walker-Corkery, Elizabeth
Mann, Eileen
Volandes, Angelo E.
TI A randomized, controlled trial of a cardiopulmonary resuscitation (CPR)
video decision support tool for seriously ill hospitalized patients with
advanced cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9516
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902011
ER
PT J
AU Ellisen, LW
Kurian, AW
Desmond, AJ
Mills, M
Lincoln, SE
Shannon, KM
Gabree, M
Tung, NM
Ford, JM
AF Ellisen, Leif W.
Kurian, Allison W.
Desmond, Andrea J.
Mills, Meredith
Lincoln, Stephen E.
Shannon, Kristen M.
Gabree, Michele
Tung, Nadine M.
Ford, James M.
TI Clinical impact of multi-gene panel testing for hereditary breast and
ovarian cancer risk assessment
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Stanford Univ, Stanford, CA 94305 USA.
InVitae, San Francisco, CA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1513
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900380
ER
PT J
AU Enzinger, PC
Abrams, TA
Chan, JA
McCleary, NJ
Zheng, H
Kwak, EL
Yurgelun, M
Blaszkowsky, LS
Cleary, JM
Wolpin, BM
Meyerhardt, JA
Regan, E
Graham, C
Straw, K
Fuchs, CS
Kelly, RJ
AF Enzinger, Peter C.
Abrams, Thomas Adam
Chan, Jennifer A.
McCleary, Nadine Jackson
Zheng, Hui
Kwak, Eunice Lee
Yurgelun, Matthew
Blaszkowsky, Lawrence Scott
Cleary, James M.
Wolpin, Brian M.
Meyerhardt, Jeffrey A.
Regan, Eileen
Graham, Christopher
Straw, Katharine
Fuchs, Charles S.
Kelly, Ronan Joseph
TI Multicenter phase 2: Capecitabine (CAP) plus oxaliplatin (OX) plus
bevacizumab (BEV) plus trastuzumab (TRAS) for patients (pts) with
metastatic esophagogastric cancer (MEGCA)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4038
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900877
ER
PT J
AU Farago, AF
Zheng, ZL
Muzikansky, A
Gainor, JF
Iafrate, AJ
Engelman, JA
Le, LP
Shaw, AT
AF Farago, Anna F.
Zheng, Zongli
Muzikansky, Alona
Gainor, Justin F.
Iafrate, A. John
Engelman, Jeffrey A.
Le, Long P.
Shaw, Alice Tsang
TI Clinical implementation of anchored multiplex PCR with targeted
next-generation sequencing for detection of ALK, ROS1, RET and NTRK1
fusions in non-small cell lung carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8095
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901807
ER
PT J
AU Faustman, DL
AF Faustman, Denise L.
TI Inactivation of highly potent regulatory T cells (Tregs) with TNFR2
antagonist antibodies as a novel cancer immunotherapy approach.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Charlestown, MA USA.
Harvard Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e14020
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902611
ER
PT J
AU Fay, AP
Kwiatkowski, DJ
Gray, KP
Thorner, A
Rini, BI
Agarwal, N
Ho, TH
Song, JX
Barrios, PM
Albiges, L
Van Allen, EM
Krajewski, KM
Porta, C
Pal, SK
Bellmunt, J
McDermott, DF
Heng, DYC
Signoretti, S
Choueiri, TK
AF Fay, Andre Poisl
Kwiatkowski, David J.
Gray, Kathryn P.
Thorner, Aaron
Rini, Brian I.
Agarwal, Neeraj
Ho, Thai Huu
Song, Jiaxi
Barrios, Pablo M.
Albiges, Laurence
Van Allen, Eliezer Mendel
Krajewski, Katherine Maragaret
Porta, Camillo
Pal, Sumanta Kumar
Bellmunt, Joaquim
McDermott, David F.
Heng, Daniel Yick Chin
Signoretti, Sabina
Choueiri, Toni K.
TI Activating genomic mutations in the mTOR pathway to predict responses to
everolimus and temsirolimus in patients with metastatic renal cell
carcinoma (mRCC): Results from a large multi-institutional cohort
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Mayo Clin, Scottsdale, AZ USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
PUCRS Sch Med, Porto Alegre, RS, Brazil.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy.
City Hope Natl Med Ctr, Duarte, CA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4519
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900987
ER
PT J
AU Felip, E
Orlov, S
Park, K
Yu, CJ
Tsai, CM
Nishio, M
Dols, MC
McKeage, MJ
Su, WC
Mok, T
Scagliotti, GV
Spigel, D
Branle, F
Emeremni, C
Quadrigli, M
Shaw, AT
AF Felip, Enriqueta
Orlov, Sergey
Park, Keunchil
Yu, Chong-Jen
Tsai, Chun-Ming
Nishio, Makoto
Dols, Manuel Cobo
McKeage, Mark James
Su, Wu-Chou
Mok, Tony
Scagliotti, Giorgio V.
Spigel, David
Branle, Fabrice
Emeremni, Chetachi
Quadrigli, Massimiliano
Shaw, Alice Tsang
TI ASCEND-3: A single-arm, open-label, multicenter phase II study of
ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK
plus ) non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vall dHebron Univ, Barcelona, Spain.
St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea.
Natl Taiwan Univ, Taipei 10764, Taiwan.
Taipei Vet Gen Hosp, Taipei, Taiwan.
Japanese Fdn Canc Res, Tokyo, Japan.
Hosp Reg Univ Carlos Haya, Med Oncol Sect, Malaga, Spain.
Auckland City Hosp, Auckland, New Zealand.
Univ Auckland, Auckland 1, New Zealand.
Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan.
Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
Univ Turin, Turin, Italy.
Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA.
Novartis Pharma AG, Basel, Switzerland.
Novartis Pharmaceut, E Hanover, NJ USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 26
Z9 26
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8060
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901772
ER
PT J
AU Fenaux, P
Al-Kali, A
Baer, MR
Sekeres, MA
Roboz, GJ
Gaidano, G
Silverman, LR
Scott, BL
Greenberg, P
Platzbecker, U
Steensma, DP
Kreuzer, KA
Godley, LA
Collins, R
Atallah, EL
Azarnia, N
Garcia-Manero, G
AF Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Silverman, Lewis R.
Scott, Bart L.
Greenberg, Peter
Platzbecker, Uwe
Steensma, David P.
Kreuzer, Karl A.
Godley, Lucy A.
Collins, Robert
Atallah, Ehab L.
Azarnia, Nozar
Garcia-Manero, Guillermo
TI Overall survival (OS) and baseline disease characteristics in MDS
patients with primary HMA failure in a randomized, controlled, phase III
study of rigosertib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hosp St Louis, Paris, France.
Mayo Clin, Rochester, MN USA.
Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Cleveland Clin, Leukemia Program, Dept Hematol & Oncol, Cleveland, OH 44106 USA.
Weill Cornell Med Coll, New York, NY USA.
Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Stanford Univ, Stanford, CA 94305 USA.
Univ Hosp Carl Gustav Carus TUD, Dresden, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Cologne, Cologne, Germany.
Univ Chicago, Chicago, IL 60637 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Onconova Therapeut Inc, Pennington, NJ USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e18079
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903801
ER
PT J
AU Ferrari, AC
Alumkal, JJ
Stein, MN
Mayer, TM
Torneten, S
Babb, J
Taplin, ME
DiPaola, RS
Beer, TM
AF Ferrari, Anna C.
Alumkal, Joshi J.
Stein, Mark N.
Mayer, Tina M.
Torneten, Sarah
Babb, James
Taplin, Mary-Ellen
DiPaola, Robert S.
Beer, Tomasz M.
TI LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate
cancer (CRPC) patients (pts) progressing on second line anti-androgen
(AA): NYU-08479/PCCTC.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NYU, Perlmutter Canc Ctr, Langone Med Ctr, New York, NY USA.
OHSU, Portland, OR USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
NYU, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5050
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901094
ER
PT J
AU Ferrario, C
Welch, S
Chaves, JM
Walker, LN
Krop, IE
Hamilton, EP
Borges, VF
Moulder, SL
AF Ferrario, Cristiano
Welch, Stephen
Chaves, Jorge M.
Walker, Luke N.
Krop, Ian E.
Hamilton, Erika Paige
Borges, Virginia F.
Moulder, Stacy L.
TI ONT-380 in the treatment of HER2+breast cancer central nervous system
(CNS) metastases (mets)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
London Reg Canc Prog, London, ON, Canada.
Northwest Med Specialties PLLC, Tacoma, WA USA.
Oncothyreon, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 612
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901404
ER
PT J
AU Fishbein, JN
Nipp, RD
El-Jawahri, A
Pirl, WF
Moran, S
McCarty, C
Eusebio, J
Gallagher, ER
Park, ER
Jackson, VA
Greer, JA
Temel, JS
AF Fishbein, Joel Nathan
Nipp, Ryan David
El-Jawahri, Areej
Pirl, William F.
Moran, Samantha
McCarty, Caitlin
Eusebio, Justin
Gallagher, Emily R.
Park, Elyse R.
Jackson, Vicki A.
Greer, Joseph A.
Temel, Jennifer S.
TI Depression and anxiety among family caregivers of patients with advanced
cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Harvard Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Brookline, MA USA.
MGH Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9514
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902009
ER
PT J
AU Fizazi, K
Shore, ND
Tammela, TLJ
Sarapohja, T
Vuorela, A
Kuss, I
Snapir, A
Smith, MR
AF Fizazi, Karim
Shore, Neal D.
Tammela, Teuvo L. J.
Sarapohja, Toni
Vuorela, Annamari
Kuss, Iris
Snapir, Amir
Smith, Matthew Raymond
CA ARAMIS Investigators
TI ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with
high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Tampere Univ Hosp, Dept Urol, Tampere, Finland.
Orion Corp Orion Pharma, Turku, Finland.
Orion Corp Orion Pharma, Espoo, Finland.
Bayer HealthCare Pharmaceut Inc, Berlin, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5080
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904789
ER
PT J
AU Fuchs, CS
Tabernero, J
Al-Batran, SE
Chau, I
Ilson, DH
Van Cutsem, E
Ferry, D
Emig, M
Melemed, AS
Vanvoorden, V
Hsu, YZ
Xu, YH
Sashegyi, A
Das, M
Shah, MA
AF Fuchs, Charles S.
Tabernero, Josep
Al-Batran, Salah-Eddin
Chau, Ian
Ilson, David H.
Van Cutsem, Eric
Ferry, David
Emig, Michael
Melemed, Allen S.
Vanvoorden, Veerle
Hsu, Yanzhi
Xu, Yihuan
Sashegyi, Andreas
Das, Mayukh
Shah, Manish A.
TI A randomized, double-blind, placebo-controlled phase III study of
cisplatin plus a fluoropyrimidine with or without ramucirumab as
first-line therapy in patients with metastatic gastric or
gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Univ Canc Ctr, Inst Clin Res UCT, Frankfurt, Germany.
Royal Marsden, London, England.
Royal Marsden, Surrey, England.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium.
Eli Lilly & Co, Bridgewater, NJ USA.
Lilly Deutschland GmbH, Bad Homburg, Germany.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
Eli Lilly & Co, Brussels, Belgium.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4131
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904739
ER
PT J
AU Fuchs, CS
Denker, AE
Tabernero, J
Van Cutsem, E
Ohtsu, A
Lam, B
Koshiji, M
Bang, YJ
AF Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
TI Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for
recurrent or metastatic gastric or gastroesophageal junction (GEJ)
adenocarcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
Seoul Natl Univ, Coll Med, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4135
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904743
ER
PT J
AU Fuchs, CS
Tabernero, J
Tomasek, J
Chau, I
Melichar, B
Safran, H
Tehfe, MA
Dumitru, F
Topuzov, E
Schlittler, L
Udrea, AA
Campbell, W
Brincat, S
Emig, M
Melemed, SA
Hozak, RR
Ferry, D
Caldwell, W
Ajani, JA
AF Fuchs, Charles S.
Tabernero, Josep
Tomasek, Jiri
Chau, Ian
Melichar, Bohuslav
Safran, Howard
Tehfe, Mustapha Ali
Dumitru, Filip
Topuzov, Eldar
Schlittler, Luis
Udrea, Anghel Adrian
Campbell, William
Brincat, Stephen
Emig, Michael
Melemed, Symantha A.
Hozak, Rebecca R.
Ferry, David
Caldwell, William
Ajani, Jaffer A.
TI Candidate biomarker analyses in gastric or gastro-esophageal junction
carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo
(PL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Masaryk Univ, Masaryk Mem Canc Inst, Fac Med, Brno, Czech Republic.
Royal Marsden, London, England.
Royal Marsden, London, Surrey, England.
Univ Palackeho, Fak Nemocnice, Onkol Klin, Lekarska Fak, Olomouc, Czech Republic.
Brown Univ, Oncol Res Grp, Providence, RI 02912 USA.
CHUM, Montreal, PQ, Canada.
Spitalul Judetean Urgenta, Baia Mare, Romania.
Hosp Cida Passo Fundo, Passo Fundo, Brazil.
Medisprof SRL, Cluj Napoca, Romania.
Hosp Herrera Llerandi, Guatemala City, Guatemala.
Sir Paul Boffa Hosp, Taxbiex, Malta.
Lilly Deutschland GmbH, Bad Homburg, Germany.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
Eli Lilly & Co, Bridgewater, NJ USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4029
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900868
ER
PT J
AU Fuchs, CS
Muro, K
Tomasek, J
Van Cutsem, E
Cho, JY
Oh, SC
Safran, H
Bodoky, G
Chau, I
Shimada, Y
Dumitru, F
Al-Batran, SE
Passalacqua, R
Ohtsu, A
Emig, M
Ferry, D
Chandrawansa, K
Hsu, YZ
Sashegyi, A
Wilke, H
AF Fuchs, Charles S.
Muro, Kei
Tomasek, Jiri
Van Cutsem, Eric
Cho, Jae Yong
Oh, Sang Cheul
Safran, Howard
Bodoky, Gyorgy
Chau, Ian
Shimada, Yasuhiro
Dumitru, Filip
Al-Batran, Salah-Eddin
Passalacqua, Rodolfo
Ohtsu, Atsushi
Emig, Michael
Ferry, David
Chandrawansa, Kumari
Hsu, Yanzhi
Sashegyi, Andreas
Wilke, Hansjochen
TI Prognostic factor analysis of overall survival (OS) in gastric cancer
from two phase III studies of second-line ramucirumab (RAM) (REGARD and
RAINBOW) using pooled individual patient (pt) data
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan.
Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic.
Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium.
Gangnam Severance Hosp, Seoul, South Korea.
Korea Univ Guro Hosp, Seoul, South Korea.
Brown Univ, Oncol Res Grp, Providence, RI 02912 USA.
Szent Laszlo Hosp, Budapest, Hungary.
Royal Marsden, London, England.
Royal Marsden, London, Surrey, England.
Natl Canc Ctr, Tokyo, Japan.
Spitalul Judetean Urgenta, Baia Mare, Romania.
Univ Canc Ctr, Inst Clin Res, Frankfurt, Germany.
Ist Ospitalieri Cremona, Cremona, Italy.
Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan.
Lilly Deutschland GmbH, Bad Homburg, Germany.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
Eli Lilly & Co, Bridgewater, NJ USA.
Kliniken Essen Mitte Ctr Pallat Care, Essen, Germany.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4028
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900867
ER
PT J
AU Gainor, JF
Sequist, LV
Shaw, AT
Azzoli, CG
Piotrowska, Z
Huynh, T
Fulton, L
Schultz, K
Hata, AN
Engelman, JA
Mino-Kenudson, M
AF Gainor, Justin F.
Sequist, Lecia V.
Shaw, Alice Tsang
Azzoli, Christopher G.
Piotrowska, Zofia
Huynh, Tiffany
Fulton, Linnea
Schultz, Katherine
Hata, Aaron N.
Engelman, Jeffrey A.
Mino-Kenudson, Mari
TI Clinical correlation and frequency of programmed death ligand-1 (PD-L1)
expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer
(NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8012
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901725
ER
PT J
AU Gakis, G
Morgan, TM
Daneshmand, S
Keegan, KA
Clayman, RH
Mischinger, J
Zaid, HB
Hrbacek, J
Ali-El-Dein, B
Galland, S
Olugbade, K
Rink, M
Fristche, HM
Burger, M
Chang, S
Babjuk, M
Thalmann, GN
Stenzl, A
Efstathiou, JA
AF Gakis, Georgios
Morgan, Todd Matthew
Daneshmand, Siamak
Keegan, Kirk A.
Clayman, Rebecca Helen
Mischinger, Johannes
Zaid, Harras B.
Hrbacek, Jan
Ali-El-Dein, Bedeir
Galland, Sigolene
Olugbade, Kola
Rink, Michael
Fristche, Hans-Martin
Burger, Maximilian
Chang, Sam
Babjuk, Marek
Thalmann, George N.
Stenzl, Arnulf
Efstathiou, Jason Alexander
TI Impact of salvage surgery and radiotherapy on overall survival in
patients with recurrent primary urethral cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Eberhard Karls Univ Tuebingen, Tubingen, Germany.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Univ Tubingen, Dept Urol, Tubingen, Germany.
Charles Univ Prague, Dept Urol, Sch Med 2, Prague, Czech Republic.
Mansoura Clin, Urol & Nephrol Ctr, Mansoura, Egypt.
Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
Univ Regensburg, D-93053 Regensburg, Germany.
Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic.
Univ Hosp Motol, Prague, Czech Republic.
Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland.
Univ Tubingen, Dept Urol, Tubingen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4568
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901039
ER
PT J
AU Gan, HK
Papadopoulos, KP
Fichtel, L
Lassman, AB
Merrell, R
Van Den Bent, MJ
Kumthekar, P
Scott, AM
Pedersen, M
Gomez, EJ
Fischer, JS
Ames, W
Xiong, H
Lee, HJ
Munasinghe, W
Roberts-Rapp, L
Ansell, P
Holen, KD
Lai, R
Reardon, DA
AF Gan, Hui K.
Papadopoulos, Kyriakos P.
Fichtel, Lisa
Lassman, Andrew B.
Merrell, Ryan
Van Den Bent, Martin J.
Kumthekar, Priya
Scott, Andrew M.
Pedersen, Michelle
Gomez, Erica J.
Fischer, Judee S.
Ames, William
Xiong, Hao
Lee, Ho-Jin
Munasinghe, Wijith
Roberts-Rapp, Lisa
Ansell, Peter
Holen, Kyle D.
Lai, Rose
Reardon, David A.
TI Phase I study of ABT-414 mono- or combination therapy with temozolomide
(TMZ) in recurrent glioblastoma (GBM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Austin Hlth, Melbourne, Vic, Australia.
Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.
South Texas Oncol & Hematol, San Antonio, TX USA.
Columbia Univ, Med Ctr, New York, NY USA.
Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
NorthShore Univ Hlth Syst, Evanston, IL USA.
Erasmus MC Canc Ctr, Rotterdam, Netherlands.
Northwestern Univ, Chicago, IL 60611 USA.
AbbVie Inc, N Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2016
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900475
ER
PT J
AU Gandhi, L
Shaw, A
Gadgeel, SM
Riely, G
Cetnar, J
West, HJ
Camidge, DR
Socinski, MA
Chiappori, A
Mekhail, T
Chao, BH
Borghaei, H
Gold, KA
Zeaiter, AH
Bordogna, W
Balas, B
Puig, O
Henschel, V
Ou, SHI
AF Gandhi, Leena
Shaw, Alice
Gadgeel, Shirish M.
Riely, Gregory
Cetnar, Jeremy
West, Howard Jack
Camidge, D. Ross
Socinski, Mark A.
Chiappori, Alberto
Mekhail, Tarek
Chao, Bo H.
Borghaei, Hossein
Gold, Kathryn A.
Zeaiter, Ali Hassan
Bordogna, Walter
Balas, Bogdana
Puig, Oscar
Henschel, Volkmar
Ou, Sai-Hong Ignatius
CA NP28761 Study Investigators
TI A phase II, open-label, multicenter study of the ALK inhibitor alectinib
in an ALK plus non-small-cell lung cancer (NSCLC) US/Canadian population
who had progressed on crizotinib (NP28761).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Swedish Canc Inst, Seattle, WA USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Florida Hosp, Inst Canc, Orlando, FL USA.
Ohio State Univ, Columbus, OH 43210 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
F Hoffmann La Roche Ltd, Basel, Switzerland.
Roche, New York, NY USA.
UC Irvine Sch Med, Irvine, CA USA.
NR 0
TC 11
Z9 11
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8019
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901732
ER
PT J
AU Gangadhar, TC
Mehnert, J
Patnaik, A
Hamid, O
Carlino, MS
Hodi, FS
Blank, CU
Ribas, A
Robert, C
Kondic, AG
Ahamadi, M
Freshwater, T
de Greef, R
van Vugt, M
Lubiniecki, G
Ebbinghaus, S
Kang, SP
Daud, A
AF Gangadhar, Tara C.
Mehnert, Janice
Patnaik, Amita
Hamid, Omid
Carlino, Matteo S.
Hodi, F. Stephen
Blank, Christian U.
Ribas, Antoni
Robert, Caroline
Kondic, Anna Georgieva
Ahamadi, Malidi
Freshwater, Tomoko
de Greef, Rik
van Vugt, Marianne
Lubiniecki, Gregory
Ebbinghaus, Scot
Kang, Soonmo Peter
Daud, Adil
TI Population pharmacokinetic (popPK) model of pembrolizumab (pembro;
MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
START, San Antonio, TX USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Westmead Hosp, Baulkham Hills, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Netherlands Canc Inst, Amsterdam, Netherlands.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Gustave Roussy, Villejuif, France.
Merck & Co Inc, Kenilworth, NJ USA.
UC San Francisco, San Francisco, CA USA.
NR 0
TC 1
Z9 1
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3058
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900692
ER
PT J
AU Garber, JE
Tung, NM
Elkin, EP
Allen, B
Hartman, AR
Singh, N
Wenstrup, RJ
Winer, EP
Lin, NU
AF Garber, Judy Ellen
Tung, Nadine M.
Elkin, Eric P.
Allen, Brian
Hartman, Anne-Renee
Singh, Nanda
Wenstrup, Richard J.
Winer, Eric P.
Lin, Nancy U.
TI Predisposing germline mutations in high grade ER+HER2-breast cancer (BC)
patients diagnosed (Dx)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Myriad Genet Inc, Salt Lake City, UT USA.
Myriad Genet Labs Inc, Salt Lake City, UT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900370
ER
PT J
AU Garcia-Manero, G
Schiffer, CA
Godley, LA
Paquette, R
Platzbecker, U
Robbins, PB
Norton, J
Karakunnel, JJ
Lindsley, RC
AF Garcia-Manero, Guillermo
Schiffer, Charles Alan
Godley, Lucy A.
Paquette, Ronald
Platzbecker, Uwe
Robbins, Paul B.
Norton, Jonathan
Karakunnel, Joyson Joseph
Lindsley, Robert Coleman
TI Phase 1 study to evaluate the safety and tolerability of MEDI4736, an
anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic
syndrome (MDS) after treatment with hypomethylating agents.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany.
MedImmune, Gaithersburg, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS7103
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904846
ER
PT J
AU Gelhorn, H
Tong, S
Maclaine, G
Healey, JH
Bukata, SV
Keedy, VL
Anthony, SP
Wagner, AJ
Von Hoff, DD
Singh, AS
Becerra, C
Hanlon, J
Lenderking, W
Murray, L
Hsu, HH
Lin, PS
Tap, WD
AF Gelhorn, Heather
Tong, Sandra
Maclaine, Grant
Healey, John H.
Bukata, Susan V.
Keedy, Vicki Leigh
Anthony, Stephen Patrick
Wagner, Andrew J.
Von Hoff, Daniel D.
Singh, Arun S.
Becerra, Carlos
Hanlon, Jennifer
Lenderking, William
Murray, Lindsey
Hsu, Henry H.
Lin, Paul S.
Tap, William D.
TI Patient-reported outcome instruments meaningful and relevant for
tenosynovial giant cell tumor (TGCT): A qualitative study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Evidera, Bethesda, MD USA.
Plexxikon Inc, Berkeley, CA USA.
Sankyo UK Ltd, Gerrards Cross, Bucks, England.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Vanderbilt Univ Sch Med, Nashville, TN USA.
Evergreen Hematol & Oncol US Oncol, Spokane, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
TGen, Scottsdale, AZ USA.
Sammons Canc Ctr US Oncol, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10521
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900157
ER
PT J
AU Gerber, DE
Oxnard, GR
Mandrekar, SJ
Dahlberg, SE
Malik, SM
Mooney, MM
Abrams, JS
Janne, PA
Li, TH
Ramalingam, SS
Vokes, EE
Govindan, R
AF Gerber, David E.
Oxnard, Geoffrey R.
Mandrekar, Sumithra J.
Dahlberg, Suzanne Eleanor
Malik, Shakun M.
Mooney, Margaret M.
Abrams, Jeffrey S.
Janne, Pasi A.
Li, Tianhong
Ramalingam, Suresh S.
Vokes, Everett E.
Govindan, Ramaswamy
TI ALCHEMIST: a clinical trial platform to bring genomic discovery and
molecularly targeted therapies to early-stage lung cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Clin Invest Branch CTEP DCTD, Rockville, MD USA.
NCI, Bethesda, MD 20892 USA.
UC Davis Comprehens Canc Ctr, Sacramento, CA USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Chicago, Dept Med, Chicago, IL 60637 USA.
Washington Univ, Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS7583
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904847
ER
PT J
AU Gerstner, ER
Zhang, Z
Fink, JR
Muzi, M
Hanna, L
Greco, E
Mintz, A
Kostakoglu, L
Eikman, EA
Prah, M
Schmainda, KM
Sorensen, GA
Barboriak, D
Mankoff, DA
AF Gerstner, Elizabeth Robins
Zhang, Zheng
Fink, James R.
Muzi, Mark
Hanna, Lucy
Greco, Erin
Mintz, Akiva
Kostakoglu, Lale
Eikman, Edward A.
Prah, Melissa
Schmainda, Kathleen M.
Sorensen, Gregory A.
Barboriak, Daniel
Mankoff, David A.
TI ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using
FMISO PET and MRI.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brown Univ, Providence, RI 02912 USA.
Univ Washington, Seattle, WA 98195 USA.
Wake Forest Univ, Winston Salem, NC 27109 USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Duke Univ, Durham, NC USA.
Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2024
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900483
ER
PT J
AU Ghiaseddin, A
Reardon, DA
Massey, W
Mannerino, A
Lipp, ES
Herndon, JE
McSherry, F
Desjardins, A
Randazzo, DM
Vlahovic, G
Friedman, HS
Peters, KB
AF Ghiaseddin, Ashley
Reardon, David A.
Massey, Woody
Mannerino, Alexandra
Lipp, Eric S.
Herndon, James E.
McSherry, Frances
Desjardins, Annick
Randazzo, Dina M.
Vlahovic, Gordana
Friedman, Henry S.
Peters, Katherine B.
TI Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Ctr Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2034
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900493
ER
PT J
AU Giannakis, M
Shukla, S
Mu, JX
Nishihara, R
Yamauchi, M
Sukawa, Y
Qian, ZR
Nosho, K
Inamura, K
Bahl, S
Ng, K
Chan, AT
Meyerhardt, JA
Gabriel, SB
Lander, E
Wu, C
Getz, G
Fuchs, CS
Ogino, S
Garraway, LA
AF Giannakis, Marios
Shukla, Sachet
Mu, Jasmine Xinmeng
Nishihara, Reiko
Yamauchi, Mai
Sukawa, Yasutaka
Qian, Zhi Rong
Nosho, Katsuhiko
Inamura, Kentaro
Bahl, Samira
Ng, Kimmie
Chan, Andrew T.
Meyerhardt, Jeffrey A.
Gabriel, Stacey B.
Lander, Eric
Wu, Catherine
Getz, Gad
Fuchs, Charles S.
Ogino, Shuji
Garraway, Levi A.
TI Comprehensive molecular characterization of colorectal cancer reveals
genomic predictors of immune cell infiltrates.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Broad Inst MIT & Harvard, Cambridge, MA USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Broad Inst, Cambridge, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3505
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900725
ER
PT J
AU Gitlitz, BJ
Morosini, D
Sable-Hunt, AL
Addario, BJ
Jennings, MB
Mach, SL
Oxnard, GR
AF Gitlitz, Barbara J.
Morosini, Deborah
Sable-Hunt, Alicia L.
Addario, Bonnie J.
Jennings, Mark Byron
Mach, Stacy L.
Oxnard, Geoffrey R.
TI The genomics of Young Lung Cancer Study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
Fdn Med Inc, Cambridge, MA USA.
ALCMI, San Carlos, CA USA.
Bonnie J Addario Lung Canc Fdn, San Carlos, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS11110
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904668
ER
PT J
AU Goldwirt, L
Verreault, M
Levasseur, C
Schmitt, C
Guehennec, J
Labussiere, M
Haidar, S
Mokhtari, K
Mourah, S
Hoang-Xuan, K
Sanson, M
Wen, PY
Ligon, KL
Delattre, JY
Idbaih, A
AF Goldwirt, Lauriane
Verreault, Maite
Levasseur, Camille
Schmitt, Charlotte
Guehennec, Jeremy
Labussiere, Marianne
Haidar, Sam
Mokhtari, Karima
Mourah, Samia
Hoang-Xuan, Khe
Sanson, Marc
Wen, Patrick Y.
Ligon, Keith L.
Delattre, Jean-Yves
Idbaih, Ahmed
TI Brain distribution of the MDM2 inhibitor, RG7112: Single dose escalation
and repeated doses studies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hop St Louis, AP HP, Dept Pharmacol, Paris, France.
Univ Paris 06, INSERM, CRICM, UMR S975,U975,CNRS,UMR 7225, Paris, France.
Ctr Rech Inst Cerveau & Moelle Epiniere, UMR U975, Paris, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Hop La Pitie Salpetriere, Paris, France.
Hop St Louis, AP HP, Pharmacol & Genet Deparment, Paris, France.
UPMC, AP HP, CRIMC, Paris, France.
Univ Paris 06, CRICM, Neurol 2, Paris, France.
DFCI, Boston, MA USA.
Univ Paris 06, Pitie Salpetriere Hosp, Paris, France.
Univ Paris 06, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e13582
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902575
ER
PT J
AU Golshan, M
Cirrincione, CT
Carey, LA
Sikov, WM
Berry, DA
Burstein, HJ
Overmoyer, B
Henry, NL
Somlo, G
Port, ER
Winer, EP
Hudis, CA
Ollila, DW
AF Golshan, Mehra
Cirrincione, Constance T.
Carey, Lisa A.
Sikov, William M.
Berry, Donald A.
Burstein, Harold J.
Overmoyer, Beth
Henry, Norah Lynn
Somlo, George
Port, Elisa R.
Winer, Eric P.
Hudis, Clifford A.
Ollila, David W.
TI Impact of neoadjuvant therapy on breast conservation rates in
triple-negative and HER2-positive breast cancer: Combined results of
CALGB 40603 and 40601 (Alliance).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1007
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900079
ER
PT J
AU Goodman, LM
Moeller, M
Dalby, CK
Azzouqa, A
Guthrie, AE
Earl, MA
Velcheti, V
Shapiro, MA
Pennell, NA
Stevenson, J
AF Goodman, Lindsey Martin
Moeller, Machelle
Dalby, Carole Kathleen
Azzouqa, Abdel
Guthrie, Amy E.
Earl, Marc A.
Velcheti, Vamsidhar
Shapiro, Marc A.
Pennell, Nathan A.
Stevenson, James
TI Effect of improving guideline-based prophylactic growth factor (pGCSF)
use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in
non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic
Taussig Cancer Institute (TCI) Quality Improvement (QI) Project
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Cleveland Clin, Cleveland Hts, OH USA.
Cleveland Clin Fdn, Cleveland, OH 44195 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6565
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901480
ER
PT J
AU Gore, ME
Hackshaw, A
Brady, WE
Penson, RT
Zaino, RJ
McCluggage, WG
Ganesan, R
Wilkinson, N
Perren, T
Montes, A
Summers, J
Lord, R
Dark, GG
Rustin, GJS
Mackean, MJ
Reed, N
Kehoe, S
Christensen, H
Ledermann, JA
Gershenson, DM
AF Gore, Martin Eric
Hackshaw, Allan
Brady, William E.
Penson, Richard T.
Zaino, Richard J.
McCluggage, W. Glenn
Ganesan, Raji
Wilkinson, Nafisa
Perren, Timothy
Montes, Ana
Summers, Jeffrey
Lord, Rosemary
Dark, Graham G.
Rustin, Gordon J. S.
Mackean, Melanie J.
Reed, Nicholas
Kehoe, Sean
Christensen, Helen
Ledermann, Jonathan A.
Gershenson, David Marc
TI Multicentre trial of carboplatin/paclitaxel versus
oxaliplatin/capecitabine, each with/without bevacizumab, as first line
chemotherapy for patients with mucinous epithelial ovarian cancer
(mEOC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Royal Marsden Hosp NHS Trust, London, England.
UCL, Canc Inst CRUK, London, England.
UCL Canc Trials Ctr, London, England.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Massachusetts Gen Hosp, Braintree, MA USA.
Harvard Med Sch, Braintree, MA USA.
Hershey Med Ctr, Hershey, PA USA.
Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland.
Birmingham Womens NHS Fdn Trust, Birmingham, W Midlands, England.
Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England.
Guys & St Thomas NHS Trust, London, England.
Maidstone Maritime Hosp, Maidstone, Kent, England.
Clatterbridge Canc Ctr, Bebington, England.
Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
Mt Vernon Hosp, Northwood, Middx, England.
Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland.
Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England.
CR UK & UCL Canc Trials Ctr, London, England.
UCL, Inst Canc, London, England.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5528
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901188
ER
PT J
AU Goss, GD
Vokes, EE
Gordon, MS
Gandhi, L
Papadopoulos, KP
Rasco, DW
Pedersen, M
Fischer, JS
Chu, K
Ames, W
Xiong, H
Lee, HJ
Zeng, JW
Roberts-Rapp, L
Ansell, P
Reilly, E
Holen, KD
Tolcher, AW
AF Goss, Glenwood D.
Vokes, Everett E.
Gordon, Michael S.
Gandhi, Leena
Papadopoulos, Kyriakos P.
Rasco, Drew Warren
Pedersen, Michelle
Fischer, Judee S.
Chu, Katharine
Ames, William
Xiong, Hao
Lee, Ho-Jin
Zeng, Jiewei
Roberts-Rapp, Lisa
Ansell, Peter
Reilly, Ed
Holen, Kyle D.
Tolcher, Anthony W.
TI ABT-414 in patients with advanced solid tumors likely to overexpress the
epidermal growth factor receptor (EGFR).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ottawa Hosp Canc Ctr, Ottawa, ON, Canada.
Univ Chicago, Chicago, IL 60637 USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
South Texas Accelerated Res Therapeut, San Antonio, TX USA.
AbbVie Inc, N Chicago, IL USA.
AbbVie, N Chicago, IL USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2510
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900543
ER
PT J
AU Goyal, L
Zheng, H
Yurgelun, M
Abrams, TA
Kwak, EL
Cleary, JM
Knowles, M
Regan, E
Gisondi, A
Sheehan, S
Khachatryan, A
Nardi, V
Borger, DR
Duda, GD
Zhu, AX
AF Goyal, Lipika
Zheng, Hui
Yurgelun, Matthew
Abrams, Thomas Adam
Kwak, Eunice Lee
Cleary, James M.
Knowles, Michelle
Regan, Eileen
Gisondi, Amy
Sheehan, Susan
Khachatryan, Anna
Nardi, Valentina
Borger, Darrell R.
Duda, Gabriel Dan
Zhu, Andrew X.
TI A phase II and biomarker study of cabozantinib (XL-184) in patients
(pts) with advanced cholangiocarcinoma (CCA)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 MGH Canc Ctr, Brookline, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
MGH Canc Ctr, Boston, MA USA.
MGH, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15124
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902897
ER
PT J
AU Grimm, SA
Kumthekar, P
Chamberlain, MC
Schiff, D
Wen, PY
Iwamoto, FM
Reardon, DA
Purow, B
Raizer, JJ
AF Grimm, Sean Aaron
Kumthekar, Priya
Chamberlain, Marc C.
Schiff, David
Wen, Patrick Y.
Iwamoto, Fabio Massaiti
Reardon, David A.
Purow, Benjamin
Raizer, Jeffrey J.
TI Phase II trial of bevacizumab in patients with surgery and radiation
refractory progressive meningioma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Northwestern Univ, Chicago, IL 60611 USA.
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
Northwestern Univ, Lurie Comp Canc Ctr, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2055
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900513
ER
PT J
AU Grushko, TA
Filiaci, VL
Montag, AG
Apushkin, MA
Marzullo, B
Monovich, L
Ramirez, NC
Birrer, MJ
Olopade, OI
Fleming, GF
AF Grushko, Tatyana A.
Filiaci, Virginia L.
Montag, Anthony G.
Apushkin, Marsha A.
Marzullo, Brandon
Monovich, Laura
Ramirez, Nilsa C.
Birrer, Michael J.
Olopade, Olufunmilayo I.
Fleming, Gini F.
CA NRG Oncology Gynecologic Oncology
TI The value of TOP2A as a target for anthracycline-based chemotherapy in
advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology
Group study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
NRG Oncol, Buffalo, NY USA.
GOG Fdn Inc SDMC, Buffalo, NY USA.
Illinois Pathol Inc, Berwyn, IL USA.
SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA.
SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Buffalo, NY 14260 USA.
Nationwide Childrens Hosp, Res Inst, Biopathol Ctr, Gynecol Oncol Grp,Tissue Bank, Columbus, OH USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16509
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903306
ER
PT J
AU Guarino, MJ
Starodub, A
Masters, GA
Heist, RS
Messersmith, WA
Bardia, A
Ocean, AJ
Thomas, SS
Maliakal, PP
Wegener, WA
Sharkey, RM
Wilhelm, F
Goldenberg, DM
AF Guarino, Michael J.
Starodub, Alexander
Masters, Gregory A.
Heist, Rebecca Suk
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Thomas, Sajeve Samuel
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
TI Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38
antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase
I/II clinical experience.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA.
Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA.
Helen F Graham Canc Ctr, Newark, DE USA.
Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Univ Colorado Canc Ctr, Aurora, CO USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Florida, Windermere, FL USA.
Immunomedics Inc, Morris Plains, NJ USA.
Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2504
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900537
ER
PT J
AU Gulley, JL
Giacchino, JL
Breitmeyer, JB
Franzusoff, AJ
Panicali, D
Schlom, J
Kantoff, PW
AF Gulley, James L.
Giacchino, Jeannie Lorraine
Breitmeyer, James Bradley
Franzusoff, Alexis J.
Panicali, Dennis
Schlom, Jeffrey
Kantoff, Philip W.
TI Prospect: A randomized double-blind phase 3 efficacy study of
PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic
metastatic castration-resistant prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, NIH, Bethesda, MD 20892 USA.
Bavarian Nord AS, Mountain View, CA USA.
Bavarian Nord Inc, Mountain View, CA USA.
Bavarian Nord Inc, Mountain View, CA USA.
NCI, Lab Tumor Immunol & Biol, NIH, Bethesda, MD 20892 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5081
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904790
ER
PT J
AU Gunturi, A
Aung, S
McDermott, DF
Buchbinder, EI
AF Gunturi, Anasuya
Aung, Sandra
McDermott, David F.
Buchbinder, Elizabeth Iannotti
TI A retrospective analysis of high-dose aldesleukin (HD IL-2) following
immune checkpoint blockade (ICB) in metastatic melanoma (MM) and
metastatic renal cell carcinoma (mRCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Prometheus Labs, San Diego, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3053
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900687
ER
PT J
AU Haas, NB
Manola, J
Flaherty, K
Uzzo, RG
Atkins, MB
Dutcher, JP
Wood, CG
Kane, CJ
Jewett, MAS
Coomes, B
Matin, SF
Kuzel, T
Sexton, WJ
Wong, YN
Choueiri, TK
Pili, R
Puzanov, I
Kohli, M
Stadler, WM
DiPaola, RS
AF Haas, Naomi B.
Manola, Judith
Flaherty, Keith
Uzzo, Robert G.
Atkins, Michael B.
Dutcher, Janice P.
Wood, Christopher G.
Kane, Christopher J.
Jewett, Michael A. S.
Coomes, Bob
Matin, Surena F.
Kuzel, Timothy
Sexton, Wade Jeffers
Wong, Yu-Ning
Choueiri, Toni K.
Pili, Roberto
Puzanov, Igor
Kohli, Manish
Stadler, Walter Michael
DiPaola, Robert S.
CA ECOG ACRIN 2805 Authors Grp
TI Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for
unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Lombardi Comprehens Canc Ctr, Washington, DC USA.
Our Lady Mercy Canc Ctr, New York, NY USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
Canc Res Patient Advocate, Atlanta, GA USA.
Northwestern Univ, Chicago, IL 60611 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL 33612 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Mayo Clin, Rochester, MN USA.
Univ Chicago, Chicago, IL 60637 USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4508
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900976
ER
PT J
AU Hahn, NM
Picus, J
Bambury, RM
Pal, SK
Hart, LL
Grivas, P
Milowsky, MI
Alva, AS
Sonpavde, G
Mortazavi, A
Bellmunt, J
Guancial, EA
Gupta, S
Chao, RC
Collier, MA
Christensen, J
Chen, I
Rosenberg, JE
AF Hahn, Noah M.
Picus, Joel
Bambury, Richard Martin
Pal, Sumanta Kumar
Hart, Lowell L.
Grivas, Petros
Milowsky, Matthew I.
Alva, Ajjai Shivaram
Sonpavde, Guru
Mortazavi, Amir
Bellmunt, Joaquim
Guancial, Elizabeth A.
Gupta, Sumati
Chao, Richard C.
Collier, Mary A.
Christensen, James
Chen, Isan
Rosenberg, Jonathan E.
TI A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat
in patients with urothelial carcinoma (UC) and inactivating alterations
of acetyltransferase genes.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
Washington Univ, Div Oncol, St Louis, MO USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Florida Canc Specialists, Ft Myers, FL USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
Ohio State Univ, Wexner Med Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Rochester, Wilmot Canc Inst, Rochester, NY USA.
Huntsman Canc Inst, Fruit Hts, UT USA.
Mirati Therapeut Inc, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4575
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904767
ER
PT J
AU Hamilton, EP
Birrer, MJ
DiCarlo, BA
Gaillard, S
Martin, LP
Nemunaitis, JJ
Perez, RP
Schilder, RJ
Annunziata, CM
Begley, CG
Hager, SJ
AF Hamilton, Erika Paige
Birrer, Michael J.
DiCarlo, Brian Anthony
Gaillard, Stephanie
Martin, Lainie P.
Nemunaitis, John J.
Perez, Raymond P.
Schilder, Russell J.
Annunziata, Christina M.
Begley, Colin G.
Hager, Steven Jeffrey
TI A phase 1b, open-label, non-randomized multicenter study of birinapant
in combination with conatumumab in subjects with relapsed epithelial
ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Coastal Integrat Canc Care, San Luis Obispo, CA USA.
Duke Canc Inst, Durham, NC USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Mary Crowley Canc Res Ctr, Dallas, TX USA.
Univ Kansas, Fairway, KS USA.
Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
NCI, NIH, Bethesda, MD 20892 USA.
TetraLog Pharmaceut, Westlake Village, CA USA.
Calif Canc Associates Res & Excellence, Fresno, CA USA.
RI Annunziata, Christina/L-3219-2016; Perez, Raymond/R-6159-2016
OI Annunziata, Christina/0000-0003-2033-6532; Perez,
Raymond/0000-0002-7432-2411
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5571
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901236
ER
PT J
AU Harshman, LC
Wang, XD
Nakabayashi, M
Xie, WL
Valenca, LB
Werner, L
Yu, YJ
Kantoff, A
Sweeney, C
Mucci, LA
Pomerantz, M
Lee, GSM
Kantoff, PW
AF Harshman, Lauren Christine
Wang, Xiaodong
Nakabayashi, Mari
Xie, Wanling
Valenca, Loana Bueno
Werner, Lillian
Yu, Yongjiang
Kantoff, Aaron
Sweeney, Christopher
Mucci, Lorelei A.
Pomerantz, Mark
Lee, Gwo-Shu Mary
Kantoff, Philip W.
TI Statin use at the time of initiation of androgen deprivation therapy and
time to progression in patients with hormone-sensitive prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China.
Apple Tree Partners, New York, NY USA.
Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5024
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901066
ER
PT J
AU Harshman, LC
Werner, L
Wong, YN
Yu, EY
Alva, AS
Crabb, SJ
Powles, T
Rosenberg, JE
Baniel, J
Vaishampayan, UN
Berthold, DR
Ladoire, S
Hussain, SA
Milowsky, MI
Agarwal, N
Necchi, A
Pal, SK
Recine, F
Bellmunt, J
Galsky, MD
AF Harshman, Lauren Christine
Werner, Lillian
Wong, Yu-Ning
Yu, Evan Y.
Alva, Ajjai Shivaram
Crabb, Simon J.
Powles, Thomas
Rosenberg, Jonathan E.
Baniel, Jack
Vaishampayan, Ulka N.
Berthold, Dominik R.
Ladoire, Sylvain
Hussain, Syed A.
Milowsky, Matthew I.
Agarwal, Neeraj
Necchi, Andrea
Pal, Sumanta Kumar
Recine, Federica
Bellmunt, Joaquim
Galsky, Matt D.
CA RISC Investigators
TI Adjuvant chemotherapy for residual disease after neoadjuvant
chemotherapy for muscle invasive urothelial cancer (MIUC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
Univ Southampton, Southampton, Hants, England.
Barts Hlth, Barts Canc Inst, London, England.
Royal Free NHS Trust, London, England.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Rabin Med Ctr, Petah Tivka, Israel.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
CHU Vaudois, Lausanne, Switzerland.
Georges Francois Leclerc Canc Ctr, Dijon, France.
Univ Liverpool, Clatterbridge Canc Ctr, Liverpool L69 3BX, Merseyside, England.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Ist Nazl Tumori Milan, Milan, MI, Italy.
City Hope Natl Med Ctr, Duarte, CA USA.
San Camillo Forlanini Hosp, Rome, Italy.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4524
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900992
ER
PT J
AU Heinemann, V
Niedzwiecki, D
Pearline, RV
Grothey, A
Hochster, HS
Goldberg, RM
Innocenti, F
Mayer, RJ
Schilsky, RL
Blanke, CD
Bertagnolli, MM
Venook, AP
Stinzing, S
O'Neil, BH
AF Heinemann, Volker
Niedzwiecki, Donna
Pearline, Rachel V.
Grothey, Axel
Hochster, Howard S.
Goldberg, Richard M.
Innocenti, Federico
Mayer, Robert J.
Schilsky, Richard L.
Blanke, Charles David
Bertagnolli, Monica M.
Venook, Alan P.
Stinzing, Sebastian
O'Neil, Bert H.
TI Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in
patients previously treated with oxaliplatin-based adjuvant therapy: A
combined analysis of data from FIRE-3 and CALGB 80405
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany.
Univ Munich, Klinikum Grosshadern, Ctr Comprehens Canc, D-80539 Munich, Germany.
Duke Univ, Cary, NC USA.
UC San Francisco, San Francisco, CA USA.
Mayo Clin, Rochester, MN USA.
Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Richard J Solove Res Inst, Columbus, OH USA.
Univ N Carolina, Chapel Hill, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Amer Soc Clin Oncol, Alexandria, VA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
LMU, Munich, Germany.
Indiana Univ Hlth Univ Hosp, Indianapolis, IN USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3585
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900804
ER
PT J
AU Heinrich, MC
von Mehren, M
Demetri, GD
Fletcher, JA
Sun, JCG
Kerstein, D
Conlan, MG
George, S
AF Heinrich, Michael C.
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Kerstein, David
Conlan, Maureen G.
George, Suzanne
TI Ponatinib efficacy and safety in patients (pts) with advanced
gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor
(TKI) failure: Results from a phase 2 study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
Ariad Pharmaceut Inc, Cambridge, MA USA.
ARIAD Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10535
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900172
ER
PT J
AU Heinrich, MC
Hodgson, JG
von Mehren, M
Demetri, GD
Fletcher, JA
Sun, JCG
Pritchard, JR
Zhang, S
Rivera, VM
George, S
AF Heinrich, Michael C.
Hodgson, J. Graeme
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Pritchard, Justin R.
Zhang, Sen
Rivera, Victor M.
George, Suzanne
TI Detection of KIT mutants in circulating tumor DNA (ctDNA) and their
association with ponatinib anti-tumor activity in patients (pts) with
advanced gastrointestinal stromal tumors (GIST)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10517
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900152
ER
PT J
AU Heng, DYC
Stukalin, I
Wells, C
Donskov, F
Rini, BI
Lee, JL
Bjarnason, GA
Beuselinck, B
Smoragiewicz, M
Alva, AS
Srinivas, S
Wood, L
Brugarolas, J
Pal, SK
Yuasa, T
Broom, RJ
Kanesvaran, R
Bamias, A
Knox, JJ
Choueiri, TK
AF Heng, Daniel Yick Chin
Stukalin, Igor
Wells, Connor
Donskov, Frede
Rini, Brian I.
Lee, Jae-Lyun
Bjarnason, Georg A.
Beuselinck, Benoit
Smoragiewicz, Martin
Alva, Ajjai Shivaram
Srinivas, Sandy
Wood, Lori
Brugarolas, James
Pal, Sumanta Kumar
Yuasa, Takeshi
Broom, Reuben James
Kanesvaran, Ravindran
Bamias, Aristotelis
Knox, Jennifer J.
Choueiri, Toni K.
TI Third-line therapy in metastatic renal cell carcinoma (mRCC): Results
from the International mRCC Database Consortium (IMDC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Tom Baker Canc Clin, Calgary, AB, Canada.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium.
BC Canc Agcy, Vancouver, BC, Canada.
Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan.
Auckland City Hosp, Auckland, New Zealand.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Athens, Dept Clin Therapeut, Athens, Greece.
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15578
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903121
ER
PT J
AU Hertz, DL
Kidwell, KM
Thibert, JN
Gersch, CL
Regan, MM
Skaar, TC
Henry, NL
Hayes, D
Van Poznak, C
Rae, JM
AF Hertz, Daniel Louis
Kidwell, Kelley M.
Thibert, Jacklyn N.
Gersch, Christina L.
Regan, Meredith M.
Skaar, Todd C.
Henry, Norah Lynn
Hayes, Daniel
Van Poznak, Catherine
Rae, James M.
TI Comparison of genotyping performance in DNA extracted from matched FFPE
tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ Sch Med, Indianapolis, IN USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Michigain Hlth Syst, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1528
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900395
ER
PT J
AU Hodi, FS
Postow, MA
Chesney, JA
Pavlick, AC
Robert, C
Grossmann, KF
McDermott, DF
Linette, GP
Meyer, N
Giguere, JK
Agarwala, SS
Shaheen, MF
Ernstoff, MS
Minor, DR
Salama, A
Taylor, MH
Ott, PA
Horak, CE
Gagnier, P
Wolchok, JD
AF Hodi, F. Stephen
Postow, Michael Andrew
Chesney, Jason Alan
Pavlick, Anna C.
Robert, Caroline
Grossmann, Kenneth F.
McDermott, David F.
Linette, Gerald P.
Meyer, Nicolas
Giguere, Jeffrey K.
Agarwala, Sanjiv S.
Shaheen, Montaser F.
Ernstoff, Marc S.
Minor, David R.
Salama, April
Taylor, Matthew Hiram
Ott, Patrick Alexander
Horak, Christine E.
Gagnier, Paul
Wolchok, Jedd D.
TI Clinical response, progression-free survival (PFS), and safety in
patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO)
combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069
study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
NYU, Perlmutter Canc Ctr, New York, NY USA.
Gustave, Roussy, France.
Univ Paris Sud, Villejuif Paris Sud, France.
Huntsman Canc Inst, Salt Lake City, UT USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Washington Univ, St Louis, MO USA.
Inst Univ Canc, Toulouse, France.
NCORP Carolinas, Greenville, SC USA.
St Lukes Canc Ctr, Bethlehem, PA USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA.
Calif Pacific Melanoma Ctr, San Francisco, CA USA.
Duke Univ, Durham, NC USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9004
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901914
ER
PT J
AU Holdhoff, M
Ye, XB
Nabors, LB
Desai, AS
Mikkelsen, T
Lesser, G
Read, WL
Lieberman, FS
Supko, J
Fisher, JD
Desideri, S
Grossman, SA
Schiff, D
AF Holdhoff, Matthias
Ye, Xiaobu
Nabors, Louis B.
Desai, Arati Suvas
Mikkelsen, Tom
Lesser, Glenn
Read, William L.
Lieberman, Frank S.
Supko, Jeff
Fisher, Joy D.
Desideri, Serena
Grossman, Stuart A.
Schiff, David
CA ABTC Investigators
TI Timed-sequential therapy with mibefradil and temozolomide in patients
with recurrent high-grade gliomas: A phase I Adult Brain Tumor
Consortium study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ Penn, Philadelphia, PA 19104 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
Emory Univ, Atlanta, GA 30322 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2033
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900492
ER
PT J
AU Holstein, SA
Owzar, K
Richardson, PG
Jiang, C
Hofmeister, CC
Hassoun, H
Hurd, DD
Stadtmauer, EA
Giralt, S
Devine, SM
Hars, V
Postiglione, JR
Weisdorf, DJ
Vij, R
Moreb, JS
Callander, NS
Martin, TG
Shea, TC
Anderson, KC
McCarthy, PL
AF Holstein, Sarah A.
Owzar, Kouros
Richardson, Paul G.
Jiang, Chen
Hofmeister, Craig C.
Hassoun, Hani
Hurd, David Duane
Stadtmauer, Edward Allen
Giralt, Sergio
Devine, Steven M.
Hars, Vera
Postiglione, John R.
Weisdorf, Daniel Jordan
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Martin, Thomas G.
Shea, Thomas C.
Anderson, Kenneth Carl
McCarthy, Philip L.
TI Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs.
placebo (PBO) maintenance therapy after single autologous stem cell
transplant (ASCT) for multiple myeloma (MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Wake Forest Univ, Winston Salem, NC 27109 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Univ Minnesota, Minneapolis, MN USA.
Washington Univ, Sch Med, St Louis, MO USA.
Univ Florida, Gainesville, FL USA.
Univ Wisconsin, Fitchburg, WI USA.
UC San Francisco, San Francisco, CA USA.
Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8523
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901835
ER
PT J
AU Hong, DS
Garrido-Laguna, I
Krop, IE
Subbiah, V
Werner, TL
Cotter, CM
Hamilton, EP
Velastegui, K
Xuan, DW
Bugarini, R
Gollerkeri, A
Burris, HA
AF Hong, David S.
Garrido-Laguna, Ignacio
Krop, Ian E.
Subbiah, Vivek
Werner, Theresa Louise
Cotter, Christine M.
Hamilton, Erika Paige
Velastegui, Karen
Xuan, Dawei
Bugarini, Roberto
Gollerkeri, Ashwin
Burris, Howard A.
TI First-in-human dose escalation, safety, and PK study of a novel
EFNA4-ADC in patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Utah, Salt Lake City, UT USA.
Sarah Cannon Res Inst, Brentwood, TN USA.
Pfizer, La Jolla, CA USA.
Pfizer Inc, Clin Pharmacol, Biotechnol Clin Dev, La Jolla, CA USA.
Pfizer Biotechnol Clin Dev, La Jolla, CA USA.
Pfizer BioTherapeut, Cambridge, MA USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2520
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900553
ER
PT J
AU Hong, TS
Wo, JYL
Yeap, BY
Ben-Josef, E
McDonnell, EI
Drapek, LC
Blaszkowsky, LS
Kwak, EL
Clark, JW
Goyal, L
Ryan, DP
Javle, MM
Wolfgang, JA
Arellano, R
Mullen, JT
Ferrone, C
Tanabe, K
DeLaney, TF
Crane, CH
Zhu, AX
AF Hong, Theodore S.
Wo, Jennifer Yon-Li
Yeap, Beow Y.
Ben-Josef, Edgar
McDonnell, Erin I.
Drapek, Lorraine C.
Blaszkowsky, Lawrence Scott
Kwak, Eunice Lee
Clark, Jeffrey W.
Goyal, Lipika
Ryan, David P.
Javle, Milind M.
Wolfgang, John A.
Arellano, Ronald
Mullen, John Thomas
Ferrone, Cristina
Tanabe, Kenneth
DeLaney, Thomas F.
Crane, Christopher H.
Zhu, Andrew X.
TI Multi-institutional phase II study of high dose, hypofractionated proton
beam therapy (HF-PBT) for unresectable primary liver cancers: Long term
outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Waban, MA USA.
Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Danvers, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
MGH Canc Ctr, Brookline, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4020
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900859
ER
PT J
AU Horn, L
Spigel, DR
Gettinger, SN
Antonia, SJ
Gordon, MS
Herbst, RS
Sequist, LV
Chappey, C
Kowanetz, M
Sandler, A
Soria, JC
AF Horn, Leora
Spigel, David R.
Gettinger, Scott N.
Antonia, Scott Joseph
Gordon, Michael S.
Herbst, Roy S.
Sequist, Lecia V.
Chappey, Colombe
Kowanetz, Marcin
Sandler, Alan
Soria, Jean-Charles
TI Clinical activity, safety and predictive biomarkers of the engineered
antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC):
update from a phase Ia study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Yale Sch Med, New Haven, CT USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Genentech Inc, San Francisco, CA 94080 USA.
Gustave Roussy Canc Campus, Drug Dev Dept, Villejuif, France.
NR 0
TC 23
Z9 24
U1 2
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8029
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901742
ER
PT J
AU Howitt, BE
Sholl, LM
Ritterhouse, L
Watkins, JC
Rodig, SJ
Strickland, K
D'Andrea, AD
Matulonis, U
Konstantinopoulos, P
AF Howitt, Brooke E.
Sholl, Lynette M.
Ritterhouse, Lauren
Watkins, Jaclyn C.
Rodig, Scott J.
Strickland, Kyle
D'Andrea, Alan D.
Matulonis, Ursula
Konstantinopoulos, Panagiotis
TI Association of POLE-mutated and MSI endometrial cancers with an elevated
number of tumor-infiltrating and peritumoral lymphocytes and higher
expression of PD-L1.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematopathol,Dept Pathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 2
Z9 2
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5511
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901170
ER
PT J
AU Hungria, VTM
San Miguel, JF
Yoon, SS
Beksac, M
Dimopoulos, MA
Elghandour, A
Jedrzejczak, WW
Guenther, A
Nakorn, TN
Siritanaratkul, N
Schlossman, RL
Hou, J
Moreau, P
Lonial, S
Lee, JH
Einsele, H
Sopala, M
Bengoudifa, BR
Corrado, C
Richardson, PG
AF Hungria, Vania T. M.
San Miguel, Jesus F.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
Richardson, Paul G.
TI Analysis of outcomes based on response for patients with relapsed or
relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1
study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil.
Univ Navarra Clin, Pamplona, Spain.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Ankara Univ, TR-06100 Ankara, Turkey.
Hellen Cooperat Oncol Grp HeCOG, Athens, Greece.
Univ Alexandria, Alexandria, Egypt.
Med Univ Warsaw, Warsaw, Poland.
2nd Dept Med, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany.
Chulalongkorn Univ, Bangkok, Timor Leste, Thailand.
Siriraj Hosp, Bangkok, Thailand.
Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
Chang Zheng Hosp, Shanghai, Peoples R China.
CHU Nantes, Hotel Dieu HME, F-44035 Nantes 01, France.
Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
Gachon Univ, Inchon, South Korea.
Univ Hosp Wuerzburg, Wurzburg, Germany.
Novartis Pharma AG, Basel, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI richard, chrystelle/K-8595-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8575
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901887
ER
PT J
AU Hurley, J
Hu, L
Brock, G
Sinclair, I
Sullivan, RJ
O'Neill, VJ
Skog, J
Flaherty, K
AF Hurley, James
Hu, Lan
Brock, Graham
Sinclair, Ian
Sullivan, Ryan J.
O'Neill, Vincent J.
Skog, Johan
Flaherty, Keith
TI Profiling exosomal mRNAs in patients undergoing immunotherapy for
malignant melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Exosome Diagnost, Cambridge, MA USA.
Exosome Diagnost, St Paul, MN USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Exosome Diagnost, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e22159
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904538
ER
PT J
AU Huynh, T
Chi, A
Oyarvide, VM
Gainor, JF
Hata, AN
Lanuti, M
Mark, EJ
Engelman, JA
Mino-Kenudson, M
AF Huynh, Tiffany
Chi, Anthony
Oyarvide, Vicente Morales
Gainor, Justin F.
Hata, Aaron N.
Lanuti, Michael
Mark, Eugene J.
Engelman, Jeffrey A.
Mino-Kenudson, Mari
TI Clinicopathological characteristics of squamous cell carcinoma of the
lung with programmed cell death ligand 1 (PD-L1) protein expression.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hostpital, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7554
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901684
ER
PT J
AU Huynh, T
Oyarvide, VM
Uruga, H
Bozkurtlar, E
Gainor, JF
Hata, AN
Mark, EJ
Lanuti, M
Engelman, JA
Mino-Kenudson, M
AF Huynh, Tiffany
Oyarvide, Vicente Morales
Uruga, Hironori
Bozkurtlar, Emine
Gainor, Justin F.
Hata, Aaron N.
Mark, Eugene J.
Lanuti, Michael
Engelman, Jeffrey A.
Mino-Kenudson, Mari
TI Clinicopathological and molecular parameters of lung adenocarcinomas
(ADC) associated with programmed cell death ligand 1 (PD-L1) protein
expression.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hostpital, Boston, MA USA.
Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7555
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901685
ER
PT J
AU Infante, JR
Naing, A
Papadopoulos, KP
Autio, KA
Ott, PA
Wong, DJL
Falchook, GS
Patel, MR
Pant, S
Whiteside, M
Bendell, JC
Bauer, TM
Janku, F
Javle, MM
Hong, DS
Oft, M
AF Infante, Jeffrey R.
Naing, Aung
Papadopoulos, Kyriakos P.
Autio, Karen A.
Ott, Patrick Alexander
Wong, Deborah Jean Lee
Falchook, Gerald Steven
Patel, Manish R.
Pant, Shubham
Whiteside, Melinda
Bendell, Johanna C.
Bauer, Todd Michael
Janku, Filip
Javle, Milind M.
Hong, David S.
Oft, Martin
TI A first-in-human dose escalation study of PEGylated recombinant human
IL-10 (AM0010) in advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
START Ctr Canc Care, San Antonio, TX USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Sarah Cannon Res Inst HealthONE, Denver, CO USA.
Sarah Cannon Res Inst Florida Canc Specialists, Sarasota, FL USA.
Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA.
ARMO BioSci, Redwood City, CA USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3017
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900651
ER
PT J
AU Infante, JR
Janku, F
Tolcher, AW
Patel, MR
Sullivan, RJ
Flaherty, K
Carvajal, RD
Varghese, AM
Wong, DJL
Sznol, M
Sosman, JA
Wang-Gillam, A
Burris, HA
Ribas, A
Patel, SP
Welsch, DJ
Saha, S
AF Infante, Jeffrey R.
Janku, Filip
Tolcher, Anthony W.
Patel, Manish R.
Sullivan, Ryan J.
Flaherty, Keith
Carvajal, Richard D.
Varghese, Anna M.
Wong, Deborah Jean Lee
Sznol, Mario
Sosman, Jeffrey Alan
Wang-Gillam, Andrea
Burris, Howard A.
Ribas, Antoni
Patel, Sapna Pradyuman
Welsch, Dean J.
Saha, Saurabh
TI Dose escalation stage of a first-in-class phase I study of the novel
oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with
advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
START, San Antonio, TX USA.
Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Columbia Univ Medcl Ctr, New York, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Yale Univ, New Haven, CT USA.
Vanderbilt Univ Sch Med, Nashville, TN USA.
Washington Univ, Div Oncol, St Louis, MO USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
BioMed Valley Discoveries, Kansas City, MO USA.
BioMed Valley Discoveries, Wellesley, MA USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2506
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900539
ER
PT J
AU Irwin, ML
Cartmel, B
Harrigan, M
Sanft, TB
Wong, C
Hughes, M
Hootsmans, N
Winterhalter, B
Shockro, L
O'Connor, K
Tolaney, SM
Mayer, EL
Yung, RL
Freedman, RA
Ligibel, JA
AF Irwin, Melinda L.
Cartmel, Brenda
Harrigan, Maura
Sanft, Tara Beth
Wong, Celeste
Hughes, Meghan
Hootsmans, Norbert
Winterhalter, Bridget
Shockro, Laura
O'Connor, Keelin
Tolaney, Sara M.
Mayer, Erica L.
Yung, Rachel Lynn
Freedman, Rachel A.
Ligibel, Jennifer A.
TI Impact of the LIVESTRONG at the YMCA Program on physical activity,
fitness, and quality of life in cancer survivors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Univ, Sch Publ Hlth, New Haven, CT USA.
Yale Canc Ctr, New Haven, CT USA.
Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Waban, MA USA.
Dana Farber Canc Inst, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9508
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902003
ER
PT J
AU Ivanova, JI
Saverno, K
Sung, J
Duh, MS
Zhao, C
Cai, XP
Vekeman, F
Peevyhouse, A
Dhawan, R
Fuchs, CS
AF Ivanova, Jasmina I.
Saverno, Kimberly
Sung, Jennifer
Duh, Mei Sheng
Zhao, Chen
Cai, Xiaopeng
Vekeman, Francis
Peevyhouse, Aaron
Dhawan, Ravinder
Fuchs, Charles S.
TI Real-world treatment patterns and effectiveness among patients with
metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in
community oncology practices in the United States (US).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Anal Grp Inc, New York, NY USA.
Vector Oncol, Memphis, TN USA.
Sanofi US, Bridgewater, NJ USA.
Anal Grp Inc, Boston, MA USA.
Anal Grp Inc, Montreal, PQ, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e14554
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902670
ER
PT J
AU Jakubowiak, AJ
Offidani, M
Pegourie, B
De La Rubia, J
Garderet, L
Laribi, K
Bosi, A
Marasca, R
Laubach, J
Mohrbacher, A
Carella, AM
Singhal, AK
Tsao, C
Lynch, MJ
Bleickardt, EW
Jou, YM
Palumbo, A
AF Jakubowiak, Andrzej J.
Offidani, Massimo
Pegourie, Brigitte
De La Rubia, Javier
Garderet, Laurent
Laribi, Kamel
Bosi, Alberto
Marasca, Roberto
Laubach, Jacob
Mohrbacher, Ann
Carella, Angelo Michele
Singhal, Anil K.
Tsao, Claire
Lynch, Mark John
Bleickardt, Eric W.
Jou, Ying-Ming
Palumbo, Antonio
TI A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with
or without elotuzumab (Elo) in patients (pts) with relapsed/refractory
multiple myeloma (RRMM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Azienda Osped Univ Osped Riuniti Ancona, Ancona, Italy.
CHU Grenoble, Hop Albert Michallon, F-38043 Grenoble, France.
HUP La Fe, Valencia, Spain.
Hop St Antoine, F-75571 Paris, France.
Ctr Hosp, Le Mans, France.
Azienda Osped Univ Careggi, Florence, Italy.
Azienda Osped Univ, Policlin Modena, Modena, Italy.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
IRCCS San Martino IST, Genoa, Italy.
AbbVie Biotherapeut Inc ABR, Redwood City, CA USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Osped Molinette, AOU San Giovanni Battista Torino, Turin, Italy.
RI Marasca, Roberto/I-8072-2013
OI Marasca, Roberto/0000-0002-6431-6878
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8573
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901885
ER
PT J
AU Jalbut, MM
Brunner, AM
Amrein, PC
Attar, EC
Ballen, KK
Hobbs, G
Perry, AM
Joseph, CP
Neuberg, DS
Fathi, AT
AF Jalbut, Marla M.
Brunner, Andrew Mark
Amrein, Philip C.
Attar, Eyal C.
Ballen, Karen K.
Hobbs, Gabriela
Perry, Ashley M.
Joseph, Christelle P.
Neuberg, Donna S.
Fathi, Amir Tahmasb
TI Infectious complications in AML patients treated with induction vs.
hypomethylating therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Agios, Cambridge, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7065
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901601
ER
PT J
AU Je, YJ
Ghatalia, P
Nguyen, PL
Trinh, QD
Choueiri, TK
Sonpavde, G
AF Je, Youjin
Ghatalia, Pooja
Paul Linh Nguyen
Quoc-Dien Trinh
Choueiri, Toni K.
Sonpavde, Guru
TI Fatigue with vascular endothelial growth factor receptor tyrosine kinase
inhibitors and mammalian target of rapamycin inhibitors in patients with
malignancies: A meta-analysis of randomized clinical trials
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Kyung Hee Univ, Seoul, South Korea.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dept Surg, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15583
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903126
ER
PT J
AU Jemal, A
Freedman, RA
Lin, CC
Sineshaw, H
DeSantis, C
Ward, EM
AF Jemal, Ahmedin
Freedman, Rachel A.
Lin, Chun Chieh
Sineshaw, Helmneh
DeSantis, Carol
Ward, Elizabeth Mary
TI Temporal trends in and predictors of receipt of contralateral breast
mastectomy among US men diagnosed with breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Amer Canc Soc, Atlanta, GA 30329 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17522
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903495
ER
PT J
AU Jhaveri, KL
Hamilton, EP
Miller, K
Roche, M
Berger, MS
Winer, EP
Lin, NU
AF Jhaveri, Komal L.
Hamilton, Erika Paige
Miller, Kathy
Roche, Maria
Berger, Mark S.
Winer, Eric P.
Lin, Nancy U.
TI A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase
inhibitor (TKI) tesevatinib in combination with trastuzumab for patients
with HER2+metastatic breast cancer (MBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NYU, Inst Canc, New York, NY USA.
Sarah Cannon Res Inst, Brentwood, Essex, England.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Kadmon Corp, Wilmington, MA USA.
Kadmon Corp, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 608
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901397
ER
PT J
AU Johnson, DB
Menzies, AM
Zimmer, L
Eroglu, Z
Ye, F
Zhao, SL
Sucker, A
Rizos, H
Hugo, W
Gutzmer, R
Kefford, R
Gogas, H
Kong, XJ
Scolyer, RA
Garraway, LA
Sosman, JA
Ribas, A
Lo, R
Long, GV
Schadendorf, D
AF Johnson, Douglas Buckner
Menzies, Alexander M.
Zimmer, Lisa
Eroglu, Zeynep
Ye, Fei
Zhao, Shilin
Sucker, Antje
Rizos, Helen
Hugo, Willy
Gutzmer, Ralf
Kefford, Richard
Gogas, Helen
Kong, Xiangju
Scolyer, Richard A.
Garraway, Levi A.
Sosman, Jeffrey Alan
Ribas, Antoni
Lo, Roger
Long, Georgina V.
Schadendorf, Dirk
TI BRAF inhibitor acquired resistance: A multicenter meta-analysis of the
spectrum and clinical implications of resistance mechanisms.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Univ, Nashville, TN 37235 USA.
Melanoma Inst Australia, Mosman, NSW, Australia.
Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Essen, Germany.
City Hope Natl Med Ctr, Pasadena, CA USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Hosp Essen, Essen, Germany.
Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
Univ Calif Los Angeles, Los Angeles, CA USA.
Hannover Med Sch, D-30623 Hannover, Germany.
Crown Princess Mary Canc Ctr, Sydney, NSW, Australia.
Hellen Cooperat Oncol Grp HeCOG, Athens, Greece.
Univ Sydney, Royal Prince Alfred Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Melanoma Inst Australia, Sydney, NSW, Australia.
Univ Sydney, Sydney, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9008
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901918
ER
PT J
AU Jones, JA
Wach, M
Robak, T
Brown, JR
Menter, AR
Vandenberghe, E
Ysebaert, L
Wagner-Johnston, ND
Polikoff, J
Salman, HS
Taylor, KM
Coutre, S
Spurgeon, SEF
Kendall, SD
Flinn, I
Dreiling, L
Dubowy, R
Cho, YJ
Peterman, S
Owen, C
AF Jones, Jeffrey Alan
Wach, Malgorzata
Robak, Tadeusz
Brown, Jennifer R.
Menter, Alexander R.
Vandenberghe, Elizabeth
Ysebaert, Loic
Wagner-Johnston, Nina D.
Polikoff, Jonathan
Salman, Huda S.
Taylor, Kerry McDonald
Coutre, Steven
Spurgeon, Stephen Edward Forbes
Kendall, Stephan Disean
Flinn, Ian
Dreiling, Lyndah
Dubowy, Ronald
Cho, Yoonjin
Peterman, Sissy
Owen, Carolyn
TI Results of a phase III randomized, controlled study evaluating the
efficacy and safety of idelalisib (IDELA) in combination with ofatumumab
(OFA) for previously treated chronic lymphocytic leukemia (CLL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ohio State Univ, Columbus, OH 43210 USA.
Med Univ Lublin, Lublin, Poland.
Med Univ Lodz, Lodz, Poland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Kaiser Permanente Med Grp, Denver, CO USA.
St James Hosp, Dublin 8, Ireland.
CHU Toulouse, Toulouse, France.
Washington Univ, Sch Med, Dept Med, St Louis, MO USA.
Kaiser Hosp San Diego, San Marcos, CA USA.
GRU Canc Ctr, Augusta, GA USA.
Haematol & Oncol Clin Australia Mater, South Brisbane, Australia.
Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
UCS Canc Ctr, Utah Canc Specialists, Salt Lake City, UT USA.
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
Gilead Sci Inc, Foster City, CA USA.
Alberta Hlth Serv, Calgary, AB, Canada.
NR 0
TC 13
Z9 13
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7023
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901559
ER
PT J
AU Jonker, DJ
Laurie, SA
Cote, GM
Flaherty, K
Fuchs, CS
Chugh, R
Smith, DC
Edenfield, WJ
Conkling, PR
Mier, JW
Goodwin, RA
Kwak, EL
Abrams, TA
Goel, R
Cleary, JM
Li, W
Li, YZ
Jemison, J
Hitron, M
Li, C
AF Jonker, Derek J.
Laurie, Scott Andrew
Cote, Gregory Michael
Flaherty, Keith
Fuchs, Charles S.
Chugh, Rashmi
Smith, David C.
Edenfield, William Jeffery
Conkling, Paul R.
Mier, James Walter
Goodwin, Rachel Anne
Kwak, Eunice Lee
Abrams, Thomas Adam
Goel, Rakesh
Cleary, James M.
Li, Wei
Li, Youzhi
Jemison, Jamileh
Hitron, Matthew
Li, Chiang
TI Phase 1 extension study of BBI503, a first-in-class cancer stemness
kinase inhibitor, in patients with advanced colorectal cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ottawa Hosp Canc Ctr, Ottawa, ON, Canada.
Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
Greenville Hosp Syst Univ Med Ctr, Inst Translat Oncol Res, Greenville, SC USA.
Virginia Oncol Associates, Norfolk, VA USA.
Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Dept Med, Boston, MA 02215 USA.
Ottawa Hosp, NCIC CTG, Ottawa, ON, Canada.
Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Ottawa Hosp, Ottawa, ON, Canada.
Boston Biomed Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3615
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900834
ER
PT J
AU Juric, D
De Bono, JS
LoRusso, P
Nemunaitis, JJ
Heath, EI
Kwak, EL
Macarulla, T
Geuna, E
Luken, MJD
Patel, C
Kuida, K
Sankoh, S
Zohren, F
Shou, YP
Tabernero, J
AF Juric, Dejan
De Bono, Johann Sebastian
LoRusso, Patricia
Nemunaitis, John J.
Heath, Elisabeth I.
Kwak, Eunice Lee
Macarulla, Teresa
Geuna, Elena
Luken, Maria Jose de Miguel
Patel, Chirag
Kuida, Keisuke
Sankoh, Serap
Zohren, Fabian
Shou, Yaping
Tabernero, Josep
TI First-in-human, phase I, dose-escalation study of selective PI3K alpha
isoform inhibitor MLN1117 in patients (pts) with advanced solid
malignancies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Inst Canc Res, Sutton, Surrey, England.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
Yale Canc Ctr, New Haven, CT USA.
Mary Crowley Canc Res Ctr, Dallas, TX USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
Fdn Piemonte Oncol Candiolo Canc Inst, Candiolo, Italy.
Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
Millennium Pharmaceut Inc, Cambridge, MA USA.
VHIO, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2501
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900535
ER
PT J
AU Karachaliou, N
Nilsson, RJA
Berenguer, J
Capitan, AG
Schellen, P
Teixido, C
Kuiper, JL
Drees, E
Grabowska, M
van Keulen, M
Tannous, JM
Heideman, D
Thunnissen, E
Dingemans, AMC
Ramirez, SV
Tannous, BA
Drozdowskyj, A
Smit, EF
Wurdinger, T
Rosell, R
AF Karachaliou, Niki
Nilsson, R. Jonas A.
Berenguer, Jordi
Capitan, Ana Gimenez
Schellen, Pepijn
Teixido, Cristina
Kuiper, Justine Leonie
Drees, Esther
Grabowska, Magda
van Keulen, Marte
Tannous, Jihane M.
Heideman, Danielle
Thunnissen, Erik
Dingemans, Anne-Marie C.
Ramirez, Santiago Viteri
Tannous, Bakhos A.
Drozdowskyj, Ana
Smit, Egbert F.
Wurdinger, Thomas
Rosell, Rafael
TI EML4-ALK rearrangement in blood platelets and outcome to crizotinib in
non-small-cell lung cancer patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Quiron Dexeus Univ Inst, Translat Res Unit, Barcelona, Spain.
VU Canc Ctr Amsterdam, Neurooncol Res Grp, Dept Neurosurg, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, Amsterdam, Netherlands.
Pangaea Biotech SL, Barcelona, Spain.
Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA.
Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
Maastricht Univ, Med Ctr, Maastricht, Netherlands.
Med Oncol Serv, Barcelona, Spain.
Pivotal, Madrid, Spain.
VU Univ Med, Canc Ctr Amsterdam, Dept Pulm Dis, Amsterdam, Netherlands.
Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands.
Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8082
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901794
ER
PT J
AU Katz, MS
Utengen, A
Anderson, PF
Thompson, MA
Fisch, M
Johnston, C
Attai, DJ
Aase, L
Miller, RS
Lee, T
Dizon, DS
AF Katz, Matthew S.
Utengen, Audun
Anderson, Patricia F.
Thompson, Michael A.
Fisch, Michael
Johnston, Claire
Attai, Deanna J.
Aase, Lee
Miller, Robert Stephen
Lee, Thomas
Dizon, Don S.
TI Disease-specific hashtags for online communication about cancer care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Radiat Oncol Associates, Lowell, MA USA.
Symplur LLC, Los Angeles, CA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Aurora Hlth Care, Aurora Res Inst, Milwaukee, WI USA.
AIM Specialty Hlth, Chicago, IL USA.
ASCO, Alexandria, VA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Mayo Clin, Rochester, MN USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6520
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901435
ER
PT J
AU Katz, MS
Topham, A
Manola, J
Scroggins, MJ
Smith, ML
Mitchell, EP
Catalano, RB
Marinucci, DM
Giantonio, BJ
Comis, RL
AF Katz, Michael S.
Topham, Allan
Manola, Judith
Scroggins, Mary Jackson
Smith, Mary Lou
Mitchell, Edith P.
Catalano, Robert B.
Marinucci, Donna M.
Giantonio, Bruce J.
Comis, Robert Leo
TI Medically Underrepresented Populations In National Cancer Institute
(NCI) Sponsored Cancer Clinical Trials: Refining the Calculation of
Accrual Targets
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 ECOG ACRIN, North Hollywood, CA USA.
Coalit Canc Cooperat Grp, Philadelphia, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
My Sisters Care, Washington, DC USA.
Res Advocacy Network, Naperville, IL USA.
Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Drexel Univ, Philadelphia, PA 19104 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17598
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903564
ER
PT J
AU Keenan, T
Moy, B
Mroz, EA
Ross, K
Niemierko, A
Rocco, JW
Isakoff, SJ
Ellisen, LW
Bardia, A
AF Keenan, Tanya
Moy, Beverly
Mroz, Edmund A.
Ross, Kenneth
Niemierko, Andrzej
Rocco, James William
Isakoff, Steven J.
Ellisen, Leif W.
Bardia, Aditya
TI Genomic landscape of primary breast cancer in black vs. white women and
association with tumor recurrence.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Ohio State Univ, Columbus, OH 43210 USA.
MEEI MGH, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6553
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901468
ER
PT J
AU Kim, CC
Najita, JS
Tan, SYM
Varada, S
Tong, LX
Dunbar, H
Lee, MY
Seery, VJ
Buchbinder, EI
Tawa, NE
Fuller, J
Frankenthaler, RA
McDermott, DF
Lee, SJ
Atkins, MB
AF Kim, Caroline C.
Najita, Julie S.
Tan, Sally Yi-Meng
Varada, Sowmya
Tong, Lana X.
Dunbar, Haili
Lee, Mee-young
Seery, Virginia J.
Buchbinder, Elizabeth Iannotti
Tawa, Nicholas E.
Fuller, Jennifer
Frankenthaler, Robert Andrew
McDermott, David F.
Lee, Sandra J.
Atkins, Michael B.
TI Factors associated with worse outcome for patients with AJCC stage IIC
relative to stage IIIA melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Sidney Kimmel Med Coll, Philadelphia, PA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9078
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901988
ER
PT J
AU Kim, M
Alexander, BM
Burke, L
Jha, A
AF Kim, Miranda
Alexander, Brian Michael
Burke, Laura
Jha, Ashish
TI Contribution of cancer care to total spending among high-cost Medicare
beneficiaries
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Rad Onc Prog, Boston, MA USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6620
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901534
ER
PT J
AU Kim, SB
Tan, AR
Im, SA
Villanueva, R
Valero, V
Saura, C
Oliveira, M
Isakoff, SJ
Singel, SM
Dent, RA
AF Kim, Sung-Bae
Tan, Antoinette R.
Im, Seock-Ah
Villanueva, Rafael
Valero, Vicente
Saura, Cristina
Oliveira, Mafalda
Isakoff, Steven J.
Singel, Stina Mui
Dent, Rebecca Alexandra
TI LOTUS: A randomized, phase II, multicenter, placebo-controlled study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with
paclitaxel (Pac) as front-line treatment for patients (pts) with
metastatic triple-negative breast cancer (TNBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Asan Med Ctr, Seoul, South Korea.
Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA.
Seoul Natl Univ, Coll Med, Seoul, South Korea.
ICO Duran & Reinals, Inst Catala Oncol, Lhospitalet De Llobregat, Spain.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Vall dHebron Univ Hosp, SOLTI, Barcelona, Spain.
Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Genentech Roche, San Francisco, CA USA.
Natl Canc Ctr Singapore, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS1111
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904667
ER
PT J
AU Kollmannsberger, CK
Sharma, S
Shapiro, G
Chi, KN
Christensen, J
Tassell, VR
Chao, RC
Faltaos, D
Hurwitz, H
AF Kollmannsberger, Christian K.
Sharma, Sunil
Shapiro, Geoffrey
Chi, Kim N.
Christensen, James
Tassell, Vanessa Roberts
Chao, Richard C.
Faltaos, Demiana
Hurwitz, Herbert
TI Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in
patients (pts) with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
BC Canc Agcy, Vancouver, BC, Canada.
Mirati Therapeut Inc, San Diego, CA USA.
Duke Univ, Med Ctr, Durham, NC USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2589
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900622
ER
PT J
AU Krasner, CN
Birrer, MJ
Berlin, ST
Buss, MK
Eliasof, S
Garmey, EG
Hennessey, M
Horowitz, NS
Konstantinopoulos, P
Matulonis, UA
AF Krasner, Carolyn N.
Birrer, Michael J.
Berlin, Suzanne T.
Buss, Mary K.
Eliasof, Scott
Garmey, Edward Graeme
Hennessey, Meliessa
Horowitz, Neil S.
Konstantinopoulos, Panagiotis
Matulonis, Ursula A.
TI Targeting VEGFRi resistance through HIF-1 alpha suppression: Phase II
clinical trial evaluating CRLX101 as monotherapy and in combination with
bevacizumab in recurrent platinum resistant ovarian cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Dana Farber Canc Inst, York, ME USA.
Beth Israel Deaconess Med Ctr, Newton, MA USA.
Cerulean Pharma Inc, Cambridge, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5614
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904803
ER
PT J
AU Kris, MG
Johnson, BE
Kwiatkowski, DJ
Wistuba, II
Berry, LD
Haura, EB
Socinski, MA
Ramalingam, SS
Glisson, BS
Waqar, SN
Otterson, GA
Schiller, JH
Garon, EB
Cetnar, JP
Politi, KA
Brahmer, JR
Sequist, LV
Lovly, CM
Kugler, K
Bunn, PA
AF Kris, Mark G.
Johnson, Bruce E.
Kwiatkowski, David J.
Wistuba, Ignacio Ivan
Berry, Lynne D.
Haura, Eric B.
Socinski, Mark A.
Ramalingam, Suresh S.
Glisson, Bonnie S.
Waqar, Saiama Naheed
Otterson, Gregory Alan
Schiller, Joan H.
Garon, Edward B.
Cetnar, Jeremy Paul
Politi, Katerina A.
Brahmer, Julie R.
Sequist, Lecia V.
Lovly, Christine Marie
Kugler, Kelly
Bunn, Paul A.
TI Migration to next-generation sequencing and the identification of RET
and ROS1 rearrangements plus PTEN and MET protein expression in tumor
specimens from patients with lung adenocarcinomas: Lung Cancer Mutation
Consortium (LCMC 2.0).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Washington Univ, St Louis, MO USA.
Ohio State Univ, Columbus, OH 43210 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles Translat Res Oncol US Network, Los Angeles, CA 90095 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Yale Univ, Sch Med, New Haven, CT USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ Colorado, Colorado Canc Ctr Denver, Aurora, CO USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8094
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901806
ER
PT J
AU Kulke, MH
Niedzwiecki, D
Foster, NR
Fruth, B
Kunz, PL
Kennecke, HF
Wolin, EM
Venook, AP
AF Kulke, Matthew H.
Niedzwiecki, Donna
Foster, Nathan R.
Fruth, Briant
Kunz, Pamela L.
Kennecke, Hagen F.
Wolin, Edward M.
Venook, Alan P.
TI Randomized phase II study of everolimus (E) versus everolimus plus
bevacizumab (E plus B) in patients (Pts) with locally advanced or
metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701
(Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Cary, NC USA.
North Cent Canc Treatment Grp, Rochester, MN USA.
Mayo Clin Canc Ctr, Rochester, MN USA.
Stanford Univ Sch Med, Stanford, CA USA.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Univ Kentucky, Lexington, KY USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4005
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900844
ER
PT J
AU Kummar, S
Do, KT
Coyne, GHO
Turkbey, B
Meltzer, PS
Polley, E
Horneffer, Y
Juwara, L
Antony, R
Choyke, PL
Mitchell, SA
Helman, LJ
Chen, A
Doroshow, JH
AF Kummar, Shivaani
Do, Khanh Tu
Coyne, Geraldine Helen O'Sullivan
Turkbey, Baris
Meltzer, Paul S.
Polley, Eric
Horneffer, Yvonne
Juwara, Lamin
Antony, Ramya
Choyke, Peter L.
Mitchell, Sandra A.
Helman, Lee J.
Chen, Alice
Doroshow, James H.
TI Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive
fibromatosis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Sch Med, Phase Clin Res Program 1, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Early Clin Trials Dev Program, Bethesda, MD USA.
NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA.
Ctr Canc Res, Bethesda, MD USA.
NCI, Div Canc Treatment & Diag, Rockville, MD USA.
NCI, Bethesda, MD 20892 USA.
Leidos Biomed Res Inc, Frederick, MD USA.
NCI, NIH, Bethesda, MD 20892 USA.
NCI, Rockville, MD USA.
NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
Div Canc Treatment & Diag, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10563
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900203
ER
PT J
AU Kunz, PL
Catalano, PJ
Nimeiri, HS
Fisher, GA
Longacre, TA
Schrijver, I
Reidy, DL
Strosberg, JR
O'Dwyer, PJ
Benson, A
AF Kunz, Pamela L.
Catalano, Paul J.
Nimeiri, Halla Sayed
Fisher, George A.
Longacre, Teri A.
Schrijver, Iris
Reidy, Diane Lauren
Strosberg, Jonathan R.
O'Dwyer, Peter J.
Benson, Al Bowen
TI A randomized study of temozolomide or temozolomide and capecitabine in
patients with advanced pancreatic neuroendocrine tumors: A trial of the
ECOG-ACRIN Cancer Research Group (E2211).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS4145
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904753
ER
PT J
AU Kutsch, N
Bahlo, J
Byrd, JC
Dohner, H
Eichhorst, B
Else, M
Geisler, C
Grever, MR
Lepretre, S
Bergman, M
Neuberg, DS
Oscier, D
Rosenquist, R
Robak, T
Shanafelt, TD
Stilgenbauer, S
Hallek, MJ
AF Kutsch, Nadine
Bahlo, Jasmin
Byrd, John C.
Dohner, Hartmut
Eichhorst, Barbara
Else, Monica
Geisler, Christian
Grever, Michael R.
Lepretre, Stephane
Bergman, Manuela
Neuberg, Donna S.
Oscier, David
Rosenquist, Richard
Robak, Tadeusz
Shanafelt, Tait D.
Stilgenbauer, Stephan
Hallek, Michael J.
CA Int CLL-IPI Working Grp
TI The international Prognostic Index for patients with CLL (CLL-IPI): An
international meta-analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany.
Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.
Inst Canc Res London, Div Mol Pathol, London, England.
Rigshosp, DK-2100 Copenhagen, Denmark.
Ohio State Univ, Columbus, OH 43210 USA.
Henri Becquerel Hosp, Rouen, France.
Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England.
Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden.
Med Univ Lodz, Lodz, Poland.
Mayo Clin, Rochester, MN USA.
Univ Hosp Ulm, Ulm, Germany.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7002
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901540
ER
PT J
AU Kvale, EA
Rocque, GB
Bevis, KS
Acemgil, A
Taylor, RA
Demark-Wahnefried, W
Kenzik, K
Li, YF
Meneses, K
Martin, M
Fouad, M
Partridge, EE
Pisu, M
AF Kvale, Elizabeth Ann
Rocque, Gabrielle Betty
Bevis, Kerri S.
Acemgil, Aras
Taylor, Richard A.
Demark-Wahnefried, Wendy
Kenzik, Kelly
Li, Yufeng
Meneses, Karen
Martin, Michelle
Fouad, Mona
Partridge, Edward E.
Pisu, Maria
TI Distress in older adult cancer patients approaching end of life
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Birmingham VA Med Ctr, Birmingham, AL USA.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9548
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902043
ER
PT J
AU Kwak, EL
Lennerz, JK
Szymonifka, J
Corcoran, RB
Clark, JW
Russo, AL
Borger, DR
Blaszkowsky, LS
Dias, LE
Faris, JE
Murphy, JE
Fidias, P
Lennes, IT
Azzoli, CG
Gainor, JF
Mullen, JT
Lauwers, GY
Ryan, DP
Iafrate, AJ
Hong, TS
AF Kwak, Eunice Lee
Lennerz, Jochen K.
Szymonifka, Jackie
Corcoran, Ryan Bruce
Clark, Jeffrey W.
Russo, Andrea Lyn
Borger, Darrell R.
Blaszkowsky, Lawrence Scott
Dias, Lauren Elizabeth
Faris, Jason Edward
Murphy, Janet E.
Fidias, Panos
Lennes, Inga Tolin
Azzoli, Christopher G.
Gainor, Justin F.
Mullen, John Thomas
Lauwers, Gregory Y.
Ryan, David P.
Iafrate, A. John
Hong, Theodore S.
TI Clinical characteristics and treatment outcomes of patients with
metastatic, MET-amplified esophagogastric cancers.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Canc Res & Biostat, Seattle, WA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Massachusetts Gen North Shore Canc Ctr, Danvers, MA USA.
Univ Arizona, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4043
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900882
ER
PT J
AU Lacouture, ME
Keefe, DMK
Sonis, ST
Giri, N
Wang, T
Reisman, A
Sbar, E
Gernhardt, DR
Jatoi, A
AF Lacouture, Mario E.
Keefe, Dorothy Mary Kate
Sonis, Stephen T.
Giri, Nagdeep
Wang, Tao
Reisman, Arlene
Sbar, Eric
Gernhardt, Diana R.
Jatoi, Aminah
TI Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an
EGFR inhibitor with no rash or diarrhea improvement from corticosteroids
or probiotics.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Royal Adelaide Hosp, Adelaide, SA 5000, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Pfizer Oncol, La Jolla, CA USA.
Pfizer Oncol, Groton, CT USA.
Pfizer Oncol, New York, NY USA.
Pfizer Oncol, Collegeville, PA USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e19049
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903903
ER
PT J
AU Lagmay, JP
Krailo, MD
Dang, H
Kim, A
Hawkins, DS
Beaty, O
Widemann, BC
Zwerdling, T
Bomgaars, L
Langevin, AM
Grier, HE
Weigel, B
Blaney, S
Gorlick, RG
Janeway, KA
AF Lagmay, Joanne P.
Krailo, Mark D.
Dang, Ha
Kim, AeRang
Hawkins, Douglas S.
Beaty, Orren
Widemann, Brigitte C.
Zwerdling, Theodore
Bomgaars, Lisa
Langevin, Anne-Marie
Grier, Holcombe E.
Weigel, Brenda
Blaney, Susan
Gorlick, Richard Greg
Janeway, Katherine A.
TI Outcome of recurrent osteosarcoma patients enrolled in seven phase II
trials through CCG, POG, and COG: Learning from the past to move
forward.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Florida, Shands Hosp Children, Gainesville, FL USA.
Childrens Onc Grp, Arcadia, CA USA.
Childrens Oncol Grp, Arcadia, CA USA.
Ctr Canc & Blood Disorders, Washington, DC USA.
Seattle Childrens Hosp, Seattle, WA USA.
Mission Hosp, Fairview, NC USA.
NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
Univ Calif Davis, Sacramento, CA USA.
Texas Childrens Canc Ctr, Houston, TX USA.
Univ Texas Med Hlth Ctr San Antonio, San Antonio, TX USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Minnesota, Minneapolis, MN USA.
Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.
Childrens Hosp, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10042
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900049
ER
PT J
AU Lampson, BL
Santos, A
Janne, PA
Oxnard, GR
AF Lampson, Benjamin L.
Santos, Abigail
Janne, Pasi A.
Oxnard, Geoffrey R.
TI Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant
non-small cell lung carcinoma (NSCLC): A retrospective analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8074
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901786
ER
PT J
AU Lancet, JE
Othus, M
DeAngelo, DJ
Coutre, S
Komrokji, RS
Tallman, MS
Litzow, MR
Appelbaum, FR
AF Lancet, Jeffrey E.
Othus, Megan
DeAngelo, Daniel J.
Coutre, Steven
Komrokji, Rami S.
Tallman, Martin S.
Litzow, Mark Robert
Appelbaum, Frederick R.
TI Safety and tolerability of the combination of ATRA plus arsenic trioxide
(ATO) plus gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic
leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
SWOG Stat Ctr, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mayo Clin, Rochester, MN USA.
Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7016
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901552
ER
PT J
AU Land, SR
Warren, GW
Moinpour, C
Ostroff, JS
Crafts, J
Folz, J
Gulley, JL
Szabo, E
Chollette, V
Brandon, TH
Duffy, S
Hatsukami, DK
Dresler, CM
Gritz, ER
Schnoll, R
Sarna, L
Rigotti, N
Buckner, JC
Mitchell, SA
Toll, B
AF Land, Stephanie R.
Warren, Graham Walter
Moinpour, Carol
Ostroff, Jamie S.
Crafts, Jennifer
Folz, Jasmine
Gulley, James L.
Szabo, Eva
Chollette, Veronica
Brandon, Thomas H.
Duffy, Sonia
Hatsukami, Dorothy K.
Dresler, Carolyn M.
Gritz, Ellen R.
Schnoll, Robert
Sarna, Linda
Rigotti, Nancy
Buckner, Jan C.
Mitchell, Sandra A.
Toll, Benjamin
TI Standardizing measurement of tobacco use in cancer clinical trials
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Westat Corp, Rockville, MD USA.
NCI, NIH, Bethesda, MD 20892 USA.
NCI, Potomac, MD USA.
NCI, Rockville, MD USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Masonic Canc Ctr, Minneapolis, MN USA.
Tobacco Cessat & Control Subcomm, Rockville, MD USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mayo Clin, Rochester, MN USA.
Yale Univ, New Haven, CT USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9550
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902045
ER
PT J
AU Landry, JC
Feng, Y
Prabhu, RS
Cohen, SJ
Staley, CA
Whittington, RM
Sigurdson, ER
Nimeiri, HS
Verma, UN
Benson, A
AF Landry, Jerome Carl
Feng, Yang
Prabhu, Roshan Sudhir
Cohen, Steven J.
Staley, Charles A.
Whittington, Richard M.
Sigurdson, Elin R.
Nimeiri, Halla Sayed
Verma, Udit N.
Benson, Al Bowen
TI Phase II trial of preoperative radiation with concurrent capecitabine,
oxaliplatin, and bevacizumab followed by surgery and postoperative
5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in
patients with locally advanced rectal cancer: 5-year clinical outcomes
of a trial of the ECOG-ACRIN Cancer Research Group (E3204)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Southeast Radiat Oncol Grp, Charlotte, NC USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
VA New Jersey Healthcare Syst, E Orange, NJ USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3592
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900811
ER
PT J
AU Landsburg, DJ
Petrich, AM
Abramson, JS
Sohani, A
Press, OW
Cassaday, RD
Chavez, JC
Song, KW
Zelenetz, AD
Gandhi, M
Shah, NM
Fenske, T
Jasso, J
Medeiros, LJ
Yang, DT
Nabhan, C
AF Landsburg, Daniel Jeffrey
Petrich, Adam Matthew
Abramson, Jeremy S.
Sohani, Aliyah
Press, Oliver W.
Cassaday, Ryan Daniel
Chavez, Julio C.
Song, Kevin W.
Zelenetz, Andrew David
Gandhi, Mitul
Shah, Namrata Mahendra
Fenske, Timothy
Jasso, Jesse
Medeiros, L. Jeffrey
Yang, David T.
Nabhan, Chadi
TI Analysis of "double-hit" lymphoma cases by genetic subtype
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA.
Northwestern Univ, Chicago, IL 60611 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Washington, Seattle, WA 98195 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Northwestern, Chicago, IL USA.
Med Coll Wisconsin, W Allis, WI USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8543
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901855
ER
PT J
AU Lassen, UN
Mau-Soerensen, M
Kung, AL
Wen, PY
Lee, EQ
Plotkin, SR
Muhic, A
Rashal, T
Williams, T
McCauley, D
Ellis, J
Saint-Martin, JR
Carlson, R
Frenkel, R
Shacham, S
Mirza, MR
Kauffman, M
Lassman, AB
AF Lassen, Ulrik Niels
Mau-Soerensen, Morten
Kung, Andrew L.
Wen, Patrick Y.
Lee, Eudocia Quant
Plotkin, Scott R.
Muhic, Aida
Rashal, Tami
Williams, Tony
McCauley, Dilara
Ellis, Joel
Saint-Martin, Jean-Richard
Carlson, Robert
Frenkel, Ran
Shacham, Sharon
Mirza, Mansoor Raza
Kauffman, Michael
Lassman, Andrew B.
TI A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of
oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Rigshosp, DK-2100 Copenhagen, Denmark.
Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark.
Columbia Univ, Med Ctr, New York, NY USA.
Herbert Irving Comprehens Canc Ctr, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Karyopharm Therapeut Inc, Newton, MA USA.
Karyopharm Europe GMBH, Munich, Germany.
NR 0
TC 0
Z9 0
U1 5
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2044
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900503
ER
PT J
AU Laubach, J
Raje, NS
Yee, AJ
Armand, P
Schlossman, RL
Rosenblatt, J
Hedlund, JA
Martin, MG
Reynolds, CH
Shain, KH
Zackon, I
Stampleman, L
Boswell, E
Chuma, S
Liguori, R
Handisides, D
Kroll, S
Anderson, KC
Richardson, PG
Ghobrial, IM
AF Laubach, Jacob
Raje, Noopur S.
Yee, Andrew Jenho
Armand, Philippe
Schlossman, Robert L.
Rosenblatt, Jacalyn
Hedlund, Jacquelyn Ann
Martin, Michael Gary
Reynolds, Craig H.
Shain, Kenneth H.
Zackon, Ira
Stampleman, Laura
Boswell, Erica
Chuma, Stacey
Liguori, Rebecca
Handisides, Damian
Kroll, Stew
Anderson, Kenneth Carl
Richardson, Paul G.
Ghobrial, Irene M.
TI Preliminary safety and efficacy of evofosfamide (TH-302), an
investigational hypoxia-activated prodrug, combined with bortezomib and
dexamethasone in patients with relapsed/refractory multiple myeloma (RR
MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
Beth Israel Deaconess, Boston, MA USA.
Maine Ctr Canc Med, Scarborough, ME USA.
West Clin, Memphis, TN USA.
Ocala Oncol Ctr, Ocala, FL USA.
H Lee Moffitt Canc Ctr & Res Inst, St Petersburg, FL USA.
Albany Medcl Ctr, New York Onc Hem, Albany, NY USA.
Pacific Canc Care, Salinas, CA USA.
Blood Canc Res Partnership, Boston, MA USA.
Threshold Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8579
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901891
ER
PT J
AU Lee, EQ
Muzikansky, A
Gerstner, ER
Kuhn, JG
Reardon, DA
Nayak, L
Norden, AD
Doherty, LM
Rifenburg, J
LaFrankie, DC
Pulverenti, J
Vardam-Kaur, T
Stokes, D
Smith, KH
McCluskey, CS
Gaffey, SC
Batchelor, T
Duda, DG
Jain, RK
Wen, PY
AF Lee, Eudocia Quant
Muzikansky, Alona
Gerstner, Elizabeth Robins
Kuhn, John G.
Reardon, David A.
Nayak, Lakshmi
Norden, Andrew David
Doherty, Lisa M.
Rifenburg, Jennifer
LaFrankie, Debra C.
Pulverenti, Julee
Vardam-Kaur, Trupti
Stokes, Deirdre
Smith, Katrina Howard
McCluskey, Christine Sceppa
Gaffey, Sarah C.
Batchelor, Tracy
Duda, Dan G.
Jain, Rakesh K.
Wen, Patrick Y.
TI Phase I study of plerixafor and bevacizumab in recurrent high-grade
glioma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Dana Farber Canc Ctr Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2080
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904677
ER
PT J
AU Lee, TY
Ng, CS
Zhang, Z
Lee, S
Marques, H
Burgers, K
Su, F
Bauza, J
Mannel, RS
Walker, JL
Huh, WK
Rubin, SC
DiSilvestro, P
Martin, LP
Chan, JK
Bookman, MA
Coleman, RL
AF Lee, Ting-Yim
Ng, Chaan S.
Zhang, Zheng
Lee, Susanna
Marques, Helga
Burgers, Kyle
Su, Feng
Bauza, Joseph
Mannel, Robert S.
Walker, Joan L.
Huh, Warner King
Rubin, Stephen C.
DiSilvestro, Paul
Martin, Lainie P.
Chan, John K.
Bookman, Michael A.
Coleman, Robert L.
TI CT perfusion as an early biomarker of treatment efficacy in advanced
ovarian cancer: An ECOG-ACRIN and NRG GOG study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Lawson Hlth Res Inst, London, ON, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Brown Univ, Providence, RI 02912 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Western Univ, Robarts Res Inst, London, ON, Canada.
Western Univ, Robarts Res Inst, London, England.
ACRIN, Philadelphia, PA USA.
Univ Oklahoma, Oklahoma City, OK USA.
OUHSC, Stephenson Canc Ctr, Oklahoma City, OK USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Providence, RI 02912 USA.
Calif Pacific Palo Alto Med Fdn, Sutter Res Inst, San Francisco, CA USA.
Univ Arizona, Tucson, AZ USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5522
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901182
ER
PT J
AU Lennerz, JK
Stenzinger, A
AF Lennerz, Jochen K.
Stenzinger, Albrecht
TI Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
Natl Ctr Tumor Dis, Heidelberg, Germany.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4023
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900862
ER
PT J
AU Lheureux, S
Weberpals, JI
Hendrickson, AEW
Fleming, GF
Olawaiye, A
Brana, I
Mackay, H
Dhani, NC
Wilson, MK
Rodriguez-Freixinos, V
Martin-Lorente, C
Ward, J
Chang, K
Wang, L
Speers, V
Karakasis, K
Bowering, VL
Chen, A
Brenton, J
Oza, AM
AF Lheureux, Stephanie
Weberpals, Johanne Ingrid
Hendrickson, Andrea Elisabeth Wahner
Fleming, Gini F.
Olawaiye, Alexander
Brana, Irene
Mackay, Helen
Dhani, Neesha C.
Wilson, Michelle K.
Rodriguez-Freixinos, Victor
Martin-Lorente, Cristina
Ward, Jacklyn
Chang, Karen
Wang, Lisa
Speers, Vanessa
Karakasis, Katherine
Bowering, Valerie Lydia
Chen, Alice
Brenton, James
Oza, Amit M.
TI A randomized, placebo-controlled phase II trial comparing gemcitabine
monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in
women with recurrent, platinum-resistant epithelial ovarian, primary
peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo,
Chicago, and California consortia.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Princess Margaret Canc Ctr, Toronto, ON, Canada.
Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada.
Mayo Clin, Rochester, MN USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Massachusetts Gen Hosp, Chestnut Hill, MA USA.
UHN Princess Margaret Hosp, Cambridge, ON, Canada.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Div Med Oncol & Hematol,Dept Med, Toronto, ON, Canada.
Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada.
Univ Hlth Network, Toronto, ON, Canada.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5613
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904802
ER
PT J
AU Lheureux, S
Ledermann, JA
Runswick, S
Hodgson, DR
Timms, K
Lanchbury, JS
Kaye, SB
Gourley, C
Bowtell, D
Kohn, EC
Scott, CL
Matulonis, U
Panzarella, T
Dougherty, BA
Barrett, JC
Lai, ZW
O'Connor, M
Robertson, JD
Ho, TW
Oza, AM
AF Lheureux, Stephanie
Ledermann, Jonathan A.
Runswick, Sarah
Hodgson, Darren R.
Timms, Kirsten
Lanchbury, Jerry S.
Kaye, Stanley B.
Gourley, Charlie
Bowtell, David
Kohn, Elise C.
Scott, Clare L.
Matulonis, Ursula
Panzarella, Tony
Dougherty, Brian Andrew
Barrett, J. Carl
Lai, Zhongwu
O'Connor, Mark
Robertson, Jane D.
Ho, Tony Weishiu
Oza, Amit M.
TI Genomic characterization of long-term responders to olaparib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Princess Margaret Canc Ctr, Toronto, ON, Canada.
UCL, Inst Canc, London, England.
AstraZeneca, Macclesfield, Cheshire, England.
Myriad Genet Inc, Salt Lake City, UT USA.
Inst Canc Res, London SW3 6JB, England.
Royal Marsden NHS Fdn Trust, London, England.
Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
NIH, NCI, Bethesda, MD 20892 USA.
Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Princess Margaret Hosp, Dept Biostat, Toronto, ON M4X 1K9, Canada.
Univ Toronto, Toronto, ON, Canada.
AstraZeneca, Waltham, MA USA.
Astra Zeneca, Wilmington, DE USA.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5566
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901230
ER
PT J
AU Li, HR
Choueiri, TK
Wells, C
Agarwal, N
Donskov, F
Lee, JL
Broom, RJ
Yuasa, T
Rini, BI
Pal, SK
Wood, L
Ernst, DS
Kollmannsberger, CK
Vaishampayan, UN
Rha, SY
Bjarnason, GA
Knox, JJ
Saleem, S
Beuselinck, B
Heng, DYC
AF Li, Haoran
Choueiri, Toni K.
Wells, Connor
Agarwal, Neeraj
Donskov, Frede
Lee, Jae-Lyun
Broom, Reuben James
Yuasa, Takeshi
Rini, Brian I.
Pal, Sumanta Kumar
Wood, Lori
Ernst, D. Scott
Kollmannsberger, Christian K.
Vaishampayan, Ulka N.
Rha, Sun Young
Bjarnason, Georg A.
Knox, Jennifer J.
Saleem, Sadia
Beuselinck, Benoit
Heng, Daniel Yick Chin
TI Characteristics of metastatic renal cell carcinoma (mRCC) patients
treated with delayed targeted therapy: Results from the International
mRCC Consortium (IMDC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Univ Ulsan Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Auckland City Hosp, Auckland, New Zealand.
Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan.
Cleveland Clin Taussig Canc Inst, Cleveland, OH USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
London Reg Canc Ctr, London, ON N6A 4L6, Canada.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Yonsei Univ Coll Med, Seoul, South Korea.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4558
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901029
ER
PT J
AU Lin, CC
Bruinooge, SS
Kirkwood, KM
Olsen, CC
Bajorin, DF
Jemal, A
Giordano, SH
Goldstein, M
Guadagnolo, BA
Kosty, MP
Hopkins, S
Yu, JB
Arnone, A
Hanley, AE
Stevens, S
Hershman, DL
AF Lin, Chun Chieh
Bruinooge, Suanna S.
Kirkwood, Kelsey M.
Olsen, Christine Cecilia
Bajorin, Dean F.
Jemal, Ahmedin
Giordano, Sharon Hermes
Goldstein, Michael
Guadagnolo, Beverly Ashleigh
Kosty, Michael P.
Hopkins, Shane
Yu, James B.
Arnone, Anna
Hanley, Amy E.
Stevens, Stephanie
Hershman, Dawn L.
TI Association between geographic access to cancer care and receipt of
chemotherapy: Geographic distribution of oncologists and travel distance
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Amer Canc Soc, Atlanta, GA 30329 USA.
Amer Soc Clin Oncol, Alexandria, VA USA.
Massachusetts Gen Hosp, Newton, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Scripps Res Inst, La Jolla, CA 92037 USA.
William R Bliss Canc Ctr, Ames, IA USA.
Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA.
Amer Soc Radiat Oncol, Fairfax, VA USA.
Amer Soc Clin Oncol, Chicago, IL USA.
Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17561
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903531
ER
PT J
AU Lin, JJ
Cardarella, S
Lydon, CA
Dahlberg, SE
Jackman, DM
Janne, PA
Johnson, BE
AF Lin, Jessica Jiyeong
Cardarella, Stephanie
Lydon, Christine A.
Dahlberg, Suzanne Eleanor
Jackman, David Michael
Janne, Pasi A.
Johnson, Bruce E.
TI Clinical predictors of 5-year survival in patients with EGFR-mutant
metastatic NSCLC treated with EGFR-TKIs.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Brighton, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8071
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901783
ER
PT J
AU Lipton, A
Smith, MR
Fizazi, K
Stopeck, A
Henry, DH
Shore, N
Saad, F
Spencer, A
Zhu, L
Warner, DJ
AF Lipton, Allan
Smith, Matthew R.
Fizazi, Karim
Stopeck, Alison
Henry, David H.
Shore, Neal
Saad, Fred
Spencer, Andrew
Zhu, Li
Warner, Douglas J.
TI Bone turnover marker (BTM) levels and clinical outcomes in advanced
cancer patients (pts) treated with antiresorptive bone therapies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Penn State Hematol Oncol, Hershey, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Paris 11, Dept Canc Med, Inst Gustave Roussy, Villejuif, France.
Stony Brook Canc Ctr, Dept Internal Med, Stony Brook, NY USA.
Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19107 USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Univ Montreal, Ctr Hosp, Dept Surg, Montreal, PQ, Canada.
Monash Univ, Dept Clin Haematol, Clayton, Vic, Australia.
Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e22236
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904605
ER
PT J
AU Liu, J
Lee, JM
Luo, WX
Birrer, MJ
Whalen, C
Houston, ND
Obermayer, E
Spagnoletti, T
Barry, WT
Kohn, EC
Ivy, SP
Matulonis, U
AF Liu, Joyce
Lee, Jung-min
Luo, Weixiu
Birrer, Michael J.
Whalen, Christin
Houston, Nicole D.
Obermayer, Elizabeth
Spagnoletti, Tatum
Barry, William Thomas
Kohn, Elise C.
Ivy, S. Percy
Matulonis, Ursula
TI A phase 1 study optimizing the dosing of olaparib tablet formulation
combined with cediranib in recurrent ovarian cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Newton, MA USA.
NIH, Bethesda, MD 20892 USA.
Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
NCI, NIH, Bethesda, MD 20892 USA.
NCI, CTEP, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5559
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901222
ER
PT J
AU Liu, SV
Powderly, JD
Camidge, DR
Ready, N
Heist, RS
Hodi, FS
Giaccone, G
Liu, B
Wallin, J
Funke, RP
Waterkamp, D
Gettinger, SN
AF Liu, Stephen V.
Powderly, John D.
Camidge, D. Ross
Ready, Neal
Heist, Rebecca Suk
Hodi, F. Stephen
Giaccone, Giuseppe
Liu, Bo
Wallin, Jeffrey
Funke, Roel Peter
Waterkamp, Daniel
Gettinger, Scott N.
TI Safety and efficacy of MPDL3280A (anti-PDL1) in combination with
platinum-based doublet chemotherapy in patients with advanced non-small
cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Georgetown Univ Hosp, Washington, DC 20007 USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Duke Univ, Med Ctr, Chapel Hill, NC USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, NIH, Bethesda, MD 20892 USA.
Genentech Inc, San Francisco, CA 94080 USA.
F Hoffmann La Roche Ltd, Basel, Switzerland.
Yale Sch Med, New Haven, CT USA.
NR 0
TC 20
Z9 20
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8030
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901743
ER
PT J
AU Long, GV
Stroyakovskiy, D
Gogas, H
Levchenko, E
De Braud, FG
Larkin, JMG
Garbe, C
Jouary, T
Hauschild, A
Grob, JJ
Chiarion-Sileni, V
Lebbe, C
Mandala, M
Millward, M
DeMarini, DJ
Irani, JG
Jin, F
Swann, RS
Mookerjee, B
Flaherty, K
AF Long, Georgina V.
Stroyakovskiy, Daniil
Gogas, Helen
Levchenko, Evgeny
De Braud, Filippo G.
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Jin, Fan
Swann, R. Suzanne
Mookerjee, Bijoyesh
Flaherty, Keith
TI Overall survival in COMBI-d, a randomized, double-blinded, phase III
study comparing the combination of dabrafenib and trametinib with
dabrafenib and placebo as first-line therapy in patients (pts) with
unresectable or metastatic BRAF V600E/K mutation-positive cutaneous
melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Melanoma Inst Australia, Sydney, NSW, Australia.
Univ Sydney, Sydney, NSW, Australia.
Moscow City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia.
Univ Athens, Sch Med, Dept Med 1, GR-11527 Athens, Greece.
Petrov Res Inst Oncol, St Petersburg, Russia.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Royal Marsden NHS Fdn Trust, London, England.
Univ Tubingen, Tubingen, Germany.
Hop Francois Mitterrand, Pau, France.
Univ Kiel, Kiel, Germany.
Aix Marseille Univ, Hop Timone, Marseille, France.
Veneto Oncol Inst, Padua, Italy.
Hop St Louis, AP HP, Dept Dermatol, Paris, France.
Papa Giovanni XXIII Hosp, Bergamo, Italy.
Sir Charles Gairdner Hosp, Perth, WA, Australia.
GlaxoSmithKline, Collegeville, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 102
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900101
ER
PT J
AU Lonial, S
Dimopoulos, MA
Palumbo, A
White, D
Grosicki, S
Spicka, I
Walter-Croneck, A
Moreau, P
Mateos, MV
Magen-Nativ, H
Belch, A
Reece, DE
Beksac, M
Taniwaki, M
Rollig, C
Singhal, AK
Katz, J
Bleickardt, EW
Poulart, V
Richardson, PG
AF Lonial, Sagar
Dimopoulos, Meletios A.
Palumbo, Antonio
White, Darrell
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Moreau, Philippe
Mateos, Maria-Victoria
Magen-Nativ, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Taniwaki, Masafumi
Roellig, Christoph
Singhal, Anil K.
Katz, Jessica
Bleickardt, Eric W.
Poulart, Valerie
Richardson, Paul G.
CA ELOQUENT-2 Investigators
TI ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide
(Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients
(pts) with relapsed/refractory multiple myeloma (RRMM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
Univ Athens, Athens 11528, Greece.
AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy.
Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada.
Silesian Med Univ, Fac Publ Hlth, Dept Canc Prevent, Katowice, Poland.
Prague Gen Hosp, Prague, Czech Republic.
Med Univ Lublin, Lublin, Poland.
Univ Hosp, Nantes, France.
Univ Hosp Salamanca IBSAL, Salamanca, Spain.
Tel Aviv Univ, Ramat Aviv, Israel.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Univ Alberta, Edmonton, AB, Canada.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Ankara Univ, TR-06100 Ankara, Turkey.
Kyoto Prefectural Univ Med, Kyoto, Japan.
Univ Klinikum TU, Dresden, Germany.
AbbVie Biotherapeut Inc ABR, Redwood City, CA USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Bristol Myers Squibb, Braine Lalleud, Belgium.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI richard, chrystelle/K-8595-2015
NR 0
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8508
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901821
ER
PT J
AU Luis, IMVD
Oh, C
Wang, ZG
Dipiro, P
Macrae, EM
Painter, C
Kryukov, G
Krop, IE
Winer, EP
Lin, NU
Wagle, N
AF Luis, Ines Maria Vaz Duarte
Oh, Coyin
Wang, Zhigang
Dipiro, Pamela
Macrae, Erin Macrae
Painter, Corrie
Kryukov, Gregory
Krop, Ian E.
Winer, Eric P.
Lin, Nancy U.
Wagle, Nikhil
TI Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC)
patients (pts) with extraordinary responses to trastuzumab (T)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Broad Inst, Cambridge, MA USA.
Ohio State Univ, Stefanie Spielman Comprehens Breast Ctr, Wexner Med Ctr, Columbus, OH 43210 USA.
Broad Inst MIT & Harvard, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 611
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901403
ER
PT J
AU Luis, IMVD
Lin, NU
Keating, NL
Lii, J
Barry, WT
Winer, EP
Freedman, RA
AF Luis, Ines Maria Vaz Duarte
Lin, Nancy U.
Keating, Nancy Lynn
Lii, Joyce
Barry, William Thomas
Winer, Eric P.
Freedman, Rachel A.
TI Factors associated with early mortality in metastatic breast cancer
(MBC) in a population based cohort
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
Dana Farber Canc Inst, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1577
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900443
ER
PT J
AU Luke, JJ
Donahue, H
Nishino, M
Giobbie-Hurder, A
Davis, M
Bailey, N
Ott, PA
Hodi, FS
AF Luke, Jason John
Donahue, Hilary
Nishino, Mizuki
Giobbie-Hurder, Anita
Davis, Meredith
Bailey, Nancy
Ott, Patrick Alexander
Hodi, F. Stephen
TI Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in
advanced melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago Med, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20025
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904048
ER
PT J
AU Madenci, AL
Fisher, S
Diller, L
Goldsby, RE
Leisenring, WM
Oeffinger, KC
Robison, LL
Sklar, CA
Stovall, M
Weathers, R
Armstrong, GT
Yasui, Y
Weldon, CB
AF Madenci, Arin L.
Fisher, Stacey
Diller, Lisa
Goldsby, Robert E.
Leisenring, Wendy M.
Oeffinger, Kevin C.
Robison, Leslie L.
Sklar, Charles A.
Stovall, Marilyn
Weathers, Rita
Armstrong, Gregory T.
Yasui, Yutaka
Weldon, Christopher Bertero
TI Intestinal obstruction in survivors of childhood cancer: A report from
the Childhood Cancer Survivor Study (CCSS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Univ Alberta, Edmonton, AB, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
UCSF Sch Med, Dept Pediat, Greenbrae, CA USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
Boston Childrens Hosp, Dept Surg, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10071
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900081
ER
PT J
AU Malempati, S
Weigel, B
Anderson, JR
Parham, D
Teot, LA
Rodeberg, DA
Yock, TI
Shulkin, BL
Hawkins, DS
AF Malempati, Suman
Weigel, Brenda
Anderson, James R.
Parham, David
Teot, Lisa A.
Rodeberg, David A.
Yock, Torunn I.
Shulkin, Barry L.
Hawkins, Douglas S.
TI Early results from Children's Oncology Group (COG) ARST08P1: Pilot
studies of cixutumumab or temozolomide with intensive multiagent
chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Minnesota, Minneapolis, MN USA.
Univ Nebraska Med Ctr, Omaha, NE USA.
Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
Childrens Hosp Boston, Boston, MA USA.
E Carolina Univ, Greenville, NC USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Seattle Childrens Hosp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10015
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900019
ER
PT J
AU Malhotra, S
Huang, K
Simeunovic, K
Vinnakota, R
Gavrancic, T
Villanueva, N
Dietz, D
Fenn, K
Beck, K
Coker, C
Park, YHA
Acharyya, S
AF Malhotra, Sheetal
Huang, Kan
Simeunovic, Kosana
Vinnakota, Ravi
Gavrancic, Tatjana
Villanueva, Nicholas
Dietz, Donny
Fenn, Kathleen
Beck, Kristen
Coker, Courtney
Park, Yeun-Hee Anna
Acharyya, Swarnali
TI Survival in veterans with lung cancer: Cancer cachexia and the
importance of weight.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 North Cent Bronx Hosp, Bronx, NY USA.
New York Presbyterian Columbia Med Ctr, Ft Lee, NJ USA.
JJ Peters VA Med Ctr, Bronx, NY USA.
James J Peters VA Med Ctr, New York, NY USA.
Columbia Univ, Dept Med, Med Ctr, New York, NY USA.
Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
Columbia Univ, Inst Canc Genet, New York, NY USA.
Onc & Hem White Plains, Mt Vernon, NY USA.
Columbia Univ, Canc Genet 4Inst, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20608
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904225
ER
PT J
AU Malhotra, S
Wu, DPH
Park, YHA
AF Malhotra, Sheetal
Wu, David Ping-Hsin
Park, Yeun-Hee Anna
TI National data on sorafenib therapy adherence for veterans with
hepatocellular carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 North Cent Bronx Hosp, Bronx, NY USA.
Yale Univ Internal Med, New Haven, CT USA.
James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9593
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902088
ER
PT J
AU Maloney, KW
Angiolillo, AL
Schore, RJ
Devidas, M
Lu, XM
Wang, C
Friedmann, AM
Mattano, LA
Loh, ML
Raetz, EA
Stork, LC
Winick, NJ
Hunger, S
Carroll, WL
AF Maloney, Kelly W.
Angiolillo, Anne L.
Schore, Reuven J.
Devidas, Meenakshi
Lu, Xiaomin
Wang, Cindy
Friedmann, Alison M.
Mattano, Leonard A.
Loh, Mignon L.
Raetz, Elizabeth A.
Stork, Linda C.
Winick, Naomi J.
Hunger, Stephen
Carroll, William L.
TI Association of intravenous (IV) and intramuscular (IM) pegaspargase
(PEG) administration with rate of adverse events (AE) in standard risk
(SR) Acute Lymphoblastic Leukemia (ALL) Children's Oncology Group (COG)
trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Childrens Hosp Colorado, Aurora, CO USA.
Childrens Natl Med Ctr, Washington, DC 20010 USA.
Childrens Natl Medcal Ctr, Washington, DC USA.
Univ Florida, Gainesville, FL USA.
Massachusetts Gen Hosp, Reading, MA USA.
HARP Pharma Consulting LLC, Mystic, CT USA.
UC San Francisco, San Francisco, CA USA.
Univ Utah, Salt Lake City, UT USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
NYU, Langone Med Ctr, New York, NY USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10035
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900041
ER
PT J
AU Margolin, KA
Tawbi, HAH
Ernstoff, MS
Hodi, FS
McDermott, DF
Edwards, R
Avila, A
Atkins, MB
AF Margolin, Kim Allyson
Tawbi, Hussein Abdul-Hassan
Ernstoff, Marc S.
Hodi, F. Stephen
McDermott, David F.
Edwards, Robin
Avila, Alexandre
Atkins, Michael B.
TI A multi-center phase II open-label study (CheckMate 204) to evaluate
safety and efficacy of nivolumab (NIVO) in combination with ipilimumab
(IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL)
metastatic to the brain.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
Cytokine Working Grp, Stanford, CA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Cleveland Clin Fdn, Cleveland, OH 44195 USA.
Cytokine Working Grp, Cleveland, OH USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cytokine Working Grp, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Bristol Myers Squibb, Plainsboro, NJ USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Cytokine Working Grp, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS9080
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904878
ER
PT J
AU Marron, JM
Cronin, A
Kang, TI
Mack, JW
AF Marron, Jonathan Michael
Cronin, Angel
Kang, Tammy I.
Mack, Jennifer W.
TI Intended and unintended consequences: Ethics, communication, and
prognostic disclosure in pediatric oncology
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9515
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902010
ER
PT J
AU Martinez, A
Hernandez, A
Arpi, O
Menendez, S
Iarchouk, N
Gavilan, E
Bellosillo, B
Arum, M
Rojo, F
Mullane, SA
Choueiri, TK
Rovira, A
Albanell, J
Brake, R
Bellmunt, J
AF Martinez, Alejandro
Hernandez, Anna
Arpi, Oriol
Menendez, Silvia
Iarchouk, Natalia
Gavilan, Elena
Bellosillo, Beatriz
Arum, Montserrat
Rojo, Federico
Mullane, Stephanie A.
Choueiri, Toni K.
Rovira, Ana
Albanell, Joan
Brake, Rachael
Bellmunt, Joaquim
TI Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and
MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in
clinical trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hosp del Mar, Canc Res Program, IMIM Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain.
Univ Hosp del Mar, IMIM, Barcelona, Spain.
Takeda Pharmaceut Int Co, Cambridge, MA USA.
Univ Hosp del Mar, Mol Cytogenet Lab, Dept Pathol, Barcelona, Spain.
Hosp del Mar, IMIM, Barcelona, Spain.
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain.
Brigham & Womens Canc Ctr, Bladder Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Hosp del Mar, Dept Med Oncol, Barcelona, Spain.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15520
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903068
ER
PT J
AU Massarelli, E
Haddad, RI
Lee, JJ
Lin, HY
Garden, AS
Blumenschein, GR
William, WN
Tishler, RB
Glisson, BS
Gold, KA
Johnson, FM
Rabinowits, G
Ginsberg, LE
Williams, MD
Myers, J
Kies, MS
Papadimitrakopoulou, V
AF Massarelli, Erminia
Haddad, Robert I.
Lee, J. Jack
Lin, Heather Y.
Garden, Adam S.
Blumenschein, George R.
William, William Nassib
Tishler, Roy B.
Glisson, Bonnie S.
Gold, Kathryn A.
Johnson, Faye M.
Rabinowits, Guilherme
Ginsberg, Lawrence E.
Williams, Michelle D.
Myers, Jeffrey
Kies, Merrill S.
Papadimitrakopoulou, Vassiliki
TI Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab,
docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based
local therapy in previously untreated, locally advanced head and neck
squamous cell carcinoma (LAHNSCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6001
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901313
ER
PT J
AU Matulonis, U
Wright, AA
Collins, SA
Campos, SM
Konstantinopoulos, P
MacNeill, K
Morrissey, S
Patterson, V
Whalen, C
Liu, J
AF Matulonis, Ursula
Wright, Alexi A.
Collins, Siobhan A.
Campos, Susana M.
Konstantinopoulos, Panagiotis
MacNeill, Kimberley
Morrissey, Stephanie
Patterson, Victoria
Whalen, Christin
Liu, Joyce
TI A single arm, single stage phase II trial of trametinib (GSK1120212) and
GSK2141795 in persistent or recurrent cervical cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Newton, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5618
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904807
ER
PT J
AU Matulonis, U
Friedlander, M
Du Bois, A
Gourley, C
Vergote, I
Rustin, GJS
Scott, CL
Meier, W
Shapira-Frommer, R
Safra, T
Matei, D
Fielding, A
McMurtry, E
Spencer, S
Mann, H
Parry, D
Ledermann, JA
AF Matulonis, Ursula
Friedlander, Michael
Du Bois, Andreas
Gourley, Charlie
Vergote, Ignace
Rustin, Gordon J. S.
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
McMurtry, Emma
Spencer, Stuart
Mann, Helen
Parry, David
Ledermann, Jonathan A.
TI Frequency, severity and timing of common adverse events (AEs) with
maintenance olaparib in patients (pts) with platinum-sensitive relapsed
serous ovarian cancer (PSR SOC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Prince Wales Canc Ctr, Randwick, NSW, Australia.
AGO, Essen, Germany.
Kliniken Essen Mitte, Essen, Germany.
Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Univ Hosp Leuven, Leuven, Belgium.
Mt Vernon Hosp, Northwood, Middx, England.
Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
Evangel Krankenhaus, Dusseldorf, Germany.
Sheba Med Ctr, Ramat Gan, Israel.
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
AstraZeneca, Macclesfield, Cheshire, England.
UCL, Inst Canc, London, England.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5550
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901213
ER
PT J
AU Mayer, IA
Singer, CF
Fasching, PA
Holmes, FA
Gnant, M
Estevez, LG
Campone, M
Hubalek, M
Wolff, AC
Perez-Fidalgo, JA
Winer, EP
Atalla-Vidam, G
Kanwal, C
Blumenstein, L
Fretault, N
Diaz-Padilla, I
Arteaga, CL
AF Mayer, Ingrid A.
Singer, Christian F.
Fasching, Peter A.
Holmes, Frankie Ann
Gnant, Michael
Estevez, Laura G.
Campone, Mario
Hubalek, Michael
Wolff, Antonio C.
Perez-Fidalgo, Jose Alejandro
Winer, Eric P.
Atalla-Vidam, Gena
Kanwal, Charu
Blumenstein, Lars
Fretault, Nathalie
Diaz-Padilla, Ivan
Arteaga, Carlos L.
TI A Phase II study of the safety and efficacy of alpelisib or buparlisib
plus letrozole in neoadjuvant treatment of postmenopausal women with
HR+/HER2-, PIK3CA mutant or wild-type breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Med Univ Vienna, Vienna, Austria.
Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany.
US Oncol, Texas, Houston, TX USA.
Med Univ Vienna, Vienna, Austria.
Comprehens Canc Ctr Clara Campal CIOCC, Madrid, Spain.
Canc Inst West ICO, Nantes, France.
Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria.
Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Hosp Clin Univ Valencia, Valencia, Spain.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Pharma AG, Basel, Switzerland.
Novartis Pharma SAS, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS633
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904825
ER
PT J
AU McKay, RR
Werner, L
Fiorillo, M
Dumas, K
Roberts, J
Mamlouk, K
Taplin, ME
AF McKay, Rana R.
Werner, Lillian
Fiorillo, Matthew
Dumas, Kathryn
Roberts, Jennifer
Mamlouk, Khalid
Taplin, Mary-Ellen
TI Activity of sequential therapies (txs) in patients (pts) with castration
resistant prostate cancer (CRPC) previously treated with galeterone
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Tokai Pharma, Cambridge, MA USA.
Tokai Pharmaceut Inc, Cambridge, MA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16072
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903242
ER
PT J
AU McKay, RR
Werner, L
Harshman, LC
Bellmunt, J
Sweeney, C
Rosenberg, JE
VanAllen, E
Walsh, MK
Vaishampayan, UN
McDermott, DF
Choueiri, TK
AF McKay, Rana R.
Werner, Lillian
Harshman, Lauren Christine
Bellmunt, Joaquim
Sweeney, Christopher
Rosenberg, Jonathan E.
VanAllen, Eliezer
Walsh, Meghara K.
Vaishampayan, Ulka N.
McDermott, David F.
Choueiri, Toni K.
TI A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in
patients (pts) with metastatic renal cell carcinoma (mRCC) progressing
on prior vascular endothelial growth factor (VEGF) therapies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4559
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901030
ER
PT J
AU McQuade, JL
Chen, G
Panka, DJ
Reuben, A
Bassett, RL
Joon, A
Lazar, AJF
Tetzlaff, MT
Simpson, L
Mouton, R
Patel, SP
Glitza, IC
Hwu, WJ
Amaria, RN
Diab, A
Hwu, P
Wargo, JA
Sullivan, RJ
Kim, K
Davies, MA
AF McQuade, Jennifer Leigh
Chen, Guo
Panka, David J.
Reuben, Alexandre
Bassett, Roland L.
Joon, Aron
Lazar, Alexander J. F.
Tetzlaff, Michael T.
Simpson, Lauren
Mouton, Rosalind
Patel, Sapna Pradyuman
Glitza, Isabella Claudia
Hwu, Wen-Jen
Amaria, Rodabe Navroze
Diab, Adi
Hwu, Patrick
Wargo, Jennifer Ann
Sullivan, Ryan J.
Kim, Kevin
Davies, Michael A.
TI Phase II study of dabrafenib and trametinib following progression on
BRAF inhibitor monotherapy in metastatic melanoma: Exploration of
clinical and molecular predictors of response.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
UnMD Anderson Canc Ctr, Houston, TX USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Calif Pacific Med Ctr, Res Inst, Oakland, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20051
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904069
ER
PT J
AU McWilliams, RR
Ko, AH
Chiorean, EG
Kwak, EL
Lenz, HJ
Nadler, PI
Wood, DL
Fujimori, M
Morita, K
Inada, T
Kouji, H
AF McWilliams, Robert R.
Ko, Andrew H.
Chiorean, E. Gabriela
Kwak, Eunice Lee
Lenz, Heinz-Josef
Nadler, Paul I.
Wood, Debra L.
Fujimori, Masamoto
Morita, Kohei
Inada, Tetsuhi
Kouji, Hiroyuki
TI A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin
modulator, plus gemcitabine (GEM) in patients with advanced pancreatic
adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
UC San Francisco Helen Diller Family Comprehens C, San Francisco, CA USA.
Univ Washington, Seattle, WA 98195 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
Nadler Pharma Assoc LLC, Randolph, NJ USA.
Nadler Pharma Associates LLC, Randolph, NJ USA.
PRISM Pharma Co Ltd, Yokohama, Kanagawa, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15270
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903029
ER
PT J
AU Meyer, L
Cronin, A
Sun, CC
Bookman, MA
Burger, RA
Cristea, MC
Griggs, JJ
Levenback, CF
Mantia-Smaldone, G
Matulonis, U
Niland, JC
O'Malley, DM
Wright, AA
AF Meyer, Larissa
Cronin, Angel
Sun, Charlotte C.
Bookman, Michael A.
Burger, Robert Allen
Cristea, Mihaela C.
Griggs, Jennifer J.
Levenback, Charles F.
Mantia-Smaldone, Gina
Matulonis, Ursula
Niland, Joyce C.
O'Malley, David M.
Wright, Alexi A.
TI Use of neoadjuvant chemotherapy in advanced ovarian cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Arizona Oncol, Tucson, AZ USA.
Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA.
City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
RI OMalley, David/E-3789-2011
NR 0
TC 1
Z9 1
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5563
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901227
ER
PT J
AU Miklos, DB
Arora, M
Cutler, CS
Nakamura, R
Juretic, M
Li, YF
Styles, LA
James, DF
Jaglowski, SM
AF Miklos, David Bernard
Arora, Mukta
Cutler, Corey S.
Nakamura, Ryotaro
Juretic, Manuela
Li, Yunfeng
Styles, Lori Appel
James, Danelle Frances
Jaglowski, Samantha Mary
TI A multicenter open-label phase 1b/2 study of ibrutinib in steroid
dependent or refractory chronic graft versus host disease (cGVHD)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Stanford, CA 94305 USA.
Univ Minnesota, Minneapolis, MN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Pharmacyclics Inc, Sunnyvale, CA USA.
Ohio State Univ, Columbus, OH 43210 USA.
RI Jaglowski, Samantha/E-3304-2011
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7024
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901560
ER
PT J
AU Miller, K
Cortes, J
Hurvitz, SA
Krop, IE
Tripathy, D
Verma, S
Riahi, K
Reynolds, JG
Wickham, TJ
Molnar, I
Yardley, DA
AF Miller, Kathy
Cortes, Javier
Hurvitz, Sara A.
Krop, Ian E.
Tripathy, Debu
Verma, Sunil
Riahi, Kaveh
Reynolds, Joseph G.
Wickham, Thomas J.
Molnar, Istvan
Yardley, Denise A.
TI HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus
trastuzumab with chemotherapy of physician's choice plus trastuzumab, in
anthracycline naive HER2-positive, locally advanced/metastatic breast
cancer patients previously treated with pertuzumab and ado-trastuzumab
emtansine (T-DM1).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Vall DHebron Univ Hosp, Barcelona, Spain.
UCLA Healthcare Hematol Oncol Breast Oncol Progra, Santa Monica, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Merrimack Pharma, Cambridge, MA USA.
Merrimack Pharmaceut Inc, Cambridge, MA USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS641
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904833
ER
PT J
AU Mok, T
Spigel, D
Felip, E
deMarinis, F
Ahn, MJ
Groen, HJM
Wakelee, HA
Hida, T
Crino, L
Nishio, M
Scagliotti, GV
Branle, F
Emeremni, C
Quadrigli, M
Zhang, J
Shaw, AT
AF Mok, Tony
Spigel, David
Felip, Enriqueta
deMarinis, Filippo
Ahn, Myung-Ju
Groen, Harry J. M.
Wakelee, Heather A.
Hida, Toyoaki
Crino, Lucio
Nishio, Makoto
Scagliotti, Giorgio V.
Branle, Fabrice
Emeremni, Chetachi
Quadrigli, Massimiliano
Zhang, Jie
Shaw, Alice Tsang
TI ASCEND-2: A single-arm, open-label, multicenter phase II study of
ceritinib in adult patients (pts) with ALK-rearranged (ALK plus )
non-small cell lung cancer (NSCLC) previously treated with chemotherapy
and crizotinib (CRZ).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA.
Vall dHebron Univ, Barcelona, Spain.
European Inst Oncol, Thorac Oncol Div, Milan, Italy.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Groningen, Groningen, Netherlands.
Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands.
Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan.
Osped S Maria Misericordia, Med Oncol, Perugia, Italy.
Japanese Fdn Canc Res, Tokyo, Japan.
Univ Turin, Turin, Italy.
Novartis Pharma AG, Basel, Switzerland.
Novartis Pharmaceut, E Hanover, NJ USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 23
Z9 23
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8059
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901771
ER
PT J
AU Moore, KN
Martin, LP
Seward, SM
Bauer, TM
O'Malley, DM
Perez, RP
Oza, AM
Jeong, W
Kirby, MW
Zhou, YH
Michenzie, MF
Ponte, J
Ruiz-Soto, R
Birrer, MJ
AF Moore, Kathleen N.
Martin, Lainie P.
Seward, Shelly Marie
Bauer, Todd Michael
O'Malley, David M.
Perez, Raymond P.
Oza, Amit M.
Jeong, Woondong
Kirby, Maurice William
Zhou, Yinghui
Michenzie, Mary F.
Ponte, Joseph
Ruiz-Soto, Rodrigo
Birrer, Michael J.
TI Preliminary single agent activity of IMGN853, a folate receptor alpha
(FR alpha)-targeting antibody-drug conjugate (ADC), in
platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase
I trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Wayne State Univ, Karmanos Canc Inst, Huntington Woods, MI USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
Univ Kansas, Fairway, KS USA.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Westchester Hem Onc Grp, Westchester, NY USA.
ImmunoGen Inc, Waltham, MA USA.
Immunogen, Waltham, MA USA.
ImmunoGen Inc, Dedham, MA USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
RI OMalley, David/E-3789-2011; Perez, Raymond/R-6159-2016
OI Perez, Raymond/0000-0002-7432-2411
NR 0
TC 5
Z9 5
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5518
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901177
ER
PT J
AU Morris, MJ
Higano, CS
Scher, HI
Sweeney, C
Antonarakis, ES
Shevrin, DH
Ryan, CJ
Loriot, Y
Fizazi, K
Pandit-Taskar, N
Garcia-Vargas, JE
Lyseng, K
Bloma, M
Carrasquillo, JA
AF Morris, Michael J.
Higano, Celestia S.
Scher, Howard I.
Sweeney, Christopher
Antonarakis, Emmanuel S.
Shevrin, Daniel H.
Ryan, Charles J.
Loriot, Yohann
Fizazi, Karim
Pandit-Taskar, Neeta
Garcia-Vargas, Jose E.
Lyseng, Kari
Bloma, Marianne
Carrasquillo, Jorge A.
TI Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on
prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in
patients (pts) with castration-resistant prostate cancer (CRPC) and bone
metastases (mets): A phase 1/2a clinical trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Evanston Hosp Kellogg Canc Ctr, NorthShore Univ Hlth Syst, Evanston, IL USA.
UC San Francisco Helen Diller Family Comprehens C, San Francisco, CA USA.
Univ Paris 11, Dept Med Oncol, Inst Gustave Roussy, Villejuif, France.
Bayer HealthCare, Whippany, NJ USA.
Bayer AS, Oslo, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5012
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901054
ER
PT J
AU Mostaghel, EA
Cho, EP
Wright, JL
Loda, M
Marck, B
Matsumoto, AM
Tamae, D
Penning, TM
Balk, SP
Kantoff, PW
Nelson, P
Taplin, ME
Montgomery, RB
AF Mostaghel, Elahe A.
Cho, Eunpi
Wright, Jonathan Lawrence
Loda, Massimo
Marck, Brett
Matsumoto, Alvin M.
Tamae, Daniel
Penning, Trevor M.
Balk, Steven P.
Kantoff, Philip W.
Nelson, Peter
Taplin, Mary-Ellen
Montgomery, Robert B.
TI Association of SLCO transport genes with intraprostatic abiraterone
(ABI) levels and pathologic outcomes in men with high-risk localized
prostate cancer (PCa).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Washington, Sch Med, Seattle, WA USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Washington, Seattle, WA 98195 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Washington Oncol, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5013
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901055
ER
PT J
AU Motzer, R
Hutson, T
Glen, H
Michaelson, D
Molina, AM
Eisen, T
Jassem, J
Zolnierek, J
Maroto, P
Mellado, B
Melichar, B
Tomasek, J
Kim, HJ
Wood, K
Dutcus, C
Larkin, JMG
AF Motzer, Robert
Hutson, Thomas
Glen, Hilary
Michaelson, Dror
Molina, Ana M.
Eisen, Timothy
Jassem, Jacek
Zolnierek, Jakub
Maroto, Pablo
Mellado, Begona
Melichar, Bohuslav
Tomasek, Jiri
Kim, Han-Joo
Wood, Karen
Dutcus, Corina
Larkin, James M. G.
TI Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus
(EVE), and LEN plus EVE in patients (pts) with metastatic renal cell
carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
Addenbrookes Hosp, Cambridge, England.
Med Univ, Gdansk, Poland.
Inst Warszawie, Ctr Onkol, Warsaw, Poland.
Dept Oncol Med, Barcelona, Spain.
Hosp Clin Barcelona, Dept Med Oncol, IDIBAPS, Translat Genom & Targeted Therapeut Oncol, Barcelona, Spain.
Lekarska Fak Univ Palackeho Fak Nemocnice, Onkol Klin, Olomouc, Czech Republic.
Masaryk Univ, Masaryk Mem Canc Inst, Brno, Czech Republic.
Eisai Inc, Woodcliff Lake, NJ USA.
Eisai Ltd, Hatfield, Herts, England.
Royal Marsden NHS Hosp, London, England.
NR 0
TC 6
Z9 6
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4506
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900974
ER
PT J
AU Mullane, SA
Werner, L
Zhou, CW
Taplin, ME
Choueiri, TK
Bellmunt, J
Bowden, M
AF Mullane, Stephanie A.
Werner, Lillian
Zhou, Chensheng Willa
Taplin, Mary-Ellen
Choueiri, Toni K.
Bellmunt, Joaquim
Bowden, Michaela
TI Predicting outcome in metastatic urothelial cancer (UC) receiving
docetaxel (DT): miRNA profiling in pre and post therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Canc Ctr, Bladder Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15518
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903066
ER
PT J
AU Murray, B
Albiges, L
Van Allen, EM
Cherniack, A
Fay, AP
Meyerson, M
Choueiri, TK
AF Murray, Bradley
Albiges, Laurence
Van Allen, Eliezer Mendel
Cherniack, Andrew
Fay, Andre Poisl
Meyerson, Matthew
Choueiri, Toni K.
TI Precision medicine approach in kidney cancer: A pan renal cell carcinoma
(RCC) study across three cancer genome atlas (TCGA) datasets for
clinically relevant target identification.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Broad Inst, Boston, MA USA.
Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Broad Inst, Cambridge, MA USA.
HSL PUCRS, Oncol Serv & Oncol Res Unit, Porto Alegre, RS, Brazil.
Harvard Univ, Sch Med, Dana Farber Canc Inst,MIT, Massachusetts Gen Hosp,Brigham & Womens Hosp,Broa, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4564
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901035
ER
PT J
AU Muss, HB
Berry, DA
Cirrincione, CT
Theodoulou, M
Hurria, A
Cohen, HJ
Partridge, A
Norton, L
Hudis, CA
Winer, EP
AF Muss, Hyman B.
Berry, Donald A.
Cirrincione, Constance T.
Theodoulou, Maria
Hurria, Arti
Cohen, Harvey Jay
Partridge, Ann
Norton, Larry
Hudis, Clifford A.
Winer, Eric P.
TI Standard chemotherapy versus capcitabine for older women with early
stage breast cancer: An update of CALGB/CTSU/Alliance 49907
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Chapel Hill, NC USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1022
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900104
ER
PT J
AU Myers, AP
Filiaci, VL
Zhang, YP
Pearl, M
Behbakht, K
Makker, V
Hanjani, P
Zweizig, S
Burke, JJ
Downey, G
Leslie, KK
Birrer, MJ
Fleming, GF
AF Myers, Andrea P.
Filiaci, Virginia L.
Zhang, Yuping
Pearl, Michael
Behbakht, Kian
Makker, Vicky
Hanjani, Parviz
Zweizig, Susan
Burke, James J.
Downey, Gordon
Leslie, Kimberly K.
Birrer, Michael J.
Fleming, Gini F.
TI Tumor mutational analysis of GOG248, a phase II study of temsirolimus or
temsirolimus and alternating megestrol acetate and tamoxifen for
advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology
Group study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Novartis Inst Biomed Res, Cambridge, MA USA.
NRG Oncol, Buffalo, NY USA.
GOG Fdn Inc SDMC, Buffalo, NY USA.
Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
Univ Hosp Stony Brook, New York, NY USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Abington Memor Hosp, Gladwyne, PA USA.
Univ Massachusetts Memor Hlth Care, Worcester, MA USA.
Mercer Univ, Sch Med, Savannah, GA USA.
Gynecol Oncol West Michigan, Grand Rapids, MI USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5592
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901259
ER
PT J
AU Neal, JW
Dahlberg, SE
Wakelee, HA
Aisner, SC
Bowden, M
Carbone, DP
Ramalingam, SS
AF Neal, Joel W.
Dahlberg, Suzanne Eleanor
Wakelee, Heather A.
Aisner, Seena C.
Bowden, Michaela
Carbone, David Paul
Ramalingam, Suresh S.
TI Cabozantinib (C), erlotinib (E) or the combination (E plus C) as
second-or third-line therapy in patients with EGFR wild-type (wt)
non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the
ECOG-ACRIN Cancer Research Group (E1512).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Rutgers New Jersey Med Sch, Newark, NJ USA.
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8003
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901716
ER
PT J
AU Nechuta, SJ
Caan, BJ
Chen, WY
Dwek, M
Gao, M
Flatt, S
Poole, E
Patterson, RE
Pierce, JP
Robertson, C
Swann, R
Zheng, W
Shu, XO
AF Nechuta, Sarah Jean
Caan, Bette J.
Chen, Wendy Y.
Dwek, Miriam
Gao, Min
Flatt, Shirley
Poole, Elizabeth
Patterson, Ruth E.
Pierce, John P.
Robertson, Claire
Swann, Ruth
Zheng, Wei
Shu, Xiao-Ou
TI Post-diagnosis BMI and physical activity in association with
triple-negative breast cancer prognosis: Results from 5 prospective
cohorts
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Univ Sch Med, Nashville, TN USA.
Kaiser Permanente No Calif, Oakland, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Westminster, London W1R 8AL, England.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1507
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900374
ER
PT J
AU Ng, K
Venook, AP
Sato, K
Yuan, C
Hollis, BW
Niedzwiecki, D
Ye, C
Chang, IW
O'Neil, BH
Innocenti, F
Lenz, HJ
Blanke, CD
Mayer, RJ
Fuchs, CS
Meyerhardt, JA
AF Ng, Kimmie
Venook, Alan P.
Sato, Kaori
Yuan, Chen
Hollis, Bruce W.
Niedzwiecki, Donna
Ye, Cynthia
Chang, I-Wen
O'Neil, Bert H.
Innocenti, Federico
Lenz, Heinz-Josef
Blanke, Charles David
Mayer, Robert J.
Fuchs, Charles S.
Meyerhardt, Jeffrey A.
TI Vitamin D status and survival of metastatic colorectal cancer patients:
Results from CALGB/SWOG 80405 (Alliance).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Duke Univ, Cary, NC USA.
Duke Univ, Durham, NC USA.
Southeastern Med Oncol, Goldsboro, NC USA.
Indiana Univ, Hlth Univ Hosp, Indianapolis, IN 46204 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900723
ER
PT J
AU Nipp, RD
El-Jawahri, A
Pirl, WF
Fishbein, JN
Moran, S
McCarty, C
Eusebio, J
Gallagher, ER
Park, ER
Jackson, VA
Greer, JA
Temel, JS
AF Nipp, Ryan David
El-Jawahri, Areej
Pirl, William F.
Fishbein, Joel Nathan
Moran, Samantha
McCarty, Caitlin
Eusebio, Justin
Gallagher, Emily R.
Park, Elyse R.
Jackson, Vicki A.
Greer, Joseph A.
Temel, Jennifer S.
TI Quality of life and mood in patients with advanced cancer: Associations
with prognostic understanding and coping style
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Harvard Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Brookline, MA USA.
MGH Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9517
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902012
ER
PT J
AU Nipp, RD
Finkelstein, D
Powell, E
Vittorio, L
Birrer, N
Chabner, BA
Lee, H
Moy, B
AF Nipp, Ryan David
Finkelstein, Daniel
Powell, Elizabeth
Vittorio, Lisa
Birrer, Nicole
Chabner, Bruce Allan
Lee, Hang
Moy, Beverly
TI Financial burden of cancer clinical trials: Impact of an equity program
intervention
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Harvard Canc Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6501
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901416
ER
PT J
AU O'Neill, AF
Dearling, JLJ
Tupper, T
Modiste, R
Dai, GP
Quang-de Nguyen
Kung, AL
Packard, A
AF O'Neill, Allison Frances
Dearling, Jason L. J.
Tupper, Tanya
Modiste, Rebecca
Dai, Guangping
Quang-de Nguyen
Kung, Andrew L.
Packard, Alan
TI ImmunoPET compared with conventional imaging modalities for the
detection of Ewing sarcoma metastases in a preclinical model.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
Boston Childrens Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA USA.
Dana Farber Canc Inst, Lurie Family Imaging Ctr, Ctr Biomed Imaging Oncol, Boston, MA 02115 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10048
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900055
ER
PT J
AU O'Neill, VJ
Enderle, D
Wheler, JJ
Koestler, T
Berking, C
Skog, J
Noerholm, M
Flaherty, K
Janku, F
AF O'Neill, Vincent J.
Enderle, Daniel
Wheler, Jennifer J.
Koestler, Tina
Berking, Carola
Skog, Johan
Noerholm, Mikkel
Flaherty, Keith
Janku, Filip
TI Detection of low abundant somatic mutations in circulating exosomal RNA
and cfDNA with next-generation sequencing.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Exosome Diagnost, Cambridge, MA USA.
Exosome Diagnost, Munich, Germany.
Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
Univ Munich LMU, Dept Dermatol, Munich, Germany.
Exosome Diagnost, New York, NY USA.
Exosome Diagnost GmbH, Martinsried, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 11061
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900320
ER
PT J
AU O'Reilly, EM
Mahalingam, D
Roach, JM
Schultes, BC
Rosano, ME
Miller, PJ
Wolf, J
Flaherty, K
Ryan, DP
AF O'Reilly, Eileen Mary
Mahalingam, Devalingam
Roach, James M.
Schultes, Birgit Corinna
Rosano, Molly E.
Miller, Paul Justin
Wolf, Julie
Flaherty, Keith
Ryan, David P.
TI Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of
necuparanib combined with nab-paclitaxel and gemcitabine in patients
with metastatic pancreatic cancer: Phase 1 results
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, New York, NY 10021 USA.
Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
Momenta Pharmaceut, Cambridge, MA USA.
Momenta Pharmaceut Inc, Cambridge, MA USA.
Novella Clin, Boulder, CO USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4114
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900952
ER
PT J
AU Ohtsu, A
Yoshino, T
Wahba, MM
Benedetti, FM
Mayer, RJ
Van Cutsem, E
AF Ohtsu, Atsushi
Yoshino, Takayuki
Wahba, Mona M.
Benedetti, Fabio M.
Mayer, Robert J.
Van Cutsem, Eric
CA RECOURSE Study Grp
TI Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive
care in patients with metastatic colorectal cancer: Geographic subgroups
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
Taiho Oncol Inc, Princeton, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Leuven, Leuven, Belgium.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3564
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900783
ER
PT J
AU Oliveira, M
Saura, C
Gonzalez-Martin, A
Andersen, JC
Fisher, JG
Calvo, I
Ciruelos, E
Gil, M
De La Pena, L
Llobet-Canela, M
Choi, Y
Jia, SD
Yalamanchili, S
Singel, SM
Patel, PH
Baselga, J
Isakoff, SJ
AF Oliveira, Mafalda
Saura, Cristina
Gonzalez-Martin, Antonio
Andersen, Jay C.
Fisher, Julie Gottlieb
Calvo, Isabel
Ciruelos, Eva
Gil, Miquel
De La Pena, Lorena
Llobet-Canela, Marta
Choi, YounJeong
Jia, Shidong
Yalamanchili, Sreenivasu
Singel, Stina Mui
Patel, Premal H.
Baselga, Jose
Isakoff, Steven J.
TI FAIRLANE: A phase II randomized, double-blind, study of the Akt
inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel
(Pac) as neoadjuvant treatment for early stage triple-negative breast
cancer (TNBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
Vall dHebron Univ Hosp, SOLTI, Barcelona, Spain.
GEICO, Madrid, Spain.
MD Anderson Canc Ctr Spain, Madrid, Spain.
Compass Onc, Portland, OR USA.
Levine Canc Inst, Charlotte, NC USA.
Ctr Integral Oncol Clara Campal, Madrid, Spain.
Hosp Univ 12 Octubre, Madrid, Spain.
Catalan Inst Oncol, Barcelona, Spain.
SOLTI, Breast Canc Res Grp, Barcelona, Spain.
Genentech Inc, San Francisco, CA 94080 USA.
Genentech Roche, San Francisco, CA USA.
Genentech Inc, Redwood City, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS1112
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904671
ER
PT J
AU Olszanski, AJ
Middleton, MR
Bahleda, R
Heist, RS
Rangachari, L
Zhou, XF
Bozon, V
Kneissl, M
Macarulla, T
AF Olszanski, Anthony J.
Middleton, Mark R.
Bahleda, Rastilav
Heist, Rebecca Suk
Rangachari, Lakshmi
Zhou, Xiaofei
Bozon, Viviana
Kneissl, Michelle
Macarulla, Teresa
TI A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480
plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A
kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts)
with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Oxford Univ Hosp NHS Trust, Oxford, England.
Univ Paris Sud, Gustave Roussy, Villejuif, France.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2609
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904687
ER
PT J
AU Olszewski, AJ
Fallah, J
Castillo, JJ
AF Olszewski, Adam J.
Fallah, Jaleh
Castillo, Jorge J.
TI Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in
the United States (US): Analysis of the National Cancer Data Base (NCDB)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
Mem Hosp Rhode Isl, Providence, RI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1521
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900388
ER
PT J
AU Ott, PA
Callahan, MK
Odunsi, K
Park, AJ
Pan, LS
Venhaus, RR
Karakunnel, JJ
Hodi, FS
Wolchok, JD
AF Ott, Patrick Alexander
Callahan, Margaret K.
Odunsi, Kunle
Park, Andrew J.
Pan, Linda S.
Venhaus, Ralph Rudolph
Karakunnel, Joyson Joseph
Hodi, F. Stephen
Wolchok, Jedd D.
TI A phase I study to evaluate the safety and tolerability of MEDI4736, an
anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination
with tremelimumab in patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Ludwig Inst Canc Res, New York, NY USA.
Medimmune Inc, Gaithersburg, MD 20878 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS3099
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904715
ER
PT J
AU Ott, PA
Fernandez, MEE
Hiret, S
Kim, DW
Moss, RA
Winser, T
Yuan, S
Cheng, JD
Piperdi, B
Mehnert, JM
AF Ott, Patrick Alexander
Fernandez, Maria Elena Elez
Hiret, Sandrine
Kim, Dong-Wan
Moss, Rebecca Anne
Winser, Tammy
Yuan, Sammy
Cheng, Jonathan D.
Piperdi, Bilal
Mehnert, Janice M.
TI Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small
cell lung cancer (SCLC): Preliminary safety and efficacy results from
KEYNOTE-028.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Hosp Valle De Hebron, Barcelona, Spain.
ICO Rene Gauducheau, Nantes, France.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
Merck & Co Inc, Kenilworth, NJ USA.
NR 0
TC 4
Z9 4
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7502
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901632
ER
PT J
AU Oxnard, GR
Ramalingam, SS
Ahn, MJ
Kim, SW
Yu, HA
Saka, H
Horn, L
Goto, K
Ohe, Y
Cantarini, M
Frewer, P
Lahn, M
Yang, JCH
AF Oxnard, Geoffrey R.
Ramalingam, Suresh S.
Ahn, Myung-Ju
Kim, Sang-We
Yu, Helena Alexandra
Saka, Hideo
Horn, Leora
Goto, Koichi
Ohe, Yuichiro
Cantarini, Mireille
Frewer, Paul
Lahn, Michael
Yang, James Chih-Hsin
TI Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291
combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Nagoya Med Ctr, Nagoya, Aichi, Japan.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
AstraZeneca, Macclesfield, Cheshire, England.
Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan.
Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan.
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2509
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900542
ER
PT J
AU Oxnard, GR
Heng, JC
Root, EJ
Rainville, IR
Sable-Hunt, AL
Shane-Carson, KP
Carbone, DP
Wiesner, GL
Garber, JE
AF Oxnard, Geoffrey R.
Heng, Jennifer C.
Root, Elizabeth J.
Rainville, Irene R.
Sable-Hunt, Alicia L.
Shane-Carson, Kate P.
Carbone, David Paul
Wiesner, Georgia L.
Garber, Judy Ellen
TI Initial results of a prospective, multicenter trial to study inherited
lung cancer risk associated with germline EGFR T790M: INHERIT EGFR
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Addario Lung Canc Med Inst ALCMI, San Carlos, CA USA.
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1505
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900372
ER
PT J
AU Padron, E
Dezern, AE
Vaddi, K
Scherle, PA
Zhang, Q
Ma, Y
Balasis, M
Tinsley, S
Ramadan, H
Zimmerman, C
Steensma, DP
Roboz, GJ
Lancet, JE
List, AF
Sekeres, MA
Komrokji, RS
AF Padron, Eric
Dezern, Amy Elizabeth
Vaddi, Kris
Scherle, Peggy A.
Zhang, Qing
Ma, Yan
Balasis, Maria
Tinsley, Sara
Ramadan, Hanadi
Zimmerman, Casandra
Steensma, David P.
Roboz, Gail J.
Lancet, Jeffrey E.
List, Alan F.
Sekeres, Mikkael A.
Komrokji, Rami S.
TI A multi-institution phase I trial of ruxolitinib in chronic
myelomonocytic leukemia (CMML)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Incyte Corp, Wilmington, DE USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
New York Presbyterian Hosp, New York, NY USA.
Cleveland Clin, Dept Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7021
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901557
ER
PT J
AU Paes, FR
Luis, IMVD
Costa, RB
Metzger, O
Hughes, ME
Losk, K
Camuso, K
Bunnell, CA
Golshan, M
Winer, EP
Lin, NU
AF Paes, Flavia Rocha
Luis, Ines Maria Vaz Duarte
Costa, Rafael Brant
Metzger Filho, Otto
Hughes, Melissa E.
Losk, Katya
Camuso, Kristen
Bunnell, Craig Alan
Golshan, Mehra
Winer, Eric P.
Lin, Nancy U.
TI Variation in the use of granulocyte-colony stimulating factor (G-CSF)
for dose dense paclitaxel: A single institution retrospective study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oncoclin Brasil, Belo Horizonte, MG, Brazil.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 561
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901273
ER
PT J
AU Pal, SK
Ali, SM
Chalmers, Z
Karam, JA
Elvin, JA
Chmielecki, J
Yelensky, R
Van Allen, EM
Lipson, D
Wang, K
Fay, AP
Miller, VA
Stephens, P
Ross, JS
Choueiri, TK
AF Pal, Sumanta Kumar
Ali, Siraj Mahamed
Chalmers, Zachary
Karam, Jose A.
Elvin, Julia Andrea
Chmielecki, Juliann
Yelensky, Roman
Van Allen, Eliezer Mendel
Lipson, Doron
Wang, Kai
Fay, Andre Poisl
Miller, Vincent A.
Stephens, Phil
Ross, Jeffrey S.
Choueiri, Toni K.
TI Comprehensive genomic profiling of 443 patients with advanced renal cell
carcinoma (RCC) to reveal clinically relevant genomic alterations and to
aid in classification of rare subtypes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 City Hope Natl Med Ctr, Duarte, CA USA.
Fdn Med Inc, Cambridge, MA USA.
Fdn Med Inc, Boston, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4520
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900988
ER
PT J
AU Palmbos, PL
Feng, FYC
Tomlins, SA
Kelly, WK
Morgans, AK
Taplin, ME
Agarwal, N
Antonarakis, ES
Twardowski, P
Jacobson, J
Davenport, MS
Daignault, S
Knudsen, KE
Hussain, M
AF Palmbos, Phillip Lee
Feng, Felix Yi-Chung
Tomlins, Scott A.
Kelly, William Kevin
Morgans, Alicia Katherine
Taplin, Mary-Ellen
Agarwal, Neeraj
Antonarakis, Emmanuel S.
Twardowski, Przemyslaw
Jacobson, Jon
Davenport, Matthew S.
Daignault, Stephanie
Knudsen, Karen E.
Hussain, Maha
TI A randomized phase II study of androgen deprivation therapy with or
without PD0332991 in RB-positive metastatic hormone-sensitive prostate
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Michigain Hlth Syst, Ypsilanti, MI USA.
Univ Michigan Hlth Syst, Dept Radiat Oncol, Ann Arbor, MI USA.
Univ Michigan Hlth Syst, Dept Pathol, Ann Arbor, MI USA.
Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5074
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904783
ER
PT J
AU Papadimitrakopoulou, V
Patnaik, A
Borghaei, H
Stevenson, J
Gandhi, L
Gubens, MA
Yang, JCH
Sequist, LV
Ge, JY
Bourque, J
Bachman, RD
Im, E
Gadgeel, SM
AF Papadimitrakopoulou, Vassiliki
Patnaik, Amita
Borghaei, Hossein
Stevenson, James
Gandhi, Leena
Gubens, Matthew A.
Yang, James Chih-Hsin
Sequist, Lecia V.
Ge, Joy Yang
Bourque, Jennifer
Bachman, Robert D.
Im, Ellie
Gadgeel, Shirish M.
TI Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC)
as front-line therapy for advanced non-small cell lung cancer (NSCLC):
KEYNOTE-021 Cohorts A and C.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
START, San Antonio, TX USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Cleveland Clin Fdn, Cleveland, OH 44195 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
UC San Francisco, San Francisco, CA USA.
Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan.
Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
NR 0
TC 21
Z9 23
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8031
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901744
ER
PT J
AU Parton, M
Bardia, A
Kummel, S
Estevez, LG
Huang, CS
Castan, JC
Borrego, MR
Telli, ML
Lluch, A
Lopez, R
Beck, JT
Ismail-Khan, R
Chen, SC
Hurvitz, SA
Mayer, IA
Atienza, RS
Cameron, S
Krygowski, M
Kim, SB
AF Parton, Marina
Bardia, Aditya
Kummel, Sherko
Estevez, Laura G.
Huang, Chiun-Sheng
Castan, Javier Cortes
Borrego, Manuel Ruiz
Telli, Melinda L.
Lluch, Ana
Lopez, Rafael
Beck, J. Thaddeus
Ismail-Khan, Roohi
Chen, Shin-Cheh
Hurvitz, Sara A.
Mayer, Ingrid A.
Atienza, Rolando S.
Cameron, Scott
Krygowski, Mizue
Kim, Sung-Bae
TI A phase II, open-label, neoadjuvant, randomized study of LCL161 with
paclitaxel in patients with triple-negative breast cancer (TNBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Royal Marsden Hosp, London SW3 6JJ, England.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Kliniken Essen Mitte KEM, Essen, Germany.
Comprehens Canc Ctr Clara Campal CIOCC, Madrid, Spain.
Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Taipei 10764, Taiwan.
Vall dHebron Inst Oncol VHIO, Barcelona, Spain.
Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Hosp Clin Univ Valencia, Valencia, Spain.
Hosp Clin Univ Santiago de Compostela, Santiago De Compostela, Spain.
Highlands Oncol Grp, Fayetteville, AR USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Chang Gung Mem Hosp, Taipei 10591, Taiwan.
UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Inst BioMed Res, Cambridge, MA USA.
Univ Ulsan, Coll Med, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1014
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900095
ER
PT J
AU Partridge, AH
Ruddy, KJ
Barry, WT
Greaney, M
Ligibel, JA
Sprunck-Harrild, K
Rosenberg, SM
Baker, E
Hoverman, JR
Emmons, K
AF Partridge, Ann H.
Ruddy, Kathryn Jean
Barry, William Thomas
Greaney, Mary
Ligibel, Jennifer A.
Sprunck-Harrild, Kim
Rosenberg, Shoshana M.
Baker, Emily
Hoverman, J. Russell
Emmons, Karen
TI Young and strong: A randomized study to improve care for young women
with breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Univ Rhode Isl, Kingston, RI 02881 USA.
Texas Onc PA, Dallas, TX USA.
Kaiser, Oakland, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9588
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902083
ER
PT J
AU Patel, MR
Bauer, TM
Liu, SV
Drilon, AE
Wheler, JJ
Shaw, AT
Farago, AF
Ou, SHI
Luo, D
Yeh, L
Hornby, Z
Senderowicz, AM
Lim, J
AF Patel, Manish R.
Bauer, Todd Michael
Liu, Stephen V.
Drilon, Alexander E.
Wheler, Jennifer J.
Shaw, Alice Tsang
Farago, Anna F.
Ou, Sai-Hong Ignatius
Luo, David
Yeh, Litain
Hornby, Zachary
Senderowicz, Adrian Mario
Lim, Jonathan
TI STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and
ALK inhibitor, in patients with advanced solid tumors with relevant
molecular alterations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Georgetown Univ Hosp, Washington, DC 20007 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
UC Irvine Med Ctr, Chao Family Comp Canc Ctr, Orange, CA USA.
Ignyta Inc, San Diego, CA USA.
Ignyta, San Diego, CO USA.
IGNYTA Inc, Somerville, MA USA.
NR 0
TC 8
Z9 8
U1 4
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2596
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900629
ER
PT J
AU Patnaik, A
Socinski, MA
Gubens, MA
Gandhi, L
Stevenson, J
Bachman, RD
Bourque, J
Ge, JY
Im, E
Gadgeel, SM
AF Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
TI Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI)
as second-line therapy for advanced non-small cell lung cancer (NSCLC):
KEYNOTE-021 cohort D.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 START, San Antonio, TX USA.
Univ Pittsburgh, Pittsburgh, PA USA.
UC San Francisco, San Francisco, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cleveland Clin Fdn, Cleveland, OH 44195 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
NR 0
TC 1
Z9 1
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8011
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901724
ER
PT J
AU Penson, RT
Berlin, ST
Konstantinopoulos, P
Krasner, CN
Matulonis, U
Ambrosio, A
Suzin, D
Collins, SA
Birrer, MJ
Cohen, YC
AF Penson, Richard T.
Berlin, Suzanne T.
Konstantinopoulos, Panagiotis
Krasner, Carolyn N.
Matulonis, Ursula
Ambrosio, Allison
Suzin, Daphne
Collins, Siobhan A.
Birrer, Michael J.
Cohen, Yael Chava
TI A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in
recurrent platinum-resistant Mullerian cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Braintree, MA USA.
Harvard Univ, Sch Med, Braintree, MA USA.
Dana Farber Canc Inst, York, ME USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA.
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5542
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901204
ER
PT J
AU Petrylak, DP
Powles, T
Bellmunt, J
Braiteh, FS
Loriot, Y
Zambrano, CC
Burris, HA
Kim, JW
Teng, SLM
Bruey, JM
Hegde, P
Abidoye, OO
Vogelzang, NJ
AF Petrylak, Daniel Peter
Powles, Thomas
Bellmunt, Joaquim
Braiteh, Fadi S.
Loriot, Yohann
Zambrano, Cristina Cruz
Burris, Howard A.
Kim, Joseph W.
Teng, Siew-Leng Melinda
Bruey, Jean-Marie
Hegde, Priti
Abidoye, Oyewale O.
Vogelzang, Nicholas J.
TI A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival
data in urothelial bladder cancer (UBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Canc Ctr, New Haven, CT USA.
Barts Hlth, Barts Canc Inst, London, England.
Royal Free NHS Trust, London, England.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Nevada, Sch Med, Comprehens Canc Ctr Nevada, Las Vegas, NV 89154 USA.
Gustave Roussy, Dept Canc Med, Grand Paris, Villejuif, France.
Univ Hosp Vall dHebron, Barcelona, Spain.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Yale Univ, Med Ctr, Yale Canc Ctr, New Haven, CT USA.
Genentech Inc, San Francisco, CA 94080 USA.
Genentech Inc, San Francisco, CA 94080 USA.
Genentech Inc, San Francisco, CA USA.
US Oncol Network, Carolina Urol Res Ctr, Myrtle Beach, SC USA.
NR 0
TC 15
Z9 15
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4501
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900969
ER
PT J
AU Pili, R
Manola, J
Carducci, MA
Dutcher, JP
Appleman, LJ
Groteluschen, DL
DiPaola, RS
AF Pili, Roberto
Manola, Judith
Carducci, Michael Anthony
Dutcher, Janice P.
Appleman, Leonard Joseph
Groteluschen, David L.
DiPaola, Robert S.
TI Randomized phase II study of two different doses of AVE0005 (VEGF Trap,
aflibercept) in patients (pts) with metastatic renal cell carcinoma
(RCC): An ECOG-ACRIN study [E4805].
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Our Lady Mercy Canc Ctr, New York, NY USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Green Bay Onc, Green Bay, WI USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4549
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901020
ER
PT J
AU Piotrowska, Z
Costa, DB
Huberman, M
Oxnard, GR
Gainor, JF
Heist, RS
Muzikansky, A
Shaw, AT
Niederst, MJ
Fulton, L
Engelman, JA
Sequist, LV
AF Piotrowska, Zofia
Costa, Daniel Botelho
Huberman, Mark
Oxnard, Geoffrey R.
Gainor, Justin F.
Heist, Rebecca Suk
Muzikansky, Alona
Shaw, Alice Tsang
Niederst, Matthew J.
Fulton, Linnea
Engelman, Jeffrey A.
Sequist, Lecia V.
TI Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Charlestown, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8015
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901728
ER
PT J
AU Pirl, WF
Lerner, J
Eusebio, J
Traeger, L
Fields, L
El-Jawahri, A
Greer, JA
Temel, JS
AF Pirl, William F.
Lerner, Jennifer
Eusebio, Justin
Traeger, Lara
Fields, Lauren
El-Jawahri, Areej
Greer, Joseph A.
Temel, Jennifer S.
TI Association between oncologists' dispositional affect and depressive
symptoms in their patients with metastatic cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Brookline, MA USA.
Harvard Univ, Cambridge, MA 02138 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9559
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902054
ER
PT J
AU Planchard, D
Groen, HJM
Kim, TM
Rigas, JR
Souquet, PJ
Baik, CS
Barlesi, F
Mazieres, J
Quoix, EA
Curtis, CM
Mookerjee, B
Bartlett-Pandite, AN
Tucker, C
D'Amelio, A
Johnson, BE
AF Planchard, David
Groen, Harry J. M.
Kim, Tae Min
Rigas, James R.
Souquet, Pierre Jean
Baik, Christina S.
Barlesi, Fabrice
Mazieres, Julien
Quoix, Elisabeth A.
Curtis, C. Martin
Mookerjee, Bijoyesh
Bartlett-Pandite, Arundathy N.
Tucker, Christine
D'Amelio, Anthony
Johnson, Bruce E.
TI Interim results of a phase II study of the BRAF inhibitor (BRAFi)
dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in
patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell
lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Gustave Roussy, Villejuif, France.
Univ Groningen, Groningen, Netherlands.
Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 AV Groningen, Netherlands.
Seoul Natl Univ Hosp, Seoul, South Korea.
Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
Lyon Sud Hosp, Acute Resp Med & Thorac Oncol Dept, Pierre Benite, France.
Lyon Univ, Inst Canc, Lyon Univ Hosp, Pierre Benite, France.
Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France.
CHU Toulouse, Hop Larrey, Toulouse, France.
Hop Univ Strasbourg, Strasbourg, France.
GlaxoSmithKline, Res Triangle Pk, NC USA.
GlaxoSmithKline, Collegeville, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 11
Z9 14
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8006
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901719
ER
PT J
AU Plimack, ER
Bellmunt, J
Gupta, S
Berger, R
Montgomery, RB
Heath, K
Juco, J
Emancipator, K
Pathiraja, K
Lunceford, JK
Perini, RF
O'Donnell, PH
AF Plimack, Elizabeth R.
Bellmunt, Joaquim
Gupta, Shilpa
Berger, Raanan
Montgomery, Robert B.
Heath, Karl
Juco, Jonathan
Emancipator, Kenneth
Pathiraja, Kumudu
Lunceford, Jared K.
Perini, Rodolfo F.
O'Donnell, Peter H.
TI Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results
and biomarker analysis from KEYNOTE-012
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Genitourinary Clin Res, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL 33612 USA.
Chaim Sheba Med Ctr, Div Med Oncol, IL-52621 Tel Hashomer, Israel.
Univ Washington Oncol, Seattle, WA USA.
Merck & Co Inc, Kenilworth, NJ USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 38
Z9 38
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4502
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900970
ER
PT J
AU Poorvu, PD
Gelber, SI
Rosenberg, SM
Tamimi, RM
Ruddy, KJ
Bober, SL
Borges, VF
Come, SE
Schapira, L
Partridge, AH
AF Poorvu, Philip Daniel
Gelber, Shari I.
Rosenberg, Shoshana M.
Tamimi, Rulla M.
Ruddy, Kathryn Jean
Bober, Sharon L.
Borges, Virginia F.
Come, Steven E.
Schapira, Lidia
Partridge, Ann H.
TI Treatment-related amenorrhea among young women one year following
diagnosis of early-stage breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9523
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902018
ER
PT J
AU Powell, SF
Liu, SV
Sukari, A
Chung, CH
Bauml, J
Haddad, RI
Gause, CK
Niewood, M
Gammage, LL
Brown, H
Meister, A
Cheng, JD
Gitau, MM
AF Powell, Steven Francis
Liu, Stephen V.
Sukari, Ammar
Chung, Christine H.
Bauml, Joshua
Haddad, Robert I.
Gause, Christine K.
Niewood, Michelle
Gammage, Linda L.
Brown, Holly
Meister, Amy
Cheng, Jonathan D.
Gitau, Mark M.
TI KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients
(pts) with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) who have failed platinum and cetuximab.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sanford Hlth, Sioux Falls, SD USA.
Georgetown Univ, Washington, DC USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Johns Hopkins Univ, Baltimore, MD USA.
Univ Penn, Perelman Sch Med, Phialdelphia, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Incyte Corp, Wilmington, DE USA.
Sanford Roger Maris Canc Ctr, Fargo, ND USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS3094
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904710
ER
PT J
AU Quiles, CW
Gottsch, S
Thakrar, U
Fraile, B
Billett, A
AF Quiles, Chris Wong
Gottsch, Stephanie
Thakrar, Usha
Fraile, Belen
Billett, Amy
TI Relationship between health care charges and ambulatory central line
associated blood stream infections (CLABSI) in pediatric
hematology-oncology patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17793
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903726
ER
PT J
AU Trinh, QD
Abdollah, F
Sammon, JD
Nguyen, PL
Choueiri, TK
Preston, MA
Menon, M
Weissman, JS
Kibel, AS
AF Quoc-Dien Trinh
Abdollah, Firas
Sammon, Jesse D.
Paul Linh Nguyen
Choueiri, Toni K.
Preston, Mark A.
Menon, Mani
Weissman, Joel S.
Kibel, Adam Stuart
TI Prevalence of non-recommended screening for prostate cancer and breast
cancer in the United States.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Vattikuti Urol Inst, Detroit, MI USA.
Henry Ford Hosp, Detroit, MI 48202 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17528
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903501
ER
PT J
AU Rafii, S
Gourley, C
Ang, JE
Kumar, R
Geuna, E
Rye, T
Ashcroft, L
Powell, B
Shapira-Frommer, R
Friedlander, M
Chen, LM
Matulonis, U
Kaufman, B
De Greve, J
Oza, AM
Banerjee, SN
Gore, ME
Molife, LR
Kaye, SB
Yap, TA
AF Rafii, Saeed
Gourley, Charlie
Ang, Joo Ern
Kumar, Rajiv
Geuna, Elena
Rye, Tzyvia
Ashcroft, Linda
Powell, Bethan
Shapira-Frommer, Ronnie
Friedlander, Michael
Chen, Lee-may
Matulonis, Ursula
Kaufman, Bella
De Greve, Jacques
Oza, Amit M.
Banerjee, Susana N.
Gore, Martin Eric
Molife, L. Rhoda
Kaye, Stanley B.
Yap, Timothy Anthony
TI What clinical factors influence advanced BRCA1/2 mutant ovarian cancer
patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor
(PARPi) treatment?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Canc Res, Sutton, Surrey, England.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Royal Marsden Hosp, Sutton, Surrey, England.
Royal Marsden Hosp, London SW3 6JJ, England.
Inst Canc Res, Osasco, Italy.
Royal Marsden, Osasco, Italy.
Univ Edinburgh, Clin Trials Unit, Edinburgh, Midlothian, Scotland.
Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England.
UC San Francisco, San Francisco, CA USA.
Sheba Med Ctr, Ramat Gan, Israel.
Prince Wales Canc Ctr, Randwick, NSW, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Ramat Gan, Israel.
Oncol Ctr UZBrussel, Brussels, Belgium.
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
Royal Marsden Hosp NHS Trust, London, England.
Inst Canc Res, London SW3 6JB, England.
Royal Marsden NHS Fdn Trust, London, England.
RI De Greve, Jacques/J-4939-2012
OI De Greve, Jacques/0000-0002-2389-0742
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5546
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901208
ER
PT J
AU Raje, NS
Terpos, E
Durie, BG
Garcia-Sanz, R
Shimizu, K
Willenbacher, W
Zhu, L
Warner, DJ
Palumbo, A
AF Raje, Noopur S.
Terpos, Evangelos
Durie, Brian G.
Garcia-Sanz, Ramon
Shimizu, Kazuyuki
Willenbacher, Wolfgang
Zhu, Li
Warner, Douglas J.
Palumbo, Antonio
TI Denosumab compared with zoledronic acid for the treatment of bone
disease in adults with newly diagnosed multiple myeloma: An
international, randomized, double-blind trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Athens, Sch Med, Alexandra Gen Hosp, GR-11527 Athens, Greece.
Cedars Sinai Comp Canc Ctr, Los Angeles, CA USA.
Univ Hosp Salamanca, Salamanca, Spain.
Tokai Chuo Hosp, Nagoya, Aichi, Japan.
Med Univ Innsbruck, A-6020 Innsbruck, Austria.
Amgen Inc, Thousand Oaks, CA 91320 USA.
AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS8611
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904873
ER
PT J
AU Ramalingam, SS
Yang, JCH
Lee, CK
Kurata, T
Kim, DW
John, T
Nogami, N
Ohe, Y
Rukazenkov, Y
Frewer, P
Cantarini, M
Ghiorghiu, S
Janne, PA
AF Ramalingam, Suresh S.
Yang, James Chih-Hsin
Lee, Chee Khoon
Kurata, Takayasu
Kim, Dong-Wan
John, Thomas
Nogami, Naoyuki
Ohe, Yuichiro
Rukazenkov, Yuri
Frewer, Paul
Cantarini, Mireille
Ghiorghiu, Serban
Janne, Pasi A.
TI AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for
EGFR mutation-positive advanced non-small cell lung cancer (NSCLC):
Results from a phase 1 expansion cohort.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan.
Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan.
St George Hosp, Sydney, NSW, Australia.
Kansai Med Univ, Hirakata Hosp, Osaka, Japan.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia.
Natl Hosp Org, Shikoku Canc Ctr, Clin Res Inst, Matsuyama, Ehime, Japan.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
AstraZeneca, Macclesfield, Cheshire, England.
AstraZeneca, Cambridge, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 3
Z9 3
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8000
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901713
ER
PT J
AU Reardon, DA
Dietrich, J
Kaley, TJ
Gan, HK
Dunn, GP
Cloughesy, TF
Lim, M
Clarke, JL
Park, AJ
Pan, LS
Lai, DW
Karakunnel, JJ
Robbins, PB
Narwal, R
Venhaus, RR
AF Reardon, David A.
Dietrich, Jorg
Kaley, Thomas Joseph
Gan, Hui Kong
Dunn, Gavin P.
Cloughesy, Timothy Francis
Lim, Michael
Clarke, Jennifer Leigh
Park, Andrew J.
Pan, Linda S.
Lai, Dominic W.
Karakunnel, Joyson Joseph
Robbins, Paul B.
Narwal, Rajesh
Venhaus, Ralph Rudolph
TI Phase II study to evaluate the clinical efficacy and safety of MEDI4736
in patients with glioblastoma (GBM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Ctr Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Austin Hlth, Heidelberg, Vic, Australia.
Washington Univ, Sch Med, St Louis, MO USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
UC San Francisco, San Francisco, CA USA.
Ludwig Inst Canc Res, New York, NY USA.
MedImmune, Gaithersburg, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2077
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904674
ER
PT J
AU Reardon, DA
Schuster, J
Tran, DD
Fink, KL
Nabors, LB
Li, G
Bota, DA
Lukas, RV
Desjardins, A
Ashby, LS
Duic, JP
Mrugala, MM
Werner, A
Hawthorne, T
He, Y
Green, JA
Yellin, MJ
Turner, CD
Davis, TA
Sampson, JH
AF Reardon, David A.
Schuster, James
Tran, David Dinh
Fink, Karen L.
Nabors, Louis B.
Li, Gordon
Bota, Daniela Annenelie
Lukas, Rimas Vincas
Desjardins, Annick
Ashby, Lynn Stuart
Duic, J. Paul
Mrugala, Maciej M.
Werner, Andrea
Hawthorne, Thomas
He, Yi
Green, Jennifer A.
Yellin, Michael Jay
Turner, Christopher D.
Davis, Thomas A.
Sampson, John H.
CA ReACT Study Grp
TI ReACT: Overall survival from a randomized phase II study of rindopepimut
(CDX-110) plus bevacizumab in relapsed glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Washington Univ, St Louis, MO USA.
Baylor Res Inst, Dallas, TX USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
UC Irvine Med Ctr, Orange, CA USA.
Univ Chicago, Chicago, IL 60637 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Barrow Neurol Inst, Phoenix, AZ 85013 USA.
Neurol Surg PC, Long Isl Brain Tumor Ctr, Lake Success, NY USA.
Univ Washington, Seattle, WA 98195 USA.
Celldex Therapeut Inc, Hampton, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2009
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900468
ER
PT J
AU Redig, AJ
Taibi, M
Oxnard, GR
Boucher, D
Rabin, MS
Marcoux, JP
Gandhi, L
Huberman, M
Rangachari, D
Lucca, JV
Morse, LK
Andan, M
Johnson, BE
Costa, DB
Janne, PA
Jackman, DM
AF Redig, Amanda J.
Taibi, Myriam
Oxnard, Geoffrey R.
Boucher, David
Rabin, Michael S.
Marcoux, J. Paul
Gandhi, Leena
Huberman, Mark
Rangachari, Deepa
Lucca, Joan Vern
Morse, Linda K.
Andan, MaChristine
Johnson, Bruce E.
Costa, Daniel Botelho
Janne, Pasi A.
Jackman, David Michael
TI A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively
assess biopsy feasibility and acquired resistance at disease
progression.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Sudbury, MA USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Israel Deaconess Medcl Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8076
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901788
ER
PT J
AU Redig, AJ
Mach, SL
Capelletti, M
Fontes, C
Shi, YL
Chalasani, P
Dahlberg, SE
Janne, PA
AF Redig, Amanda J.
Mach, Stacy L.
Capelletti, Marzia
Fontes, Caitlin
Shi, Yunling
Chalasani, Poornima
Dahlberg, Suzanne Eleanor
Janne, Pasi A.
TI Clinical and molecular characteristics of NF1 mutant lung cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Redig, Amanda J.; Mach, Stacy L.; Capelletti, Marzia; Fontes, Caitlin; Shi, Yunling; Chalasani, Poornima; Dahlberg, Suzanne Eleanor; Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8022
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901735
ER
PT J
AU Rettig, EM
Wentz, A
Posner, MR
Gross, ND
Haddad, RI
Gillison, ML
Quon, H
Sikora, AG
Stott, W
Lorch, JH
Gourin, CG
Miles, B
Richmon, J
Misiukiewicz, K
Chung, CH
Fakhry, C
D'Souza, G
AF Rettig, Eleni Marie
Wentz, Alicia
Posner, Marshall R.
Gross, Neil D.
Haddad, Robert I.
Gillison, Maura L.
Quon, Harry
Sikora, Andrew Gregory
Stott, Will
Lorch, Jochen H.
Gourin, Christine Gail
Miles, Brett
Richmon, Jeremy
Misiukiewicz, Krzysztof
Chung, Christine H.
Fakhry, Carole
D'Souza, Gypsyamber
TI Prognostic implication of persistent HPV16 DNA detection in oral rinses
for HPV-positive oropharyngeal carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA.
Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA.
Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Baylor Coll Med, Houston, TX 77030 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
Mt Sinai Med Ctr, Dept Otolaryngol, New York, NY 10029 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6005
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901317
ER
PT J
AU Ribas, A
Puzanov, I
Gajewski, T
Long, GV
Dummer, R
Kirkwood, JM
VanderWalde, A
Cebon, JS
McArthur, GA
Gause, CK
Chen, L
Kaufman, DR
Chou, J
Andtbacka, RHI
Hodi, FS
AF Ribas, Antoni
Puzanov, Igor
Gajewski, Thomas
Long, Georgina V.
Dummer, Reinhard
Kirkwood, John M.
VanderWalde, Ari
Cebon, Jonathan S.
McArthur, Grant A.
Gause, Christine K.
Chen, Lisa
Kaufman, David Ross
Chou, Jeffrey
Andtbacka, Robert Hans Ingemar
Hodi, F. Stephen
TI A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus
pembrolizumab vs pembrolizumab monotherapy in previously untreated,
unresected, stage IIIB-IV melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Chicago, Chicago, IL 60637 USA.
Melanoma Inst Australia, Sydney, NSW, Australia.
Univ Sydney, Sydney, NSW, Australia.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA.
Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
Merck & Co Inc, Kenilworth, NJ USA.
Amgen Inc, Thousand Oaks, CA 91320 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 2
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS9081
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904879
ER
PT J
AU Ribas, A
Butler, M
Lutzky, J
Lawrence, DP
Robert, C
Miller, W
Linette, GP
Ascierto, PA
Kuzel, T
Algazi, AP
Postow, MA
Nathan, PD
Curti, BD
Robbins, PB
Li, X
Blake-Haskins, JA
Gordon, MS
AF Ribas, Antoni
Butler, Marcus
Lutzky, Jose
Lawrence, Donald P.
Robert, Caroline
Miller, Wilson
Linette, Gerald P.
Ascierto, Paolo Antonio
Kuzel, Timothy
Algazi, Alain Patrick
Postow, Michael Andrew
Nathan, Paul D.
Curti, Brendan D.
Robbins, Paul B.
Li, Xia
Blake-Haskins, John A.
Gordon, Michael S.
TI Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib)
and/or MEK (trametinib) inhibitors in advanced melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Paris Sud, Villejuif, France.
McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
Washington Univ, St Louis, MO USA.
Ist Nazl Tumori Fdn Pascale, Naples, Italy.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
UCSF Med Ctr, San Francisco, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mt Vernon Hosp, Northwood, Middx, England.
Earle A Chiles Res Inst, Providence Canc Ctr, Portland, OR USA.
Medimmune Inc, Gaithersburg, MD 20878 USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
NR 0
TC 20
Z9 20
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3003
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900637
ER
PT J
AU Ribas, A
Robert, C
Hodi, FS
Wolchok, JD
Joshua, AM
Hwu, WJ
Weber, JS
Zarour, HM
Kefford, R
Loboda, A
Albright, A
Kang, SP
Ebbinghaus, S
Yearley, J
Murphy, E
Nebozhyn, M
Lunceford, JK
McClanahan, T
Ayers, M
Daud, A
AF Ribas, Antoni
Robert, Caroline
Hodi, F. Stephen
Wolchok, Jedd D.
Joshua, Anthony M.
Hwu, Wen-Jen
Weber, Jeffrey S.
Zarour, Hassane M.
Kefford, Richard
Loboda, Andrey
Albright, Andrew
Kang, Soonmo Peter
Ebbinghaus, Scot
Yearley, Jennifer
Murphy, Erin
Nebozhyn, Michael
Lunceford, Jared K.
McClanahan, Terri
Ayers, Mark
Daud, Adil
TI Association of response to programmed death receptor 1 (PD-1) blockade
with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene
signature.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Macquarie Univ, Sydney, NSW 2109, Australia.
Westmead Hosp, Sydney, NSW, Australia.
Merck & Co Inc, Kenilworth, NJ USA.
UC San Francisco, San Francisco, CA USA.
NR 0
TC 27
Z9 27
U1 2
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3001
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900635
ER
PT J
AU Richardson, PG
Bensmaine, A
Doerr, T
Wang, JM
Zaki, MH
AF Richardson, Paul G.
Bensmaine, Amine
Doerr, Thomas
Wang, Jianming
Zaki, Mohamed H.
CA MM-007 Study Investigators
TI MM-007: A phase 3 trial comparing the efficacy and safety of
pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX
[PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or
refractory multiple myeloma (RRMM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Celgene Corp, Summit, NJ USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS8610
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904872
ER
PT J
AU Rizvi, NA
Garon, EB
Leighl, N
Hellmann, MD
Patnaik, A
Gandhi, L
Eder, JP
Rangwala, RA
Lubiniecki, G
Zhang, J
Emancipator, K
Roach, CM
Rutledge, R
Hui, RN
Ahn, MJ
Horn, L
Felip, E
Costa, EC
AF Rizvi, Naiyer A.
Garon, Edward B.
Leighl, Natasha
Hellmann, Matthew David
Patnaik, Amita
Gandhi, Leena
Eder, Joseph Paul
Rangwala, Reshma A.
Lubiniecki, Gregory
Zhang, Jin
Emancipator, Kenneth
Roach, Charlotte M.
Rutledge, Ruth
Hui, Rina
Ahn, Myung-Ju
Horn, Leora
Felip, Enriqueta
Costa, Enric Carcereny
TI Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro;
MK-3475) as first-line therapy for PD-L1-positive metastatic non-small
cell lung cancer (NSCLC): Updated data from KEYNOTE-001.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Columbia Univ, Med Ctr, New York, NY USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
START, San Antonio, TX USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Canc Ctr, New Haven, CT USA.
Merck & Co Inc, Kenilworth, NJ USA.
Dako, Carpinteria, CA USA.
Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain.
RI Zhang, Jin/E-8298-2017
NR 0
TC 7
Z9 7
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8026
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901739
ER
PT J
AU Robert, C
Joshua, AM
Kefford, R
Joseph, RW
Wolchok, JD
Hodi, FS
Hamid, O
Weber, JS
Gangadhar, TC
Dronca, RS
Patnaik, A
Zarour, HM
Hwu, WJ
Hersey, P
Daud, A
Giannotti, M
Li, XN
Ebbinghaus, S
Kang, SP
Ribas, A
AF Robert, Caroline
Joshua, Anthony M.
Kefford, Richard
Joseph, Richard Wayne
Wolchok, Jedd D.
Hodi, F. Stephen
Hamid, Omid
Weber, Jeffrey S.
Gangadhar, Tara C.
Dronca, Roxana Stefania
Patnaik, Amita
Zarour, Hassane M.
Hwu, Wen-Jen
Hersey, Peter
Daud, Adil
Giannotti, Maxine
Li, Xiaoyun Nicole
Ebbinghaus, Scot
Kang, Soonmo Peter
Ribas, Antoni
TI Association of immune-related thyroid disorders with pembrolizumab
(pembro, MK-3475) in patients (pts) with advanced melanoma treated in
KEYNOTE-001.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Gustave Roussy, Villejuif, France.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Macquarie Univ, Sydney, NSW 2109, Australia.
Westmead Hosp, Sydney, NSW, Australia.
Mayo Clin, Jacksonville, FL 32224 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Mayo Clin, Rochester, MN USA.
START, San Antonio, TX USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Sydney, Sydney, NSW 2006, Australia.
UC San Francisco, San Francisco, CA USA.
Merck & Co Inc, Kenilworth, NJ USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9050
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901960
ER
PT J
AU Rosenberg, AR
Bradford, M
Bona, KO
Shaffer, M
Wolfe, J
Syrjala, K
Baker, KS
AF Rosenberg, Abby R.
Bradford, Miranda
Bona, Kira O'Neil
Shaffer, Michele
Wolfe, Joanne
Syrjala, Karen
Baker, Kevin Scott
TI Screening for self-efficacy and distress: A report from the "Resilience
in Adolescents and Young Adults with Cancer" study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
Seattle Childrens Hosp, Seattle, WA USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e21037
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904373
ER
PT J
AU Rosenberg, AR
Bradford, M
Bona, KO
Shaffer, M
Wolfe, J
Syrjala, K
Baker, KS
AF Rosenberg, Abby R.
Bradford, Miranda
Bona, Kira O'Neil
Shaffer, Michele
Wolfe, Joanne
Syrjala, Karen
Baker, Kevin Scott
TI Risky behaviors during cancer therapy: A report from the "Resilience in
Adolescents and Young adults with Cancer" study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
Seattle Childrens Hosp, Seattle, WA USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e21035
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904371
ER
PT J
AU Rosenberg, SM
Ruddy, KJ
Tamimi, RM
Gelber, SI
Schapira, L
Borges, VF
Come, SE
Meyer, ME
Winer, EP
Partridge, AH
AF Rosenberg, Shoshana M.
Ruddy, Kathryn Jean
Tamimi, Rulla M.
Gelber, Shari I.
Schapira, Lidia
Borges, Virginia F.
Come, Steven E.
Meyer, Meghan E.
Winer, Eric P.
Partridge, Ann H.
TI Ovarian function suppression, symptom burden, and quality of life in
young women with breast cancer: A prospective study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 515
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901122
ER
PT J
AU Rosenblat, TL
Jurcic, JG
Heaney, ML
Raza, A
Mears, JG
Santos, R
Carrillo, D
Gonzales, J
Harwood, K
Santos, M
Zhang, R
Ibanez, G
Hogdal, L
Crombie, JL
Djaballah, H
Scandura, JM
Letai, AG
Frattini, MG
AF Rosenblat, Todd Louis
Jurcic, Joseph G.
Heaney, Mark L.
Raza, Azra
Mears, J. Gregory
Santos, Ruth
Carrillo, Diana
Gonzales, Jacquelyn
Harwood, Katherine
Santos, Martin
Zhang, Rong
Ibanez, Glorymar
Hogdal, Leah
Crombie, Jennifer Leigh
Djaballah, Hakim
Scandura, Joseph M.
Letai, Anthony G.
Frattini, Mark G.
TI A phase I trial of a pharmacodynamically-conceived
decitabine/thioguanine combination in patients with advanced myeloid
malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Columbia Univ, Medcl Ctr, New York, NY USA.
Columbia Univ, Med Ctr, New York, NY USA.
Columbia Univ, New York, NY USA.
CUMC, New York, NY USA.
MSKCC, New York, NY USA.
DFCI, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Inst Pasteur Korea, Bundang, South Korea.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e18025
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903758
ER
PT J
AU Rubinstein, MMZ
Gray, RJ
Sparano, JA
Zujewski, J
Whelan, TJ
Albain, KS
Hayes, DF
Geyer, CE
Dees, EC
Perez, EA
Keane, MM
Vallejos, C
Goggins, TF
Mayer, IA
Brufsky, A
Toppmeyer, D
Kaklamani, VG
Atkins, JN
Berenberg, JL
Sledge, GW
AF Rubinstein, Maria M. Zlobinsky
Gray, Robert James
Sparano, Joseph A.
Zujewski, JoAnne
Whelan, Timothy Joseph
Albain, Kathy S.
Hayes, Daniel F.
Geyer, Charles E.
Dees, Elizabeth Claire
Perez, Edith A.
Keane, Maccon M.
Vallejos, Carlos
Goggins, Timothy F.
Mayer, Ingrid A.
Brufsky, Adam
Toppmeyer, Deborah
Kaklamani, Virginia G.
Atkins, James Norman
Berenberg, Jeffrey L.
Sledge, George W.
TI Recurrence score and clinicopathologic characteristics of TAILORx
participants by race and ethnicity.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Montefiore Med Ctr, Bronx, NY 10467 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NIH, Bethesda, MD 20892 USA.
Canc Care Ontario, Hamilton, ON, Canada.
SWOG, NRG Oncol NSABP, Maywood, IL USA.
Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA.
Univ N Carolina, Chapel Hill, NC USA.
Mayo Clin, Jacksonville, FL 32224 USA.
West Ireland Canc Ctr, Galway, Ireland.
Inst Nacl Enfermedades Neoplas, Lima, Peru.
Fox Valley Hem Onc, Appleton, WI USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
NRG Oncol NSABP, Pittsburgh, PA USA.
Magee Womens Hosp, Pittsburgh, PA USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA.
Southeastern Medcl Ctr, Goldsboro, NC USA.
Tripler Army Medcl Ctr, Honolulu, HI USA.
Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
RI Whelan, Timothy/D-3185-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 533
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901140
ER
PT J
AU Ruddy, KJ
Guo, H
Baker, E
Goldstein, M
Mullaney, EE
Shulman, LN
Partridge, AH
AF Ruddy, Kathryn Jean
Guo, Hao
Baker, Emily
Goldstein, Matthew
Mullaney, Erin E.
Shulman, Lawrence N.
Partridge, Ann H.
TI Coordinated follow-up Breast Cancer Survivorship Care Program study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Stanford Univ, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17727
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903674
ER
PT J
AU Ryan, CJ
Kheoh, T
Li, JH
Molina, A
De Porre, P
Carles, J
Efstathiou, E
Kantoff, PW
Mulders, PFA
Saad, F
Griffin, TW
Chi, KN
AF Ryan, Charles J.
Kheoh, Thian
Li, Jinhui
Molina, Arturo
De Porre, Peter
Carles, Joan
Efstathiou, Eleni
Kantoff, Philip W.
Mulders, Peter F. A.
Saad, Fred
Griffin, Thomas W.
Chi, Kim N.
TI Prognostic index model (PIM) for overall survival (OS) in metastatic
castration-resistant prostate cancer (mCRPC) patients (pts) without
prior chemotherapy treated with abiraterone acetate (AA).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Janssen Res & Dev, San Diego, CA USA.
Johnson & Johnson Med China, Shanghai, Peoples R China.
Janssen Res & Dev, Menlo Pk, CA USA.
Janssen Res & Dev, Beerse, Belgium.
Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
Univ Montreal, Montreal, PQ, Canada.
Janssen Res & Dev, Los Angeles, CA USA.
BC Canc Agcy, Vancouver, BC, Canada.
RI Mulders, Peter/H-8076-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5047
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901090
ER
PT J
AU Ryan, CJ
Crawford, ED
Shore, ND
Underwood, W
Londhe, A
Black, SC
McGowan, T
Kantoff, PW
AF Ryan, Charles J.
Crawford, E. David
Shore, Neal D.
Underwood, Willie
Londhe, Anil
Black, Shawn C.
McGowan, Tracy
Kantoff, Philip W.
TI IMAAGEN trial update: Effect of abiraterone acetate and low dose
prednisone on PSA and radiographic disease progression in patients with
non-metastatic castration-resistant prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Univ Colorado, Denver, CO 80202 USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Janssen Res & Dev, Horsham, PA USA.
Janssen Pharmaceut, Horsham, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5053
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901097
ER
PT J
AU Sabado, RL
Pavlick, AC
Gnjatic, S
Hasan, F
Spadaccia, M
Oner, BS
Dong, HQ
Holman, RM
Vengco, I
Muren, C
Escano, C
Yepes, E
Stein, C
Jungbluth, AA
Pan, LS
Venhaus, RR
Salazar, AM
Ott, PA
Bhardwaj, N
AF Sabado, Rachel Lubong
Pavlick, Anna C.
Gnjatic, Sacha
Hasan, Farah
Spadaccia, Meredith
Oner, Bike Su
Dong, Hanqing
Holman, Rose Marie
Vengco, Isabelita
Muren, Caroline
Escano, Crystal
Yepes, Ethel
Stein, Claire
Jungbluth, Achim A.
Pan, Linda S.
Venhaus, Ralph Rudolph
Salazar, Andres M.
Ott, Patrick Alexander
Bhardwaj, Nina
TI Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or
without Montanide ISA-51 VG in patients with melanoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NYU, Ctr Canc, New York, NY USA.
NYU, Sch Med, Inst Canc, New York, NY USA.
NYU, Inst Canc, New York, NY USA.
Ludwig Inst Canc Res, New York, NY USA.
Oncovir Inc, Washington, DC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e14034
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902623
ER
PT J
AU Sacher, AG
Sholl, LM
Mach, SL
Johnson, BE
Hammerman, PS
Janne, PA
Oxnard, GR
AF Sacher, Adrian G.
Sholl, Lynette M.
Mach, Stacy L.
Johnson, Bruce E.
Hammerman, Peter S.
Janne, Pasi A.
Oxnard, Geoffrey R.
TI Feasibility of next-generation sequencing (NGS) for squamous non-small
cell lung cancer (NSCLC): Implications for the NCI LungMAP study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Cambridge, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Newton Ctr, MA USA.
RI Sacher, Adrian/I-8080-2016
OI Sacher, Adrian/0000-0001-7865-2701
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8096
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901808
ER
PT J
AU Sacher, AG
Paweletz, C
Alden, R
O'Connell, A
Mach, SL
Janne, PA
Oxnard, GR
AF Sacher, Adrian G.
Paweletz, Cloud
Alden, Ryan
O'Connell, Allison
Mach, Stacy L.
Janne, Pasi A.
Oxnard, Geoffrey R.
TI A prospective validation of plasma ddPCR for rapid EGFR and KRAS
genotyping of advanced NSCLC patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Cambridge, MA USA.
Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Sacher, Adrian/I-8080-2016
OI Sacher, Adrian/0000-0001-7865-2701
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 11089
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900347
ER
PT J
AU Sagara, Y
Barry, WT
Mallory, MA
Wong, SM
Aydogan, F
DeSantis, S
Golshan, M
AF Sagara, Yasuaki
Barry, William Thomas
Mallory, Melissa Anne
Wong, Stephanie M.
Aydogan, Fatih
DeSantis, Stephen
Golshan, Mehra
TI The survival benefit offered by the surgical management of low-grade
ductal carcinoma in situ of the breast.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1006
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900068
ER
PT J
AU Saha, S
Berbiglia, L
Shaik, M
Gernand, J
Saha, SK
Hicks, M
Arora, ML
Wiese, D
AF Saha, Sukamal
Berbiglia, Lindsay
Shaik, Mohammed
Gernand, Jill
Saha, Supriya Kumar
Hicks, Michael
Arora, Madan L.
Wiese, David
TI Biological difference of right versus left colon cancer: An analysis of
the National Cancer Data Base and Surveillance, Epidemiology and End
Results.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Michigan State Univ, McLaren Reg Med Ctr, Flint, MI USA.
McLaren Reg Med Ctr, Flint, MI USA.
Michigan State Univ, E Lansing, MI 48824 USA.
Massachusetts Gen Hosp, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e14624
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902721
ER
PT J
AU Sampson, JH
Vlahovic, G
Sahebjam, S
Omuro, AMP
Baehring, JM
Hafler, DA
Voloschin, AD
Paliwal, P
Grosso, J
Coric, V
Cloughesy, TF
Lim, M
Reardon, DA
AF Sampson, John H.
Vlahovic, Gordana
Sahebjam, Solmaz
Omuro, Antonio Marcilio Padula
Baehring, Joachim M.
Hafler, David A.
Voloschin, Alfredo Daniel
Paliwal, Prashni
Grosso, Joseph
Coric, Vlad
Cloughesy, Timothy F.
Lim, Michael
Reardon, David A.
TI Preliminary safety and activity of nivolumab and its combination with
ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Med Ctr, Durham, NC USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Yale Univ, Sch Med, New Haven, CT USA.
Emory Univ, Sch Med, Atlanta, GA USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 2
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3010
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900644
ER
PT J
AU San Miguel, JF
Hungria, VTM
Yoon, SS
Beksac, M
Dimopoulos, MA
Elghandour, A
Jedrzejczak, WW
Guenther, A
Nakorn, TN
Siritanaratkul, N
Schlossman, RL
Hou, J
Moreau, P
Lonial, S
Lee, JH
Einsele, H
Sopala, M
Bengoudifa, BR
Corrado, C
Richardson, PG
AF San Miguel, Jesus F.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
Richardson, Paul G.
TI Panobinostat plus bortezomib and dexamethasone in patients with relapsed
or relapsed and refractory multiple myeloma who received prior
bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Navarra Clin, Pamplona, Spain.
Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Ankara Univ, TR-06100 Ankara, Turkey.
Hellen Cooperat Oncol Grp HeCOG, Athens, Greece.
Univ Alexandria, Alexandria, Egypt.
Med Univ Warsaw, Warsaw, Poland.
Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany.
Chulalongkorn Univ, Bangkok, Timor Leste, Thailand.
Siriraj Hosp, Bangkok, Thailand.
Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
Chang Zheng Hosp, Shanghai, Peoples R China.
CHU Nantes, Hotel Dieu HME, F-44035 Nantes 01, France.
Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
Gachon Univ, Inchon, South Korea.
Univ Hosp Wuerzburg, Wurzburg, Germany.
Novartis Pharma AG, Basel, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI richard, chrystelle/K-8595-2015
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8526
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901838
ER
PT J
AU Sarantopoulos, J
Mita, AC
He, AR
Wade, JL
Hsueh, CT
Morris, JC
Lockhart, AC
Quinn, D
Hwang, JJ
Mier, JW
Zhang, WP
Wack, C
Yin, J
Clot, PF
Rixe, O
AF Sarantopoulos, John
Mita, Alain C.
He, Aiwu Ruth
Wade, James Lloyd
Hsueh, Chung-Tsen
Morris, John Charles
Lockhart, Albert C.
Quinn, David
Hwang, Jimmy J.
Mier, James Walter
Zhang, Wenping
Wack, Claudine
Yin, Jian
Clot, Pierre-Francois
Rixe, Olivier
TI Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts)
with hepatic impairment (HI).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, Washington, DC USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Innovat Ctr Biomed Informat, Washington, DC USA.
Canc Care Ctr Decatur, Decatur, IL USA.
Loma Linda Univ, Div Med Oncol Hematol, Loma Linda, CA 92350 USA.
Univ Cincinnati, Dept Med, Inst Canc, Div Hematol Oncol, Cincinnati, OH USA.
Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA.
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Dept Med, Boston, MA 02215 USA.
Sanofi Rech, Bridgewater, NJ USA.
Sanofi Rech, Chilly Mazarin, France.
Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2538
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900571
ER
PT J
AU Sartor, AO
Fernandez, DC
Morris, MJ
Iagaru, A
Brown, A
Almeida, F
Sweeney, C
Smith, MR
Dicker, A
Wong, YN
Shore, ND
Gratt, J
Petrenciuc, O
Germino, J
Vogelzang, NJ
AF Sartor, A. Oliver
Fernandez, Daniel Celestino
Morris, Michael J.
Iagaru, Andrei
Brown, Alan
Almeida, Fabio
Sweeney, Christopher
Smith, Matthew Raymond
Dicker, Adam
Wong, Yu-Ning
Shore, Neal D.
Gratt, Jeremy
Petrenciuc, Oana
Germino, Joseph
Vogelzang, Nicholas J.
TI Ra-223 experience in pretreated patients: EAP setting.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tulane Canc Ctr, New Orleans, LA USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Stanford Univ, Stanford, CA 94305 USA.
21st Century Oncol, Ft Myers, FL USA.
Arizona Mol Imaging Ctr, Phoenix, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Bayer HealthCare, Whippany, NJ USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5063
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901108
ER
PT J
AU Scher, HI
Morris, MJ
Stadler, WM
Higano, CS
Halabi, S
Smith, MR
Basch, EM
Fizazi, K
Ryan, CJ
Antonarakis, ES
Corn, PG
Liu, G
De Bono, JS
Schwartz, LH
Beer, TM
Kelly, WK
Hussain, M
Sartor, AO
Kantoff, PW
Armstrong, AJ
AF Scher, Howard I.
Morris, Michael J.
Stadler, Walter Michael
Higano, Celestia S.
Halabi, Susan
Smith, Matthew Raymond
Basch, Ethan M.
Fizazi, Karim
Ryan, Charles J.
Antonarakis, Emmanuel S.
Corn, Paul Gettys
Liu, Glenn
De Bono, Johann Sebastian
Schwartz, Lawrence H.
Beer, Tomasz M.
Kelly, William Kevin
Hussain, Maha
Sartor, A. Oliver
Kantoff, Philip W.
Armstrong, Andrew J.
TI The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in
castration-resistant prostate cancer (CRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
Duke Univ Med Ctr, Durham, NC USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Wisconsin Carbone Canc Ctr, Madison, WI USA.
Inst Canc Res, Sutton, Surrey, England.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
Columbia Univ Med Ctr, New York Presbyterian Hosp, New York, NY USA.
Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA.
Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Univ Michigan Comprehens Canc Ctr, Ann Arbor, MI USA.
Tulane Canc Ctr, New Orleans, LA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Duke Univ, Duke Canc Inst, Durham, NC USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5000
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901042
ER
PT J
AU Schlumberger, M
Elisei, R
Muller, S
Schoffski, P
Brose, MS
Shah, MH
Licitra, LF
Jarzab, B
Medvedev, V
Kreissl, M
Cohen, EEW
Wirth, LJ
Ali, HY
Hessel, C
Yaron, Y
Ball, DW
Nelkin, B
Sherman, SI
AF Schlumberger, Martin
Elisei, Rossella
Mueller, Stefan
Schoeffski, Patrick
Brose, Marcia S.
Shah, Manisha H.
Licitra, Lisa F.
Jarzab, Barbara
Medvedev, Viktor
Kreissl, Michael
Cohen, Ezra E. W.
Wirth, Lori J.
Ali, Haythem Y.
Hessel, Colin
Yaron, Yifah
Ball, Douglas Wilmot
Nelkin, Barry
Sherman, Steven I.
TI Final overall survival analysis of EXAM, an international, double-blind,
randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in
medullary thyroid carcinoma (MTC) patients with documented RECIST
progression at baseline.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Gustave Roussy, Villejuif, France.
Univ Pisa, Dept Endocrinol, Pisa, Italy.
Univ Klinikum Essen, Essen, Germany.
Univ Hosp Leuven, Leuven, Belgium.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland.
Inst Oncol, Gliwice, Poland.
Med Radiol Res Ctr, Obninsk, Russia.
Klinikum Augsburg, Augsburg, Germany.
Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Exelixis Inc, San Francisco, CA USA.
Johns Hopkins Univ, Baltimore, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 2
Z9 2
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6012
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901324
ER
PT J
AU Schoffski, P
Maki, RG
Italiano, A
Gelderblom, H
Grignani, G
De Camargo, VP
Bauer, S
Rha, SY
Chawla, SP
Blay, JY
Hohenberger, P
D'Adamo, DR
Wang, B
Chmielowski, B
Le Cesne, A
Demetri, GD
Patel, S
AF Schoeffski, Patrick
Maki, Robert G.
Italiano, Antoine
Gelderblom, Hans
Grignani, Giovanni
De Camargo, Veridiana Pires
Bauer, Sebastian
Rha, Sun Young
Chawla, Sant P.
Blay, Jean-Yves
Hohenberger, Peter
D'Adamo, David R.
Wang, Benjamin
Chmielowski, Bartosz
Le Cesne, Axel
Demetri, George D.
Patel, Shreyaskumar
TI Randomized, open-label, multicenter, phase III study of eribulin versus
dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic
sarcoma (ADI).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hosp Leuven, Leuven, Belgium.
Mt Sinai Med Ctr, New York, NY 10029 USA.
CLCC Inst Bergonie, Bordeaux, France.
Leiden Univ, Med Ctr, Leiden, Netherlands.
Fdn Piemonte Oncol IRCC, Candiolo, Italy.
Hosp Sirio Libanes, Sao Paulo, Brazil.
West German Canc Ctr, Essen, Germany.
Severance Hosp, Seoul, South Korea.
Sarcoma Oncol Ctr, Santa Monica, CA USA.
Univ Lyon 1, F-69365 Lyon, France.
Ctr Leon Berard, F-69373 Lyon, France.
Univ Mannheim, Med Ctr, D-68131 Mannheim, Germany.
Eisai Inc, Woodcliff Lake, NJ USA.
Eisai, Woodcliff Lake, NJ USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
Inst Gustave Roussy, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA LBA7005
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904641
ER
PT J
AU Schrag, D
Dueck, AC
Naughton, MJ
Niedzwiecki, D
Earle, C
Shaw, JE
Grothey, A
Hochster, HS
Blanke, CD
Venook, AP
AF Schrag, Deborah
Dueck, Amylou C.
Naughton, Michelle Joy
Niedzwiecki, Donna
Earle, Craig
Shaw, James Edward
Grothey, Axel
Hochster, Howard S.
Blanke, Charles David
Venook, Alan P.
TI Cost of chemotherapy for metastatic colorectal cancer with either
bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Alliance Stat & Data Ctr, Scottsdale, AZ USA.
Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
Duke Univ, Cary, NC USA.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
Medstar Washington Hosp Ctr, Washington, DC USA.
Mayo Clin, Rochester, MN USA.
Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6504
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901419
ER
PT J
AU Schwartz, GK
Adkins, D
Heist, RS
Abbott, M
Barber, SL
Chao, RC
Neuteboom, STC
Chen, I
Christensen, J
Bauer, TM
AF Schwartz, Gary K.
Adkins, Douglas
Heist, Rebecca Suk
Abbott, Maura
Barber, Stephanie L.
Chao, Richard C.
Neuteboom, Saskia T. C.
Chen, Isan
Christensen, James
Bauer, Todd Michael
TI A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK)
inhibitor, MGCD516, in patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Columbia Univ, Med Ctr, New York, NY USA.
Washington Univ, Sch Med, St Louis, MO USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Mirati Therapeut Inc, San Diego, CA USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2621
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904699
ER
PT J
AU Sequist, LV
Goldman, JW
Wakelee, HA
Camidge, DR
Yu, HA
Varga, A
Solomon, B
Oxnard, GR
Ou, SHI
Papadimitrakopoulou, V
Chao, BH
Liu, SV
Reckamp, KL
Spira, AI
Piotrowska, Z
Despain, D
Karlovich, CA
Yurasov, S
Soria, JC
AF Sequist, Lecia V.
Goldman, Jonathan Wade
Wakelee, Heather A.
Camidge, D. Ross
Yu, Helena Alexandra
Varga, Andrea
Solomon, Ben
Oxnard, Geoffrey R.
Ou, Sai-Hong Ignatius
Papadimitrakopoulou, Vassiliki
Chao, Bo H.
Liu, Stephen V.
Reckamp, Karen L.
Spira, Alexander I.
Piotrowska, Zofia
Despain, Darrin
Karlovich, Chris Alan
Yurasov, Sergey
Soria, Jean-Charles
TI Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive
non-small cell lung cancer (NSCLC) patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif Los Angeles, Santa Monica, CA USA.
Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Inst Gustave Roussy, Villejuif, France.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
UC Irvine Med Ctr, Chao Family Comp Canc Ctr, Orange, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Georgetown Univ Hosp, Washington, DC 20007 USA.
City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA.
US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Clovis Oncol Inc, San Francisco, CA USA.
Clovis Onc, San Francisco, CA USA.
Drug Dev Dept, Villejuif, France.
NR 0
TC 13
Z9 13
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8001
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901714
ER
PT J
AU Shapiro, G
Mier, JW
Hilton, JF
Gandhi, L
Chau, NG
Bullock, AJ
Supko, JG
Verselis, SJ
Murgo, K
Sze, C
Gotthardt, S
Wolanski, A
Alexander, WJ
Kumar, A
Holden, SA
Chafai-Fadela, K
Ram, S
Menon, KE
AF Shapiro, Geoffrey
Mier, James Walter
Hilton, John Frederick
Gandhi, Leena
Chau, Nicole G.
Bullock, Andrea J.
Supko, Jeffrey G.
Verselis, Sigitas Jonas
Murgo, Kayla
Sze, Cameron
Gotthardt, Susan
Wolanski, Andrew
Alexander, W. James
Kumar, Ashok
Holden, Sylvia Adell
Chafai-Fadela, Karima
Ram, Siya
Menon, Krishna E.
TI A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic
study of thioureidobutyronitrile, a novel p53 targeted therapy, in
patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Dept Med, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Cellceutix Corp, Beverly, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2613
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904691
ER
PT J
AU Shapiro, G
LoRusso, P
Vaishampayan, UN
Kittaneh, M
Hilton, JF
Cleary, JM
Velastegui, K
Xuan, DW
Hua, S
Shazer, RL
Borghaei, H
AF Shapiro, Geoffrey
LoRusso, Patricia
Vaishampayan, Ulka N.
Kittaneh, Muaiad
Hilton, John Frederick
Cleary, James M.
Velastegui, Karen
Xuan, Dawei
Hua, Steven
Shazer, Ronald L.
Borghaei, Hossein
TI First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC
in patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Canc Ctr, New Haven, CT USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Karmanos Canc Inst, Detroit, MI USA.
Univ Ottawa, Ottawa, ON, Canada.
Pfizer, La Jolla, CA USA.
Pfizer Inc, Clin Pharmacol, Biotechnol Clin Dev, La Jolla, CA USA.
Pfizer, San Diego, CA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS2603
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904681
ER
PT J
AU Sharma, M
Gray, E
Mehrotra, S
Wu, KH
Barry, WT
Hudis, CA
Winer, EP
Lyss, AP
Toppmeyer, D
Moreno-Aspitia, A
Rugo, HS
Ratain, MJ
Gobburu, J
AF Sharma, Manish
Gray, Elizabeth
Mehrotra, Shailly
Wu, Kehua
Barry, William Thomas
Hudis, Clifford A.
Winer, Eric P.
Lyss, Alan P.
Toppmeyer, Deborah
Moreno-Aspitia, Alvaro
Rugo, Hope S.
Ratain, Mark J.
Gobburu, Jogarao
TI A model-based approach to dose optimization of neurotoxic chemotherapy
for metastatic breast cancer (MBC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago Med, Chicago, IL USA.
Univ Maryland, Baltimore, MD 21201 USA.
Peking Univ, Beijing 100871, Peoples R China.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Heartland Canc Res NCORP, St Louis, MO USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1041
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900124
ER
PT J
AU Shaw, AT
Bauer, TM
Felip, E
Besse, B
James, LP
Clancy, JS
Mugundu, G
Martini, JF
Abbattista, A
Solomon, BJ
AF Shaw, Alice Tsang
Bauer, Todd Michael
Felip, Enriqueta
Besse, Benjamin
James, Leonard Philip
Clancy, Jill S.
Mugundu, Ganesh
Martini, Jean-Francois
Abbattista, Antonello
Solomon, Benjamin J.
TI Clinical activity and safety of PF-06463922 from a dose escalation study
in patients with advanced ALK+ or ROS1+NSCLC.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Gustave Roussy, Villejuif, France.
Pfizer, New York, NY USA.
Invent Clin, Princeton, NJ USA.
Pfizer, San Diego, CA USA.
Pfizer, Milan, Italy.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
NR 0
TC 14
Z9 14
U1 2
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8018
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901731
ER
PT J
AU Shore, ND
Concepcion, RS
Smith, MR
Pieczonka, CM
Nguyen, S
Belkoff, LH
Firlit, R
McCoy, C
DeVries, T
Freedland, SJ
AF Shore, Neal D.
Concepcion, Raoul S.
Smith, Matthew Raymond
Pieczonka, Christopher Michael
Son Nguyen
Belkoff, Laurence H.
Firlit, Robert
McCoy, Candice
DeVries, Todd
Freedland, Stephen J.
TI PREDICT, a study evaluating baseline (BL) disease characteristics
predictive of a positive imaging study for distant metastases in
patients (pts) with castration-resistant prostate cancer (CRPC):
Preliminary data.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Urol Associates PC, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Associated Med Profess, Syracuse, NY USA.
Kansas City Urol Care, Kansas City, KS USA.
Urol Consultants Southeastern Penn, Bala Cynwyd, PA USA.
Dendreon Corp, Seattle, WA USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16028
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903203
ER
PT J
AU Shu, CA
Pike, MC
Jotwani, AR
Friebel, TM
Soslow, RA
Levine, DA
Robson, ME
Konner, JA
Blum, JL
Neuhausen, SL
Garber, JE
Daly, MB
Isaacs, C
Eeles, RA
Ganz, PA
Aghajanian, C
Offit, K
Domchek, SM
Rebbeck, TR
Kauff, ND
AF Shu, Catherine A.
Pike, Malcolm C.
Jotwani, Anjali R.
Friebel, Tara M.
Soslow, Robert A.
Levine, Douglas A.
Robson, Mark E.
Konner, Jason A.
Blum, Joanne Lorraine
Neuhausen, Susan L.
Garber, Judy Ellen
Daly, Mary Beryl
Isaacs, Claudine
Eeles, Ros A.
Ganz, Patricia A.
Aghajanian, Carol
Offit, Kenneth
Domchek, Susan M.
Rebbeck, Timothy R.
Kauff, Noah D.
TI Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy
(RRSO) in women with BRCA mutations (BRCA plus ): A multicenter,
prospective study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Texas Onc PA, Dallas, TX USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1504
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900371
ER
PT J
AU Shusterman, S
London, WB
Hank, JA
Parisi, MT
Shulkin, BL
Servaes, SEN
Naranjo, A
Shimada, H
Gan, J
Gillies, S
Maris, JM
Park, JR
Sondel, PM
AF Shusterman, Suzanne
London, Wendy B.
Hank, Jacquelyn A.
Parisi, Marguerite T.
Shulkin, Barry L.
Servaes, Sabah-E-Noor
Naranjo, Arlene
Shimada, Hiroyuki
Gan, Jacek
Gillies, Stephen
Maris, John M.
Park, Julie R.
Sondel, Paul M.
TI A feasibility and phase II study of the hu14.18-IL2 immunocytokine in
combination with GM-CSF and isotretinoin in patients with recurrent or
refractory neuroblastoma: A Children's Oncology Group study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Childrens Hosp Canc Ctr, Boston, MA USA.
Univ Wisconsin, Madison, WI USA.
Seattle Childrens Hosp, Seattle, WA USA.
Jude Childrens Res Hosp, Memphis, TN USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
Univ Florida, Childrens Oncol Grp, Stat & Data Ctr, Gainesville, FL USA.
Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
Provenance Biopharmaceut Corp, Carlisle, ME USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
Seattle Childrens Hosp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10017
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900021
ER
PT J
AU Silverman, LR
Fenaux, P
Al-Kali, A
Baer, MR
Sekeres, MA
Roboz, GJ
Gaidano, G
Scott, BL
Greenberg, P
Platzbecker, U
Steensma, DP
Kreuzer, KA
Godley, LA
Collins, R
Atallah, EL
Azarnia, N
Garcia-Manero, G
AF Silverman, Lewis R.
Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Scott, Bart L.
Greenberg, Peter
Platzbecker, Uwe
Steensma, David P.
Kreuzer, Karl A.
Godley, Lucy A.
Collins, Robert
Atallah, Ehab L.
Azarnia, Nozar
Garcia-Manero, Guillermo
TI Prognostic and predictive value of IPSS-R in assessing overall survival
(OS) in a phase III study of rigosertib in second-line higher-risk (HR)
MDS patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mt Sinai Med Ctr, New York, NY 10029 USA.
Hosp St Louis, Paris, France.
Mayo Clin, Rochester, MN USA.
Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
Cleveland Clin, Dept Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA.
Weill Cornell Med Coll, New York, NY USA.
Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Stanford Univ, Stanford, CA 94305 USA.
TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Cologne, Cologne, Germany.
Univ Chicago, Chicago, IL 60637 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Onconova Therapeut Inc, Pennington, NJ USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7092
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901628
ER
PT J
AU Singh, S
Buzzoni, R
Carnaghi, C
Fazio, N
Pavel, ME
Wolin, EM
Tomasek, J
Raderer, M
Lahner, H
Lam, DH
Cauwel, H
Valle, JW
Delle Fave, G
Van Cutsem, E
Strosberg, JR
Tesselaar, ME
Shimada, Y
Oh, DY
Kulke, MH
Yao, JC
AF Singh, Simron
Buzzoni, Roberto
Carnaghi, Carlo
Fazio, Nicola
Pavel, Marianne E.
Wolin, Edward M.
Tomasek, Jiri
Raderer, Markus
Lahner, Harald
Lam, Du Hung
Cauwel, Helene
Valle, Juan W.
Delle Fave, Gianfranco
Van Cutsem, Eric
Strosberg, Jonathan R.
Tesselaar, Margot Et
Shimada, Yasuhiro
Oh, Do-Youn
Kulke, Matthew H.
Yao, James C.
CA RADIANT-4 Study Grp
TI Baseline demographics of patients from the randomized,
placebo-controlled, double-blind, phase III RADIANT-4 study of
everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine
tumors (NET).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
IRCCS Ist Clin Humanitas, Rozzano, Italy.
European Inst Oncol, Milan, Italy.
Charite Berlin Campus Virchow Klinikum, Berlin, Germany.
Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic.
AKH, Univ Klin Innere Med 1, Vienna, Austria.
Univ Klinikum Essen, Zentrum Innere Med, Essen, Germany.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Pharma AG, Basel, Switzerland.
Univ Manchester, Christie Hosp, Inst Canc Studies, Manchester, Lancs, England.
Univ Roma La Sapienza, Azienda Osped St Andrea, Rome, Italy.
Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium.
KULeuven, Leuven, Belgium.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Nederlands Kanker Inst Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Natl Canc Ctr, Tokyo, Japan.
Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15197
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902962
ER
PT J
AU Siravegna, G
Mussolin, B
Buscarino, M
Corti, G
Crisafulli, G
Ponzetti, A
Cremolini, C
Lamba, S
Avallone, A
Rospo, G
Veronese, S
Budillon, A
Montagut, C
Racca, P
Corcoran, RB
Di Nicolantonio, F
Loupakis, F
Siena, S
Sartore-Bianchi, A
Bardelli, A
AF Siravegna, Giulia
Mussolin, Benedetta
Buscarino, Michela
Corti, Giorgio
Crisafulli, Giovanni
Ponzetti, Agostino
Cremolini, Chiara
Lamba, Simona
Avallone, Antonio
Rospo, Giuseppe
Veronese, Silvio
Budillon, Alfredo
Montagut, Clara
Racca, Patrizia
Corcoran, Ryan Bruce
Di Nicolantonio, Federica
Loupakis, Fotios
Siena, Salvatore
Sartore-Bianchi, Andrea
Bardelli, Alberto
TI Raise and decline of KRAS mutant clones in colorectal cancers (CRCs)
treated with multiple rounds of anti-EGFR antibodies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fdn Piemonte Oncol IRCCS, Ist Candiolo, Candiolo, Italy.
IRCCS, Candiolo Canc Inst FPO, Turin, Italy.
San Giovanni Battista Hosp, Montalto Dora, Italy.
Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy.
Inst Canc Res & Treatment, IRCC, Candiolo, Italy.
Natl Canc Inst Naples, Naples, Italy.
Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy.
Hosp del Mar, Dept Med Oncol, Res Inst, Canc Res Program,IMIM, Barcelona, Spain.
Hosp del Mar, Dept Med Oncol, Barcelona, Spain.
San Giovanni Battista Hosp, Turin, Italy.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Turin, Candiolo, Italy.
RI Di Nicolantonio, Federica/A-2503-2011
OI Di Nicolantonio, Federica/0000-0001-9618-2010
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 11073
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900331
ER
PT J
AU Smith, MR
Parker, C
Tombal, BF
Miller, K
Saad, F
Fang, F
Zhang, A
Kornacker, M
Higano, CS
AF Smith, Matthew Raymond
Parker, Chris
Tombal, Bertrand F.
Miller, Kurt
Saad, Fred
Fang, Fang
Zhang, Amily
Kornacker, Martin
Higano, Celestia S.
TI ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in
combination with abiraterone acetate (abiraterone) and prednisone in the
treatment of asymptomatic or mildly symptomatic chemotherapy-naive
patients (pts) with bone predominant metastatic castration-resistant
prostate cancer (mCRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
Inst Canc Res, Sutton, Surrey, England.
Clin Univ St Luc, B-1200 Brussels, Belgium.
Charite, D-13353 Berlin, Germany.
Univ Montreal, Montreal, PQ, Canada.
Bayer HealthCare, Whippany, NJ USA.
Bayer Pharma AG, Berlin, Germany.
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5082
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904791
ER
PT J
AU Somaiah, N
Block, MS
Kim, JW
Shapiro, G
Hwu, P
Eder, JP
Jones, RL
Gnjatic, S
Lu, HL
Hsu, FJ
Pollack, S
AF Somaiah, Neeta
Block, Matthew Stephen
Kim, Joseph W.
Shapiro, Geoffrey
Hwu, Patrick
Eder, Joseph Paul
Jones, Robin Lewis
Gnjatic, Sacha
Lu, Hailing
Hsu, Frank James
Pollack, Seth
TI Phase I, first-in-human trial of LV305 in patients with advanced or
metastatic cancer expressing NY-ESO-1.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA.
Mayo Clin, Rochester, MN USA.
Yale Univ, Sch Med, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
Immune Design, Seattle, WA USA.
FHCRC, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3021
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900655
ER
PT J
AU Sonpavde, G
Pond, GR
Rosenberg, JE
Bajorin, DF
Regazzi, AM
Mullane, SA
Niegisch, G
Albers, P
Necchi, A
di Lorenzo, G
Fougeray, R
Ko, YJ
Rozzi, A
Matsumoto, K
Lee, JL
Kitamura, H
Kume, H
Milowsky, MI
Choueiri, TK
Bellmunt, J
AF Sonpavde, Guru
Pond, Gregory Russell
Rosenberg, Jonathan E.
Bajorin, Dean F.
Regazzi, Ashley Marie
Mullane, Stephanie A.
Niegisch, Guenter
Albers, Peter
Necchi, Andrea
di Lorenzo, Giuseppe
Fougeray, Ronan
Ko, Yoo-Joung
Rozzi, Antonio
Matsumoto, Kazumasa
Lee, Jae-Lyun
Kitamura, Hiroshi
Kume, Haruki
Milowsky, Matthew I.
Choueiri, Toni K.
Bellmunt, Joaquim
TI Externally validated improved 5-factor prognostic model in patients
(pts) receiving salvage systemic therapy for advanced urothelial
carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Ontario Clin Oncol Grp OCOG, Hamilton, ON, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Bladder Canc Ctr, Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Ist Nazl Tumori Milan, Milan, MI, Italy.
Univ Naples Federico II, Med Oncol Unit, Dept Clin Med, Naples, Italy.
Inst Rech Pierre Fabre, Boulogne, France.
Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
Ist Neurotraumatol Italiano Grottaferrata, Clin Oncol Unit, Grottaferrata, Italy.
Kitasato Inst, Dept Urol, Sch Med, Sagamihara, Kanagawa, Japan.
Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea.
Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido, Japan.
Univ Tokyo, Fac Med, Dept Urol, Tokyo 113, Japan.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4527
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900995
ER
PT J
AU Spigel, DR
Reckamp, KL
Rizvi, NA
Poddubskaya, E
West, HJ
Eberhardt, WEE
Baas, P
Antonia, SJ
Pluzanski, A
Vokes, EE
Holgado, E
Waterhouse, DM
Ready, N
Gainor, JF
Aren, OR
Horn, L
Paz-Ares, L
Baudelet, C
Lestini, BJ
Brahmer, JR
AF Spigel, David R.
Reckamp, Karen L.
Rizvi, Naiyer A.
Poddubskaya, Elena
West, Howard Jack
Eberhardt, Wilfried Ernst Erich
Baas, Paul
Antonia, Scott Joseph
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David Michael
Ready, Neal
Gainor, Justin F.
Aren, Osvaldo Rudy
Horn, Leora
Paz-Ares, Luis
Baudelet, Christine
Lestini, Brian Joseph
Brahmer, Julie R.
TI A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed
death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or
metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NN Blokhin Russian Canc Res Ctr, Moscow, Russia.
Swedish Canc Inst, Seattle, WA USA.
Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Ruhrlandklin, Essen, Germany.
Univ Duisburg Essen, Essen, Germany.
Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Inst Marii Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Hosp Madrid, Norte Sanchinarro, Spain.
Oncol Hematol Care, Blue Ash, OH USA.
Duke Univ, Med Ctr, Durham, NC USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Ctr Int Estudios Clin, Santiago, Chile.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Hosp Univ Virgen Del Rocio, Seville, Spain.
Bristol Myers Squibb Co, Princeton, NJ USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
NR 0
TC 8
Z9 8
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8009
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901722
ER
PT J
AU Starodub, A
Ocean, AJ
Messersmith, WA
Picozzi, VJ
Guarino, MJ
Bardia, A
Thomas, SS
Berlin, J
Shah, MA
Maliakal, PP
Wegener, WA
Sharkey, RM
Wilhelm, F
Goldenberg, DM
AF Starodub, Alexander
Ocean, Allyson J.
Messersmith, Wells A.
Picozzi, Vincent J.
Guarino, Michael J.
Bardia, Aditya
Thomas, Sajeve Samuel
Berlin, Jordan
Shah, Manish A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
TI Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38
antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II
clinical experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA.
Weill Cornell Med Coll, New York, NY USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Virginia Mason Med Ctr, Seattle, WA 98101 USA.
Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Univ Florida, Windermere, FL USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Immunomedics Inc, Morris Plains, NJ USA.
Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3546
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900765
ER
PT J
AU Steinestel, J
Luedeke, M
Arndt, A
Schnoeller, T
Lennerz, JK
Maier, C
Cronauer, M
Steinestel, K
Boegemann, M
Schrader, AJ
AF Steinestel, Julie
Luedeke, Manuel
Arndt, Annette
Schnoeller, Thomas
Lennerz, Jochen K.
Maier, Christiane
Cronauer, Marcus
Steinestel, Konrad
Boegemann, Martin
Schrader, Andres Jan
TI Detecting predictive androgen receptor modifications in circulating
prostate cancer cells.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hosp Muenster, Urol Clin, Munster, Germany.
Univ Hosp Ulm, Urol Clin, Ulm, Germany.
Bundeswehrkrankenhaus Ulm, Inst Pathol & Mol Pathol, Ulm, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Ulm, Dept Urol, Sch Med, D-89069 Ulm, Germany.
Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany.
Univ Munster, Dept Urol, D-48149 Munster, Germany.
Univ Munster, Dept Urol, Med Ctr, D-48149 Munster, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5067
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901112
ER
PT J
AU Stover, DG
Selfors, LM
Coloff, JL
Brugge, JS
Winer, EP
AF Stover, Daniel G.
Selfors, Laura M.
Coloff, Jonathan L.
Brugge, Joan S.
Winer, Eric P.
TI Meta-analysis of breast cancer expression data using published gene
signatures to reveal key cellular processes implicated in
chemosensitivity and resistance.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Brookline, MA USA.
Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 509
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901116
ER
PT J
AU Strickland, K
Howitt, BE
Rodig, SJ
Ritterhouse, L
D'Andrea, AD
Matulonis, U
Konstantinopoulos, P
AF Strickland, Kyle
Howitt, Brooke E.
Rodig, Scott J.
Ritterhouse, Lauren
D'Andrea, Alan D.
Matulonis, Ursula
Konstantinopoulos, Panagiotis
TI Tumor infiltrating and peritumoral T cells and expression of PD-L1 in
BRCA1/2-mutated high grade serous ovarian cancers.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematopathol,Dept Pathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5512
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901171
ER
PT J
AU Sullivan, RJ
O'Neill, VJ
Brinkmann, K
Enderle, D
Koestler, T
Spiel, A
Emenegger, J
Noerholm, M
Skog, J
Berking, C
Flaherty, K
AF Sullivan, Ryan J.
O'Neill, Vincent J.
Brinkmann, Kay
Enderle, Daniel
Koestler, Tina
Spiel, Alexandra
Emenegger, Jennifer
Noerholm, Mikkel
Skog, Johan
Berking, Carola
Flaherty, Keith
TI Plasma-based monitoring of BRAF mutations during therapy for malignant
melanoma (MM) using combined exosomal RNA and cell-free DNA analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Exosome Diagnost, Cambridge, MA USA.
Exosome Diagnost, Munich, Germany.
Exosome Diagnost GmbH, Martinsried, Germany.
Exosome Diagnost, New York, NY USA.
Univ Munich, Munich, Germany.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9017
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901927
ER
PT J
AU Sullivan, RJ
Weber, JS
Patel, SP
Dummer, R
Miller, WH
Cosgrove, D
Carlino, MS
Tan, DSW
Lebbe, C
Cipani, T
Elez, E
Maacke, H
Nikolopoulos, P
Aout, M
De Parseval, LA
Ascierto, PA
AF Sullivan, Ryan J.
Weber, Jeffrey S.
Patel, Sapna Pradyuman
Dummer, Reinhard
Miller, Wilson H.
Cosgrove, David
Carlino, Matteo S.
Tan, Daniel Shao-Weng
Lebbe, Celeste
Cipani, Tiziana
Elez, Elena
Maacke, Heiko
Nikolopoulos, Panagiotis
Aout, Mounir
De Parseval, Laure A.
Ascierto, Paolo Antonio
TI A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus
MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients
naive to BRAFi treatment.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
Sidney Kimmel Comp Canc Ctr, Baltimore, MD USA.
Westmead Hosp, Baulkham Hills, Australia.
Natl Canc Ctr Singapore, Singapore, Singapore.
Hop St Louis, Assistance Publ Hop Paris, Dept Dermatol, Paris, France.
Osped Niguarda Ca Granda, Milan, Italy.
VHIO, Barcelona, Spain.
Novartis, Holm, Germany.
Novartis Pharma AG, Basel, Switzerland.
Ist Nazl Tumori IRCCS, Naples, Italy.
NR 0
TC 10
Z9 10
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9007
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901917
ER
PT J
AU Sun, T
Du, Z
Fei, T
Brown, M
Lee, GSM
Chen, YW
Liu, XS
Kantoff, PW
AF Sun, Tong
Du, Zhou
Fei, Teng
Brown, Myles
Lee, Gwo-Shu Mary
Chen, Yiwen
Liu, Xiaole Shirley
Kantoff, Philip W.
TI Long non-coding RNA-mediated PTEN regulation in prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16081
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903251
ER
PT J
AU Sweeney, C
Sartor, AO
Vogelzang, NJ
Shore, ND
Cislo, P
Bangerter, K
Morris, MJ
AF Sweeney, Christopher
Sartor, A. Oliver
Vogelzang, Nicholas J.
Shore, Neal D.
Cislo, Paul
Bangerter, Keith
Morris, Michael J.
TI Effect of radium-223 dichloride (Ra-223) on pain from US EAP.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Tulane Canc Ctr, New Orleans, LA USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Bayer HealthCare, Whippany, NJ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16086
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903253
ER
PT J
AU Sweeney, C
Gray, KP
Harshman, LC
Taplin, ME
Pace, AF
Dumas, K
Supko, JG
Zukotynski, KA
Bernard, BD
Pomerantz, M
Elfiky, A
Kantoff, PW
AF Sweeney, Christopher
Gray, Kathryn P.
Harshman, Lauren Christine
Taplin, Mary-Ellen
Pace, Amanda Fredericks
Dumas, Kathryn
Supko, Jeffrey G.
Zukotynski, Katherine A.
Bernard, Brandon David
Pomerantz, Mark
Elfiky, Aymen
Kantoff, Philip W.
TI Phase 1 study with expansion cohorts of cabozantinib (C) plus
abiraterone (A) in metastatic castration resistant prostate cancer
(mCRPC): Investigator-sponsored study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Toronto, Sunnybrook Hosp, Toronto, ON, Canada.
Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5037
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901079
ER
PT J
AU Tan, DSW
Seto, T
Leighl, NB
Riely, GJ
Sequist, LV
Felip, E
Wolf, J
Yang, JCH
Matushansky, I
Yu, XL
Schmitz, SFH
Cui, XM
Kim, DW
AF Tan, Daniel Shao-Weng
Seto, Takashi
Leighl, Natasha B.
Riely, Gregory J.
Sequist, Lecia V.
Felip, Enriqueta
Wolf, Juergen
Yang, James Chih-Hsin
Matushansky, Igor
Yu, Xiaolu
Schmitz, Shu-Fang Hsu
Cui, Xiaoming
Kim, Dong-Wan
TI First-in-human phase I study of EGF816, a third generation,
mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small
cell lung cancer (NSCLC) harboring T790M.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Natl Canc Ctr Singapore, Singapore, Singapore.
Kyushu Natl Canc Ctr, Fukuoka, Japan.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany.
Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany.
Natl Taiwan Univ Hosp, Taipei, Taiwan.
Natl Taiwan Univ, Taipei 10764, Taiwan.
Novartis Pharmaceut, E Hanover, NJ USA.
China Novartis Inst BioMed Res, Shanghai, Peoples R China.
Novartis Pharma AG, Basel, Switzerland.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
NR 0
TC 1
Z9 1
U1 2
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8013
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901726
ER
PT J
AU Taplin, ME
Antonarakis, ES
Dransfield, DT
Ferrante, KJ
De Bono, JS
AF Taplin, Mary-Ellen
Antonarakis, Emmanuel S.
Dransfield, Daniel T.
Ferrante, Karen J.
De Bono, Johann Sebastian
TI Androgen receptor modulation optimized for response: Splice variant
(ARMOR3-SV)-Randomized, open-label, multicenter, controlled study of
galeterone vs enzalutamide in men with metastatic castration-resistant
prostate cancer (mCRPC) expressing AR-V7 splice variant.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Tokai Pharma, Cambridge, MA USA.
Inst Canc Res, Sutton, Surrey, England.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5069
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904778
ER
PT J
AU Taplin, ME
Jacobus, SJ
Fiorillo, M
Ledet, EM
Cotogno, P
Steinberger, AE
Jacene, HA
Sartor, O
McKay, RR
AF Taplin, Mary-Ellen
Jacobus, Susanna J.
Fiorillo, Matthew
Ledet, Elisa M.
Cotogno, Patrick
Steinberger, Allie E.
Jacene, Heather A.
Sartor, Oliver
McKay, Rana R.
TI Clinical practice patterns of Radium-223 (R223) utilization and
variables associated with completion of therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Tulane Canc Ctr, New Orleans, LA USA.
Tulane Canc Ctr, Off Clin Res, New Orleans, LA USA.
Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16076
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903246
ER
PT J
AU Temel, JS
Currow, DC
Fearon, K
Yan, Y
Friend, J
Abernethy, AP
AF Temel, Jennifer S.
Currow, David Christopher
Fearon, Kenneth
Yan, Ying
Friend, John
Abernethy, Amy Pickar
TI Phase III trials of anamorelin in patients with advanced non-small cell
lung cancer (NSCLC) and cachexia (ROMANA 1 and 2)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Flinders Univ S Australia, Adelaide, SA 5001, Australia.
Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.
Helsinn Therapeut US Inc, Bridgewater, NJ USA.
Duke Univ, Durham, NC USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9500
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901989
ER
PT J
AU Ter-Minassian, M
Brooks, NV
Brais, LK
Chan, JA
Christiani, DC
Lin, XH
Gabriel, S
Dinet, J
Kulke, MH
AF Ter-Minassian, Monica
Brooks, Nichole V.
Brais, Lauren K.
Chan, Jennifer A.
Christiani, David C.
Lin, Xihong
Gabriel, Sylvie
Dinet, Jerome
Kulke, Matthew H.
TI Association of progression-free survival with overall survival (OS) in
patients (pts) with neuroendocrine tumor (NET) treated with somatostatin
analogs
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Ipsen Pharma, Boulougne Billancourt, France.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4090
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900928
ER
PT J
AU Thompson, JA
Motzer, R
Molina, AM
Choueiri, TK
Heath, EI
Kollmannsberger, CK
Redman, BG
Sangha, RS
Ernst, DS
Pili, R
Butturini, A
Wiseman, A
Trave, F
Anand, B
Huang, Y
Reyno, LM
AF Thompson, John A.
Motzer, Robert
Molina, Ana M.
Choueiri, Toni K.
Heath, Elisabeth I.
Kollmannsberger, Christian K.
Redman, Bruce G.
Sangha, Randeep S.
Ernst, D. Scott
Pili, Roberto
Butturini, Anna
Wiseman, Aya
Trave, Fabio
Anand, Banmeet
Huang, Yao
Reyno, Leonard M.
TI Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in
advanced refractory renal cell carcinomas (RRCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Seattle Canc Care Alliance, Seattle, WA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Medcl Coll, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada.
Univ Michigan, Ann Arbor, MI 48109 USA.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
London Reg Canc Ctr, London, ON N6A 4L6, Canada.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Agensys, Santa Monica, CA USA.
Agensys Inc, Santa Monica, CA USA.
NR 0
TC 4
Z9 4
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2503
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900536
ER
PT J
AU Tolaney, SM
Beeram, M
Beck, JT
Conlin, AK
Dees, EC
Dickler, MN
Helsten, TL
Conkling, PR
Edenfield, WJ
Richards, DA
Turner, PK
Cai, N
Chan, EM
Pant, S
Becerra, C
Kalinsky, K
Puhalla, S
Rexer, BN
Burris, HA
Goetz, MP
AF Tolaney, Sara M.
Beeram, Muralidhar
Beck, J. Thaddeus
Conlin, Alison Katherine
Dees, Elizabeth Claire
Dickler, Maura N.
Helsten, Teresa L.
Conkling, Paul R.
Edenfield, William Jeffery
Richards, Donald A.
Turner, P. Kellie
Cai, Na
Chan, Edward Michael
Pant, Shubham
Becerra, Carlos
Kalinsky, Kevin
Puhalla, Shannon
Rexer, Brent Neil
Burris, Howard A.
Goetz, Matthew P.
TI A phase Ib study of abemaciclib with therapies for metastatic breast
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
START Ctr Canc Care, San Antonio, TX USA.
Highlands Oncol Grp, Fayetteville, AR USA.
Providence Canc Ctr, Oncol & Hematol Care Clin, Portland, OR USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif San Diego, La Jolla, CA USA.
Virginia Oncol Associates, Norfolk, VA USA.
ITOR Greenville Hosp Syst, Clin Res Unit, Greenville, SC USA.
Texas Oncol Tyler, Tyler, TX USA.
Eli Lilly & Co, Indianapolis, IN 46285 USA.
Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA.
Texas Oncol Baylor Sammons Canc Ctr, Dallas, TX USA.
Columbia Univ, Med Ctr, New York, NY USA.
Univ Pittsburgh, Med Ctr, Womens Canc Program, Magee Womens Hosp UMPC, Pittsburgh, PA USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Sarah Cannon Res Inst SCRI, Nashville, TN USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 3
Z9 3
U1 1
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 522
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901129
ER
PT J
AU Tolaney, SM
Ziehr, DR
Guo, H
Barry, WT
Higgins, MJ
Isakoff, SJ
Brock, JE
Ivanova, E
Paweletz, C
Demeo, M
Ramaiya, NH
Overmoyer, B
Jain, RK
Duda, DG
Winer, EP
AF Tolaney, Sara M.
Ziehr, David R.
Guo, Hao
Barry, William Thomas
Higgins, Michaela Jane
Isakoff, Steven J.
Brock, Jane E.
Ivanova, Elena
Paweletz, Cloud
Demeo, Michelle
Ramaiya, Nikhil H.
Overmoyer, Beth
Jain, Rakesh K.
Duda, Dan G.
Winer, Eric P.
TI A Phase II study of cabozantinib for metastatic triple-negative breast
cancer (TNBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Mater Misericordiae Univ Hosp, Dublin, Ireland.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1080
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900240
ER
PT J
AU Traeger, L
McDonnell, TM
McCarty, C
Greer, JA
Temel, JS
AF Traeger, Lara
McDonnell, Theresa Margaret
McCarty, Caitlin
Greer, Joseph A.
Temel, Jennifer S.
TI Patient-reported outcomes of a nurse practitioner-led intervention to
enhance chemotherapy symptom management.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20732
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904328
ER
PT J
AU Tripathy, D
Bardia, A
Hurvitz, SA
Harbeck, N
Colleoni, M
Franke, FA
Chow, LWC
Im, SA
Shao, ZM
Keyserlingk, JR
Soler, LM
Horan, M
Dhuria, SV
Hughes, G
Lu, YS
AF Tripathy, Debu
Bardia, Aditya
Hurvitz, Sara A.
Harbeck, Nadia
Colleoni, Marco
Franke, Fabio A.
Chow, Louis W. C.
Im, Seock-Ah
Shao, Zhimin
Keyserlingk, John R.
Soler, Lidia Mongay
Horan, Melissa
Dhuria, Shyeilla V.
Hughes, Gareth
Lu, Yen-Shen
TI Phase III, randomized, double-blind, placebo-controlled study of
ribociclib (LEE011) in combination with either tamoxifen and goserelin
or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the
treatment of premenopausal women with HR+, HER2-advanced breast cancer
(aBC): MONALEESA-7.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
UCLA Jonsson Comprehens Ctr, Los Angeles, CA USA.
Univ Munich, Breast Ctr, Munich, Germany.
Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy.
CACON, Hosp Caridade Ijui, Ijui, Brazil.
Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China.
Seoul Natl Univ, Coll Med, Seoul, South Korea.
Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.
Ville Marie Med Ctr, Montreal, PQ, Canada.
Novartis Pharmaceut, E Hanover, NJ USA.
Novartis Pharma AG, Basel, Switzerland.
Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
NR 0
TC 1
Z9 1
U1 3
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS625
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904817
ER
PT J
AU Trippa, L
Wen, PY
Alexander, BM
AF Trippa, Lorenzo
Wen, Patrick Y.
Alexander, Brian Michael
TI Incorporating biomarkers into adaptive clinical trials.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e13009
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902462
ER
PT J
AU Trudeau, ME
Winer, EP
Steinberg, JL
Liosatos, M
Poondru, S
Dydo, MN
Peterson, AC
Gradishar, WJ
AF Trudeau, Maureen E.
Winer, Eric P.
Steinberg, Joyce Leta
Liosatos, Maggie
Poondru, Srinivasu
Dydo, Michael Nicholas
Peterson, Amy C.
Gradishar, William John
TI A phase 2 single-arm study to assess clinical activity, efficacy and
safety of enzalutamide (ENZA) with trastuzumab in HER2+AR+ metastatic or
locally advanced breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Astellas Pharma US Inc, Northbrook, IL USA.
Astellas, Northbrook, IL USA.
Astellas Pharma Global Dev, Northbrook, IL USA.
Astellas, Deerfield, IL USA.
Medivation Inc, San Francisco, CA USA.
Northwestern Univ, Lurie Comp Canc Ctr, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS640
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904832
ER
PT J
AU Tung, NM
Garber, JE
Torous, V
Hacker, MR
Freeman, GJ
Rodig, SJ
Poles, E
Alexander, BM
Lee, LJ
Collins, LC
Schnitt, SJ
AF Tung, Nadine M.
Garber, Judy Ellen
Torous, Vanda
Hacker, Michele R.
Freeman, Gordon James
Rodig, Scott J.
Poles, Emily
Alexander, Brian Michael
Lee, Larissa Janeen
Collins, Laura C.
Schnitt, Stuart J.
TI Prevalence and predictors of androgen receptor (AR) and programmed
death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic
triple negative breast cancer (TNBC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Div Hematopathol, Dept Pathol,Med Sch, Boston, MA 02115 USA.
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
Harvard Rad Onc Prog, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1005
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900057
ER
PT J
AU Tutt, ANJ
Kaufman, B
Gelber, RD
Mc Fadden, E
Goessl, CD
Viale, G
Arahmani, A
Fumagalli, D
Azim, HA
Wu, WT
Grocholewicz, A
Costantino, JP
Rastogi, P
Garber, JE
Geyer, CE
AF Tutt, Andrew Nicholas James
Kaufman, Bella
Gelber, Richard D.
Mc Fadden, Eleanor
Goessl, Carsten Dietrich
Viale, Giuseppe
Arahmani, Amal
Fumagalli, Debora
Azim, Hatem Abdel
Wu, Wenting
Grocholewicz, Anna
Costantino, Joseph P.
Rastogi, Priya
Garber, Judy Ellen
Geyer, Charles E.
TI OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in
patients with high-risk HER2-negative breast cancer (BC) and a germline
BRCA1/2 mutation (gBRCAm).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Kings Coll London, Sch Med, London WC2R 2LS, England.
Chaim Sheba Med Ctr, Ramat Gan, Israel.
Tel Aviv Univ, Sackler Fac Med, Ramat Gan, Israel.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Frontier Sci, Kingussie, Inverness, Scotland.
AstraZeneca, Gaithersburg, MD USA.
European Inst Oncol, Div Pathol, Milan, Italy.
Breast Int Grp, Brussels, Belgium.
Inst Jules Bordet, B-1000 Brussels, Belgium.
AstraZeneca, Gaithersburg, MD USA.
AstraZeneca, Warsaw, Poland.
NRG Oncol, Pittsburgh, PA USA.
Univ Pittsburgh, Pittsburgh, PA USA.
NRG Oncol, NSABP, Pittsburgh, PA USA.
UPMC, Ctr Canc, Pittsburgh, PA USA.
Virginia Commonwealth Univ, Massey Canc Ctr, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS1109
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904664
ER
PT J
AU Van Allen, EM
Kryukov, G
Bielski, C
Samocha, K
Fromer, M
Seepo, S
Gentry, C
Neale, B
Sweeney, C
Garraway, LA
Taplin, ME
AF Van Allen, Eliezer Mendel
Kryukov, Gregory
Bielski, Craig
Samocha, Kaitlin
Fromer, Menachem
Seepo, Sara
Gentry, Carleen
Neale, Benjamin
Sweeney, Christopher
Garraway, Levi A.
Taplin, Mary-Ellen
TI Transgenerational genomic effect of chemotherapy exposure in testicular
cancer survivors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Broad Inst MIT & Harvard, Cambridge, MA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1543
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900410
ER
PT J
AU Van Cutsem, E
Benedetti, FM
Mizuguchi, H
Mayer, RJ
Ohtsu, A
AF Van Cutsem, Eric
Benedetti, Fabio M.
Mizuguchi, Hirokazu
Mayer, Robert J.
Ohtsu, Atsushi
CA RECOURSE Study Grp
TI TAS-102 vs placebo (PBO) in patients (pts) >= 65 years (y) with
metastatic colorectal cancer (mCRC): An age-based analysis of the
RECOURSE trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Hosp Leuven, Leuven, Belgium.
Taiho Oncol Inc, Princeton, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3595
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900814
ER
PT J
AU Van Loon, K
Zhang, L
Creasman, JM
Choti, MA
Yao, JC
Kulke, MH
Nakakura, EK
Bloomston, M
Benson, A
Shah, MH
Strosberg, JR
Zornosa, CC
Bobiak, S
Bergsland, EK
AF Van Loon, Katherine
Zhang, Li
Creasman, Jennifer M.
Choti, Michael A.
Yao, James C.
Kulke, Matthew H.
Nakakura, Eric K.
Bloomston, Mark
Benson, Al Bowen
Shah, Manisha H.
Strosberg, Jonathan R.
Zornosa, Carrie C.
Bobiak, Sarah
Bergsland, Emily K.
TI Recurrence following surgical resection of gastroenteropancreatic
neuroendocrine tumors (NETs): An analysis from the NCCN oncology
outcomes database
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
UC San Francisco, San Francisco, CA USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Texas SW Med Ctr Dallas, Dept GI Med Oncol, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Richard J Solove Res Inst, Columbus, OH USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Natl Comp Canc Network, Ft Washington, MD USA.
Natl Comprehens Canc Network, Ft Washington, MD USA.
UC San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4107
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900945
ER
PT J
AU VanDusen, H
Traeger, L
Fishbein, JN
Keenan, T
Greer, JA
Pirl, WF
Jackson, VA
Eusebio, J
Gallagher, ER
Graubert, TA
Peppercorn, JM
Spitzer, TR
Ballen, KK
McAfee, SL
Dey, B
Chen, YB
Temel, JS
El-Jawahri, A
AF VanDusen, Harry
Traeger, Lara
Fishbein, Joel Nathan
Keenan, Tanya
Greer, Joseph A.
Pirl, William F.
Jackson, Vicki A.
Eusebio, Justin
Gallagher, Emily R.
Graubert, Timothy A.
Peppercorn, Jeffrey M.
Spitzer, Thomas R.
Ballen, Karen K.
McAfee, Steven L.
Dey, Bimalangshu
Chen, Yi-Bin Albert
Temel, Jennifer S.
El-Jawahri, Areej
TI Psychological distress during hospitalization for hematopoietic stem
cell transplantation to predict lower quality of life and high
post-traumatic stress disorder symptoms at 6 months post-transplant.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Brookline, MA USA.
Washington Univ, St Louis, MO USA.
Duke Canc Inst, Durham, NC USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Needham, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9557
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902052
ER
PT J
AU Varga, A
Piha-Paul, SA
Ott, PA
Mehnert, JM
Berton-Rigaud, D
Johnson, EA
Cheng, JD
Yuan, S
Rubin, EH
Matei, DE
AF Varga, Andrea
Piha-Paul, Sarina Anne
Ott, Patrick Alexander
Mehnert, Janice M.
Berton-Rigaud, Dominique
Johnson, Elizabeth A.
Cheng, Jonathan D.
Yuan, Sammy
Rubin, Eric H.
Matei, Daniela E.
TI Antitumor activity and safety of pembrolizumab in patients (pts) with
PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib
study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Gustave Roussy, Villejuif, France.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
ICO Ctr Rene Gauducheau, St Herblain, France.
Merck & Co Inc, Kenilworth, NJ USA.
Indiana Univ, Indianapolis, IN 46204 USA.
NR 0
TC 13
Z9 13
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 5510
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901169
ER
PT J
AU Visvanathan, K
Fackler, MJ
Zhang, Z
Lopez-Bujanda, Z
Jeter, S
Sokoll, LJ
Cope, L
Umbricht, C
Euhus, D
Carpenter, JT
Storniolo, AM
Nanda, R
Lin, NU
Carey, LA
Ingle, JN
Sukumar, S
Wolff, AC
AF Visvanathan, Kala
Fackler, Mary Jo
Zhang, Zhe
Lopez-Bujanda, Zoila
Jeter, Stacie
Sokoll, Lori J.
Cope, Leslie
Umbricht, Christopher
Euhus, David
Carpenter, John T.
Storniolo, Anna Maria
Nanda, Rita
Lin, Nancy U.
Carey, Lisa A.
Ingle, James N.
Sukumar, Saraswati
Wolff, Antonio C.
TI DNA methylation in serum as an independent marker of outcome and
treatment response in TBCRC 005: A prospective study in metastatic
breast cancer (MBC) patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Johns Hopkins, Baltimore, MD USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Chicago, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ N Carolina, Chapel Hill, NC USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 518
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901125
ER
PT J
AU Wagner, AJ
Banerji, U
Mahipal, A
Somaiah, N
Hirsch, HA
Fancourt, C
Levonas, A
Lam, R
Meister, A
Kemp, RK
Knox, C
Rose, S
Hong, DS
AF Wagner, Andrew J.
Banerji, Udai
Mahipal, Amit
Somaiah, Neeta
Hirsch, Heather Anne
Fancourt, Craig
Levonas, Amy
Lam, Raymond
Meister, Amy
Kemp, Ramon Karmel
Knox, Clayton
Rose, Shelonitda
Hong, David S.
TI A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in
patients (pts) with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Canc Res, London SW3 6JB, England.
Royal Marsden NHS Fdn Trust, London, England.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA.
Merck & Co Inc, Kenilworth, NJ USA.
Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA.
NR 0
TC 3
Z9 3
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 10564
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900204
ER
PT J
AU Wainberg, ZA
Shapiro, G
Curigliano, G
Leong, S
Kristeleit, RS
Maqueda, MA
Britten, CD
Milella, M
Middleton, MR
Olszanski, AJ
Vaishampayan, UN
Lopez-Martin, JA
Gelmon, KA
Brega, N
Pierce, KJ
Perea, R
Houk, BE
Pathan, N
Gollerkeri, A
Razak, ARA
AF Wainberg, Zev A.
Shapiro, Geoffrey
Curigliano, Giuseppe
Leong, Stephen
Kristeleit, Rebecca Sophie
Maqueda, Maria Alsina
Britten, Carolyn D.
Milella, Michele
Middleton, Mark R.
Olszanski, Anthony J.
Vaishampayan, Ulka N.
Lopez-Martin, Jose A.
Gelmon, Karen A.
Brega, Nicoletta
Pierce, Kristen J.
Perea, Rachelle
Houk, Brett Edward
Pathan, Nuzhat
Gollerkeri, Ashwin
Razak, Albiruni R. A.
TI Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with
other antitumor agents.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Ist Europeo Oncol, Milan, Italy.
Univ Colorado, Ctr Canc, Aurora, CO USA.
UCL, Inst Canc, London, England.
Hosp Valle De Hebron, Barcelona, Spain.
Med Univ S Carolina, Charleston, SC 29425 USA.
Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy.
Oxford NIHR Biomed Res Ctr, Oxford, England.
Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Hosp 12 Octubre, E-28041 Madrid, Spain.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Pfizer Italia, Milan, Italy.
Pfizer Oncol, Groton, CT USA.
Pfizer Worldwide Res & Dev, San Diego, CA USA.
Pfizer Inc, Carlsbad, CA USA.
Pfizer, San Diego, CA USA.
Pfizer BioTherapeut, Cambridge, MA USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2590
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900623
ER
PT J
AU Wanebo, HJ
Liss, A
Bowen, W
AF Wanebo, Harold J.
Liss, Andrew
Bowen, Wayne
TI Effect of C6Ceramide on chemotoxicity of gemcitabine against
chemoresistant pancreatic cell lines.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Landmark Med Ctr, Bristol, RI USA.
Massachusets Gen Hosp, Boston, MA USA.
Brown Univ, Providence, RI 02912 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e15286
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903041
ER
PT J
AU Wang, EH
Corso, CD
Park, HSM
Chen, AB
Kim, AW
Wilson, LD
Decker, RH
Yu, JB
AF Wang, Elyn H.
Corso, Christopher D.
Park, Henry Soo-Min
Chen, Aileen B.
Kim, Anthony W.
Wilson, Lynn D.
Decker, Roy H.
Yu, James B.
TI Association between radiation dose and outcomes with postoperative
radiotherapy for N0-N1 non-small-cell-lung cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA.
Yale New Haven Med Ctr, New Haven, CT 06504 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Univ, Sch Med, Dept Surg, Thorac Surg Sect, New Haven, CT 06510 USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 7538
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901668
ER
PT J
AU Wargo, JA
Lawrence, DP
Cooper, ZA
Frederick, DT
Giobbie-Hurder, A
Piris, A
Rubin, KM
Fadden, R
Reuben, A
Starker, L
Flaherty, K
Sharpe, A
Sullivan, RJ
AF Wargo, Jennifer Ann
Lawrence, Donald P.
Cooper, Zachary A.
Frederick, Dennie T.
Giobbie-Hurder, Anita
Piris, Adriano
Rubin, Krista M.
Fadden, Riley
Reuben, Alexandre
Starker, Lee
Flaherty, Keith
Sharpe, Arlene
Sullivan, Ryan J.
TI A phase II study of combined therapy with vemurafenib (vem) and
high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with
metastatic melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e20074
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904089
ER
PT J
AU Warren, LE
Chen, MH
Denham, JW
Steigler, A
Renshaw, AA
Loffredo, MJ
Kantoff, PW
D'Amico, AV
AF Warren, Laura Elizabeth
Chen, Ming-Hui
Denham, James William
Steigler, Allison
Renshaw, Andrew A.
Loffredo, Marian J.
Kantoff, Philip W.
D'Amico, Anthony Victor
TI Gleason grade 5 and the risk of death from prostate cancer following
radiation with or without 6 months of conventional androgen deprivation
therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA 2300 USA.
Univ Connecticut, Storrs, CT USA.
Calvary Mater Newcastle, Waratah, NSW 02115, Australia.
Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 02115, Australia.
Baptist Hosp Miami, Miami, FL USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e16099
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903264
ER
PT J
AU Watters, JW
Dickson, MA
Schwartz, GK
Le Cesne, A
Bahleda, R
Wagner, AJ
Choy, E
De Jonge, MJ
Light, M
Jung, J
Lee, JS
Mace, S
AF Watters, James Wilson
Dickson, Mark Andrew
Schwartz, Gary K.
Le Cesne, Axel
Bahleda, Rastislav
Wagner, Andrew J.
Choy, Edwin
De Jonge, Maja J.
Light, Madelyn
Jung, Joonil
Lee, Joon Sang
Mace, Sandrine
TI TP53 mutations emerge in circulating cell-free DNA obtained from
patients undergoing treatment with the HDM2 antagonist SAR405838.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sanofi, Cambridge, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Columbia Univ Med Ctr, New York, NY USA.
Inst Gustave Roussy, Villejuif, France.
Inst Gustave Roussy, Drug Dev Dept, Villejuif, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.
Sanofi Oncol, Cambridge, MA USA.
Sanofi Oncol, Vitry Sur Seine, France.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2515
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900548
ER
PT J
AU Wheeler, HE
Travis, LB
Budnick, A
Feldman, DR
Einhorn, LH
Hamilton, RJ
Vaughn, DJ
Beard, C
Fung, C
Johnson, E
Moore, MJ
Sahasrabudhe, DM
Fossa, SD
Sesso, HD
Dolan, ME
Frisina, RD
AF Wheeler, Heather E.
Travis, Lois B.
Budnick, Amy
Feldman, Darren Richard
Einhorn, Lawrence H.
Hamilton, Robert James
Vaughn, David J.
Beard, Clair
Fung, Chunkit
Johnson, Eileen
Moore, Malcolm J.
Sahasrabudhe, Deepak M.
Fossa, Sophie D.
Sesso, Howard D.
Dolan, M. Eileen
Frisina, Robert D.
CA Platinum Study Grp
TI Comprehensive characterization of cisplatin-related hearing loss in US
and Canadian Testicular Cancer Survivors (TCS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA.
Univ Rochester, Sch Med & Dent, Rochester, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
Univ Hlth Network, Toronto, ON, Canada.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA.
Oslo Univ Hosp, Oslo, Norway.
Univ Oslo, Oslo, Norway.
Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ S Florida, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9570
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036902065
ER
PT J
AU Williams, SG
Davis, ID
Sweeney, C
Stockler, MR
Martin, AJ
Marchesin, V
Deignan, O
McDermott, R
Long, AP
Roncolato, FT
Yip, S
Hague, W
Tu, E
Coskinas, X
Nguyen, PL
AF Williams, Scott G.
Davis, Ian D.
Sweeney, Christopher
Stockler, Martin R.
Martin, Andrew James
Marchesin, Vittorio
Deignan, Olwyn
McDermott, Ray
Long, Anne Poh
Roncolato, Felicia T.
Yip, Sonia
Hague, Wendy
Tu, Emily
Coskinas, Xanthi
Nguyen, Paul Linh
TI Randomised phase 3 trial of enzalutamide in androgen deprivation therapy
with radiation therapy for high risk, clinically localised prostate
cancer: The ANZUP ENZARAD Trial (ANZUP 1303).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Peter MacCallum Canc Ctr, East Melbourne, Australia.
Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia.
Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia.
ICORG, Dublin, Ireland.
Royal Perth Hosp, Willetton, WA, Australia.
NHMRC Clin Trials Ctr, Camperdown, NSW, Australia.
Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia.
NHMRC Clin Trials Ctr, Sydney, NSW, Australia.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Stockler, Martin/N-3859-2016
OI Stockler, Martin/0000-0003-3793-8724
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS5078
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904787
ER
PT J
AU Winkfield, KM
Osuagwu, C
Powell, E
Freeman, E
Sprague-Martinez, L
AF Winkfield, Karen Marie
Osuagwu, Chidinma
Powell, Elizabeth
Freeman, Elmer
Sprague-Martinez, Linda
TI A multi-level community engaged study exploring barriers to cancer care
and clinical trial participation among black Bostonians.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
CCHERS Inc, Boston, MA USA.
Boston Univ, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e17536
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036903509
ER
PT J
AU Winton, EF
Devos, T
Oh, ST
Platzbecker, U
Wadleigh, M
Jun, S
Lee, P
Deng, W
Gupta, V
AF Winton, Elliott F.
Devos, Timothy
Oh, Stephen T.
Platzbecker, Uwe
Wadleigh, Martha
Jun, Susie
Lee, Peter
Deng, Wei
Gupta, Vikas
TI Phase III randomized, double-blind, active-controlled study of
momelotinib versus ruxolitinib in patients with myelofibrosis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Sch Med, Atlanta, GA USA.
Univ Ziekenhuizen Leuven UZ Leuven, Leuven, Belgium.
Washington Univ, St Louis, MO USA.
TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Gilead Sci Inc, Foster City, CA USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS7101
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904844
ER
PT J
AU Wolchok, JD
Hamid, O
Ribas, A
Robert, C
Kefford, R
Hwu, WJ
Weber, JS
Joshua, AM
Gangadhar, TC
Dronca, RS
Daud, A
Patnaik, A
Joseph, RW
Zarour, HM
Li, XN
Xue, DH
Ebbinghaus, S
Kang, SP
Perrone, AM
Hodi, FS
AF Wolchok, Jedd D.
Hamid, Omid
Ribas, Antoni
Robert, Caroline
Kefford, Richard
Hwu, Wen-Jen
Weber, Jeffrey S.
Joshua, Anthony M.
Gangadhar, Tara C.
Dronca, Roxana Stefania
Daud, Adil
Patnaik, Amita
Joseph, Richard Wayne
Zarour, Hassane M.
Li, Xiaoyun Nicole
Xue, Dahai
Ebbinghaus, Scot
Kang, Soonmo Peter
Perrone, Andrea Marie
Hodi, F. Stephen
TI Atypical patterns of response in patients (pts) with metastatic melanoma
treated with pembrolizumab (MK-3475) in KEYNOTE-001.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Gustave Roussy, Villejuif, France.
Macquarie Univ, Sydney, NSW 2109, Australia.
Westmead Hosp, Sydney, NSW, Australia.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Mayo Clin, Rochester, MN USA.
UC San Francisco, San Francisco, CA USA.
START, San Antonio, TX USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Merck & Co Inc, Kenilworth, NJ USA.
Merck & Co Inc, West Point, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 3000
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900634
ER
PT J
AU Wong, SM
Freedman, RA
Stamell, E
Sagara, Y
Brock, JE
DeSantis, S
Golshan, M
AF Wong, Stephanie M.
Freedman, Rachel A.
Stamell, Emily
Sagara, Yasuaki
Brock, Jane E.
DeSantis, Stephen
Golshan, Mehra
TI Risk of axillary node metastasis in Paget disease with invasive ductal
carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Brookline, MA USA.
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 1054
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900177
ER
PT J
AU Wong, YN
Epstein, AJ
Mitra, N
Vachani, A
Hin, S
Yang, L
Smith-McLallen, A
Armstrong, K
Groeneveld, PW
AF Wong, Yu-Ning
Epstein, Andrew J.
Mitra, Nandita
Vachani, Anil
Hin, Sakhena
Yang, Lin
Smith-McLallen, Aaron
Armstrong, Katrina
Groeneveld, Peter W.
TI Impact of age on the associations between genomic testing in breast
cancer (BrCA) and chemotherapy (chemo) use and costs
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Independence Blue Cross, Philadelphia, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6528
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901443
ER
PT J
AU Wright, AA
Keating, NL
Ayanian, J
Chrischilles, EA
Kahn, KL
Ritchie, C
Earle, C
Landrum, MB
AF Wright, Alexi A.
Keating, Nancy Lynn
Ayanian, John
Chrischilles, Elizabeth A.
Kahn, Katherine Leslie
Ritchie, Christine
Earle, Craig
Landrum, Mary Beth
TI Family perspectives on aggressive cancer care near the end of life
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Iowa, Coll Publ Hlth, Iowa City, IA USA.
Univ Calif Los Angeles, David Geffen Sch Medcn, Los Angeles, CA USA.
Univ Calif, Oakland, CA USA.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
Harvard Univ, Sch Med, Dept Healh Care Policy, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6517
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901432
ER
PT J
AU Yabroff, KR
Dowling, E
Guy, G
Banegas, M
McNeel, TS
Davidoff, AJ
Chawla, N
Hartigan, DB
Han, XS
Kent, EE
Li, CY
Virgo, KS
Rodriguez, J
de Moor, J
Zheng, ZY
Jemal, A
Ekwueme, DU
AF Yabroff, K. Robin
Dowling, Emily
Guy, Gery
Banegas, Matthew
McNeel, Timothy S.
Davidoff, Amy J.
Chawla, Neetu
Hartigan, Danielle Blanch
Han, Xuesong
Kent, Erin E.
Li, Chunyu
Virgo, Katherine S.
Rodriguez, Juan
de Moor, Janet
Zheng, Zhiyuan
Jemal, Ahmedin
Ekwueme, Donatus U.
TI Financial hardship associated with cancer in the United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Rockville, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Ctr Dis Control & Prevent, Atlanta, GA USA.
IMS, Rockville, MD USA.
Yale Univ, Sch Publ Hlth, New Haven, CT USA.
Kaiser Permanente No Calif, Oakland, CA USA.
Bentley Univ, Saugus, MA USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Emory Univ, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 6608
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901522
ER
PT J
AU Yanagita, M
Paweletz, C
O'Connell, A
Jackman, DM
Kuang, Y
Oxnard, GR
Janne, PA
AF Yanagita, Masahiko
Paweletz, Cloud
O'Connell, Allison
Jackman, David Michael
Kuang, Yanan
Oxnard, Geoffrey R.
Janne, Pasi A.
TI A prospective evaluation of cell free DNA (cfDNA) genotyping and
circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts)
treated with erlotinib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Faber Canc Inst, Boston, MA USA.
Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 11068
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900327
ER
PT J
AU Yao, JC
Guthrie, K
Moran, C
Strosberg, JR
Kulke, MH
Chan, JA
LoConte, NK
McWilliams, RR
Wolin, EM
Mattar, BI
McDonough, S
Chen, HX
Blanke, CD
Hochster, HS
AF Yao, James C.
Guthrie, Katherine
Moran, Cesar
Strosberg, Jonathan R.
Kulke, Matthew H.
Chan, Jennifer A.
LoConte, Noelle K.
McWilliams, Robert R.
Wolin, Edward M.
Mattar, Bassam Ibrahim
McDonough, Shannon
Chen, Helen X.
Blanke, Charles David
Hochster, Howard S.
TI SWOG S0518: Phase III prospective randomized comparison of depot
octreotide plus interferon alpha-2b versus depot octreotide plus
bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients
(NCT00569127)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Wisconsin, Madison, WI USA.
Mayo Clin, Rochester, MN USA.
Univ Kentucky, Lexington, KY USA.
Canc Ctr Kansas PA, Wichita, KS USA.
SWOG Stat Ctr, Seattle, WA USA.
CTEP Natl Canc Inst, Rockville, MD USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Yale Univ Sch Med, Dept Med Oncol, New Haven, CT USA.
NR 0
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4004
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900843
ER
PT J
AU Yen, CC
Chen, WM
Chen, PCH
Wu, HTH
Shiau, CY
Chen, TH
Liu, CL
Chao, TC
Tzeng, CH
Chang, WYH
Chiou, HJ
Fletcher, JA
AF Yen, Chueh-Chuan
Chen, Wei-Ming
Chen, Paul Chih-Hsueh
Wu, Hung-Ta Hondar
Shiau, Cheng-Ying
Chen, Tain-Hsiung
Liu, Chien-Lin
Chao, Ta-Chung
Tzeng, Cheng-Hwai
Chang, Wayne Yen-Hwa
Chiou, Hong-Jen
Fletcher, Jonathan A.
TI The role of AURKA in liposarcoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Taipei Vet Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan.
Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan.
Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan.
Taipei Vet Gen Hosp, Dept Radiol, Taipei, Taiwan.
Taipei Vet Gen Hosp, Taipei, Taiwan.
Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan.
Taipei Vet Gen Hosp, Dept Urol, Taipei, Taiwan.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e21512
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904388
ER
PT J
AU Yock, TI
Weyman, EA
Goldberg, S
Eaton, BR
Kasper, HB
MacDonald, SM
Pulsifer, MB
Ebb, D
Srichankij, SP
Delahaye, J
Tarbell, N
Kuhlthau, K
AF Yock, Torunn I.
Weyman, Elizabeth A.
Goldberg, Saveli
Eaton, Bree Ruppert
Kasper, Hallie Bieber
MacDonald, Shannon M.
Pulsifer, Margaret B.
Ebb, David
Srichankij, Sean P.
Delahaye, Jennifer
Tarbell, Nancy
Kuhlthau, Karen
TI HRQoL in medulloblastoma patients enrolled on a prospective phase II
study of proton radiation.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Emory Univ, Atlanta, GA 30322 USA.
Francis H Burr Proton Ctr, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA e21029
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904367
ER
PT J
AU Yopp, AC
Singal, AG
Arriaga, YE
Verma, UN
Shan, J
Kallinteris, NL
Beg, MS
Mansour, JC
Zhu, H
AF Yopp, Adam Charles
Singal, Amit G.
Arriaga, Yull Edwin
Verma, Udit N.
Shan, Joseph
Kallinteris, Nikoletta L.
Beg, Muhammad Shaalan
Mansour, John C.
Zhu, Hao
TI A phase I/II study of bavituximab and sorafenib in advanced
hepatocellular carcinoma (HCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Peregrine Pharmaceut Inc, Tustin, CA USA.
Univ Texas SW Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4109
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900947
ER
PT J
AU Yu, HA
Oxnard, GR
Spira, AI
Horn, L
Weiss, J
Feng, Y
West, HJ
Giaccone, G
Evans, TL
Kelly, RJ
Fleege, T
Poondru, S
Jie, F
Aoyama, K
Foley, MA
Whitcomb, D
Keating, AT
Krivoshik, AP
AF Yu, Helena Alexandra
Oxnard, Geoffrey R.
Spira, Alexander I.
Horn, Leora
Weiss, Jared
Feng, Yan
West, Howard Jack
Giaccone, Giuseppe
Evans, Tracey L.
Kelly, Ronan Joseph
Fleege, Tanya
Poondru, Srinivasu
Jie, Fei
Aoyama, Koji
Foley, Margaret A.
Whitcomb, Debbie
Keating, Anne Therese
Krivoshik, Andrew P.
TI Phase I dose escalation study of ASP8273, a mutant-selective
irreversible EGFR inhibitor, in subjects with EGFR mutation positive
NSCLC.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Case Western Reserve Univ, Univ Hosp, Broadview Hts, OH USA.
Swedish Canc Inst, Seattle, WA USA.
NCI, NIH, Bethesda, MD 20892 USA.
Univ Penn, Wynnewood, PA USA.
Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Astellas Pharma Global Dev, Northbrook, IL USA.
Astellas Pharma Inc, Northbrook, IL USA.
Astellas Pharma, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8083
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901795
ER
PT J
AU Yu, HA
Sima, CS
Reales, D
Jordan, S
Rudin, CM
Kris, MG
Michor, F
Pao, W
Riely, GJ
AF Yu, Helena Alexandra
Sima, Camelia S.
Reales, Dalicia
Jordan, Shomari
Rudin, Charles M.
Kris, Mark G.
Michor, Franziska
Pao, William
Riely, Gregory J.
TI A phase I study of twice weekly pulse dose and daily low dose erlotinib
as initial treatment for patients (pts) with EGFR-mutant lung cancers.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8017
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901730
ER
PT J
AU Zanna, C
Vaslin, A
Voss, MH
Heist, RS
Hierro, C
Supko, JG
Nakai, K
Ishii, N
Menetrey, A
Roubaudi-Fraschini, MC
Cordier, J
Douchain, J
Nicolas-Metral, V
AF Zanna, Claudio
Vaslin, Anne
Voss, Martin Henner
Heist, Rebecca Suk
Hierro, Cinta
Supko, Jeffrey G.
Nakai, Kiyohiko
Ishii, Nobuya
Menetrey, Annick
Roubaudi-Fraschini, Marie-Claude
Cordier, Julien
Douchain, Jerome
Nicolas-Metral, Valerie
TI Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347
(CH5183284), a novel FGFR inhibitor.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Debiopharm Int SA, Lausanne, Switzerland.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
VHIO, Barcelona, Spain.
Chugai Pharmaceut Co Ltd, Kamakura, Kanagawa, Japan.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 2540
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900573
ER
PT J
AU Zhang, Y
Sestak, I
Cuzick, JM
Dowsett, M
Schnabel, CA
Sgroi, D
AF Zhang, Yi
Sestak, Ivana
Cuzick, Jack M.
Dowsett, Mitchell
Schnabel, Catherine A.
Sgroi, Dennis
TI Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2
and prediction of relative endocrine benefit from tamoxifen and
anastrozole in HR plus breast cancer: A TransATAC study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 BioTheranostics, San Diego, CA USA.
Queen Mary Univ London, Ctr Canc Prevent, London, England.
Royal Marsden Hosp, London SW3 6JJ, England.
Massachusetts Gen Hosp, Avon Fdn, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 526
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901133
ER
PT J
AU Zhou, CW
Mullane, SA
Werner, L
Taplin, ME
Fay, AP
Choueiri, TK
Takeda, DY
Bowden, M
Bellmunt, J
AF Zhou, Chensheng Willa
Mullane, Stephanie A.
Werner, Lillian
Taplin, Mary-Ellen
Fay, Andre Poisl
Choueiri, Toni K.
Takeda, David Yoshio
Bowden, Michaela
Bellmunt, Joaquim
TI Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in
cisplatin-treated bladder cancer patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil.
HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4530
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901001
ER
PT J
AU Zhou, Y
Gottlieb, L
Cartmel, B
Li, FY
Ercolano, EA
Harrigan, M
McCorkle, R
Ligibel, JA
Von Gruenigen, VE
Gogoi, R
Schwartz, PE
Risch, HA
Irwin, ML
AF Zhou, Yang
Gottlieb, Linda
Cartmel, Brenda
Li, Fangyong
Ercolano, Elizabeth A.
Harrigan, Maura
McCorkle, Ruth
Ligibel, Jennifer A.
Von Gruenigen, Vivian E.
Gogoi, Radhika
Schwartz, Peter E.
Risch, Harvey A.
Irwin, Melinda L.
TI Randomized trial of exercise on quality of life and fatigue in women
diagnosed with ovarian cancer: The Women's Activity and Lifestyle Study
in Connecticut (WALC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Canc Ctr, New Haven, CT USA.
Yale Univ, Sch Publ Hlth, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Summa Akron City Hosp, Akron, OH USA.
Geisinger Med Ctr, Danville, PA 17822 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 9505
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901994
ER
PT J
AU Zhu, AX
Baron, AD
Malfertheiner, P
Kudo, M
Kawazoe, S
Pezet, D
Weissinger, F
Brandi, G
Barone, C
Okusaka, T
Wada, Y
Park, JO
Ryoo, BY
Cho, JY
Chung, HC
Li, CP
Yen, CJ
Lee, KD
Yang, L
Chau, I
AF Zhu, Andrew X.
Baron, Ari David
Malfertheiner, Peter
Kudo, Masatoshi
Kawazoe, Seiji
Pezet, Denis
Weissinger, Florian
Brandi, Giovanni
Barone, Carlo
Okusaka, Takuji
Wada, Yoshiyuki
Park, Joon Oh
Ryoo, Baek-Yeol
Cho, Jae Yong
Chung, Hyun Cheol
Li, Chung-Pin
Yen, Chia-Jui
Lee, Kuan-Der
Yang, Ling
Chau, Ian
TI Ramucirumab (RAM) as second-line treatment in patients (pts) with
advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by
Child-Pugh (CP) score
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
Calif Pacific Med Ctr, San Francisco, CA USA.
Univ Magdeburg, D-39106 Magdeburg, Germany.
Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka 589, Japan.
Saga Ken Med Ctr Koseikan, Saga, Japan.
CHU Estaing, Clermont Ferrand, France.
Evangel Krankenhaus Bielefeld, Bielefeld, Germany.
Policlin St Orsola Malpighi, Bologna, Italy.
Univ Cattolica Sacro Cuore, I-00168 Rome, Italy.
Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan.
Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Gangnam Severance Hosp, Seoul, South Korea.
Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Shinchon Dong, South Korea.
Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei, Taiwan.
Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan.
Chang Gung Mem Hosp, Chiayi, Taiwan.
Eli Lilly & Co, Bridgewater, NJ USA.
Royal Marsden, London, England.
Royal Marsden, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 4108
PG 2
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036900946
ER
PT J
AU Zimmerman, TM
Griffith, KA
Jasielec, J
Rosenbaum, CA
McDonnell, K
Waite-Marin, J
Berdeja, JG
Raje, NS
Reece, DE
Vij, R
Alonge, M
Rosebeck, S
Gurbuxani, S
Faham, M
Kong, KA
Levy, J
Jakubowiak, AJ
AF Zimmerman, Todd M.
Griffith, Kent A.
Jasielec, Jagoda
Rosenbaum, Cara Ann
McDonnell, Kathryn
Waite-Marin, Jessica
Berdeja, Jesus G.
Raje, Noopur S.
Reece, Donna Ellen
Vij, Ravi
Alonge, Mattina
Rosebeck, Shaun
Gurbuxani, Sandeep
Faham, Malek
Kong, Katherine A.
Levy, Joan
Jakubowiak, Andrzej J.
TI Phase II MMRC trial of extended treatment with carfilzomib (CFZ),
lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell
transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Chicago, IL 60637 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Northshore Univ Hlth Syst, Evanston, IL USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Washington Univ, Sch Med, St Louis, MO USA.
Sequenta Inc, San Francisco, CA USA.
Multiple Myeloma Res Consortium, Norwalk, CT USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA 8510
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036901823
ER
PT J
AU Zonder, JA
Raje, NS
Scott, EC
Hofmeister, CC
Lendvai, N
Anderson, LD
Hari, P
Orloff, GJ
Berdeja, JG
Singhal, S
Craig, M
Valent, JN
Ptaszynski, M
Schreiber, J
Aitchison, R
Usmani, SZ
AF Zonder, Jeffrey A.
Raje, Noopur S.
Scott, Emma Catherine
Hofmeister, Craig C.
Lendvai, Nikoletta
Anderson, Larry Don
Hari, Parameswaran
Orloff, Gregory Joshua
Berdeja, Jesus G.
Singhal, Seema
Craig, Michael
Valent, Jason Neil
Ptaszynski, Mieke
Schreiber, Jennifer
Aitchison, Roger
Usmani, Saad Zafar
TI A multicenter, randomized, open-label, phase 2 study of carfilzomib with
or without ARRY-520 (filanesib) in patients with advanced multiple
myeloma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Karmanos Canc Inst, Detroit, MI USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Fairfax Northern Virginia Hem Onc, Fairfax, VA USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Northwestern Univ, Sch Med, Chicago, IL USA.
W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.
Cleveland Clin, Eastlake, OH USA.
Array BioPharma Inc, Boulder, CO USA.
Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA TPS8612
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904874
ER
PT J
AU Tan, XY
Li, BB
Lu, XG
Jia, F
Santori, C
Menon, P
Li, H
Zhang, BH
Zhao, JJ
Zhang, K
AF Tan, Xuyu
Li, Ben B.
Lu, Xueguang
Jia, Fei
Santori, Clarissa
Menon, Priyanka
Li, Hui
Zhang, Bohan
Zhao, Jean J.
Zhang, Ke
TI Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID GOLD NANOPARTICLES; CELLULAR UPTAKE; BINDING-PROPERTIES;
BLOCK-COPOLYMERS; DNA; DELIVERY; DOXORUBICIN
AB The simultaneous intracellular delivery of multiple types of payloads, such as hydrophobic drugs and nucleic acids, typically requires complex carrier systems. Herein; we demonstrate a, self-deliverable form of nucleic acid-drug nanostructure that is composed almost entirely of payload molecules. Upon light activation, the nanostructure sheds the nucleic acid shell, while the core, which consists of prodrug molecules, disintegrates via an irreversible self-immolative process, releasing free drug molecules and small molecule fragments. We demonstrate that the nanostructures exhibit enhanced stability against DNase I compared with free DNA, and that the model drug (camptothecin) released exhibits similar efficacy as free, unmodified drugs toward cancer cells.
C1 [Tan, Xuyu; Lu, Xueguang; Jia, Fei; Santori, Clarissa; Menon, Priyanka; Zhang, Ke] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
[Li, Hui; Zhang, Bohan; Zhang, Ke] Hunan Univ, Inst Chem Biol & Nanomed, Changsha 410081, Hunan, Peoples R China.
[Li, Ben B.; Zhao, Jean J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Li, Ben B.; Zhao, Jean J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA.
RP Zhang, K (reprint author), Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
EM k.zhang@neu.edu
FU Northeastern University start-up; NEU-DFCI seed grant; NSF CAREER award
[1453255]
FX The authors thank William Fowle at the NEU Biology Department for help
with the TEM. Financial support from Northeastern University start-up,
NEU-DFCI seed grant, and NSF CAREER award (1453255) is gratefully
acknowledged.
NR 39
TC 37
Z9 38
U1 19
U2 133
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 20
PY 2015
VL 137
IS 19
BP 6112
EP 6115
DI 10.1021/jacs.5b00795
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA CI8WT
UT WOS:000355053100001
PM 25924099
ER
PT J
AU Izgu, EC
Fahrenbach, AC
Zhang, N
Li, L
Zhang, W
Larsen, AT
Blain, JC
Szostak, JW
AF Izgu, Enver Cagri
Fahrenbach, Albert C.
Zhang, Na
Li, Li
Zhang, Wen
Larsen, Aaron T.
Blain, J. Craig
Szostak, Jack W.
TI Uncovering the Thermodynamics of Monomer Binding for RNA Replication
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID TEMPLATE-DIRECTED SYNTHESIS; NUCLEIC-ACID; HAIRPIN OLIGONUCLEOTIDES;
MOLECULAR-DYNAMICS; CIRCULAR-DICHROISM; NMR; DNA; HYDRATION; RESIDUES;
COMPLEX
AB The nonenzymatic replication of primordial RNA is thought to have been a critical step in the origin of life. However, despite decades of effort, the poor rate and fidelity of model template copying reactions have thus far prevented an experimental demonstration of nonenzymatic RNA replication. The overall rate and fidelity of template copying depend, in part, on the affinity of free ribonucleotides to the RNA primer-template complex. We have now used H-1 NMR spectroscopy to directly measure the thermodynamic association constants, K(a)s, of the standard ribonucleotide monophosphates (rNMPs) to native RNA primer-template complexes. The binding affinities of rNMPs to duplexes with a complementary single-nucleotide overhang follow the order C > G > A > U. Notably, these monomers bind more strongly to RNA primer-template complexes than to the analogous DNA complexes. The relative binding affinities of the rNMPs for complementary RNA primer-template complexes are in good quantitative agreement with the predictions of a nearest-neighbor analysis. With respect to G:U wobble base-pairing, we find that the binding of rGMP to a primer-template complex with a 5'-U overhang is approximately 10-fold weaker than to the complementary 5'-C overhang. We also find that the binding of rGMP is only about 2-fold weaker than the binding of rAMP to 5'-U, consistent with the poor fidelity observed in the nonenzymatic copying of U residues in RNA templates. The accurate K-a measurements for ribonudeotides obtained in this study will be useful for designing higher fidelity, more effective RNA replication systems.
C1 [Izgu, Enver Cagri; Fahrenbach, Albert C.; Zhang, Na; Li, Li; Zhang, Wen; Larsen, Aaron T.; Blain, J. Craig; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA.
[Izgu, Enver Cagri; Fahrenbach, Albert C.; Zhang, Na; Li, Li; Zhang, Wen; Larsen, Aaron T.; Blain, J. Craig; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Izgu, Enver Cagri; Fahrenbach, Albert C.; Li, Li; Zhang, Wen; Larsen, Aaron T.; Szostak, Jack W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Fahrenbach, Albert C.; Szostak, Jack W.] Tokyo Inst Technol, Earth Life Sci Inst, Meguro Ku, Tokyo 1528550, Japan.
[Szostak, Jack W.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, 185 Cambridge St, Boston, MA 02114 USA.
EM szostak@molbio.mgh.harvard.edu
FU Research Fellowship from the Earth-Life Science Institute at the Tokyo
Institute of Technology; Simons Foundation [290363]
FX We thank Dr. Ayan Pal, Dr. Anders Bjorkbom, and Weicheng Zhang for
providing technical assistance; Dr. Aaron Engelhart, Dr. Victor
Lelyveld, and Noam Prywes for helpful discussions. J.W.S. is an
Investigator of the Howard Hughes Medical Institute. A.C.F. is supported
by a Research Fellowship from the Earth-Life Science Institute at the
Tokyo Institute of Technology. This work was supported in part by a
grant (290363) from the Simons Foundation to J.W.S.
NR 38
TC 7
Z9 7
U1 2
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 20
PY 2015
VL 137
IS 19
BP 6373
EP 6382
DI 10.1021/jacs.5b02707
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA CI8WT
UT WOS:000355053100040
PM 25901790
ER
PT J
AU Zhou, YB
Han, C
Li, DL
Yu, ZJ
Li, FM
Li, F
An, Q
Bai, HL
Zhang, XJ
Duan, ZF
Kan, QC
AF Zhou, Yubing
Han, Chao
Li, Duolu
Yu, Zujiang
Li, Fengmei
Li, Feng
An, Qi
Bai, Huili
Zhang, Xiaojian
Duan, Zhenfeng
Kan, Quancheng
TI Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human
breast cancer cell proliferation and growth
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUTANT P53; TARGETED THERAPY; ER-ALPHA; PROTEIN; GENE; CARCINOMA; CDK11;
AMPLIFICATION; TRANSCRIPTION; RESISTANCE
AB Cyclin-dependent kinases (CDKs) play important roles in the development of many types of cancers by binding with their paired cyclins. However, the function of CDK11 larger protein isomer, CDK11(p110), in the tumorigenesis of human breast cancer remains unclear. In the present study, we explored the effects and molecular mechanisms of CDK11(p110) in the proliferation and growth of breast cancer cells by determining the expression of CDK11(p110) in breast tumor tissues and examining the phenotypic changes of breast cancer cells after CDK11(p110) knockdown. We found that CDK11(p110) was highly expressed in breast tumor tissues and cell lines. Tissue microarray analysis showed that elevated CDK11(p110) expression in breast cancer tissues significantly correlated with poor differentiation, and was also associated with advanced TNM stage and poor clinical prognosis for breast cancer patients. In vitro knockdown of CDK11(p110) by siRNA significantly inhibited cell growth and migration, and dramatically induced apoptosis in breast cancer cells. Flow cytometry demonstrated that cells were markedly arrested in G1 phase of the cell cycle after CDK11(p110) downregulation. These findings suggest that CDK11(p110) is critical for the proliferation and growth of breast cancer cells, which highlights CDK11(p110) may be a promising therapeutic target for the treatment of breast cancer.
C1 [Zhou, Yubing; Han, Chao; Li, Duolu; Li, Feng; An, Qi; Zhang, Xiaojian; Duan, Zhenfeng; Kan, Quancheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou 450052, Peoples R China.
[Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Mol Biol Lab, Boston, MA 02114 USA.
[Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA USA.
[Yu, Zujiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China.
[Li, Fengmei] Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Obstet & Gynecol, Zhengzhou 450007, Peoples R China.
[Bai, Huili] Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Pathol, Zhengzhou 450007, Peoples R China.
RP Kan, QC (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.
EM qckan19632012@163.com
FU National Natural Science Foundation of China [81402266, 81372875]; Key
Project of Scientific and Technological Research of the Education
Department of Henan Province [14B320036]; Medical Science and Technology
Research Projects of Henan Province [201403074]; Youth Innovation Fund
of the First Affiliated Hospital of Zhengzhou University
FX This work was supported by the National Natural Science Foundation of
China (No.: 81402266 and 81372875), the Key Project of Scientific and
Technological Research of the Education Department of Henan Province
(No.: 14B320036) and Medical Science and Technology Research Projects of
Henan Province (No.: 201403074). This study was also supported by the
Youth Innovation Fund of the First Affiliated Hospital of Zhengzhou
University.
NR 59
TC 6
Z9 6
U1 3
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 20
PY 2015
VL 5
AR 10433
DI 10.1038/srep10433
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ3PE
UT WOS:000355395500001
PM 25990212
ER
PT J
AU Gandhi, PU
Gaggin, HK
Belcher, AM
Harisiades, JE
Basile, A
Falco, A
Rosati, A
Piscione, F
Januzzi, JL
Turco, MC
AF Gandhi, Parul U.
Gaggin, Hanna K.
Belcher, Arianna M.
Harisiades, Jamie E.
Basile, Anna
Falco, Antonia
Rosati, Alessandra
Piscione, Federico
Januzzi, James L., Jr.
Turco, M. Caterina
TI Analysis of BAG3 plasma concentrations in patients with acutely
decompensated heart failure
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE BAG3; BCL-2 athanogene 3; Heart failure; Prognosis
ID SENSITIVITY TROPONIN-T; NATRIURETIC PEPTIDE; RISK STRATIFICATION;
PROTEIN; BIOMARKER; STRESS
AB Background: BCL-2-associated athanogene 3 (BAG3) is a protein implicated in the cardiomyocyte stress response and genesis of cardiomyopathy. Extracellular BAG3 is measurable in patients with heart failure (HF), but the relationship of BAG3 with HF prognosis is unclear.
Methods: BAG3 plasma concentrations were measured in 39 acutely decompensated HF patients; the primary endpoint was death at 1 year. Baseline characteristics were compared by vital status and median BAG3 concentration. Correlation of BAG3 with left ventricular ejection fraction (LVEF) and other biomarkers was performed. Prognostic value was assessed using Cox proportional hazards regression and Kaplan-Meier analysis.
Results: At baseline, median BAG3 was significantly higher in decedents (N = 11) than survivors (N = 28; 1489 ng/mL versus 50 ng/mL; P = 0.04); decedents also had worse renal function and higher median natriuretic peptide (NP) and sST2.BAG3 was not significantly correlated with NPs, mid-regional pro-adrenomedullin, sST2, or eGFR, however. Mortality was increased in patients with supra-median BAG3 (>336 ng/mL; 42.1% versus 15.0%, P = 0.06). In age and LVEF-adjusted Cox proportional hazards, BAG3 remained a significant mortality predictor (HR = 3.20; 95% CI = 134-7.65; P = 0.02); those with supra-median BAG3 had significantly shorter time-to-death (P = 0.04).
Conclusion: The stress response protein BAG3 is measurable in patients with ADHF and may be prognostic for death. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Gandhi, Parul U.; Gaggin, Hanna K.; Belcher, Arianna M.; Harisiades, Jamie E.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Basile, Anna; Falco, Antonia; Rosati, Alessandra] Univ Salerno, Dept Pharm, I-84084 Fisciano, SA, Italy.
[Basile, Anna; Falco, Antonia; Rosati, Alessandra; Turco, M. Caterina] Univ Salerno, BIOUNIVERSA Srl, I-84084 Fisciano, SA, Italy.
[Piscione, Federico; Turco, M. Caterina] Univ Salerno, Dept Med & Surg, Baronissi, SA, Italy.
RP Turco, MC (reprint author), Univ Salerno, Via Ponte don Melillo, I-84084 Fisciano, Italy.
EM mcturco@unisa.it
FU Dennis and Marilyn Barry Fellowship in Cardiology; Clark Fund for
Cardiac Research Innovation; Roman W. DeSanctis Clinical Scholar
Endowment; Hutter Family Professorship
FX Dr. Gandhi is supported by the Dennis and Marilyn Barry Fellowship in
Cardiology, Dr. Gaggin is supported in part by the Clark Fund for
Cardiac Research Innovation, and Dr. Januzzi is supported in part by the
Roman W. DeSanctis Clinical Scholar Endowment and the Hutter Family
Professorship.
NR 28
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAY 20
PY 2015
VL 445
BP 73
EP 78
DI 10.1016/j.cca.2015.02.048
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CI8LP
UT WOS:000355024100014
PM 25753466
ER
PT J
AU Rodriguez-Reyna, TS
Mercado-Velazquez, P
Yu, N
Alosco, S
Ohashi, M
Lebedeva, T
Cruz-Lagunas, A
Nunez-Alvarez, C
Cabiedes-Contreras, J
Vargas-Alarcon, G
Granados, J
Zuniga, J
Yunis, E
AF Rodriguez-Reyna, Tatiana S.
Mercado-Velazquez, Pamela
Yu, Neng
Alosco, Sharon
Ohashi, Marina
Lebedeva, Tatiana
Cruz-Lagunas, Alfredo
Nunez-Alvarez, Carlos
Cabiedes-Contreras, Javier
Vargas-Alarcon, Gilberto
Granados, Julio
Zuniga, Joaquin
Yunis, Edmond
TI HLA Class I and II Blocks Are Associated to Susceptibility, Clinical
Subtypes and Autoantibodies in Mexican Systemic Sclerosis (SSc) Patients
SO PLOS ONE
LA English
DT Article
ID DNA TOPOISOMERASE-I; HLA-DQB1 1ST DOMAIN; ANTICENTROMERE ANTIBODY;
JAPANESE PATIENTS; DISEASE SEVERITY; ETHNIC-GROUPS; SCLERODERMA;
HAPLOTYPES; FEATURES; ALLELES
AB Introduction
Human leukocyte antigen (HLA) polymorphism studies in Systemic Sclerosis (SSc) have yielded variable results. These studies need to consider the genetic admixture of the studied population. Here we used our previously reported definition of genetic admixture of Mexicans using HLA class I and II DNA blocks to map genetic susceptibility to develop SSc and its complications.
Methods
We included 159 patients from a cohort of Mexican Mestizo SSc patients. We performed clinical evaluation, obtained SSc-associated antibodies, and determined HLA class I and class II alleles using sequence-based, high-resolution techniques to evaluate the contribution of these genes to SSc susceptibility, their correlation with the clinical and autoantibody profile and the prevalence of Amerindian, Caucasian and African alleles, blocks and haplotypes in this population.
Results
Our study revealed that class I block HLA-C*12:03-B*18:01 was important to map susceptibility to diffuse cutaneous (dc) SSc, HLA-C*07:01-B*08:01 block to map the susceptibility role of HLA-B*08:01 to develop SSc, and the C*07:02-B*39:05 and C*07:02-B*39:06 blocks to map the protective role of C*07: 02 in SSc. We also confirmed previous associations of HLA-DRB1*11:04 and -DRB1*01 to susceptibility to develop SSc. Importantly, we mapped the protective role of DQB1*03:01 using three Amerindian blocks. We also found a significant association for the presence of anti-Topoisomerase I antibody with HLA-DQB1*04:02, present in an Amerindian block (DRB1*08:02-DQB1*04:02), and we found several alleles associated to internal organ damage. The admixture estimations revealed a lower proportion of the Amerindian genetic component among SSc patients.
Conclusion
This is the first report of the diversity of HLA class I and II alleles and haplotypes Mexican patients with SSc. Our findings suggest that HLA class I and class II genes contribute to the protection and susceptibility to develop SSc and its different clinical presentations as well as different autoantibody profiles in Mexicans.
C1 [Rodriguez-Reyna, Tatiana S.; Mercado-Velazquez, Pamela; Nunez-Alvarez, Carlos; Cabiedes-Contreras, Javier] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico.
[Yu, Neng; Alosco, Sharon; Ohashi, Marina; Lebedeva, Tatiana] Amer Red Cross Northeast Div, HLA Lab, Dedham, MA USA.
[Cruz-Lagunas, Alfredo; Zuniga, Joaquin] Inst Nacl Enfermedades Respiratorias Ismael Cosio, Dept Immunol, Mexico City, DF, Mexico.
[Vargas-Alarcon, Gilberto] Inst Nacl Cardiol Ignacio Chavez, Basic & Technol Res Subdirect, Mexico City, DF, Mexico.
[Granados, Julio] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Transplant Dept, Mexico City, DF, Mexico.
[Yunis, Edmond] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA.
[Yunis, Edmond] Harvard Univ, Sch Med, Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA.
[Yunis, Edmond] Harvard Univ, Sch Med, Boston, MA USA.
RP Zuniga, J (reprint author), Inst Nacl Enfermedades Respiratorias Ismael Cosio, Dept Immunol, Mexico City, DF, Mexico.
EM joazu@yahoo.com; eyunis@partners.org
FU Mexican Council of Science and Technology (CONACYT)
[SALUD-2013-1-202576]; Research Funds of the National Institute of
Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico
FX This work was supported by the Mexican Council of Science and Technology
(CONACYT), [Grant number SALUD-2013-1-202576], www.conacyt.mx; and by
the Research Funds of the National Institute of Respiratory Diseases
Ismael Cosio Villegas, Mexico City, Mexico, www.iner.salud.gob.mx.
NR 56
TC 3
Z9 3
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2015
VL 10
IS 5
AR UNSP e0126727
DI 10.1371/journal.pone.0126727
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7CV
UT WOS:000354921400074
PM 25993664
ER
PT J
AU Herman, JD
Pepper, LR
Cortese, JF
Estiu, G
Galinsky, K
Zuzarte-Luis, V
Derbyshire, ER
Ribacke, U
Lukens, AK
Santos, SA
Patel, V
Clish, CB
Sullivan, WJ
Zhou, HH
Bopp, SE
Schimmel, P
Lindquist, S
Clardy, J
Mota, MM
Keller, TL
Whitman, M
Wiest, O
Wirth, DF
Mazitschek, R
AF Herman, Jonathan D.
Pepper, Lauren R.
Cortese, Joseph F.
Estiu, Guillermina
Galinsky, Kevin
Zuzarte-Luis, Vanessa
Derbyshire, Emily R.
Ribacke, Ulf
Lukens, Amanda K.
Santos, Sofia A.
Patel, Vishal
Clish, Clary B.
Sullivan, William J., Jr.
Zhou, Huihao
Bopp, Selina E.
Schimmel, Paul
Lindquist, Susan
Clardy, Jon
Mota, Maria M.
Keller, Tracy L.
Whitman, Malcolm
Wiest, Olaf
Wirth, Dyann F.
Mazitschek, Ralph
TI The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a
dual-stage target of febrifugine and its analogs
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID ANTIMALARIAL-DRUG DISCOVERY; AMINO-ACID STARVATION; MESH EWALD METHOD;
PLASMODIUM-FALCIPARUM; SACCHAROMYCES-CEREVISIAE; LIVER STAGE;
CRYPTOSPORIDIUM-PARVUM; HALOFUGINONE LACTATE; MOLECULAR-DYNAMICS; RODENT
MALARIA
AB The emergence of drug resistance is a major limitation of current antimalarials. The discovery of new druggable targets and pathways including those that are critical for multiple life cycle stages of the malaria parasite is a major goal for developing next-generation antimalarial drugs. Using an integrated chemogenomics approach that combined drug resistance selection, whole-genome sequencing, and an orthogonal yeast model, we demonstrate that the cytoplasmic prolyl-tRNA (transfer RNA) synthetase (PfcPRS) of the malaria parasite Plasmodium falciparum is a biochemical and functional target of febrifugine and its synthetic derivative halofuginone. Febrifugine is the active principle of a traditional Chinese herbal remedy for malaria. We show that treatment with febrifugine derivatives activated the amino acid starvation response in both P. falciparum and a transgenic yeast strain expressing PfcPRS. We further demonstrate in the Plasmodium berghei mouse model of malaria that halofuginol, a new halofuginone analog that we developed, is active against both liver and asexual blood stages of the malaria parasite. Halofuginol, unlike halofuginone and febrifugine, is well tolerated at efficacious doses and represents a promising lead for the development of dual-stage next-generation antimalarials.
C1 [Herman, Jonathan D.; Cortese, Joseph F.; Galinsky, Kevin; Lukens, Amanda K.; Clish, Clary B.; Clardy, Jon; Wirth, Dyann F.; Mazitschek, Ralph] Broad Inst, Program Infect Dis, Cambridge, MA 02142 USA.
[Herman, Jonathan D.; Lukens, Amanda K.; Bopp, Selina E.; Wirth, Dyann F.; Mazitschek, Ralph] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Herman, Jonathan D.] Harvard MIT Div Hlth Sci & Technol, Boston, MA 02115 USA.
[Herman, Jonathan D.] Harvard Univ, Sch Med, Harvard MIT PhD Program, Boston, MA 02115 USA.
[Pepper, Lauren R.; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Estiu, Guillermina; Wiest, Olaf] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.
[Estiu, Guillermina; Wiest, Olaf] Univ Notre Dame, Ctr Rare & Neglected Dis, Notre Dame, IN 46556 USA.
[Zuzarte-Luis, Vanessa; Mota, Maria M.] Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal.
[Derbyshire, Emily R.; Patel, Vishal; Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Santos, Sofia A.; Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Santos, Sofia A.] Univ Lisbon, Fac Farm, Inst Invest Med iMed ULisbon, P-1640003 Lisbon, Portugal.
[Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA.
[Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Toxicol, Indianapolis, IN 46202 USA.
[Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Microbiol, Indianapolis, IN 46202 USA.
[Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Immunol, Indianapolis, IN 46202 USA.
[Schimmel, Paul] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA.
[Schimmel, Paul] Scripps Res Inst, Jupiter, FL 33458 USA.
[Lindquist, Susan] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.
[Keller, Tracy L.; Whitman, Malcolm] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
[Wiest, Olaf] Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, Lab Computat Chem & Drug Design, Shenzhen 518055, Peoples R China.
RP Mazitschek, R (reprint author), Broad Inst, Program Infect Dis, Cambridge, MA 02142 USA.
EM dfwirth@hsph.harvard.edu; rmazitschek@mgh.harvard.edu
RI ZHOU, HUIHAO/L-6133-2016;
OI Zuzarte-Luis, Vanessa/0000-0003-0023-5953; Mota, Maria
Manuel/0000-0002-2858-1041
FU Gates Foundation [OPP1086203]; NIH [AI105786, 5F32AI084440-02, CA92577,
GM099796]; Center for Rare and Neglected Diseases at the University of
Notre Dame; NSF through TeraGrid grant [TG-CHE090124]; National
Foundation for Cancer Research [SFRH/BD/80162/2011,
PTDC/SAU-MIC/113697/2009]; Fundacao para a Ciencia e Tecnologia,
Portugal [EXCL/IMI-MIC/0056/2012]; Howard Hughes Medical Institute;
Center for Systems Biology, Massachusetts General Hospital
FX We gratefully acknowledge financial support from the Gates Foundation
(D.F.W. and R.M., OPP1086203), the NIH (D.F.W.) AI105786 (W.J.S.),
5F32AI084440-02 (L.R.P.), CA92577 (P.S.), and GM099796 (E.R.D.), the
Center for Rare and Neglected Diseases at the University of Notre Dame
(O.W. and G.E.), generous allocation of computing resources by the NSF
through TeraGrid grant TG-CHE090124 (O.W.), a fellowship from the
National Foundation for Cancer Research (P.S.), SFRH/BD/80162/2011
(S.A.S.), PTDC/SAU-MIC/113697/2009 (V.Z.-L.), and EXCL/IMI-MIC/0056/2012
(M.M.M.) (Fundacao para a Ciencia e Tecnologia, Portugal), Howard Hughes
Medical Institute (S.L.), and start-up funding provided by the Center
for Systems Biology, Massachusetts General Hospital (R.M.).
NR 70
TC 11
Z9 11
U1 2
U2 24
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 20
PY 2015
VL 7
IS 288
AR 288ra77
DI 10.1126/scitranslmed.aaa3575
PG 9
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA CI5PA
UT WOS:000354808900005
PM 25995223
ER
PT J
AU Sandler, HM
Hu, C
Rosenthal, SA
Sartor, O
Gomella, LG
Amin, M
Purdy, J
Michalski, JM
Garzotto, M
Pervez, N
Balogh, AG
Rodrigues, G
Souhami, L
Reaume, MN
Williams, SG
Hannan, R
Horwitz, EM
Raben, A
Paulus, R
Shipley, WU
AF Sandler, Howard M.
Hu, Chen
Rosenthal, Seth A.
Sartor, Oliver
Gomella, Leonard G.
Amin, Mahul
Purdy, James
Michalski, Jeff M.
Garzotto, Mark
Pervez, Nadeem
Balogh, Alexander G.
Rodrigues, George
Souhami, Luis
Reaume, M. Neil
Williams, Scott G.
Hannan, Raquibul
Horwitz, Eric M.
Raben, Adam
Paulus, Rebecca
Shipley, William U.
TI A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus
AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and
prednisone for localized, high-risk prostate cancer (RTOG 0521).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA.
NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA.
Sutter Canc Ctr, Sacramento, CA USA.
Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Univ Calif Davis, Sacramento, CA USA.
Washington Univ, St Louis, MO USA.
Portland VA Med Ctr, Portland, OR USA.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Tom Baker Canc Clin, Calgary, AB, Canada.
London Reg Canc Program, Dept Radiat Oncol, London, ON, Canada.
McGill Univ, Ctr Hlth, Dept Radiat Oncol, Montreal, PQ, Canada.
Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Helen F Graham Canc Ctr, Newark, DE USA.
Ctr Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA LBA5002
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904638
ER
PT J
AU Seiwert, TY
Haddad, RI
Gupta, S
Mehra, R
Tahara, M
Berger, R
Lee, SH
Burtness, B
Le, DT
Heath, K
Blum, A
Dolled-Filhart, M
Emancipator, K
Pathiraja, K
Cheng, JD
Chow, LQ
AF Seiwert, Tanguy Y.
Haddad, Robert I.
Gupta, Shilpa
Mehra, Ranee
Tahara, Makoto
Berger, Raanan
Lee, Se-Hoon
Burtness, Barbara
Le, Dung T.
Heath, Karl
Blum, Amy
Dolled-Filhart, Marisa
Emancipator, Kenneth
Pathiraja, Kumudu
Cheng, Jonathan D.
Chow, Laura Q.
TI Antitumor activity and safety of pembrolizumab in patients (pts) with
advanced squamous cell carcinoma of the head and neck (SCCHN):
Preliminary results from KEYNOTE-012 expansion cohort.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA.
JHU, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Merck & Co Inc, Kenilworth, NJ USA.
Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA LBA6008
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904640
ER
PT J
AU Wolchok, JD
Chiarion-Sileni, V
Gonzalez, R
Rutkowski, P
Grob, JJ
Cowey, CL
Lao, CD
Schadendorf, D
Ferrucci, PF
Smylie, M
Dummer, R
Hill, AG
Haanen, JBAG
Maio, M
McArthur, GA
Yang, A
Rollin, L
Horak, CE
Larkin, JMG
Hodi, FS
AF Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean Jacques
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew Graham
Haanen, John B. A. G.
Maio, Michele
McArthur, Grant A.
Yang, Arvin
Rollin, Linda
Horak, Christine E.
Larkin, James M. G.
Hodi, F. Stephen
TI Efficacy and safety results from a phase III trial of nivolumab (NIVO)
alone or combined with ipilimumab (IPI) versus IPI alone in
treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate
067).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 29-JUN 02, 2015
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Oncol Inst Veneto IRCCS, Padua, Italy.
Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
Hosp Timone, Marseille, France.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany.
European Inst Oncol, Milan, Italy.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Univ Spital Zurich, Zurich, Switzerland.
Tasman Oncol Res, Southport, Qld, Australia.
Netherlands Canc Inst, Amsterdam, Netherlands.
Univ Hosp Siena, Siena, Italy.
Peter MacCallum Canc Ctr, East Melbourne, Australia.
Bristol Myers Squibb Co, Princeton, NJ USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Royal Marsden Hosp, London SW3 6JJ, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2015
VL 33
IS 15
SU S
MA LBA1
PG 1
WC Oncology
SC Oncology
GA CM9OA
UT WOS:000358036904630
ER
PT J
AU Medaglia, JD
VanKirk, KK
Oswald, CB
Church, LWP
AF Medaglia, John D.
VanKirk, Kathryn K.
Oswald, Cameron B.
Church, L. W. Preston
TI Interdisciplinary Differential Diagnosis and Care of a Patient with
Atypical Delusional Parasitosis due to early HIV-related Dementia
SO CLINICAL NEUROPSYCHOLOGIST
LA English
DT Article
DE Neuropsychological assessment; Treatment planning.; HIV
ID NEUROCOGNITIVE DISORDERS; INFESTATION; DISEASE; ERA
AB Objective: To provide a differential diagnosis and recommendations for care for an individual with suspected delusional parasitosis secondary to human immunodeficiency virus (HIV). Method: A 62-year-old male with sexually acquired, chronic, and well-managed HIV infection was referred for neuropsychological evaluation and treatment recommendations following extensive self-manipulation of a sternoclavicular cystic mass and superficial skin lesions over most of his body. The patient reported that he had pulled long calcified tendrils out of the mass over a period of several weeks and that "encapsulated fat" was flowing beneath his skin. Results: Numerous lab panels were negative for any acute medical pathology. Clinical neuroimaging was unremarkable. Neuropsychological evaluation revealed a profile consistent with mild neurocognitive disorder due to HIV. Medical and behavioral recommendations were made for the management of delusional thought processes consistent with atypical delusional parasitosis and other symptoms. The patient was responsive to carefully crafted provider feedback and his delusional and somatic symptoms decreased significantly with risperidone. Conclusions: This case illustrates the utility of neuropsychological assessment and provider feedback in the diagnosis and care of HIV-related neurocognitive disorder, the context of a delusional disorder.
C1 [Medaglia, John D.] Moss Rehabil Res Inst, Elkins Pk, PA USA.
[Medaglia, John D.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
[VanKirk, Kathryn K.; Oswald, Cameron B.; Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Dept Neuropsychol, Charleston, SC USA.
[VanKirk, Kathryn K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Church, L. W. Preston] Med Univ S Carolina, Div Infect Dis, Charleston, SC 29425 USA.
RP Medaglia, JD (reprint author), Univ Penn, Moss Rehabil Res Inst, Translat Neurosci, 316 Hayden Hall, Philadelphia, PA 19104 USA.
EM medaglia@seas.upenn.edu
NR 24
TC 0
Z9 0
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1385-4046
EI 1744-4144
J9 CLIN NEUROPSYCHOL
JI Clin. Neuropsychol.
PD MAY 19
PY 2015
VL 29
IS 4
BP 559
EP 569
DI 10.1080/13854046.2015.1042921
PG 11
WC Psychology, Clinical; Clinical Neurology; Psychology
SC Psychology; Neurosciences & Neurology
GA CM8FZ
UT WOS:000357935100011
PM 25978635
ER
PT J
AU Yetisen, AK
Montelongo, Y
Qasim, MM
Butt, H
Wilkinson, TD
Monteiro, MJ
Yun, SH
AF Yetisen, Ali K.
Montelongo, Yunuen
Qasim, Malik M.
Butt, Haider
Wilkinson, Timothy D.
Monteiro, Michael J.
Yun, Seok Hyun
TI Photonic Nanosensor for Colorimetric Detection of Metal Ions
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID FUNCTIONALIZED GOLD NANOPARTICLES; TURN-ON; MERCURY(II) DETECTION;
HOLOGRAPHIC SENSORS; AQUEOUS-SOLUTION; LIVING CELL; LEAD; FLUORESCENT;
CADMIUM; LABEL
AB The real-time sensing of metal ions at point of care requires integrated sensors with low energy and sample consumption, reversibility, and rapid recovery. Here, we report a photonic nanosensor that reversibly and quantitatively reports on variation in the concentrations of Pb2+ and Cu2+ ions in aqueous solutions (<500 mu L) in the visible region of the spectrum (lambda(max) approximate to 400-700 nm). A single 6 ns laser pulse (lambda = 532 nm) was used to pattern an similar to 10 mu m thick photosensitive recording medium. This formed periodic AgBr nanocrystal (phi similar to 5-20 nm) concentrated regions, which produced Bragg diffraction upon illumination with a white light source. The sensor functionalized with 8-hydroxyquinoline allowed sensing through inducing Donnan osmotic pressure and tuning its lattice spacing. The sensor quantitatively measured Pb2+ and Cu2+ ion concentrations within the dynamic range of 0.1-10.0 mM with limits of detection of 11.4 and 18.6 mu M in under 10 min. The sensor could be reset in 3 min and was reused at least 100 times without compromising its accuracy. The plasmonic nanosensor represents a simple and label-free analytical platform with potential scalability for applications in medical diagnostics and environmental monitoring.
C1 [Yetisen, Ali K.; Yun, Seok Hyun] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Yetisen, Ali K.; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Montelongo, Yunuen; Qasim, Malik M.; Wilkinson, Timothy D.] Univ Cambridge, Dept Engn, Ctr Mol Mat Photon & Elect, Cambridge CB3 0FA, England.
[Butt, Haider] Univ Birmingham, Sch Mech Engn, Birmingham B15 2TT, W Midlands, England.
[Monteiro, Michael J.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
RP Yetisen, AK (reprint author), Harvard Univ, Sch Med, 50 Blossom St, Boston, MA 02114 USA.
EM ay283@cam.ac.uk
RI Montelongo, Yunuen/H-4955-2012; Monteiro, Michael/C-5658-2009;
OI Montelongo, Yunuen/0000-0002-1266-183X; Monteiro,
Michael/0000-0001-5624-7115; Butt, Haider/0000-0003-2434-9525
NR 74
TC 23
Z9 23
U1 4
U2 87
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD MAY 19
PY 2015
VL 87
IS 10
BP 5101
EP 5108
DI 10.1021/ac504274q
PG 8
WC Chemistry, Analytical
SC Chemistry
GA CI8YN
UT WOS:000355057700015
PM 25710792
ER
PT J
AU Balaj, L
Atai, NA
Chen, WL
Mu, D
Tannous, BA
Breakefield, XO
Skog, J
Maguire, CA
AF Balaj, Leonora
Atai, Nadia A.
Chen, Weilin
Mu, Dakai
Tannous, Bakhos A.
Breakefield, Xandra O.
Skog, Johan
Maguire, Casey A.
TI Heparin affinity purification of extracellular vesicles
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HEAT-SHOCK PROTEINS; SULFATE PROTEOGLYCANS; PROTEOMIC ANALYSIS;
CARCINOMA CELLS; EXOSOMES; MICROVESICLES; CANCER; RNA; IDENTIFICATION;
BIOMARKERS
AB Extracellular vesicles (EVs) are lipid membrane vesicles released by cells. They carry active biomolecules including DNA, RNA, and protein which can be transferred to recipient cells. Isolation and purification of EVs from culture cell media and biofluids is still a major challenge. The most widely used isolation method is ultracentrifugation (UC) which requires expensive equipment and only partially purifies EVs. Previously we have shown that heparin blocks EV uptake in cells, supporting a direct EV-heparin interaction. Here we show that EVs can be purified from cell culture media and human plasma using ultrafiltration (UF) followed by heparin-affinity beads. UF/heparinpurified EVs from cell culture displayed the EV marker Alix, contained a diverse RNA profile, had lower levels of protein contamination, and were functional at binding to and uptake into cells. RNA yield was similar for EVs isolated by UC. We were able to detect mRNAs in plasma samples with comparable levels to UC samples. In conclusion, we have discovered a simple, scalable, and effective method to purify EVs taking advantage of their heparin affinity.
C1 [Balaj, Leonora; Atai, Nadia A.; Chen, Weilin; Mu, Dakai; Tannous, Bakhos A.; Breakefield, Xandra O.; Maguire, Casey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Balaj, Leonora; Atai, Nadia A.; Chen, Weilin; Mu, Dakai; Tannous, Bakhos A.; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Atai, Nadia A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1012 WX Amsterdam, Netherlands.
[Skog, Johan] Exosome Diagnost Inc, Cambridge, MA USA.
RP Maguire, CA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM cmaguire@mgh.harvard.edu
FU NIH/NINDS [1 R21 NS081374-01]; American Brain Tumor Association
Discovery Grant; NIH/NCI [CA069246, CA141226, CA156009, CA141150]; FMD
MGH ECOR Fellowship; Richard Floor Biorepository; PHS [P30NS045776]
FX This work was supported by NIH/NINDS 1 R21 NS081374-01 (C.A.M.) and an
American Brain Tumor Association Discovery Grant (C.A.M.); NIH/NCI
grants CA069246 (X.O.B), CA141226 (X.O.B.); CA156009 (X.O.B.) CA141150
(X.O.B.); LB is supported by an FMD MGH ECOR Fellowship and the Richard
Floor Biorepository. We gratefully acknowledge the Neuroscience Center
PCR Core facility, which is funded by PHS grant P30NS045776. We thank
Maria Ericsson of the Harvard Conventional Electron Microscopy Core for
performing the TEM analysis of EV samples. We thank Ross Tomaino of the
Harvard Medical School's Taplin Biological Mass Spectrometry facility
for performing the mass spectrometry analysis of EV proteins
NR 47
TC 21
Z9 21
U1 3
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 19
PY 2015
VL 5
AR 10266
DI 10.1038/srep10266
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2EK
UT WOS:000355296800001
PM 25988257
ER
PT J
AU Kerlikowske, K
Zhu, WW
Tosteson, ANA
Sprague, BL
Tice, JA
Lehman, CD
Miglioretti, DL
AF Kerlikowske, Karla
Zhu, Weiwei
Tosteson, Anna N. A.
Sprague, Brian L.
Tice, Jeffrey A.
Lehman, Constance D.
Miglioretti, Diana L.
CA Breast Canc Surveillance
TI Identifying Women With Dense Breasts at High Risk for Interval Cancer A
Cohort Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID POSTMENOPAUSAL HORMONE-THERAPY; CARCINOMA IN-SITU; SCREENING
MAMMOGRAPHY; DIGITAL MAMMOGRAPHY; TUMOR CHARACTERISTICS; UNITED-STATES;
TOMOSYNTHESIS; PERFORMANCE; ULTRASOUND; OUTCOMES
AB Background: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider.
Objective: To better direct discussions of supplemental imaging by determining which combinations of breast cancer risk and Breast Imaging Reporting and Data System (BI-RADS) breast density categories are associated with high interval cancer rates.
Design: Prospective cohort.
Setting: Breast Cancer Surveillance Consortium (BCSC) breast imaging facilities.
Patients: 365 426 women aged 40 to 74 years who had 831 455 digital screening mammography examinations.
Measurements: BI-RADS breast density, BCSC 5-year breast cancer risk, and interval cancer rate (invasive cancer <= 12 months after a normal mammography result) per 1000 mammography examinations. High interval cancer rate was defined as more than 1 case per 1000 examinations.
Results: High interval cancer rates were observed for women with 5-year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts). The interval rate of advanced-stage disease was highest (> 0.4 case per 1000 examinations) among women with 5-year risk of 2.50% or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts). Five-year risk was low to average (0% to 1.66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.63 and 0.72 to 0.89 case per 1000 examinations, respectively.
Limitation: The benefit of supplemental imaging was not assessed.
Conclusion: Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patientprovider discussions about alternative screening strategies.
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
Univ Washington, Sch Med, Seattle, WA 98109 USA.
Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA.
Univ Vermont, Burlington, VT USA.
Univ Calif Davis, Davis, CA 95616 USA.
RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.
FU National Cancer Institute [P01 CA154292, HHSN261201100031C, U54
CA163303]
FX This work was supported by the National Cancer Institute-funded BCSC
(P01 CA154292, HHSN261201100031C, and U54 CA163303). The collection of
cancer data used in this study was supported in part by several state
public health departments and cancer registries throughout the United
States. A full description of these sources is available at
http://breastscreening.cancer.gov/work/acknowledgement.html.
NR 40
TC 32
Z9 32
U1 0
U2 18
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 19
PY 2015
VL 162
IS 10
BP 673
EP +
DI 10.7326/M14-1465
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI8IF
UT WOS:000355015200016
PM 25984843
ER
PT J
AU Thomas, MP
Liu, X
Whangbo, J
McCrossan, G
Sanborn, KB
Basar, E
Walch, M
Lieberman, J
AF Thomas, Marshall P.
Liu, Xing
Whangbo, Jennifer
McCrossan, Geoffrey
Sanborn, Keri B.
Basar, Emre
Walch, Michael
Lieberman, Judy
TI Apoptosis Triggers Specific, Rapid, and Global mRNA Decay with 3 '
Uridylated Intermediates Degraded by DIS3L2
SO CELL REPORTS
LA English
DT Article
ID GENOME-WIDE DETERMINATION; CELL-DEATH; SACCHAROMYCES-CEREVISIAE;
TRANSLATION INHIBITION; DEGRADATION PATHWAY; CASPASE ACTIVATION;
CYTOPLASMIC RNA; NUCLEIC-ACIDS; ZCCHC11 TUT4; CYTOCHROME-C
AB Apoptosis is a tightly coordinated cell death program that damages mitochondria, DNA, proteins, and membrane lipids. Little is known about the fate of RNA as cells die. Here, we show that mRNAs, but not noncoding RNAs, are rapidly and globally degraded during apoptosis. mRNA decay is triggered early in apoptosis, preceding membrane lipid scrambling, genomic DNA fragmentation, and apoptotic changes to translation initiation factors. mRNA decay depends on mitochondrial outer membrane permeabilization and is amplified by caspase activation. 3 ' truncated mRNA decay intermediates with nontemplated uridylate-rich tails are generated during apoptosis. These tails are added by the terminal uridylyl transferases (TUTases) ZCCHC6 and ZCCHC11, and the uridylated transcript intermediates are degraded by the 3 ' to 5 ' exonuclease DIS3L2. Knockdown of DIS3L2 or the TUTases inhibits apoptotic mRNA decay, translation arrest, and cell death, whereas DIS3L2 overexpression enhances cell death. Our results suggest that global mRNA decay is an overlooked hallmark of apoptosis.
C1 [Thomas, Marshall P.; Liu, Xing; Whangbo, Jennifer; McCrossan, Geoffrey; Sanborn, Keri B.; Basar, Emre; Walch, Michael; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
RP Lieberman, J (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
EM judy.lieberman@childrens.harvard.edu
OI Sanborn, Keri/0000-0002-5071-4349
FU NSF; NIH [AI045587]
FX We thank Nancy Kedersha, Ashish Lal, and Aaron Deutsch for advice and
technical assistance; Paul Anderson and Steve Buratowski for valuable
advice; and Andrej Dziembowski and Britt Glaunsinger for plasmids. This
work was supported by an NSF graduate research fellowship to M.P.T. and
NIH grant AI045587 to J.L.
NR 44
TC 20
Z9 20
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY 19
PY 2015
VL 11
IS 7
BP 1079
EP 1089
DI 10.1016/j.celrep.2015.04.026
PG 11
WC Cell Biology
SC Cell Biology
GA CI4LI
UT WOS:000354719900009
PM 25959823
ER
PT J
AU Givertz, MM
Anstrom, KJ
Redfield, MM
Deswal, A
Haddad, H
Butler, J
Tang, WHW
Dunlap, ME
LeWinter, MM
Mann, DL
Felker, GM
O'Connor, CM
Goldsmith, SR
Ofili, EO
Saltzberg, MT
Margulies, KB
Cappola, TP
Konstam, MA
Semigran, MJ
McNulty, SE
Lee, KL
Shah, MR
Hernandez, AF
AF Givertz, Michael M.
Anstrom, Kevin J.
Redfield, Margaret M.
Deswal, Anita
Haddad, Haissam
Butler, Javed
Tang, W. H. Wilson
Dunlap, Mark E.
LeWinter, Martin M.
Mann, Douglas L.
Felker, G. Michael
O'Connor, Christopher M.
Goldsmith, Steven R.
Ofili, Elizabeth O.
Saltzberg, Mitchell T.
Margulies, Kenneth B.
Cappola, Thomas P.
Konstam, Marvin A.
Semigran, Marc J.
McNulty, Steven E.
Lee, Kerry L.
Shah, Monica R.
Hernandez, Adrian F.
CA NHLBI Heart Failure Clinical Res
TI Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure
Patients The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure
Patients (EXACT-HF) Study
SO CIRCULATION
LA English
DT Article
DE allopurinol; clinical trial; heart failure; xanthine oxidase
ID NITROSO-REDOX IMBALANCE; LEFT-VENTRICULAR MASS; URIC-ACID; OXIDATIVE
STRESS; ALLOPURINOL USE; HEALTH-STATUS; OXYPURINOL; SURVIVAL; TRIAL;
CARDIOMYOPATHY
AB Background-Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes.
Methods and Results-We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction <= 40%, and serum uric acid levels >= 9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment. Secondary end points included change in quality of life, submaximal exercise capacity, and left ventricular ejection fraction. Uric acid levels were significantly reduced with allopurinol in comparison with placebo (treatment difference, -4.2 [-4.9, -3.5] mg/dL and -3.5 [-4.2, -2.7] mg/dL at 12 and 24 weeks, respectively, both P<0.0001). At 24 weeks, there was no significant difference in clinical status between the allopurinol-and placebo-treated patients (worsened 45% versus 46%, unchanged 42% versus 34%, improved 13% versus 19%, respectively; P=0.68). At 12 and 24 weeks, there was no significant difference in change in Kansas City Cardiomyopathy Questionnaire scores or 6-minute walk distances between the 2 groups. At 24 weeks, left ventricular ejection fraction did not change in either group or between groups. Rash occurred more frequently with allopurinol (10% versus 2%, P=0.01), but there was no difference in serious adverse event rates between the groups (20% versus 15%, P=0.36).
Conclusions-In high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or left ventricular ejection fraction at 24 weeks.
C1 [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Anstrom, Kevin J.; Felker, G. Michael; O'Connor, Christopher M.; McNulty, Steven E.; Lee, Kerry L.; Hernandez, Adrian F.] Duke Univ, Med Ctr, Durham, NC USA.
[Redfield, Margaret M.] Mayo Clin, Rochester, MN USA.
[Deswal, Anita] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Haddad, Haissam] Ottawa Heart Inst, Ottawa, ON, Canada.
[Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Tang, W. H. Wilson] Cleveland Clin, Cleveland, OH USA.
[Dunlap, Mark E.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[LeWinter, Martin M.] Univ Vermont, Burlington, VT 05405 USA.
[Mann, Douglas L.] Washington Univ, St Louis, MO USA.
[Goldsmith, Steven R.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Ofili, Elizabeth O.] Morehouse Sch Med, Atlanta, GA 30310 USA.
[Saltzberg, Mitchell T.] Christiana Care Hlth Syst, Newark, DE USA.
[Margulies, Kenneth B.; Cappola, Thomas P.] Univ Penn, Philadelphia, PA 19104 USA.
[Konstam, Marvin A.] Tufts Med Ctr, Boston, MA USA.
[Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shah, Monica R.] NHLBI, Bethesda, MD 20892 USA.
RP Givertz, MM (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.
EM mgivertz@partners.org
RI Hernandez, Adrian F./A-7818-2016
OI Hernandez, Adrian F./0000-0003-3387-9616
FU National Institutes of Health: NHLBI [U10HL084904, U01HL084861,
U10HL110312, U109HL110337, U01HL084889, U01HL084890, U01HL084891,
U10HL110342, U10HL110262, U01HL084931, U10HL110297, U10HL110302, U10
HL110309, U10HL110336, U10HL110338]; National Center for Advancing
Translational Sciences [UL1TR000454, UL1TR000439]; National Institute on
Minority Health and Health Disparities [8 U54 MD007588]
FX This work was supported by grants from the National Institutes of
Health: NHLBI (coordinating center: U10HL084904; regional clinical
centers: U01HL084861, U10HL110312, U109HL110337, U01HL084889,
U01HL084890, U01HL084891, U10HL110342, U10HL110262, U01HL084931,
U10HL110297, U10HL110302, U10 HL110309, U10HL110336, U10HL110338); the
National Center for Advancing Translational Sciences (UL1TR000454,
UL1TR000439); and the National Institute on Minority Health and Health
Disparities (8 U54 MD007588).
NR 41
TC 34
Z9 34
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAY 19
PY 2015
VL 131
IS 20
BP 1763
EP 1771
DI 10.1161/CIRCULATIONAHA.114.014536
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CI2XC
UT WOS:000354610300013
PM 25986447
ER
PT J
AU Schuster, C
Gerold, KD
Schober, K
Probst, L
Boerner, K
Kim, MJ
Ruckdeschel, A
Serwold, T
Kissler, S
AF Schuster, Cornelia
Gerold, Kay D.
Schober, Kilian
Probst, Lilli
Boerner, Kevin
Kim, Mi-Jeong
Ruckdeschel, Anna
Serwold, Thomas
Kissler, Stephan
TI The Autoimmunity-Associated Gene CLEC16A Modulates Thymic Epithelial
Cell Autophagy and Alters T Cell Selection
SO IMMUNITY
LA English
DT Article
ID MHC CLASS-II; PROTEIN; SUSCEPTIBILITY; MOLECULES; COMPLEX; ANTIGEN;
IDENTIFICATION; COMPARTMENTS; THYMOCYTES; EXPRESSION
AB CLEC16A variation has been associated with multiple immune-mediated diseases, including type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, celiac disease, Crohn's disease, Addison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idiopathic arthritis, and alopecia areata. Despite strong genetic evidence implicating CLEC16A in autoimmunity, this gene's broad association with disease remains unexplained. We generated Clec16a knock-down (KD) mice in the nonobese diabetic (NOD) model for type 1 diabetes and found that Clec16a silencing protected against autoimmunity. Disease protection was attributable to T cell hyporeactivity, which was secondary to changes in thymic epithelial cell (TEC) stimuli that drive thymocyte selection. Our data indicate that T cell selection and reactivity were impacted by Clec16a variation in thymic epithelium owing to Clec16a's role in TEC autophagy. These findings provide a functional link between human CLEC16A variation and the immune dysregulation that underlies the risk of autoimmunity.
C1 [Schuster, Cornelia; Schober, Kilian; Boerner, Kevin; Kim, Mi-Jeong; Ruckdeschel, Anna; Serwold, Thomas; Kissler, Stephan] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Gerold, Kay D.; Probst, Lilli; Kissler, Stephan] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, D-97080 Wurzburg, Germany.
RP Kissler, S (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM stephan.kissler@joslin.harvard.edu
OI , /0000-0003-3062-7800
FU NIH [P30DK036836]; Deutsche Forschungsgemeinschaft [DFG FZ82]; JDRF
[2-2010-383]; Mary K. Iacocca Fellowship by Iacocca Foundation
FX The authors thank Nicole Hain for technical assistance, Daniela
Blassfeld for help with the initial cloning and validation of lentiviral
vectors, Jennifer Hollister-Lock for advice with islet purification and
insulin measurements, and the Joslin DRC (NIH Award Number P30DK036836)
Flow Cytometry Core facility for help with cell sorting. This work was
supported in part by funding from the Deutsche Forschungsgemeinschaft to
the Rudolf Virchow Center (DFG FZ82), by a Career Development Award from
JDRF to S.K. (2-2010-383), and by a Mary K. Iacocca Fellowship provided
by the Iacocca Foundation to C.S.
NR 40
TC 12
Z9 12
U1 6
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD MAY 19
PY 2015
VL 42
IS 5
BP 942
EP 952
DI 10.1016/j.immuni.2015.04.011
PG 11
WC Immunology
SC Immunology
GA CI5VH
UT WOS:000354827400019
PM 25979422
ER
PT J
AU Anahtar, MN
Byme, EH
Doherty, KE
Bowman, BA
Yamamoto, HS
Soumillon, M
Padavattan, N
Ismail, N
Moodley, A
Sabatini, ME
Ghebremichael, MS
Nusbaum, C
Huttenhower, C
Virgin, HW
Ndung'u, T
Dong, KL
Walker, BD
Fichorova, RN
Kwon, DS
AF Anahtar, Melis N.
Byme, Elizabeth H.
Doherty, Kathleen E.
Bowman, Brittany A.
Yamamoto, Hidemi S.
Soumillon, Magali
Padavattan, Nikita
Ismail, Nasreen
Moodley, Amber
Sabatini, Mary E.
Ghebremichael, Musie S.
Nusbaum, Chad
Huttenhower, Curtis
Virgin, Herbert W.
Ndung'u, Thumbi
Dong, Krista L.
Walker, Bruce D.
Fichorova, Raina N.
Kwon, Douglas S.
TI Cervicovaginal Bacteria Are a Major Modulator of Host Inflammatory
Responses in the Female Genital Tract
SO IMMUNITY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; NEISSERIA-GONORRHOEAE; VAGINAL MICROBIOME;
EPITHELIAL-CELLS; PREGNANT-WOMEN; INFECTION; VAGINOSIS; INTERLEUKIN-6;
EXPRESSION; PROTECTION
AB Colonization by Lactobacillus in the female genital tract is thought to be critical for maintaining genital health. However, little is known about how genital microbiota influence host immune function and modulate disease susceptibility. We studied a cohort of asymptomatic young South African women and found that the majority of participants had genital communities with low Lactobacillus abundance and high ecological diversity. High-diversity communities strongly correlated with genital pro-inflammatory cytokine concentrations in both cross-sectional and longitudinal analyses. Transcriptional profiling suggested that genital antigen-presenting cells sense gram-negative bacterial products in situ via Toll-like receptor 4 signaling, contributing to genital inflammation through activation of the NF-kappa B signaling pathway and recruitment of lymphocytes by chemokine production. Our study proposes a mechanism by which cervicovaginal microbiota impact genital inflammation and thereby might affect a woman's reproductive health, including her risk of acquiring HIV.
C1 [Anahtar, Melis N.; Byme, Elizabeth H.; Doherty, Kathleen E.; Bowman, Brittany A.; Ghebremichael, Musie S.; Ndung'u, Thumbi; Dong, Krista L.; Walker, Bruce D.; Kwon, Douglas S.] Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
[Anahtar, Melis N.] Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA.
[Yamamoto, Hidemi S.; Fichorova, Raina N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[Soumillon, Magali; Nusbaum, Chad] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Padavattan, Nikita; Ismail, Nasreen; Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, ZA-4001 Durban, KwaZulu Natal, South Africa.
[Moodley, Amber; Dong, Krista L.] Females Rising Educ Support & Hlth, ZA-4066 Durban, KwaZulu Natal, South Africa.
[Sabatini, Mary E.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV K RITH, ZA-4001 Durban, KwaZulu Natal, South Africa.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Walker, Bruce D.; Kwon, Douglas S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA.
RP Kwon, DS (reprint author), Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
EM dkwon@mgh.harvard.edu
OI Ndung'u, Thumbi/0000-0003-2962-3992
FU Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative
(IAVI) [UKZNRSA1001]; NIAID [1R01AI111918, RO1AI067073, 5R01AI079085];
Burroughs Wellcome Fund; NIGMS [T32GM007753]; Paul and Daisy Soros
Fellowship; South African Research Chairs Initiative; Howard Hughes
Medical Institute
FX We would like to thank the FRESH participants; T. Cele for performing
the pelvic exams; T. Sikhakhane, S. Ngcobo, and S. Zungu for clinical
support; H. Shen for flow cytometric assistance; A. Lisanti for
performing tissue staining; B. Corleis, C. Gosmann, and G. Olson for
critical feedback and assistance; S. Karim, L. Liebenberg, N. Samsunder,
and N. Garrett for helpful discussions regarding mucosal sampling; C.
Monaco and S. Handley for discussions about sample preparation and
sequencing; and L. Hoisington-Lopez for sequencing support. This work
was supported by the Collaboration for AIDS Vaccine Discovery of the
Bill and Melinda Gates Foundation, the International AIDS Vaccine
Initiative (IAVI) (UKZNRSA1001), and the NIAID (1R01AI111918 and
RO1AI067073). D.S.K. received additional support from the Burroughs
Wellcome Fund. M.N.A. was supported by award number T32GM007753 from the
NIGMS, and the Paul and Daisy Soros Fellowship. R.N.F. and H.S.Y were
supported by the NIAID (5R01AI079085). T.N. received additional support
from the South African Research Chairs Initiative and an International
Early Career Scientist Award from the Howard Hughes Medical Institute.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIGMS or the NIH.
NR 46
TC 46
Z9 46
U1 4
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD MAY 19
PY 2015
VL 42
IS 5
BP 965
EP 976
DI 10.1016/j.immuni.2015.04.019
PG 12
WC Immunology
SC Immunology
GA CI5VH
UT WOS:000354827400021
PM 25992865
ER
PT J
AU Ganguli, I
Wasfy, JH
Ferris, TG
AF Ganguli, Ishani
Wasfy, Jason H.
Ferris, Timothy G.
TI What Is the Right Number of Clinic Appointments? Visit Frequency and the
Accountable Care Organization
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Ganguli, Ishani; Wasfy, Jason H.; Ferris, Timothy G.] Harvard Univ, Sch Med, Boston, MA USA.
[Ganguli, Ishani; Wasfy, Jason H.; Ferris, Timothy G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ferris, Timothy G.] Partners HealthCare, Boston, MA USA.
RP Ganguli, I (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 205, Boston, MA 02114 USA.
EM ishani.ganguli@gmail.com
NR 8
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 19
PY 2015
VL 313
IS 19
BP 1905
EP 1906
DI 10.1001/jama.2015.3356
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4BK
UT WOS:000354691200007
PM 25844726
ER
PT J
AU Rao, RC
Ballard, TNS
Chen, TC
AF Rao, Rajesh C.
Ballard, Tiffany N. S.
Chen, Teresa C.
TI Iris Heterochromia and Unilateral Eyelash Hypertrichosis
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID BIMATOPROST; GLAUCOMA; MECHANISM; GROWTH
C1 [Rao, Rajesh C.] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
[Rao, Rajesh C.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48105 USA.
[Ballard, Tiffany N. S.] Univ Michigan, Dept Surg, Sect Plast Surg, Ann Arbor, MI 48105 USA.
[Chen, Teresa C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Rao, RC (reprint author), Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St,Brehm Room 8326, Ann Arbor, MI 48105 USA.
EM rajeshr@med.umich.edu
FU NEI NIH HHS [K12EY022299, K12 EY022299]
NR 10
TC 0
Z9 0
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 19
PY 2015
VL 313
IS 19
BP 1967
EP 1968
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI4BK
UT WOS:000354691200019
PM 25988467
ER
PT J
AU Richard, J
Veillette, M
Brassard, N
Iyerc, SS
Roger, M
Martin, L
Pazgier, M
Schon, A
Freire, E
Routy, JP
Smith, AB
Park, J
Jones, DM
Courter, JR
Melillo, BN
Kaufmann, DE
Hahn, BH
Permar, SR
Haynes, BF
Madani, N
Sodroski, JG
Finzi, A
AF Richard, Jonathan
Veillette, Maxime
Brassard, Nathalie
Iyerc, Shilpa S.
Roger, Michel
Martin, Loic
Pazgier, Marzena
Schoen, Arne
Freire, Ernesto
Routy, Jean-Pierre
Smith, Amos B., III
Park, Jongwoo
Jones, David M.
Courter, Joel R.
Melillo, Bruno N.
Kaufmann, Daniel E.
Hahn, Beatrice H.
Permar, Sallie R.
Haynes, Barton F.
Madani, Navid
Sodroski, Joseph G.
Finzi, Andres
TI CD4 mimetics sensitize HIV-1-infected cells to ADCC
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE HIV-1; envelope glycoproteins; gp120; CD4 mimetics; ADCC
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXICITY-MEDIATING ANTIBODIES; VACCINE
EFFICACY TRIAL; HIV-1 ENTRY INHIBITORS; STRUCTURE-BASED DESIGN; VPU
PROTEIN; GP120; ENVELOPE; EPITOPES; BINDING
AB HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformation on their surface are preferentially targeted by antibody-dependent cell-mediated cytotoxicity (ADCC). HIV-1 has evolved a sophisticated mechanism to avoid exposure of ADCC-mediating Env epitopes by down-regulating CD4 and by limiting the overall amount of Env at the cell surface. Here we report that small-molecule CD4-mimetic compounds induce the CD4-bound conformation of Env, and thereby sensitize cells infected with primary HIV-1 isolates to ADCC mediated by antibodies present in sera, cervicovaginal lavages, and breast milk from HIV-1-infected individuals. Importantly, we identified one CD4 mimetic with the capacity to sensitize endogenously infected ex vivo-amplified primary CD4 T cells to ADCC killing mediated by autologous sera and effector cells. Thus, CD4 mimetics hold the promise of therapeutic utility in preventing and controlling HIV-1 infection.
C1 [Richard, Jonathan; Veillette, Maxime; Brassard, Nathalie; Roger, Michel; Finzi, Andres] Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ H3C 3J7, Canada.
[Richard, Jonathan; Veillette, Maxime; Roger, Michel; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada.
[Iyerc, Shilpa S.; Hahn, Beatrice H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Iyerc, Shilpa S.; Hahn, Beatrice H.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Martin, Loic] Inst Biol & Technol Saclay, Serv Ingn Mol Proteines, Commissariat Eergie Atom, F-91191 Gif Sur Yvette, France.
[Pazgier, Marzena] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
[Pazgier, Marzena] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
[Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[Routy, Jean-Pierre; Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
[Smith, Amos B., III; Park, Jongwoo; Jones, David M.; Courter, Joel R.; Melillo, Bruno N.] Univ Penn, Sch Arts & Sci, Dept Chem, Philadelphia, PA 19104 USA.
[Kaufmann, Daniel E.] Harvard Univ, Massachusetts Gen Hosp, Massachusetts Inst, Ragon Inst, Cambridge, MA 02139 USA.
[Kaufmann, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ H2X 0A9, Canada.
[Kaufmann, Daniel E.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
[Permar, Sallie R.; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA.
[Madani, Navid; Sodroski, Joseph G.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Madani, Navid; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Div Aids, Boston, MA 02115 USA.
[Madani, Navid; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Finzi, A (reprint author), Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ H3C 3J7, Canada.
EM bhahn@upenn.edu; andres.finzi@umontreal.ca
RI MARTIN, loic/E-1627-2011
OI MARTIN, loic/0000-0002-7940-2955
FU Canada Foundation; Canadian Institutes of Health Research operating
[119334, 134117]; Fonds de Recherche Quebec Sante Establishment of Young
Scientist [26702]; FRQS AIDS and Infectious Diseases Network; CIHR
Doctoral Research Award [291485]; CIHR Fellowship Award [135349];
Research Scholar Career Award of the Quebec Health Research Fund
[25131]; NIH [R01AI111789, R01AI114266, R01AI087181, R01HL092565,
P30AI045008, GM56550, AI100645, UM1AI24755, UM1AI100663, AI106380,
AI090682]; International AIDS Vaccine Initiative; Bill and Melinda Gates
Foundation [OPP1033109]; National Science Foundation [MCB-1157506];
amfAR [107431-45-RFNT]; Ragon Institute Innovation Award
FX We thank Yvette McLaughlin and Elizabeth Carpelan for help in manuscript
preparation. We also thank the Centre de Recherche du CHUM Flow
Cytometry Platform for technical assistance, Mario Legault for cohort
coordination, and Mathieu Coutu for producing sCD4. We thank Kimberly
Barbas from Children's Hospital Boston for providing the samples from
the uninfected women. We are thankful for all subjects' participation
and collaboration. This work was supported by a Canada Foundation for
Innovation Program Leader grant, by Canadian Institutes of Health
Research operating Grants 119334 and 134117, by Fonds de Recherche
Quebec Sante Establishment of Young Scientist Grant 26702 (to A.F.), and
by the FRQS AIDS and Infectious Diseases Network. A.F. is the recipient
of a Canada Research Chair on Retroviral Entry. M.V. was supported by
CIHR Doctoral Research Award 291485. J.R. is the recipient of CIHR
Fellowship Award 135349. J.-P.R. is the holder of the Louis Lowenstein
Chair in Hematology and Oncology. D.E.K. is supported by Research
Scholar Career Award of the Quebec Health Research Fund 25131. This
study was also supported by NIH Grants R01AI111789, R01AI114266,
R01AI087181, R01HL092565, P30AI045008, GM56550, AI100645, UM1AI24755,
UM1AI100663, and AI106380; the International AIDS Vaccine Initiative;
the Bill and Melinda Gates Foundation (Grant OPP1033109); the National
Science Foundation (Grant MCB-1157506); and the late William F.
McCarty-Cooper. N.M. was supported by amfAR Grant 107431-45-RFNT, NIH
Grant AI090682, and a Ragon Institute Innovation Award.
NR 52
TC 26
Z9 26
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 19
PY 2015
VL 112
IS 20
BP E2687
EP E2694
DI 10.1073/pnas.1506755112
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI4OD
UT WOS:000354729500019
PM 25941367
ER
PT J
AU Sjolin-Goodfellow, H
Frushicheva, MP
Ji, QQ
Cheng, DA
Kadlecek, TA
Cantor, AJ
Kuriyan, J
Chakraborty, AK
Salomon, AR
Weiss, A
AF Sjoelin-Goodfellow, Hanna
Frushicheva, Maria P.
Ji, Qinqin
Cheng, Debra A.
Kadlecek, Theresa A.
Cantor, Aaron J.
Kuriyan, John
Chakraborty, Arup K.
Salomon, Arthur R.
Weiss, Arthur
TI The catalytic activity of the kinase ZAP-70 mediates basal signaling and
negative feedback of the T cell receptor pathway
SO SCIENCE SIGNALING
LA English
DT Article
ID PHOSPHOTYROSINE-BINDING DOMAIN; SYK ACTIVATION SWITCH; TYROSINE
PHOSPHORYLATION; MASS-SPECTROMETRY; STRUCTURAL BASIS; ZETA-CHAIN;
IMMUNOLOGICAL SYNAPSE; AUTOIMMUNE ARTHRITIS; INTERDOMAIN B; IMMUNE CELLS
AB T cell activation by antigens binding to the T cell receptor (TCR) must be properly regulated to ensure normal T cell development and effective immune responses to pathogens and transformed cells while avoiding autoimmunity. The Src family kinase Lck and the Syk family kinase ZAP-70 (zeta chain-associated protein kinase of 70 kD) are sequentially activated in response to TCR engagement and serve as critical components of the TCR signaling machinery that leads to T cell activation. We performed amass spectrometry-based phosphoproteomic study comparing the quantitative differences in the temporal dynamics of phosphorylation in stimulated and unstimulated T cells with or without inhibition of ZAP-70 catalytic activity. The data indicated that the kinase activity of ZAP-70 stimulates negative feedback pathways that target Lck and thereby modulate the phosphorylation patterns of the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 and zeta chain components of the TCR and of signaling molecules downstream of Lck, including ZAP-70. We developed a computational model that provides a mechanistic explanation for the experimental findings on ITAM phosphorylation in wild-type cells, ZAP-70-deficient cells, and cells with inhibited ZAP-70 catalytic activity. This model incorporated negative feedback regulation of Lck activity by the kinase activity of ZAP-70 and predicted the order in which tyrosines in the ITAMs of TCR z chains must be phosphorylated to be consistent with the experimental data.
C1 [Sjoelin-Goodfellow, Hanna; Cheng, Debra A.; Kadlecek, Theresa A.; Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.
[Sjoelin-Goodfellow, Hanna; Cheng, Debra A.; Kadlecek, Theresa A.; Weiss, Arthur] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Frushicheva, Maria P.; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02142 USA.
[Ji, Qinqin; Salomon, Arthur R.] Brown Univ, Dept Chem, Providence, RI 02912 USA.
[Cantor, Aaron J.; Kuriyan, John] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
[Cantor, Aaron J.; Kuriyan, John] Univ Calif Berkeley, Calif Inst Quantitat Biosci, Berkeley, CA 94720 USA.
[Kuriyan, John] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
[Kuriyan, John] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
[Kuriyan, John] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA.
[Chakraborty, Arup K.] MIT, Dept Phys, Cambridge, MA 02142 USA.
[Chakraborty, Arup K.] MIT, Dept Chem, Cambridge, MA 02142 USA.
[Chakraborty, Arup K.] MIT, Dept Biol Engn, Cambridge, MA 02142 USA.
[Chakraborty, Arup K.] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA.
[Chakraborty, Arup K.] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA.
[Chakraborty, Arup K.] Harvard Univ, Cambridge, MA 02139 USA.
[Salomon, Arthur R.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA.
RP Salomon, AR (reprint author), Brown Univ, Dept Chem, Providence, RI 02912 USA.
EM arupc@mit.edu; as@brown.edu; aweiss@medicine.ucsf.edu
OI Kadlecek, Theresa/0000-0002-1020-8169
FU NIH [P01 AI91580, R01 AI083636]; Wenner-Gren Foundations, Sweden;
Stiftelsen Blanceflor Boncompagni Ludovisi, fodd Bildt; Sweden-America
Foundation; Cancer Research Institute Irvington Fellowship
FX This work was supported in part by NIH grants P01 AI91580 and R01
AI083636; Wenner-Gren Foundations, Sweden (to H.S.-G.); Stiftelsen
Blanceflor Boncompagni Ludovisi, fodd Bildt (to H.S.-G.); Sweden-America
Foundation (to H.S.-G.); and Cancer Research Institute Irvington
Fellowship (to M.P.F.).
NR 94
TC 4
Z9 4
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAY 19
PY 2015
VL 8
IS 377
AR ra49
DI 10.1126/scisignal.2005596
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CI5DG
UT WOS:000354772500003
PM 25990959
ER
PT J
AU Aragam, KG
Dai, D
Neely, ML
Bhatt, DL
Roe, MT
Rumsfeld, JS
Gurm, HS
AF Aragam, Krishna G.
Dai, Dadi
Neely, Megan L.
Bhatt, Deepak L.
Roe, Matthew T.
Rumsfeld, John S.
Gurm, Hitinder S.
TI Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing
Percutaneous Coronary Intervention in the United States
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE cardiac rehabilitation; percutaneous coronary intervention; quality of
care; secondary prevention
ID ACUTE MYOCARDIAL-INFARCTION; ARTERY-DISEASE PATIENTS; SECONDARY
PREVENTION; HEART-DISEASE; AMERICAN-COLLEGE; EXERCISE; ASSOCIATION;
GUIDELINES; OUTCOMES; PROGRAM
AB BACKGROUND Rates of referral to cardiac rehabilitation after percutaneous coronary intervention (PCI) have been historically low despite the evidence that rehabilitation is associated with lower mortality in PCI patients.
OBJECTIVES This study sought to determine the prevalence of and factors associated with referral to cardiac rehabilitation in a national PCI cohort, and to assess the association between insurance status and referral patterns.
METHODS Consecutive patients who underwent PCI and survived to hospital discharge in the National Cardiovascular Data Registry between July 1, 2009 and March 31, 2012 were analyzed. Cardiac rehabilitation referral rates, and patient and institutional factors associated with referral were evaluated for the total study population and for a subset of Medicare patients presenting with acute myocardial infarction.
RESULTS Patients who underwent PCI (n = 1,432,399) at 1,310 participating hospitals were assessed. Cardiac rehabilitation referral rates were 59.2% and 66.0% for the overall population and the AMI/Medicare subgroup, respectively. In multivariable analyses, presentation with ST-segment elevation myocardial infarction (odds ratio 2.99; 95% confidence interval: 2.92 to 3.06) and non-ST-segment elevation myocardial infarction (odds ratio: 1.99; 95% confidence interval: 1.94 to 2.03) were associated with increased odds of referral to cardiac rehabilitation. Models adjusted for insurance status showed significant site-specific variability in referral rates, with more than one-quarter of all hospitals referring <20% of patients.
CONCLUSIONS Approximately 60% of patients undergoing PCI in the United States are referred for cardiac rehabilitation. Site-specific variation in referral rates is significant and is unexplained by insurance coverage. These findings highlight the potential need for hospital-level interventions to improve cardiac rehabilitation referral rates after PCI. (C) 2015 by the American College of Cardiology Foundation.
C1 [Aragam, Krishna G.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Dai, Dadi; Neely, Megan L.; Roe, Matthew T.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Gurm, Hitinder S.] Univ Michigan, Med Ctr, Div Cardiovasc Med, Ann Arbor, MI USA.
RP Aragam, KG (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 8-852, Boston, MA 02114 USA.
EM karagam@gmail.com
RI 刘, 李陆/H-8469-2015;
OI Gurm, Hitinder/0000-0002-1646-0218
FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic;
Sanofi; Medicines Company; Eli Lilly; Revalesio; American College of
Cardiology; American Heart Association; Familial Hyperlipidemia
Foundation; National Institutes of Health; Agency for Health Care
Research and Quality
FX Institute, Mayo Clinic, and the Population and Health Research
Institute; has received research grants from Amarin, AstraZeneca,
Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi, and The
Medicines Company; and has taken part in unfunded research at FlowCo,
PLx Pharma, and Takeda. Dr. Roe has received research funding from Eli
Lilly, Revalesio, Sanofi, American College of Cardiology, American Heart
Association, and the Familial Hyperlipidemia Foundation; and has
received consulting or honoraria from Eli Lilly, AstraZeneca, Sanofi,
Janssen Pharmaceuticals, Merck, Regeneron, and Daiichi-Sankyo. Dr. Gurm
has received research funding from the National Institutes of Health and
the Agency for Health Care Research and Quality. All other authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.
NR 43
TC 14
Z9 14
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 19
PY 2015
VL 65
IS 19
BP 2079
EP 2088
DI 10.1016/j.jacc.2015.02.063
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CH8DA
UT WOS:000354265100006
PM 25975470
ER
PT J
AU Jorgenson, LA
Newsome, WT
Anderson, DJ
Bargmann, CI
Brown, EN
Deisseroth, K
Donoghue, JP
Hudson, KL
Ling, GSF
MacLeish, PR
Marder, E
Normann, RA
Sanes, JR
Schnitzer, MJ
Sejnowski, TJ
Tank, DW
Tsien, RY
Ugurbil, K
Wingfield, JC
AF Jorgenson, Lyric A.
Newsome, William T.
Anderson, David J.
Bargmann, Cornelia I.
Brown, Emery N.
Deisseroth, Karl
Donoghue, John P.
Hudson, Kathy L.
Ling, Geoffrey S. F.
MacLeish, Peter R.
Marder, Eve
Normann, Richard A.
Sanes, Joshua R.
Schnitzer, Mark J.
Sejnowski, Terrence J.
Tank, David W.
Tsien, Roger Y.
Ugurbil, Kamil
Wingfield, John C.
TI The BRAIN Initiative: developing technology to catalyse neuroscience
discovery
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE BRAIN Initiative; neural circuitry; neurotechnology
ID RETINAL CELL-TYPES; NEURAL CIRCUITS; FUNCTIONAL ARCHITECTURE; SENSORY
STIMULATION; CEREBRAL-CORTEX; VISUAL-CORTEX; RESOLUTION; NEURONS;
RECONSTRUCTION; OPTOGENETICS
AB The evolution of the field of neuroscience has been propelled by the advent of novel technological capabilities, and the pace at which these capabilities are being developed has accelerated dramatically in the past decade. Capitalizing on this momentum, the United States launched the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to develop and apply new tools and technologies for revolutionizing our understanding of the brain. In this article, we review the scientific vision for this initiative set forth by the National Institutes of Health and discuss its implications for the future of neuroscience research. Particular emphasis is given to its potential impact on the mapping and study of neural circuits, and how this knowledge will transform our understanding of the complexity of the human brain and its diverse array of behaviours, perceptions, thoughts and emotions.
C1 [Jorgenson, Lyric A.; Hudson, Kathy L.] NIH, Off Director, Bethesda, MD 20892 USA.
[Newsome, William T.; Deisseroth, Karl; Schnitzer, Mark J.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.
[Newsome, William T.] Stanford Univ, Stanford Neurosdences Inst, Stanford, CA 94305 USA.
[Anderson, David J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.
[Anderson, David J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.
[Bargmann, Cornelia I.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA.
[Bargmann, Cornelia I.] Rockefeller Univ, Lulu & Anthony Wang Lab Neural Circuits & Behav, New York, NY 10065 USA.
[Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
[Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Deisseroth, Karl] Stanford Univ, Dept Psychiat & Behav Sci, Dept Bioengn, Stanford, CA 94305 USA.
[Donoghue, John P.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA.
[Ling, Geoffrey S. F.] Def Adv Res Projects Agcy, Biol Technol Off, Arlington, VA 22203 USA.
[MacLeish, Peter R.] Morehouse Sch Med, Neurosci Inst, Dept Neurobiol, Atlanta, GA 30310 USA.
[Marder, Eve] Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.
[Marder, Eve] Brandeis Univ, Volen Ctr, Waltham, MA 02454 USA.
[Normann, Richard A.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
[Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Schnitzer, Mark J.] Stanford Univ, James H Clark Ctr Biomed Engn & Sci, CNC Program, Stanford, CA 94305 USA.
[Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.
[Sejnowski, Terrence J.] Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA.
[Tank, David W.] Princeton Univ, Princeton Neurosci Inst, Bezos Ctr Neural Circuit Dynam, Princeton, NJ 08544 USA.
[Tank, David W.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
[Tsien, Roger Y.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.
[Tsien, Roger Y.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
[Ugurbil, Kamil] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55454 USA.
[Wingfield, John C.] Natl Sci Fdn, Directorate Biol Sci, Arlington, VA 22230 USA.
RP Jorgenson, LA (reprint author), NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA.
EM bnewsome@stanford.edu
OI Bargmann, Cornelia/0000-0002-8484-0618
FU National Institutes of Health; Howard Hughes Medical Institute
FX The authors thank the National Institutes of Health and the Howard
Hughes Medical Institute for supporting the publication of this article.
NR 82
TC 22
Z9 23
U1 5
U2 37
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD MAY 19
PY 2015
VL 370
IS 1668
BP 8
EP 19
AR UNSP 20140164
DI 10.1098/rstb.2014.0164
PG 12
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CH5JH
UT WOS:000354071400002
ER
PT J
AU Tsai, TY
Li, JS
Wang, SB
Li, PY
Kwon, YM
Li, GA
AF Tsai, Tsung-Yuan
Li, Jing-Sheng
Wang, Shaobai
Li, Pingyue
Kwon, Young-Min
Li, Guoan
TI Principal component analysis in construction of 3D human knee joint
models using a statistical shape model method
SO COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
LA English
DT Article
DE fluoroscopic images; 3D knee model; statistical shape model; knee
ID PROXIMAL FEMUR; RECONSTRUCTION; SURFACE; REGISTRATION; IMAGES;
ARTHROPLASTY; PELVIS
AB The statistical shape model (SSM) method that uses 2D images of the knee joint to predict the three-dimensional (3D) joint surface model has been reported in the literature. In this study, we constructed a SSM database using 152 human computed tomography (CT) knee joint models, including the femur, tibia and patella and analysed the characteristics of each principal component of the SSM. The surface models of two in vivo knees were predicted using the SSM and their 2D bi-plane fluoroscopic images. The predicted models were compared to their CT joint models. The differences between the predicted 3D knee joint surfaces and the CT image-based surfaces were 0.30 +/- 0.81mm, 0.34 +/- 0.79mm and 0.36 +/- 0.59mm for the femur, tibia and patella, respectively (average +/- standard deviation). The computational time for each bone of the knee joint was within 30s using a personal computer. The analysis of this study indicated that the SSM method could be a useful tool to construct 3D surface models of the knee with sub-millimeter accuracy in real time. Thus, it may have a broad application in computer-assisted knee surgeries that require 3D surface models of the knee.
C1 [Tsai, Tsung-Yuan; Li, Jing-Sheng; Wang, Shaobai; Li, Pingyue; Kwon, Young-Min; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, Boston, MA 02114 USA.
[Li, Pingyue] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Orthopaed Surg, Guangzhou 510010, Guangdong, Peoples R China.
RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, 55 Fruit St,GRJ-1215, Boston, MA 02114 USA.
EM gli1@partners.org
OI Tsai, Tsung-Yuan/0000-0003-1522-2987
FU NIAMS NIH HHS [R01 AR055612]
NR 34
TC 2
Z9 2
U1 1
U2 68
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1025-5842
EI 1476-8259
J9 COMPUT METHOD BIOMEC
JI Comput. Methods Biomech. Biomed. Eng.
PD MAY 19
PY 2015
VL 18
IS 7
BP 721
EP 729
DI 10.1080/10255842.2013.843676
PG 9
WC Computer Science, Interdisciplinary Applications; Engineering,
Biomedical
SC Computer Science; Engineering
GA AT7UD
UT WOS:000345141700004
PM 24156375
ER
PT J
AU Honda, JR
Hess, T
Malcolm, KC
Ovrutsky, AR
Bai, XY
Irani, VR
Dobos, KM
Chan, ED
Flores, SC
AF Honda, Jennifer R.
Hess, Tamara
Malcolm, Kenneth C.
Ovrutsky, Alida R.
Bai, Xiyuan
Irani, Vida R.
Dobos, Karen M.
Chan, Edward D.
Flores, Sonia C.
TI Pathogenic Nontuberculous Mycobacteria Resist and Inactivate
Cathelicidin: Implication of a Novel Role for Polar Mycobacterial Lipids
SO PLOS ONE
LA English
DT Article
ID AVIUM COMPLEX; CELL-WALL; LUNG-DISEASE; ANTIMICROBIAL PEPTIDES; COLONY
MORPHOLOGY; EPITHELIAL-CELLS; TUBERCULOSIS; EXPRESSION; SURFACE;
GLYCOPEPTIDOLIPIDS
AB Nontuberculous mycobacteria (NTM) are a large group of environmental organisms with worldwide distribution, but only a relatively few are known to be pathogenic. Chronic, debilitating lung disease is the most common manifestation of NTM infection, which is often refractory to treatment. The incidence and prevalence of NTM lung disease are increasing in the United States and in many parts of the world. Hence, a more complete understanding of NTM pathogenesis will provide the foundation to develop innovative approaches to treat this recalcitrant disease. Herein, we demonstrate that several species of NTM show broad resistance to the antimicrobial peptide, cathelicidin (LL-37). Resistance to LL-37 was not significantly different between M. avium that contain serovar-specific glycopeptidolipid (GPL, M. avium(ssGPL)) and M. avium that do not (M. avium(Delta ssGPL)). Similarly, M. abscessus containing non-specific GPL (M. abscessus(nsGPL(+))) or lacking nsGPL (M. abscessus(nsGPL(-))) remained equally resistant to LL-37. These findings would support the notion that GPL are not the components responsible for NTM resistance to LL-37. Unexpectedly, the growth of M. abscessus(nsGPL(-)) increased with LL-37 or scrambled LL-37 peptide in a dose-dependent fashion. We also discovered that LL-37 exposed to NTM had reduced antimicrobial activity, and initial work indicates that this is likely due to inactivation of LL-37 by lipid component(s) of the NTM cell envelope. We conclude that pathogenic NTM resist and inactivate LL-37. The mechanism by which NTM circumvent the antimicrobial activity of LL-37 remains to be determined.
C1 [Honda, Jennifer R.; Malcolm, Kenneth C.; Chan, Edward D.; Flores, Sonia C.] Univ Colorado, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA.
[Honda, Jennifer R.; Malcolm, Kenneth C.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Natl Jewish Hlth, Denver, CO USA.
[Hess, Tamara] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
[Irani, Vida R.] Indiana Univ Penn, Dept Biol, Indiana, PA USA.
[Honda, Jennifer R.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO 80045 USA.
EM Jennifer.Honda@ucdenver.edu
RI Dobos, Karen/D-1170-2017
OI Dobos, Karen/0000-0001-7115-8524
FU National Institutes of Health (NIH) [3R01HL059785-09S1]; University of
Colorado Anschutz Medical Campus Pulmonary and Critical Care Division;
NIH NRSA Infectious Disease Training Award [T32-AI007447-19]; Tim Gill
Endowment for AIDS Research, NIH NRSA Pulmonary and Critical Care
Medicine Training Award [T32 HL 7085-83]; Potts Memorial Foundation
FX Study support was provided in part by Institutional Funds and the
National Institutes of Health (NIH) Supplement 3R01HL059785-09S1 for
SCF, University of Colorado Anschutz Medical Campus Pulmonary and
Critical Care Division. JRH is supported by a NIH NRSA Infectious
Disease Training Award (T32-AI007447-19), the Tim Gill Endowment for
AIDS Research, NIH NRSA Pulmonary and Critical Care Medicine Training
Award (T32 HL 7085-83), and the Potts Memorial Foundation.
NR 54
TC 0
Z9 0
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2015
VL 10
IS 5
AR e0126994
DI 10.1371/journal.pone.0126994
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7BG
UT WOS:000354917300075
PM 25993058
ER
PT J
AU Yang, KS
Kohler, RH
Landon, M
Giedt, R
Weissleder, R
AF Yang, Katherine S.
Kohler, Rainer H.
Landon, Matthieu
Giedt, Randy
Weissleder, Ralph
TI Single cell resolution in vivo imaging of DNA damage following PARP
inhibition
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; BREAST-CANCER;
OVARIAN-CANCER; TUMOR-CELLS; OPEN-LABEL; CHROMATIN; OLAPARIB; REPAIR;
IDENTIFICATION
AB Targeting DNA repair pathways is a powerful strategy to treat cancers. To gauge efficacy in vivo, typical response markers include late stage effects such as tumor shrinkage, progression free survival, or invasive repeat biopsies. These approaches are often difficult to answer critical questions such as how a given drug affects single cell populations as a function of dose and time, distance from microvessels or how drug concentration (pharmacokinetics) correlates with DNA damage (pharmacodynamics). Here, we established a single-cell in vivo pharmacodynamic imaging read-out based on a truncated 53BP1 double-strand break reporter to determine whether or not poly(ADPribose) polymerase (PARP) inhibitor treatment leads to accumulation of DNA damage. Using this reporter, we show that not all PARP inhibitor treated tumors incur an increase in DNA damage. The method provides a framework for single cell analysis of cancer therapeutics in vivo.
C1 [Yang, Katherine S.; Kohler, Rainer H.; Landon, Matthieu; Giedt, Randy; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Landon, Matthieu; Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU NIH [P50 CA086355, R01CA164448]; [T32 CA 79443]
FX We would like to thank Alex Zaltsman for assistance in DeltaVision
imaging and Matt Sebas for assistance in mouse surgical procedures. This
study was supported by the following grants from the NIH: P50 CA086355
and R01CA164448. K.Y. was supported by T32 CA 79443.
NR 51
TC 4
Z9 4
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 18
PY 2015
VL 5
AR 10129
DI 10.1038/srep10129
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ1UJ
UT WOS:000355269800001
PM 25984718
ER
PT J
AU Atri, A
Hendrix, SB
Pejovic, V
Hofbauer, RK
Edwards, J
Molinuevo, JL
Graham, SM
AF Atri, Alireza
Hendrix, Suzanne B.
Pejovic, Vojislav
Hofbauer, Robert K.
Edwards, John
Luis Molinuevo, Jose
Graham, Stephen M.
TI Cumulative, additive benefits of memantine-donepezil combination over
component monotherapies in moderate to severe Alzheimer's dementia: a
pooled area under the curve analysis
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Article
ID SEVERE IMPAIRMENT BATTERY; CONTROLLED-TRIAL; CHOLINESTERASE-INHIBITORS;
RECEIVING DONEPEZIL; DISEASE; VALIDITY; DRUGS; INVENTORY; EFFICACY;
THERAPY
AB Introduction: Treatment in moderate or severe Alzheimer's disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI combination to ChEI monotherapy. We utilized area-under-the-curve (AUC) analysis to assess six-month cumulative treatment efficacy of memantine-donepezil combination versus component monotherapies on individual clinical domains and on a composite index.
Methods: Data were pooled from 1,408 individuals with moderate to severe AD from four six-month randomized trials of memantine monotherapy (n = 570) or add-on therapy (donepezil-only subset: n = 847). AUC changes from baseline on measures of cognition (SIB), function (ADCS-ADL(19)), behavior (NPI), global status (CIBIC-Plus), and a composite index (4D-CI: equally weighted composite of four domain measures) were calculated using the trapezoidal rule and evaluated via analysis of covariance (ANCOVA) (2-sided-alpha = 0.05). AUC results were contrasted with visit-by-visit changes from baseline ("snapshot analysis"), performed using a mixed-effects model with repeated measures (MMRM).
Results: Over the entire six-month period, placebo-only treatment was associated with significant cumulative worsening on all outcomes. Memantine-donepezil combination showed significantly greater AUC improvements (point x week) on the SIB, NPI, and CIBIC-Plus than placebo-donepezil (SIB: 68.4 versus 32.0, P = 0.019; NPI: -74.3 versus -28.2, P = 0.003; CIBIC-Plus: -2.5 versus 1.4, P = 0.006) and memantine-only monotherapies (SIB: 68.4 versus 12.0, P < 0.001; NPI: -74.3 versus -7.4, P < 0.001; CIBIC-Plus: -2.5 versus 2.7, P < 0.001), whereas these comparisons were not significant for the ADCS-ADL(19) (memantine-donepezil (1.4) versus placebo-donepezil (-0.9), P = 0.407; versus memantine-only (-12.2), P = 0.310). Composite index analysis demonstrated significant cumulative advantages of memantine-donepezil combination (630.0) over placebo-donepezil (344.7, P < 0.001) and memantine-only (152.1, P < 0.001) treatments. Combining memantine and donepezil had an additive effect. Compared with AUC analysis, baseline-to-endpoint change-score analysis underestimated effects of combination therapy, monotherapies, or both.
Conclusions: This large pooled area-under-the-curve analysis of randomized-trial data in moderate to severe AD provides ecologically valid support that adding memantine to stable donepezil results in overall clinical benefits that are additive compared with individual monotherapies, continue to accumulate through six-month treatment, and are at least 50% greater than those of monotherapies.
C1 [Atri, Alireza] Ray Dolby Brain Hlth Ctr, San Francisco, CA 94114 USA.
[Atri, Alireza] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94114 USA.
[Atri, Alireza] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Atri, Alireza] Harvard Univ, Sch Med, Boston, MA USA.
[Hendrix, Suzanne B.] Pentara Corp, Salt Lake City, UT USA.
[Pejovic, Vojislav] Prescott Med Commun Grp, Chicago, IL USA.
[Hofbauer, Robert K.; Edwards, John; Graham, Stephen M.] Forest Res Inst Inc, Jersey City, NJ USA.
[Luis Molinuevo, Jose] Hosp Clin Barcelona, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain.
[Luis Molinuevo, Jose] Barcelona Beta Brain Res Ctr, Barcelona, Spain.
RP Atri, A (reprint author), Ray Dolby Brain Hlth Ctr, CPMC Davies Campus,45 Castro St,Suite 220, San Francisco, CA 94114 USA.
EM atria@cpmcri.org
OI Molinuevo, Jose Luis/0000-0003-0485-6001
FU Forest Research Institute; Forest Laboratories, Inc., New York
FX The study was funded by Forest Research Institute, an affiliate of
Actavis Inc, the US marketer of memantine. The reported analyses were
performed by Pentara Corporation biostatisticians under the direction of
S. Hendrix and in collaboration with A. Atri. The original studies
included in the analysis were supported by funding from Forest
Laboratories, Inc., New York. The authors wish to acknowledge the
invaluable contribution of the principal investigators in the original
trials [5-8], the administrative and editorial assistance of Prescott
Medical Communications Group, Chicago, IL (especially Dr. Michael L.
Miller, formerly of the Prescott Group), Dr. Michael Tocco (previously
of FRI) for early discussions and input in the study's design and
coordination, Dr. Victor Otcheretko (FRI) for the coordination and
completion of the study analyses and manuscript, and Noel Ellison, MS,
of Pentara Corporation for assistance with data analyses. Finally, and
most importantly, we express our deep gratitude for the commitment of
the study participants and their caregivers, whose dedication and
generous participation in clinical trials made this research possible.
NR 32
TC 11
Z9 11
U1 5
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD MAY 18
PY 2015
VL 7
AR 28
DI 10.1186/s13195-015-0109-2
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CI7FM
UT WOS:000354928300001
PM 25991927
ER
PT J
AU Kim, M
Choi, W
Choi, Y
Yoon, C
Choi, W
AF Kim, Moonseok
Choi, Wonjun
Choi, Youngwoon
Yoon, Changhyeong
Choi, Wonshik
TI Transmission matrix of a scattering medium and its applications in
biophotonics
SO OPTICS EXPRESS
LA English
DT Article
ID MULTIMODE OPTICAL-FIBER; DISORDERED MEDIUM; PHASE MICROSCOPY;
FULL-FIELD; REAL-TIME; LIGHT; ILLUMINATION; SYSTEMS; LOCALIZATION;
CONJUGATION
AB A conventional lens has well-defined transfer function with which we can form an image of a target object. On the contrary, scattering media such as biological tissues, multimode optical fibers and layers of disordered nanoparticles have highly complex transfer function, which makes them impractical for the general imaging purpose. In recent studies, we presented a method of experimentally recording the transmission matrix of such media, which is a measure of the transfer function. In this review paper, we introduce two major applications of the transmission matrix: enhancing light energy delivery and imaging through scattering media. For the former, we identified the eigenchannels of the transmission matrix with large eigenvalues and then coupled light to those channels in order to enhance light energy delivery through the media. For the latter, we solved matrix inversion problem to reconstruct an object image from the distorted image by the scattering media. We showed the enlargement of the numerical aperture of imaging systems with the use of scattering media and demonstrated endoscopic imaging through a single multimode optical fiber working in both reflectance and fluorescence modes. Our approach will pave the way of using scattering media as unique optical elements for various biophotonics applications. (C) 2015 Optical Society of America
C1 [Kim, Moonseok] Harvard Univ, Sch Med, Cambridge, MA 02139 USA.
[Kim, Moonseok] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Choi, Wonjun] Univ Exeter, Dept Phys & Astron, Exeter EX4 4QL, Devon, England.
[Choi, Youngwoon] Korea Univ, Sch Biomed Engn, Seoul 136701, South Korea.
[Kim, Moonseok; Choi, Wonjun; Yoon, Changhyeong; Choi, Wonshik] Korea Univ, Dept Phys, Seoul 136701, South Korea.
[Choi, Wonshik] Ctr Mol Spect & Dynam, Seoul 136701, South Korea.
RP Choi, W (reprint author), Korea Univ, Dept Phys, Seoul 136701, South Korea.
EM wonshik@korea.ac.kr
FU IT RD Program [R2013080003]; Global Frontier Program [2014M3A6B3063710,
IBS-R023-D1-2015-a00]; Basic Science Research Program [2013R1A1A2062560,
2013R1A1A2062808]; Nano-Material Technology Development Program through
the National Research Foundation of Korea (NRF) - Ministry of Science,
ICT & Future Planning [2011-0020205]; Korea Health Technology R&D
Project - Ministry of Health & Welfare, South Korea [HI14C0748]
FX This research was supported by the IT R&D Program (R2013080003), the
Global Frontier Program (2014M3A6B3063710), IBS-R023-D1-2015-a00, the
Basic Science Research Program (2013R1A1A2062560, 2013R1A1A2062808) and
the Nano-Material Technology Development Program (2011-0020205) through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Science, ICT & Future Planning. It was also supported by the Korea
Health Technology R&D Project (HI14C0748) funded by the Ministry of
Health & Welfare, South Korea.
NR 47
TC 11
Z9 11
U1 5
U2 27
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 18
PY 2015
VL 23
IS 10
BP 12648
EP 12668
DI 10.1364/OE.23.012648
PG 21
WC Optics
SC Optics
GA CI4GQ
UT WOS:000354706800018
PM 26074520
ER
PT J
AU Kim, M
Choi, W
Yoon, C
Kim, GH
Kim, SH
Yi, GR
Park, QH
Choi, W
AF Kim, Moonseok
Choi, Wonjun
Yoon, Changhyeong
Kim, Guang Hoon
Kim, Seung-hyun
Yi, Gi-Ra
Park, Q-Han
Choi, Wonshik
TI Exploring anti-reflection modes in disordered media
SO OPTICS EXPRESS
LA English
DT Article
ID TIME-REVERSAL; FLUCTUATIONS; TOMOGRAPHY; SYSTEMS; REGIME; PHASE; PULSE
AB Sensing and manipulating targets hidden under scattering media are universal problems that take place in applications ranging from deep-tissue optical imaging to laser surgery. A major issue in these applications is the shallow light penetration caused by multiple scattering that reflects most of incident light. Although advances have been made to eliminate image distortion by a scattering medium, dealing with the light reflection has remained unchallenged. Here we present a method to minimize reflected intensity by finding and coupling light into the anti-reflection modes of a scattering medium. In doing so, we achieved more than a factor of 3 increase in light penetration. Our method of controlling reflected waves makes it readily applicable to in vivo applications in which detector sensors can only be positioned at the same side of illumination and will therefore lay the foundation of advancing the working depth of many existing optical imaging and treatment technologies. (C) 2015 Optical Society of America
C1 [Kim, Moonseok] Harvard Univ, Sch Med, Cambridge, MA 02139 USA.
[Kim, Moonseok] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Choi, Wonjun] Univ Exeter, Dept Phys & Astron, Exeter EX4 4QL, Devon, England.
[Kim, Moonseok; Choi, Wonjun; Yoon, Changhyeong; Park, Q-Han; Choi, Wonshik] Korea Univ, Dept Phys, Seoul 136701, South Korea.
[Kim, Guang Hoon] RSS Ctr, Korea Electrotechnol Res Inst, Seoul 121835, South Korea.
[Kim, Seung-hyun; Yi, Gi-Ra] Sungkyunkwan Univ, Sch Chem Engn, Suwon 440746, South Korea.
[Choi, Wonshik] Ctr Mol Spect & Dynam, Seoul 136701, South Korea.
RP Choi, W (reprint author), Korea Univ, Dept Phys, Seoul 136701, South Korea.
EM wonshik@korea.ac.kr
FU IT RD Program [R2013080003]; Global Frontier Program [2014M3A6B3063710];
Basic Science Research Program [2013R1A1A2062560, 2013R1A1A2062808];
Nano-Material Technology Development Program through the National
Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future
Planning [2011-0020205]; Korea Health Technology R&D Project - Ministry
of Health & Welfare, South Korea [HI14C0748]; [IBS-R023-D1-2015-a00]
FX This research was supported by the IT R&D Program (R2013080003), the
Global Frontier Program (2014M3A6B3063710), IBS-R023-D1-2015-a00, the
Basic Science Research Program (2013R1A1A2062560, 2013R1A1A2062808) and
the Nano-Material Technology Development Program (2011-0020205) through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Science, ICT & Future Planning. It was also supported by the Korea
Health Technology R&D Project (HI14C0748) funded by the Ministry of
Health & Welfare, South Korea.
NR 29
TC 4
Z9 4
U1 0
U2 9
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 18
PY 2015
VL 23
IS 10
BP 12740
EP 12749
DI 10.1364/OE.23.012740
PG 10
WC Optics
SC Optics
GA CI4GQ
UT WOS:000354706800026
PM 26074528
ER
PT J
AU Yang, B
Qu, ML
Wang, RG
Chatterton, JE
Liu, XB
Zhu, B
Narisawa, S
Millan, JL
Nakanishi, N
Swoboda, K
Lipton, SA
Zhang, DX
AF Yang, Bo
Qu, Mingliang
Wang, Rengang
Chatterton, Jon E.
Liu, Xiao-Bo
Zhu, Bing
Narisawa, Sonoko
Millan, Jose Luis
Nakanishi, Nobuki
Swoboda, Kathryn
Lipton, Stuart A.
Zhang, Dongxian
TI The critical role of membralin in postnatal motor neuron survival and
disease
SO ELIFE
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED
PROTEIN RESPONSE; HEREDITARY SPASTIC PARAPLEGIA; ER-ASSOCIATED
DEGRADATION; SPINAL MUSCULAR-ATROPHY; RECEPTOR SUBUNIT NR3B; MOUSE
MODEL; NEURODEGENERATIVE DISEASES; MISFOLDED GLYCOPROTEINS
AB Hitherto, membralin has been a protein of unknown function. Here, we show that membralin mutant mice manifest a severe and early-onset motor neuron disease in an autosomal recessive manner, dying by postnatal day 5-6. Selective death of lower motor neurons, including those innervating the limbs, intercostal muscles, and diaphragm, is predominantly responsible for this fatal phenotype. Neural expression of a membralin transgene completely rescues membralin mutant mice. Mechanistically, we show that membralin interacts with Erlin2, an endoplasmic reticulum (ER) membrane protein that is located in lipid rafts and known to be important in ER-associated protein degradation (ERAD). Accordingly, the degradation rate of ERAD substrates is attenuated in cells lacking membralin. Membralin mutations or deficiency in mouse models induces ER stress, rendering neurons more vulnerable to cell death. Our study reveals a critical role of membralin in motor neuron survival and suggests a novel mechanism for early-onset motor neuron disease.
C1 [Yang, Bo; Qu, Mingliang; Wang, Rengang; Chatterton, Jon E.; Zhu, Bing; Nakanishi, Nobuki; Lipton, Stuart A.; Zhang, Dongxian] Sanford Burnham Med Res Inst, Neurosci & Aging Res Ctr, La Jolla, CA USA.
[Liu, Xiao-Bo] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Electron Microscopy Lab, Davis, CA 95616 USA.
[Narisawa, Sonoko; Millan, Jose Luis] Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA USA.
[Swoboda, Kathryn] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.
RP Zhang, DX (reprint author), Sanford Burnham Med Res Inst, Neurosci & Aging Res Ctr, La Jolla, CA USA.
EM dzhang@sbmri.org
FU National Institutes of Health (NIH) [R01 NS43434, P01 HD29587, P30
NS076411, R01 NS086890]
FX National Institutes of Health (NIH) R01 NS43434 Dongxian Zhang; National
Institutes of Health (NIH) P01 HD29587 Stuart A Lipton; National
Institutes of Health (NIH) P30 NS076411 Stuart A Lipton; National
Institutes of Health (NIH) R01 NS086890 Stuart A Lipton
NR 72
TC 0
Z9 2
U1 2
U2 2
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAY 15
PY 2015
VL 4
AR e06500
DI 10.7554/eLife.06500
PG 19
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DJ5RM
UT WOS:000374267600001
ER
PT J
AU Calderwood, SB
Collier, TL
Gouverneur, V
Liang, SH
Vasdev, N
AF Calderwood, Samuel B.
Collier, Thomas L.
Gouverneur, Veronique
Liang, Steven H.
Vasdev, Neil
TI Continuous-Flow Microfluidic [F-18]Radiofluorination of Spirocyclic
Iodonium(III) Ylides
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Meeting Abstract
C1 [Calderwood, Samuel B.; Gouverneur, Veronique] Univ Oxford, Chem Res Lab, Oxford, Oxon, England.
[Collier, Thomas L.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
EI 1099-1344
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD MAY 15
PY 2015
VL 58
SU 1
MA 174
BP S174
EP S174
PG 1
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DD5GH
UT WOS:000369950200175
ER
PT J
AU Rotstein, BH
Bonab, AA
Livni, E
Perlis, RH
Liang, SH
Vasdev, N
AF Rotstein, Benjamin H.
Bonab, Ali A.
Livni, Eli
Perlis, Roy H.
Liang, Steven H.
Vasdev, Neil
TI Radiosynthesis and evaluation of [C-11]isradipine, a calcium channel
antagonist, for PET neuroimaging
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Meeting Abstract
C1 [Rotstein, Benjamin H.; Bonab, Ali A.; Livni, Eli; Liang, Steven H.; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med & Mol Imaging, Boston, MA USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Human Genet Res, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
EI 1099-1344
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD MAY 15
PY 2015
VL 58
SU 1
MA 298
BP S298
EP S298
PG 1
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DD5GH
UT WOS:000369950200299
ER
PT J
AU Hsieh, CL
Botta, G
Gao, S
Li, TT
Van Allen, EM
Treacy, DJ
Cai, CM
He, HH
Sweeney, CJ
Brown, M
Balk, SP
Nelson, PS
Garraway, LA
Kantoff, P
AF Hsieh, Chen-Lin
Botta, Ginevra
Gao, Shuai
Li, Tiantian
Van Allen, Eliezer M.
Treacy, Daniel J.
Cai, Changmeng
He, Housheng Hansen
Sweeney, Christopher J.
Brown, Myles
Balk, Steven P.
Nelson, Peter S.
Garraway, Levi A.
Kantoff, PhilipW.
TI PLZF, a Tumor Suppressor Genetically Lost in Metastatic
Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to
Androgen Deprivation Therapy
SO CANCER RESEARCH
LA English
DT Article
ID TARGETED THERAPY; MECHANISMS; PROTEIN; AXIS; GENE; MYC
AB Whole-exome sequencing of metastatic castration-resistant prostate cancer (mCRPC) reveals that 5% to 7% of tumors harbor promyelocytic leukemia zinc finger (PLZF) protein homozygous deletions. PLZF is a canonical androgen-regulated putative tumor suppressor gene whose expression is inhibited by androgen deprivation therapy (ADT). Here, we demonstrate that knockdown of PLZF expression promotes a CRPC and enzalutamide-resistant phenotype in prostate cancer cells. Reintroduction of PLZF expression is sufficient to reverse androgen-independent growth mediated by PLZF depletion. PLZF loss enhances CRPC tumor growth in a xenograft model. Bioinformatic analysis of the PLZF cistrome shows that PLZF negatively regulates multiple pathways, including the MAPK pathway. Accordingly, our data support an oncogenic program activated by ADT. This acquired mechanism together with the finding of genetic loss in CRPC implicates PLZF inactivation as a mechanism promoting ADT resistance and the CRPC phenotype. (C) 2015 AACR.
C1 [Hsieh, Chen-Lin; Botta, Ginevra; Li, Tiantian; Van Allen, Eliezer M.; Treacy, Daniel J.; Sweeney, Christopher J.; Brown, Myles; Garraway, Levi A.; Kantoff, PhilipW.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Van Allen, Eliezer M.; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Van Allen, Eliezer M.; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Botta, Ginevra; Garraway, Levi A.] Broad Inst, Cambridge, MA USA.
[Gao, Shuai; Cai, Changmeng; Balk, Steven P.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Gao, Shuai; Cai, Changmeng; Balk, Steven P.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
[He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Nelson, Peter S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
RP Kantoff, P (reprint author), Dana Farber Canc Inst, Suite D1230,450 Brookline Ave, Boston, MA 02215 USA.
EM levi_garraway@dfci.harvard.edu; philip_kantoff@dfci.harvard.edu
OI Brown, Myles/0000-0002-8213-1658; Cai, Changmeng/0000-0002-8701-2586
FU DF/HCC Prostate Cancer SPORE [P50 CA090381-12]; DoD Postdoctoral
Training Award [W81XWH-13-1-0383, PC121543]; Starr Cancer Consortium;
Prostate SPORE; PCF/Mazzone Award; PNW SPORE [P50 CA097186]; NIH
[P01CA163227, P01CA085859, P01 CA163227, K99CA166507]; Cancer-Prostate
Cancer Foundation Prostate Dream Team Translational Research Grant
[SU2C-AACR-DT0712]
FX The work from the laboratory of P.W. Kantoff was supported by DF/HCC
Prostate Cancer SPORE (P50 CA090381-12) and C.-L. Hsieh was supported by
DoD Postdoctoral Training Award (W81XWH-13-1-0383). The work from the
laboratory of L.A. Garraway was supported by Starr Cancer Consortium,
Prostate SPORE, PCF/Mazzone Award, and G. Botta was supported by DoD
Postdoctoral Training Award (PC121543). The rapid autopsy program and
tissue/tumor collection and analyses were supported by PNW SPORE (P50
CA097186), NIH (P01CA163227), and NIH (P01CA085859). S.P. Balk was
supported by NIH (P01 CA163227). M. Brown was supported by NIH
(P01CA163227). C. Cai was supported by NIH K99CA166507. E.M. Van Allen
was supported by NIH 1 K08 CA188615-01 and a Stand Up To Cancer-Prostate
Cancer Foundation Prostate Dream Team Translational Research Grant
(SU2C-AACR-DT0712). StandUp To Cancer is a program of the Entertainment
Industry Foundation administered by the American Association for Cancer
Research.
NR 16
TC 6
Z9 6
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2015
VL 75
IS 10
BP 1944
EP 1948
DI 10.1158/0008-5472.CAN-14-3602
PG 5
WC Oncology
SC Oncology
GA CL9XP
UT WOS:000357332700004
PM 25808865
ER
PT J
AU Maiso, P
Huynh, D
Moschetta, M
Sacco, A
Aljawai, Y
Mishima, Y
Asara, JM
Roccaro, AM
Kimmelman, AC
Ghobrial, IM
AF Maiso, Patricia
Huynh, Daisy
Moschetta, Michele
Sacco, Antonio
Aljawai, Yosra
Mishima, Yuji
Asara, John M.
Roccaro, Aldo M.
Kimmelman, Alec C.
Ghobrial, Irene M.
TI Metabolic Signature Identifies Novel Targets for Drug Resistance in
Multiple Myeloma
SO CANCER RESEARCH
LA English
DT Article
ID INDUCIBLE FACTOR 1-ALPHA; CANCER-CELLS; GLUCOSE-METABOLISM; LYSYL
OXIDASE; IN-VIVO; HYPOXIA; TUMOR; GLYCOLYSIS; INHIBITOR; PATHWAY
AB Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow. The main cause of resistance in myeloma is the minimal residual disease cells that are resistant to the original therapy, including bortezomib treatment and high-dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in multiple myeloma cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain-of-function studies using LDHA or HIF1A induced resistance in bortezomib-sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance. (C) 2015 AACR.
C1 [Maiso, Patricia; Huynh, Daisy; Moschetta, Michele; Sacco, Antonio; Aljawai, Yosra; Mishima, Yuji; Roccaro, Aldo M.; Ghobrial, Irene M.] Dana Farber Canc Inst, Med Oncol, Boston, MA USA.
[Maiso, Patricia; Huynh, Daisy; Moschetta, Michele; Sacco, Antonio; Aljawai, Yosra; Mishima, Yuji; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Asara, John M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.
[Kimmelman, Alec C.] Dana Farber Canc Inst, Dept Radiat Oncol, Div Genom Stabil & DNA Repair, Boston, MA 02115 USA.
RP Ghobrial, IM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brooklyn Ave, Boston, MA 02115 USA.
EM irene_ghobrial@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016;
OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924;
Roccaro, Aldo/0000-0002-1872-5128
FU EHA (European Hematology Association); SPORE [P50 CA100707]; NIH
[R01CA154648]; Leukemia and Lymphoma Society; Miguel Servet program from
Instituto de Salud Carlos III
FX This work was supported in part by EHA (European Hematology
Association), SPORE P50 CA100707, NIH R01CA154648, Leukemia and Lymphoma
Society, and Miguel Servet program from Instituto de Salud Carlos III.
NR 45
TC 21
Z9 23
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2015
VL 75
IS 10
BP 2071
EP 2082
DI 10.1158/0008-5472.CAN-14-3400
PG 12
WC Oncology
SC Oncology
GA CL9XP
UT WOS:000357332700016
PM 25769724
ER
PT J
AU Klingler, S
Guo, BF
Yao, J
Yan, HY
Zhang, L
Vaseva, AV
Chen, SD
Canoll, P
Horner, J
Wang, YA
Paik, JH
Ying, HQ
Zheng, HW
AF Klingler, Stefan
Guo, Baofeng
Yao, Jun
Yan, Haiyan
Zhang, Ling
Vaseva, Angelina V.
Chen, Sida
Canoll, Peter
Horner, James W.
Wang, Y. Alan
Paik, Ji-Hye
Ying, Haoqiang
Zheng, Hongwu
TI Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma
Can Occur through EGFR-Dependent and -Independent Mechanisms
SO CANCER RESEARCH
LA English
DT Article
ID INTEGRATED GENOMIC ANALYSIS; LUNG-CANCER; RECEPTOR GENE; MUTANT EGFR;
HUMAN GLIOBLASTOMAS; KINASE INHIBITORS; MET AMPLIFICATION; STEM-CELLS;
MUTATIONS; GEFITINIB
AB Epidermal growth factor receptor (EGFR) is highly amplified, mutated, and overexpressed in human malignant gliomas. Despite its prevalence and growth-promoting functions, therapeutic strategies to inhibit EGFR kinase activity have not been translated into profound beneficial effects in glioma clinical trials. To determine the roles of oncogenic EGFR signaling in glioma-genesis and tumor maintenance, we generated a novel glioma mouse model driven by inducible expression of a mutant EGFR (EGFR*). Using combined genetic and pharmacologic interventions, we revealed that EGFR*-driven gliomas were insensitive to EGFR tyrosine kinase inhibitors, although they could efficiently inhibit EGFR* autophosphorylation in vitro and in vivo. This is in contrast with the genetic suppression of EGFR* induction that led to significant tumor regression and prolonged animal survival. However, despite their initial response to genetic EGFR* extinction, all tumors would relapse and propagate independent of EGFR*. We further showed that EGFR*-independent tumor cells existed prior to treatment and were responsible for relapse following genetic EGFR* suppression. And, the addition of a PI3K/mTOR inhibitor could significantly delay relapse and prolong animal survival. Our findings shed mechanistic insight into EGFR drug resistance in glioma and provide a platform to test therapies targeting aberrant EGFR signaling in this setting. (C) 2015 AACR.
C1 [Klingler, Stefan; Guo, Baofeng; Zhang, Ling; Vaseva, Angelina V.; Chen, Sida; Zheng, Hongwu] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Yao, Jun; Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
[Yan, Haiyan] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Canoll, Peter] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
[Horner, James W.; Wang, Y. Alan] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
[Paik, Ji-Hye] Weill Cornell Med Coll, Dept Pathol, New York, NY USA.
RP Zheng, HW (reprint author), Cold Spring Harbor Lab, One Bungtown Rd, Cold Spring Harbor, NY 11724 USA.
EM hzheng@cshl.edu
FU V Foundation Scholar Grant; Sontag Foundation Distinguished Scientist
Grant; Bradley Zankel Foundation; Sidney Kimmel Foundation Scholars
Award; National Cancer Institute Cancer Center Support Grant Development
Funds [CA45508]; SPORE [P50CA127001]
FX This work is supported by a V Foundation Scholar Grant and a Sontag
Foundation Distinguished Scientist Grant (H. Zheng). Additional funding
was provided by the Bradley Zankel Foundation. H. Zheng is also
supported by Sidney Kimmel Foundation Scholars Award and National Cancer
Institute Cancer Center Support Grant Development Funds (Grant CA45508).
Y.A. Wang is supported by SPORE (P50CA127001).
NR 44
TC 3
Z9 4
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2015
VL 75
IS 10
BP 2109
EP 2119
DI 10.1158/0008-5472.CAN-14-3122
PG 11
WC Oncology
SC Oncology
GA CL9XP
UT WOS:000357332700019
PM 25808866
ER
PT J
AU Xiao, YP
Freeman, GJ
AF Xiao, Yanping
Freeman, Gordon J.
TI A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
SO CLINICAL CANCER RESEARCH
LA English
DT Editorial Material
ID B7 FAMILY; MEMBER; IDENTIFICATION
AB HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy. (C)2015 AACR.
C1 [Xiao, Yanping; Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Freeman, GJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Gordon_Freeman@dfci.harvard.edu
FU NCI NIH HHS [P50CA101942, P50 CA101942, U54 CA163125, U54CA163125];
NIAID NIH HHS [AI100665, HHSN272201100018C, P01 AI056299, P01AI056299];
PHS HHS [HHSN272201100018C]
NR 9
TC 7
Z9 7
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2201
EP 2203
DI 10.1158/1078-0432.CCR-14-2658
PG 3
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500003
PM 25869386
ER
PT J
AU Katayama, R
Lovly, CM
Shaw, AT
AF Katayama, Ryohei
Lovly, Christine M.
Shaw, Alice T.
TI Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A
Paradigm for Precision Cancer Medicine
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID LARGE-CELL LYMPHOMA; REARRANGED NSCLC PATIENTS; ALK INHIBITOR ALECTINIB;
NON-HODGKINS-LYMPHOMA; ROS ONCOGENE 1; GROWTH-FACTOR; CRIZOTINIB
RESISTANCE; ACQUIRED-RESISTANCE; FUSION GENE; MUTATIONS
AB The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL). Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others. Importantly, ALK serves as a validated therapeutic target in these diseases. Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clinical use. These ALK inhibitors have all shown remarkable clinical outcomes in ALK-rearranged NSCLC. Unfortunately, as is the case for other kinase inhibitors in clinical use, sensitive tumors inevitably relapse due to acquired resistance. This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC. (C)2015 AACR.
C1 [Katayama, Ryohei] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan.
[Lovly, Christine M.] Vanderbilt Univ, Dept Med, Nashville, TN USA.
[Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Shaw, Alice T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Katayama, R (reprint author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.
EM ryohei.katayama@jfcr.or.jp
FU JSPS KAKENHI [25710015]; Ministry of Health Labour and Welfare; NIH
[R01CA121210, P01CA129243, R01CA164273]; Damon Runyon Clinical
Investigator award; LUNGevity career development award; National
Foundation for Cancer Research
FX R. Katayama was supported by JSPS KAKENHI grant number 25710015 and the
Ministry of Health Labour and Welfare. C.M. Lovly was supported by the
NIH under award numbers R01CA121210 and P01CA129243 and also by a Damon
Runyon Clinical Investigator award and LUNGevity career development
award. A.T. Shaw was supported by the NIH under award number R01CA164273
and by the National Foundation for Cancer Research.
NR 80
TC 50
Z9 50
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2227
EP 2235
DI 10.1158/1078-0432.CCR-14-2791
PG 9
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500009
PM 25979929
ER
PT J
AU Gandara, DR
Hammerman, PS
Sos, ML
Lara, PN
Hirsch, FR
AF Gandara, David R.
Hammerman, Peter S.
Sos, Martin L.
Lara, Primo N., Jr.
Hirsch, Fred R.
TI Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PHASE-III; PLUS CARBOPLATIN; GEMCITABINE; MUTATIONS; THERAPY;
CHEMOTHERAPY; CARCINOMAS; PACLITAXEL; ERLOTINIB; SURVIVAL
AB Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged behind the now more common non-small cell lung cancer histologic subtype of adenocarcinoma. However, recent efforts to define the complex biology underlying SCC have begun to bear fruit in a multitude of ways, including characterization of previously unknown genomic and signaling pathways, delineation of new, potentially actionable molecular targets, and subsequent development of a large number of agents directed against unique SCC-associated molecular abnormalities. For the first time, SCC-specific prognostic gene signatures and predictive biomarkers of new therapeutic agents are emerging. In addition, recent and ongoing clinical trials, including the Lung-MAP master protocol, have been designed to facilitate approval of targeted therapy-biomarker combinations. In this comprehensive review, we describe the current status of SCC therapeutics, recent advances in the understanding of SCC biology and prognostic gene signatures, and the development of innovative new clinical trials, all of which offer new hope for patients with advanced SCC. (C)2015 AACR.
C1 [Gandara, David R.; Lara, Primo N., Jr.] Calif State Univ Sacramento, Davis Comprehens Canc Ctr, Sacramento, CA 95819 USA.
[Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Sos, Martin L.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, Dept Translat Genom, D-50931 Cologne, Germany.
[Sos, Martin L.] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Network Genom Med, Cologne, Germany.
[Hirsch, Fred R.] Univ Colorado Denver, Dept Med Med Oncol & Pathol, Aurora, CO USA.
RP Gandara, DR (reprint author), Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Suite 3016,4501 X St, Sacramento, CA 95817 USA.
EM david.gandara@ucdmc.ucdavis.edu
FU NIH [P30CA93373, K08CA163677]; German Federal Ministry of Education and
Research (BMBF) [01ZX1406]; NCI/SPECS [UO1CA157715]
FX D.R. Gandara and P.N. Lara Jr were supported by the NIH under award
number P30CA93373. P.S. Hammerman was supported by the NIH under award
number K08CA163677. M.L. Sos was supported by the German Federal
Ministry of Education and Research (BMBF) within the framework of the
e:Med research and funding concept (grant #01ZX1406). F.R. Hirsch and
D.R. Gandara were supported by the NCI/SPECS under award number
UO1CA157715.
NR 44
TC 16
Z9 16
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2236
EP 2243
DI 10.1158/1078-0432.CCR-14-3039
PG 8
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500010
PM 25979930
ER
PT J
AU Carvajal, RD
Lawrence, DP
Weber, JS
Gajewski, TF
Gonzalez, R
Lutzky, J
O'Day, SJ
Hamid, O
Wolchok, JD
Chapman, PB
Sullivan, RJ
Teitcher, JB
Ramaiya, N
Giobbie-Hurder, A
Antonescu, CR
Heinrich, MC
Bastian, BC
Corless, CL
Fletcher, JA
Hodi, FS
AF Carvajal, Richard D.
Lawrence, Donald P.
Weber, Jeffrey S.
Gajewski, Thomas F.
Gonzalez, Rene
Lutzky, Jose
O'Day, Steven J.
Hamid, Omid
Wolchok, Jedd D.
Chapman, Paul B.
Sullivan, Ryan J.
Teitcher, Jerrold B.
Ramaiya, Nikhil
Giobbie-Hurder, Anita
Antonescu, Cristina R.
Heinrich, Michael C.
Bastian, Boris C.
Corless, Christopher L.
Fletcher, Jonathan A.
Hodi, F. Stephen
TI Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations
Following Progression to Prior KIT Inhibition
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMORS; METASTATIC MELANOMA; IMATINIB
RESISTANCE; COMPLETE RESPONSE; MUCOSAL MELANOMA; MAJOR RESPONSE;
MUTATIONS; SUNITINIB; THERAPY; MULTICENTER
AB Purpose: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown.
Experimental Design: We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases. The primary endpoint was 4-month disease control rate. Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS). A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, respectively.
Results: Twenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B). Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint. Two partial responses were observed in cohort A (18.2%; 90% CI, 3%-47%); none were observed in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 months) and 9.1 months (90% CI, 4.3-14.2 months), respectively, in all treated patients.
Conclusions: Nilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy. The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited. (C)2015 AACR.
C1 [Carvajal, Richard D.; Wolchok, Jedd D.; Chapman, Paul B.; Teitcher, Jerrold B.; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Carvajal, Richard D.; Wolchok, Jedd D.; Chapman, Paul B.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Lawrence, Donald P.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Weber, Jeffrey S.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Gajewski, Thomas F.] Univ Chicago, Chicago, IL 60637 USA.
[Gonzalez, Rene] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Lutzky, Jose] Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA.
[O'Day, Steven J.] Beverly Hills Canc Ctr, Beverly Hills, CA USA.
[Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
[Ramaiya, Nikhil; Giobbie-Hurder, Anita; Fletcher, Jonathan A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Heinrich, Michael C.; Corless, Christopher L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bastian, Boris C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Hodi, FS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM Stephen_hodi@dfci.harvard.edu
FU Novartis; NIH/NCI [P01 CA025874]
FX Funding for this trial was provided by Novartis. R.D. Carvajal and B.C.
Bastian received funding from NIH/NCI grant P01 CA025874.
NR 29
TC 14
Z9 14
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2289
EP 2296
DI 10.1158/1078-0432.CCR-14-1630
PG 8
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500016
PM 25695690
ER
PT J
AU Lum, LG
Thakur, A
Al-Kadhimi, Z
Colvin, GA
Cummings, FJ
Legare, RD
Dizon, DS
Kouttab, N
Maizel, A
Colaiace, W
Liu, Q
Rathore, R
AF Lum, Lawrence G.
Thakur, Archana
Al-Kadhimi, Zaid
Colvin, Gerald A.
Cummings, Francis J.
Legare, Robert D.
Dizon, Don S.
Kouttab, Nicola
Maizel, Abby
Colaiace, William
Liu, Qin
Rathore, Ritesh
TI Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical
Trial
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; NON-HODGKINS-LYMPHOMA; BISPECIFIC ANTIBODIES;
MONOCLONAL-ANTIBODY; HIGH-RISK; CAPECITABINE; CHEMOTHERAPY; TRASTUZUMAB;
CYTOTOXICITY; TOLERABILITY
AB Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed anti-CD3-activated T cells (ATC) in combination with low-dose IL-2 and granulocyte-macrophage colony-stimulating factor to determine safety, maximum tolerated dose (MTD), technical feasibility, T-cell trafficking, immune responses, time to progression, and overall survival (OS).
Experimental Design: ATC were expanded from leukapheresis product using IL2 and anti-CD3 monoclonal antibody and armed with HER2Bi. In 3+3 dose escalation design, groups of 3 patients received 5, 10, 20, or 40 x 10(9) armed ATC (aATC) per infusion.
Results: There were no dose-limiting toxicities and the MTD was not defined. It was technically feasible to grow 160 x 10(9) ATC from a single leukapheresis. aATC persisted in the blood for weeks and trafficked to tumors. Infusions of aATC induced anti-breast cancer responses and increases in immunokines. At 14.5 weeks after enrollment, 13 of 22 (59.1%) evaluable patients had stable disease and 9 of 22 (40.9%) had progressive disease. The median OS was 36.2 months for all patients, 57.4 months for HER2 3+ patients, and 27.4 months for HER2 0-2+ patients.
Conclusions: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors. These results provide a strong rationale for conducting phase II trials. (C)2015 AACR.
C1 [Lum, Lawrence G.; Thakur, Archana; Al-Kadhimi, Zaid] Wayne State Univ, Dept Oncol, Detroit, MI 48201 USA.
[Lum, Lawrence G.; Thakur, Archana; Al-Kadhimi, Zaid] Karmanos Canc Inst, Detroit, MI USA.
[Lum, Lawrence G.; Al-Kadhimi, Zaid] Wayne State Univ, Dept Med, Detroit, MI 48201 USA.
[Lum, Lawrence G.] Wayne State Univ, Dept Immunol & Microbiol, Detroit, MI 48201 USA.
[Colvin, Gerald A.] South Cty Hosp, Wakefield, RI USA.
[Cummings, Francis J.; Rathore, Ritesh] Roger Williams Hosp, Dept Med, Div Hematol & Oncol, Providence, RI USA.
[Legare, Robert D.; Maizel, Abby] Brown Univ, Women & Infants Hosp, Providence, RI USA.
[Dizon, Don S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Med, Boston, MA USA.
[Kouttab, Nicola] Roger Williams Med Ctr, Dept Pathol, Providence, RI USA.
[Colaiace, William] Roger Williams Med Ctr, Dept Nucl Med, Providence, RI USA.
[Liu, Qin] Wistar Inst Anat & Biol, Dept Med, Philadelphia, PA 19104 USA.
RP Lum, LG (reprint author), Wayne State Univ, 4100 John R St, Detroit, MI 48201 USA.
EM luml@karmanos.org
FU National Cancer Institute of the NIH [CA092344, CA140314]; NIH
[P30CA22453]; Young Family Foundation; Raymond Neag Foundation
FX This study was supported by the National Cancer Institute of the NIH
under award numbers CA092344 (to L.G. Lum) and CA140314 (to L.G. Lum).
The Microscopy, Imaging and Cytometry Resources Core is supported, in
part, by NIH Center grant P30CA22453 to The Karmanos Cancer Institute,
Wayne State University and the Perinatology Research Branch of the
National Institutes of Child Health and Development, Wayne State
University. The studies were also supported by the Young Family
Foundation and the Raymond Neag Foundation.
NR 33
TC 14
Z9 15
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2305
EP 2314
DI 10.1158/1078-0432.CCR-14-2280
PG 10
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500018
PM 25688159
ER
PT J
AU Hasegawa, M
Sinha, RK
Kumar, M
Alam, M
Yin, L
Raina, D
Kharbanda, A
Panchamoorthy, G
Gupta, D
Singh, H
Kharbanda, S
Kufe, D
AF Hasegawa, Masanori
Sinha, Raj Kumar
Kumar, Manoj
Alam, Maroof
Yin, Li
Raina, Deepak
Kharbanda, Akriti
Panchamoorthy, Govind
Gupta, Dikshi
Singh, Harpal
Kharbanda, Surender
Kufe, Donald
TI Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel
GO-203 Nanoparticle Formulation
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; DOWN-REGULATING TIGAR; BETA-CATENIN; ONCOPROTEIN;
PEPTIDE; INHIBITION; DELIVERY; TRANSCRIPTION; ACTIVATION; EXPRESSION
AB Purpose: The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities.
Experimental Design: Encapsulation of the MUC1-C inhibitor GO-203 in novel polymeric nanoparticles was studied for effects on intracellular targeting of MUC1-C signaling and function.
Results: Our results show that loading GO-203 into tetrablock polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG copolymers is achievable and, notably, is enhanced by increasing PEG chain length. In addition, we found that release of GO-203 from these nanoparticles is controllable over at least 7 days. GO-203/nanoparticle treatment of MUC1-C-positive breast and lung cancer cells in vitro was more active with less frequent dosing than that achieved with nonencapsulated GO-203. Moreover, treatment with GO-203/nanoparticles blocked MUC1-C homodimerization, consistent with on-target effects. GO-203/nanoparticle treatment was also effective in downregulating TIGAR, disrupting redox balance, and inhibiting the self-renewal capacity of cancer cells. Significantly, weekly administration of GO-203/nanoparticles to mice bearing syngeneic or xenograft tumors was associated with regressions that were comparable with those found when dosing on a daily basis with GO-203.
Conclusions: These findings thus define an effective approach for (i) sustained administration of GO-203 in polymeric PLA(PEG-PPG-PEG) nanoparticles to target MUC1-C in cancer cells and (ii) the potential delivery of other anticancer peptide drugs. (C)2015 AACR.
C1 [Hasegawa, Masanori; Alam, Maroof; Yin, Li; Kharbanda, Akriti; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Sinha, Raj Kumar; Kumar, Manoj; Gupta, Dikshi; Singh, Harpal] Indian Inst Technol, Ctr Biomed Engn, New Delhi 110016, India.
[Raina, Deepak; Panchamoorthy, Govind; Kharbanda, Surender] Genus Oncol, Boston, MA USA.
RP Kufe, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.
EM harpal2000@yahoo.com; donald_kufe@dfci.harvard.edu
FU NCI of the NIH [CA166480, CA97098]; Lung Cancer Research Foundation;
Department of Science and Technology, Government of India
FX This study was supported by the NCI of the NIH under award numbers
CA166480 and CA97098, the Lung Cancer Research Foundation, and the
Department of Science and Technology, Government of India.
NR 44
TC 6
Z9 6
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2338
EP 2347
DI 10.1158/1078-0432.CCR-14-3000
PG 10
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500021
PM 25712682
ER
PT J
AU Stubbs, MC
Kim, W
Bariteau, M
Davis, T
Vempati, S
Minehart, J
Witkin, M
Qi, J
Krivtsov, AV
Bradner, JE
Kung, AL
Armstrong, SA
AF Stubbs, Matthew C.
Kim, Wonil
Bariteau, Megan
Davis, Tina
Vempati, Sridhar
Minehart, Janna
Witkin, Matthew
Qi, Jun
Krivtsov, Andrei V.
Bradner, James E.
Kung, Andrew L.
Armstrong, Scott A.
TI Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic
Option for B-ALL
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE
RESPONSE; CANCER-THERAPY; CELLS; EXPRESSION; APOPTOSIS; ACETYLATION;
MAINTENANCE; COMBINATION
AB Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms.
Experimental Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity. Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL. Mouse xenografts of B-cell malignancy-derived cell lines and a pediatric B-ALL were used to demonstrate pharmacologic efficacy.
Results: Nonselective HDAC inhibitors were cytotoxic to a panel of B-ALL cell lines as well as to xenografted human leukemia patient samples. Assessment of isoform-specific HDACi indicated that targeting HDAC1-3 with class I HDAC-specific inhibitors was sufficient to inhibit growth of B-ALL cell lines. Furthermore, shRNA-mediated knockdown of HDAC1 or HDAC2 resulted in growth inhibition in these cells. We then assessed a compound that specifically inhibits only HDAC1 and HDAC2. This compound suppressed growth and induced apoptosis in B-ALL cell lines in vitro and in vivo, whereas it was far less effective against other B-cell-derived malignancies.
Conclusions: Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL. (C)2015 AACR.
C1 [Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Krivtsov, Andrei V.; Kung, Andrew L.; Armstrong, Scott A.] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Div Hematol Oncol, Boston, MA USA.
[Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Qi, Jun; Krivtsov, Andrei V.; Bradner, James E.; Kung, Andrew L.; Armstrong, Scott A.] Harvard Univ, Sch Med, Boston, MA USA.
[Minehart, Janna; Witkin, Matthew; Krivtsov, Andrei V.; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
[Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kung, Andrew L.; Armstrong, Scott A.] Harvard Stem Cell Inst, Boston, MA USA.
RP Stubbs, MC (reprint author), Incyte Corp, 1801 Augustine Cut Off, Wilmington, DE 19803 USA.
EM mstubbs@incyte.com
OI Kung, Andrew/0000-0002-9091-488X
FU NCI [CA068484]; NIH [CA128972]; Leukemia and Lymphoma Society; MMRF
FX This work was supported by NCI grant CA068484 (to S.A. Armstrong), NIH
grant CA128972 (to J. Qi and J.E. Bradner), the Leukemia and Lymphoma
Society, and the MMRF (to J.E. Bradner).
NR 44
TC 9
Z9 9
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2015
VL 21
IS 10
BP 2348
EP 2358
DI 10.1158/1078-0432.CCR-14-1290
PG 11
WC Oncology
SC Oncology
GA CL9YQ
UT WOS:000357335500022
PM 25688158
ER
PT J
AU Pandol, SJ
Edderkaoui, M
AF Pandol, Stephen J.
Edderkaoui, Mouad
TI What are the macrophages and stellate cells doing in pancreatic
adenocarcinoma?
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Review
DE stellate cells; macrophages; pancreatic cancer; periostin; TGF-beta
ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; DUCTAL
ADENOCARCINOMA; GROWTH-FACTOR; INTRAEPITHELIAL NEOPLASIA; INDUCE
FIBROSIS; TRANSGENIC MICE; NAB-PACLITAXEL; ACINAR-CELLS; TUMOR-GROWTH
AB Pancreatic ductal adenocarcinoma is a devastating disease characterized by a dense desmoplastic stroma. Chemo- and radio-therapeutic strategies based on targeting cancer cells have failed in improving the outcome of this cancer suggesting important roles for stroma in therapy resistance. Cells in the tumor stroma have been shown to regulate proliferation, resistance to apoptosis and treatments, epithelial to mesenchymal transition (EMT) and stemness of cancer cells. Stellate cells in their activated state have been thought over the past decade to only have tumor promoting roles. However, recent findings suggest that stellate cells may have protective roles as well. The present review highlights the latest findings on the role of two major components of tumor stroma, pancreatic stellate cells and macrophages, in promoting or inhibiting pancreatic cancer, focused on their effects on EMT and cancer stemness.
C1 [Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
[Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA.
[Pandol, Stephen J.; Edderkaoui, Mouad] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Pandol, Stephen J.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Med, Vet Affairs Los Angeles, 8700 Beverly Blvd,Davis Bldg,Suite 3100, Los Angeles, CA 90048 USA.
EM mouad.edderkaoui@cshs.org
FU Department of Veterans Affairs [K01AA019996, P01CA163200]
FX Supported by K01AA019996, P01CA163200 and Department of Veterans
Affairs.
NR 52
TC 2
Z9 2
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD MAY 15
PY 2015
VL 6
AR 125
DI 10.3389/fphys.2015.00125
PG 6
WC Physiology
SC Physiology
GA CM3NN
UT WOS:000357589200001
PM 26029109
ER
PT J
AU Tsai, AC
Weiser, SD
Dilworth, SE
Shumway, M
Riley, ED
AF Tsai, Alexander C.
Weiser, Sheri D.
Dilworth, Samantha E.
Shumway, Martha
Riley, Elise D.
TI Violent Victimization, Mental Health, and Service Utilization Outcomes
in a Cohort of Homeless and Unstably Housed Women Living With or at Risk
of Becoming Infected With HIV
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE depressive disorder; HIV; partner violence; quality of life; rape
ID INTIMATE PARTNER VIOLENCE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL;
DIAGNOSTIC INTERVIEW SCHEDULE; ANTIDEPRESSANT MEDICATION TREATMENT;
POISSON REGRESSION APPROACH; LONGITUDINAL DATA-ANALYSIS; SUB-SAHARAN
AFRICA; DOMESTIC VIOLENCE; ANTIRETROVIRAL THERAPY
AB Most studies about the association between exposure to violence and higher psychological vulnerability have been cross-sectional in nature. Using longitudinal data from the Shelter, Health, and Drug Outcomes Among Women Study on 300 homeless or unstably housed women infected with or at risk of becoming infected with human immunodeficiency virus who were living in San Francisco, California, in 2008-2012, we examined the relationship between recent violent victimization and mental health status, mental health-related emergency department visits, and psychiatric hospitalization. We used generalized estimating equations to account for potentially confounding time-invariant and time-varying variables, including comorbid psychiatric conditions and lifetime history of child abuse. A total of 207 (69%) women experienced childhood abuse. The median number of psychiatric diagnoses per woman at baseline was 8 (interquartile range, 5-11). Recent exposure to violence was associated with lower mental health status (b = -1.85, 95% confidence interval: -3.02, -0.68) and higher risks of mental health-related emergency department visits (adjusted risk ratio = 2.96, 95% confidence interval: 1.51, 5.78) and psychiatric hospitalizations (adjusted risk ratio = 2.32, 95% confidence interval: 1.10, 4.91). We did not find strong evidence of a reciprocal relationship. Among homeless or unstably housed women with severe preexisting comorbid psychiatric conditions, recent violence has adverse mental health consequences. Reducing ongoing violence may improve mental health in this population.
C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Weiser, Sheri D.; Dilworth, Samantha E.; Riley, Elise D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shumway, Martha] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM actsai@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU National Institute on Drug Abuse [R01DA015605]; National Institute of
Mental Health at the US National Institutes of Health [K23MH096620];
Robert Wood Johnson Foundation Health and Society Scholars Program
FX The Shelter, Health, and Drug Outcomes Among Women Study was funded by
the National Institute on Drug Abuse (grant R01DA015605). Additional
salary support was provided by the National Institute of Mental Health
(grant K23MH096620 to A.C.T.) at the US National Institutes of Health
and by the Robert Wood Johnson Foundation Health and Society Scholars
Program (A.C.T.).
NR 91
TC 9
Z9 9
U1 8
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2015
VL 181
IS 10
BP 817
EP 826
DI 10.1093/aje/kwu350
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CK4FY
UT WOS:000356179700011
PM 25834138
ER
PT J
AU Khan, M
Shunmugavel, A
Dhammu, TS
Matsuda, F
Singh, AK
Singh, I
AF Khan, Mushfiquddin
Shunmugavel, Anandakumar
Dhammu, Tajinder S.
Matsuda, Fumiyo
Singh, Avtar K.
Singh, Inderjit
TI Oral administration of cytosolic PLA2 inhibitor arachidonyl
trifluoromethyl ketone ameliorates cauda equina compression injury in
rats
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Lumbar spinal canal stenosis; Cauda equina compression; Cytosolic
phospholipase A2; Neuroinflammation; Arachidonyl trifluoromethyl ketone;
Pain; Motor function
ID SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; LOW-BACK-PAIN; PHOSPHOLIPASE
A(2); NEUROPATHIC PAIN; LYSOPHOSPHATIDIC ACID; THERAPEUTIC TARGETS;
SECONDARY INJURY; POTENT INHIBITOR; NERVE LIGATION
AB Background: Phospholipase A2 (PLA2)-derived proinflammatory lipid mediators such as prostaglandin E2 (PGE2), leukotrienes B4 (LTB4), lysophosphatidylcholine (LPC), and free fatty acids (FFA) are implicated in spinal cord injury (SCI) pathologies. Reducing the levels of these injurious bioactive lipid mediators is reported to ameliorate SCI. However, the specific role of the group IVA isoform of PLA2 cytosolic PLA2 (cPLA2) in lumbar spinal canal stenosis (LSS) due to cauda equina compression (CEC) injury is not clear. In this study, we investigated the role of cPLA2 in a rat model of CEC using a non-toxic cPLA2-preferential inhibitor, arachidonyl trifluoromethyl ketone (ATK).
Methods: LSS was induced in adult female rats by CEC procedure using silicone blocks within the epidural spaces of L4 to L6 vertebrae. cPLA2 inhibitor ATK (7.5 mg/kg) was administered by oral gavage at 2 h following the CEC. cPLA2-derived injurious lipid mediators and the expression/activity of cPLA2, 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2) were assessed. ATK-treated (CEC + ATK) were compared with vehicle-treated (CEC + VEH) animals in terms of myelin levels, pain threshold, and motor function.
Results: ATK treatment of CEC animals reduced the phosphorylation of cPLA2 (pcPLA2) determined by Western blot, improved locomotor function evaluated by rotarod task, and reduced pain threshold evaluated by mechanical hyperalgesia method. Levels of FFA and LPC, along with PGE2 and LTB4, were reduced in CEC + ATK compared with CEC + VEH group. However, ATK treatment reduced neither the activity/expression of 5-LOX nor the expression of COX-2 in CEC + VEH animals. Increased cPLA2 activity in the spinal cord from CEC + VEH animals correlated well with decreased spinal cord as well as cauda equina fiber myelin levels, which were restored after ATK treatment.
Conclusion: The data indicate that cPLA2 activity plays a significant role in tissue injury and pain after LSS. Reducing the levels of proinflammatory and tissue damaging eicosanoids and the deleterious lipid mediator LPC shows therapeutic potential. ATK inhibits cPLA2 activity, thereby decreasing the levels of injurious lipid mediators, reducing pain, improving functional deficits, and conferring protection against LSS injury. Thus, it shows potential for preclinical evaluation in LSS.
C1 [Khan, Mushfiquddin; Shunmugavel, Anandakumar; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan.
[Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.
EM khanm@musc.edu; singhi@musc.edu
FU Extramural Research Facilities Program of the National Center for
Research Resources [CO6 RR018823, CO6 RR0015455]; NIH [07506];
[NS-72511]; [NS-22576]; [NS-37766]; [DC00422]
FX This work was supported by grants NS-72511, NS-22576, and NS-37766 and
DC00422; 07506 from the NIH, CO6 RR018823 and CO6 RR0015455 from the
Extramural Research Facilities Program of the National Center for
Research Resources. We are grateful to Dr. Thomas G. Smith from the MUSC
Writing Center for his valuable editing and correction of the
manuscript. We would like to thank Ms. Danielle Lowe for assistance with
statistical analysis and manuscript review. We would also like to thank
Ms. Joyce Bryan for procurement of animals and chemicals and Ms. Terry
Hope for secretarial assistance.
NR 70
TC 1
Z9 1
U1 2
U2 76
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD MAY 15
PY 2015
VL 12
AR 94
DI 10.1186/s12974-015-0311-y
PG 12
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA CK4SQ
UT WOS:000356213900001
PM 25971887
ER
PT J
AU Orr, N
Dudbridge, F
Dryden, N
Maguire, S
Novo, D
Perrakis, E
Johnson, N
Ghoussaini, M
Hopper, JL
Southey, MC
Apicella, C
Stone, J
Schmidt, MK
Broeks, A
Van't Veer, LJ
Hogervorst, FB
Fasching, PA
Haeberle, L
Ekici, AB
Beckmann, MW
Gibson, L
Aitken, Z
Warren, H
Sawyer, E
Tomlinson, I
Kerin, MJ
Miller, N
Burwinkel, B
Marme, F
Schneeweiss, A
Sohn, C
Guenel, P
Truong, T
Cordina-Duverger, E
Sanchez, M
Bojesen, SE
Nordestgaard, BG
Nielsen, SF
Flyger, H
Benitez, J
Zamora, MP
Perez, JIA
Menendez, P
Anton-Culver, H
Neuhausen, SL
Brenner, H
Dieffenbach, AK
Arndt, V
Stegmaier, C
Hamann, U
Brauch, H
Justenhoven, C
Bruning, T
Ko, YD
Nevanlinna, H
Aittomaki, K
Blomqvist, C
Khan, S
Bogdanova, N
Dork, T
Lindblom, A
Margolin, S
Mannermaa, A
Kataja, V
Kosma, VM
Hartikainen, JM
Chenevix-Trench, G
Beesley, J
Lambrechts, D
Moisse, M
Floris, G
Beuselinck, B
Chang-Claude, J
Rudolph, A
Seibold, P
Flesch-Janys, D
Radice, P
Peterlongo, P
Peissel, B
Pensotti, V
Couch, FJ
Olson, JE
Slettedahl, S
Vachon, C
Giles, GG
Milne, RL
McLean, C
Haiman, CA
Henderson, BE
Schumacher, F
Le Marchand, L
Simard, J
Goldberg, MS
Labreche, F
Dumont, M
Kristensen, V
Alnaes, GG
Nord, S
Borresen-Dale, AL
Zheng, W
Deming-Halverson, S
Shrubsole, M
Long, JR
Winqvist, R
Pylkas, K
Jukkola-Vuorinen, A
Grip, M
Andrulis, IL
Knight, JA
Glendon, G
Tchatchou, S
Devilee, P
Tollenaar, RAEM
Seynaeve, CM
Van Asperen, CJ
Garcia-Closas, M
Figueroa, J
Chanock, SJ
Lissowska, J
Czene, K
Darabi, H
Eriksson, M
Klevebring, D
Hooning, MJ
Hollestelle, A
van Deurzen, CHM
Kriege, M
Hall, P
Li, JM
Liu, JJ
Humphreys, K
Cox, A
Cross, SS
Reed, MWR
Pharoah, PDP
Dunning, AM
Shah, M
Perkins, BJ
Jakubowska, A
Lubinski, J
Jaworska-Bieniek, K
Durda, K
Ashworth, A
Swerdlow, A
Jones, M
Schoemaker, MJ
Meindl, A
Schmutzler, RK
Olswold, C
Slager, S
Toland, AE
Yannoukakos, D
Muir, K
Lophatananon, A
Stewart-Brown, S
Siriwanarangsan, P
Matsuo, K
Ito, H
Iwata, H
Ishiguro, J
Wu, AH
Tseng, CC
Van den Berg, D
Stram, DO
Teo, SH
Yip, CH
Kang, P
Ikram, MK
Shu, XO
Lu, W
Gao, YT
Cai, H
Kang, D
Choi, JY
Park, SK
Noh, DY
Hartman, M
Miao, H
Lim, WY
Lee, SC
Sangrajrang, S
Gaborieau, V
Brennan, P
McKay, J
Wu, PE
Hou, MF
Yu, JC
Shen, CY
Blot, W
Cai, QY
Signorello, LB
Luccarini, C
Bayes, C
Ahmed, S
Maranian, M
Healey, CS
Gonzalez-Neira, A
Pita, G
Alonso, MR
Alvarez, N
Herrero, D
Tessier, DC
Vincent, D
Bacot, F
Hunter, DJ
Lindstrom, S
Dennis, J
Michailidou, K
Bolla, MK
Easton, DF
Silva, ID
Fletcher, O
Peto, J
AF Orr, Nick
Dudbridge, Frank
Dryden, Nicola
Maguire, Sarah
Novo, Daniela
Perrakis, Eleni
Johnson, Nichola
Ghoussaini, Maya
Hopper, John L.
Southey, Melissa C.
Apicella, Carmel
Stone, Jennifer
Schmidt, Marjanka K.
Broeks, Annegien
Van't Veer, Laura J.
Hogervorst, Frans B.
Fasching, Peter A.
Haeberle, Lothar
Ekici, Arif B.
Beckmann, Matthias W.
Gibson, Lorna
Aitken, Zoe
Warren, Helen
Sawyer, Elinor
Tomlinson, Ian
Kerin, Michael J.
Miller, Nicola
Burwinkel, Barbara
Marme, Frederik
Schneeweiss, Andreas
Sohn, Chistof
Guenel, Pascal
Truong, Therese
Cordina-Duverger, Emilie
Sanchez, Marie
Bojesen, Stig E.
Nordestgaard, Borge G.
Nielsen, Sune F.
Flyger, Henrik
Benitez, Javier
Zamora, Maria Pilar
Perez, Jose Ignacio Arias
Menendez, Primitiva
Anton-Culver, Hoda
Neuhausen, Susan L.
Brenner, Hermann
Dieffenbach, Aida Karina
Arndt, Volker
Stegmaier, Christa
Hamann, Ute
Brauch, Hiltrud
Justenhoven, Christina
Bruning, Thomas
Ko, Yon-Dschun
Nevanlinna, Heli
Aittomaki, Kristiina
Blomqvist, Carl
Khan, Sofia
Bogdanova, Natalia
Dork, Thilo
Lindblom, Annika
Margolin, Sara
Mannermaa, Arto
Kataja, Vesa
Kosma, Veli-Matti
Hartikainen, Jaana M.
Chenevix-Trench, Georgia
Beesley, Jonathan
Lambrechts, Diether
Moisse, Matthieu
Floris, Guiseppe
Beuselinck, Benoit
Chang-Claude, Jenny
Rudolph, Anja
Seibold, Petra
Flesch-Janys, Dieter
Radice, Paolo
Peterlongo, Paolo
Peissel, Bernard
Pensotti, Valeria
Couch, Fergus J.
Olson, Janet E.
Slettedahl, Seth
Vachon, Celine
Giles, Graham G.
Milne, Roger L.
McLean, Catriona
Haiman, Christopher A.
Henderson, Brian E.
Schumacher, Fredrick
Le Marchand, Loic
Simard, Jacques
Goldberg, Mark S.
Labreche, France
Dumont, Martine
Kristensen, Vessela
Alnaes, Grethe Grenaker
Nord, Silje
Borresen-Dale, Anne-Lise
Zheng, Wei
Deming-Halverson, Sandra
Shrubsole, Martha
Long, Jirong
Winqvist, Robert
Pylkas, Katri
Jukkola-Vuorinen, Arja
Grip, Mervi
Andrulis, Irene L.
Knight, Julia A.
Glendon, Gord
Tchatchou, Sandrine
Devilee, Peter
Tollenaar, Robertus A. E. M.
Seynaeve, Caroline M.
Van Asperen, Christi J.
Garcia-Closas, Montserrat
Figueroa, Jonine
Chanock, Stephen J.
Lissowska, Jolanta
Czene, Kamila
Darabi, Hatef
Eriksson, Mikael
Klevebring, Daniel
Hooning, Maartje J.
Hollestelle, Antoinette
van Deurzen, Carolien H. M.
Kriege, Mieke
Hall, Per
Li, Jingmei
Liu, Jianjun
Humphreys, Keith
Cox, Angela
Cross, Simon S.
Reed, Malcolm W. R.
Pharoah, Paul D. P.
Dunning, Alison M.
Shah, Mitul
Perkins, Barbara J.
Jakubowska, Anna
Lubinski, Jan
Jaworska-Bieniek, Katarzyna
Durda, Katarzyna
Ashworth, Alan
Swerdlow, Anthony
Jones, Michael
Schoemaker, Minouk J.
Meindl, Alfons
Schmutzler, Rita K.
Olswold, Curtis
Slager, Susan
Toland, Amanda E.
Yannoukakos, Drakoulis
Muir, Kenneth
Lophatananon, Artitaya
Stewart-Brown, Sarah
Siriwanarangsan, Pornthep
Matsuo, Keitaro
Ito, Hidema
Iwata, Hiroji
Ishiguro, Junko
Wu, Anna H.
Tseng, Chiu-Chen
Van den Berg, David
Stram, Daniel O.
Teo, Soo Hwang
Yip, Cheng Har
Kang, Peter
Ikram, Mohammad Kamran
Shu, Xiao-Ou
Lu, Wei
Gao, Yu-Tang
Cai, Hui
Kang, Daehee
Choi, Ji-Yeob
Park, Sue K.
Noh, Dong-Young
Hartman, Mikael
Miao, Hui
Lim, Wei Yen
Lee, Soo Chin
Sangrajrang, Suleeporn
Gaborieau, Valerie
Brennan, Paul
McKay, James
Wu, Pei-Ei
Hou, Ming-Feng
Yu, Jyh-Cherng
Shen, Chen-Yang
Blot, William
Cai, Qiuyin
Signorello, Lisa B.
Luccarini, Craig
Bayes, Caroline
Ahmed, Shahana
Maranian, Mel
Healey, Catherine S.
Gonzalez-Neira, Anna
Pita, Guillermo
Alonso, M. Rosario
Alvarez, Nuria
Herrero, Daniel
Tessier, Daniel C.
Vincent, Daniel
Bacot, Francois
Hunter, David J.
Lindstrom, Sara
Dennis, Joe
Michailidou, Kyriaki
Bolla, Manjeet K.
Easton, Douglas F.
Silva, Isabel dos Santos
Fletcher, Olivia
Peto, Julian
CA GENICA Network
kConFab Investigators
Australian Ovarian Canc Study Grp
TI Fine-mapping identifies two additional breast cancer susceptibility loci
at 9q31.2
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ESTROGEN-RECEPTOR-ALPHA; CONFER SUSCEPTIBILITY;
FUNCTIONAL VARIANTS; COMMON VARIANTS; ANALYSES REVEAL; RISK LOCUS;
EXPRESSION; BINDING; FOXA1
AB We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2. Here, we report a fine-mapping analysis of the 9q31.2 susceptibility locus using 43 160 cases and 42 600 controls of European ancestry ascertained from 52 studies and a further 5795 cases and 6624 controls of Asian ancestry from nine studies. Single nucleotide polymorphism (SNP) rs676256 was most strongly associated with risk in Europeans (odds ratios [OR] = 0.90 [0.88-0.92]; P-value = 1.58 x 10(-25)). This SNP is one of a cluster of highly correlated variants, including rs865686, that spans 14.5 kb. We identified two additional independent association signals demarcated by SNPs rs10816625 (OR = 1.12 [1.08-1.17]; P-value = 7.89 x 10(-09)) and rs13294895 (OR = 1.09 [1.06-1.12]; P-value = 2.97 x 10(-11)). SNP rs10816625, but not rs13294895, was also associated with risk of breast cancer in Asian individuals (OR = 1.12 [1.06-1.18]; P-value = 2.77 x 10(-05)). Functional genomic annotation using data derived from breast cancer cell-line models indicates that these SNPs localise to putative enhancer elements that bind known drivers of hormone-dependent breast cancer, including ER-alpha, FOXA1 and GATA-3. In vitro analyses indicate that rs10816625 and rs13294895 have allele-specific effects on enhancer activity and suggest chromatin interactions with the KLF4 gene locus. These results demonstrate the power of dense genotyping in large studies to identify independent susceptibility variants. Analysis of associations using subjects with different ancestry, combined with bioinformatic and genomic characterisation, can provide strong evidence for the likely causative alleles and their functional basis.
C1 [Orr, Nick; Dryden, Nicola; Maguire, Sarah; Novo, Daniela; Perrakis, Eleni; Johnson, Nichola; Garcia-Closas, Montserrat; Ashworth, Alan; Fletcher, Olivia] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
[Orr, Nick; Dryden, Nicola; Maguire, Sarah; Novo, Daniela; Perrakis, Eleni; Johnson, Nichola; Garcia-Closas, Montserrat; Ashworth, Alan; Swerdlow, Anthony; Schoemaker, Minouk J.; Fletcher, Olivia] Inst Canc Res, Div Breast Canc Res, London SW3 6JB, England.
[Garcia-Closas, Montserrat; Swerdlow, Anthony; Jones, Michael; Schoemaker, Minouk J.] Inst Canc Res, Div Genet & Epidemiol, London SW3 6JB, England.
[Dudbridge, Frank; Gibson, Lorna; Aitken, Zoe; Silva, Isabel dos Santos; Peto, Julian] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England.
[Ghoussaini, Maya; Pharoah, Paul D. P.; Dunning, Alison M.; Shah, Mitul; Perkins, Barbara J.; Luccarini, Craig; Bayes, Caroline; Ahmed, Shahana; Maranian, Mel; Healey, Catherine S.; Easton, Douglas F.] Univ Cambridge, Dept Oncol, Ctr Canc Genet Epidemiol, Cambridge, England.
[Dennis, Joe; Michailidou, Kyriaki; Bolla, Manjeet K.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England.
[Hopper, John L.; Apicella, Carmel; Giles, Graham G.; Milne, Roger L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia.
[Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.
[Stone, Jennifer] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Perth, WA 6009, Australia.
[Schmidt, Marjanka K.; Broeks, Annegien; Hogervorst, Frans B.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands.
[Haeberle, Lothar; Beckmann, Matthias W.] Univ Hosp Erlangen, Dept Gynecol & Obstet, Univ Breast Ctr Franconia, D-91054 Erlangen, Germany.
[Ekici, Arif B.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Warren, Helen] Queen Mary Univ London, Dept Clin Pharmacol, William Harvey Res Inst, Barts & London Sch Med, London, England.
[Warren, Helen] Queen Mary Univ London, NIHR Barts Cardiovasc Biomed Res Unit, London, England.
[Sawyer, Elinor] Guys Hosp, Kings Coll London, Div Canc Studies, London SE1 9RT, England.
[Tomlinson, Ian] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
[Tomlinson, Ian] Univ Oxford, Oxford Biomed Res Ctr, Oxford OX1 2JD, England.
[Kerin, Michael J.; Miller, Nicola] Univ Hosp Galway, Inst Clin Sci, Galway, Ireland.
[Burwinkel, Barbara; Marme, Frederik; Schneeweiss, Andreas; Sohn, Chistof] Heidelberg Univ, Dept Obstet & Gynecol, D-69120 Heidelberg, Germany.
[Marme, Frederik; Schneeweiss, Andreas] Heidelberg Univ, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, D-69120 Heidelberg, Germany.
[Guenel, Pascal; Truong, Therese; Cordina-Duverger, Emilie; Sanchez, Marie] CESP Ctr Res Epidemiol & Populat Hlth, Inserm Natl Inst Hlth & Med Res, U1018, Environm Epidemiol Canc, Villejuif, France.
[Guenel, Pascal; Truong, Therese; Cordina-Duverger, Emilie; Sanchez, Marie] Univ Paris 11, UMRS 1018, Villejuif, France.
[Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen Gen Populat Study, DK-2730 Herlev, Denmark.
[Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark.
[Flyger, Henrik] Copenhagen Univ Hosp, Herlev Hosp, Dept Breast Surg, DK-2730 Copenhagen, Denmark.
[Benitez, Javier] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Madrid 28029, Spain.
[Benitez, Javier] Ctr Invest Red Enfermedades Raras CIBERER, Valencia 46010, Spain.
[Zamora, Maria Pilar] Hosp Univ La Paz, Serv Oncol Med, Madrid 28046, Spain.
[Perez, Jose Ignacio Arias] Hosp Monte Naranco, Serv Cirugia Gen & Especialidades, Oviedo 33012, Spain.
[Menendez, Primitiva] Hosp Monte Naranco, Serv Anat Patol, Oviedo 33012, Spain.
[Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA.
[Neuhausen, Susan L.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA.
[Brenner, Hermann; Dieffenbach, Aida Karina; Arndt, Volker] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Brenner, Hermann; Dieffenbach, Aida Karina; Brauch, Hiltrud; Ashworth, Alan] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
[Hamann, Ute] German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany.
[Chang-Claude, Jenny; Rudolph, Anja; Seibold, Petra] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Stegmaier, Christa] Saarland Canc Registry, Saarbrucken, Germany.
[Brauch, Hiltrud; Justenhoven, Christina] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Brauch, Hiltrud; Justenhoven, Christina] Univ Tubingen, Tubingen, Germany.
[Bruning, Thomas] Inst Ruhr Univ Bochum IPA, Inst Prevent & Occupat Med German Social Accid In, Bochum, Germany.
[Ko, Yon-Dschun] Johanniter Krankenhaus, Evangel Kliniken Bonn gGmbH, Dept Internal Med, Bonn, Germany.
Univ Bonn, Inst Pathol, Fac Med, Bonn, Germany.
[GENICA Network] Univ Med Ctr Hamburg Eppendorf, Inst Occupat Med & Maritime Med, Hamburg, Germany.
[Nevanlinna, Heli; Khan, Sofia] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland.
[Aittomaki, Kristiina] Univ Helsinki, Dept Clin Genet, Helsinki, Finland.
[Blomqvist, Carl] Univ Helsinki, Dept Oncol, Helsinki, Finland.
[Blomqvist, Carl] Helsinki Univ Hosp, Helsinki, Finland.
[Bogdanova, Natalia] Hannover Med Sch, Dept Radiat Oncol, Hannover, Germany.
[Bogdanova, Natalia; Dork, Thilo] Hannover Med Sch, Dept Obstet & Gynaecol, Hannover, Germany.
[Lindblom, Annika] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Margolin, Sara] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Univ Eastern Finland, Sch Med, Inst Clin Med Pathol & Forens Med, Kuopio, Finland.
[Kataja, Vesa] Univ Eastern Finland, Sch Med, Inst Clin Med, Oncol, Kuopio, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Dept Clin Pathol, Imaging Ctr, SF-70210 Kuopio, Finland.
[Kataja, Vesa] Kuopio Univ Hosp, Ctr Eastern Finland, Bioctr Kuopio, SF-70210 Kuopio, Finland.
[Kataja, Vesa] Jyvaskyla Cent Hosp, Cent Finland Hlth Care Dist, Jyvaskyla, Finland.
[Chenevix-Trench, Georgia; Beesley, Jonathan] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
[kConFab Investigators; Australian Ovarian Canc Study Grp] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Lambrechts, Diether; Moisse, Matthieu] VIB, VRC, Leuven, Belgium.
[Lambrechts, Diether; Moisse, Matthieu] Univ Leuven, Dept Oncol, Lab Translat Genet, Leuven, Belgium.
[Floris, Guiseppe; Beuselinck, Benoit] Univ Hosp Gasthuisberg, Leuven, Belgium.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Clin Canc Registry, Dept Canc Epidemiol, Hamburg, Germany.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Inst Med Biometr & Epidemiol, Hamburg, Germany.
[Radice, Paolo] Fdn IRCCS Ist Nazl Tumori INT, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent & Predict Med, Milan, Italy.
[Peissel, Bernard] Fdn IRCCS Ist Nazl Tumori INT, Unit Med Genet, Dept Prevent & Predict Med, Milan, Italy.
[Peterlongo, Paolo; Pensotti, Valeria] Fdn Ist FIRC Oncol Mol, IFOM, Milan, Italy.
[Pensotti, Valeria] Cogentech Canc Genet Test Lab, Milan, Italy.
[Couch, Fergus J.; Olswold, Curtis; Slager, Susan] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Olson, Janet E.; Slettedahl, Seth; Vachon, Celine] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Giles, Graham G.; Milne, Roger L.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[McLean, Catriona] Alfred Hosp, Anat Pathol, Melbourne, Vic, Australia.
[Haiman, Christopher A.; Henderson, Brian E.; Schumacher, Fredrick; Wu, Anna H.; Tseng, Chiu-Chen; Van den Berg, David; Stram, Daniel O.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Epidemiol Program, Honolulu, HI 96813 USA.
[Simard, Jacques; Dumont, Martine] Ctr Hosp Univ Quebec, Res Ctr, Canc Genom Lab, Quebec City, PQ, Canada.
[Simard, Jacques; Dumont, Martine] Univ Laval, Quebec City, PQ, Canada.
[Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ, Canada.
[Goldberg, Mark S.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada.
[Labreche, France] Univ Montreal, Dept Sante Environm & Sante Travail, Dept Med Sociale & Prevent, Montreal, PQ, Canada.
[Kristensen, Vessela; Alnaes, Grethe Grenaker; Nord, Silje; Borresen-Dale, Anne-Lise] Radiumhospitalet, Oslo Univ Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
[Kristensen, Vessela; Borresen-Dale, Anne-Lise] Univ Oslo UiO, Inst Clin Med, N-0450 Oslo, Norway.
[Zheng, Wei; Deming-Halverson, Sandra; Shrubsole, Martha; Long, Jirong; Shu, Xiao-Ou; Cai, Hui; Blot, William; Cai, Qiuyin] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Div Epidemiol,Dept Med,Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Winqvist, Robert; Pylkas, Katri] Univ Oulu, Oulu Univ Hosp, Lab Canc Genet & Tumor Biol, Dept Clin Genet, Oulu, Finland.
[Winqvist, Robert; Pylkas, Katri] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Oulu, Finland.
[Jukkola-Vuorinen, Arja] Univ Oulu, Oulu Univ Hosp, Dept Oncol, Oulu, Finland.
[Grip, Mervi] Univ Oulu, Oulu Univ Hosp, Dept Surg, Oulu, Finland.
[Andrulis, Irene L.; Glendon, Gord] Mt Sinai Hosp, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada.
[Knight, Julia A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada.
[Andrulis, Irene L.] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Mol Genet, Toronto, ON, Canada.
[Knight, Julia A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.
[Tchatchou, Sandrine] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands.
[Tollenaar, Robertus A. E. M.] Leiden Univ, Med Ctr, Dept Surg Oncol, NL-2300 RC Leiden, Netherlands.
[Seynaeve, Caroline M.; Hooning, Maartje J.; Hollestelle, Antoinette; Kriege, Mieke] Erasmus MC Canc Inst, Family Canc Clin, Dept Med Oncol, Rotterdam, Netherlands.
[Van Asperen, Christi J.] Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RC Leiden, Netherlands.
[Figueroa, Jonine; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Lissowska, Jolanta; Klevebring, Daniel] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland.
[Lissowska, Jolanta; Klevebring, Daniel] Inst Oncol, Warsaw, Poland.
[Czene, Kamila; Darabi, Hatef; Eriksson, Mikael; Hall, Per; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden.
[van Deurzen, Carolien H. M.] Erasmus Univ, Dept Pathol, Med Ctr, NL-3000 DR Rotterdam, Netherlands.
[Li, Jingmei; Liu, Jianjun] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
[Cox, Angela] Univ Sheffield, Dept Oncol, Sheffield Canc Res, Sheffield, S Yorkshire, England.
[Cross, Simon S.] Univ Sheffield, Dept Neurosci, Acad Unit Pathol, Sheffield, S Yorkshire, England.
[Reed, Malcolm W. R.] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England.
[Jakubowska, Anna; Lubinski, Jan; Jaworska-Bieniek, Katarzyna; Durda, Katarzyna] Pomeranian Med Univ, Dept Genet & Pathol, PL-70115 Szczecin, Poland.
[Meindl, Alfons] Tech Univ Munich, Div Gynaecol & Obstet, D-81675 Munich, Germany.
[Schmutzler, Rita K.] Univ Cologne, Ctr Hereditary Breast & Ovarian Canc, CIO, Fac Med, D-50931 Cologne, Germany.
[Schmutzler, Rita K.] Univ Cologne, CMMC, Fac Med, D-50931 Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Cologne, Germany.
[Toland, Amanda E.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
[Yannoukakos, Drakoulis] Natl Ctr Sci Res Demokritos, Aghia Paraskevi Attikis, IRRP, Mol Diagnost Lab, Athens, Greece.
[Muir, Kenneth; Stewart-Brown, Sarah] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England.
[Muir, Kenneth; Lophatananon, Artitaya] Univ Manchester, Instt Populat Hlth, Manchester, Lancs, England.
[Siriwanarangsan, Pornthep] Minist Publ Hlth, Nonthaburi, Thailand.
[Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 812, Japan.
[Ito, Hidema] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
[Iwata, Hiroji; Ishiguro, Junko] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan.
[Teo, Soo Hwang; Kang, Peter] Sime Darby Med Ctr, Canc Res Initiat Fdn, Subang Jaya, Selangor, Malaysia.
[Teo, Soo Hwang; Yip, Cheng Har] Univ Malaya, Canc Res Inst, Med Ctr, Breast Canc Res Unit, Kuala Lumpur, Malaysia.
[Ikram, Mohammad Kamran] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 168751, Singapore.
[Lu, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China.
[Gao, Yu-Tang] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
[Kang, Daehee; Park, Sue K.] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
[Noh, Dong-Young] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea.
[Kang, Daehee; Choi, Ji-Yeob; Park, Sue K.] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea.
[Kang, Daehee; Choi, Ji-Yeob; Park, Sue K.] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.
[Hartman, Mikael; Miao, Hui; Lim, Wei Yen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
[Hartman, Mikael] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 117595, Singapore.
[Hartman, Mikael; Miao, Hui] Natl Univ Hlth Syst, Singapore, Singapore.
[Lee, Soo Chin] Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore.
[Lee, Soo Chin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
[Sangrajrang, Suleeporn] Natl Canc Inst, Bangkok, Thailand.
[Gaborieau, Valerie; Brennan, Paul; McKay, James] Int Agcy Res Canc, F-69372 Lyon, France.
[Wu, Pei-Ei] Acad Sinica, Taiwan Biobank, Taipei 115, Taiwan.
[Wu, Pei-Ei] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
[Hou, Ming-Feng; Shen, Chen-Yang] Kaohsiung Med Univ, Chung Ho Mem Hosp, Ctr Canc, Kaohsiung 804, Taiwan.
[Hou, Ming-Feng; Shen, Chen-Yang] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Kaohsiung 804, Taiwan.
[Yu, Jyh-Cherng] Triserv Gen Hosp, Dept Surg, Taipei 114, Taiwan.
[Yu, Jyh-Cherng] Natl Def Med Ctr, Taipei 114, Taiwan.
[Shen, Chen-Yang] China Med Univ, Sch Publ Hlth, Taichung 404, Taiwan.
[Blot, William] Int Inst Epidemiol, Rockville, MD USA.
[Signorello, Lisa B.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Signorello, Lisa B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hunter, David J.; Lindstrom, Sara] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Gonzalez-Neira, Anna; Pita, Guillermo; Alonso, M. Rosario; Alvarez, Nuria; Herrero, Daniel] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Human Genotyping CEGEN Unit, Madrid, Spain.
[Gonzalez-Neira, Anna; Pita, Guillermo; Tessier, Daniel C.; Vincent, Daniel; Bacot, Francois] Ctr Innovat Genome Quebec, Montreal, PQ, Canada.
[Tessier, Daniel C.; Vincent, Daniel; Bacot, Francois] McGill Univ, Montreal, PQ, Canada.
RP Orr, N (reprint author), Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.
EM nicholas.orr@icr.ac.uk
RI Bruning, Thomas/G-8120-2015; Garcia-Closas, Montserrat /F-3871-2015;
Andrulis, Irene/E-7267-2013; Knight, Julia/A-6843-2012; Yip,
Cheng-Har/B-1909-2010; Teo, Soo-hwang/H-2353-2014; Li,
Jingmei/I-2904-2012; Shrubsole, Martha/K-5052-2015; Hartikainen,
Jaana/E-6256-2015; Hartman, Mikael/B-4324-2011; Dork, Thilo/J-8620-2012;
Bowtell, David/H-1007-2016; Nord, Silje/R-5212-2016; Brenner,
Hermann/B-4627-2017; Peissel, Bernard/E-8187-2017;
OI Bruning, Thomas/0000-0001-9560-5464; Garcia-Closas, Montserrat
/0000-0003-1033-2650; Li, Jingmei/0000-0001-8587-7511; Shrubsole,
Martha/0000-0002-5591-7575; Bowtell, David/0000-0001-9089-7525;
Yannoukakos, Drakoulis/0000-0001-7509-3510; Dunning, Alison
Margaret/0000-0001-6651-7166; Ikram, Mohammad
Kamran/0000-0003-0173-9571; Giles, Graham/0000-0003-4946-9099; Nord,
Silje/0000-0002-3271-5356; Brenner, Hermann/0000-0002-6129-1572;
Peissel, Bernard/0000-0001-9233-3571; dos Santos Silva,
Isabel/0000-0002-6596-8798; Schoemaker, Minouk/0000-0001-8403-2234;
Cross, Simon/0000-0003-2044-1754; Aitken, Zoe/0000-0002-5413-2450; Khan,
Sofia/0000-0003-4185-8882; Cox, Angela/0000-0002-5138-1099; Moisse,
Matthieu/0000-0001-8880-9311
FU Cancer Research UK [C1287/A10118, C1287/A12014, C1287/A 10710,
C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692,
C8197/A16565]; European Community [223175 (HEALTH-F2-2009-223175)];
National Institutes of Health [CA128978, R01 CA77398]; Post-Cancer GWAS
initiative (GAME-ON initiative) [1U19 CA148537, 1U19 CA148065, 1U19
CA148112]; Department of Defence [W81XWH-10-1-0341]; Canadian Institutes
of Health Research (CIHR); Komen Foundation for the Cure; Breast Cancer
Research Foundation; Ovarian Cancer Research Fund; National Cancer
Institute (USA) [UM1 CA164920]; Dutch Cancer Society [NKI 2007-3839,
2009 4363]; BBMRI-NL - Dutch government [NWO 184.021.007]; Dutch
National Genomics Initiative; ELAN-Fond of the University Hospital of
Erlangen; Breakthrough Breast Cancer; NHS; National Cancer Research
Network (NCRN); NIHR Comprehensive Biomedical Research Centre, Guy's &
St. Thomas' NHS Foundation Trust in partnership with King's College
London, UK; Oxford Biomedical Research Centre; Dietmar-Hopp Foundation;
Helmholtz Society; German Cancer Research Center (DKFZ); Fondation de
France; Institut National du Cancer (INCa); Ligue Nationale contre le
Cancer; Ligue contre le Cancer Grand Ouest; Agence Nationale de Securite
Sanitaire (ANSES) Agence Nationale de la Recherche (ANR); Chief
Physician Johan Boserup and Lise Boserup Fund; Danish Medical Research
Council; Herlev Hospital; Genome Spain Foundation; Red Tematica de
Investigacion Cooperativa en Cancer; Asociacion Espanola Contra el
Cancer; Fondo de Investigacion Sanitario [PI11/00923, PI081120];
Instituto de Salud Carlos III; California Breast Cancer Act; California
Breast Cancer Research Fund [97-10500]; Lon V Smith Foundation
[LVS39420]; Baden Wurttemberg Ministry of Science, Research and Arts;
German Cancer Aid (Deutsche Krebshilfe); Deutsche Krebshilfe [107 352];
Federal Ministry of Education and Research (BMBF) Germany [01KW9975/5,
01KW9976/8, 01KW9977/0, 01KW0114]; Robert Bosch Foundation, Stuttgart;
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg; Institute for
Prevention and Occupational Medicine of the German Social Accident
Insurance; Institute of the Ruhr University Bochum (IPA), Bochum;
Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH;
Johanniter Krankenhaus, Bonn, Germany; Helsinki University Central
Hospital Research Fund; Academy of Finland [266528, 250083, 122715];
Finnish Cancer Society; Nordic Cancer Union; Sigrid Juselius Foundation;
Stockholm County Council; Karolinska Institutet; Swedish Cancer Society;
Gustav V Jubilee foundation; Government Funding (EVO) of Kuopio
University Hospital; Cancer Fund of North Savo; Finnish Cancer
Organizations; University of Eastern Finland; National Breast Cancer
Foundation; National Health and Medical Research Council (NHMRC);
Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria,
Tasmania and South Australia; Cancer Foundation of Western Australia;
Stichting tegen Kanker [232-2008, 196-2010]; FWO; Deutsche Krebshilfe
e.V. [70-2892-BR I]; Hamburg Cancer Society; German Cancer Research
Center; Federal Ministry of Education and Research (BMBF), Germany
[01KH0402]; Italian Association for Cancer Research (AIRC); Fondazione
IRCCS Istituto Nazionale Tumori; NIH [CA128978, CA116167, CA176785,
CA63464, CA54281, CA098758, CA132839, R01CA100374, R01CA64277,
R01CA148667, R37CA70867]; NIH Specialized Program of Research Excellence
(SPORE) in Breast Cancer [CA116201]; VicHealth and Cancer Council
Victoria; Australian NHMRC [209057, 251553, 504711]; Quebec Breast
Cancer Foundation; Canadian Institutes of Health Research [CRN-87521];
Ministry of Economic Development, Innovation and Export Trade
[PSR-SIIRI-701]; Norwegian Research council [155218/V40, 175240/S10];
FUGE-NFR [181600/V11]; Swizz Bridge Award; National Health and Medical
Research Council of Australia; New South Wales Cancer Council; Victorian
Health Promotion Foundation (Australia); Victorian Breast Cancer
Research Consortium; Friends of Hannover Medical School; Rudolf Bartling
Foundation; Finnish Cancer Foundation; Academy of Finland (Center of
Excellence) [251314]; University of Oulu; University of Oulu Support
Foundation; EVO funds for Oulu University Hospital; Dutch Cancer Society
(RUL) [1997-1505]; Biobanking and Biomolecular Resources Research
Infrastructure (BBMRI-NL) [CP16]; National Cancer Institute, Department
of Health and Human Services, USA; Marit and Hans Rausings Initiative
Against Breast Cancer; Dutch Cancer Society (DDHK) [2004-3124,
2009-4318]; Agency for Science, Technology and Research of (A*STAR); US
National Institute of Health (NIH); Susan G. Komen Breast Cancer
Foundation; Yorkshire Cancer Research [S295, S299, S305PA]; UK National
Institute for Health Research Biomedical Research Centre at the
University of Cambridge; DKFZ; Specialized Program of Research
Excellence (SPORE) in Breast Cancer [CA116201]; National Institutes of
Health Grant [P30 CA016056]; Hellenic Cooperative Oncology Group [HR
R_BG/04]; Greek General Secretary for Research and Technology (GSRT)
Program, Research Excellence II; European Union (European Social
Fund-ESF); Greek national funds through the Operational Program
'Education and Lifelong Learning' of the National Strategic Reference
Framework (NSRF)-ARISTEIA; Institute of Cancer Research (ICR), London;
Breast Cancer Research Trust, UK; Ministry of Education, Science,
Sports, Culture and Technology of Japan; Ministry Health, Labour and
Welfare of Japan; Health and Labour Sciences Research Grants for
Research on Applying Health Technology from Ministry Health, Labour and
Welfare of Japan; National Cancer Center Research and Development Fund;
California Breast Cancer Research Program [1RB-0287, 3PB-0102, 5PB-0018,
10PB-0098]; California Department of Health; Malaysian Ministry of
Science, Technology and Innovation (MOSTI); Malaysian Ministry of Higher
Education [UM.C/HlR/MOHE/06]; Cancer Research Initiatives Foundation
(CARIF); Biomedical Research Council, Singapore [BMRC08/1/35/19/550];
National Medical Research Council, Singapore (NMRC/CG/SERI); Genetic
Associations and Mechanisms in Oncology (GAME-ON) Network [U19
CA148065]; BRL (Basic Research Laboratory) program through National
Research Foundation of Korea - Ministry of Education, Science and
Technology [2012-0000347]; National Medical Research Council; Biomedical
Research Council [05/1/21/19/425]; National Cancer Institute, Thailand;
Taiwan Biobank project of the Institute of Biomedical Sciences, Academia
Sinica, Taiwan; National Program of Cancer Registries, Centers for
Disease Control and Prevention (CDC); Charity Open Access Fund (COAF);
[KULPFV/10/016-SymBioSysII]; [P30 CA68485]; [PBZ_KBN_122/P05/2004];
[N01CN25403]
FX BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by
the European Community's Seventh Framework Programme under grant
agreement number 223175 (grant number HEALTH-F2-2009-223175). Funding
for the iCOGS infrastructure came from: the European Community's Seventh
Framework Programme under grant agreement no. 223175
(HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118,
C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007,
C5047/A10692 and C8197/A16565), the National Institutes of Health
(CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065
and 1U19 CA148112-the GAME-ON initiative), the Department of Defence
(W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR)
for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation
for the Cure, the Breast Cancer Research Foundation, and the Ovarian
Cancer Research Fund. The Australian Breast Cancer Family Study (ABCFS)
was supported by grant UM1 CA164920 from the National Cancer Institute
(USA). The ABCS study was supported by the Dutch Cancer Society (grants
NKI 2007-3839; 2009 4363); BBMRI-NL, which is a Research Infrastructure
financed by the Dutch government (NWO 184.021.007) and the Dutch
National Genomics Initiative. The work of the BBCC was partly funded by
ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by
Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS
funding to the NIHR Biomedical Research Centre, and the National Cancer
Research Network (NCRN). E.S. is supported by NIHR Comprehensive
Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in
partnership with King's College London, UK. I.T. is supported by the
Oxford Biomedical Research Centre. The BSUCH study was supported by the
Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer
Research Center (DKFZ). The CECILE study was funded by Fondation de
France, Institut National du Cancer (INCa), Ligue Nationale contre le
Cancer, Ligue contre le Cancer Grand Ouest, Agence Nationale de Securite
Sanitaire (ANSES) Agence Nationale de la Recherche (ANR). The CGPS was
supported by the Chief Physician Johan Boserup and Lise Boserup Fund,
the Danish Medical Research Council and Herlev Hospital. The CNIO-BCS
was supported by the Genome Spain Foundation, the Red Tematica de
Investigacion Cooperativa en Cancer and grants from the Asociacion
Espanola Contra el Cancer and the Fondo de Investigacion Sanitario
(PI11/00923 and PI081120). The Human Genotyping-CEGEN Unit (CNIO) is
supported by the Instituto de Salud Carlos III. The CTS was initially
supported by the California Breast Cancer Act of 1993 and the California
Breast Cancer Research Fund (contract 97-10500) and is currently funded
through the National Institutes of Health (R01 CA77398). Collection of
cancer incidence data was supported by the California Department of
Public Health as part of the statewide cancer reporting program mandated
by California Health and Safety Code Section 103885. H.A.C receives
support from the Lon V Smith Foundation (LVS39420). The ESTHER study was
supported by a grant from the Baden Wurttemberg Ministry of Science,
Research and Arts. Additional cases were recruited in the context of the
VERDI study, which was supported by a grant from the German Cancer Aid
(Deutsche Krebshilfe). The GC-HBOC was supported by Deutsche Krebshilfe
(107 352).; The GENICA was funded by the Federal Ministry of Education
and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0
and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention
and Occupational Medicine of the German Social Accident Insurance,
Institute of the Ruhr University Bochum (IPA), Bochum, as well as the
Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH,
Johanniter Krankenhaus, Bonn, Germany. The HEBCS was financially
supported by the Helsinki University Central Hospital Research Fund,
Academy of Finland (266528), the Finnish Cancer Society, and The Nordic
Cancer Union and the Sigrid Juselius Foundation. Financial support for
KARBAC was provided through the regional agreement on medical training
and clinical research (ALF) between Stockholm County Council and
Karolinska Institutet, The Swedish Cancer Society and the Gustav V
Jubilee foundation. The KBCP was financially supported by the special
Government Funding (EVO) of Kuopio University Hospital grants, Cancer
Fund of North Savo, the Finnish Cancer Organizations, and by the
strategic funding of the University of Eastern Finland. 'kConFab' is
supported by a grant from the National Breast Cancer Foundation, and
previously by the National Health and Medical Research Council (NHMRC),
the Queensland Cancer Fund, the Cancer Councils of New South Wales,
Victoria, Tasmania and South Australia, and the Cancer Foundation of
Western Australia. LMBC is supported by the 'Stichting tegen Kanker'
(232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and
the KULPFV/10/016-SymBioSysII. The MARIE study was supported by the
Deutsche Krebshilfe e.V. [70-2892-BR I], the Hamburg Cancer Society, the
German Cancer Research Center and the Federal Ministry of Education and
Research (BMBF), Germany (01KH0402). MBCSG is supported by grants from
the Italian Association for Cancer Research (AIRC) and by funds from the
Italian citizens who allocated the 5/1000 share of their tax payment in
support of the Fondazione IRCCS Istituto Nazionale Tumori, according to
Italian laws (INT-Institutional strategic projects '5 x 1000'). The
MCBCS was supported by the NIH grants CA128978, CA116167 and CA176785
and NIH Specialized Program of Research Excellence (SPORE) in Breast
Cancer (CA116201), and the Breast Cancer Research Foundation and a
generous gift from the David F. and Margaret T. Grohne Family Foundation
and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment
was funded by VicHealth and Cancer Council Victoria. The MCCS was
further supported by Australian NHMRC grants 209057, 251553 and 504711
and by infrastructure provided by Cancer Council Victoria. The MEC was
support by NIH grants CA63464, CA54281, CA098758 and CA132839. The work
of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the
Canadian Institutes of Health Research for the 'CIHR Team in Familial
Risks of Breast Cancer' program-grant # CRN-87521 and the Ministry of
Economic Development, Innovation and Export Trade-grant # PSR-SIIRI-701.
The NBCS was supported by grants from the Norwegian Research council,
155218/V40, 175240/S10 to A.L.B.D., FUGE-NFR 181600/V11 to V.N.K. and a
Swizz Bridge Award to A.L.B.D. The NBHS was supported by NIH grant
R01CA100374. Biological sample preparation was conducted by the Survey
and Biospecimen Shared Resource, which is supported by P30 CA68485.; The
OBCS was supported by research grants from the Finnish Cancer
Foundation, the Academy of Finland (grant number 250083, 122715 and
Center of Excellence grant number 251314), the Finnish Cancer
Foundation, the Sigrid Juselius Foundation, the University of Oulu, the
University of Oulu Support Foundation and the special Governmental EVO
funds for Oulu University Hospital-based research activities. OFBCR was
supported by grant UM1 CA164920 from the National Cancer Institute
(USA). The ORIGO study was supported by the Dutch Cancer Society (RUL
1997-1505) and the Biobanking and Biomolecular Resources Research
Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural
Research Funds of the National Cancer Institute, Department of Health
and Human Services, USA. The pKARMA study was supported by Marit and
Hans Rausings Initiative Against Breast Cancer. The RBCS was funded by
the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC
study was supported by funding from the Agency for Science, Technology
and Research of (A*STAR), the US National Institute of Health (NIH) and
the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by
Yorkshire Cancer Research S295, S299, S305PA. SEARCH is funded by a
programme grant from Cancer Research UK (C490/A10124) and supported by
the UK National Institute for Health Research Biomedical Research Centre
at the University of Cambridge. The SZBCS was supported by Grant
PBZ_KBN_122/P05/2004. SKKDKFZS is supported by the DKFZ. The TNBCC was
supported by: a Specialized Program of Research Excellence (SPORE) in
Breast Cancer (CA116201), a grant from the Breast Cancer Research
Foundation, a generous gift from the David F. and Margaret T. Grohne
Family Foundation and the Ting Tsung and Wei Fong Chao Foundation, the
Stefanie Spielman Breast Cancer fund and the OSU Comprehensive Cancer
Center, DBBR (a CCSG Share Resource by National Institutes of Health
Grant P30 CA016056), the Hellenic Cooperative Oncology Group research
grant (HR R_BG/04) and the Greek General Secretary for Research and
Technology (GSRT) Program, Research Excellence II, the European Union
(European Social Fund-ESF), and Greek national funds through the
Operational Program 'Education and Lifelong Learning' of the National
Strategic Reference Framework (NSRF)-ARISTEIA. The UKBGS is funded by
Breakthrough Breast Cancer and the Institute of Cancer Research (ICR),
London. ICR acknowledges NHS funding to the NIHR Biomedical Research
Centre. The ACP study is funded by the Breast Cancer Research Trust, UK.
The HERPACC was supported by a Grant-in-Aid for Scientific Research on
Priority Areas from the Ministry of Education, Science, Sports, Culture
and Technology of Japan, by a Grant-in-Aid for the Third Term
Comprehensive 10-Year Strategy for Cancer Control from Ministry Health,
Labour and Welfare of Japan, by Health and Labour Sciences Research
Grants for Research on Applying Health Technology from Ministry Health,
Labour and Welfare of Japan and by National Cancer Center Research and
Development Fund. LAABC is supported by grants (1RB-0287, 3PB-0102,
5PB-0018 and 10PB-0098) from the California Breast Cancer Research
Program. Incident breast cancer cases were collected by the USC Cancer
Surveillance Program (CSP) which is supported under subcontract by the
California Department of Health. The CSP is also part of the National
Cancer Institute's Division of Cancer Prevention and Control
Surveillance, Epidemiology, and End Results Program, under contract
number N01CN25403.; MYBRCA is funded by research grants from the
Malaysian Ministry of Science, Technology and Innovation (MOSTI),
Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer
Research Initiatives Foundation (CARIF). Additional controls were
recruited by the Singapore Eye Research Institute, which was supported
by a grant from the Biomedical Research Council (BMRC08/1/35/19/550),
Singapore and the National Medical Research Council, Singapore
(NMRC/CG/SERI/2010). The SBCGS was supported primarily by NIH grants
R01CA64277, R01CA148667 and R37CA70867. Biological sample preparation
was conducted by the Survey and Biospecimen Shared Resource, which is
supported by P30 CA68485. The scientific development and funding of this
project were, in part, supported by the Genetic Associations and
Mechanisms in Oncology (GAME-ON) Network U19 CA148065. SEBCS was
supported by the BRL (Basic Research Laboratory) program through the
National Research Foundation of Korea funded by the Ministry of
Education, Science and Technology (2012-0000347). SGBCC is funded by the
National Medical Research Council start-up Grant and Centre Grant
(NMRC/CG/NCIS/2010). Additional controls were recruited by the Singapore
Consortium of Cohort Studies-Multi-ethnic cohort (SCCS-MEC), which was
funded by the Biomedical Research Council, grant number: 05/1/21/19/425.
The TBCS was funded by The National Cancer Institute, Thailand. The
TWBCS is supported by the Taiwan Biobank project of the Institute of
Biomedical Sciences, Academia Sinica, Taiwan. The NBHS was supported by
NIH grant R01CA100374. Biological sample preparation was conducted by
the Survey and Biospecimen Shared Resource, which is supported by P30
CA68485. The SCCS is supported by a grant from the National Institutes
of Health (R01 CA092447). The Arkansas Central Cancer Registry is fully
funded by a grant from National Program of Cancer Registries, Centers
for Disease Control and Prevention (CDC). Funding to pay the Open Access
publication charges for this article was provided by the Charity Open
Access Fund (COAF).
NR 47
TC 10
Z9 10
U1 3
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2015
VL 24
IS 10
BP 2966
EP 2984
DI 10.1093/hmg/ddv035
PG 19
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CJ2PK
UT WOS:000355326800022
PM 25652398
ER
PT J
AU Hasegawa, K
Jartti, T
Mansbach, JM
Laham, FR
Jewell, AM
Espinola, JA
Piedra, PA
Camargo, CA
AF Hasegawa, Kohei
Jartti, Tuomas
Mansbach, Jonathan M.
Laham, Federico R.
Jewell, Alan M.
Espinola, Janice A.
Piedra, Pedro A.
Camargo, Carlos A., Jr.
TI Respiratory Syncytial Virus Genomic Load and Disease Severity Among
Children Hospitalized With Bronchiolitis: Multicenter Cohort Studies in
the United States and Finland
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE bronchiolitis; infants; children; genomic load; respiratory syncytial
virus; hospitalization; length of stay; intensive care unit; mechanical
ventilation; cohort study
ID REAL-TIME PCR; LENGTH-OF-STAY; VIRAL LOAD; IMMUNE-RESPONSES; INFECTION;
INFANTS; MANAGEMENT; DIAGNOSIS; ETIOLOGY; ASSOCIATION
AB Methods.aEuro integral Two multicenter prospective cohort studies in the United States and Finland used the same protocol to enroll children aged < 2 years hospitalized for bronchiolitis and collect nasopharyngeal aspirates. By using real-time polymerase chain reaction analysis, patients were classified into 3 genomic load status groups: low, intermediate, and high. Outcome measures were a length of hospital stay (LOS) of a parts per thousand yen3 days and intensive care use, defined as admission to the intensive care unit or use of mechanical ventilation.
Results.aEuro integral Of 2615 enrolled children, 1764 (67%) had RSV bronchiolitis. Children with a low genomic load had a higher unadjusted risk of having a length of stay of a parts per thousand yen3 days (52%), compared with children with intermediate and those with high genomic loads (42% and 51%, respectively). In a multivariable model, the risk of having a length of stay of a parts per thousand yen3 days remained significantly higher in the groups with intermediate (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.20-1.69) and high (OR, 1.58; 95% CI, 1.29-1.94) genomic loads. Similarly, children with a high genomic load had a higher risk of intensive care use (20%, compared with 15% and 16% in the groups with low and intermediate genomic loads, respectively). In a multivariable model, the risk remained significantly higher in the group with a high genomic load (OR, 1.43; 95% CI, 1.03-1.99).
Conclusion.aEuro integral Children with a higher RSV genomic load had a higher risk for more-severe bronchiolitis.
C1 [Hasegawa, Kohei; Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Cambridge, MA 02138 USA.
[Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Med, Boston, MA USA.
[Laham, Federico R.] Arnold Palmer Hosp Children, Dept Infect Dis, Orlando, FL USA.
[Jewell, Alan M.; Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol & Pediat, Houston, TX 77030 USA.
[Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.
RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Ste 410, Boston, MA 02114 USA.
EM khasegawa1@partners.org
FU National Institutes of Health [U01 AI-67693]
FX This work was supported by the National Institutes of Health (grant U01
AI-67693). The content of this manuscript is solely the responsibility
of the authors and does not necessarily represent the official views of
the NIAID or NIH.
NR 39
TC 21
Z9 22
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2015
VL 211
IS 10
BP 1550
EP 1559
DI 10.1093/infdis/jiu658
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CI4MG
UT WOS:000354723000005
PM 25425699
ER
PT J
AU Meya, DB
Okurut, S
Zziwa, G
Rolfes, MA
Kelsey, M
Cose, S
Joloba, M
Naluyima, P
Palmer, BE
Kambugu, A
Mayanja-Kizza, H
Bohjanen, PR
Eller, MA
Wahl, SM
Boulware, DR
Manabe, YC
Janoff, EN
AF Meya, David B.
Okurut, Samuel
Zziwa, Godfrey
Rolfes, Melissa A.
Kelsey, Melander
Cose, Steve
Joloba, Moses
Naluyima, Prossy
Palmer, Brent E.
Kambugu, Andrew
Mayanja-Kizza, Harriet
Bohjanen, Paul R.
Eller, Michael A.
Wahl, Sharon M.
Boulware, David R.
Manabe, Yuka C.
Janoff, Edward N.
TI Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With
Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE cryptococcal meningitis; cryptococcus; HIV; cerebrospinal fluid; immune
responses; cell activation
ID CENTRAL-NERVOUS-SYSTEM; CD4(+) T-CELLS; HIV-1-INFECTED PATIENTS;
ANTIRETROVIRAL THERAPY; CLINICAL-FEATURES; INFECTED PATIENTS;
HIV-INFECTION; NEOFORMANS; TUBERCULOSIS; MECHANISMS
AB Methods.aEuro integral We characterized the lineage and activation status of mononuclear cells in blood and CSF of HIV-infected patients with noncryptococcal meningitis (NCM) (n = 10), those with CM at day 0 (n = 40) or day 14 (n = 21) of antifungal therapy, and those with CM-IRIS (n = 10).
Results.aEuro integral At diagnosis, highly activated CD8(+) T cells predominated in CSF in both CM and NCM. CM-IRIS was associated with an increasing frequency of CSF CD4(+) T cells (increased from 2.2% to 23%; P = .06), a shift in monocyte phenotype from classic to an intermediate/proinflammatory, and increased programmed death ligand 1 expression on natural killer cells (increased from 11.9% to 61.6%, P = .03). CSF cellular responses were distinct from responses in peripheral blood.
Conclusions.aEuro integral After CM, T cells in CSF tend to evolve with the development of IRIS, with increasing proportions of activated CD4(+) T cells, migration of intermediate monocytes to the CSF, and declining fungal burden. These changes provide insight into IRIS pathogenesis and could be exploited to more effectively treat CM and prevent CM-IRIS.
C1 [Meya, David B.; Kambugu, Andrew; Manabe, Yuka C.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.
[Meya, David B.; Cose, Steve; Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda.
[Joloba, Moses] Makerere Univ, Dept Microbiol, Sch Biomed Sci, Kampala, Uganda.
[Okurut, Samuel; Zziwa, Godfrey] Makerere Univ Reed Project, Kampala, Uganda.
[Cose, Steve] Uganda Virus Res Inst, Med Res Council, Uganda Res Unit AIDS, Entebbe, Uganda.
[Meya, David B.; Rolfes, Melissa A.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA.
[Kelsey, Melander; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado, Aurora, CO USA.
[Kelsey, Melander; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Baltimore, MD USA.
[Manabe, Yuka C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA.
[Eller, Michael A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA.
[Eller, Michael A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA.
[Wahl, Sharon M.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA.
[Cose, Steve] London Sch Hyg & Trop Med, London, England.
RP Meya, DB (reprint author), Makerere Univ, Coll Hlth Sci, Infect Dis Inst, POB 22418, Kampala, Uganda.
EM david.meya@gmail.com
OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba,
Moses/0000-0002-0334-9983; Boulware, David/0000-0002-4715-0060; Cose,
Stephen/0000-0002-5156-037X
FU National Institutes of Health [R01AI078934, U01AI089244, NS065713,
R01AI108479, K24AI096925, T32AI055433, R21NS065713]; Wellcome Trust
(Training Health Researchers into Vocational Excellence [THRiVE]) in
East Africa [087540]; GlaxoSmithKline Collaborative Investigator
Research Award; Veterans Affairs Research Service
FX This work was supported by the National Institutes of Health (grants
R01AI078934, U01AI089244, NS065713, R01AI108479, K24AI096925,
T32AI055433, and R21NS065713); the Wellcome Trust (Training Health
Researchers into Vocational Excellence [THRiVE]) in East Africa (grant
087540), the GlaxoSmithKline Collaborative Investigator Research Award,
and the Veterans Affairs Research Service.
NR 45
TC 9
Z9 9
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2015
VL 211
IS 10
BP 1597
EP 1606
DI 10.1093/infdis/jiu664
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CI4MG
UT WOS:000354723000010
PM 25492918
ER
PT J
AU Tanner, NT
Silvestri, GA
AF Tanner, Nichole T.
Silvestri, Gerard A.
TI Screening for Lung Cancer Using Low-Dose Computed Tomography Are We
Headed for DANTE's Paradise or Inferno?
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID TRIAL
C1 [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equity & Rural Outreach Innovat Ctr, Charleston, SC USA.
RP Tanner, NT (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.
NR 17
TC 2
Z9 2
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 15
PY 2015
VL 191
IS 10
BP 1100
EP 1101
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CI8KO
UT WOS:000355021400005
PM 25978569
ER
PT J
AU Black, JC
Atabakhsh, E
Kim, J
Biette, KM
Van Rechem, C
Ladd, B
Burrowes, PD
Donado, C
Mattoo, H
Kleinstiver, BP
Song, B
Andriani, G
Joung, JK
Iliopoulos, O
Montagna, C
Pillai, S
Getz, G
Whetstine, JR
AF Black, Joshua C.
Atabakhsh, Elnaz
Kim, Jaegil
Biette, Kelly M.
Van Rechem, Capucine
Ladd, Brendon
Burrowes, Paul D.
Donado, Carlos
Mattoo, Hamid
Kleinstiver, Benjamin P.
Song, Bing
Andriani, Grasiella
Joung, J. Keith
Iliopoulos, Othon
Montagna, Cristina
Pillai, Shiv
Getz, Gad
Whetstine, Johnathan R.
TI Hypoxia drives transient site-specific copy gain and drug-resistant gene
expression
SO GENES & DEVELOPMENT
LA English
DT Article
DE CNV; JmjC; KDM4A; hypoxia; site-specific copy gain; tumor heterogeneity
ID HISTONE DEMETHYLASES; NECK-CANCER; HETEROGENEITY; PROGRESSION; PROTEIN;
KDM4A; CELLS; CKS1B; REREPLICATION; AMPLIFICATION
AB Copy number heterogeneity is a prominent feature within tumors. The molecular basis for this heterogeneity remains poorly characterized. Here, we demonstrate that hypoxia induces transient site-specific copy gains (TSSGs) in primary, nontransformed, and transformed human cells. Hypoxia-driven copy gains are not dependent on HIF1 alpha or HIF2 alpha; however, they are dependent on the KDM4A histone demethylase and are blocked by inhibition of KDM4A with a small molecule or the natural metabolite succinate. Furthermore, this response is conserved at a syntenic region in zebrafish cells. Regions with site-specific copy gain are also enriched for amplifications in hypoxic primary tumors. These tumors exhibited amplification and overexpression of the drug resistance gene CKS1B, which we recapitulated in hypoxic breast cancer cells. Our results demonstrate that hypoxia provides a biological stimulus to create transient site-specific copy alterations that could result in heterogeneity within tumors and cell populations. These findings have major implications in our understanding of copy number heterogeneity and the emergence of drug resistance genes in cancer.
C1 [Black, Joshua C.; Atabakhsh, Elnaz; Biette, Kelly M.; Van Rechem, Capucine; Ladd, Brendon; Burrowes, Paul D.; Donado, Carlos; Mattoo, Hamid; Song, Bing; Iliopoulos, Othon; Pillai, Shiv; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA 02129 USA.
[Kim, Jaegil; Getz, Gad] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA.
[Kleinstiver, Benjamin P.; Joung, J. Keith; Getz, Gad] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Canc Ctr,Med Sch, Charlestown, MA 02129 USA.
[Kleinstiver, Benjamin P.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.
[Andriani, Grasiella; Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, Pathol, Bronx, NY 10461 USA.
[Iliopoulos, Othon] Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02114 USA.
RP Whetstine, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA 02129 USA.
EM jwhetstine@hms.harvard.edu
RI Black, Joshua/Q-2484-2015
FU American Cancer Society [RSG-13-115-01-CCG, CA059267, R01GM097360];
American Lung Association Lung Cancer Discovery Award; National
Institutes of Health [U24CA143845]; Massachusetts General Hospital
Executive Committee on Research (ECOR) Tosteson Post-doctoral
Fellowship; Senior Research Training Fellowship from the American Lung
Association; Fund for Medical Discovery; Marsha Rivkin Center for
Ovarian Cancer Research; National Sciences and Engineering Research
Council of Canada; National Institutes of Health Director's Pioneer
Award [DP1 GM105378]; Jim and Ann Orr Research Scholar Award; AbbVie;
Canada Foundation for Innovation (CFI); Canadian Institutes of Health
Research (CIHR); Genome Canada; Ontario Genomics Institute [OGI-055];
GlaxoSmithKline; Novartis Research Foundation; Ontario Ministry of
Economic Development and Innovation; Pfizer; Structural Genomics
Consortium; Jane Coffin Childs Memorial Fund for Medical Research;
Boehringer Ingelheim; Janssen; Lilly Canada; Takeda; Wellcome Trust
[092809/Z/10/Z]; [1RO1CA160458]
FX We are grateful to Ravi Mylvaganamand the Massachusetts General Hospital
Flow Cytometry core for assistance with the cell sorting. We thank
Danette Daniels for providing reagents. We also thank Tony Kossiakoff,
Edyta Marcon, Cheryl Arrowsmith, and members of the Structural Genomics
Consortium Antibody Team for contributions to generating recombinant
KDM4A-P006. This work was supported by funding to J.R.W. from the
American Cancer Society (RSG-13-115-01-CCG), CA059267, and R01GM097360.
J.R.W. is a Tepper Family Massachusetts General Hospital Research
Scholar and Leukemia and Lymphoma Society Scholar. J.R.W. is a recipient
of an American Lung Association Lung Cancer Discovery Award. G.G. and
J.K. are supported by National Institutes of Health (U24CA143845).
J.C.B. was a Fellow of The Jane Coffin Childs Memorial Fund for Medical
Research. This investigation has been aided by a grant from The Jane
Coffin Childs Memorial Fund for Medical Research. J.C.B. is supported by
a Massachusetts General Hospital Executive Committee on Research (ECOR)
Tosteson Post-doctoral Fellowship. E.A. is supported by a Senior
Research Training Fellowship from the American Lung Association. A
post-doctoral fellowship was provided by the Fund for Medical Discovery
(C.V.R.). This research was supported in part by a grant from the Marsha
Rivkin Center for Ovarian Cancer Research (C.V.R.). B.P.K. is supported
by a post-doctoral fellowship from the National Sciences and Engineering
Research Council of Canada. This work was supported by a National
Institutes of Health Director's Pioneer Award (DP1 GM105378) and The Jim
and Ann Orr Research Scholar Award (both to J.K.J.). This work was
supported by funding to O.I. from 1RO1CA160458. The Structural Genomics
Consortium is a registered charity (no. 1097737) that receives funds
from AbbVie, Boehringer Ingelheim, the Canada Foundation for Innovation
(CFI), the Canadian Institutes of Health Research (CIHR), Genome Canada,
Ontario Genomics Institute (grant OGI-055), GlaxoSmithKline, Janssen,
Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of
Economic Development and Innovation, Pfizer, Takeda, and Wellcome Trust
(grant 092809/Z/10/Z), Work in the Kossiakoff laboratory was funded by
the Structural Genomics Consortium and National Institutes of Health.
NR 49
TC 12
Z9 13
U1 1
U2 9
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD MAY 15
PY 2015
VL 29
IS 10
BP 1018
EP 1031
DI 10.1101/gad.259796.115
PG 14
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA CI6ND
UT WOS:000354875500004
PM 25995187
ER
PT J
AU Tu, HC
Schwitalla, S
Qian, ZR
LaPier, GS
Yermalovich, A
Ku, YC
Chen, SC
Viswanathan, SR
Zhu, H
Nishihara, R
Inamura, K
Kim, SA
Morikawa, T
Mima, K
Sukawa, Y
Yang, JH
Meredith, G
Fuchs, CS
Ogino, S
Daley, GQ
AF Tu, Ho-Chou
Schwitalla, Sarah
Qian, Zhirong
LaPier, Grace S.
Yermalovich, Alena
Ku, Yuan-Chieh
Chen, Shann-Ching
Viswanathan, Srinivas R.
Zhu, Hao
Nishihara, Reiko
Inamura, Kentaro
Kim, Sun A.
Morikawa, Teppei
Mima, Kosuke
Sukawa, Yasutaka
Yang, Juhong
Meredith, Gavin
Fuchs, Charles S.
Ogino, Shuji
Daley, George Q.
TI LIN28 cooperates with WNT signaling to drive invasive intestinal and
colorectal adenocarcinoma in mice and humans
SO GENES & DEVELOPMENT
LA English
DT Article
DE LIN28; let-7 miRNA; WNT; oncogene cooperation; invasive adenocarcinoma;
colorectal cancer
ID COLON-CANCER; STEM-CELLS; MICROSATELLITE INSTABILITY;
GLUCOSE-METABOLISM; PIK3CA MUTATION; MOUSE MODELS; ASPIRIN USE; LET-7;
EXPRESSION; MICRORNA
AB Colorectal cancer (CRC) remains a major contributor to cancer-related mortality. LIN28A and LIN28B are highly related RNA-binding protein paralogs that regulate biogenesis of let-7 microRNAs and influence development, metabolism, tissue regeneration, and oncogenesis. Here we demonstrate that overexpression of either LIN28 paralog cooperates with the Wnt pathway to promote invasive intestinal adenocarcinoma in murine models. When LIN28 alone is induced genetically, half of the resulting tumors harbor Ctnnb1 (beta-catenin) mutation. When overexpressed in Apc(Min/+) mice, LIN28 accelerates tumor formation and enhances proliferation and invasiveness. In conditional genetic models, enforced expression of a LIN28-resistant form of the let-7 microRNA reduces LIN28-induced tumor burden, while silencing of LIN28 expression reduces tumor volume and increases tumor differentiation, indicating that LIN28 contributes to tumor maintenance. We detected aberrant expression of LIN28A and/or LIN28B in 38% of a large series of human CRC samples (n = 595), where LIN28 expression levels were associated with invasive tumor growth. Our late-stage CRC murine models and analysis of primary human tumors demonstrate prominent roles for both LIN28 paralogs in promoting CRC growth and progression and implicate the LIN28/let-7 pathway as a therapeutic target.
C1 [Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Qian, Zhirong; Nishihara, Reiko; Inamura, Kentaro; Kim, Sun A.; Morikawa, Teppei; Mima, Kosuke; Sukawa, Yasutaka; Yang, Juhong; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ku, Yuan-Chieh; Chen, Shann-Ching; Meredith, Gavin] Thermo Fisher Sci Inc, San Francisco, CA 94080 USA.
[Zhu, Hao] Univ Texas Southwestern, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02138 USA.
RP Daley, GQ (reprint author), Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
RI Zhu, Hao/L-5114-2013
OI Zhu, Hao/0000-0002-8417-9698
FU National Institutes of Health (NIH) [R01GM107536, F31 CA186444-01, K07
CA190673, P01CA127003, RO1CA151993]; Ellison Medical Foundation;
American Association for Cancer Research Fight Colorectal Cancer
Postdoctoral Fellowship; EMBO post-doctoral fellowship; Agrusa Fund for
Colorectal Cancer Research; DFIC Friends
FX We thank Achia Urbach, John Powers, Ramesh Shivdasani, and Xi He for
invaluable discussion and advice. We thank Michael C.F. Chen for
providing E12.5 embryonic intestine tissues, and Roderick Bronson and
the Harvard Medical School Rodent Histopathology Core for mouse tissue
pathology. G.Q.D. is supported by grants from the National Institutes of
Health (NIH; R01GM107536) and the Ellison Medical Foundation and is an
affiliate member of the Broad Institute and an investigator of the
Howard Hughes Medical Institute and the Manton Center for Orphan Disease
Research. H.-C.T. is supported by the American Association for Cancer
Research Fight Colorectal Cancer Postdoctoral Fellowship. S.S. is
supported by an EMBO post-doctoral fellowship. A.Y. is supported by NIH
F31 CA186444-01 predoctoral fellowship. R.N. is supported by NIH K07
CA190673. C.S. F. is supported by NIH P01CA127003 and Agrusa Fund for
Colorectal Cancer Research. S.O. is supported by NIH RO1CA151993 and
DFIC Friends.
NR 65
TC 14
Z9 15
U1 0
U2 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD MAY 15
PY 2015
VL 29
IS 10
BP 1074
EP 1086
DI 10.1101/gad.256693.114
PG 13
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA CI6ND
UT WOS:000354875500008
PM 25956904
ER
PT J
AU Boyce, RM
Muiru, A
Reyes, R
Ntaro, M
Mulogo, E
Matte, M
Siedner, MJ
AF Boyce, Ross M.
Muiru, Anthony
Reyes, Raquel
Ntaro, Moses
Mulogo, Edgar
Matte, Michael
Siedner, Mark J.
TI Impact of rapid diagnostic tests for the diagnosis and treatment of
malaria at a peripheral health facility in Western Uganda: an
interrupted time series analysis
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Rapid diagnostic tests; Outcomes; Case management; Antibiotics
ID AFRICAN CHILDREN; MICROSCOPY; IMPLEMENTATION; PNEUMONIA; TANZANIA;
OVERLAP
AB Background: The World Health Organization recommends that all suspected malaria cases receive a parasitological diagnosis prior to treatment with artemisinin-based combination therapy. A recent meta-analysis of clinical trials evaluating RDTs for the management of patients with fever found substantial reductions in anti-malarial prescriptions when health workers adhered to treatment protocols based on test results. However few studies have reported on the impact of RDTs on health systems outside research settings.
Methods: The study comprised a retrospective interrupted time series analysis, comparing rates of malaria diagnosis, treatment, and resource utilization before and after introduction of RDTs at a peripheral health facility in rural Western Uganda. The use of malaria diagnostic tests was graphically depicted throughout the study period and fit regression models to identify correlates of three outcomes of interest: (1) length of stay (2) the proportion of patients referred to a higher-level health facility, and (3) administration of antibiotics.
Results: Over the course of the study period, 14,357 individuals underwent diagnostic testing for malaria with either a RDT (9,807) or microscopy (4,550). The proportion of patients with parasite-based diagnoses more than tripled to 34 % after the introduction of RDTs. RDTs largely replaced microscopy as the diagnostic method of choice. Compared to patients admitted during the pre-RDT period, patients admitted to the health centre with malaria in the post-RDT period had significantly reduced odds of being referred to another health centre (AOR = 0.49, P = 0.038), receiving antibiotics (AOR = 0.42, P < 0.001), and a significantly shorter mean length of stay (beta = -0.32 days, 95 % CI -0.52 to -0.13).
Conclusions: This study is one of the few to demonstrate significant improvement in clinical outcomes and process measures following the introduction of RDTs for the diagnosis of malaria at a rural health facility in Uganda. The results show a reduction in referrals and shorter mean inpatient LOS even as antibiotics were prescribed less frequently. This change greatly increased laboratory throughput and the resultant proportion of patients receiving a parasite-based diagnosis.
C1 [Boyce, Ross M.; Muiru, Anthony; Reyes, Raquel; Siedner, Mark J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Muiru, Anthony; Siedner, Mark J.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Ntaro, Moses; Mulogo, Edgar; Matte, Michael] Mbarara Univ Sci & Technol, Dept Community Hlth, Mbarara, Uganda.
RP Boyce, RM (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA.
EM rmboyce@mgh.harvard.edu
OI Boyce, Ross/0000-0002-9489-6324
FU NIMH NIH HHS [K23 MH099916]
NR 21
TC 7
Z9 7
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 15
PY 2015
VL 14
AR 203
DI 10.1186/s12936-015-0725-0
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CI6DI
UT WOS:000354848500003
PM 25971788
ER
PT J
AU Wakabayashi-Ito, N
Ajjuri, RR
Henderson, BW
Doherty, OM
Breakefield, XO
O'Donnell, JM
Ito, N
AF Wakabayashi-Ito, Noriko
Ajjuri, Rami R.
Henderson, Benjamin W.
Doherty, Olugbenga M.
Breakefield, Xandra O.
O'Donnell, Janis M.
Ito, Naoto
TI Mutant human torsinA, responsible for early-onset dystonia, dominantly
suppresses GTPCH expression, dopamine levels and locomotion in
Drosophila melanogaster
SO BIOLOGY OPEN
LA English
DT Article
DE Dystonia; Drosophila; GTP cyclohydrolase; TorsinA; Movement disorder
ID MESSENGER-RNA LOCALIZATION; TYROSINE-HYDROXYLASE; NUCLEAR-ENVELOPE; DYT1
DYSTONIA; PUNCH LOCUS; GENE-EXPRESSION; CELLS; SEQUENCES; BIOSYNTHESIS;
INCLUSIONS
AB Dystonia represents the third most common movement disorder in humans with over 20 genetic loci identified. TOR1A (DYT1), the gene responsible for the most common primary hereditary dystonia, encodes torsinA, an AAA ATPase family protein. Most cases of DYT1 dystonia are caused by a 3 bp (Delta GAG) deletion that results in the loss of a glutamic acid residue (Delta E302/303) in the carboxyl terminal region of torsinA. This torsinA Delta E mutant protein has been speculated to act in a dominant-negative manner to decrease activity of wild type torsinA. Drosophila melanogaster has a single torsin-related gene, dtorsin. Null mutants of dtorsin exhibited locomotion defects in third instar larvae. Levels of dopamine and GTP cyclohydrolase (GTPCH) proteins were severely reduced in dtorsin-null brains. Further, the locomotion defect was rescued by the expression of human torsinA or feeding with dopamine.
Here, we demonstrate that human torsinA Delta E dominantly inhibited locomotion in larvae and adults when expressed in neurons using a pan-neuronal promoter Elav. Dopamine and tetrahydrobiopterin (BH4) levels were significantly reduced in larval brains and the expression level of GTPCH protein was severely impaired in adult and larval brains. When human torsinA and torsinA Delta E were co-expressed in neurons in dtorsin-null larvae and adults, the locomotion rates and the expression levels of GTPCH protein were severely reduced. These results support the hypothesis that torsinA Delta E inhibits wild type torsinA activity. Similarly, neuronal expression of a Drosophila Dtorsin Delta E equivalent mutation dominantly inhibited larval locomotion and GTPCH protein expression. These results indicate that both torsinA Delta E and DtorsinDE act in a dominant-negative manner. We also demonstrate that Dtorsin regulates GTPCH expression at the post-transcriptional level. This Drosophila model of DYT1 dystonia provides an important tool for studying the differences in the molecular function between the wild type and the mutant torsin proteins.
C1 [Wakabayashi-Ito, Noriko; Breakefield, Xandra O.; Ito, Naoto] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA.
[Wakabayashi-Ito, Noriko; Breakefield, Xandra O.; Ito, Naoto] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02129 USA.
[Ajjuri, Rami R.; Henderson, Benjamin W.; Doherty, Olugbenga M.; O'Donnell, Janis M.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA.
RP Ito, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA.
EM iton@helix.mgh.harvard.edu
FU National Institute of Neurological Disorders and Stroke (NINDS)
[P30-NS045776]; Dystonia Medical Research Foundation; Bachmann-Strauss
Dystonia and Parkinson Foundation; University of Alabama; NINDS [the
National Institutes of Health (NIH)] [R15 NS078728]; NIH/NINDS [P50
NS037409]; Department of Defense [W81XWH-12-1-0380]
FX The RT-PCR core was supported in part by a grant from National Institute
of Neurological Disorders and Stroke (NINDS) [P30-NS045776]. The support
for this work was provided by Dystonia Medical Research Foundation (to
N.I. and X.O.B.); Bachmann-Strauss Dystonia and Parkinson Foundation (to
N.I. and X.O.B.); the University of Alabama (to J.M.O., R.R.A., B.W.H.,
and O.M.D.); NINDS [the National Institutes of Health (NIH)] [R15
NS078728 to J.M.O.; NIH/NINDS P50 NS037409 to N.I. and X.O.B.]; and
Department of Defense (Peer Reviewed Medical Research Program)
[W81XWH-12-1-0380 to N.I.].
NR 50
TC 0
Z9 0
U1 0
U2 4
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 2046-6390
J9 BIOL OPEN
JI Biol. Open
PD MAY 15
PY 2015
VL 4
IS 5
BP 585
EP 595
DI 10.1242/bio.201411080
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CI3BC
UT WOS:000354621400001
PM 25887123
ER
PT J
AU Cheng, A
Owens, D
AF Cheng, Andrew
Owens, David
TI Marfan syndrome, inherited aortopathies and exercise: What is the right
answer?
SO HEART
LA English
DT Review
ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION;
CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION;
RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; ASSOCIATION; RECOMMENDATIONS
AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist.
C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA.
[Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA.
RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM ACheng@cardiology.washington.edu
OI Owens, David/0000-0002-7293-9688
NR 39
TC 1
Z9 1
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD MAY 15
PY 2015
VL 101
IS 10
BP 752
EP 757
DI 10.1136/heartjnl-2014-306440
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CH8GR
UT WOS:000354274900006
PM 25911666
ER
PT J
AU Wong, CC
Ramanathan, DS
Gulati, T
Won, SJ
Ganguly, K
AF Wong, Chelsea C.
Ramanathan, Dhakshin S.
Gulati, Tanuj
Won, Seok Joon
Ganguly, Karunesh
TI An automated behavioral box to assess forelimb function in rats
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE Motor learning; Reach; Electrophysiology
ID FOREBRAIN CHOLINERGIC SYSTEM; SPINAL-CORD-INJURY; MOTOR CORTEX; CORTICAL
PLASTICITY; TASK; STROKE; IMPAIRMENT; RECOVERY
AB Background: Rodent forelimb reaching behaviors are commonly assessed using a single-pellet reach-to-grasp task. While the task is widely recognized as a very sensitive measure of distal limb function, it is also known to be very labor-intensive, both for initial training and the daily assessment of function.
New method: Using components developed by open-source electronics platforms, we have designed and tested a low-cost automated behavioral box to measure forelimb function in rats. Our apparatus, made primarily of acrylic, was equipped with-multiple sensors to control the duration and difficulty of the task, detect reach outcomes, and dispense pellets. Our control software, developed in MATLAB, was also used to control a camera in order to capture and process video during reaches. Importantly, such processing could monitor task performance in near real-time.
Results: We further demonstrate that the automated apparatus can be used to expedite skill acquisition, thereby increasing throughput as well as facilitating studies of early versus late motor learning. The setup is also readily compatible with chronic electrophysiological monitoring.
Comparison with existing methods: Compared to a previous version of this task, our setup provides a more efficient method to train and test rodents for studies of motor learning and recovery of function after stroke. The unbiased delivery of behavioral cues and outcomes also facilitates electrophysiological studies.
Conclusions: In summary, our automated behavioral box will allow high-throughput and efficient monitoring of rat forelimb function in both healthy and injured animals. Published by Elsevier B.V.
C1 [Wong, Chelsea C.; Ramanathan, Dhakshin S.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94158 USA.
[Wong, Chelsea C.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Ramanathan, Dhakshin S.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94158 USA.
[Ramanathan, Dhakshin S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Neurol & Rehabil Serv, 1700 Owens St,Rm 479, San Francisco, CA 94158 USA.
EM karunesh.ganguly@ucsf.edu
FU U.S. Department of Veterans Affairs [CDA-2B6674W]; Burroughs Wellcome
Fund [1009855]; American Heart Association/Stroke Association
[0875016N]; UCSF Department of Neurology
FX This work was supported by the U.S. Department of Veterans Affairs
(CDA-2B6674W), the Burroughs Wellcome Fund (1009855), the American Heart
Association/Stroke Association (0875016N) and departmental funds from
the UCSF Department of Neurology. We would also like to thank Roy
Tangsombatvisit for assistance with the design and the manufacturing of
the reach boxes.
NR 33
TC 6
Z9 6
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
EI 1872-678X
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD MAY 15
PY 2015
VL 246
BP 30
EP 37
DI 10.1016/j.jneumeth.2015.03.008
PG 8
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CI1KC
UT WOS:000354502100004
PM 25769277
ER
PT J
AU Lowry, KP
Gazelle, GS
Gilmore, ME
Johanson, C
Munshi, V
Choi, SE
Tramontano, AC
Kong, CY
McMahon, PM
AF Lowry, Kathryn P.
Gazelle, G. Scott
Gilmore, Michael E.
Johanson, Colden
Munshi, Vidit
Choi, Sung Eun
Tramontano, Angela C.
Kong, Chung Yin
McMahon, Pamela M.
TI Personalizing Annual Lung Cancer Screening for Patients With Chronic
Obstructive Pulmonary Disease: A Decision Analysis
SO CANCER
LA English
DT Article
DE lung neoplasms; chronic obstructive pulmonary disease; cancer screening;
decision analysis
ID NUTRITION-EXAMINATION-SURVEY; MODERATE COPD PATIENTS; SERVICES
TASK-FORCE; LOW-DOSE CT; UNITED-STATES; NATIONAL-HEALTH; RISK;
MORTALITY; IMPACT; ASSOCIATION
AB BACKGROUNDLung cancer screening with annual chest computed tomography (CT) is recommended for current and former smokers with a 30-pack-year smoking history. Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lung cancer and may benefit from screening at lower pack-year thresholds.
METHODSWe used a previously validated simulation model to compare the health benefits of lung cancer screening in current and former smokers ages 55-80 with 30 pack-years with hypothetical programs using lower pack-year thresholds for individuals with COPD (20, 10, and 1 pack-years). Calibration targets for COPD prevalence and associated lung cancer risk were derived using the Framingham Offspring Study limited data set. We performed sensitivity analyses to evaluate the stability of results across different rates of adherence to screening, increased competing mortality risk from COPD, and increased surgical ineligibility in individuals with COPD. The primary outcome was projected life expectancy.
RESULTSPrograms using lower pack-year thresholds for individuals with COPD yielded the highest life expectancy gains for a given number of screens. Highest life expectancy was achieved when lowering the pack-year threshold to 1 pack-year for individuals with COPD, which dominated all other screening strategies. These results were stable across different adherence rates to screening and increases in competing mortality risk for COPD and surgical ineligibility.
CONCLUSIONSCurrent and former smokers with COPD may disproportionately benefit from lung cancer screening. A lower pack-year threshold for screening eligibility may benefit this high-risk patient population. Cancer 2015;121:1556-1562. (c) 2015 American Cancer Society.
A microsimulation model was used to evaluate the health benefits of hypothetical lung cancer screening programs targeting individuals with chronic obstructive pulmonary disease compared with programs with eligibility based on smoking history alone. Programs incorporating lower pack-year thresholds for individuals with COPD achieved the highest life expectancy per number of screens.
C1 [Lowry, Kathryn P.; Gazelle, G. Scott; Kong, Chung Yin; McMahon, Pamela M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Lowry, Kathryn P.; Gazelle, G. Scott; Gilmore, Michael E.; Johanson, Colden; Munshi, Vidit; Choi, Sung Eun; Tramontano, Angela C.; Kong, Chung Yin; McMahon, Pamela M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Gazelle, G. Scott] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Lowry, KP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA.
EM klowry@partners.org
FU American Cancer Society [RSG 2008A060554]; National Cancer Institute
[R01 CA97337, R00 CA126147, U01CA152956]; National Institute of Health
[R01 DA036497]; Radiological Society of North America; Harvard Medical
School
FX This research was supported by grants from the American Cancer Society
(RSG 2008A060554, to G. Scott Gazelle), the National Cancer Institute
(R01 CA97337, to G. Scott Gazelle, R00 CA126147 to G. Scott Gazelle, and
U01CA152956 to Pamela M. McMahon and Chung Yin Kong), the National
Institute of Health (R01 DA036497 to Chung Yin Kong and Colden
Johanson), the Radiological Society of North America (to Kathryn P.
Lowry), and Harvard Medical School (to Kathryn P. Lowry).
NR 41
TC 5
Z9 5
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2015
VL 121
IS 10
BP 1556
EP 1562
DI 10.1002/cncr.29225
PG 7
WC Oncology
SC Oncology
GA CH7LB
UT WOS:000354216800008
PM 25652107
ER
PT J
AU Percac-Lima, S
Cronin, PR
Ryan, DP
Chabner, BA
Daly, EA
Kimball, AB
AF Percac-Lima, Sanja
Cronin, Patrick R.
Ryan, David P.
Chabner, Bruce A.
Daly, Emily A.
Kimball, Alexandra B.
TI Patient Navigation Based on Predictive Modeling Decreases No-Show Rates
in Cancer Care
SO CANCER
LA English
DT Article
DE patient navigation; cancer care; predictive modeling; no-show;
disparities
ID RANDOMIZED-CONTROLLED-TRIAL; NEWLY-DIAGNOSED CANCER; COLORECTAL-CANCER;
IMPROVE CARE; BREAST; PROGRAM; WOMEN; ABNORMALITIES; APPOINTMENTS;
POPULATION
AB BACKGROUNDPatient adherence to appointments is key to improving outcomes in health care. No-show appointments contribute to suboptimal resource use. Patient navigation and telephone reminders have been shown to improve cancer care and adherence, particularly in disadvantaged populations, but may not be cost-effective if not targeted at the appropriate patients.
METHODSIn 5 clinics within a large academic cancer center, patients who were considered to be likely (the top 20th percentile) to miss a scheduled appointment without contacting the clinic ahead of time (no-shows) were identified using a predictive model and then randomized to an intervention versus a usual-care group. The intervention group received telephone calls from a bilingual patient navigator 7 days before and 1 day before the appointment.
RESULTSOver a 5-month period, of the 40,075 appointments scheduled, 4425 patient appointments were deemed to be at high risk of a no-show event. After the patient navigation intervention, the no-show rate in the intervention group was 10.2% (167 of 1631), compared with 17.5% in the control group (280 of 1603) (P<.001). Reaching a patient or family member was associated with a significantly lower no-show rate (5.9% and 3.0%, respectively; P<.001 and .006, respectively) compared with leaving a message (14.7%: P=.117) or no contact (no-show rate, 21.6%: P=.857).
CONCLUSIONSTelephone navigation targeted at those patients predicted to be at high risk of visit nonadherence was found to effectively and substantially improve patient adherence to cancer clinic appointments. Further studies are needed to determine the long-term impact on patient outcomes, but short-term gains in the optimization of resources can be recognized immediately. Cancer 2015;121:1662-1670. (c) 2015 American Cancer Society.
Targeted patient navigation over the telephone to patients determined by predictive modeling to be at high risk of being no-shows for appointments can effectively and substantially increase patient adherence to cancer clinic appointments and improve adherence to cancer care.
C1 [Percac-Lima, Sanja] Harvard Univ, Sch Med, Dept Med, Div Gen Internal Med,Massachusetts Gen Hosp, Boston, MA USA.
[Percac-Lima, Sanja; Ryan, David P.; Chabner, Bruce A.; Daly, Emily A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
[Percac-Lima, Sanja] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA.
[Cronin, Patrick R.; Kimball, Alexandra B.] Massachusetts Gen Hosp, Practice Improvement, Boston, MA 02114 USA.
[Cronin, Patrick R.] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA.
[Kimball, Alexandra B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA.
RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA.
EM spercaclima@mgh.harvard.edu
FU Lazarex Cancer Foundation
FX The study was partially funded by Lazarex Cancer Foundation.
NR 33
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2015
VL 121
IS 10
BP 1662
EP 1670
DI 10.1002/cncr.29236
PG 9
WC Oncology
SC Oncology
GA CH7LB
UT WOS:000354216800020
PM 25585595
ER
PT J
AU Vega, RM
Kim, J
Hollander, A
Hattangadi-Gluth, J
Michalski, J
Tarbell, NJ
Yock, TI
Bussiere, M
MacDonald, SM
AF Vega, Raymond Mailhot
Kim, Jane
Hollander, Abby
Hattangadi-Gluth, Jona
Michalski, Jeff
Tarbell, Nancy J.
Yock, Torunn I.
Bussiere, Marc
MacDonald, Shannon M.
TI Cost Effectiveness of Proton Versus Photon Radiation Therapy With
Respect to the Risk of Growth Hormone Deficiency in Children
SO CANCER
LA English
DT Article
DE proton therapy; cost effectiveness; pediatric brain tumors; radiation;
growth hormone deficiency
ID DECISION-MAKING; BEAM THERAPY; REPLACEMENT; UTILITY
AB BACKGROUNDProton therapy in pediatrics may improve the risk/benefit profile of radiotherapy at a greater upfront financial cost, but it may prove to be cost effective if chronic medical complications can be avoided. Tools to assist with decision making are needed to aid in selecting pediatric patients for protons, and cost-effectiveness models can provide an objective method for this.
METHODSA Markov cohort-simulation model was developed to assess the expected costs and effectiveness for specific radiation doses to the hypothalamus with protons versus photons in pediatric patients. Costing data included cost of investment and the diagnosis and management of growth hormone deficiency. Longitudinal outcomes data were used to inform risk parameters for the model. With costs in 2012 US dollars and effectiveness measured in quality-adjusted life years, incremental cost-effectiveness ratios were used to measure outcomes.
RESULTSProton therapy was cost effective for some scenarios based on the difference in hypothalamic sparing. Although some scenarios were not cost effective, others were not only cost effective for proton therapy but also demonstrated that protons were cost saving compared with photons.
CONCLUSIONSThe current results provide the first evidence-based guide for identifying children with brain tumors who may benefit the most from proton therapy with respect to endocrine dysfunction. Proton therapy may be more cost effective for scenarios in which radiation dose to the hypothalamus can be spared, but protons may not be cost effective when tumors are involving or directly adjacent to the hypothalamus if there is a high dose to this structure. Cancer 2015;121:1694-1702. (c) 2015 American Cancer Society.
Although proton therapy is costly, it may sometimes be cost effective compared with traditional photon therapy, especially when treating pediatric tumors. The authors present data regarding strategy favorability between proton versus photon radiotherapy for pediatric brain tumors and analyze the cost effectiveness and the risk and cost of growth hormone deficiency with specific dose comparisons between modalities.
C1 [Vega, Raymond Mailhot] NYU, Sch Med, Dept Radiat Oncol, New York, NY USA.
[Kim, Jane] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
[Hollander, Abby] Washington Univ, Sch Med, St Louis Childrens Hosp, St Louis, MO USA.
[Hattangadi-Gluth, Jona] Univ Calif San Diego, Radiat Med & Appl Sci, La Jolla, CA 92093 USA.
[Michalski, Jeff] Washington Univ, Siteman Canc Ctr, St Louis Sch Med, St Louis, MO USA.
[Tarbell, Nancy J.; Yock, Torunn I.; Bussiere, Marc; MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Yawkey 112, Boston, MA 02114 USA.
EM smacdonald@partners.org
FU Conquer Cancer Foundation
FX Dr. Mailhot Vega was supported by a medical student grant from Conquer
Cancer Foundation.
NR 22
TC 6
Z9 6
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2015
VL 121
IS 10
BP 1694
EP 1702
DI 10.1002/cncr.29209
PG 9
WC Oncology
SC Oncology
GA CH7LB
UT WOS:000354216800024
ER
PT J
AU Shih, HA
Sherman, JC
Nachtigall, LB
Colvin, MK
Fullerton, BC
Daartz, J
Winrich, BK
Batchelor, TT
Thornton, LT
Mancuso, SM
Saums, MK
Oh, KS
Curry, WT
Loeffler, JS
Yeap, BY
AF Shih, Helen A.
Sherman, Janet C.
Nachtigall, Lisa B.
Colvin, Mary K.
Fullerton, Barbara C.
Daartz, Juliane
Winrich, Barbara K.
Batchelor, Tracy T.
Thornton, Lauren T.
Mancuso, Sarah M.
Saums, Michele K.
Oh, Kevin S.
Curry, William T.
Loeffler, Jay S.
Yeap, Beow Y.
TI Proton Therapy for Low-Grade Gliomas: Results From a Prospective Trial
SO CANCER
LA English
DT Article
DE low-grade glioma; proton therapy; proton radiation; late effects;
neurocognitive function; pituitary function; neuroendocrine function;
quality of life
ID RADIATION-THERAPY; COGNITIVE FUNCTION; RANDOMIZED-TRIAL; RADIOTHERAPY;
SURVIVAL
AB BACKGROUNDIn this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy.
METHODSTwenty patients with World Health Organization grade 2 glioma who were eligible for radiation therapy were enrolled in a prospective, single-arm trial of proton therapy. The patients received proton therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions. Comprehensive baseline and regular post-treatment evaluations of neurocognitive function, neuroendocrine function, and quality of life (QOL) were performed.
RESULTSAll 20 patients (median age, 37.5 years) tolerated treatment without difficulty. The median follow-up after proton therapy was 5.1 years. At baseline, intellectual functioning was within the normal range for the group and remained stable over time. Visuospatial ability, attention/working memory, and executive functioning also were within normal limits; however, baseline neurocognitive impairments were observed in language, memory, and processing speed in 8 patients. There was no overall decline in cognitive functioning over time. New endocrine dysfunction was detected in 6 patients, and all but 1 had received direct irradiation of the hypothalamic-pituitary axis. QOL assessment revealed no changes over time. The progression-free survival rate at 3 years was 85%, but it dropped to 40% at 5 years.
CONCLUSIONSPatients with low-grade glioma tolerate proton therapy well, and a subset develops neuroendocrine deficiencies. There is no evidence for overall decline in cognitive function or QOL. Cancer 2015;121:1712-1719. (c) 2015 American Cancer Society.
Patients with low-grade glioma can safely and effectively receive proton radiation therapy with no added neurocognitive impairment or quality-of-life decrement based on early experience. Radiation dose to the pituitary correlates with early neuroendocrine dysfunction.
C1 [Shih, Helen A.; Daartz, Juliane; Winrich, Barbara K.; Oh, Kevin S.; Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sherman, Janet C.; Colvin, Mary K.; Mancuso, Sarah M.] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Boston, MA 02114 USA.
[Nachtigall, Lisa B.] Massachusetts Gen Hosp, Div Endocrinol, Dept Med, Boston, MA 02114 USA.
[Fullerton, Barbara C.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Thornton, Lauren T.; Saums, Michele K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Curry, William T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Shih, HA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA.
EM hshih@mgh.harvard.edu
FU Pappas Award in Brain Tumor Research; Massachusetts General Hospital;
Federal Share of program by Massachusetts General Hospital on Proton
Therapy Research and Treatment Center [C06 CA059267]
FX This study was supported by a Pappas Award in Brain Tumor Research
sponsored by Massachusetts General Hospital and by the Federal Share of
program income earned by Massachusetts General Hospital on Proton
Therapy Research and Treatment Center (grant C06 CA059267).
NR 21
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2015
VL 121
IS 10
BP 1712
EP 1719
DI 10.1002/cncr.29237
PG 8
WC Oncology
SC Oncology
GA CH7LB
UT WOS:000354216800026
PM 25585890
ER
PT J
AU Cluzet, VC
Gerber, JS
Nachamkin, I
Metlay, JP
Zaoutis, TE
Davis, MF
Julian, KG
Royer, D
Linkin, DR
Coffin, SE
Margolis, DJ
Hollander, JE
Mistry, RD
Gavin, LJ
Tolomeo, P
Wise, JA
Wheeler, MK
Bilker, WB
Han, XY
Hu, BF
Fishman, NO
Lautenbach, E
AF Cluzet, Valerie C.
Gerber, Jeffrey S.
Nachamkin, Irving
Metlay, Joshua P.
Zaoutis, Theoklis E.
Davis, Meghan F.
Julian, Kathleen G.
Royer, David
Linkin, Darren R.
Coffin, Susan E.
Margolis, David J.
Hollander, Judd E.
Mistry, Rakesh D.
Gavin, Laurence J.
Tolomeo, Pam
Wise, Jacqueleen A.
Wheeler, Mary K.
Bilker, Warren B.
Han, Xiaoyan
Hu, Baofeng
Fishman, Neil O.
Lautenbach, Ebbing
TI Duration of Colonization and Determinants of Earlier Clearance of
Colonization With Methicillin-Resistant Staphylococcus aureus
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE methicillin-resistant Staphylococcus aureus (MRSA); MRSA colonization;
MRSA skin and soft-tissue infection; MRSA decolonization
ID SKIN INFECTIONS; HOUSEHOLD CONTACTS; RISK-FACTORS; CARRIAGE;
TRANSMISSION; MRSA; ERADICATION; PREVALENCE; CHILDREN; BACTEREMIA
AB Background. The duration of colonization and factors associated with clearance of methicillin-resistant Staphylococcus aureus (MRSA) after community-onset MRSA skin and soft-tissue infection (SSTI) remain unclear.
Methods. We conducted a prospective cohort study of patients with acute MRSA SSTI presenting to 5 adult and pediatric academic hospitals from 1 January 2010 through 31 December 2012. Index patients and household members performed self-sampling for MRSA colonization every 2 weeks for 6 months. Clearance of colonization was defined as negative MRSA surveillance cultures during 2 consecutive sampling periods. A Cox proportional hazards regression model was developed to identify determinants of clearance of colonization.
Results. Two hundred forty-three index patients were included. The median duration of MRSA colonization after SSTI diagnosis was 21 days (95% confidence interval [CI], 19-24), and 19.8% never cleared colonization. Treatment of the SSTI with clindamycin was associated with earlier clearance (hazard ratio [HR], 1.72; 95% CI, 1.28-2.30; P < .001). Older age (HR, 0.99; 95% CI, .98-1.00; P = .01) was associated with longer duration of colonization. There was a borderline significant association between increased number of household members colonized with MRSA and later clearance of colonization in the index patient (HR, 0.85; 95% CI, .71-1.01; P = .06).
Conclusions. With a systematic, regular sampling protocol, duration of MRSA colonization was noted to be shorter than previously reported, although 19.8% of patients remained colonized at 6 months. The association between clindamycin and shorter duration of colonization after MRSA SSTI suggests a possible role for the antibiotic selected for treatment of MRSA infection.
C1 [Cluzet, Valerie C.; Linkin, Darren R.; Fishman, Neil O.; Lautenbach, Ebbing] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.; Margolis, David J.; Tolomeo, Pam; Wise, Jacqueleen A.; Wheeler, Mary K.; Bilker, Warren B.; Han, Xiaoyan; Lautenbach, Ebbing] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.; Margolis, David J.; Bilker, Warren B.; Han, Xiaoyan; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Nachamkin, Irving; Hu, Baofeng] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.
[Linkin, Darren R.] Thomas Jefferson Univ Hosp, Philadelphia Vet Adm Med Ctr, Philadelphia, PA 19107 USA.
[Gavin, Laurence J.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Penn Presbyterian Med Ctr, Philadelphia, PA 19107 USA.
[Hollander, Judd E.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA.
[Julian, Kathleen G.] Lincoln Univ, Div Infect Dis, Penn State Hershey Med Ctr, Lincoln Univ, PA USA.
[Royer, David] Lincoln Univ, Dept Biol, Lincoln Univ, PA USA.
[Metlay, Joshua P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Metlay, Joshua P.] Harvard Univ, Sch Med, Boston, MA USA.
[Davis, Meghan F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA.
[Mistry, Rakesh D.] Childrens Hosp Colorado, Sect Emergency Med, Aurora, CO USA.
RP Cluzet, VC (reprint author), Hosp Univ Penn, Div Infect Dis, 3400 Spruce St,Third Floor,Silverstein Bldg,Ste E, Philadelphia, PA 19104 USA.
EM valeriec@mail.med.upenn.edu
OI Hollander, Judd/0000-0002-1318-2785
FU Pennsylvania State Department of Health; National Institutes of Health
(NIH) [K24-AI080942]; Centers for Disease Control and Prevention
Epicenters Program [U54-CK000163]
FX This work was supported by the Pennsylvania State Department of Health
(Commonwealth Universal Research Enhancement Program grant to E. L.),
the National Institutes of Health (NIH) (grant K24-AI080942 to E. L.),
and the Centers for Disease Control and Prevention Epicenters Program
(grant U54-CK000163 to E. L.).
NR 36
TC 11
Z9 11
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2015
VL 60
IS 10
BP 1489
EP 1496
DI 10.1093/cid/civ075
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CH0ON
UT WOS:000353721300007
PM 25648237
ER
PT J
AU Evans, CT
Safdar, N
AF Evans, Charlesnika T.
Safdar, Nasia
TI Current Trends in the Epidemiology and Outcomes of Clostridium difficile
Infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Clostridium difficile; epidemiology; costs
ID CARE-ASSOCIATED INFECTIONS; UNITED-STATES; DIARRHEA; RISK; METAANALYSIS;
ANTIBIOTICS; RATES; HOSPITALS; COLITIS; MULTICENTER
AB Clostridium difficile is the most frequently identified cause of nosocomial diarrhea and has been associated with epidemics of diarrhea in hospitals and long-term care facilities. The continued increase in C. difficile infection (CDI) suggests that it has surpassed other pathogens in causing healthcare-associated infections. The Centers for Disease Control and Prevention recently identified CDI as an "urgent threat" in its recent report on antibiotic resistance threats in the United States, highlighting the need for urgent and aggressive action to prevent this infection. The impact of antibiotics as a risk factor for new-onset CDI is well established; however, recognizing classes of antibiotics with the highest risks and reducing unnecessary antibiotic use are important strategies for prevention of CDI and subsequent recurrence. In addition, the recognition of the community as an important setting for onset of CDI presents a challenge and is an area for future research.
C1 [Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA.
[Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA.
[Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
RP Evans, CT (reprint author), Edward Hines Jr VA Hosp, 5000 S Fifth Ave,151H,Bldg 1,Rm D302, Hines, IL 60141 USA.
EM charlesnika.evans@va.gov
FU Presidential Early Career Award for Scientists and Engineers [USA
12-564]; VA Health Services Research and Development Service [IIR
10-148]
FX This work was supported by the Presidential Early Career Award for
Scientists and Engineers (grant number USA 12-564 to C. T. E.) and the
VA Health Services Research and Development Service (grant number IIR
10-148 to C. T. E.).
NR 43
TC 31
Z9 31
U1 1
U2 24
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2015
VL 60
SU 2
BP S66
EP S71
DI 10.1093/cid/civ140
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CH0OB
UT WOS:000353719500002
PM 25922403
ER
PT J
AU Kim, MJ
Miller, CM
Shadrach, JL
Wagers, AJ
Serwold, T
AF Kim, Mi-Jeong
Miller, Christine M.
Shadrach, Jennifer L.
Wagers, Amy J.
Serwold, Thomas
TI Young, Proliferative Thymic Epithelial Cells Engraft and Function in
Aging Thymuses
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; T-CELL; BONE-MARROW; CLONAL ANALYSIS;
IMMUNE-SYSTEM; AGE; MICE; THYMOPOIESIS; REGENERATION; PROGENITOR
AB The thymus reaches its maximum size early in life and then begins to shrink, producing fewer T cells with increasing age. This thymic decline is thought to contribute to age-related T cell lymphopenias and hinder T cell recovery after bone marrow transplantation. Although several cellular and molecular processes have been implicated in age-related thymic involution, their relative contributions are not known. Using heterochronic parabiosis, we observe that young circulating factors are not sufficient to drive regeneration of the aged thymus. In contrast, we find that resupplying young, engraftable thymic epithelial cells (TECs) to a middle-aged or defective thymus leads to thymic growth and increased T cell production. Intrathymic transplantation and in vitro colony-forming assays reveal that the engraftment and proliferative capacities of TECs diminish early in life, whereas the receptivity of the thymus to TEC engraftment remains relatively constant with age. These results support a model in which thymic growth and subsequent involution are driven by cell-intrinsic changes in the proliferative capacity of TECs, and further show that young TECs can engraft and directly drive the growth of involuted thymuses.
C1 [Kim, Mi-Jeong; Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.; Serwold, Thomas] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Kim, Mi-Jeong; Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.; Serwold, Thomas] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.] Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Paul F Glenn Labs Biol Mech Aging, Sch Med, Cambridge, MA 02138 USA.
RP Serwold, T (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.
EM thomas.serwold@joslin.harvard.edu
FU Mary K. Iacocca Foundation Research Fellowship; Harvard Stem Cell
Institute seed grant; Harvard Stem Cell Institute program project grant;
The Peabody Foundation; Alexander and Margaret Stewart Trust; The
Fleischer Foundation; The Pittsburgh Foundation; Glenn Foundation for
Medical Research; National Institutes of Health [1R01 AG033053, 1DP2
OD004345, 5U01 HL100402]; National Institutes of Health Diabetes
Research Center [P30DK036836]
FX This work was supported by a Mary K. Iacocca Foundation Research
Fellowship (to M.-J.K.), a Harvard Stem Cell Institute seed grant and a
Harvard Stem Cell Institute program project grant (to T.S.), The Peabody
Foundation (to T.S.), the Alexander and Margaret Stewart Trust (to
T.S.), The Fleischer Foundation (to T.S.), The Pittsburgh Foundation (to
T.S.), the Glenn Foundation for Medical Research (to A.J.W.), the
National Institutes of Health (Grants 1R01 AG033053, 1DP2 OD004345, and
5U01 HL100402 to A.J.W.), and the National Institutes of Health Diabetes
Research Center (Grant P30DK036836).
NR 57
TC 5
Z9 6
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2015
VL 194
IS 10
BP 4784
EP 4795
DI 10.4049/jimmunol.1403158
PG 12
WC Immunology
SC Immunology
GA CH0RB
UT WOS:000353728800021
PM 25870244
ER
PT J
AU Sise, ME
Hirsch, JS
Canetta, PA
Herlitz, L
Mohan, S
AF Sise, Meghan E.
Hirsch, Jamie S.
Canetta, Pietro A.
Herlitz, Leal
Mohan, Sumit
TI Nonalbumin proteinuria predominates in biopsy-proven tenofovir
nephrotoxicity
SO AIDS
LA English
DT Article
DE antiviral therapy; kidney; nephrotoxicity; proteinuria; reverse
transcriptase inhibitors; tenofovir
ID HIV-INFECTED PATIENTS; URINARY ALBUMIN; CARDIOVASCULAR RISK;
DYSFUNCTION; MICROALBUMINURIA; ABNORMALITIES; THERAPY; WOMEN
AB Objective: Tenofovir disoproxil fumarate (TDF) nephrotoxicity is characterized by proximal renal tubular injury and dysmorphic mitochondria resulting in proteinuria, orthoglycemic glycosuria, and other markers of proximal tubular dysfunction. The objective of this study was to determine the pattern of proteinuria in patients with biopsy-proven TDF nephrotoxicity.
Design: Retrospective chart review.
Methods: Patients with biopsy-proven TDF nephrotoxicity were identified and their medical charts and biopsy reports were reviewed. Comparison was made with HIV-infected patients not on TDF who underwent kidney biopsy.
Results: We identified 43 biopsy-proven cases of TDF nephrotoxicity; mean age 54.7 +/- 0.4 years, 53% men, 42% whites. Thirty-seven cases reported proteinuria by dipstick of which only 60% had at least 2+ proteinuria. Twenty-seven patients had urine protein quantified by either 24-h collection or spot urine protein-to-creatinine ratio; median proteinuria was 1742 mg/day [interquartile range (IQR) 1200-2000 mg] and 1667 mg/g creatinine (IQR 851-1967 mg/g), respectively. Ten patients had concurrent urinary albumin measured, with a median 236 mg/g creatinine (IQR 137-343 mg/g). The mean urine albumin-to-urine protein ratio (uAPR) was 0.17 (IQR 0.14-0.19), confirming that TDF nephrotoxicity is primarily associated with nonalbumin proteinuria. Control cases had a uAPR of 0.65 (IQR 0.55-0.79) P< 0.001. Histopathology showed the predominance of proximal tubular injury with characteristic mitochondrial abnormalities.
Conclusion: In the largest published cohort of patients with biopsy-proven TDF nephrotoxicity, we show that low uAPR is a reliable feature of this disease. Because of the predominance of nonalbumin proteinuria, dipstick urinalysis may be unreliable in TDF nephrotoxicity. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Sise, Meghan E.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Hirsch, Jamie S.; Canetta, Pietro A.; Mohan, Sumit] Columbia Univ, Med Ctr, Dept Med, Div Nephrol, New York, NY USA.
[Hirsch, Jamie S.] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY USA.
[Herlitz, Leal] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA.
RP Sise, ME (reprint author), 165 Cambridge St,Suite 302, Boston, MA 02114 USA.
EM msise@partners.org
OI Canetta, Pietro/0000-0003-1130-5486; Mohan, Sumit/0000-0002-5305-9685
NR 23
TC 9
Z9 10
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAY 15
PY 2015
VL 29
IS 8
BP 941
EP 946
DI 10.1097/QAD.0000000000000628
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CH2TR
UT WOS:000353878100009
PM 25784440
ER
PT J
AU Robles, LY
Singh, S
Fisichella, PM
AF Robles, Lourdes Y.
Singh, Satish
Fisichella, Piero Marco
TI Emerging enhanced imaging technologies of the esophagus: spectroscopy,
confocal laser endomicroscopy, and optical coherence tomography
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Review
DE Spectroscopy; Inelastic (Raman) scattering spectroscopy; Optical
coherence tomography; Barrett esophagus; Confocal laser endomicroscopy;
Confocal microscopy
ID HIGH-GRADE DYSPLASIA; IN-VIVO DIAGNOSIS; INDUCED AUTOFLUORESCENCE
SPECTROSCOPY; ELASTIC-SCATTERING SPECTROSCOPY; BARRETTS-ESOPHAGUS;
FLUORESCENCE SPECTROSCOPY; RADIOFREQUENCY ABLATION; RAMAN-SPECTROSCOPY;
CONTROLLED-TRIAL; GASTROINTESTINAL TISSUES
AB Background: Despite advances in diagnoses and therapy, esophageal adenocarcinoma remains a highly lethal neoplasm. Hence, a great interest has been placed in detecting early lesions and in the detection of Barrett esophagus (BE). Advanced imaging technologies of the esophagus have then been developed with the aim of improving biopsy sensitivity and detection of preplastic and neoplastic cells. The purpose of this article was to review emerging imaging technologies for esophageal pathology, spectroscopy, confocal laser endomicroscopy (CLE), and optical coherence tomography (OCT).
Methods: We conducted a PubMed search using the search string "esophagus or esophageal or oesophageal or oesophagus" and "Barrett or esophageal neoplasm" and "spectroscopy or optical spectroscopy" and "confocal laser endomicroscopy" and "confocal microscopy" and "optical coherence tomography." The first and senior author separately reviewed all articles. Our search identified: 19 in vivo studies with spectroscopy that accounted for 1021 patients and 4 ex vivo studies; 14 clinical CLE in vivo studies that accounted for 941 patients and 1 ex vivo study with 13 patients; and 17 clinical OCT in vivo studies that accounted for 773 patients and 2 ex vivo studies.
Results: Human studies using spectroscopy had a very high sensitivity and specificity for the detection of BE. CLE showed a high interobserver agreement in diagnosing esophageal pathology and an accuracy of predicting neoplasia. We also found several clinical studies that reported excellent diagnostic sensitivity and specificity for the detection of BE using OCT.
Conclusions: Advanced imaging technology for the detection of esophageal lesions is a promising field that aims to improve the detection of early esophageal lesions. Although advancing imaging techniques improve diagnostic sensitivities and specificities, their integration into diagnostic protocols has yet to be perfected. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Robles, Lourdes Y.] Univ Calif Irvine, Dept Surg, Irvine, CA 92717 USA.
[Singh, Satish] Boston Univ, Boston VA Healthcare Syst, Div Gastroenterol, Boston, MA 02215 USA.
[Fisichella, Piero Marco] Harvard Univ, Sch Med, Dept Surg, Boston VA Healthcare Syst, Boston, MA 02115 USA.
RP Fisichella, PM (reprint author), Harvard Univ, Sch Med, Boston VA Healthcare Syst, Dept Surg, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM piero.fisichella@va.gov
OI Fisichella, P. Marco/0000-0002-7697-7884
FU Mauna Kea Technologies
FX L.Y.R. and P.M.F. have no conflicts of interest to declare. S.S. has
received educational support from Mauna Kea Technologies.
NR 85
TC 5
Z9 5
U1 6
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD MAY 15
PY 2015
VL 195
IS 2
BP 502
EP 514
DI 10.1016/j.jss.2015.02.045
PG 13
WC Surgery
SC Surgery
GA CG9QH
UT WOS:000353651600016
PM 25819772
ER
PT J
AU Repunte-Canonigo, V
Herman, MA
Kawamura, T
Kranzler, HR
Sherva, R
Gelernter, J
Farrer, LA
Roberto, M
Sanna, PP
AF Repunte-Canonigo, Vez
Herman, Melissa A.
Kawamura, Tomoya
Kranzler, Henry R.
Sherva, Richard
Gelernter, Joel
Farrer, Lindsay A.
Roberto, Marisa
Sanna, Pietro Paolo
TI Nf1 Regulates Alcohol Dependence-Associated Excessive Drinking and
Gamma-Aminobutyric Acid Release in the Central Amygdala in Mice and Is
Associated with Alcohol Dependence in Humans
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Alcohol dependence; Amygdala; Electrophysiology; GABA; Genetic
association; Presynaptic mechanisms
ID CHRONIC ETHANOL EXPOSURE; LEARNING-DEFICITS; C57BL/6J MICE; GABA
RELEASE; INTERMITTENT; WITHDRAWAL; MODEL; INTOXICATION; INHIBITION;
MEMORY
AB BACKGROUND: The neurofibromatosis type 1 (Nf1) gene encodes a GTPase activating protein that negatively regulates small GTPases of the Ras family.
METHODS: We assessed alcohol-related behaviors including alcohol sensitivity, dependent and nondependent drinking, and basal and alcohol-induced gamma-aminobutyric acid (GABA) release in the central nucleus of the amygdala (CeA) in Nf1 heterozygous null mice (Nf1(+/-)). We also investigated the associations of NF1 polymorphisms with alcohol dependence risk and severity in humans.
RESULTS: Nf1(+/-) mice do not differ from wild-type mice in nondependent drinking, such as 24-hour, 2-bottle choice drinking in the dark binge drinking or limited access 2-bottle choice. However, Nf1(+/-) mice failed to escalate alcohol drinking following chronic intermittent ethanol vapor exposure (CIE) to induce dependence. Alcohol acutely increases GABA release in the CeA and alcohol dependence is characterized by increased baseline GABA release in CeA. Interestingly, GABA release in Nf1(+/-) mice is greater at baseline than wild-type mice, is not elevated by induction of dependence by CIE, and failed to show alcohol-induced facilitation both before and after CIE. Additionally, we observed that multiple variants in the human NF1 gene are associated with a quantitative measure of alcohol dependence in both African Americans and European Americans.
CONCLUSIONS: In this translational investigation, we found that Nf1 activity regulates excessive drinking and basal and ethanol-stimulated GABA release in the mouse central amygdala. We also found that genetic variation in NF1 may confer an inherent susceptibility to the transition from nondependent to dependent drinking in humans.
C1 [Repunte-Canonigo, Vez; Kawamura, Tomoya; Sanna, Pietro Paolo] Scripps Res Inst, Mol & Cellular Neurosci Dept, La Jolla, CA 92037 USA.
[Herman, Melissa A.; Roberto, Marisa] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
[Kranzler, Henry R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network Mental Illness Res Ed, Philadelphia, PA USA.
[Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Ctr Clin, Philadelphia, PA USA.
[Sherva, Richard; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02215 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Psychiat, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Genet, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Neurobiol, West Haven, CT 06516 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
RP Sanna, PP (reprint author), Scripps Res Inst, Mol & Cellular Med, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM psanna@scripps.edu
OI Farrer, Lindsay/0000-0001-5533-4225
FU National Institutes of Health [F32 AA020430, AA015566, AA017371,
AA020960, AA013191, AA013498, AA021491, AA021667, AA11330, AA17535,
DA12690, DA12849, DA18432, DA028909, N01-HG-65403, HHSN268200782096C];
Pearson Center for Alcoholism and Addiction Research; National
Institutes of Health Genes, Environment and Health Initiative [U01
HG004422, U01HG004438]; National Institute on Alcohol Abuse and
Alcoholism; National Institute on Drug Abuse; Lilly; Lundbeck; AbbVie;
Ethypharm; Pfizer
FX This work was supported by National Institutes of Health Grants F32
AA020430, AA015566, AA017371, AA020960, AA013191, AA013498, AA021491,
AA021667, AA11330, AA17535, DA12690, DA12849, DA18432, and DA028909 and
the Pearson Center for Alcoholism and Addiction Research. Genotyping
services for a part of our genome-wide association study were provided
by the Center for Inherited Disease Research and Yale University (Center
for Genome Analysis). Center for Inherited Disease Research is fully
funded through a federal contract from the National Institutes of Health
to The Johns Hopkins University (contract number N01-HG-65403). The
publicly available datasets used for the analyses described in this
manuscript were obtained from dbGaP at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0
00092.v1.p1 through dbGaP accession number phs000092.v1.p. Funding
support for the Study of Addiction: Genetics and Environment was
provided through the National Institutes of Health Genes, Environment
and Health Initiative (U01 HG004422). Study of Addiction: Genetics and
Environment is one of the genome-wide association studies funded as part
of the Gene Environment Association Studies under Genes, Environment and
Health Initiative. Assistance with phenotype harmonization and genotype
cleaning, as well as with general study coordination, was provided by
the Gene Environment Association Studies Coordinating Center (U01
HG004446).; Assistance with data cleaning was provided by the National
Center for Biotechnology Information. Support for collection of datasets
and samples was provided by the Collaborative Study on the Genetics of
Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine
Dependence (P01 CA089392), and the Family Study of Cocaine Dependence
(R01 DA013423). Funding support for genotyping, which was performed at
the Johns Hopkins University Center for Inherited Disease Research, was
provided by the National Institutes of Health Genes, Environment and
Health Initiative (U01HG004438), the National Institute on Alcohol Abuse
and Alcoholism, the National Institute on Drug Abuse, and the National
Institutes of Health contract "High throughput genotyping for studying
the genetic contributions to human disease" (HHSN268200782096C).; HRK
has been a consultant or advisory board member with Alkermes, Lilly,
Lundbeck, Otsuka, Pfizer, and Roche. He has also received honoraria from
the Alcohol Clinical Trials Initiative of the American Society of
Clinical Psychopharmacology, which is supported by Lilly, Lundbeck,
AbbVie, Ethypharm, and Pfizer. All other authors report no biomedical
financial interests or potential conflicts of interest.
NR 33
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2015
VL 77
IS 10
BP 870
EP 879
DI 10.1016/j.biopsych.2014.07.031
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CG8LP
UT WOS:000353559600006
PM 25483400
ER
PT J
AU Freeman, S
Yu, RJ
Egorova, N
Chen, XY
Kirsch, I
Claggett, B
Kaptchuk, TJ
Gollub, RL
Kong, J
AF Freeman, Sonya
Yu, Rongjun
Egorova, Natalia
Chen, Xiaoyan
Kirsch, Irving
Claggett, Brian
Kaptchuk, Ted J.
Gollub, Randy L.
Kong, Jian
TI Distinct neural representations of placebo and nocebo effects
SO NEUROIMAGE
LA English
DT Article
DE Placebo; Nocebo; Expectancy; Positive expectancy; Negative expectancy;
fMRI; Pain
ID INDIVIDUAL-DIFFERENCES; INDUCED EXPECTATIONS; CLINICAL-TRIALS; DORSAL
STRIATUM; BRAIN ACTIVITY; PAIN; ANALGESIA; FMRI; MECHANISMS; ANXIETY
AB Expectations shape the way we experience the world. In this study, we used fMRI to investigate how positive and negative expectation can change pain experiences in the same cohort of subjects. We first manipulated subjects' treatment expectation of the effectiveness of three inert creams, with one cream labeled "Lidocaine" (positive expectancy), one labeled "Capsaicin" (negative expectancy) and one labeled "Neutral" by surreptitiously decreasing, increasing, or not changing respectively, the intensity of the noxious stimuli administered following cream application. We then used fMRI to investigate the signal changes associated with administration of identical pain stimuli before and after the treatment and control creams. Twenty-four healthy adults completed the study. Results showed that expectancy significantly modulated subjective pain ratings. After controlling for changes in the neutral condition, the subjective pain rating changes evoked by positive and negative expectancies were significantly associated. fMRI results showed that the expectation of an increase in pain induced significant fMRI signal changes in the insula, orbitofrontal cortex, and periaqueductal gray, whereas the expectation of pain relief evoked significant fMRI signal changes in the striatum. No brain regions were identified as common to both "Capsaicin" and "Lidocaine" conditioning. There was also no significant association between the brain response to identical noxious stimuli in the pain matrix evoked by positive and negative expectancies. Our findings suggest that positive and negative expectancies engage different brain networks to modulate our pain experiences, but, overall, these distinct patterns of neural activation result in a correlated placebo and nocebo behavioral response. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Freeman, Sonya; Yu, Rongjun; Egorova, Natalia; Chen, Xiaoyan; Gollub, Randy L.; Kong, Jian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Kirsch, Irving; Kaptchuk, Ted J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Placebo Studies, Charlestown, MA 02129 USA.
[Claggett, Brian] Harvard Univ, Sch Med, Div Cardiovasc Med, Charlestown, MA 02129 USA.
[Yu, Rongjun] Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore.
RP Kong, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 120,2nd Ave Suite 101, Charlestown, MA 02129 USA.
EM kongj@nmr.mgh.harvard.edu
RI Egorova, Natalia/N-9118-2015
OI Egorova, Natalia/0000-0002-9244-2900
FU NCCAM [R01AT006364, R01AT005280]; [P01 AT006663]
FX This work was supported by R01AT006364 (NCCAM) to Jian Kong, R01AT005280
(NCCAM) to Randy Gollub, and P01 AT006663 to Bruce Rosen.
NR 75
TC 7
Z9 7
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2015
VL 112
BP 197
EP 207
DI 10.1016/j.neuroimage.2015.03.015
PG 11
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CG3TV
UT WOS:000353203400020
PM 25776211
ER
PT J
AU Liu, HB
Cadaneanu, RM
Lai, K
Zhang, BH
Huo, LH
An, DS
Li, XM
Lewis, MS
Garraway, IP
AF Liu, Haibo
Cadaneanu, Radu M.
Lai, Kevin
Zhang, Baohui
Huo, Lihong
An, Dong Sun
Li, Xinmin
Lewis, Michael S.
Garraway, Isla P.
TI Differential Gene Expression Profiling of Functionally and
Developmentally Distinct Human Prostate Epithelial Populations
SO PROSTATE
LA English
DT Article
DE human prostate epithelial microarray; fetal prostate; prostate stem
cell; basal cell; prostate tissue regeneration; prostate tubule
initiation
ID STEM-CELLS; LUMINAL CELLS; BASAL-CELLS; MURINE; CANCER; IDENTIFICATION;
SUBPOPULATION; DISEASE; MARKER; TISSUE
AB BACKGROUNDHuman fetal prostate buds appear in the 10th gestational week as solid cords, which branch and form lumens in response to androgen 1. Previous in vivo analysis of prostate epithelia isolated from benign prostatectomy specimens indicated that Epcam(+)CD44(-)CD49f(Hi) basal cells possess efficient tubule initiation capability relative to other subpopulations 2. Stromal interactions and branching morphogenesis displayed by adult tubule-initiating cells (TIC) are reminiscent of fetal prostate development. In the current study, we evaluated in vivo tubule initiation by human fetal prostate cells and determined expression profiles of fetal and adult epithelial subpopulations in an effort to identify pathways used by TIC.
METHODSImmunostaining and FACS analysis based on Epcam, CD44, and CD49f expression demonstrated the majority (99.9%) of fetal prostate epithelial cells (FC) were Epcam(+)CD44(-) with variable levels of CD49f expression. Fetal populations isolated via cell sorting were implanted into immunocompromised mice. Total RNA isolation from Epcam(+)CD44(-)CD49f(Hi) FC, adult Epcam(+)CD44(-)CD49f(Hi) TIC, Epcam(+)CD44(+)CD49f(Hi) basal cells (BC), and Epcam(+)CD44(-)CD49f(Lo) luminal cells (LC) was performed, followed by microarray analysis of 19 samples using the Affymetrix Gene Chip Human U133 Plus 2.0 Array. Data was analyzed using Partek Genomics Suite Version 6.4. Genes selected showed >2-fold difference in expression and P<5.00E-2. Results were validated with RT-PCR.
RESULTSGrafts retrieved from Epcam(+)CD44(-) fetal cell implants displayed tubule formation with differentiation into basal and luminal compartments, while only stromal outgrowths were recovered from Epcam- fetal cell implants. Hierarchical clustering revealed four distinct groups determined by antigenic profile (TIC, BC, LC) and developmental stage (FC). TIC and BC displayed basal gene expression profiles, while LC expressed secretory genes. FC had a unique profile with the most similarities to adult TIC. Functional, network, and canonical pathway identification using Ingenuity Pathway Analysis Version 7.6 compiled genes with the highest differential expression (TIC relative to BC or LC). Many of these genes were found to be significantly associated with prostate tumorigenesis.
CONCLUSIONSOur results demonstrate clustering gene expression profiles of FC and adult TIC. Pathways associated with TIC are known to be deregulated in cancer, suggesting a cell-of-origin role for TIC versus re-emergence of pathways common to these cells in tumorigenesis. Prostate 75: 764-776, 2015. (c) The Authors. The Prostate, published by Wiley Periodicals, Inc.
C1 [Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; Garraway, Isla P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; An, Dong Sun; Li, Xinmin; Garraway, Isla P.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[An, Dong Sun] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
[An, Dong Sun; Garraway, Isla P.] Univ Calif Los Angeles, Broad Stem Cell Ctr, Los Angeles, CA USA.
[Li, Xinmin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Lewis, Michael S.; Garraway, Isla P.] West Los Angeles VA Hosp, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
RP Garraway, IP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
EM igarraway@mednet.ucla.edu
FU National Institutes of Health [CA-16042, AI-28697 U54 CA 143931];
Department of Defense [PC073073]; Prostate Cancer Foundation Challenge
and Young Investigator Awards; Jean Perkins Foundation; Margaret E.
Early Medical Research Trust
FX Grant sponsor: National Institutes of Health awards; Grant numbers:
CA-16042; AI-28697 U54 CA 143931; Grant sponsor: Department of Defense;
Grant number: PC073073; Grant sponsor: Prostate Cancer Foundation
Challenge and Young Investigator Awards; Grant sponsor: Jean Perkins
Foundation; Grant sponsor: Margaret E. Early Medical Research Trust.
NR 25
TC 2
Z9 2
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD MAY 15
PY 2015
VL 75
IS 7
BP 764
EP 776
DI 10.1002/pros.22959
PG 13
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA CF7DL
UT WOS:000352716300009
PM 25663004
ER
PT J
AU Aiken, CB
Weisler, RH
Sachs, GS
AF Aiken, Chris B.
Weisler, Richard H.
Sachs, Gary S.
TI The Bipolarity index: a clinician-rated measure of diagnostic confidence
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Mood disorders; Psychiatric diagnosis; Psychometrics
ID MOOD DISORDER QUESTIONNAIRE; ADJUNCTIVE ORAL ZIPRASIDONE; II-DISORDER;
PRIVATE-PRACTICE; DOUBLE-BLIND; DEPRESSION; SPECTRUM; PREVALENCE;
VALIDITY; MANIA
AB Background: The Bipolarity Index is a clinician-rated scale that rates cardinal features of the disorder across five domains: signs and symptoms, age of onset, course of illness, response to treatment, and family history. We tested the Index in routine clinical practice to identify the optimal cut-off for distinguishing bipolar from non-bipolar disorders.
Method: Sequential patients in a private practice were rated with the Bipolarity Index (n=1903) at intake. Diagnoses were made with the MINI-6.0.0 International Neuropsychiatric Interview according to DSM-IV-TR criteria, except that cases of antidepressant-induced mania and hypomania were included in the bipolar group. A subset completed the self-rated Mood Disorder Questionnaire (MDQ) (n=1620) or Bipolar Spectrum Diagnostic Scale (BSDS) (n=1179). The primary analysis compared Bipolarity Index scores for bipolar vs. non-bipolar patients using receiver operator curves (ROC) to determine the optimal cut-off score. Secondary outcomes repeated this analysis with the MDQ MDQ-7 (using only the symptomatic items of the MDQ) and BSDS.
Results: At a cut-off of >= 50, the Bipolarity Index had a high sensitivity (0.91) and specificity (0.90). Optimal cut-offs for self-rated scales were: MDQ >= 7 (sensitivity 0.74, specificity 0.71); MDQ-7: (sensitivity 0.77, specificity 0.77); BSDS: >= 12 (sensitivity 0.71, specificity 0.77).
Limitations: The study utilized one rater at a single practice site; the rater was not blinded to the results of the MINI.
Conclusion: The Bipolarity Index can enhance the clinical assessment of mood disorders and, at a score >= 50 has good sensitivity and specificity for identifying bipolar disorders. (C) 2015 Elsevier By. All rights reserved.
C1 [Aiken, Chris B.] Mood Treatment Ctr, Winston Salem, NC 27106 USA.
[Aiken, Chris B.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Weisler, Richard H.] Univ N Carolina, Chapel Hill, NC USA.
[Weisler, Richard H.] Duke Univ, Med Ctr, Durham, NC USA.
[Sachs, Gary S.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA.
[Sachs, Gary S.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA.
[Sachs, Gary S.] Bracket LLC, Wayne, PA USA.
RP Aiken, CB (reprint author), Mood Treatment Ctr, 1615 Polo Rd, Winston Salem, NC 27106 USA.
EM christopher.aiken.med.99@aya.yale.edu
FU Abbott; Alcobra; Agency for Toxic Substances and Disease Registry; Astra
Zeneca; Biovail; Bristol-Myers Squibb; Burroughs Wellcome; Cenerx;
Centers of Disease Control and Prevention; Cephalon; Ciba Geigy;
CoMentis; Dainippon Sumitomo Pharma America; Eisai; Elan; Eli Lilly;
Forest; GlaxoSmithKline; Janssen; Johnson Johnson; Lundbeck; McNeil
Pharmaceuticals; Medicinova; Merck; National Institute of Mental Health;
Neurochem; New River Pharmaceuticals; Novartis; Organon; Pfizer;
Pharmacia; Repligen; Saegis; Sandoz; Sanofi; Sanofi-Synthelabo;
Schwabe/Ingenix; Sepracor; Shire; Solvay; Sunovion; Synaptic; Takeda;
TAP; Theravance; Transcept Pharma; UCB Pharma; Vela; Wyeth
FX 2. Richard Weisler: Richard Weisler, MD, in his career, has been a
consultant to, on the Speaker's Bureaus of, and/or received research
support from the following: Abbott: Speaker's Bureau, consultant,
received research support; Alcobra: consultant, received research
support: Agency for Toxic Substances and Disease Registry: consultant;
Astra Zeneca: Speaker's Bureau, consultant, received research support;
Biovail: Speaker's Bureau, consultant, received research support;
Bristol-Myers Squibb: Speaker's Bureau, consultant, received research
support, Stockholder has held or holds stock; Burroughs Wellcome:
Speaker's Bureau, received research support; Cenerx: received research
support; Centers of Disease Control and Prevention: consultant;
Cephalon: Speaker's Bureau, consultant, received research support; Ciba
Geigy: Speaker's Bureau, received research support; CoMentis: received
research support; Corcept: consultant; Cortex: Stockholder has held or
holds stock; Dainippon Sumitomo Pharma America: received research
support; Eisai: received research support; Elan: received research
support; Eli Lilly: Speaker's Bureau, consultant, received research
support; Forest: Speaker's Bureau, consultant, received research
support; GlaxoSmithKline: Speaker's Bureau, consultant, received
research support; Janssen: Speaker's Bureau, received research support;
Johnson & Johnson: Speaker's Bureau, consultant, received research
support; Lundbeck: received research support; McNeil Pharmaceuticals:
received research support; Medicinova: received research support;
Medscape: Advisory Board, consultant; Merck: received research support,
Speakers Bureau, stockholder has held or holds stock; National Institute
of Mental Health: consultant, received research support; Neurochem:
received research support; New River Pharmaceuticals: received research
support; Novartis: Speaker's Bureau, received research support; Organon:
Speaker's Bureau, consultant, received research support; Otsuka America
Pharma: consultant; Pfizer: Speaker's Bureau, consultant, received
research support, stockholder has held or holds stock; Pharmacia:
consultant, received research support; Repligen: received research
support; Saegis: received research support; Sandoz: received research
support; Sanofi: Speaker's Bureau, consultant, received research
support; Sanofi-Synthelabo: Speaker's Bureau, consultant, received
research support; Schwabe/Ingenix: received research support; Sepracor:
received research support; Shire: Speaker's Bureau, consultant, received
research support; Solvay: Speaker's Bureau, consultant; Sunovion:
Speaker's Bureau, consultant, received research support; Synaptic:
received research support; Takeda: received research support; TAP:
received research support; Theravance: received research support;
Transcept Pharma: consultant, received research support; TransTech:
consultant; UCB Pharma: received research support; Validus: Speaker's
Bureau, consultant; Vela: received research support; Wyeth: Speaker's
Bureau, consultant, received research support.
NR 42
TC 1
Z9 2
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAY 15
PY 2015
VL 177
BP 59
EP 64
DI 10.1016/j.jad.2015.02.004
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA CF0NM
UT WOS:000352240900010
PM 25745836
ER
PT J
AU Gupta, R
Vavvas, D
Asaad, WF
AF Gupta, Rajiv
Vavvas, Demetrios
Asaad, Wael F.
TI Case 15-2015: A 27-Year-Old Man with a Nail in the Eye
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID DUAL-ENERGY CT; PENETRATING CRANIOCEREBRAL INJURIES; INTERNAL
CAROTID-ARTERY; PRINCIPLES; MANAGEMENT; ANEURYSMS; SYSTEM
C1 [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA.
[Asaad, Wael F.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Vavvas, Demetrios] Massachusetts Eye & Ear Inst, Dept Ophthalmol, Boston, MA USA.
[Gupta, Rajiv] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Vavvas, Demetrios] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Asaad, Wael F.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA.
RP Gupta, R (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA.
OI Vavvas, Demetrios/0000-0002-8622-6478
NR 27
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 14
PY 2015
VL 372
IS 20
BP 1945
EP 1955
DI 10.1056/NEJMcpc1310007
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI1HB
UT WOS:000354493300012
PM 25970053
ER
PT J
AU Bianchi, G
Munshi, NC
AF Bianchi, Giada
Munshi, Nikhil C.
TI Pathogenesis beyond the cancer clone(s) in multiple myeloma
SO BLOOD
LA English
DT Review
ID UNDETERMINED SIGNIFICANCE MGUS; BONE-MARROW MICROENVIRONMENT;
MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; MONOCLONAL GAMMOPATHY;
HEMATOPOIETIC STEM; DRUG-RESISTANCE; GENE-EXPRESSION; PLASMA-CELLS;
OSTEOBLAST DIFFERENTIATION
AB Over the past 4 decades, basic research has provided crucial information regarding the cellular and molecular biology of cancer. In particular, the relevance of cancer microenvironment (including both cellular and noncellular elements) and the concept of clonal evolution and heterogeneity have emerged as important in cancer pathogenesis, immunologic escape, and resistance to therapy. Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is emblematic of the impact of cancer microenvironment and the role of clonal evolution. Although genetic and epigenetic aberrations occur in MM and evolve over time under the pressure of exogenous stimuli, they are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), suggesting that genetic mutations alone are necessary, but not sufficient, for myeloma transformation. The role of bone marrow microenvironment in mediating survival, proliferation, and resistance to therapy in myeloma is well established; and although an appealing speculation, its role in fostering the evolution of MGUS or SMM into MM is yet to be proven. In this review, we discuss MM pathogenesis with a particular emphasis on the role of bone marrow microenvironment.
C1 [Bianchi, Giada; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Vet Affairs Boston Healthcare Syst, West Roxbury, MA USA.
RP Munshi, NC (reprint author), 450 Brookline Ave, Boston, MA 02215 USA.
EM nikhil_munshi@dfci.harvard.edu
FU National Institutes of Health National Cancer Institute [PO1-155258,
RO1-124929, P50-100707, PO1-78378]; US Department of Veterans Affairs
Merit Review Award [I01 BX001584-01]
FX This work was partly supported by National Institutes of Health National
Cancer Institute grants PO1-155258, RO1-124929, P50-100707, and
PO1-78378 and US Department of Veterans Affairs Merit Review Award I01
BX001584-01 (N.C.M.).
NR 135
TC 30
Z9 30
U1 5
U2 17
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 14
PY 2015
VL 125
IS 20
BP 3049
EP 3058
DI 10.1182/blood-2014-11-568881
PG 10
WC Hematology
SC Hematology
GA CJ7PJ
UT WOS:000355689000008
PM 25838343
ER
PT J
AU Ciuculescu, MF
Park, SY
Canty, K
Mathieu, R
Silberstein, LE
Williams, DA
AF Ciuculescu, Marioara F.
Park, Shin-Young
Canty, Kimberly
Mathieu, Ronald
Silberstein, Leslie E.
Williams, David A.
TI Perivascular deletion of murine Rac reverses the ratio of marrow
arterioles and sinusoid vessels and alters hematopoiesis in vivo
SO BLOOD
LA English
DT Article
ID STEM-CELL QUIESCENCE; BONE-MARROW; STROMAL CELLS; OSTEOBLAST
DIFFERENTIATION; STEM/PROGENITOR CELLS; PROGENITOR CELLS; RHO GTPASES;
NICHE; LOCALIZATION; ACTIVATION
AB Hematopoietic stem cells (HSCs) are localized within specialized microenvironments throughout the BM. Nestin-expressing (Nestin(+)) mesenchymal stromal cells (MSCs) are important in the perivascular space. Rac is critical for MSC cell shape in vitro, whereas its function in MSCs in vivo remains poorly characterized. We hypothesized that deletion of Rac in the Nestin(+) cells would perturb the perivascular space, altering HSC localization and hematopoiesis. Nestin-Cre-directed excision of Rac1 in Rac3(-/-) mice reduces Nestin(+) cells in the marrow. We observed a 2.7-fold decrease in homing of labeled wild-type hematopoietic cells into Rac1(Delta/Delta)Rac3(-/-) mice compared with control mice. Rac1(Delta/Delta)Rac3(-/-) mice demonstrated a marked decrease in arterioles and an increase in the number and volume of venous sinusoids in the marrow that was associated with a reduction in the numbers of immunophenotypically and functionally-defined long-term HSCs in the marrow, a decrease in colony-forming cells and a reduction in circulating progenitors. Rac-deleted animals demonstrated a significant increase in trabecular bone. These data demonstrate that Rac GTPases play an important role in the integrity of perivascular space. Increased trabecular bone and sinusoidal space and decreased arteriolar volume in this model were associated with decreased HSC, underscoring the complexity of regulation of hematopoiesis in the perivascular space.
C1 [Ciuculescu, Marioara F.; Mathieu, Ronald; Williams, David A.] Harvard Univ, Sch Med, Div Hematol & Oncol, Harvard Stem Cell Inst, Boston, MA USA.
[Park, Shin-Young; Canty, Kimberly; Silberstein, Leslie E.] Harvard Univ, Boston Childrens Hosp, Div Transfus Med, Med Sch,Harvard Stem Cell Inst, Boston, MA USA.
[Park, Shin-Young; Canty, Kimberly; Silberstein, Leslie E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA.
RP Williams, DA (reprint author), 300 Longwood Ave,Karp 08125 3, Boston, MA 02115 USA.
EM dawilliams@childrens.harvard.edu
FU National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases [DK062757]; National Heart, Lung, and
Blood Institute [R01 HL093139, P01 HL095489]; Day Kimball Healthcare
[D/12/03783]
FX This work is supported by National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases grant DK062757
(D.A.W.), National Heart, Lung, and Blood Institute grants R01 HL093139
(L.E.S.) and P01 HL095489 (L.E.S.), and Day Kimball Healthcare grant
D/12/03783 (M.F.C.).
NR 43
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 14
PY 2015
VL 125
IS 20
BP 3105
EP 3113
DI 10.1182/blood-2014-10-604892
PG 9
WC Hematology
SC Hematology
GA CJ7PJ
UT WOS:000355689000014
PM 25824687
ER
PT J
AU Nonami, A
Sattler, M
Weisberg, E
Liu, QS
Zhang, JM
Patricelli, MP
Christie, AL
Saur, AM
Kohl, NE
Kung, AL
Yoon, H
Sim, T
Gray, NS
Griffin, JD
AF Nonami, Atsushi
Sattler, Martin
Weisberg, Ellen
Liu, Qingsong
Zhang, Jianming
Patricelli, Matthew P.
Christie, Amanda L.
Saur, Amy M.
Kohl, Nancy E.
Kung, Andrew L.
Yoon, Hojong
Sim, Taebo
Gray, Nathanael S.
Griffin, James D.
TI Identification of novel therapeutic targets in acute leukemias with NRAS
mutations using a pharmacologic approach
SO BLOOD
LA English
DT Article
ID GERMINAL CENTER KINASE; CANCER-CELLS; INHIBITOR; ACTIVATION; PATHWAY;
RAS; POLYPHARMACOLOGY; RESISTANCE; DISCOVERY; SURVIVAL
AB Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypass pathways. For the purpose of identifying novel targets in NRAS-transformed cells, we performed a chemical screen using mutant NRAS transformed Ba/F3 cells to identify compounds with selective cytotoxicity. One of the compounds identified, GNF-7, potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous leukemia and acute lymphoblastic leukemia. Mechanistic analysis revealed that its effects were mediated in part through combined inhibition of ACK1/AKT and of mitogen-activated protein kinase kinase kinase kinase 2 (germinal center kinase). Similar to genetic synthetic lethal approaches, these results suggest that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes.
C1 [Nonami, Atsushi; Sattler, Martin; Weisberg, Ellen; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Nonami, Atsushi; Sattler, Martin; Weisberg, Ellen; Griffin, James D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Liu, Qingsong; Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Liu, Qingsong; Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Patricelli, Matthew P.] ActivX Biosci Inc, La Jolla, CA USA.
[Christie, Amanda L.; Saur, Amy M.; Kohl, Nancy E.; Kung, Andrew L.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA USA.
[Yoon, Hojong; Sim, Taebo] Korea Inst Sci & Technol, Chem Kinom Res Ctr, Seoul, South Korea.
[Sim, Taebo] Korea Univ KIST, Grad Sch Converging Sci & Technol, Seoul, South Korea.
RP Sim, T (reprint author), 145 Anam Ro, Seoul 136713, South Korea.
EM tbsim@kist.re.kr; nathanael_gray@dfci.harvard.edu
OI liu, qing song/0000-0002-7829-2547; Kung, Andrew/0000-0002-9091-488X
FU National Institutes of Health, National Cancer Institute [CA66996,
CA130876-04, CA154303-01A1, HG005693-01]; Kanae foundation for the
promotion of medical science; Korea Institute of Science and Technology;
creative/challenging research program of the National Research
Foundation of Korea [NRF-2011-0028676]; Korea Basic Science Institute
[D33400]
FX This study is supported by the National Institutes of Health, National
Cancer Institute grants CA66996 (J.D.G), CA130876-04 (N.S.G), and
CA154303-01A1 (N.S.G), and HG005693-01 (N.S.G), a grant from the Kanae
foundation for the promotion of medical science (A.N.), and grants from
the Korea Institute of Science and Technology (T.S.), the
creative/challenging research program of the National Research
Foundation of Korea (NRF-2011-0028676) (T.S.), and the Korea Basic
Science Institute (D33400, T.S.).
NR 32
TC 4
Z9 4
U1 2
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 14
PY 2015
VL 125
IS 20
BP 3133
EP 3143
DI 10.1182/blood-2014-12-615906
PG 11
WC Hematology
SC Hematology
GA CJ7PJ
UT WOS:000355689000018
PM 25833960
ER
PT J
AU Arvey, A
Ojesina, AI
Pedamallu, CS
Ballon, G
Jung, J
Duke, F
Leoncini, L
De Falco, G
Bressman, E
Tam, W
Chadburn, A
Meyerson, M
Cesarman, E
AF Arvey, Aaron
Ojesina, Akinyemi I.
Pedamallu, Chandra Sekhar
Ballon, Gianna
Jung, Joonil
Duke, Fujiko
Leoncini, Lorenzo
De Falco, Giulia
Bressman, Eric
Tam, Wayne
Chadburn, Amy
Meyerson, Matthew
Cesarman, Ethel
TI The tumor virus landscape of AIDS-related lymphomas
SO BLOOD
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
NON-HODGKINS-LYMPHOMA; CENTER B-CELLS; BURKITTS-LYMPHOMA;
GERMINAL-CENTER; NASOPHARYNGEAL CARCINOMA; KAPOSIS-SARCOMA; READ
ALIGNMENT; UNITED-STATES
AB Immunodeficiency dramatically increases susceptibility to cancer as a result of reduced immune surveillance and enhanced opportunities for virus-mediated oncogenesis. Although AIDS-related lymphomas(ARLs) are frequently associated with known oncogenic viruses, many cases contain no known transforming virus. To discover novel transforming viruses, we profiled a set of ARL samples using whole transcriptome sequencing. We determined that Epstein-Barr virus (EBV) was the only virus detected in the tumor samples of this cohort, suggesting that if unidentified pathogens exist in this disease, they are present in <10% of cases or undetectable by our methods. To evaluate the role of EBV in ARL pathogenesis, we analyzed viral gene expression and found highly heterogeneous patterns of viral transcription across samples. We also found significant heterogeneity of viral antigen expression across a large cohort, with many patient samples presenting with restricted type I viral latency, indicating that EBV latency proteins are under increased immunosurveillance in the post-combined antiretroviral therapies era. Furthermore, EBV infection of lymphoma cells in HIV-positive individuals was associated with a distinct host gene expression program. These findings provide insight into the joint host-virus regulatory network of primary ARL tumor samples and expand our understanding of virus-associated oncogenesis. Our findings may also have therapeutic implications, as treatment may be personalized to target specific viral and virus-associated host processes that are only present in a subset of patients.
C1 [Arvey, Aaron] Mem Sloan Kettering Canc Ctr, Dept Immunol & Microbial Pathogenesis, New York, NY 10021 USA.
[Ojesina, Akinyemi I.; Pedamallu, Chandra Sekhar; Duke, Fujiko; Meyerson, Matthew] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02139 USA.
[Ojesina, Akinyemi I.; Pedamallu, Chandra Sekhar; Jung, Joonil; Duke, Fujiko; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ballon, Gianna; Bressman, Eric; Tam, Wayne; Cesarman, Ethel] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
[Leoncini, Lorenzo; De Falco, Giulia] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy.
[Chadburn, Amy] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.
RP Cesarman, E (reprint author), Weill Cornell Med Coll, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA.
EM ecesarm@med.cornell.edu
OI Ojesina, Akinyemi/0000-0003-0755-3639
FU Starr Cancer Consortium; National Institutes of Health (NIH) National
Cancer Institute [1RC2CA148317]; Rebecca Ridley Kry Fellowship of the
Damon Runyon Cancer Research Foundation; AIDS Malignancy Clinical Trials
Consortium (NIH National Cancer Institute) [U01CA121947]; AIDS Cancer
Specimen Resource (NIH National Cancer Institute) [1UM1CA181255]
FX This project was funded by the Starr Cancer Consortium and National
Institutes of Health (NIH) National Cancer Institute grant 1RC2CA148317
(M.M. and E.C.). A.I.O. was supported by the Rebecca Ridley Kry
Fellowship of the Damon Runyon Cancer Research Foundation. The AIDS
Malignancy Clinical Trials Consortium (NIH National Cancer Institute
grant U01CA121947) and the AIDS Cancer Specimen Resource (NIH National
Cancer Institute grant 1UM1CA181255) contributed cases of ARL.
NR 47
TC 10
Z9 10
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 14
PY 2015
VL 125
IS 20
BP E14
EP E22
DI 10.1182/blood-2014-11-599951
PG 9
WC Hematology
SC Hematology
GA CJ7PJ
UT WOS:000355689000001
PM 25827832
ER
PT J
AU Liu, Y
Ye, J
Ogawa, LS
Inoue, T
Huang, Q
Chu, J
Bates, RC
Ying, W
Sonderfan, AJ
Rao, PE
Zhou, D
AF Liu, Yuan
Ye, Josephine
Ogawa, Luisa Shin
Inoue, Takayo
Huang, Qin
Chu, John
Bates, Richard C.
Ying, Weiwen
Sonderfan, Andrew J.
Rao, Patricia E.
Zhou, Dan
TI The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and
Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse
Model of Systemic Lupus Erythematosus
SO PLOS ONE
LA English
DT Article
ID HEAT-SHOCK-PROTEIN; T-CELLS; AUTOIMMUNE-DISEASE; ELEVATED LEVELS;
CANCER; ACTIVATION; MICE; AUTOANTIBODIES; SLE; INFLAMMATION
AB Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease with a diverse range of immunological and clinical manifestations. The introduction of broad spectrum immunosuppressive therapies and better management of acute disease exacerbations have improved outcomes for lupus patients over recent years. However, these regimens are burdened by substantial toxicities and confer significantly higher risks of infection, thus there remains a significant and unmet medical need for alternative treatment options, particularly those with improved safety profiles. Heat shock protein 90 (HSP90) is a ubiquitously expressed molecular chaperone that acts as an important modulator of multiple innate and adaptive inflammatory processes. Of note, accumulating clinical and experimental evidence has implicated a role for HSP90 in the pathogenesis of SLE. Here we evaluated the potential of HSP90 as a therapeutic target for this disease using the selective small molecule inhibitor ganetespib in the well-characterized MRL/lpr autoimmune mouse model. In both the prophylactic and therapeutic dosing settings, ganetespib treatment promoted dramatic symptomatic improvements in multiple disease parameters, including suppression of autoantibody production and the preservation of renal tissue integrity and function. In addition, ganetespib exerted profound inhibitory effects on disease-related lymphadenopathy and splenomegaly, and reduced pathogenic T and B cell lineage populations in the spleen. Ganetespib monotherapy was found to be equally efficacious and tolerable when compared to an effective weekly dosing regimen of the standard-of-care immunosuppressive agent cyclophosphamide. Importantly, co-treatment of ganetespib with a sub-optimal, intermittent dosing schedule of cyclophosphamide resulted in superior therapeutic indices and maximal disease control. These findings highlight the potential of HSP90 inhibition as an alternative, and potentially complementary, strategy for therapeutic intervention in SLE. Such approaches may have important implications for disease management, particularly for limiting or preventing treatment-related toxicities, a major confounding factor in current SLE therapy.
C1 [Liu, Yuan; Ye, Josephine; Ogawa, Luisa Shin; Inoue, Takayo; Chu, John; Bates, Richard C.; Ying, Weiwen; Sonderfan, Andrew J.; Rao, Patricia E.; Zhou, Dan] Synta Pharmaceut Corp, Lexington, MA 02421 USA.
[Huang, Qin] VA Boston Healthcare Syst, Dept Pharmacol & Lab Med, West Roxbury, MA USA.
RP Zhou, D (reprint author), Synta Pharmaceut Corp, Lexington, MA 02421 USA.
EM DZhou@syntapharma.com
FU Synta Pharmaceuticals Corp
FX The author(s) received no specific funding for this work. Synta
Pharmaceuticals Corp provided support in the form of salaries for
authors YL, JY, LSO, TI, JC, RB, WY, AS, PR and DZ but did not have any
additional role in the study design, data collection and analysis,
decision to publish, or preparation of the manuscript. The specific
roles of these authors are articulated in the 'author contributions'
section".
NR 53
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR e0127361
DI 10.1371/journal.pone.0127361
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600112
PM 25974040
ER
PT J
AU Hur, C
Choi, SE
Kong, CY
Wang, GQ
Xu, H
Polydorides, AD
Xue, LY
Perzan, KE
Tramontano, AC
Richards-Kortum, RR
Anandasabapathy, S
AF Hur, Chin
Choi, Sung Eun
Kong, Chung Yin
Wang, Gui-Qi
Xu, Hong
Polydorides, Alexandros D.
Xue, Li-Yan
Perzan, Katherine E.
Tramontano, Angela C.
Richards-Kortum, Rebecca R.
Anandasabapathy, Sharmila
TI High-resolution microendoscopy for esophageal cancer screening in China:
A cost-effectiveness analysis
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Cost-effectiveness analysis; Diagnostic imaging; Endoscopy; Esophageal
squamous cell cancer; Simulation disease model
ID SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL-REFLUX DISEASE; EXTENDED
TRANSTHORACIC RESECTION; TIME CONFOCAL MICROSCOPY; HIGH-RISK AREAS;
BARRETTS-ESOPHAGUS; EFFECTIVENESS MODEL; AMELANOTIC TISSUE;
SURVEILLANCE; DYSPLASIA
AB AIM: To study the cost-effectiveness of high-resolution microendoscopy (HRME) in an esophageal squamous cell carcinoma (ESCC) screening program in China.
METHODS: A decision analytic Markov model of ESCC was developed. Separate model analyses were conducted for cohorts consisting of an averagerisk population or a high-risk population in China. Hypothetical 50-year-old individuals were followed until age 80 or death. We compared three different strategies for both cohorts: (1) no screening; (2) standard endoscopic screening with Lugol's iodine staining; and (3) endoscopic screening with Lugol's iodine staining and an HRME. Model parameters were estimated from the literature as well as from GLOBOCAN, the Cancer Incidence and Mortality Worldwide cancer database. Health states in the model included non-neoplasia, mild dysplasia, moderate dysplasia, high-grade dysplasia, intramucosal carcinoma, operable cancer, inoperable cancer, and death. Separate ESCC incidence transition rates were generated for the average-risk and high-risk populations. Costs in Chinese currency were converted to international dollars (I$) and were adjusted to 2012dollars using the Consumer Price Index.
RESULTS: The main outcome measurements for this study were quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). For the average-risk population, the HRME screening strategy produced 0.043 more QALYs than the no screening strategy at an additional cost of I$646, resulting in an ICER of I$11808 per QALY gained. Standard endoscopic screening was weakly dominated. Among the high-risk population, when the HRME screening strategy was compared with the standard screening strategy, the ICER was I$8173 per QALY. For both the high-risk and average-risk screening populations, the HRME screening strategy appeared to be the most cost-effective strategy, producing ICERs below the willingness-topay threshold, I$23500 per QALY. One-way sensitivity analysis showed that, for the average-risk population, higher specificity of Lugol's iodine (> 40%) and lower specificity of HRME (< 70%) could make Lugol's iodine screening cost-effective. For the high-risk population, the results of the model were not substantially affected by varying the follow-up rate after Lugol's iodine screening, Lugol's iodine test characteristics (sensitivity and specificity), or HRME specificity.
CONCLUSION: The incorporation of HRME into an ESCC screening program could be cost-effective in China. Larger studies of HRME performance are needed to confirm these findings.
C1 [Hur, Chin; Choi, Sung Eun; Kong, Chung Yin; Perzan, Katherine E.; Tramontano, Angela C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Hur, Chin; Kong, Chung Yin] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Hur, Chin; Perzan, Katherine E.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Wang, Gui-Qi] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Endoscopy, Beijing 100021, Peoples R China.
[Xu, Hong] Jilin Univ, Hosp 1, Dept Endoscopy, Changchun 130021, Jilin Province, Peoples R China.
[Polydorides, Alexandros D.] Icahn Sch Med, Mt Sinai Med Ctr, Dept Pathol, New York, NY 10029 USA.
[Xue, Li-Yan] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China.
[Richards-Kortum, Rebecca R.] Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
[Anandasabapathy, Sharmila] Baylor Coll Med, Baylor Global Initiat, Houston, TX 77030 USA.
[Anandasabapathy, Sharmila] Baylor Coll Med, Baylor Global Innovat Ctr, Houston, TX 77030 USA.
RP Hur, C (reprint author), Massachusetts Gen Hosp, GI Hlth Outcomes Res, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM chur@mgh.harvard.edu
OI Hur, Chin/0000-0002-2819-7576
FU National Institutes of Health, United States [R01-CA140574,
U01-CA152926, R21-CA156704, R01-CA181275, K25-CA133141]
FX Supported by National Institutes of Health, United States, No.
R01-CA140574 and No. U01-CA152926 (to Hur C); No. R21-CA156704 and No.
R01-CA181275 (to Anandasabapathy S); and No. K25-CA133141 (to Kong CY).
NR 37
TC 3
Z9 4
U1 0
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 14
PY 2015
VL 21
IS 18
BP 5513
EP 5523
DI 10.3748/wjg.v21.i18.5513
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CI5MF
UT WOS:000354800200009
PM 25987774
ER
PT J
AU Desai, RJ
Huybrechts, KF
Hernandez-Diaz, S
Mogun, H
Patorno, E
Kaltenbach, K
Kerzner, LS
Bateman, BT
AF Desai, Rishi J.
Huybrechts, Krista F.
Hernandez-Diaz, Sonia
Mogun, Helen
Patorno, Elisabetta
Kaltenbach, Karol
Kerzner, Leslie S.
Bateman, Brian T.
TI Exposure to prescription opioid analgesics in utero and risk of neonatal
abstinence syndrome: population based cohort study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID WITHDRAWAL SYNDROME; UNITED-STATES; INFANTS BORN; DRUG-USE; PREGNANCY;
METHADONE; OUTCOMES; PREVALENCE; MOTHERS; WOMEN
AB OBJECTIVE
To provide absolute and relative risk estimates of neonatal abstinence syndrome (NAS) based on duration and timing of prescription opioid use during pregnancy in the presence or absence of additional NAS risk factors of history of opioid misuse or dependence, misuse of other substances, non-opioid psychotropic drug use, and smoking.
DESIGN
Observational cohort study.
SETTING
Medicaid data from 46 US states.
PARTICIPANTS
Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (>= 30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed.
MAIN OUTCOME MEASURE
Diagnosis of NAS in liveborn infants.
RESULTS
1705 cases of NAS were identified among 290 605 pregnant women filling opioid prescriptions, corresponding to an absolute risk of 5.9 per 1000 deliveries (95% confidence interval 5.6 to 6.2). Long term opioid use during pregnancy resulted in higher absolute risk of NAS per 1000 deliveries in the presence of additional risk factors of known opioid misuse (220.2 (200.8 to 241.0)), alcohol or other drug misuse (30.8 (26.1 to 36.0)), exposure to other psychotropic medications (13.1 (10.6 to 16.1)), and smoking (6.6 (4.3 to 9.6)) than in the absence of any of these risk factors (4.2 (3.3 to 5.4)). The corresponding risk estimates for short term use were 192.0 (175.8 to 209.3), 7.0 (6.0 to 8.2), 2.0 (1.5 to 2.6), 1.5 (1.0 to 2.0), and 0.7 (0.6 to 0.8) per 1000 deliveries, respectively. In propensity score matched analyses, long term prescription opioid use compared with short term use and late use compared with early use in pregnancy demonstrated greater risk of NAS (risk ratios 2.05 (95% confidence interval 1.81 to 2.33) and 1.24 (1.12 to 1.38), respectively).
CONCLUSIONS
Use of prescription opioids during pregnancy is associated with a low absolute risk of NAS in the absence of additional risk factors. Long term use compared with short term use and late use compared with early use of prescription opioids are associated with increased NAS risk independent of additional risk factors.
C1 [Desai, Rishi J.; Huybrechts, Krista F.; Mogun, Helen; Patorno, Elisabetta; Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA.
[Desai, Rishi J.; Huybrechts, Krista F.; Mogun, Helen; Patorno, Elisabetta; Bateman, Brian T.] Harvard Univ, Sch Med, Boston, MA 02120 USA.
[Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kaltenbach, Karol] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Pediat, Philadelphia, PA 19107 USA.
[Kerzner, Leslie S.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
RP Desai, RJ (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA.
EM rdesai2@partners.org
FU National Institute of Mental Health [K01 MH099141]; Eunice Kennedy
Shriver National Institute of Child Health and Human Development of the
NIH [K08HD075831]; Agency for Healthcare Research and Quality (AHRQ)
[R01HS018533]
FX All authors have completed the ICMJE uniform disclosure form at
www.icmje.org/coi_disclosure.pdf and declare: KH is supported by a
career development award from the National Institute of Mental Health
(K01 MH099141); BB is supported by a career development award from the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development of the NIH (K08HD075831). MAX pregnancy cohort creation was
supported by the Agency for Healthcare Research and Quality (AHRQ)
(Grant R01HS018533). SH-D has consulted for GlaxoSmithKline-Biologics
(Middlesex, UK) and AstraZeneca (London, UK) for unrelated projects. The
other authors declare no other relationships or activities that could
appear to have influenced the submitted work.
NR 38
TC 15
Z9 15
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAY 14
PY 2015
VL 350
AR h2102
DI 10.1136/bmj.h2102
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI5CI
UT WOS:000354770100003
PM 25975601
ER
PT J
AU Cheng, ZY
Li, JF
Niu, YJ
Zhang, XC
Woody, OZ
Xiong, Y
Djonovic, S
Millet, Y
Bush, J
McConkey, BJ
Sheen, J
Ausubel, FM
AF Cheng, Zhenyu
Li, Jian-Feng
Niu, Yajie
Zhang, Xue-Cheng
Woody, Owen Z.
Xiong, Yan
Djonovic, Slavica
Millet, Yves
Bush, Jenifer
McConkey, Brendan J.
Sheen, Jen
Ausubel, Frederick M.
TI Pathogen-secreted proteases activate a novel plant immune pathway
SO NATURE
LA English
DT Article
ID GENE-EXPRESSION ANALYSIS; PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA;
INNATE IMMUNITY; PROTEIN-KINASE; XANTHOMONAS-CAMPESTRIS; RACK1;
TRANSFORMATION; INTERACTS; IDENTIFICATION
AB Mitogen-activated protein kinase (MAPK) cascades play central roles in innate immune signalling networks in plants and animals(1,2). In plants, however, the molecular mechanisms of how signal perception is transduced to MAPK activation remain elusive(1). Here we report that pathogen-secreted proteases activate a previously unknown signalling pathway in Arabidopsis thaliana involving the G alpha, G beta, and G gamma subunits of heterotrimeric G-protein complexes, which function upstream of an MAPK cascade. In this pathway, receptor for activated C kinase 1 (RACK1) functions as a novel scaffold that binds to the G beta subunit as well as to all three tiers of the MAPK cascade, thereby linking upstream G-protein signalling to downstream activation of an MAPK cascade. The protease-G-protein-RACK1-MAPK cascade modules identified in these studies are distinct from previously described plant immune signalling pathways such as that elicited by bacterial flagellin, in which G proteins function downstream of or in parallel to an MAPK cascade without the involvement of the RACK1 scaffolding protein. The discovery of the new protease-mediated immune signalling pathway described here was facilitated by the use of the broad host range, opportunistic bacterial pathogen Pseudomonas aeruginosa. The ability of P. aeruginosa to infect both plants and animals makes it an excellent model to identify novel immunoregulatory strategies that account for its niche adaptation to diverse host tissues and immune systems.
C1 [Cheng, Zhenyu; Li, Jian-Feng; Niu, Yajie; Zhang, Xue-Cheng; Xiong, Yan; Djonovic, Slavica; Millet, Yves; Bush, Jenifer; Sheen, Jen; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Cheng, Zhenyu; Li, Jian-Feng; Niu, Yajie; Zhang, Xue-Cheng; Xiong, Yan; Djonovic, Slavica; Millet, Yves; Bush, Jenifer; Sheen, Jen; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Woody, Owen Z.; McConkey, Brendan J.] Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada.
RP Ausubel, FM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM ausubel@molbio.mgh.harvard.edu
FU Natural Sciences and Engineering Research Council of Canada; Banting
Postdoctoral Fellowships; National Science Foundation [MCB-0519898,
IOS-0929226, IOS-0618292]; National Institutes of Health [R37-GM48707,
P30 DK040561, R01-GM70567]
FX We thank G. Tena for generating the mekk1/pMEKK1::MEKK1(K361M)
transgenic line, Y. Zhang for the summ1-1 mutant, M. C. Suarez-Rodriguez
and P. J. Krysan for discussion, the Arabidopsis Biological Resource
Center for tDNA insertion lines, and M. Curtis and U. Grossniklaus for
the oestradiol-inducible binary vector. We thank S. Lory for P.
aeruginosa PAO ADD1976, and M. B. Mudgett for pVSP61. We thank N. Clay,
X. Dong, S. Somerville, and Ausubel laboratory members for reading the
manuscript. This work was supported by Natural Sciences and Engineering
Research Council of Canada and Banting Postdoctoral Fellowships awarded
to Z.C., National Science Foundation grants MCB-0519898 and IOS-0929226
and National Institutes of Health grants R37-GM48707 and P30 DK040561 to
F.M.A., and National Science Foundation grant IOS-0618292 and National
Institutes of Health grant R01-GM70567 to J.S.
NR 39
TC 29
Z9 38
U1 18
U2 116
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 14
PY 2015
VL 521
IS 7551
BP 213
EP +
DI 10.1038/nature14243
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH9SY
UT WOS:000354377800057
PM 25731164
ER
PT J
AU Mayer, RJ
Van Cutsem, E
Falcone, A
Yoshino, T
Garcia-Carbonero, R
Mizunuma, N
Yamazaki, K
Shimada, Y
Tabernero, J
Komatsu, Y
Sobrero, A
Boucher, E
Peeters, M
Tran, B
Lenz, HJ
Zaniboni, A
Hochster, H
Cleary, JM
Prenen, H
Benedetti, F
Mizuguchi, H
Makris, L
Ito, M
Ohtsu, A
AF Mayer, Robert J.
Van Cutsem, Eric
Falcone, Alfredo
Yoshino, Takayuki
Garcia-Carbonero, Rocio
Mizunuma, Nobuyuki
Yamazaki, Kentaro
Shimada, Yasuhiro
Tabernero, Josep
Komatsu, Yoshito
Sobrero, Alberto
Boucher, Eveline
Peeters, Marc
Tran, Ben
Lenz, Heinz-Josef
Zaniboni, Alberto
Hochster, Howard
Cleary, James M.
Prenen, Hans
Benedetti, Fabio
Mizuguchi, Hirokazu
Makris, Lukas
Ito, Masanobu
Ohtsu, Atsushi
CA RECOURSE Study Grp
TI Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SOLID TUMORS; PHASE-I; FLUORINATED PYRIMIDINES; ANTITUMOR-ACTIVITY;
ANTIMETABOLITE; MECHANISM; CELLS; DNA
AB BACKGROUND
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.
METHODS
In this double-blind study, we randomly assigned 800 patients, in a 2: 1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival.
RESULTS
The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001).
CONCLUSIONS
In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival.
C1 [Mayer, Robert J.; Cleary, James M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Van Cutsem, Eric; Prenen, Hans] Univ Hosp, Leuven, Belgium.
[Van Cutsem, Eric; Prenen, Hans] Katholieke Univ Leuven, Leuven, Belgium.
[Peeters, Marc] Univ Ziekenhuizen Antwerp, Edegem, Belgium.
[Falcone, Alfredo] Univ Pisa, Pisa, Italy.
[Sobrero, Alberto] IRCCS Azienda Osped Univ San Martino, Ist Nazl Ric Canc, I-16132 Genoa, Italy.
[Zaniboni, Alberto] Fdn Poliambulanza Ist Osped, Brescia, Italy.
[Yoshino, Takayuki; Ohtsu, Atsushi] Natl Canc Ctr Hosp East, Chiba, Japan.
[Mizunuma, Nobuyuki] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan.
[Yamazaki, Kentaro] Shizuoka Canc Ctr, Shizuoka, Japan.
[Shimada, Yasuhiro] Natl Canc Ctr, Tokyo, Japan.
[Komatsu, Yoshito] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan.
[Ito, Masanobu] Taiho Pharmaceut, Tokyo, Japan.
[Garcia-Carbonero, Rocio] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville, Spain.
[Tabernero, Josep] Vall dHebron Univ Hosp, Barcelona, Spain.
[Tabernero, Josep] Vall dHebron Inst Oncol, Barcelona, Spain.
[Boucher, Eveline] Ctr Eugene Marquis, Rennes, France.
[Tran, Ben] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Lenz, Heinz-Josef] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
[Hochster, Howard] Yale Canc Ctr, New Haven, CT USA.
[Benedetti, Fabio; Mizuguchi, Hirokazu] Taiho Oncol, Princeton, NJ USA.
[Makris, Lukas] Stathmi, New Hope, PA USA.
RP Mayer, RJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
RI Peeters, Marc/C-5525-2013; IBIS, NUEVAS TERAPIA/P-3415-2015;
OI Peeters, Marc/0000-0003-4969-2303; Folprecht, Gunnar/0000-0002-9321-9911
FU Taiho Oncology-Taiho Pharmaceutical
FX Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE
ClinicalTrials.gov number, NCT01607957.
NR 19
TC 100
Z9 103
U1 2
U2 14
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 14
PY 2015
VL 372
IS 20
BP 1909
EP 1919
DI 10.1056/NEJMoa1414325
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI1HB
UT WOS:000354493300006
PM 25970050
ER
PT J
AU Joy, M
AF Joy, Mark
TI Acid-Base Problems in Diabetic Ketoacidosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID LACTIC-ACIDOSIS; BICARBONATE
C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
RP Joy, M (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
EM mark.joy@va.gov
NR 4
TC 0
Z9 0
U1 1
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 14
PY 2015
VL 372
IS 20
BP 1968
EP 1968
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI1HB
UT WOS:000354493300022
PM 25970064
ER
PT J
AU Fernandez, KA
Jeffers, PWC
Lall, K
Liberman, MC
Kujawa, SG
AF Fernandez, Katharine A.
Jeffers, Penelope W. C.
Lall, Kumud
Liberman, M. Charles
Kujawa, Sharon G.
TI Aging after Noise Exposure: Acceleration of Cochlear Synaptopathy in
"Recovered" Ears
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE age-related hearing loss; auditory nerve; cochlear neuropathy; cochlear
synaptopathy; noise-induced hearing loss; temporary threshold shift
ID INDUCED HEARING-LOSS; HAIR CELL LOSS; SURFACE AMPA RECEPTORS;
AUDITORY-NERVE FIBERS; GUINEA-PIG COCHLEA; ACOUSTIC TRAUMA; CAT COCHLEA;
DEGENERATION; INNERVATION; SENSITIVITY
AB Cochlear synaptic loss, rather than hair cell death, is the earliest sign of damage in both noise-and age-related hearing impairment (Kujawa and Liberman, 2009; Sergeyenko et al., 2013). Here, we compare cochlear aging after two types of noise exposure: one producing permanent synaptic damage without hair cell loss and another producing neither synaptopathy nor hair cell loss. Adult mice were exposed (8-16 kHz, 100 or 91 dB SPL for 2 h) and then evaluated from 1 h to similar to 20 months after exposure. Cochlear function was assessed via distortion product otoacoustic emissions and auditory brainstem responses (ABRs). Cochlear whole mounts and plastic sections were studied to quantify hair cells, cochlear neurons, and the synapses connecting them. The synaptopathic noise (100 dB) caused 35-50 dB threshold shifts at 24 h. By 2 weeks, thresholds had recovered, but synaptic counts and ABR amplitudes at high frequencies were reduced by up to similar to 45%. As exposed animals aged, synaptopathy was exacerbated compared with controls and spread to lower frequencies. Proportional ganglion cell losses followed. Threshold shifts first appeared similar to 1 year after exposure and, by similar to 20 months, were up to 18 dB greater in the synaptopathic noise group. Outer hair cell losses were exacerbated in the same time frame (similar to 10% at 32 kHz). In contrast, the 91 dB exposure, producing transient threshold shift without acute synaptopathy, showed no acceleration of synaptic loss or cochlear dysfunction as animals aged, at least to similar to 1 year after exposure. Therefore, interactions between noise and aging may require an acute synaptopathy, but a single synaptopathic exposure can accelerate cochlear aging.
C1 [Fernandez, Katharine A.; Lall, Kumud; Liberman, M. Charles; Kujawa, Sharon G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Fernandez, Katharine A.; Jeffers, Penelope W. C.; Lall, Kumud; Liberman, M. Charles; Kujawa, Sharon G.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Kujawa, Sharon G.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
RP Kujawa, SG (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM sharon_kujawa@meei.harvard.edu
FU National Institute on Deafness and other Communication
Disorders-National Institutes of Health [R01 DC08577, R01 DC0188, P30
DC05209]
FX This work was supported by grants from the National Institute on
Deafness and other Communication Disorders-National Institutes of Health
(Grants R01 DC08577, R01 DC0188, and P30 DC05209).
NR 54
TC 25
Z9 26
U1 2
U2 20
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 13
PY 2015
VL 35
IS 19
BP 7509
EP 7520
DI 10.1523/JNEUROSCI.5138-14.2015
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA CL0YK
UT WOS:000356668800017
PM 25972177
ER
PT J
AU Wlodarska, M
Kostic, AD
Xavier, RJ
AF Wlodarska, Marta
Kostic, Aleksandar D.
Xavier, Ramnik J.
TI An Integrative View of Microbiome-Host Interactions in Inflammatory
Bowel Diseases
SO CELL HOST & MICROBE
LA English
DT Review
ID INTESTINAL ALKALINE-PHOSPHATASE; GENOME-WIDE ASSOCIATION; ENTERIC
NERVOUS-SYSTEM; HUMAN GUT VIROME; CROHNS-DISEASE; ENVIRONMENTAL
ENTEROPATHY; ULCERATIVE-COLITIS; FECAL MICROBIOTA; T-CELLS; COMMENSAL
BACTERIA
AB The intestinal microbiota, which is composed of bacteria, viruses, and micro-eukaryotes, acts as an accessory organ system with distinct functions along the intestinal tract that are critical for health. This review focuses on how the microbiota drives intestinal disease through alterations in microbial community architecture, disruption of the mucosal barrier, modulation of innate and adaptive immunity, and dysfunction of the enteric nervous system. Inflammatory bowel disease is used as a model system to understand these microbial-driven pathologies, but the knowledge gained in this space is extended to less-well-studied intestinal diseases that may also have an important microbial component, including environmental enteropathy and chronic colitis-associated colorectal cancer.
C1 [Wlodarska, Marta; Kostic, Aleksandar D.; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Wlodarska, Marta] Novartis Inst BioMed Res, Dev & Mol Pathways, Cambridge, MA 02139 USA.
[Kostic, Aleksandar D.; Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Kostic, Aleksandar D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Xavier, Ramnik J.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
[Xavier, Ramnik J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Xavier, Ramnik J.] MIT, Ctr Microbiome Informat & Therapeut, Cambridge, MA 02139 USA.
RP Xavier, RJ (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM xavier@molbio.mgh.harvard.edu
OI Kostic, Aleksandar/0000-0002-0837-4360
FU Helen Hay Whitney Foundation Research Fellowship; Lawrence H. Summers
Postdoctoral Fellowship; Crohn's and Colitis Foundation of America;
Leona M. and Harry B. Helmsley Charitable Trust; JDRF; National
Institutes of Health
FX A.D.K. is supported by a Helen Hay Whitney Foundation Research
Fellowship and the Lawrence H. Summers Postdoctoral Fellowship. R.J.X.
is supported by grants from the Crohn's and Colitis Foundation of
America, the Leona M. and Harry B. Helmsley Charitable Trust, JDRF, and
the National Institutes of Health. We thank Eric M. Brown and Natalia
Nedelsky for thorough editing of this manuscript.
NR 156
TC 32
Z9 34
U1 9
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 13
PY 2015
VL 17
IS 5
BP 577
EP 591
DI 10.1016/j.chom.2015.04.008
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA CK3FH
UT WOS:000356101500010
PM 25974300
ER
PT J
AU Bourguignon, LYW
Bikle, D
AF Bourguignon, Lilly Y. W.
Bikle, Daniel
TI Selective hyaluronan-CD44 signaling promotes miRNA-21 expression and
interacts with vitamin D function during cutaneous squamous cell
carcinomas progression following UV irradiation
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE hyaluronan; CD44; RhoGTPase; vitamin D; UVR; miR21; vitamin D; skin
cancer
ID TUMOR-SUPPRESSOR PDCD4; PROTEIN-KINASE-C; NF-KAPPA-B; BREAST-CANCER
CELLS; RHO-KINASE; CD44 INTERACTION; SKIN-CANCER; KERATINOCYTE
DIFFERENTIATION; TRANSCRIPTION FACTORS; INHIBITS TRANSLATION
AB Hyaluronan (HA), the major extracellular matrix component, is often anchored to CD44, a family of structurally/functionally important cell surface receptors. Recent results indicate that UV irradiation (UVR)-induced cutaneous squamous cell carcinomas (SCC) overexpress a variety of CD44 variant isoforms (CD44v), with different CD44v isoforms appear to confer malignant SCC properties. UVR also stimulates HA degradation in epidermal keratinocytes. Both large HA polymers and their UVR-induced catabolic products (small HA) selectively activate CD44-mediated cellular signaling in normal keratinocytes and SCC cells, with all of the downstream processes being mediated by RhoGTPases (e.g., Rac1 and Rho). Importantly, we found that the hormonally active form of vitamin D 1,25(OH)(2) D-3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s). The aim of this hypothesis and theory article is to question whether matrix HA and its UVR-induced catabolic products (e.g., large and small HA) can selectively activate CD44-mediated cellular signaling such as GTPase (Rac and RhA) activation. We suggested that large HA CD44 interaction promotes Rac-signaling and normal keratinocyte differentiation (lipid synthesis), DNA repair, and keratinocyte survival function. Conversely, small HA CD44 interaction stimulates RhoA activation, NFKB/Stat-3 signaling, and miR-21 production, resulting in inflammation and proliferation as well as SCC progression. We also question whether vitamin D treatment displays any effect on small HA CD44v-mediated RhoA signaling, inflammation, and SCC progression, as well as large HA CD44-mediated differentiation, DNA repair, keratinocyte survival, and normal keratinocyte function. In addition, we discussed that the topical application of signaling perturbation agents (e.g., Y27623, a ROK inhibitor) may be used to treat certain skin diseases displaying upregulation of keratinocyte proliferation such as psoriasis and actinic keratoses in order to correct the imbalance between Rac and RhoA signaling during various UV irradiation-induced skin diseases in patients. Finally, we proposed that matrix HA/CD44-signaling strategies and matrix HA (HA(S) vs. HA(L) or HA(S) -> HA(L))-based therapeutic approaches (together with vitamin D) may be used for the treatment of patients suffering a number of UV irradiation-induced skin diseases (e.g., inflammation, skin cancer, and chronic non-healing wounds).
C1 [Bourguignon, Lilly Y. W.; Bikle, Daniel] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, San Francisco, CA 94121 USA.
RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA.
EM lilly.bourguignon@ucsf.edu
FU Veterans Affairs (VA) Merit Review Awards [RR & D-1101 RX000601, BLR &
D-5101 BX000628]; United States Public Health grants [R01 CA66163]; DOD
grant
FX We gratefully acknowledge the assistance of Dr. Gerard J. Bourguignon in
the preparation and review of this manuscript. This work was supported
by Veterans Affairs (VA) Merit Review Awards (RR & D-1101 RX000601 and
BLR & D-5101 BX000628), United States Public Health grants (R01
CA66163), and DOD grant. LB is a VA Senior Research Career Scientist.
NR 80
TC 2
Z9 2
U1 5
U2 7
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 13
PY 2015
VL 6
AR 224
DI 10.3389/fimmu.2015.00224
PG 13
WC Immunology
SC Immunology
GA CJ2NQ
UT WOS:000355322100001
PM 26029210
ER
EF